

There are 1814 publications

1 Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)- CALGB 80802 (Alliance)

Ghassan K. Abou-Alfa, Donna Niedzwieski, Jennifer J. Knox, Andreas Kaubisch, James Posey, Benjam R. Tan Jr., Peter Kavan, Rakesh Goel, John J. Murray, Tanios S. Bekaii-Saab, Vincent Channing Tam, Lakshmi Rajde, Robin Kate Kelley, Abby Siegel, Jennifer Balletti, James J. Harding, Lawrence Howard Schartz, Richard M. Goldberg, Monica M. Bertagnolli, Alan P. Venook J. Clin. Oncol. vol 34 (4s) abstr 192 2016
Abstract GI <http://meetinglibrary.asco.org/content/159480-173>

2 Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB 80802 (Alliance) (C8)

Ghassan K. Abou-Alfa, Qian Shi, Jennifer J. Knox, Andreas Kaubisch, James Posey, Benjamin R. Tan Jr., Petr Kavan, Rakesh Goel, Philip Lammers, Tanios S. Bekaii-Saab, Vincent C. Tam, Lakshmi Rajdev, Robin Kate Kelley, Abby Siegel, Tyler Zemla, Imane El Dika, Alan P. Venook, Monica M. Bertagnolli, Jeffrey Meyerhardt, Eileen M. O'Reilly J Clin Oncol vol 36 (15_suppl) e16107 2018
Abstract GI http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e16107

3 A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study.

A. A. Adjei, S. J. Mandrekar, G. K. Dy, J. R. Molina, D. R. Gandara, K. L. Allen Ziegler, P. J. Stella, K. M. Jr Rowland, S. E. Schild, R. G. Zinner J. Clin. Oncol. vol 26 (15s) abstr 8080 2008
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

4 Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426

A. A. Adjei, S. J. Mandrekar, G. K. Dy, J. R. Molina, D. R. Gandara, K. L. Ziegler, P. J. Stella, K. M. Jr Rowland, S. E. Schild, R. G. Zinner J. Clin. Oncol. vol 28 (4) 614-619 2010
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/19841321>

5 A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer.

A. A. Adjei, J. R. Molina, S. L. Hillman, R. F. Luyun, N. F. Reuter, K. M. Jr Rowland, J. R. Jett, S. J. Mandrekar, S. E. Schild J. Clin. Oncol. vol 25 (18s) 396s abstr 7547 2007
Abstract Respiratory http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/7547

6 Correlation between polymorphisms in the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer (NSCLC): An NCCTG N0026 based study. Abstract 198.

A. Adjei, O. Salavaggione, S. Mandrekar, G. Dy, K. Allen-Ziegler, C. Endo, J. Molina, S. Schild 2009
Abstract Respiratory

7 Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.

Araba A Adjei, Oreste E Salavaggione, Sumithra J Mandrekar, Grace K Dy, Katie L Allen Ziegler, Chiaki Endo, Julian R Molina, Steven E Schild, Alex A Adjei J Thorac Oncol vol 5 (9) 1346-53 2010
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20651609>

8 Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance)

Anjali S. Advani, Ben Sanford, Selina Luger, Meenakshi Devidas, Eric C. Larsen, Michaela Liedtke, Peter M. Voorhees, Matthew C. Foster, David F. Claxton, Susan Geyer, Edy Parker, Kristin Coffan, William L. Carroll, Naomi J. Winick, Steven E. Coutre, Martin S. Tallman, Frederick R. Appelbaum, Harry Paul Erba, Richard M. Stone, Stephen P. Hunger, Richard A. Larson, Wendy Stock Blood vol 122 (21) Abstract 3903 2013

Abstract Leukemia <http://bloodjournal.hematologylibrary.org/content/122/21/3903.abstract>

9 Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial

Pooja P. Advani, Karla V. Ballman, Travis J. Dockter, Gerardo Colon-Otero, Edith A. Perez J. Clin. Oncol vol 34 (6) 581-587 2016

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26392097>

10 Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial.

Pooja Prem Advani, Karla V. Ballman, Travis J. Dockter, Gerardo Colon-Otero, Edith A. Perez J. Clin. Oncol. vol 32 (5s) (suppl; abstr 603) 2014

Abstract Breast http://abstracts.asco.org/144/AbstView_144_128009.html

11 Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI).

Ranjana H Advani, Haiyan Chen, Thomas M Habermann, Vicki A Morrison, Edie A Weller, Richard I Fisher, Bruce A Peterson, Randy D Gascoyne, Sandra J Horning Br. J. Haematol. vol 151 (2) 143-51 2010

Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/20735398>

12 A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: an Alliance Foundation trial (AFT-19)

Rahul Aggarwal, Scott Eggener, Ronald Chen, Glenn Heller, Akash Patnaik, Han Xiao, Douglas Weckstein, James Mohler, Mark Watson, Mary-Ellen Taplin, Linda Skoog-Sluman, Meryl Pereji, Eunice Aikins-Afful, John Kellogg Parsons, Charles J. Ryan, Michael M. Morris J Clin Oncol vol 36 (15_suppl) abstr TPS5090 2018

Abstract GU http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.TPS5090

13 The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy with Docetaxel in Patients with Metastatic Castrate Resistant Prostate Cancer: Results from a Retrospective Analysis of a Randomized Phase 3 Clinical Trial (CALGB 90401) (Alliance)

Rahul Aggarwal, Susan Halabi, William Kevin Kelly, Daniel George, John F. Mahoney, Frederick Millard, Walter M. Stadler, Michael J. Morris, Philip Kantoff, J. Paul Monk, Michael Carducci, Eric J. Small Cancer vol 119 (20) 3636-3643 2013

Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/23913744>

14 Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM) CALGB 100104 (Alliance)

Sikander Ailawadhi, Philip L. McCarthy, Sarah A. Holstein, Gail Larkins, Weiyuan Chung, Shankar Srinivasan, Amit Agarwal, Sagar Lonial J Clin Oncol vol 36 (Suppl) abstr 8050 2018

Abstract Transplant CALGB-100104, E4A03, MM-002, MM-009

<https://meetinglibrary.asco.org/record/160715/abstract>

- 15 Management of Recurrent Prostate Cancer after Radiotherapy: Long-term results from CALGB 9687, a Contemporary Prospective Multi-institutional Salvage Prostatectomy Series**
A Al-Daghmin, MH Sokoloff, S Halabi, BL Sanford, JA Eastham, PJ Walther, EJ Small, JL Mohler J Urology vol 191 (4s) e767, PD27-09 2014
Abstract GU <http://www.jurology.com/article/S0022-5347%2814%2902367-2/abstract>
- 16 Attributes and Outcomes of Older Adults in Surgical Oncology Trials: Results from ACOSOG Z901101 (Alliance)**
Waddah B. Al-Refaie, Paul A. Decker, Peter W.T. Pisters, Mitch Posner, Kelly K. Hunt, Bryan Meyers, Armin Weinberg, Heidi Nelson, Lisa Newman, Karla V. Ballman Ann. Surg. Oncol. vol 22 (Suppl 1) 80 2015
Abstract Older Adult
<http://www.surgonc.ohhttp://link.springer.com/article/10.1245%2Fs10434-015-4372-z>
- 17 Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia**
Houda Alachkar, Noreen Fulton, Ben Sanford, Greg Malnassy, Martin Mutonga, Richard A. Larson, Clara D. Bloomfield, Guido Marcucci, Yusuke Nakamura, Wendy Stock Pharmacogenomics J. vol 17 (3) 274-279 2017
Manuscript Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pubmed/27019981>
- 18 SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome**
Houda Alachkar, Ramasamy Santhanam, Kati Maharry, Klaus H. Metzeler, Xiaomeng Huang, Jessica Kohlschmidt, Jason H. Mandler, Juliana M. Benito, Christopher Hickey, Paolo Neviani, Adrienne M. Dorrance, Mirela Anghelina, Jihane Khalife, Somayeh S. Tarighat, Stefano Volinia, Susan P. Whitman, Peter Paschka, Pia Hoellerbauer, Yue-Zhong Wu, Lina Han, Brad N. Bolon, William Blum, Krzysztof Mrózek, Andrew J. Carroll, Danilo Perrotti, Michael Andreeff, Michael A. Caligiuri, Marina Konopleva, Ramiro Garzon, Clara D. Bloomfield, Guido Marcucci J. Clin. Invest vol 124 (4) 1512-1524 2014
Manuscript Leuk Corr Sci CALGB-19808, CALGB-9621
<http://www.ncbi.nlm.nih.gov/pubmed/24590286>
- 19 Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver**
S. R. Alberts, J. H. Donohue, M. R. Mahoney, G. D. Nelson, P. O. Schwarzenberger, J. W. Kugler, R. F. Morton, P. J. Flynn J. Clin. Oncol. vol 26 (15s) abstr 15006 2008
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID
- 20 NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)--interim review of toxicity**
S. R. Alberts, B. W. Morlan, G. P. Kim, H. C. Pitot, F. J. Quevedo, S. R. Dakhil, H. M. Gross, J. R. Merchan, L. R. Roberts Gastrointestinal Cancers Symposium abstr 186 2007
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=45&abstractID
- 21 Adjuvant mFOLFOX6 +/- Cetuximab in KRAS Wild Type Patients With Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147.**
S. R. Alberts, D. J. Sargent, T. C. Smyrk, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, S. N. Thibodeau, S. Nair J. Clin. Oncol. vol 28 (18s) abstr CRA3507 2010
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

22 Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147.

S. R. Alberts, S. N. Thibodeau, D. J. Sargent, M. R. Mahoney, F. Sinicrope, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, J. T. Quesenberry, T. C. Smyrk, A. Grothey, S. G. Nair J. Clin. Oncol. vol 29 (15s) abstr 3607 2011
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

23 Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver.

S. Alberts, M. R. Mahoney, J. H. Donohue, M. S. Roh, E. M. Green, D. J. Sargent, L. D. Wagman, J. S. Bolton J. Clin. Oncol. vol 25 (18s) abstr 4057 2007
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

24 Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849

S. Alberts, G. Soori, Q. Shi, D. Wagle, R. Sticca, R. Miller, J. Leenstra, P. Peller, T. Wu, H. Yoon, T. Drevyanko, S. Ko, B. Mattar, D. Nikcevich, R. Behrens, M. Khalil, G. Kim J. Clin. Oncol. vol 31 (15 suppl) abstr 4026 2013
Abstract GI <http://meetinglibrary.asco.org/content/111984-132>

25 Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial

Steven R. Alberts, Tom R. Fitch, George P. Kim, Bruce W. Morlan, Shaker R. Dakhil, Howard M. Gross, Suresh Nair Am. J. Clin. Oncol. vol 35 (4) 329-333 2012
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21422991>

26 Gemcitabine and Doxorubicin for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial

Steven R. Alberts, Joel M. Reid, Bruce W. Morlan, Gist H. Farr, John K. Camoriano, David B. Johnson, James R. Egner, Thomas E. Seay, George P. Kim Am. J. Clin. Oncol. vol 35 (5) 418-423 2012
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21555932>

27 Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66

Steven R. Alberts, Mark S. Roh, Michelle R. Mahoney, Michael J. O'Connell, David M. Nagorney, Lawrence Wagman, Thomas C. Smyrk, Timothy L. Weiland, Lily Lau Lai, Roderich E. Schwarz, Roy Molina, Todor Dentchev, John S. Bolton J Clin Oncol vol 28 (5) 853-858 2010
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20048179>

28 Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer

Steven R. Alberts, Daniel J. Sargent, Suresh Nair, Michelle R. Mahoney, Margaret Mooney, Stephen N. Thibodeau, Thomas C. Smyrk, Frank A. Sinicrope, Emily Chan, Sharlene Gill, Morton S. Kahlenberg, Anthony F. Shields, James T. Quesenberry, Thomas A. Webb, Gist H. Farr, Barbara A. Pockaj, Axel Grothey, Richard M. Goldberg JAMA vol 307 (13) 1383-1393 2012
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/22474202>

- 29 Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943.**
Steven R Alberts, Jonathan R Sande, Nathan R Foster, Fernando J Quevedo, Robert R McWilliams, John W Kugler, Tom R Fitch, Anthony J Jaslowksi J Gastrointest Cancer vol 38 (2-4) 87-94 2007
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19023677>
- 30 Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial.**
Steven R Alberts, Vera J Suman, Henry C Pitot, John K Camoriano, Joseph Rubin J Gastrointest Cancer vol 38 (1) 10-4 2007
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19065716>
- 31 Exercise and Dietary Change after Diagnosis and Cancer-related Symptoms in Long-term Survivors of Breast Cancer: CALGB 79804**
Catherine M. Alfano, Jeannette M. Day, Mira L. Katz, James E. Herndon, Marisa A. Bittoni, Jill M. Oliveri, Kathleen Donohue, Electra D. Paskett Psychooncology vol 18 (2) 128-133 2009
Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/18536022>
- 32 ACOSOG Z0030 Study Group: Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective ACOSOG Z0030 trial**
M. S. Allen, G. E. Darling, P. A. Decker, J. B. Jr Putnam, R. A. Malthaner, R. I. Inculet, D. R. Jones, R. J. Jr Mckenna, R. J. Landreneau, A. Z. S. Group J. Clin. Oncol. vol 25 (18S) abstr 7555 2007
Abstract Respiratory http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/7555
- 33 Perioperative mortality and Morbidity after Lobar versus Sublobar Resection for early stage lung cancer: A post-hoc analysis of an international randomized phase III trial (CALGB/Alliance 140503)**
Nasser K. Altorki, Xiaofei Wang, Dennis Wigle, Lin Gu, Gail Darling, Ahmad S Ashrafi, Rodney Landreneau, Daniel Miller, Moishe Liberman, David R Jones, Robert Keenan, Massimo Conti, Gavin Wright, Linda J Veit, Suresh S. Ramalingam, Mohamed Kamel, Harvey I. Pass, John D. Mitchell, Thomas Stinchcombe, Everett Vokes, Leslie J Kohman Lancet Respir Med vol 6 (12) 915-924 2018
Abstract Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/30442588>
- 34 Perioperative mortality and Morbidity after Lobar versus Sublobar Resection for early stage lung cancer: A post-hoc analysis of an international randomized phase III trial (CALGB/Alliance 140503)**
Nasser K. Altorki, Xiaofei Wang, Dennis Wigle, Lin Gu, Gail Darling, Ahmad S Ashrafi, Rodney Landreneau, Daniel Miller, Moishe Liberman, David R Jones, Robert Keenan, Massimo Conti, Gavin Wright, Linda J Veit, Suresh S. Ramalingam, Mohamed Kamel, Harvey I. Pass, John D. Mitchell, Thomas Stinchcombe, Everett Vokes, Leslie J Kohman Lancet Respir Med vol 6 (12) 915-24 2018
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/30442588>
- 35 Par-4 Down-regulation Promotes Breast Cancer Recurrence by Preventing Multinucleation following Targeted Therapy**
James V. Alvarez, Tien-chi Pan, Jason Ruth, Yi Feng, Alice Zhou, Dhruv Pant, Joshua S. Grimley, Thomas J. Wandless, Angela DeMichele, Lewis A. Chodosh Cancer Cell vol 24 (1) 2013
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/23770012>
- 36 Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods**
Ming-Wen An, Yu Han, Jeffrey P. Meyers, Jan Bogaerts, Daniel J. Sargent, Sumithra J. Mandrekar J. Clin. Oncol vol 33 (34) 4048-4057 2015
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/26503199>

- 37 Exploring the statistical and clinical impact of two interim analyses on the phase II design with option for direct assignment**
Ming-Wen An, Sumithra J. Mandrekar, Martin J. Edelman, Daniel J. Sargent *Contemp Clin Trials* vol 38 (2) 157-162 2014
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/24768938>
- 38 Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in recurrent glioblastoma (rGBM) patients (pts) treated with bevacizumab (BEV) and sorafenib (SOR).**
S. K. Anderson, J. M. Lafky, X. W. Carrero, T. K. Kimlinger, T. M. Halling, S. Kumar, P. J. Flynn, H. M. Gross, K. A. Jaeckle, J. C. Buckner *J. Clin. Oncol.* vol 29 (15s) abstr 2019 2011
Abstract Neuro-Onc <http://meetinglibrary.asco.org/content/83751-102>
- 39 Validating RNAseq-Signatures of Vorinostat (VOR) Sensitivity and Resistance in Patients with Newly Diagnosed Glioblastoma (GBM) Treated with VOR, Temozolomide and Radiation Therapy From Alliance N0874/ABTC-0902.**
S. Keith Anderson, C. Ryan Miller, Jann N. Sarkaria, Kurt A. Jaeckle, Jan C. Buckner, Keith L. Ligon, Karla V. Ballman, Dennis F. Moore Jr., Manmeet S. Ahluwalia, Eudocia Quant Lee, Elise Hovarth, Elizabeth Gerstner, Glenn J. Lesser, Michael Prados, Stuart A. Grossman, Caterina Giannini, Patrick Y. Wen, Evanthia Galanis *J. Clin. Oncol.* vol 34 (suppl) abstr 2029 2016
Abstract Neuro-Onc N0874, ABTC-0902 <http://meetinglibrary.asco.org/content/164476-176>
- 40 Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS) -- Findings from the ACCENT dataset.**
T. Andre, Q. Shi, G. Yothers, B. Bot, D. Haller, E. Van Cutsem, J. Cassidy, J. Benedetti, M. O'Connell, D. Sargent *J. Clin. Oncol.* vol 28 (15s) abstr 3616 2010
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID
- 41 Phase II clinical trial of denileukin diftitox in combination with rituximab in previously untreated follicular B-cell non-Hodgkins lymphoma**
S. M. Ansell, H. Tang, G. S. Nowakowski, D. A. Nikcevich, G. D. Nelson, C. E. Erlichman, T. E. Witzig 53rd ASH Annual Meeting and Exposition vol 116 abstr 2862 2010
Abstract Lymphoma <https://ash.confex.com/ash/2010/webprogram/Paper31618.html>
- 42 Low-Dose, Single-Agent Temsirolimus for Relapsed Mantle Cell Lymphoma**
Stephen M. Ansell, David J. Inwards, Kendrith M. Rowland, Patrick J. Flynn, Roscoe F. Morton, Dennis F. Moore, Scott H. Kaufmann, Irene Ghobrial, Paul J. Kurtin, Matthew Maurer, Christine Allmer, Thomas E. Witzig *Cancer* vol 113 (3) 508-514 2008
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/18543327>
- 43 Serum BLYS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma**
Stephen M. Ansell, Anne J. Novak, Steven Ziesmer, Tammy Price-Troska, Betsy LaPlant, Stacey R. Dillon, Thomas E. Witzig *Am J Hematol* vol 84 (2) 71-73 2009
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/19051265>
- 44 Temsirolimus and Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma: a multi-center Phase 2 Study**
Stephen M. Ansell, Hui Tang, Paul J. Kurtin, Patricia A. Koenig, David J. Inwards, Keith Shah, Steven C. Ziesmer, Andrew L. Feldman, Radha Rao, Mamta Gupta, Charles Erlichman, Thomas E. Witzig

45 Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin's Lymphoma

Stephen M. Ansell, Hui Tang, Paul J. Kurtin, Patricia A. Koenig, Grzegorz S. Nowakowski, Daniel A. Nikcevich, Garth D. Nelson, Zhizhang Yang, Deanna M. Grote, Steven C. Ziesmer, Peter T.

Silberstein, Charles Erlichman, Thomas E. Witzig *Leukemia* vol 26 (5) 1046-1052 2012

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/22015775>

46 Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data

Ogheneruona Apoe, Sin-Ho Jung, Heshan Liu, Drew K Seisler, Jayne Charlamb, Patricia Zekan, Lili X. Wang, Gary W. Unzeitig, Judy Garber, James Marshall, Marie Wood *Am J Hematol Oncol* vol 12 (7) 4-9 2016

Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/29081880>

47 Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy

Andrea B. Apolo, Irina Ostrovnaya, Susan Halabi, Alexia Iasonos, George K. Philips, Jonathan E.

Rosenberg, Jamie Riches, Eric J. Small, Matthew I. Milowsky, Dean F. Bajorin *J. Natl. Cancer Inst* vol 105 (7) 499-503 2013

Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/23411591>

48 External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy.

Andrea Borghese Apolo, George Philips, Irina Ostrovnaya, Jonathan E. Rosenberg, Matthew I.

Milowsky, Eric Jay Small, Dean F. Bajorin, Susan Halabi *J. Clin. Oncol.* vol 30 (15 suppl) abstr 4592 2012

Abstract GU

http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/4592?sid=b6130d1e-7db1-4a8a-b70c-2d7e

49 Alliance A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (MIBC) (AMBASSADOR) vs Observation

Andrea Apolo, Jonathan Rosenberg, Michael Morris, Karla Ballman, Bishoy Faltas, Ronald Chen,

Marissa Mallek, Colleen Watt, William Kim, Sandy Srinivasan, Guru Sonpavde *J Clin Oncol* vol 37 (suppl 7S) abstr TPS504 2019

Abstract GU <https://meetinglibrary.asco.org/record/169792/abstract>

50 Surgical practice patterns following NCCTG N0338 Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer.

H. Apsey, V. Roy, B. Pockaj, D. Northfelt, R. Sticca, D. A. Nikcevich, B. Mattar, T. Fitch, E. A. Perez *J. Clin. Oncol.* vol 27 (15s) abstr 623 2009

Abstract Breast

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

51 Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: Results of ACOSOG (American College Of Surgeons Oncology Group) Z1071 (Alliance) Substudy

Jane M. Armer, Karla V. Ballman, Linda McCall, Nathan C. Armer, Yuanlu Sun, Tipparat

Udmuangpia, Kelly K. Hunt, Elizabeth A. Mittendorf, David R. Byrd, Thomas B. Julian, Judy C.

Boughey *Support Care Cancer* vol 27 (2) 495-503 2019

- 52 Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection**
Jane M. Armer, Karla V. Ballman, Linda McCall, Pamela L. Ostby, Eris Zagar, Henry M. Kuerer, Kelly K. Hunt, Judy C. Boughey JAMA Surg 2019
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/31314062>
- 53 Lymphedema results of Alliance Z1071 (American College of Surgeons Oncology Group [ACOSOG]): Self-reported symptoms and limb volume changes for breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection**
Jane M. Armer, Karla Ballman, Linda McCall, Vera Suman, Yuanlu Sun, Tipparat Udmuangpia, Kelly K. Hunt, Elizabeth A. Mittendorf, David R. Byrd, Thomas B. Julian, Judy C. Boughey 2018
Abstract Breast
- 54 Symptoms and limb changes for breast cancer survivors treated with neoadjuvant chemotherapy: Lymphedema results of ACOSOG Z1071 (Alliance)**
Jane M. Armer, Karla Ballman, Linda McCall, Vera Suman, Yuanlu Sun, Tipparat Udmuangpia, Elizabeth Mittendorf, Kelly K. Hunt, David R. Bryd, Thomas Julian, Judy C. Boughey Supportive Cancer Care vol 25 (Supplement 2) pp S128-S129 (eP179) 2017
Abstract Breast <https://link.springer.com/content/pdf/10.1007%2Fs00520-017-3704-x.pdf>
- 55 Effects of a lymphedema prevention intervention on range of motion among women receiving axillary node dissection for breast cancer treatment (Alliance) CALGB 70305**
Jane M Armer, Heshan Liu, Jill Oliveri, Drew Seisler, tbd, Jennifer Le-Rademacher, Jeffrey Sloan, Electra D Paskett J. Clin. Oncol. vol 36 (15_suppl) 123-123 2018
Abstract Symptom Inter https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.7_suppl.123
- 56 Healthy Eating Index Scores are Associated with Inflammatory Markers in Breast Cancer Survivors**
Kristen Arnold, Rebecca Andridge, Amanda Logan, Lisa Yee, Maryam Lustberg, Tonya Orchard FASEB J vol 29 (1 supplement) LB267 2015
Abstract Symptom Inter
http://www.fasebj.org/gca?gca=fasebj%3B29%2F1_Supplement%2FLB267&allch=&submit=Go#abstr-
- 57 Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.**
Amanda C Ashley, Daniel J Sargent, Steven R Alberts, Axel Grothey, Megan E Campbell, Roscoe F Morton, Charles S Fuchs, Ramesh K Ramanathan, Stephen K Williamson, Brian P Findlay, Henry C Pitot, Richard M Goldberg Cancer vol 110 (3) 670-7 2007
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17559146>
- 58 Using the Skindex-16 and CTCAE to assess rash symptoms: Results of a pooled-analysis (N0993).**
P. Atherton, K. Burger, C. Loprinzi, R. Miller, A. Jatoi, J. Sloan J. Clin. Oncol. vol 28 (15s) abstr 9015 2010
Abstract Symptom Inter
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID
- 59 Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993)**
Pamela J. Atherton, Kelli N. Burger, Charles L. Loprinzi, Michelle A. Neben Wittich, Robert C. Miller, Aminah Jatoi, Jeff A. Sloan Support Care Cancer vol 20 (8) 1729-1735 2012
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/21922203>

- 60 Assessment of Patient-Reported Measures of Bowel Function Before and After Pelvic Radiotherapy: An Ancillary Study of the North Central Cancer Treatment Group Study N00CA**
Pamela J. Atherton, Michele Y. Halyard, Jeff A. Sloan, Robert C. Miller, Richard L. Deming, T. H. Patricia Tai, Kathy J. Stien, James A. Martenson Support Care Cancer vol 21 (4) 1193-1199 2013
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/23151649>
- 61 The Complementary Nature of Patient-Reported Outcomes (PROs) and Adverse Event Reporting in Cooperative Group Oncology Clinical Trials: A Pooled Analysis (NCCTG N0591)**
Pamela J. Atherton, Deborah W. Watkins-Bruner, Carolyn Gotay, Carol M. Moinpour, Daniel V. Satele, Kathryn A. Winter, Paul L. Schaefer, Benjamin Movsas, Jeff A. Sloan J Pain Symptom Manage vol 50 (4) 470-479.e9 2015
Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/26031708>
- 62 Patient Reported Outcomes Questionnaire Compliance in Cancer Cooperative Group Trials (Alliance N0992)**
Pamela J Atherton, Kelli N Burger, Levi D Pederson, Suneetha Kaggal, Jeff A Sloan Clin Trials vol 13 (6) 612-620 2016
Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/27365012>
- 63 Measurement of Affective and Activity Pain Interference Using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903**
Thomas M. Atkinson, Susan Halabi, Antonia V. Bennett, Lauren Rogak, Laura Sit, Yuelin Li, Ellen Kaplan, Ethan Basch Pain Med vol 13 (11) 1417-1424 2012
Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/23110676>
- 64 Comparison Between Clinician- and Patient-Reporting of Baseline (BL) and Post-BL Symptomatic Toxicities in Cancer Cooperative Group Clinical Trials (NCCTG N0591 [Alliance])**
Thomas M. Atkinson, Daniel V. Satele, Jeff A. Sloan, Diana Mehedint, Jackie M. Lafky, Ethan Basch, Amylou C. Dueck J. Clin. Oncol. vol 33 (suppl) abstr 9520 2015
Abstract Health Outcome <http://meetinglibrary.asco.org/content/150688-156>
- 65 Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS) CALGB 100104 (Alliance)**
Michel Attal, Antonio Palumbo, Sarah Holstein, Valérie Lauwers-Cances, Maria Teresa Petrucci, Paul Richardson, Cyrille Hulin, Patrizia Tosi, Kenneth C Anderson, Denis Caillot, Valeria Magarotto, Phillip Moreau, Zhinuan Yu, Philip L. McCarthy J. Clin. Oncol. vol 34 (suppl) abstr 8001 2016
Abstract Myeloma http://abstract.asco.org/176/AbstView_176_168948.html
- 66 Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502**
E. C. Attar, K. A. Donohue, P. C. Amrein, M. Wadleigh, D. J. Deangelo, J. E. Kolitz, B. L. Powell, P. M. Voorhees, E. S. Wang, W. Blum, A. Booth, R. M. Stone, B. K. Moser, R. Larson Blood vol 116 (abstr 331) 2010
Abstract Leukemia
<http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/331?maxtoshow=&hits=10&RESULT>
- 67 A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502.**

E. C. Attar, J. L. Johnson, P. C. Amrein, G. Lozanski, M. Wadleigh, D. J. Deangelo, J. E. Kolitz, B. L. Powell, P. M. Voorhees, E. S. Wang, W. G. Blum, G. Marcucci, C. D. Bloomfield, B. K. Moser, R. M. Stone, R. A. Larson *J. Clin. Oncol.* vol 30 (suppl) abstr 6526 2012

Abstract Leukemia

http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/6526?sid=aa5f32f6-7ed6-4e0e-aa1a-247c9;

68 Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study

E. C. Attar, K. Maharry, K. Mrozek, M. D. Radmacher, S. P. Whitman, P. Paschka, C. Langer, K. B. Holland, B. L. Powell, J. E. Kolitz, A. J. Carroll, R. A. Larson, G. Marcucci, C. D. Bloomfield *Blood* vol 114 (22) 645-646 2009

Abstract *Leuk Corr Sci* CALGB-10502, CALGB-20202, CALGB-20502, CALGB-8461

<http://www.bloodjournal.org/content/114/22/1616>

69 Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502

Eyal C. Attar, Jeffrey L. Johnson, Philip C. Amrein, Gerard Lozanski, Martha Wadleigh, Daniel J. DeAngelo, Jonathan E. Kolitz, Bayard L. Powell, Peter Voorhees, Eunice S. Wang, William Blum, Richard M. Stone, Guido Marcucci, Clara D. Bloomfield, Barry Moser, Richard A. Larson *J. Clin. Oncol.* vol 31 (7) 923-929 2013

Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/23129738>

70 Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance)

Arnaud Augert, Qing Zhang, Breanna Bates, Min Cui, Xiaofei Wang, Gary Wildey, Afshin Dowlati, David MacPherson *J Thorac Oncol* vol 12 (4) 704-713 2017

Manuscript *Sequencing* <http://www.ncbi.nlm.nih.gov/pubmed/28007623>

71 Cytarabine, daunorubicin and etoposide (ADE) chemotherapy in acute myeloid leukemia (AML) patients >= 60 years (CALGB 9720)

M. R. Baer, S. L. George, B. L. Sanford, S. M. Bothun, K. Mrozek, K. L. O'Loughlin, J. E. Kolitz, J. O. Moore, R. M. Stone, B. L. Powell, M. A. Caligiuri, C. D. Bloomfield, R. A. Larson *Blood* vol 110 (11) 94A-94A 2007

Abstract *Leukemia* CALGB-8461, CALGB-9720

<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;110/11/296>

72 Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies

M. R. Baer, S. L. George, B. L. Sanford, R. M. Stone, G. Marcucci, R. J. Mayer, R. A. Larson *J. Clin. Oncol.* vol 28 (15s) abstr 6531 2010

Abstract *Leukemia* C8525, CALGB-10201, CALGB-8923, CALGB-9720

http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.6531

73 Cancer and Leukemia Group B studies of recombinant Interleukin-2 maintenance therapy in acute myeloid leukemia

M. R. Baer, J. E. Kolitz, S. L. George, M. A. Caligiuri, R. A. Larson *Ann Hematol* vol 87 (Supplement 1) S28-S29 2008

Abstract *Leukemia* <http://link.springer.com/content/pdf/10.1007%2Fs00277-008-0443-6>

74 Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720

MR Baer, SL George, BL Sanford, K Mrózek, JE Kolitz, JO Moore, RM Stone, BL Powell, MA Caligiuri, CD Bloomfield, RA Larson *Leukemia* vol 25 (5) 2011
Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/21321569>

75 Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720

Maria R. Baer, Stephen L. George, Michael A. Caligiuri, Ben L. Sanford, Sandra M. Bothun, Krzysztof Mrózek, Jonathan E. Kolitz, Bayard L. Powell, Joseph O. Moore, Richard M. Stone, John Anastasi, Clara D. Bloomfield, Richard A. Larson *J Clin Oncol* vol 26 (30) 4934-4939 2008
Manuscript *Leukemia* CALGB-8461, CALGB-9720, CALGB-9760
<http://www.ncbi.nlm.nih.gov/pubmed/18591543>

76 Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720

Maria R. Baer, Stephen L. George, Michael A. Caligiuri, Ben L. Sanford, Sandra M. Bothun, Krzysztof Mrózek, Jonathan E. Kolitz, Bayard L. Powell, Joseph R. Moore, Richard M. Stone, John Anastasi, Clara D. Bloomfield, Richard A. Larson *J. Clin. Oncol.* vol 26 (30) 4934-4939 2008
Abstract *Leukemia* CALGB-10201, CALGB-10502, CALGB-10503, CALGB-10603, CALGB-19808, CALGB-8525, CALGB-8923, CALGB-9022, CALGB-9222, CALGB-9420, CALGB-9621, CALGB-9720 <http://jco.ascopubs.org/content/26/30/4934.abstract>

77 Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance)

Maria Q. Bagstrom, Mark A. Socinski, Xiaofei F. Wang, Lin Gu, Thomas E. Stinchcombe, Martin J. Edelman, Sherman Baker, Josephine Feliciano, Paul Novotny, Olwen Hahn, Jeffrey A. Crawford, Everett E. Vokes *J Thorac Oncol* vol 12 (5) 843-849 2017
Manuscript *Respiratory* CALGB-30607, CALGB-70701
<http://www.ncbi.nlm.nih.gov/pubmed/28161554>

78 Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).

Dean F Bajorin, Susan Halabi, Eric Small *Clin Genitourin Cancer* vol 7 (3) E66-70 2009
Manuscript *GU* <http://www.ncbi.nlm.nih.gov/pubmed/19815484>

79 A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101

R. Michael Baldwin, Kouros Owzar, Hitoshi Zembutsu, Aparna Chhibber, Michiaki Kubo, Chen Jiang, Dorothy Watson, Rachel J. Eclov, Joel Mefford, Howard L. McLeod, Paula N. Friedman, Clifford A. Hudis, Eric P. Winer, Eric M. Jorgenson, John S. Witte, Lawrence N. Shulman, Yusuke Nakamura, Mark J. Ratain, Deanna L. Kroetz *Clin. Cancer Res.* vol 18 (18) 5099-5109 2012
Manuscript *PPP* <http://www.ncbi.nlm.nih.gov/pubmed/22843789>

80 The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

Karla V. Ballman, Jan C. Buckner, Paul D. Brown, Caterina Giannini, Patrick J. Flynn, Betsy R. LaPlant, Kurt A. Jaeckle *Neuro-oncol* vol 9 (1) 29-38 2007
Manuscript *Neuro-Onc* <http://www.ncbi.nlm.nih.gov/pubmed/17108063>

81 Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of widely used two prognostic calculators

A. Bardia, C. Loprinzi, A. Grothey, G. Nelson, S. Alberts, S. Patiyil, S. Thome, S. Gill, D. Sargent J. Clin. Oncol. vol 27 (15S) e15031 2009
Abstract GI
<http://jco.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B27%2F15S%2Fe15031>

82 Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators

Aditya Bardia, Charles Loprinzi, Axel Grothey, Garth Nelson, Steven Alberts, Smitha Menon, Stephan Thome, Sharlene Gill, Dan Sargent Semin Oncol vol 37 (1) 39-46 2010
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20172363>

83 Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101

Myra Barginear, Amylou C. Dueck, Jacob B. Allred, Craig Bunnell, Harvey J. Cohen, Rachel A. Freedman, Arti Hurria, Gretchen Kimmick, Jennifer G. LeRademacher, Stuart Lichtman, Hyman B. Muss, Lawrence N. Shulman, M. Sitiki Copur, David Biggs, Bhuvanewari Ramaswamy, Jacqueline M. Lafky, Aminah Jatoi Oncologist vol 24 (5) 617-23 2019
Manuscript Older Adult CALGB-40101, CALGB-70301
<http://www.ncbi.nlm.nih.gov/pubmed/30409792>

84 Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

N L Bartlett, D Niedzwiecki, J L Johnson, J W Friedberg, K B Johnson, K van Besien, A D Zelenetz, B D Cheson, G P Canellos Ann. Oncol. vol 18 (6) 1071-9 2007
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/17426059>

85 A phase I/II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin's disease: Preliminary results of CALGB 59804

N. Bartlett, D. Niedzwiecki, J. Johnson, J. W. Friedberg, A. D. Zelenetz, G. P. Canellos Proc Am Soc Clin Oncol vol 22 abstr 2275 2003
Abstract Lymphoma
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=23&abstractID

86 Phase II Study of 9-aminocamptothecin in Previously Treated Lymphomas: Results of Cancer and Leukemia Group B 9551

Nancy L. Bartlett, Jeffrey L. Johnson, Nina Wagner-Johnston, Mark J. Ratain, Bruce A. Peterson Cancer Chemother. Pharmacol. vol 63 (5) 793-798 2009
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/18648813>

87 Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

Nancy L Bartlett, Wyndham H Wilson, Sin-Ho Jung, Eric D Hsi, Matthew J Maurer, Levi D Pederson, Mei-Yin C Polley, Brandelyn N Pitcher, Bruce D Cheson, Brad S Kahl, Jonathan W Friedberg, Louis M Staudt, Nina D Wagner-Johnston, Kristie A Blum, Jeremy S Abramson, Nishitha M Reddy, Jane N Winter, Julie E Chang, Ajay K Gopal, Amy Chadburn, Susan Mathew, Richard I Fisher, Kristy L Richards, Heiko Schöder, Andrew D Zelenetz, John P Leonard J. Clin. Oncol. vol 37(21): (21) 1790-9 2019
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/30939090>

88 The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5)

D. L. Barton, P. J. Atherton, B. A. Bauer, D. F. Jr Moore, B. I. Mattar, B. I. Lavasseur, K. M. Jr

Rowland, R. T. Zon, N. A. Lelindqwister, G. G. Nagargoje, T. I. Morgenthaler, J. A. Sloan, C. L. Loprinzi *J Support Oncol* vol 9 (1) 24-31 2011
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/21399726>

89 Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9

D. L. Barton, B. I. Lavoisier, J. A. Sloan, A. N. Stawis, K. A. Flynn, M. Dyar, D. B. Johnson, P. J. Atherton, B. Diekmann, C. L. Loprinzi *J. Clin. Oncol.* vol 28 (20) 3278-3283 2010
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/20498389>

90 A phase III trial evaluating three doses of citalopram for hot flashes: NCCTG trial N05C9

D. L. Barton, B. Lavoisier, J. A. Sloan, P. J. Stella, K. Flynn, M. Dyar, S. R. Dakhil, P. J. Atherton, B. Diekmann *J. Clin. Oncol.* vol 26 (May 20 supplement) abstr 9538 2008
Abstract Symptom Inter
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

91 Phase III evaluation of American ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N07C2

D. L. Barton, H. Liu, S. R. Dakhil, B. M. Linnquist, J. A. Sloan, C. R. Nichols, T. W. Mcginn, E. P. Balcueva, G. R. Seeger, C. L. Loprinzi *J. Clin. Oncol.* vol 30 (15 supplement) abstr 9001, Oral Abstract Session, Patient and Survivor Care 2012
Abstract Symptom Inter
http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/3514?sid=0055954a-dce9-4db0-b477-d76e

92 Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: A randomized, double-blind trial, N07C2

D. L. Barton, H. Liu, S. R. Dakhil, B. Linnquist, J. A. Sloan, C. R. Nichols, T. W. Mcginn, P. J. Stella, G. R. Seeger, A. Sood, C. L. Loprinzi *J. Natl. Cancer Inst.* vol 105 (15) 1230-8 2013
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/23853057>

93 Long-acting methylphenidate for cancer-related fatigue: NCCTG trial N05C7

D. L. Barton, A. R. Moraska, A. Sood, J. A. Sloan, J. J. Suh, P. C. Griffin, D. B. Johnson, A. A. Ali, P. T. Silberstein, C. L. Loprinzi *J. Clin. Oncol.* vol 28 (supplement) abstr 9004 2010
Abstract Symptom Inter
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

94 Can gabapentin improve control of delayed nausea and vomiting (N/V)? A phase III placebo controlled trial, N08C3 (Alliance)

D. L. Barton, J. A. Sloan, P. J. Novotny, J. Fuloria, L. A. Kottschade, A. P. Lyss, A. J. Jaslowski, M. A. Mazurczak, S. C. Blair, S. A. Terstriep, C. L. Loprinzi *Support Care Cancer* vol 21 (suppl 1) abstr 0562 2013
Abstract Symptom Inter <http://link.springer.com/article/10.1007%2Fs00520-013-1798-3>

95 Does gabapentin prevent delayed chemotherapy-induced nausea and vomiting (N/V)? Results of a randomized placebo controlled trial, NCCTG N08C3 (Alliance)

D. L. Barton, J. A. Sloan, P. J. Novotny, J. Fuloria, L. A. Kottschade, A. P. Lyss, A. J. Jaslowski, M. Mazurczak, S. C. Blair, S. A. Terstriep, C. L. Loprinzi *J. Clin. Oncol.* vol 31 (15, suppl) abstr 9513 2013
Abstract Symptom Inter <http://meetinglibrary.asco.org/content/111391-132>

96 A pilot, multi-dose, placebo-controlled evaluation of american ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N03CA

D. L. Barton, G. S. Soori, B. Bauer, J. Sloan, P. A. Johnson, C. Figueras, S. Duane, S. Dakhil, H. Liu,

C. L. Loprinzi J. Clin. Oncol. vol 25 (18s) abstr 9001 2007
Abstract Symptom Inter
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

97 A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA

D. L. Barton, E. J. Wos, R. Qin, B. I. Mattar, N. B. Green, K. S. Lanier, J. D. 3rd Bearden, J. W. Kugler, K. L. Hoff, P. S. Reddy, K. M. Jr Rowland, M. Riepl, B. Christensen, C. L. Loprinzi Support Care Cancer vol 19 (6) 833-841 2011
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/20496177>

98 A randomized controlled trial evaluating a topical treatment for chemotherapy-induced neuropathy: NCCTG trial N06CA

D. L. Barton, E. Wos, R. Qin, B. Mattar, N. Green, K. Lanier, J. Bearden, J. Kugler, K. Rowland Jr, C. Loprinzi J. Clin. Oncol. vol 27 (15s) abstr 9531 2009
Abstract Symptom Inter
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

99 Adiponectin: A novel biomarker for cancer-related fatigue?; NCCTG study N07C2 (Alliance)

D. Barton, H. Liu, A. Tan, J. Sloan, C. Loprinzi Support Care Cancer vol 21 (suppl 1) abstr 0560 2013
Abstract Symptom Inter <http://link.springer.com/article/10.1007%2Fs00520-013-1798-3>

100 The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9

Debra L. Barton, Kelli Burger, Paul J. Novotny, Tom R. Fitch, Sadhna Kohli, Gamini Soori, Mary Beth Wilwerding, Jeff A. Sloan, Lisa A. Kottschade, Kendrith M. Rowland, Shaker R. Dakhil, Daniel A. Nikcevich, Charles L. Loprinzi Support Care Cancer vol 21 (4) 1185-1192 2013
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/23150188>

101 Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance)

Debra L. Barton, Lynne T. Shuster, Travis Dockter, Pamela J. Atherton, Jacqueline Thielen, Stephen N. Birrell, Richa Sood, Patricia Griffin, Shelby A. Terstriep, Bassam Mattar, Jacqueline M. Lafky, Charles L. Loprinzi Support Care Cancer vol 26 (4) 1335-43 2018
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/29164377>

102 Evaluating the efficacy of vaginal dehydroepiandrosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)

Debra L. Barton, Jeff A. Sloan, Lynne T. Shuster, Paula Gill, Patricia Griffin, Kathleen Flynn, Shelby A. Terstriep, Fauzia N. Rana, Travis Dockter, Pamela J. Atherton, Michaela Tsai, Keren Sturtz, Jacqueline M. Lafky, Mike Riepl, Jacqueline Thielen, Charles L. Loprinzi Support Care Cancer vol 26 (2) 643-650 2018
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/28921241>

103 Impact of vaginal dehydroepiandrosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance)

Debra L. Barton, Jeff A. Sloan, Lynne T Shuster, Paula Gill, James D. Bearden, David B Johnson, Philip J. Stella, Shelby A. Terstriep, Fauzia N. Rana, Daniel M. Anderson, Charles L. Loprinzi J. Clin. Oncol. vol 32 (15_suppl) 9507 2014
Abstract Symptom Inter http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9507

104 Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a

randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA

Debra L. Barton, Gamini S. Soori, Brent A. Bauer, Jeff A. Sloan, Patricia A. Johnson, Cesar Figueras, Steven Duane, Bassam Mattar, Heshan Liu, Pamela J. Atherton, Bradley Christensen, Charles L. Loprinzi Support Care Cancer vol 18 (2) 179-187 2010
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/19415341>

105 Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy, NCCTG N08C3 (Alliance)

Debra L. Barton, Gita Thanarajasingam, Jeff A. Sloan, Brent Diekmann, Jyotsna Fuloria, Lisa A. Kottschade, Alan P. Lyss, Anthony J. Jaslowski, Mirosław A. Mazurczak, Scott C. Blair, Shelby Terstriep, Charles L. Loprinzi Cancer vol 120 (22) 3575-3583 2014
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/25043153>

106 Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3.

Debra L Barton, Donald B Wender, Jeff A Sloan, Robert J Dalton, Ernie P Balcueva, Pamela J Atherton, Albert M Bernath, Wanda L DeKrey, Tim Larson, James D Bearden, Paul C Carpenter, Charles L Loprinzi J. Natl. Cancer Inst. vol 99 (9) 672-9 2007
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/17470735>

107 Addressing the Complexities of Sexual Health in Female Cancer Survivors: NCCTG N10C1 (Alliance)

Debra Barton, Travis Dockter, Pamela Atherton, Joanne Lester, Breanna Weisbrod, Jeff Sloan 2014
Abstract Symptom Inter
https://cans.memberclicks.net/assets/140915_sos%20onsite%20program_final%20lowres.pdf

108 Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials

Ethan Basch, Amylou C. Dueck, Lauren J. Rogak, Lori M. Minasian, William Kevin Kelly, Ann M. O'Mara, Andrea M. Denicoff, Drew Seisler, Pamela J. Atherton, Electra Paskett, Lisa Carey, Maura Dickler, Rebecca S. Heist, Andrew Himmelstein, Hope S. Rugo, William M. Sikov, Mark A. Socinski, Alan P. Venook, Douglas J. Weckstein, Diana E. Lake, David D. Biggs, Rachel A. Freedman, Charles Kuzma, Jeffrey J. Kirshner, Deborah Schrag JAMA Oncol vol 3 (8) 1043-1050 2017
Manuscript Health Outcome CALGB-30607, CALGB-30610, CALGB-40502, CALGB-40503, CALGB-40601, CALGB-70501, CALGB-70604, CALGB-80405, CALGB-90401
<http://www.ncbi.nlm.nih.gov/pubmed/28208174>

109 Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048

Ethan Basch, Amylou C. Dueck, Lauren J. Rogak, Sandra A. Mitchell, Lori M. Minasian, Andrea M. Denicoff, Jennifer K. Wind, Mary C. Shaw, Narre Heon, Qian Shi, Brenda Ginos, Garth D. Nelson, Jeffrey P. Meyers, George J. Chang, Harvey J. Mamon, Martin R. Weiser, Tatjana Kolevska, Bryce B. Reeve, Deborah Watkins Bruner, Deborah Schrag J. Clin. Oncol vol 36 (31) 3120-25 2018
Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/30204536>

110 Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Patients with Hematologic Malignancies Who Relapse following Autologous Transplantation: A Multi-Institutional Prospective Study from the Cancer and Leukemia Group B (CALGB trial 100002)

Asad Bashey, Kouros Owzar, Jeffrey L. Johnson, Peggy S. Edwards, Michael Kelly, Lee-Ann Baxter-Lowe, Steven Devine, Sherif Farag, David Hurd, Edward Ball, Philip McCarthy, John Lister, Thomas C. Shea, Charles Linker Biol. Blood Marrow Transplant. vol 17 (4) 2011
Manuscript Transplant <http://www.ncbi.nlm.nih.gov/pubmed/20674758>

- 111 Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and MicroRNA (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study**
H. Becker, K. Maharry, M. D. Radmacher, D. Margeson, K. Mrozek, S. P. Whitman, Y. Z. Wu, K. H. Metzeler, S. Schwind, K. B. Holland, J. E. Kolitz, A. J. Carroll, M. A. Caligiuri, M. R. Baer, R. A. Larson, G. Marcucci, C. D. Bloomfield *Blood* vol 116 (21) 255-255 2010
Abstract *Leuk Corr Sci* C8525, CALGB-10201, CALGB-19808, CALGB-20202, CALGB-20502, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720
<https://ash.confex.com/ash/2010/webprogram/Paper27627.html>
- 112 NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML)**
H. Becker, G. Marcucci, K. Maharry, D. Margeson, M. D. Radmacher, S. P. Whitman, K. Mrozek, M. R. Baer, R. A. Larson, C. D. Bloomfield, Calgb *J. Clin. Oncol.* vol 27 (15) abstr 7000 2009
Abstract *Leuk Corr Sci* CALGB-10201, CALGB-20202, CALGB-8461, CALGB-9720
<http://meetinglibrary.asco.org/content/37032>
- 113 Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (>= 60 years y) and Younger (< 60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study**
H. Becker, G. Marcucci, K. Maharry, M. D. Radmacher, K. Mrozek, S. P. Whitman, P. Paschka, D. Margeson, Y. Z. Wu, S. Schwind, C. Langer, M. R. Baer, A. J. Carroll, M. A. Caligiuri, J. E. Kolitz, R. A. Larson, C. D. Bloomfield *Blood* vol 114 (22) 138-138 2009
Abstract *Correl Sci NOS* C8525, CALGB-10201, CALGB-19808, CALGB-20202, CALGB-20502, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720
<http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/326?maxtoshow=&hits=10&RESULT>
- 114 CEBPA double mutations impact favorably on the outcome of older adults with wild-type NPM1 cytogenetically normal acute myeloid leukemia and are associated with distinct gene- and microRNA-expression patterns**
H. Becker, G. Marcucci, K. Maharry, M. Radmacher, Y. Wu, K. Mrozek, S. Whitman, D. Margeson, K. Holland, S. Schwind, K. Metzeler, B. Powell, T. Carter, J. Kolitz, M. Wetzler, A. Carroll, M. Baer, J. O. Moore, M. Caligiuri, R. Larson, C. Bloomfield *Haematologica* vol 95(suppl. 2) 247 abstr 593 2010
Abstract *Leuk Corr Sci* C8525, CALGB-10201, CALGB-20202, CALGB-20502, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9665, CALGB-9720
<http://online.haematologica.org/EHA15/browserecord.php?-action=browse&-recid=6663>
- 115 Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8**
Heiko Becker, Kati Maharry, Krzysztof Mrózek, Stefano Volinia, Ann-Kathrin Eisfeld, Michael D. Radmacher, Jessica Kohlschmidt, Klaus H. Metzeler, Sebastian Schwind, Susan P. Whitman, Jason H. Mendler, Yue-Zhong Wu, Deedra Nicolet, Peter Paschka, Bayard L. Powell, Thomas H. Carter, Meir Wetzler, Jonathan E. Kolitz, Andrew J. Carroll, Maria R. Baer, Michael A. Caligiuri, Richard M. Stone, Guido Marcucci, Clara D. Bloomfield *Leukemia* vol 28 (8) 1754-1758 2014
Manuscript *Leuk Corr Sci* C8525, CALGB-10201, CALGB-10502, CALGB-10503, CALGB-10603, CALGB-19808, CALGB-8923, CALGB-9022, CALGB-9222, CALGB-9420, CALGB-9621, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/24651097>
- 116 Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study**

Heiko Becker, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Klaus H. Metzeler, Susan P. Whitman, Sebastian Schwind, Jessica Kohlschmidt, Yue-Zhong Wu, Bayard L. Powell, Thomas H. Carter, Jonathan E. Kolitz, Meir Wetzler, Andrew J. Carroll, Maria R. Baer, Joseph O. Moore, Michael A. Caligiuri, Richard A. Larson, Guido Marcucci, Clara D. Bloomfield *Haematologica* vol 96 (10) 1488-95 2011

Manuscript *Leuk Corr Sci* C8525, CALGB-10201, CALGB-19808, CALGB-20202, CALGB-20502, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720
<http://www.ncbi.nlm.nih.gov/pubmed/21659357>

117 Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Heiko Becker, Guido Marcucci, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Dean Margeson, Susan P. Whitman, Peter Paschka, Kelsi B. Holland, Sebastian Schwind, Yue-Zhong Wu, Bayard L. Powell, Thomas H. Carter, Jonathan E. Kolitz, Meir Wetzler, Andrew J. Carroll, Maria R. Baer, Joseph O. Moore, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield *Blood* vol 116 (5) 788-792 2010

Manuscript *Leuk Corr Sci* C8525, CALGB-10201, CALGB-19808, CALGB-20202, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720
<http://www.ncbi.nlm.nih.gov/pubmed/20442368>

118 Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

Heiko Becker, Guido Marcucci, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Dean Margeson, Susan P. Whitman, Yue-Zhong Wu, Sebastian Schwind, Peter Paschka, Bayard L. Powell, Thomas H. Carter, Jonathan E. Kolitz, Meir Wetzler, Andrew J. Carroll, Maria R. Baer, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield *J Clin Oncol* vol 28 (4) 596-604 2010

Manuscript *Leuk Corr Sci* CALGB-10201, CALGB-19808, CALGB-20202, CALGB-8461, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/20026798>

119 Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy

Himisha Beltran, Alexander W Wyatt, Edmund C Chedgy, Adam Donoghue, Matti Annala, Evan W Warner, Kevin Beja, Michael Sigouros, Fan Mo, Ladan Fazli, Colin C Collins, James Eastham, Michael Morris, Mary-Ellen Taplin, Andrea Sboner, Susan Halabi, Martin E Gleave *Clin. Cancer Res.* vol 23 (22) 6802-6811 2017

Manuscript *GU* <http://www.ncbi.nlm.nih.gov/pubmed/28842510>

120 Evaluation of mode equivalence of the MSKCC Bowel Function Instrument, LASA Quality of Life, and Subjective Significance Questionnaire items administered by Web, interactive voice response system (IVRS), and paper

Antonia V. Bennett, Kathleen Keenoy, Marwan Shouery, Ethan Basch, Larissa K. Temple *Qual Life Res* vol 25 (5) 1123-1130 2016

Manuscript *Health Outcome* <http://www.ncbi.nlm.nih.gov/pubmed/26590838>

121 Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).

Emily K. Bergsland, Michelle R. Mahoney, Timothy R. Asmis, Nathan Hall, Priya Kumthekar, Michael L. Maitland, Donna Niedzwiecki, Andrew B. Nixon, Eileen Mary O'Reilly, Lawrence Howard Schwartz, Jeff A. Sloan, Jonathan Strosberg, Jeffrey A. Meyerhardt *J Clin Oncol* vol 37 (Suppl) abstr 4005 2019

Abstract *GI* http://abstracts.asco.org/239/AbstView_239_247995.html

- 122 Adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression: patient-reported outcomes in the TEXT and SOFT randomised trials**
Jürg Bernhard, Weixiu Luo, Karin Ribí, Marco Colleoni, Harold J. Burstein, Carlo Tondini, Graziella Pinotti, Simon Spazzapan, Thomas Ruhstaller, Fabio Puglisi, Lorenzo Pavesi, Vani Parmar, Meredith M. Regan, Olivia Pagani, Gini F. Fleming, Prudence A. Francis, Karen N. Price, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Barbara A. Walley *Lancet Oncol.* vol 16 (7) 848-58 2015
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26092816>
- 123 High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials**
D. A. Berry, N. T. Ueno, M. M. Johnson, X. Lei, V. Lopez, J. Caputo, M. Bregni, T. Demirer *Breast Cancer Res. Treat.* vol 106 (S5-S5) 2007
Abstract Breast <http://www.springerlink.com/content/kx32107830v15316/fulltext.pdf>
- 124 High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials**
Donald A. Berry, Naoto T. Ueno, Marcella M. Johnson, Xiudong Lei, Jean Caputo, Sjoerd Rodenhuis, William P. Peters, Robert C. Leonard, William E. Barlow, Martin S. Tallman, Jonas Bergh, Ulrike A. Nitz, Alessandro M. Gianni, Russell L. Bassar, Axel R. Zander, R. Charles Coombes, Henri Roché, Yutaka Tokuda, Elisabeth G.E. de Vries, Gabriel N. Hortobagyi, John P. Crown, Paolo Pedrazzoli, Marco Bregni, Taner Demirer *J. Clin. Oncol* vol 29 (24) 3214-3223 2011
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/21768471>
- 125 Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581**
M. M. Bertagnolli, D. Niedzwiecki, M. Hall, S. D. Jewell, R. J. Mayer, R. M. Goldberg, T. A. Colacchio, R. S. Warren, M. Redston *J. Clin. Oncol.* vol 27 (15s) abstr 4012 2009
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=65&abstractID=
- 126 Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803**
Monica M. Bertagnolli, Donna Niedzwiecki, Carolyn C. Compton, Hejin P. Hahn, Margaret Hall, Beatrice Damas, Scott D. Jewell, Robert J. Mayer, Richard M. Goldberg, Leonard B. Saltz, Robert S. Warren, Mark Redston *J Clin Oncol* vol 27 (11) 1814-1821 2009
Manuscript GI C89803, C150705 <http://www.ncbi.nlm.nih.gov/pubmed/19273709>
- 127 Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer—A Study of CALGB 9581 and 89803**
Monica M. Bertagnolli, Mark Redston, Carolyn C. Compton, Donna Niedzwiecki, Robert J. Mayer, Richard M. Goldberg, Thomas A. Colacchio, Leonard B. Saltz, Robert S. Warren *J Clin Oncol* vol 29 (23) 3153-3162 2011
Manuscript GI C89803, C9581, C150705 <http://www.ncbi.nlm.nih.gov/pubmed/21747089>
- 128 p27Kip1 in Stage III Colon Cancer: Implications for Outcome Following Adjuvant Chemotherapy in CALGB 89803**
Monica M. Bertagnolli, Robert S. Warren, Donna Niedzwiecki, Elke Mueller, Carolyn C. Compton, Mark Redston, Margaret Hall, Hejin P. Hahn, Scott D. Jewell, Robert J. Mayer, Richard M. Goldberg, Leonard B. Saltz, Massimo Loda *Clin Cancer Res* vol 15 2116-2122 2009
Manuscript GI C89803, C150705 <http://www.ncbi.nlm.nih.gov/pubmed/19276255>

- 129 Effect of age on the pharmacokinetics of busulfan (Bu): An Alliance study.**
J. H. Beumer, L. D. Lewis, K. Owzar, C. Jiang, J. L. Holleran, S. M. Christner, W. G. Blum, S. M. Devine, J. E. Kolitz, C. A. Linker, R. A. Larson, M. J. Ratain, M. J. Egorin *J. Clin. Oncol.* vol 30 (15 suppl) abstr 2533 2012
Abstract PPP CALGB-10503, CALGB-19808, CALGB-100103
http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/2533?sid=5342c90d-7d4e-467b-ae5d-6d23
- 130 Effect of Age on the Pharmacokinetics of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation; an Alliance study (CALGB 10503, 19808, and 100103)**
Jan H. Beumer, Kouros Owzar, Lionel D. Lewis, Chen Jiang, Julianne L. Holleran, Susan M. Christner, William Blum, Steven Devine, Jonathan E. Kolitz, Charles Linker, Ravi Vij, Edwin P Alyea, Richard A. Larson, Mark J. Ratain, Merrill J. Egorin *Cancer Chemother. Pharmacol.* vol 74 (5) 927-938 2014
Manuscript PPP C19808, CALGB-100103, CALGB-10503
<http://www.ncbi.nlm.nih.gov/pubmed/25163570>
- 131 Sequencing symptom control: Results from the Alliance N08C1 and N08CA genetics of chemotherapy neuropathy trials**
A. S. Beutler, A. Kulkarni, R. Kanwar, R. Qin, J. M. Cunningham, T. M. Therneau, C. L. Loprinzi
AACR 2013 Annual Meeting abstr LB-196 2013
Abstract Symptom Inter N08C1, N08CA
<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=d4332bf8-005b-4cb2-a378-921ae478208>
- 132 Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy**
Andreas S. Beutler, Amit A. Kulkarni, Rahul Kanwar, Christopher J. Klein, Terry M. Therneau, Rui Qin, Michaela S. Banck, Ganesh K. Boora, Kathryn J. Ruddy, Yanhong Wu, Regenia L. Smalley, Julie M. Cunningham, Nguyet Anh Le-Lindqwister, Peter Beyerlein, Gary P. Schroth, Anthony J. Windebank, Stephan Züchner, Charles L. Loprinzi *Ann. Neurol.* vol 76 (5) 727-737 2014
Manuscript Symptom Inter N08C1, N08CA <http://www.ncbi.nlm.nih.gov/pubmed/25164601>
- 133 An intensive sequenced adjuvant chemotherapy regimen for breast cancer.**
S Bhardwaj, J F Holland, L Norton *Cancer Invest.* vol 11 (1) 6-9 1993
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/8422597>
- 134 Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3)**
B Bhatnagar, JS Blachly, J Kohlschmidt, A-K Eisfeld, S Volinia, D Nicolet, AJ Carroll, AW Block, JE Kolitz, RM Stone, K Mrózek, JC Byrd, CD Bloomfield *Leukemia* vol 30 (7) 1586-1589 2016
Manuscript Leuk Corr Sci C8461, CALGB-20202, C8525, CALGB-10102, CALGB-10201, CALGB-10503, CALGB-10603, CALGB-11002, CALGB-19808, CALGB-8923, CALGB-9120, CALGB-9222, CALGB-9621, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/26669971>
- 135 Acute myeloid leukemia (AML) patients with an isolated trisomy display increased frequency of spliceosome mutations CALGB 8461 and 20202 (Alliance)**
Bhavana Bhatnagar, Ann-Kathrin Eisfeld, Krzysztof Mrózek, Jessica Kohlschmidt, Deedra Nicolet, Jonathan Kolitz, Bayard L. Powell, John C. Byrd, Clara D. Bloomfield *Blood* vol 130 (Suppl 1) 2691 2017
Abstract Leuk Corr Sci CALGB-20202, CALGB-8461
http://www.bloodjournal.org/content/130/Suppl_1/2691
- 136 Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia**
Bhavana Bhatnagar, Ann-Kathrin Eisfeld, Deedra Nicolet, Krzysztof Mrózek, James S. Blachly,

Shelley Orwick, David M. Lucas, Jessica Kohlschmidt, William Blum, Jonathan E. Kolitz, Richard M. Stone, Clara D. Bloomfield, John C. Byrd Br. J. Haematol. vol 175 (2) 226-236 2016
Manuscript Leuk Corr Sci CALGB-20202, CALGB-10201, CALGB-10502, CALGB-10503,
CALGB-10603, CALGB-19808, CALGB-9222, CALGB-9621, CALGB-9720
<http://www.ncbi.nlm.nih.gov/pubmed/27476855>

137 Discovery of SNPs associated with chemotherapy-induced peripheral neuropathy (CIPN) using model estimated parameters as phenotypes CALGB 40502 (Alliance)

Jiraganya Bhongsatiern, P. Carbonetto, Katherina C. Chua, S. Mehrotra, P.D. Evans, E.R. Gamazon, Hope Rugo, D.L. Kroetz, Jogarao V. Gobburu, Mark J. Ratain, N.J. Cox, Manish R. Sharma
CLINICAL PHARMACOLOGY & THERAPEUTICS vol 103 (Suppl S1) S25 2018
Abstract PPP <https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.993>

138 Mutational Landscape and Clinical Outcome Associated with Different Rearrangements Involving 11q23/MLL in De Novo Acute Myeloid Leukemia (AML) CALB 8461 and 20202 (Alliance)

Marius Bill, Einfeld Ann-Kathrin, Mrózek Krzysztof, Jessica Kohlschmidt, Nicolet Deedra, Christopher J. Walker, James S. Blachly, Andrew J. Carroll, J Kolitz, Bayard L. Powell, Eunice S. Wang, Richard M. Stone, Albert de la Chapelle, John C. Byrd, Clara D. Bloomfield Blood vol 130 (Suppl 1) 3960 2017
Abstract Leuk Corr Sci CALGB-20202, CALGB-8461
http://www.bloodjournal.org/content/130/Suppl_1/3960

139 Prognostic impact of the 2017 European Leukemianet (ELN) classification of adult patients (pts) with acute myeloid leukemia (AML) treated on Cancer and Leukemia Group B (CALGB)/Alliance protocols

Marius Bill, K Mrózek, J. Kohlschmidt, D. Nicolet, A.-K. Einfeld, D. Papaioannou, J.E. Kolitz, B.L. Powell, A.J. Carroll, J.C. Byrd, C.D. Bloomfield HemaSphere vol 3 (Issue) 68–69 2019
Abstract Leuk Corr Sci C8461, CALGB-20202, CALGB-9665
https://journals.lww.com/hemasphere/Fulltext/2019/06001/PROGNOSTIC_IMPACT_OF_THE_2017_E

140 A 17-gene leukemia stem cell (LSC) score in adult patients (pts) with acute myeloid leukemia (AML) reveals a distinct mutational landscape and refines current European Leukemianet (ELN) genetic risk stratification (Alliance)

Marius Bill, Deedra Nicolet, Ann-Kathrin Einfeld, Krzysztof Mrózek, Christopher J. Walker, Jessica Kohlschmidt, Dimitrios Papaioannou, Jonathan E. Kolitz, Bayard L. Powell, John C Byrd, Ramiro Garzon, Clara D. Bloomfield Blood vol 132 (Suppl 1) 289 2018
Abstract Leuk Corr Sci CALGB-20202, CALGB-8461
http://www.bloodjournal.org/content/132/Suppl_1/289

141 Prognostic and biologic significance of transfer RNA-derived small RNAs(tsRNAs) expression in younger adult patients (pts) with cytogenetically normal acute myeloid leukemia (CN-AML)

Marius Bill, Dario Veneziano, Jessica Kohlschmidt, Krzysztof Mrózek, Giovanni Nigita, Maria G. Krantz, Deedra Nicolet, Dimitrios Papaioannou, Allison E. Walker, Zachary Brannan, Bayard L. Powell, Richard M. Stone, Geoffrey L. Uy, Jonathan E. Kolitz, Eunice S. Wang, Adrienne M. Dorrance, John Byrd, Carlo M. Croce, Ramiro Garzon, Clara D. Bloomfield Blood vol 132 (Suppl 1) 89 2018
Abstract Leuk Corr Sci C8461, C9665, CALGB-20202
http://www.bloodjournal.org/content/132/Suppl_1/89?sso-checked=true

142 Perioperative Patient Reported Outcomes Predict Serious Postoperative Complications: A Secondary Analysis of the COST Trial

Juliane Bingener, Jeff A. Sloan, Paul J. Novotny, Barbara A. Pockaj, Heidi Nelson J. Gastrointest. Surg. vol 19 (1) 65-71 2015

- 143 Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105**
A. W. Blackstock, M. A. Socinski, J. Bogart, L. Gu, X. Wang, M. Green, E. E. Vokes J. Clin. Oncol. vol 24 (18s) abstr 7042 2006
Abstract Respiratory http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/7042
- 144 Impact of young (Y) age on efficacy and safety in advanced colorectal cancer (aCRC): A pooled analysis examining 6,286 patients (pts) from nine first-line phase III chemotherapy (CT) trials**
C. D. Blanke, B. M. Bot, D. M. Thomas, A. Bleyer, C. Kohne, M. T. Seymour, A. De Gramont, R. M. Goldberg, D. J. Sargent, LIVESTRONG Young Adult Alliance (LSYAA) J. Clin. Oncol. vol 28 (15s) abstr 3520 2010
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID
- 145 Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials**
Charles D. Blanke, Brian M. Bot, David M. Thomas, Archie Bleyer, Claus-Henning Kohne, Matthew T. Seymour, Aimery de Gramont, Richard M. Goldberg, Daniel J. Sargent J. Clin. Oncol vol 29 (20) 2781-2786 2011
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21646604>
- 146 Meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer.**
H. Bleiberg, D. J. Sargent J. Clin. Oncol. vol 29 (suppl) abstr 4109 2011
Abstract GI NCCTG-79-41-51, NCCTG-83-41-51 <http://meetinglibrary.asco.org/content/83472-102>
- 147 Alliance A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma**
Orin Bloch, Qian Shi, S. Keith Anderson, Michael Knopp, Jeffrey Raizer, Jennifer Clarke, Allen Waziri, Howard Colman, Jeffrey Bruce, Jeffrey Olson, John Schwerkoske, Andrew Parsa, Joon Uhm, Priya Kumthekar, Evanthia Galanis, Ian Parney Neuro-Oncology vol 19 (suppl 6) abstr ATIM-14. 2017
Abstract Neuro-Onc
https://watermark.silverchair.com/nox168.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9
- 148 Cognitive Function and Discontinuation of Adjuvant Hormonal Therapy in Older Breast Cancer Survivors: CALGB 369901 (Alliance)**
Shirley M. Bluethmann, Catherine M. Alfano, Jonathan D. Clapp, George Luta, Brent J. Small, Arti Hurria, Harvey J. Cohen, Steven Sugarman, Hyman Muss, Claudine Isaacs, Jeanne S. Mandelblatt Breast Cancer Res. Treat. vol 165 (3) 677-686 2017
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/28653250>
- 149 Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502**
K. A. Blum, J. L. Johnson, S.-H. Jung, B. D. Cheson, N. L. Bartlett Blood vol 112 (11) 232 2008
Abstract Lymphoma <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;112/11/232>
- 150 Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine,**

vinorelbine, and liposomal doxorubicin is associated with an FcRIIIa-158 V/F polymorphism

K. A. Blum, S.-H. Jung, J. L. Johnson, T. S. Lin, E. D. Hsi, D. M. Lucas, J. C. Byrd, B. D. Cheson, N. L. Bartlett *Ann Oncol* vol 21 (11) 2246-54 2010
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/20423913>

151 Randomized phase 2 trial of ofatumumab and bendamustine versus ofatumumab, bendamustine and bortezomib induction and maintenance therapy in patients (pts) with previously untreated high risk follicular lymphoma (FL): results from CALGB 50904 (Alliance)

Kristie A. Blum, Sin-Ho Jung, Ian Barak, Eric D. Hsi, Nancy L. Bartlett, James N. Atkins, Nina Wagner-Johnston, Eric Hsi, Bruce D. Cheson, John P. Leonard *Blood* vol 130 (Suppl 1) 485 2017
Abstract Lymphoma http://www.bloodjournal.org/content/130/Suppl_1/485

152 Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

Kristie A Blum, Jeffrey L Johnson, Donna Niedzwiecki, George P Canellos, Bruce D Cheson, Nancy L Bartlett *Leuk. Lymphoma* vol 48 (7) 1313-9 2007
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/17613759>

153 Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.

Kristie A Blum, Jeffrey L Johnson, Donna Niedzwiecki, Lawrence D Piro, Alan Saven, Bruce A Peterson, John C Byrd, Bruce D Cheson *Cancer* vol 107 (12) 2817-25 2006
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/17120198>

154 Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).

Kristie A Blum, Mei-Yin Polley, Sin-Ho Jung, Travis J Dockter, Sarah Anderson, Eric D Hsi, Nina Wagner-Johnston, Beth Christian, Jim Atkins, Bruce D Cheson, John P Leonard, Nancy L Bartlett *Cancer* 2019
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/31174236>

155 Challenges for conducting clinical trials evaluating maintenance chemotherapy in acute myeloid leukemia (AML): a Cancer and Leukemia Group B (CALGB) study

W. Blum, K. Donohue, G. Marcucci, D. J. Deangelo, G. L. Uy, B. L. Powell, W. Stock, M. Baer, J. E. Kolitz, M. Wetzler, E. Hoke, B. K. Moser, R. A. Larson *Blood* vol 116 (21) 2176 2010
Abstract Leukemia <http://www.bloodjournal.org/content/116/21/2176>

156 Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)

W. Blum, B. Sanford, R. B. Klisovic, D. J. Deangelo, G. Uy, B. L. Powell, W. Stock, M. R. Baer, J. E. Kolitz, M. Wetzler, E. Hoke, C. D. Bloomfield, S. Geyer, G. Marcucci, R. M. Stone, R. A. Larson *Blood* vol 120 (21) -44 2012
Abstract Leukemia <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/44>

157 Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503)

William Blum, Ben L. Sanford, Rebecca Klisovic, Daniel J. DeAngelo, Geoffrey Uy, Bayard L. Powell, Wendy Stock, Maria R. Baer, Jonathan E. Kolitz, Eunice S. Wang, Eva Hoke, Krzysztof Mrózek, Jessica Kohlschmidt, Clara D. Bloomfield, Susan Geyer, Guido Marcucci, Richard M. Stone, Richard A. Larson *Leukemia* vol 31 (1) 34-39 2017
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/27624549>

- 158 Accelerated conformal radiotherapy for stage I non-small cell lung cancer (NSCLC) in patients with pulmonary dysfunction: A CALGB phase I study.**
J. Bogart, D. Watson, S. Seagren, W. Blackstock, X. Wang, R. Lenox, E. Vokes, A. T. Turrisi 3rd, M. R. Green J. Clin. Oncol. vol 25 (18S (June 20 Supplement)) 7556 2007
Abstract Respiratory http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID
- 159 Phase I Study of Accelerated Conformal Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Patients With Pulmonary Dysfunction: CALGB 39904**
Jeffrey A. Bogart, Lydia Hodgson, Stephen L. Seagren, A. William Blackstock, Xiaofei Wang, Robert Lenox, Andrew T. Turrisi, John Reilly, Ajeet Gajra, Everett E. Vokes, Mark R. Green J Clin Oncol vol 28 (2) 202-206 2010
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/19933904>
- 160 Interruptions Of Once-Daily Thoracic Radiotherapy Do Not Correlate With Outcomes In Limited Stage Small Cell Lung Cancer: Analysis of CALGB Phase III Trial 9235**
Jeffrey A. Bogart, Dorothy Watson, Edward F. McClay, Lisa Evans, James E. Herndon, Frances Laurie, Stephen L Seagren, T.J Fitzgerald, Everett Vokes, Mark R Green Lung Cancer vol 62 (1) 92-98 2008
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18367288>
- 161 Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52**
J. S. Bolton, M. J. O'Connell, M. R. Mahoney, G. H. Jr Farr, T. R. Fitch, W. J. Maples, D. M. Nagorney, J. Rubin, J. Fuloria, P. D. Steen, S. R. Alberts Clin Colorectal Cancer vol 11 (1) 31-37 2012
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21729678>
- 162 Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis.**
H Jacob Bonjer, Wim C J Hop, Heidi Nelson, Daniel J Sargent, Antonio M Lacy, Antoni Castells, Pierre J Guillou, Helen Thorpe, Julia Brown, Salvadora Delgado, Esther Kuhrij, Eva Haglind, Lars Pahlman Arch Surg vol 142 (3) 298-303 2007
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17372057>
- 163 Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance)**
Ganesh K. Boora, Rahul Kanwar, Amit A. Kulkarni, Alexej Abyzov, Jeff Sloan, Kathryn J. Ruddy, Michaela S. Banck, Charles L. Loprinzi, Andreas S. Beutler Cancer Med vol 5 (4) 631-639 2016
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/26763541>
- 164 Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance)**
Ganesh K. Boora, Amit A. Kulkarni, Rahul Kanwar, Peter Beyerlein, Rui Qin, Michaela S. Banck, Kathryn J. Ruddy, Josef Pleticha, Cynthia A. Lynch, Robert J. Behrens, Stephan Züchner, Charles L. Loprinzi, Andreas S. Beutler J. Neurol. Sci. vol 357 (0) 35-40 2015
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/26143528>
- 165 Phase IB study of sorafenib + evofosfamide in patients with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma NCCTG N1153 (Alliance)**
Mitesh J. Borad, Nathan R. Foster, Peter R. Martin, Steven Alberts, Joleen Hubbard, Alvin Silva, Thorvardur Halfdanarson, Charles Erlichman Ann. Oncol. vol 27 (2) abstr P-100 2016
Abstract Experimental http://annonc.oxfordjournals.org/content/27/suppl_2/ii29.4.short?rss=1

- 166 Activating Mutations in PIK3CA or AKT1 in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)**
A. Boudreau, C. Yau, L. Petrillo, K. Stemke-Hale, G. Mills, J. W. Gray, D. M. Wolf, L. J. Van't Veer, L. J. Esserman *Cancer Res.* vol 71 (24 Supplement 3) abstr P5-01-05 2011
Abstract *Correl Sci NOS ACRIN-6657, CALGB-150007*
http://cancerres.aacrjournals.org/content/71/24_Supplement/P5-01-05?cited-by=yes&legid=canres;71/24
- 167 Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071**
J. C. Boughey, V. J. Suman, E. A. Mittendorf, G. M. Ahrendt, L. G. Wilke, B. Taback, A. Leitch, T. S. Flippo-Morton, D. R. Byrd, D. W. Ollila, T. B. Julian, S. A. McLaughlin, K. Hunt *Annals of Surgical Oncology* vol 20 (suppl 1) S8-S9 2013
Abstract *Breast* <http://www.annsurgoncol.org/journals/articlelist.html?v=20&j=10434&i=1&t=s>
- 168 The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from the ACOSOG Z1071 trial**
J. Boughey, V. Suman, E. Mittendorf, G. Ahrendt, L. Wilke, B. Taback, A. Leitch, T. Flippo-Morton, D. Byrd, D. Ollila, T. Julian, S. McLaughlin, L. McCall, W. Symmans, H. Le-Petross, B. Haffty, T. Buchholz, K. Hunt *Cancer Res.* vol 72 (24 suppl) Abstract nr S2-1 2012
Abstract *Breast*
http://cancerres.aacrjournals.org/cgi/content/short/72/24_MeetingAbstracts/S2-1?rss=1
- 169 Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance)**
Judy C. Boughey, Karla V. Ballman, Kelly K. Hunt, Linda M. McCall, Elizabeth A. Mittendorf, Gretchen M. Ahrendt, Lee G. Wilke, Huong T. Le-Petross *J. Clin. Oncol* vol 33 (30) 3386-3393 2015
Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/25646192>
- 170 Identification and resection of the clipped node decreases the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from ACOSOG Z1071 (Alliance)**
Judy C. Boughey, Karla V. Ballman, Huong T. Le-Petross, Linda M. McCall, Elizabeth A. Mittendorf, Gretchen M. Ahrendt, Lee G. Wilke, Bret Taback, Eric C. Feliberti, Kelly K. Hunt *Ann. Surg.* vol 263 (4) 802-807 2016
Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/26649589>
- 171 Tumor Biology and Response to Chemotherapy Impact Breast Cancer-Specific Survival in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Long-term Follow-up from ACOSOG Z1071 (Alliance)**
Judy C. Boughey, Karla V. Ballman, Linda M. McCall, Elizabeth A. Mittendorf, W. Fraser Symmans, Thomas B. Julian, David Byrd, Kelly K. Hunt *Ann. Surg.* vol 266 (4) 667-676 2017
Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/28657941>
- 172 Methods impacting the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4,N1-2) who receive neoadjuvant chemotherapy–results from a prospective trial–ACOSOG Z1071 (Alliance)**
Judy C. Boughey, Karla V. Ballman, William F. Symmans, Linda M. McCall, Elizabeth A. Mittendorf, Gretchen M. Ahrendt, Lee G. Wilke, Bret Taback, Kelly K. Hunt *Cancer Res* vol 75 (9 Supplement) abstr P2-01-02 2015
Abstract *Breast* http://cancerres.aacrjournals.org/content/75/9_Supplement/P2-01-02.short?rss=1

173 Axillary Ultrasound after Neoadjuvant Chemotherapy in Patients Presenting with Node-Positive Breast Cancer (T0-T4, N1-2, M0) and its Impact on Sentinel Lymph Node Surgery in ACOSOG Z1071 (Alliance)

Judy C. Boughey, Karla Ballman, Kelly K. Hunt, Linda M. McCall, Elizabeth A. Mittendorf, Gretchen M. Ahrendt, Lee G. Wilke, Huong T. Le-Petross *Journal of the Senologic International Society* vol 2 (2) 40 (abstr SIS-0891) 2014

Abstract Breast <http://www.sisjournal.org/index.php/sisjournal/article/view/553>

174 Tumor biology and response to chemotherapy impact breast cancer specific survival in node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection: Results from ACOSOG Z1071 (Alliance)

Judy C. Boughey, Karla Ballman, Linda McCall, David Byrd, Thomas Julian, Elizabeth Mittendorf, Kelly K. Hunt 2017

Abstract Breast <http://meeting.americansurgical.org/abstracts/2017/29.cgi>

175 Factors associated with lymphedema in patients/women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection on a prospective clinical trial (Alliance) ACOSOG Z1071

Judy C. Boughey, Karla Ballman, Linda McCall, Henry Kuerer, Kelly K. Hunt, Jane M. Armer *J Clin Oncol* vol 36 (no. 15_suppl) 513-513 2018

Abstract Breast https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.513

176 Predictors of locoregional recurrence after neoadjuvant chemotherapy and surgery for node positive breast cancer: Results from ACOSOG Z1071 (Alliance)

Judy C. Boughey, Karla Ballman, Linda McCall, Elizabeth Mittendorf, Kelly Hunt *Cancer Res.* vol 77 (Suppl 4) Abstract nr P6-09-01 2017

Abstract Breast http://cancerres.aacrjournals.org/content/77/4_Supplement/P6-09-01

177 Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial

Judy C. Boughey, Linda M. McCall, Karla V. Ballman, Elizabeth A. Mittendorf, Gretchen M. Ahrendt, Lee G. Wilke, Bret Taback, A. Marilyn Leitch, Teresa Flippo-Morton, Kelly K. Hunt *Ann. Surg.* vol 260 (4) 608-616 2014

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25203877>

178 Effect of the use of immediate reconstruction on the rates of bilateral mastectomy and adjuvant radiation therapy use in women with node-positive breast cancer treated with neoadjuvant chemotherapy on ACOSOG Z1071 (Alliance).

Judy C. Boughey, Linda McCall, Bruce Haffty, Tom Buchholz, Elizabeth A. Mittendorf, Karla Ballman, Kelly K. Hunt *J. Clin. Oncol.* vol 33 (suppl) abstr 1060 2015

Abstract Breast http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1060

179 Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance)

Judy C. Boughey, Vera J. Suman, Elizabeth A. Mittendorf, Gretchen M. Ahrendt, Lee G. Wilke, Bret Taback, A. Marilyn Leitch, Teresa S. Flippo-Morton, Henry M. Kuerer, Monet Bowling, Kelly K. Hunt *Ann. Surg.* vol 261 (3) 547-552 2015

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25664534>

180 Sentinel Lymph Node Surgery after Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The American College of Surgeons Oncology Group (ACOSOG) Z1071 Clinical Trial

Judy C. Boughey, Vera J. Suman, Elizabeth A. Mittendorf, Gretchen M. Ahrendt, Lee G. Wilke, Bret

Taback, A. Marilyn Leitch, Henry M. Kuerer, Monet Bowling, Teresa S. Flippo-Morton, David R. Byrd, David W. Ollila, Thomas B. Julian, Sarah A. McLaughlin, Linda McCall, W. Fraser Symmans, Huong T. Le-Petross, Bruce G. Haffty, Thomas A. Buchholz, Heidi Nelson, Kelly K. Hunt JAMA vol 310 (14) 1455-1461 2013
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/24101169>

181 Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer; Results from CALGB 159902

Alice M. Boylan, Xiaofei F Wang, Richard Ko, Patricia M Watson, Lin Gu, David Harpole, Raphael Bueno, Leslie Kohman, Robert Kratzke J. Thorac. Cardiovasc. Surg. vol 146 (1) 206-211 2013
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/23026566>

182 LACE-Bio: validation of prognostic role of tumour lymphocytic infiltration in resectable non small cell lung cancer

E. Brambilla, C. Domerg, S. Lantuejoul, R. Kratzke, F.A. Sheperd, R. Pirker, J.Y. Douillard, T. Le Chevalier, A. Dunant, M Tsao J Thorac Oncol vol 7 (6) S29 2012
Abstract Respiratory <http://journals.lww.com/jto/Fulltext/2012/06001/Abstracts.6.aspx>

183 LACE-Bio: results of pooled analysis of prognostic and predictive values of histology and lymphocytic infiltration

E. Brambilla, M. Tsao, E. Paris, S. Lantuejoul, S. L. Graziano, F. A. Shepherd, M. Filipits, R. Rosell, J. C. Soria, J. P. Pignon Ann. Oncol. vol 21 (suppl 8, viii130) abstr 388P 2010
Abstract Respiratory http://annonc.oxfordjournals.org/content/21/suppl_8/viii122.full.pdf+html

184 Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer

Elisabeth Brambilla, Gwénaél Le Teuff, Sophie Marguet, Sylvie Lantuejoul, Ariane Dunant, Stephen Graziano, Robert Pirker, Jean-Yves Douillard, Thierry Le Chevalier, Martin Filipits, Rafael Rosell, Robert Kratzke, Helmut Popper, Jean-Charles Soria, Frances A. Shepherd, Lesley Seymour, Ming Sound Tsao J. Clin. Oncol vol 34 (11) 1223-1230 2016
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/26834066>

185 Development of Clinical Precision Medicine Approaches in Meningiomas: Alliance A071401.

Priscilla Brastianos, Qian Shi, Sandro Santagata, Keith Anderson, Suriya Jeyapalan, Dan Cahill, Elise Horvath, Fred Barker, Evanthia Galanis 2016
Abstract Neuro-Onc

186 Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance)

Justin C Brown, Sui Zhang, Donna Niedzwiecki, Leonard B Saltz, Robert J Mayer, Rex B Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Yanping Li, Xuehong Zhang, Kimmie Ng, Walter C Willett, Edward L Giovannucci, Charles S Fuchs, Jeffrey A Meyerhardt JNCI Cancer Spectr vol 2 (2) pky017 2018
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/29877501>

187 Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1

L. C. Brown, P. J. Atherton, M. A. Neben-Wittich, D. B. Wender, R. J. Behrens, T. F. Kozelsky, C. L. Loprinzi, M. G. Haddock, J. A. Martenson Jr Support Care Cancer vol 21 (10) 2869-77 2013
Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/23748483>

188 A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy

(RT) in glioblastoma multiforme (GBM)

P. D. Brown, S. Krishnan, J. Sarkaria, W. Wu, P. Mischel, W. Yong, R. Arusell, R. Jenkins, J. Buckner, C. Giannini J. Clin. Oncol. vol 26 (15s) abstr 2016 2008
Abstract Neuro-Onc

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

189 Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance)

Paul D. Brown, S. Keith Anderson, Xiomara W. Carrero, Brian P. O'Neill, Caterina Giannini, Eva Galanis, Sunjay A. Shah, Ross A. Abrams, Walter J. Curran, Jan C. Buckner, Edward G. Shaw Neurooncol Pract vol 2 (4) 199-204 2015

Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/26640699>

190 NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases.

Paul D. Brown, Anthony L. Asher, Karla V. Ballman, Elana Farace, Jane H. Cerhan, S. Keith Anderson, Xiomara W. Carrero, Fred G. Barker II, Burri Stuart H. Deming, Cynthia Menard, Caroline Chung, Volker W. Steiber, Richard, Bruce Pollock, Eva Galanis, Jan C. Buckner, Kurt Jaeckle Neuro Oncol vol 17 (suppl 5) v45-v46 2015

Abstract Neuro-Onc

http://neuro-oncology.oxfordjournals.org/content/17/suppl_5/v45.5.full?sid=0702f83e-1c38-49df-81c8-c

191 NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases

Paul D. Brown, Anthony L. Asher, Karla V. Ballman, Elana Farace, Jane H. Cerhan, S. Keith Anderson, Xiomara W. Carrero, Fred Barker, Richard Deming, Stuart Burri, Bruce Pollock, Cynthia Menard, Caroline Chung, Volker W. Stieber, Eva Galanis, Jan C. Buckner, Kurt Jaeckle J. Clin. Oncol. vol 33 (suppl) abstr LBA4 2015

Abstract Neuro-Onc <http://meetinglibrary.asco.org/content/146056-156>

192 N107C/CEC.3 (Alliance/NCIC): Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease

Paul D. Brown, Karla V. Ballman, Jane H. Cerhan, S. Keith Anderson, Xiomara W. Carrero, Anthony C. Whitton, Jeffrey Greenspoon, Ian Parney, Nadia N.I. Laack, Jonathan Ashman, Jean-Paul Bahary, Costas G. Hadjipanayis, James Urbanic, Fred G. Barker II, Elana Farace, Deepak Khuntia, Caterina Giannini, Jan C. Buckner, Evanthia Galanis, David Roberge Int. J. Radiat. Oncol. Biol. Phys. vol 96 (5) 937, abstr LBA-1 2016

Abstract Neuro-Onc [http://www.redjournal.org/article/S0360-3016\(16\)33263-1/fulltext](http://www.redjournal.org/article/S0360-3016(16)33263-1/fulltext)

193 Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases

Paul D. Brown, Kurt Jaeckle, Karla V. Ballman, Elana Farace, Jane H. Cerhan, S. Keith Anderson, Xiomara W. Carrero, Fred G. Barker, Richard Deming, Stuart H. Burri, Cynthia Ménard, Caroline Chung, Volker W. Stieber, Bruce E. Pollock, Evanthia Galanis, Jan C. Buckner, Anthony L. Asher JAMA vol 316 (4) 401-409 2016

Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/27458945>

194 Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

Paul D. Brown, Sunil Krishnan, Jann N. Sarkaria, Wenting Wu, Kurt A. Jaeckle, Joon H. Uhm, Francois J. Geoffroy, Robert Arusell, Gaspar Kitange, Robert B. Jenkins, John W. Kugler, Roscoe F. Morton, Kendrith M. Rowland, Paul Mischel, William H. Yong, Bernd W. Scheithauer, David Schiff, Caterina Giannini, Jan C. Buckner J Clin Oncol vol 26 (34) 5603-5609 2008

195 Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC-3): a multicentre, randomised, controlled, phase 3 trial

Paul D Brown, Karla V Ballman, Jane H Cerhan, S Keith Anderson, Xiomara W Carrero, Anthony C Whitton, Jeffrey Greenspoon, Ian F Parney, Nadia N I Laack, Jonathan B Ashman, Jean-Paul Bahary, Costas G Hadjipanayis, James J Urbanic, Fred G Barker, Elana Farace, Deepak Khuntia, Caterina Giannini, Jan C Buckner, Evanthia Galanis, David Roberge *Lancet Oncol.* vol 18 (8) 1049-1060 2017

Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/28687377>

196 Phase II Trial of Oral Topotecan and Intravenous Carboplatin With G-CSF Support in Previously Untreated Patients With Extensive Stage Small Cell Lung Cancer

Alan H. Bryce, Bassam Mattar, Shauna L. Hillman, Alex A. Adjei, John W. Kugler, Kendrith Rowland, Donald B. Wender, Gamini Soori, Edith A. Perez, James R. Jett *Am. J. Clin. Oncol.* vol 33 (4) 353-357 2010

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/19935387>

197 Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade.

Jan C Buckner, Judith R O'Fallon, Robert P Dinapoli, Paula J Schomberg, Gist Farr, Paul Schaefer, Caterina Giannini, Bernd W Scheithauer, Karla V Ballman *J. Neurooncol.* vol 84 (3) 279-86 2007

Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/17431544>

198 Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study

H. J. Burstein, W. T. Barry, C. Cirrincione, H. K. Chew, S. Tolaney, D. Lake, T. Pluard, K. Blackwell, E. P. Winer, C. A. Hudis *Cancer Res.* vol 70 (24 suppl 2) abstr PD05-01 2010

Abstract Breast

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/70/24_MeetingAbstracts/PD05-01

199 Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer—CALGB 40302 (Alliance)

Harold J. Burstein, Constance T. Cirrincione, William T. Barry, Helen K. Chew, Sara M. Tolaney, Diana E. Lake, Cynthia Ma, Kimberly L. Blackwell, Eric P. Winer, Clifford A. Hudis *J. Clin. Oncol.* vol 32 (35) 3959-3966 2014

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25348000>

200 Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2-positive operable breast cancer (ACOSOG Z1041)

A. U. Buzdar, F. Meric-Bernstam, J. C. Boughey, A. M. Leitch, G. Unzeitig, M. J. Ellis, M. Ewer, K. K. Hunt *J. Clin. Oncol.* vol 28 (15s) abtr 594 2010

Abstract Breast <http://meetinglibrary.asco.org/content/50348-74>

201 ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC -> P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T -> FEC+T) in HER2+ operable breast cancer

A. Buzdar, V. Suman, F. Meric-Bernstam, M. Leitch, M. Ellis, J. Boughey, G. Unzeitig, M. Royce, K. Hunt *J. Clin. Oncol.* vol 31 (15 suppl) abstr 502 2013

Abstract Breast

202 Disease-free (DFS) and overall survival (OS) data from ACOSOG Z1041 (Alliance) a randomized neoadjuvant trial comparing FEC followed by Paclitaxel plus Trastuzumab (FEC P+T) with Paclitaxel plus Trastuzumab followed by FEC plus Trastuzumab (P+T FEC+T) in HER2-positive operable breast cancer

Aman U. Buzdar, Vera J. Suman, Funda Meric-Bernstam, Ann M. Leitch, Matthew J. Ellis, Judy C. Boughey, Gary W. Unzeitig, Melanie E. Royce, Michael S. Ewer, Kelly K. Hunt *Cancer Res.* vol 76 (4 Suppl) P1-14-02 2016
Abstract Breast http://cancerres.aacrjournals.org/content/76/4_Supplement/P1-14-02.abstract

203 Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy

Aman U. Buzdar, Vera J. Suman, Funda Meric-Bernstam, Ann Marilyn Leitch, Matthew J. Ellis, Judy C. Boughey, Gary W. Unzeitig, Melanie E. Royce, Kelly K. Hunt *JAMA Oncol* vol 5 (1) 45-50 2019
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/30193295>

204 Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

Aman U Buzdar, Vera J Suman, Funda Meric-Bernstam, A Marilyn Leitch, Matthew J Ellis, Judy C Boughey, Gary Unzeitig, Melanie Royce, Linda M McCall, Michael S Ewer, Kelly K Hunt *Lancet Oncol.* vol 14 (13) 1317-1325 2013
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/24239210>

205 Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)

John C. Byrd, Amy S. Ruppert, Nyla A. Heerema, Alese E. Halvorson, Eva Hoke, Mitchell R. Smith, John E. Godwin, Stephen Couban, Todd A. Fehniger, Michael J. Thirman, Martin S. Tallman, Frederick R. Appelbaum, Richard M. Stone, Sue Robinson, Julie E. Chang, Sumithra J. Mandrekar, Richard A. Larson *Blood Adv* vol 2 (14) 1705-18 2018
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/30030269>

206 Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.

John C Byrd, Bercedis L Peterson, Kanti R Rai, David Hurd, Raymond Hohl, Michael C Perry, Jon Gockerman, Sreenivasa Nattam, Richard A Larson *Leuk. Lymphoma* vol 50 (10) 1589-96 2009
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/19863336>

207 Comparison of Residual Cancer Burden, American Joint Committee on Cancer staging and Pathologic Complete Response in Breast Cancer after Neoadjuvant Chemotherapy: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Jeffrey I. Campbell, Christina Yau, Polina Krass, Dan Moore, Lisa A. Carey, Alfred Au, David Chhieng, Dilip Giri, Chad Livasy, Carolyn Mies, Joseph Rabban, Venetia R. Sarode, Baljit Singh, Laura Esserman, Yunn-Yi Chen *Breast Cancer Res. Treat.* vol 165 (1) 181-191 2017
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/28577078>

208 What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings

M. E. Campbell, S. J. Mandrekar, S. L. Hillman, R. M. Goldberg, K. M. Rowland Jr, I. a. A. Adje, H. C. Pitot, A. Grothey, J. C. Buckner, D. J. Sargent *J. Clin. Oncol.* vol 26 (15s) 342s abstr 6520 2008

Abstract GI NCCTG-N0026, NCCTG-N9741

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

209 Waterfall plots provide detailed information on magnitude of response to conventional chemotherapy in advanced colorectal cancer (ACRC) - lessons learned from N9741.

M. Campbell, A. Grothey, D. Sargent, R. Goldberg J. Clin. Oncol. vol 25 (18s) abstr 4080 2007

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

210 The Prognostic Implications of Macrophages Expressing Proliferating Cell Nuclear Antigen in Breast Cancer Depend on Immune Context

Michael J. Campbell, Denise Wolf, Rita A. Mukhtar, Vickram Tandon, Christina Yau, Alfred Au, Frederick Baehner, Laura van't Veer, Donald Berry, Laura J. Esserman PLoS ONE vol 8 (10) 2013
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/24205370>

211 Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633

M. Capelletti, X. F. Wang, L. Gu, S. L. Graziano, R. A. Kratzke, G. M. Strauss, M. Maddaus, M. R. Green, E. E. Vokes, P. A. Janne J. Clin. Oncol. vol 28 (15s) abstr 7008 2010

Abstract Correl Sci NOS

http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7008

212 Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).

Lisa A. Carey, William Thomas Barry, Brandy Pitcher, Katherine A. Hoadley, Maggie Chon U. Cheang, Carey K. Anders, N. Lynn Henry, Sara M. Tolaney, Chau T. Dang, Ian E. Krop, Lyndsay Harris, Donald A. Berry, Charles M. Perou, Eric P. Winer, Clifford A. Hudis J. Clin. Oncol. vol 32 (15_suppl) 506 2014

Abstract Breast http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/506

213 Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

Lisa A. Carey, Donald A. Berry, Constance T. Cirrincione, William T. Barry, Brandelyn N. Pitcher, Lyndsay N. Harris, David W. Ollila, Ian E. Krop, Norah Lynn Henry, Douglas J. Weckstein, Carey K. Anders, Baljit Singh, Katherine A. Hoadley, Michael Iglesia, Maggie Chon U. Cheang, Charles M. Perou, Eric P. Winer, Clifford A. Hudis J. Clin. Oncol vol 34 (6) 542-549 2016

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26527775>

214 Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer

Lisa A. Carey, Donald A. Berry, David Ollila, Lyndsay Harris, Ian E. Krop, Douglas Weckstein, Norah Lynn Henry, Carey K. Anders, Constance Cirrincione, Eric P. Winer, Charles M. Perou, Clifford Hudis J. Clin. Oncol. vol 31 (15 suppl) abstr 500 2013

Abstract Breast

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/500?sid=211d90d6-54e6-40ec-951b-49deb

215 Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (Alliance) clinical trials

Jorge J. Castillo, Flora Mulkey, Susan Geyer, Jonathan E. Kolitz, William Blum, Bayard L. Powell, Stephen L. George, Richard A. Larson, Richard M. Stone Am. J. Hematol. vol 91 (2) 199-204 2016
Manuscript Leukemia C9621, C9710, CALGB-10503, CALGB-19808

216 Obesity Is An Adverse Prognostic Factor For Overall and Disease-Free Survival In Adult Acute Promyelocytic Leukemia But Not In Acute Myeloid Leukemia: A Pooled Analysis From Four Alliance Prospective Studies

Jorge J. Castillo, Flora Mulkey, Susan Geyer, Jonathan E. Kolitz, William Blum, Bayard L. Powell, Richard A. Larson, Richard M. Stone *Blood* vol 122 (21) 832 2013
Abstract *Leukemia* CALGB-9621, CALGB-9710, CALGB-10503, CALGB-19808
<http://bloodjournal.hematologylibrary.org/content/122/21/832.short>

217 Teaching Health-Care Providers to Query Patients With Cancer About Sexual and Gender Minority (SGM) Status and Sexual Health

Elizabeth J. Cathcart-Rake, Carmen Radecki Breitkopf, Judith Kaur, Jennifer O'Connor, Jennifer L. Ridgeway, Aminah Jatoi *Am J Hosp Palliat Care* vol 36 (6) 533-7 2019
Manuscript *Disparities* <http://www.ncbi.nlm.nih.gov/pubmed/30599758>

218 Examiner accuracy in cognitive testing in multisite brain-tumor clinical trials: an analysis from the Alliance for Clinical Trials in Oncology

Jane H Cerhan, S Keith Anderson, Alissa M Butts, Alyx B Porter, Kurt Jaeckle, Evanthia Galanis, Paul D Brown *Neurooncol Pract* vol 6 (4) 283-8 2019
Manuscript *Health Outcome* N0577, A221101, N0874, N107C
<http://www.ncbi.nlm.nih.gov/pubmed/31386061>

219 Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant (NEO) CRT followed by Local Excision (LE) in uT2 Rectal Cancer (RC)

E. Chan, Q. Shi, J. Garcia-Aguilar, B. G. Wolff, C. S. Johnson, B. Sanders, X. Carrero, M. C. Posner, D. M. Ota, C. R. Jr Thomas *Int. J. Radiat. Oncol. Biol. Phys.* vol 78 (3, Supplement) S53-S54 2010
Abstract *GI* <http://www.sciencedirect.com/science/article/pii/S0360301610011338>

220 Association of Family History with Cancer Recurrence and Survival Among Patients with Stage III Colon Cancer

Jennifer A. Chan, Jeffrey A. Meyerhardt, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, James Thomas, Paul Schaefer, Renaud Whittom, Alexander Hantel, Richard M. Goldberg, Robert S. Warren, Monica Bertagnolli, Charles S. Fuchs *JAMA* vol 299 (21) 2515-2523 2008
Manuscript *GI* <http://www.ncbi.nlm.nih.gov/pubmed/18523220>

221 Innovative estimation of survival using log-normal survival modelling on ACCENT database

J W Chapman, C J O'Callaghan, N Hu, K Ding, G A Yothers, P J Catalano, Q Shi, R G Gray, M J O'Connell, D J Sargent *Br. J. Cancer* vol 108 (4) 784-790 2013
Manuscript *GI* <http://www.ncbi.nlm.nih.gov/pubmed/23385733>

222 Comparison of innovative estimation of efficacy to standard using the ACCENT database.

J. W. Chapman, C. O'Callaghan, N. Hu, K. Ding, G. A. Yothers, P. J. Catalano, Q. Shi, R. G. Gray, M. J. O'Connell, D. J. Sargent *J. Clin. Oncol.* vol 29 (suppl) abstr 3616 2011
Abstract *GI*
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

223 Patient satisfaction with participation in phase II/III NCCTG clinical trials: Was it worth it? (N0392)

C. Chauhan, P. J. Atherton, D. Satele, A. C. Dueck, G. S. Soori, D. B. Johnson, S. J. Mandrekar, J. C. Buckner, J. A. Sloan *J. Clin. Oncol.* vol 30 (suppl) abstr 6133 2012
Abstract *Health Outcome* http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/6133

- 224 Phase 2 Trial of Pemetrexed Disodium and Carboplatin in Previously Untreated Extensive-Stage Small Cell Lung Cancer, N0423**
Cheng E. Chee, James R. Jett, Albert M. Bernath, Nathan R. Foster, Garth D. Nelson, Julian Molina, Daniel A. Nikcevich, Preston D. Steen, Patrick J. Flynn, Kendrith M. Rowland *Cancer* vol 116 (10) 2382-2389 2010
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20209614>
- 225 Quality-adjusted time without symptoms or toxicity (Q-TWiST): analysis of cabozantinib versus sunitinib in patients with advanced renal cell carcinoma of intermediate or poor risk (Alliance A031203)**
RC Chen, M Feuilly, J Meng, J Lister, F Marteau, M Morris, D George, T Choueiri *J Clin Oncol* vol 36 (Suppl) abstr 4556 2018
Abstract GU <https://meetinglibrary.asco.org/record/165040/abstract>
- 226 Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL**
S. S. Chen, R. Claus, D. M. Lucas, L. Yu, J. Qian, A. S. Ruppert, D. A. West, K. E. Williams, A. J. Johnson, F. Sablitzky, C. Plass, J. C. Byrd *Blood* vol 117 (3) 862-871 2011
Manuscript Leuk Corr Sci C9665, C20305, C9712 <http://www.ncbi.nlm.nih.gov/pubmed/21098398>
- 227 Bayesian Variable Selection with Joint Modeling of Categorical and Survival Outcomes: An Application to Individualizing Chemotherapy Treatment in Advanced Colorectal Cancer**
Wei Chen, Debashis Ghosh, Trivellore E. Raghunathan, Daniel J. Sargent *Biometrics* vol 65 (4) 1030-1040 2009
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19210736>
- 228 EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial**
H Cheng, K Ballman, M Vassilakopoulou, A C Dueck, M M Reinholz, K Tenner, J Gralow, C Hudis, N E Davidson, G Fountzilas, A E McCullough, B Chen, A Psyrris, D L Rimm, E A Perez *Br. J. Cancer* vol 111 (6) 1065-1071 2014
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25117817>
- 229 Predictive and prognostic value of gender in early stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.**
W. Y. Cheung, Q. Shi, M. O'Connell, J. Cassidy, C. D. Blanke, D. J. Kerr, E. Van Cutsem, S. R. Alberts, A. Yothers, D. J. Sargent *J. Clin. Oncol.* vol 29 (15s) abstr 3619 2011
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID
- 230 The Predictive and Prognostic Value of Sex in Early-Stage Colon Cancer: A Pooled Analysis of 33,345 Patients from the ACCENT Database**
Winson Y. Cheung, Qian Shi, Michael O'Connell, James Cassidy, Charles D. Blanke, David J. Kerr, Jeff Meyers, Eric Van Cutsem, Steven R. Alberts, Greg Yothers, Daniel J. Sargent *Clin Colorectal Cancer* vol 12 (3) 179-187 2013
Manuscript GI N0441, NCCTG-N0441 <http://www.ncbi.nlm.nih.gov/pubmed/23810482>
- 231 Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB)**
Andrea L. Cheville, Jeff A. Sloan, Donald W. Northfelt, Anand P. Jillella, Gilbert Y. Wong, James D. Bearden, Heshan Liu, Paul L. Schaefer, Benjamin T. Marchello, Bradley J. Christensen, Charles L. Loprinzi *Support Care Cancer* vol 17 (4) 451-460 2009
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/19142669>

- 232 Polygenic Inheritance of Paclitaxel-Induced Sensory Peripheral Neuropathy Driven by Axon Outgrowth Gene Sets in CALGB 40101 (Alliance)**
Aparna Chhibber, Joel Mefford, Eli A. Stahl, Sarah A. Pendergrass, R. Michael Baldwin, Kouros Owzar, Megan Li, Eric P. Winer, Clifford A. Hudis, Hitoshi Zembutsu, Michiaki Kubo, Yusuke Nakamura, Howard L. McLeod, Mark J. Ratain, Lawrence N. Shulman, Marylyn D. Ritchie, Robert M. Plenge, John S. Witte, Deanna L. Kroetz *Pharmacogenomics J.* vol 14 (4) 336-342 2014
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/24513692>
- 233 PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials**
T.K. Choueiri, A. Flaifel, W. Xie, D. Braun, M. Ficial, R. Jennings, A. Nassar, B. Escudier, D.J. George, R.J. Motzer, M.J. Morris, T. Powles, E. Wang, Y. Huang, G. Freeman, S. Signoretti *Annal Oncol* vol 29 (suppl_8) Abstr LBA34 2018
Abstract GU
https://academic.oup.com/annonc/article/29/suppl_8/mdy424.040/5141786?searchresult=1
- 234 Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial**
Toni K. Choueiri, Susan Halabi, Ben L. Sanford, Olwen Hahn, M. Dror Michaelson, Meghara K. Walsh, Darren R. Feldman, Thomas Olencki, Joel Picus, Eric J. Small, Shaker Dakhil, Daniel J. George, Michael J. Morris *J. Clin. Oncol* vol 35 (6) 591-597 2017
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/28199818>
- 235 CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: results from ALLIANCE A031203 Trial.**
Toni K. Choueiri, Susan Halabi, Ben L. Sanford, Olwen Hahn, M. Dror Michaelson, Meghara Walsh, Thomas Olencki, Joel Picus, Eric J. Small, Daniel George, Shaker Dakhil, Michael J. Morris 2016
Abstract GU
<http://www.esmo.org/Conferences/Past-Conferences/ESMO-2016-Congress/Press-Media/Cabozantinib-I>
- 236 Progression-free survival (PFS) by independent review results from ALLIANCE A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)**
Toni K. Choueiri, Colin Hessel, Susan Halabi, Ben Sanford, Olwen Hahn, Olenck T. Picus J. Small E.J. Dakhi S. Scheffold C. George D.J. Morris M.J. Michaelson *Ann Oncol* vol 28 (suppl 5) mdx440.032, LBA38 2017
Abstract GU
https://academic.oup.com/annonc/article/28/suppl_5/mdx440.032/4109944?searchresult=1
- 237 Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update**
Toni K. Choueiri, Colin Hessel, Susan Halabi, Ben Sanford, M. Dror Michaelson, Olwen Hahn, Meghara Walsh, Thomas Olencki, Joel Picus, Eric J. Small, Shaker Dakhil, Darren R. Feldman, Milan Mangeshkar, Christian Scheffold, Daniel George, Michael J. Morris *Eur. J. Cancer* vol 94 115-25 2018
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/29550566>
- 238 Meta-analysis identifies variants in S1PR1 associated with microtubule targeting agent-induced sensory peripheral neuropathy CALGB 40101 and 40502 (Alliance)**
Katherina C. Chua, Carol Ho, Tasei Mushiroda, Chen Jiang, Flora Mulkey, Hope Rugo, Michiaki

Kubo, Kouros Owzar, Lawrence N. Shulman, Deanna L. Kroetz CLINICAL PHARMACOLOGY & THERAPEUTICS vol 103 (Suppl S1) S28 2018
Abstract Breast CALGB-40101, CALGB-40502
<https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.993>

239 Incidence of late recurrence in hormone receptor-positive or negative HER2-positive breast cancer receiving adjuvant trastuzumab: The combined analysis of the NCCTG (Alliance) N9831 and NSABP (NRG) B31 Trials

Saranya Chumsri, Zhou Li, Daniel J. Serie, Afshin Mashadi-Hosseini, Gerardo Colon-Otero, Nan Song, Katherine L. Pogue-Geile, Patrick Gavin, Soon Paik, Alvaro Moreno-Aspitia, Edith A. Perez, E. Aubrey Thompson Cancer Res vol 79 (4_suppl) abstr PD3-02 2018
Abstract GI NCCTG-N9831, NSABP B-31
http://cancerres.aacrjournals.org/content/79/4_Supplement/PD3-02

240 Effects of Age and Immune Landscape on Outcome in HER2-positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials

Saranya Chumsri, Daniel J. Serie, Zhuo Li, Katherine L. Pogue-Geile, Aixa E. Soyano-Muller, Afshin Mashadi-Hosseini, Sarah Warren, Yanyan Lou, Gerardo Colon-Otero, Keith L. Knutson, Edith A. Perez, Alvaro Moreno-Aspitia, E. Aubrey Thompson Clin. Cancer Res. vol 25 (14) 4422-30 2019
Manuscript Breast N9831, NSABP B-31 <http://www.ncbi.nlm.nih.gov/pubmed/30808774>

241 Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials

Saranya Chumsri, Daniel Serie, Afshin Mashadi-Hosseini, Jennifer M. Kachergus, Sarah Warren, Gerardo Colon-Otero, Ann H. Partridge, Lisa A. Carey, Florentine Hilbers, Veerle Van Dooren, Eileen Holmes, Serena Di Cosimo, Olena Werner, Jens Bodo Huober, Jose Baselga, Christos Sotiriou, Edith A. Perez, Amylou C. Dueck, Alvaro Moreno-Aspitia, E Aubrey Thompson J Clin Oncol vol 36 (15 suppl) abstr 577 2018
Abstract GI http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.577

242 High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)

Saranya Chumsri, Jeff Sperinde, Heshan Liu, Joseph Gligorov, Jean-Philippe Spano, Martine Antoine, Alvaro Moreno Aspitia, Winston Tan, John Winslow, Christos J Petropoulos, Ahmed Chenna, Michael Bates, Jodi Marie Weidler, Weidong Huang, Amylou Dueck, Edith A. Perez Clin. Cancer Res. vol 24 (13) 3053-58 2018
Manuscript Correl Sci NOS N0337, N98-32-52 <http://www.ncbi.nlm.nih.gov/pubmed/29530935>

243 Correlation of high p95HER2:HER2 ratio with poor outcome in two phase II clinical trials of trastuzumab-treated HER2-positive metastatic breast cancer.

Saranya Chumsri, Jeff Sperinde, Heshan Liu, Joseph Gligorov, Jean-Philippe Spano, Alvaro Moreno-Aspitia, Sarah A. McLaughlin, John William Winslow, Christos J. Petropoulos, Ahmed Chenna, Michael Patrick Bates, Jodi Marie Weidler, Yolanda Lie, Weidong Huang, Edith A. Perez J Clin Oncol vol 34 (suppl) abstr 603 2016
Abstract Breast N0337, N98-32-52 <http://meetinglibrary.asco.org/content/168923-176>

244 Stereotactic Radiosurgery with or without Whole Brain Radiotherapy for Limited Brain Metastases: A Secondary Analysis of the NCCTG N0574 (Alliance) Randomized Controlled Trial

Thomas M. Churilla, Karla V. Ballman, Paul D. Brown, Erin L. Twohy, Kurt Jaeckle, Elana Farace, Jane H. Cerhan, S. Keith Anderson, Xiomara W. Carrero, Yolanda I. Garces, Fred G. Barker, Richard Deming, Jesse G. Dixon, Stuart H. Burri, Caroline Chung, Cynthia Ménard, Volker W. Stieber, Bruce E. Pollock, Evanthis Galanis, Jan C. Buckner, Anthony L. Asher Int. J. Radiat. Oncol. Biol. Phys. vol 99 (5) 1173-1178 2017

- 245 Methodological Considerations in the Design and Implementation of Clinical Trials**
Constance T. Cirrincione, Ellen M. Lavoie Smith, Herbert Pang *Semin Oncol Nurs* vol 30 (1) 74-79
2014
Manuscript Onc Nursing <http://www.ncbi.nlm.nih.gov/pubmed/24559783>
- 246 Sentinel Lymph Node Biopsy Accurately Stages the Regional Lymph Nodes for T1-T2 Oral Squamous Cell Carcinomas: Results of a Prospective Multi-Institutional Trial**
Francisco J. Civantos, Robert P. Zitsch, David E. Schuller, Amit Agrawal, Russell B. Smith, Richard Nason, Guy Petruzelli, Christine G. Gourin, Richard J. Wong, Robert L. Ferris, Adel El Naggar, John A. Ridge, Randal C. Paniello, Kouros Owzar, Linda McCall, Douglas B. Chepeha, Wendell G. Yarbrough, Jeffrey N. Myers *J Clin Oncol* vol 28 (8) 1395-1400 2010
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20142602>
- 247 Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657)**
Amy S Clark, Jinbo Chen, Shiv Kapoor, Claire Friedman, Carolyn Mies, Laura Esserman, Angela DeMichele *Cancer Med* vol 3 (3) 693-701 2014
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/24719175>
- 248 Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance)**
Jeffrey M. Clarke, Herbert Pang, Mark D. Starr, Ace Hatch, Hedy L. Kindler, Federico Innocenti, Alan P. Venook, Herbert I. Hurwitz, Andrew B. Nixon *J. Clin. Oncol.* vol 33 (suppl 3) abstr 306 2015
Abstract Correl Sci NOS
http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/306?sid=36869157-2058-48a2-9fcd-80ab78
- 249 Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia**
R. Claus, D. M. Lucas, S. Stilgenbauer, A. S. Ruppert, L. Yu, M. Zucknick, D. Mertens, A. Buhler, C. C. Oakes, R. A. Larson, N. E. Kay, D. F. Jelinek, T. J. Kipps, L. Z. Rassenti, J. G. Gribben, H. Dohner, N. A. Heerema, G. Marcucci, C. Plass, J. C. Byrd *J. Clin. Oncol.* vol 30 (20) 2483-2491 2012
Manuscript Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pubmed/22564988>
- 250 Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52**
R. Clynes, K. L. Knutson, K. Ballman, C. L. Erskine, N. Norton, S. V. Sumrall, D. Northfelt, W. Tan, C. Calfa, M. Pegram, E. A. Perez *J. Clin. Oncol.* vol 31 (15 suppl) abstr 521 2013
Abstract Breast N0337, N98-32-52
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/521?sid=9c0743c8-049a-44b6-9683-a12b8
- 251 Impact of age, comorbidity and symptoms on physical function in long-term breast cancer survivors (CALGB 70803)**
Harvey Jay Cohen, Lan Lan, Laura Archer, Alice B. Kornblith *J Geriatr Oncol* vol 3 (2) 82-89 2012
Manuscript Health Outcome C70103, CALGB-70803
<http://www.ncbi.nlm.nih.gov/pubmed/22707996>
- 252 Acute Myeloid Leukemia (AML) with 9q aberrations occurring within a non-complex karyotype is highly associated with CEBPA and NPM1 mutations - A joint analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB)**
A. Corbacioglu, S. Frohling, P. Paschka, G. Marcucci, A. Anhalt, K. Urlbauer, J. Krauter, R. A. Larson, K. Mrozek, A. S. Ruppert, A. Ganser, M. A. Caligiuri, H. Dohner, R. F. Schlenk, C. D.

Bloomfield, K. Dohner Blood vol 110 (11) 762 2007
Abstract Leuk Corr Sci CALGB-19808, CALGB-8461, CALGB-9621, CALGB-9665
<http://www.bloodjournal.org/content/110/11/762?sso-checked=true>

253 Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001

C. L. Corless, K. V. Ballman, C. Antonescu, C. D. Blanke, M. E. Blackstein, G. D. Demetri, M. Von Mehren, R. G. Maki, P. W. Pisters, R. P. Dematteo J. Clin. Oncol. vol 28 (15s) abstr 10006 2010
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

254 Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial

Christopher L. Corless, Karla V. Ballman, Cristina R. Antonescu, Violetta Kolesnikova, Robert G. Maki, Peter W.T. Pisters, Martin E. Blackstein, Charles D. Blanke, George D. Demetri, Michael C. Heinrich, Margaret von Mehren, Shreyaskumar Patel, Martin D. McCarter, Kouros Owzar, Ronald P. DeMatteo J. Clin. Oncol vol 32 (15) 1563-1570 2014
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24638003>

255 Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.

Wendy R Cornett, Linda M McCall, Rebecca P Petersen, Merrick I Ross, Henry A Briele, R Dirk Noyes, Jeffrey J Sussman, William G Kraybill, John M Kane, H Richard Alexander, Jeffrey E Lee, Paul F Mansfield, James F Pingpank, David J Winchester, Richard L White, Vijaya Chadaram, James E Herndon, Douglas L Fraker, Douglas S Tyler J. Clin. Oncol. vol 24 (25) 4196-201 2006
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/16943537>

256 ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer

R. Cote, A. E. Giuliano, D. Hawes, K. V. Ballman, P. W. Whitworth, P. W. Blumencranz, D. S. Reintgen, M. Morrow, A. M. Leitch, K. Hunt J. Clin. Oncol. vol 28 (18s) abstr CRA504 2010
Abstract Breast <http://meetinglibrary.asco.org/content/50966-74>

257 Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention.

Ivana T Croghan, Richard D Hurt, Shaker R Dakhil, Gary A Croghan, Jeff A Sloan, Paul J Novotny, Kendrith M Rowland, Albert Bernath, Mary L Loots, Nguyet A Le-Lindqwister, Loren K Tschetter, Stewart C Garneau, Kathleen A Flynn, Larry P Ebbert, Donald B Wender, Charles L Loprinzi Mayo Clin. Proc. vol 82 (2) 186-95 2007
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/17290726>

258 Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831

J. A. Crozier, A. Moreno-Aspitia, K. V. Ballman, A. C. Dueck, B. A. Pockaj, E. A. Perez Cancer vol 119 (13) 2447-2454 2013
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/23585192>

259 N0436 (Alliance): A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane-containing therapy

Jennifer A. Crozier, Pooja P. Advani, Betsy LaPlant, Timothy Hobday, Anthony J. Jaslowski, Alvaro Moreno-Aspitia, Edith A. Perez Clin. Breast Cancer vol 16 (1) 23-30 2016

- 260 A pooled exploratory analysis of the effect of tumor size on survival benefit from adjuvant platinum-based chemotherapy (ACT) in node negative (N0) non-small cell lung cancer (NSCLC)**
S. Cuffe, M. Ezzalfani, A. Bourredjem, S. L. Graziano, J. Pignon, E. Strevel, R. L. Burkes, F. Shepherd
2010
Abstract Respiratory
- 261 A Pooled Exploratory Analysis of the Impact of Tumor Size and KRAS Mutations on Survival Benefit from Adjuvant Platinum-Based Chemotherapy (ACT) in Node Negative (N0) Non-Small Cell Lung Cancer (NSCLC).**
S. Cuffe, S. Graziano, A. Bourredjem, J. P. Pignon, M. Ezzalfani, L. Seymour, E. Strevel, R. Burkes, M. Capelletti, P. A. Janne, M. S. Tsao, F. A. Shepherd J Thorac Oncol vol 6 (6) S462-463 2011
Abstract Respiratory <http://journals.lww.com/jto/toc/2011/06001>
- 262 A Pooled Exploratory Analysis of the Effect of Tumor Size and KRAS Mutations on Survival Benefit from Adjuvant Platinum-Based Chemotherapy in Node Negative Non-Small Cell Lung Cancer**
Sinead Cuffe, Abderrahmane Bourredjem, Stephen Graziano, Jean-Pierre Pignon, Caroline Domerg, Monia Ezzalfani, Lesley Seymour, Elizabeth Strevel, Ronald Burkes, Marzia Capelletti, Pasi A. Janne, Ming-Sound Tsao, Frances A. Shepherd J Thorac Oncol vol 7 (6) 963-972 2012
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/22588152>
- 263 Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)**
Elizabeth L. Cureton, Christina Yau, Michael D. Alvarado, Helen Krontiras, David W. Ollila, Cheryl A. Ewing, Sindy Monnier, Laura J. Esserman Ann. Surg. Oncol. vol 21 (9) 2889-2896 2014
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/24788555>
- 264 Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)**
Stephanie M. Cushman, Chen Jiang, Ace J. Hatch, Ivo Shterev, Alexander B. Sibley, Donna Niedzwiecki, Alan P. Venook, Kouros Owzar, Herbert I. Hurwitz, Andrew B. Nixon Clin. Cancer Res. vol 21 (5) 1078-1086 2015
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/25520391>
- 265 Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.**
M S Czuczman, J P Leonard, S Jung, J L Johnson, E D Hsi, J C Byrd, B D Cheson Ann. Oncol. vol 23 (9) 2356-62 2012
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/22357442>
- 266 A phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab (R) in previously untreated follicular lymphoma (FL): Initial report of CALGB study 50402**
M. S. Czuczman, J. L. Johnson, S. Jung, B. D. Cheson Ann. Oncol. vol 19 (suppl 4) abstr 143 2008
Abstract Lymphoma
http://annonc.oxfordjournals.org/content/19/suppl_4/iv129.full.pdf+html?sid=60de784d-8638-49b8-ba8c
- 267 FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R]**
M. S. Czuczman, J. P. Leonard, J. L. Johnson, S.-H. Jung, E. Hsi, J. C. Byrd, B. D. Cheson Blood vol 112 (11) abstr 1003 2008

268 Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.

Myron S Czuczman, Pierluigi Porcu, Jeffrey Johnson, Donna Niedzwiecki, Michael Kelly, Eric D Hsi, James R Cook, George Canellos, Bruce D Cheson *Leuk. Lymphoma* vol 48 (1) 97-103 2007
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/17325852>

269 p53 Protein Expression Status and Recurrence in Men Treated With Radiation Therapy and Androgen Suppression Therapy for Higher Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study

A. V. D'Amico, S. Halabi, R. Vollmer, M. Loffredo, E. McMahon, B. Sanford, L. Archer, N. J. Vogelzang, E. Small, P. Kantoff *Int. J. Radiat. Oncol. Biol. Phys.* vol 69 (3) S333 2007
Abstract GU CALGB-159807, CALGB-9682
<http://www.sciencedirect.com/science/article/pii/S0360301607026879>

270 Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study

Anthony V. D'Amico, Susan Halabi, Clare Tempany, David Titelbaum, George K. Philips, Marian Loffredo, Elizabeth McMahon, Ben Sanford, Nicholas J. Vogelzang, Eric J. Small *Int J Radiat Oncol Biol Phys* vol 71 (1) 9-15 2008
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/18037582>

271 p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).

Anthony V D'Amico, Susan Halabi, Robin Vollmer, Marian Loffredo, Elizabeth McMahon, Ben Sanford, Laura Archer, Nicholas J Vogelzang, Eric J Small, Philip W Kantoff *Urology* vol 71 (5) 933-7 2008
Manuscript GU CALGB-159807, CALGB-9682 <http://www.ncbi.nlm.nih.gov/pubmed/18291508>

272 Alliance A091103: A multicenter phase II study of the angiopoietin-1 and -2 peptibody trebananib (AMG386) for the treatment of angiosarcoma (AS).

Sandra P. D'Angelo, Michelle R. Mahoney, Brian Andrew Van Tine, Douglas Adkins, Maria T. Grosse Perdekamp, Mercedes M. Condy, Eliza Woodward Hartley, Cristina R. Antonescu, Gary K. Schwartz, William D. Tap *J. Clin. Oncol.* vol 32 (15_suppl) 10568 2014
Abstract Experimental http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10568

273 The impact of occult micrometastases on survival following resection of stage I non-small cell lung cancer: Final analysis of CALGB 9761

J. D'Cunha, X. Wang, S. S. Groth, R. T. Vollmer, N. Z. Abraham, L. Gu, D. L. Herzan, D. H. Harpole, G. A. Patterson, M. R. Green, R. A. Kratzke, M. A. Maddaus *J Thorac Oncol* vol 4 (9) abstr PD12.11.13 2009
Abstract Respiratory
<http://www.docstoc.com/docs/66321124/Poster-Discussion-Sessions---On-Site-Programme---20090207->

274 Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909

Lloyd E. Damon, Jeffrey L. Johnson, Donna Niedzwiecki, Bruce D. Cheson, David D. Hurd, Nancy L. Bartlett, Ann S. LaCasce, Kristie A. Blum, John C. Byrd, Michael Kelly, Wendy Stock, Charles A. Linker, George P. Canellos *J Clin Oncol* vol 27 (36) 6101-6108 2009
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/19917845>

- 275 Validation of EORTC Prognostic Factors for Adults with Low-Grade Glioma: a Report Utilizing Intergroup 86-72-511**
Thomas B. Daniels, Paul D. Brown, Sara J. Felten, Wenting Wu, Jan C. Buckner, Robert M. Arusell, Walter J. Curran, Ross A. Abrams, David Schiff, Edward G. Shaw Int J Radiat Oncol Biol Phys vol 81 (1) 218-224 2011
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/21549518>
- 276 Is there a role for older-patient-specific trials? a pooled analysis of 2277 older patients in adjuvant breast cancer trials (Alliance A151715)**
Dyda Dao, Tyler Zelma, Aminah Jatoi, Rachel Freedman, Arti Hurria, Hyman Muss, Harvey Cohen, Lawrence Shulman, Marc Citron, Budman, Ann Partridge, Lisa Carey, Jaqueline M. Lafky, Jennifer Le-Rademacher J Clin Oncol vol 36 (Suppl) abstr 10034 2018
Abstract Older Adult A151715, C8541, CALGB-40101, CALGB-49907, CALGB-9344, CALGB-9741, N89-30-52, N9831 <https://meetinglibrary.asco.org/record/163279/abstract>
- 277 OlderPatientSpecific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715)**
Dyda Dao, Tyler Zemla, Aminah Jatoi, Rachel A. Freedman, Arti Hurria, Hyman Muss, Harvey Jay Cohen, Lawrence N. Shulman, Marc Citron, Daniel Budman, Ryan McMurray, Ann Partridge, Lisa Carey, Mina S. Sedrak, Jacqueline M. Lafky, Jennifer G. LeRademacher Oncologist vol 24 (6) e284-e291 2019
Manuscript Older Adult CALGB-49907, CALGB-40401
<http://www.ncbi.nlm.nih.gov/pubmed/30975921>
- 278 Randomized Trial of Mediastinal Lymph Node Sampling versus Complete Lymphadenectomy During Pulmonary Resection in Patients with N0 or N1 (Less than Hilar) Non-Small Cell Carcinoma: Results of the ACOSOG Z0030 Trial**
G. Darling, M. Allen, P. Decker, K. Ballman, R. Landreneau, R. McKenna, D. Jones, R. Inculet, V. Rusch, J. Putnam American Association for Thoracic Oncology 90th Annual Meeting, Toronto, ON, Canada abstract 2010
Abstract Respiratory <http://aats.org/annualmeeting/Abstracts/2010/1.cgi>
- 279 Number of Lymph Nodes Harvested From a Mediastinal Lymphadenectomy**
Gail E. Darling, Mark S. Allen, Paul A. Decker, Karla Ballman, Richard A. Malthaner, Richard I. Inculet, David R. Jones, Robert J. McKenna, Rodney J. Landreneau, Joe B. Putnam Chest vol 139 (5) 1124-1129 2011
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20829340>
- 280 Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient with N0 or N1 (Less Than Hilar) Non-Small Cell Carcinoma: Results of the ACOSOG Z0030 Trial**
Gail E. Darling, Mark S. Allen, Paul A. Decker, Karla Ballman, Richard A. Malthaner, Richard. Inculet, David R. Jones, Robert J. McKenna, Rodney J. Landreneau, Valerie W. Rusch, Joe B. Putnam J. Thorac. Cardiovasc. Surg. vol 141 (3) 662-670 2011
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21335122>
- 281 Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC)**
R K Das, L Furchtgott, F-S Ou, D Swanson, B Hayete, B Harms, D Cunha, J Latourelle, D Wuest, I Khalil C Washburn, K Rich, C D Blanke, J Meyerhardt, D Niedzwiecki, A Nixon, E M O'Reilly, F Innocenti, H-J Lenz, A Venook Ann Oncol vol 29 (suppl_8) abstr 458PD 2018
Abstract GI
https://academic.oup.com/annonc/article/29/suppl_8/mdy281.006/5141120?searchresult=1

- 282 Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identifies heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC)**
Rahul K Das, Fang-Shu Ou, Cecilia Washburn, Andrew B. Nixon, Federico Innocenti, Heinz-Josef Lenz, Charles Blanke, Donna Niedzwiecki, Eileen Mary O'Reilly, Iya Khalil, Boris Hayete, Alan P. Venook *Annals of Oncology* vol 30 (Supplement_4) mdz156.019 2019
Abstract GI https://academic.oup.com/annonc/article/30/Supplement_4/mdz156.019/5526583
- 283 A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.**
Nancy A Dawson, Susan Halabi, San-San Ou, David D Biggs, Anne Kessinger, Nicholas Vogelzang, Gerald H Clamon, David M Nanus, W Kevin Kelly, Eric J Small *Clin Genitourin Cancer* vol 6 (2) 110-6 2008
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/18824434>
- 284 Association between 3 year (yr) disease free survival (DFS) and overall survival (OS) delayed with improved survival after recurrence (REC) in patients receiving cytotoxic adjuvant therapy for colon cancer: Updated findings from the 20,800 patient (Pt) ACCENT dataset**
A. De Gramont, D. Sargent *J. Clin. Oncol.* vol 26 (May 20 suppl) abstr 4007 2008
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID
- 285 Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801**
Daniel J. DeAngelo, Daohai Yu, Jeffrey L. Johnson, Steven E. Coutre, Richard M. Stone, Alison T. Stopeck, Jon P. Gockerman, Beverly S. Mitchell, Frederick R. Appelbaum, Richard A. Larson *Blood* vol 109 (12) 5136-5142 2007
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/17344466>
- 286 Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665**
Rebecca DeBoer, Gregory Koval, Flora Mulkey, Meir Wetzler, Steven Devine, Guido Marcucci, Richard M. Stone, Richard A. Larson, Clara D. Bloomfield, Susan Geyer, Charles G. Mullighan, Wendy Stock *Leuk. Lymphoma* vol 57 (10) 2298-2306 2016
Manuscript Leuk Corr Sci CALGB-10001, C9665 <http://www.ncbi.nlm.nih.gov/pubmed/26892479>
- 287 Clinical impact of ABL1 kinase and IKZF1 mutations in adults with Philadelphia chromosome-positive (PH+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB 10001 and 9665 (Alliance)**
Rebecca DeBoer, Flora Mulkey, Gregory Koval, Meir Wetzler, Guido Marcucci, Richard M. Stone, Richard A. Larson, Susan Geyer, Charles Mullighan, Wendy Stock *Haematologica* vol 99s (1) 152 (abstract S723) 2014
Abstract Leuk Corr Sci CALGB-10001, CALGB-9665
http://www.haematologica.org/content/haematol/99/supplement_1/1.full.pdf
- 288 Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor (GIST): ACOSOG Z9000 (Alliance) intergroup phase 2 trial**
Ronald P. DeMatteo, Karla V. Ballman, Cristina R. Antonescu, Christopher Corless, Violetta Kolesnikova, Margaret von Mehren, Martin D. McCarter, Jeffrey Norton, Robert G. Maki, Peter W.T. Pisters, George D. Demetri, Murray F. Brennan, Kouros Owzar *Ann. Surg.* vol 258 (3) 422-429 2013

289 Placebo-Controlled Randomized Trial of Adjuvant Imatinib Mesylate Following the Resection of Localized, Primary Gastrointestinal Stromal Tumor (GIST)

Ronald P. DeMatteo, Karla V. Ballman, Cristina R. Antonescu, Robert G. Maki, Peter W.T. Pisters, George D. Demetri, Martin E. Blackstein, Charles D. Blanke, Margaret von Mehren, Murray F. Brennan, Shreyaskumar Patel, Martin D. McCarter, Jonathan A. Polikoff, Benjamin R. Tan, Kouros Owzar *Lancet* vol 373 (9669) 1097-1104 2009

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19303137>

290 Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000

R. P. Dematteo, K. Owzar, C. R. Antonescu, R. Maki, G. D. Demetri, M. Mccarter, M. Von Mehren, P. Pisters, M. F. Brennan, K. V. Ballman *Gastrointestinal Cancers Symposium abstr 8* 2008
Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=53&abstractID

291 Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001

R. Dematteo, K. Owzar, R. Maki, P. Pisters, M. Blackstein, C. Antonescu, C. Blanke, G. Demetri, M. Von Mehren, K. Ballman *ASCO Annual Meeting Oral abstract* 2007
Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

292 Loss of p27 expression and response to neoadjuvant chemotherapy: Results from the I-SPY Trial (CALGB150007/150012, ACRIN6657)

A. Demichele, L. Dunn, P. Gimotty, C. Livasy, C. Perou, L. Carey, L. Esserman *J Clin Oncol* vol 27 (15s) abstr 11091 2009

Abstract Correl Sci NOS <http://meetinglibrary.asco.org/content/35378-65>

293 Comparison of community and central Her2 assessment on outcome of neoadjuvant chemotherapy in the I-SPY trial (CALGB 150007/150012, ACRIN 6657)

A. Demichele, C. Yau, J. Zhu, J. Wuhfkuhle, M. E. Lenburg, M. B. Buxton, S. E. Davis, C. Livasy, K. Chin, L. A. Carey, L. J. Esserman, E. F. Petricoin 3rd *Cancer Res.* vol 71 (24) P1-06-11 2011
Abstract Correl Sci NOS ACRIN-6657, CALGB-150007

http://cancerres.aacrjournals.org/content/71/24_Supplement/P1-06-11

294 In-dwelling catheters are superior to talc pleurodesis in the management of malignant pleural effusions

T. L. Demmy, L. Gu, J. Burkhalter, E. M. Toloza, T. A. D'Amico, S. L. Sutherland, X. Wang, L. E. Archer, L. Veit, L. J. Kohman *J. Clin. Oncol.* vol 28 (15s) abstr 9031 2010
Abstract Respiratory

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9031?sid=45271217-8e1e-4915-9c79-c3f21

295 Hypothetical double-consent design intervention

T. L. Demmy, L. J. Kohman, X. Wang 2010

Abstract Respiratory CALGB-30102, CALGB-9334

296 Optimal Management of Malignant Pleural Effusions (Results of CALGB 30102)

Todd L. Demmy, Lin Gu, Jack E. Burkhalter, Eric M. Toloza, Thomas A. D'Amico, Susan Sutherland, Xiaofei Wang, Laura Archer, Linda J. Veit, Leslie Kohman *J Natl Compr Canc Netw* vol 10 (8)

297 Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance).

Teresa L Deshields, Amylou C Dueck, Kerry Rogers, Jennifer R Brown, Tait Shanafelt, David Mintzer, John C Byrd *Leuk. Lymphoma* 1-4 2019

Manuscript Health Outcome CALGB-10501, CALGB-70603

<http://www.ncbi.nlm.nih.gov/pubmed/30916608>

298 A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502

S. M. Devine, K. Owzar, W. Blum, D. Deangelo, R. M. Stone, J. W. Hsu, R. E. Champlin, Y.-B. A. Chen, R. Vij, J. L. Slack, R. J. Soiffer, R. A. Larson, T. C. Shea, V. Hars, E. Bennett, S. Spangle, S. A. Giralt, S. L. Carter, M. M. Horowitz, C. Linker, E. P. 3rd Alyea *ASH Annual Meeting Abstracts* vol 120 (21) -230 2012

Abstract Transplant <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/230>

299 Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502

Steven M. Devine, Kouros Owzar, William Blum, Flora Mulkey, Richard M. Stone, Jack W. Hsu, Richard E. Champlin, Yi-Bin Chen, Ravi Vij, James Slack, Robert J. Soiffer, Richard A. Larson, Thomas C. Shea, Vera Hars, Alexander B. Sibley, Sergio Giralt, Shelly Carter, Mary M. Horowitz, Charles Linker, Edwin P. Alyea *J. Clin. Oncol* vol 33 (35) 4167-4175 2015

Manuscript Transplant <http://www.ncbi.nlm.nih.gov/pubmed/26527780>

300 Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.

Michael P DiGiovanna, David F Stern, Susan Edgerton, Gloria Broadwater, Lynn G Dressler, Daniel R Budman, I Craig Henderson, Larry Norton, Edison T Liu, Hyman B Muss, Donald A Berry, Daniel F Hayes, Ann D Thor *J. Clin. Oncol.* vol 26 (14) 2364-72 2008

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/18390970>

301 Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

Maura N. Dickler, William T. Barry, Constance T. Cirrincione, Matthew J. Ellis, Mary Ellen Moynahan, Federico Innocenti, Arti Hurria, Hope S. Rugo, Diana E. Lake, Olwen Hahn, Bryan P. Schneider, Debasish Tripathy, Lisa A. Carey, Eric P. Winer, Clifford A. Hudis *J. Clin. Oncol* vol 34 (22) 2602-2609 2016

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/27138575>

302 Phase III Trial Evaluating the Addition of Bevacizumab to Letrozole As First-line Endocrine Therapy for Treatment of Hormone-receptor Positive Advanced Breast Cancer: CALGB 40503 (Alliance)

Maura N. Dickler, William Thomas Barry, Constance T. Cirrincione, Matthew James Ellis, Mary Ellen Moynahan, Federico Innocenti, Arti Hurria, Hope S. Rugo, Diana Lake, Olwen M Hahn, Bryan P. Schneider, Debu Tripathy, Eric P. Winer, Clifford A. Hudis *J. Clin. Oncol.* vol 33 (suppl) abstr 501 2015

Abstract Breast <http://meetinglibrary.asco.org/content/143639-156>

- 303 Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma†**
M. A. Dickson, M. R. Mahoney, W. D. Tap, S. P. D'Angelo, M. L. Keohan, B. A. Van Tine, M. Agulnik, L. E. Horvath, J. S. Nair, G. K. Schwartz *Ann. Oncol* vol 27 (10) 1855-1860 2016
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/27502708>
- 304 Alliance A091102: Phase II study of MLN8237 (alisertib) in advanced/metastatic sarcoma**
Mark Andrew Dickson, Michelle R. Mahoney, Benjamin T. Marchello, Mercedes M. Condy, William D. Tap, Gary K. Schwartz *J. Clin. Oncol.* vol 31 (15 suppl) abstr TPS10594 2013
Abstract Experimental http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10527
- 305 Features Associated with Successful Recruitment of Diverse Patients onto Cancer Clinical Trials: Report from the American College of Surgeons Oncology Group**
Kathleen M. Diehl, Erin M. Green, Armin Weinberg, Wayne A. Frederick, Dennis R. Holmes, Bettye Green, Arden Morris, Henry M. Kuerer, Robert A. Beltran, Jane Mendez, Venus Gines, David M. Ota, Heidi Nelson, Lisa A. Newman *Ann. Surg. Oncol.* vol 18 (13) 3544-3550 2011
Manuscript Disparities <http://www.ncbi.nlm.nih.gov/pubmed/21681382>
- 306 Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial.**
D. M. Dilts, A. A. Adjei, S. J. Mandrekar, J. C. Buckner, L. M. Minasian, M. Rienzo, R. Ledsky, H. Massett *J. Clin. Oncol.* vol 28 (15s) abstr e16505 2010
Abstract Respiratory <http://meetinglibrary.asco.org/content/53642-74>
- 307 Allosteric Akt inhibitor MK2206 synergizes with bendamustine in promoting the apoptosis of chronic lymphocytic leukemia cells and selectively targets B-cell receptor mediated cytokine production**
W. Ding, T. D. Shanafelt, C. Lesnick, T. Sassoon, C. Secreto, C. Erlichman, J. Leis, T. G. Call, D. Bowen, S. K. Kumar, N. E. Kay *Blood* vol 120 (21) abstr 3928 2012
Abstract Leukemia <https://ash.confex.com/ash/2012/webprogram/Paper48588.html>
- 308 Akt Inhibitor MK2206 Selectively Targets CLL B-cell Receptor Induced Cytokines, Mobilizes Lymphocytes and Synergizes with Bendamustine to Induce CLL Apoptosis**
Wei Ding, Tait D. Shanafelt, Connie E. Lesnick, Charles Erlichman, Jose F. Leis, Charla Secreto, Traci R. Sassoon, Timothy G. Call, Deborah A. Bowen, Michael Conte, Shaji Kumar, Neil E. Kay *Br. J. Haematol.* vol 164 (1) 146-150 2014
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/24111951>
- 309 The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance)**
Wei Ding, Tait D. Shanafelt, Clive S. Zent, Jose F. Leis, Betsy R. LaPlant, Timothy G. Call, Curtis A. Hanson, Charles Erlichman, Thomas M. Habermann, Craig Reeder, Daniel Nikcevich, Deborah Bowen, Michael J. Conte, Justin Boysen, Charla Secreto, Connie Lesnick, Renee C. Tschumper, Diane F. Jelinek, Neil E. Kay *Blood* vol 122 (21) Abstract 2882 2013
Abstract Leukemia <http://bloodjournal.hematologylibrary.org/content/122/21/2882.abstract>
- 310 Sublobar Resection and Iodine-125 Brachytherapy for Stage 1 NSCLC, Initial Quality Assurance Review of ACOSOG Z-4032**
T. A. Dipetrillo, D. E. Heron, R. J. Landreneau, D. Logan, C. Briggs, T. J. Fitzgerald, C. R. J. Thomas, J. B. J. Putnam, B. F. Meyers, F. C. 3rd Nichols, H. C. Fernando *Int. J. Radiat. Oncol. Biol. Phys.* vol 75 (3s) S61 2009
Abstract Respiratory <http://www.redjournal.org/article/S0360-3016%2809%2901201-2/fulltext>

- 311 Clinical and Genome Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer**
M. Eileen Dolan, Omar El Charif, Heather E. Wheeler, Eric R. Gamazon, Shirin Ardeshir-Rouhani-Fard, Patrick Monahan, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Chunkit Fung, Jeri Kim, Sophie D. Fossa, Daniel L Hertz, Taisei Mushiroda, Michiaki Kubo, Lawrence H. Einhorn, Nancy J. Cox, Lois B. Travis Clin. Cancer Res. vol 23 (19) 5757-68 2017
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/28611204>
- 312 Phase III Intergroup Study of Talc Poudrage vs Talc Slurry Sclerosis for Malignant Pleural Effusion**
Carolyn M. Dresler, Jemi Olak, James E. Herndon, William G. Richards, Ernest Scalzetti, Stewart B. Fleishman, Kemp H. Kernstine, Todd Demmy, David M. Jablons, Leslie Kohman, Thomas M. Daniel, George B. Haasler, David J. Sugarbaker Chest vol 127 (3) 909-915 2005
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/15764775>
- 313 Participation in cancer pharmacogenomic studies in 8,456 patients registered to Cancer and Leukemia Group B (Alliance) clinical trials**
L. G. Dressler, A. M. Deal, D. Watson, D. Hollis, K. Owzar, K. Donohue, P. N. Friedman, M. J. Ratain, H. L. McLeod J. Clin. Oncol. vol 31 (15 suppl) abstr 6501 2013
Abstract Health Outcome CALGB-40101, CALGB-50303, CALGB-80203, CALGB-80303, CALGB-80405, CALGB-90401
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/6501?sid=e2b09ffa-e28f-45c1-afb9-2f6e54
- 314 Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance)**
Lynn G. Dressler, Allison M. Deal, Kouros Owzar, Dorothy Watson, Kathleen Donahue, Paula N. Friedman, Mark J. Ratain, Howard L. McLeod J. Natl. Cancer Inst vol 107 (10) 2015
Manuscript Health Outcome CALGB-40101, CALGB-50303, CALGB-80101, CALGB-80203, CALGB-80303, CALGB-80405, CALGB-90401 <http://www.ncbi.nlm.nih.gov/pubmed/26160883>
- 315 N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM)**
R. Dronca, D. Perez, J. Allred, W. Maples, E. Creagan, B. Pockaj, J. Kaur, J. Kuebler, B. Marchello, S. Markovic J. Clin. Oncol. vol 28 (15s) abstr 8572 2010
Abstract Experimental
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID
- 316 Phase II Study of Temozolomide (TMZ) and Everolimus (RAD001) Therapy for Metastatic Melanoma**
Roxana S. Dronca, Jacob B. Allred, Domingo G. Perez, Wendy K. Nevala, Elizabeth A.T. Lieser, Michael Thompson, William J. Maples, Edward T. Creagan, Barbara A. Pockaj, Judith S. Kaur, Timothy D. Moore, Benjamin T. Marchello, Svetomir N. Markovic Am. J. Clin. Oncol. vol 37 (4) 369-376 2014
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/23357973>
- 317 CALGB 150905 (Alliance): Rituximab broadens the anti-lymphoma response by activating unlicensed NK cells**
Juan Du, Sandra Lopez-Verges, Brandelyn N. Pitcher, Jeffrey Johnson, Sin-Ho Jung, Lili Zhou, Katharine Hsu, Myron S. Czuczman, Bruce Cheson, Lawrence Kaplan, Lewis L. Lanier, Jeffrey M. Venstrom Cancer Immunol Res vol 2 (9) 878-889 2014
Manuscript Lymphoma CALGB-150905, CALGB-50402, CALGB-50701

<http://www.ncbi.nlm.nih.gov/pubmed/24958280>

- 318 A phase II study of sorafenib in malignant mesothelioma: results of CALGB 30307**
Sarita Dubey, Pasi A. Jänne, Lee Krug, Herbert Pang, Xiaofei Wang, Robin Heinze, Colleen Watt, Jeff Crawford, Robert Kratzke, Everett Vokes, Hedy Lee Kindler J Thorac Oncol vol 5 (10) 2010
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20736856>
- 319 CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM)**
A. Z. Dudek, H. L. Kindler, G. A. Otterson, H. Pang, R. A. Kratzke, E. E. Vokes J. Clin. Oncol. vol 28 (15s) abstr 7037 2010
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID
- 320 Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report**
A. Z. Dudek, H. Pang, R. A. Kratzke, G. A. Otterson, L. Hodgson, E. E. Vokes, H. L. Kindler, Cancer, B. Leukemia Group J Thorac Oncol vol 7 (4) 755-759 2012
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/22425926>
- 321 Randomized phase 2 study of maintenance pemetrexed versus observation for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB/Alliance) 30901**
Arkadiusz Z. Dudek, Xiaofei Wang, Lin Gu, Thomas Stinchcombe, Robert Kratzke, Everett E. Vokes, Hedy L Kindler J Clin Oncol vol 37 (Suppl) abstr 8517 2019
Abstract Respiratory
https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.8517?journalCode=jco&volume=37&year=
- 322 Validity and reliability of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).**
A. C. Dueck, T. R. Mendoza, S. A. Mitchell, B. B. Reeve, K. M. Castro, A. Denicoff, A. M. O'Mara, L. J. Rogak, S. B. Clauser, D. M. Bryant, T. A. Gillis, J. D. Bearden 3rd, R. D. Siegel, J. K. Harness, D. B. Paul, C. S. S. Cleeland, J. A. Sloan, D. Schrag, L. M. Minasian, E. M. Basch J. Clin. Oncol. vol 30 (15 suppl) abstr 9047 2012
Abstract Health Outcome
http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/9047?sid=eaeacfa-0ab1-48d8-8a7b-2de08
- 323 Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance)**
A. C. Dueck, J. Singh, P. Atherton, H. Liu, P. Novotny, S. Hines, C. L. Loprinzi, E. A. Perez, A. Tan, K. Burger, X. Zhao, B. Diekmann, J. A. Sloan Osteoporos Int vol 26 (7) 1971-1977 2015
Manuscript Health Outcome N02C1, N03CC <http://www.ncbi.nlm.nih.gov/pubmed/25749740>
- 324 Calibrating clinically significant effects in survival and response endpoints in cancer clinical trials.**
A. Dueck, D. Sargent, P. Novotny, P. Decker, H. Nelson, R. Qin, J. Sloan J. Clin. Oncol. vol 29 (15 supplement) Abstract 6130 2011
Abstract Health Outcome <http://meetinglibrary.asco.org/content/85098-102>
- 325 Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).**
Amylou C. Dueck, David W. Hillman, Lisa A. Kottschade, Michele Y. Halyard, Jeff A. Sloan, Lynn M. Flickinger, Antonio C. Wolff, Lyndsay Harris, Julie Gralow, Kathleen I. Pritchard, Susan Ellard,

Nguyet Le-Lindqwister, Frances M. Boyle, Evandro de Azambuja, Wortia J. McCaskill-Stevens, Jo Anne Zujewski, Martine J. Piccart-Gebhart, Edith A. Perez J. Clin. Oncol. vol 32 (5s) (suppl; abstr 647) 2014

Abstract Breast http://abstracts.asco.org/144/AbstView_144_134049.html

326 Validity and Reliability of the U.S. National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Amylou C. Dueck, Tito R. Mendoza, Sandra A. Mitchell, Bryce B. Reeve, Kathleen M. Castro, Lauren J. Rogak, Thomas M. Atkinson, Antonia V. Bennett, Andrea M. Denicoff, Ann M. O'Mara, Yuelin Li, Steven B. Clauser, Donna M. Bryant, James D. Bearden, Theresa A. Gillis, Jay K. Harness, Robert D. Siegel, Diane B. Paul, Charles S. Cleeland, Deborah Schrag, Jeff A. Sloan, Amy P. Abernethy, Deborah W. Bruner, Lori M. Minasian, Ethan Basch JAMA Oncol vol 1 (8) 1051-1059 2015
Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/26270597>

327 A cluster-randomized study of clinician-patient shared vs standard reporting of symptomatic adverse events using PRO-CTCAE nested in a multicenter trial of multimodal therapy for rectal cancer (Alliance N1048 PROSPECT)

Amylou C. Dueck, S.A. Mitchell, Lauren I. Rogak, Brenda Ginos, Daniel J. Sargent, Qian Shi, J.M. Farma, C. Crane, H. Kennecke, A.M O'Mara, L.M. Minasian, Deborah Schrag, Ethan Basch Qual Life Res vol 24 (Suppl 1) 1-191 (abstract 2) 2015

Abstract GI

<http://download.springer.com/static/pdf/824/art%253A10.1007%252Fs11136-015-1078-4.pdf?originUrl=>

328 Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

Amylou C. Dueck, Monica M. Reinholz, Xochiquetzal J. Geiger, Kathleen Tenner, Karla Ballman, Robert B. Jenkins, Darren Riehle, Beiyun Chen, Ann E. McCullough, Nancy E. Davidson, Silvana Martino, George W. Sledge, Peter A. Kaufman, Leila A. Kutteh, Julie Gralow, Lyndsay N. Harris, James N. Ingle, Wilma L. Lingle, Edith A. Perez Clin. Cancer Res. vol 19 (20) 5798-5807 2013
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/23965903>

329 Patient-reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in NCCTG (Alliance) N1031 (Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer)

Amylou C. Dueck, Kostandinos Sideras, Jeff Sloan, Brenda F. Ginos, Shaker R. Dakhil, Ethan Basch, Edith A. Perez Quality of Life Research vol 22 (1 Supplement) 81-82 (abstr 1086) 2013

Abstract Breast <http://link.springer.com/journal/11136/22/1/suppl/page/1>

330 Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.

David B Duggan, Gina R Petroni, Jeffrey L Johnson, John H Glick, Richard I Fisher, Joseph M Connors, George P Canellos, Bruce A Peterson J. Clin. Oncol. vol 21 (4) 607-14 2003

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/12586796>

331 Radiofrequency ablation of stage Ia NSCLC in medically inoperable patients: Results from ACOSOG Z4033 (Alliance) an NCI funded multicenter trial

D. E. Dupuy, H. Fernando, S. Hillman, T. Ng, A. D. Tan, J.-A. Shepard, W. Rilling, K. Hong, J. B. Jr Putnam Chest vol 144 (4) 86A 2013

Abstract Respiratory

<http://journal.publications.chestnet.org/article.aspx?articleid=1739584&resultClick=1>

332 Radiofrequency Ablation of Stage IA NSCLC in Medically Inoperable Patients: Results from the ACOSOG Z4033 (Alliance) Trial

Damian E. Dupuy, Hiran C. Fernando, Shauna Hillman, Thomas Ng, Angelina D. Tan, Amita Sharma, William S. Rilling, Kelvin Hong, Joe B. Putnam *Cancer* vol 121 (19) 3491-3498 2015
Manuscript *Respiratory* <http://www.ncbi.nlm.nih.gov/pubmed/26096694>

333 Personality, coping, and social support as predictors of long-term quality-of-life trajectories in older breast cancer survivors: CALGB protocol 369901 (Alliance)

Estrella Durá-Ferrandis, Jeanne S. Mandelblatt, Jonathan Clapp, George Luta, Leigh Anne Faul, Gretchen Kimmick, Harvey Jay Cohen, Rachel L. Yung, Arti Hurria *Psychooncology* vol 26 (11) 1914-1921 2017

Manuscript *Older Adult* <http://www.ncbi.nlm.nih.gov/pubmed/28219113>

334 A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC).

G. K. Dy, S. J. Mandrekar, G. D. Nelson, H. J. Ross, R. H. Ansari, A. P. Lyss, P. J. Stella, S. E. Schild, J. R. Molina, A. A. Adjei *J. Clin. Oncol.* vol 28 (15s) abstr 7603 2010

Abstract *Respiratory*

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

335 N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin (C), and bevacizumab (B) in elderly patients with good performance status (PS < 2)

G. K. Dy, J. Molina, Y. Qi, R. H. Ansari, S. Thomas, H. J. Ross, J. Meyers, S. Mandrekar, A. A. Adjei *J. Clin. Oncol.* vol 30 (15 suppl) abstr 7555 2012

Abstract *Respiratory*

http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/7555?sid=292ba759-a9d8-45c0-8f1f-2ab66

336 A Front-Line “Window of Opportunity” Phase II Study of Sorafenib in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)– A North Central Cancer Treatment Group Study N03261

Grace K. Dy, Shauna L. Hillman, Kendrith M. Rowland, Julian R. Molina, Preston D. Steen, Donald B. Wender, Suresh Nair, Sumithra Mandrekar, Steven E. Schild, Alex A. Adjei *Cancer* vol 116 (24) 5686-5693 2010

Manuscript *Respiratory* <http://www.ncbi.nlm.nih.gov/pubmed/21218460>

337 Long-Term Survivors of Metastatic Colorectal Cancer Treated with Systemic Chemotherapy Alone: A North Central Cancer Treatment Group Review of 3811 Patients, N0144

Grace K. Dy, Timothy J. Hobday, Garth Nelson, Harold E. Windschitl, Michael J. O’Connell, Steven R. Alberts, Richard M. Goldberg, Daniel A. Nikcevich, Daniel J. Sargent *Clin Colorectal Cancer* vol 8 (2) 88-93 2009

Manuscript *GI* <http://www.ncbi.nlm.nih.gov/pubmed/19739269>

338 A Randomized Phase II Study of Gemcitabine and Carboplatin With or Without Cediranib as First-Line Therapy in Advanced Non-Small Cell Lung Cancer: North Central Cancer Treatment Group Study N0528

Grace K. Dy, Sumithra J. Mandrekar, Garth D. Nelson, Jeffrey P. Meyers, Araba A. Adjei, Helen J. Ross, Rafat H. Ansari, Alan P. Lyss, Philip J. Stella, Steven E. Schild, Julian R. Molina, Alex A. Adjei *J Thorac Oncol* vol 8 (1) 79-88 2013

Manuscript *Respiratory* <http://www.ncbi.nlm.nih.gov/pubmed/23232491>

339 NCCTG N0821 (Alliance): A phase II first-line study of pemetrexed, carboplatin and bevacizumab in elderly patients with advanced nonsquamous non-small cell lung cancer with good performance status

Grace K. Dy, Julian R. Molina, Yingwei Qi, Rafat Ansari, Sachdev Thomas, Helen J. Ross, Gamini Soori, Daniel Anderson, Marie Christine Aubry, Jeffrey Meyers, Araba A. Adjei, Sumithra Mandrekar, Alex A. Adjei *J Thorac Oncol* vol 9 (8) 1146-1153 2014

340 Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.

Grace K Dy, James E Krook, Erin M Green, Daniel J Sargent, Thierry Delaunoit, Roscoe F Morton, Charles S Fuchs, Ramesh K Ramanathan, Stephen K Williamson, Brian P Findlay, Barbara A Pockaj, Robert P Sticca, Steven R Alberts, Henry C Pitot, Richard M Goldberg J. Clin. Oncol. vol 25 (23) 3469-74 2007

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17687151>

341 Prognostic and predictive impact of NPM1/FLT3-ITD genotypes as defined by 2017 European LeukemiaNet (ELN) risk categorization from randomized patients with acute myeloid leukemia (AML) treated within the International RATIFY Study (ALLIANCE 10603)

Konstanze Döhner, Christian Thiede, Nikolaus Jahn, Ekaterina Panina, Agnes Gambietz, Thomas W Prior, Guido Marcucci, Dan Jones, Jürgen Krauter, Michael Heuser, Francesco Lo Coco, Tiziana Ottone, Josep Nomdedeu, Sumithra J Mandrekar, Ben L. Sanford, Kristine Laumann, Susan M. Geyer, Rebecca B. Klisovic, Andrew Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, T. M. M de Witte, Joop H. Jansen, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C Medeiros, Martin S. Tallman, Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Insa Gathmann, Axel Benner, Celine Pallaud, Richard A. Larson, Richard M. Stone, Hartmut Döhner and Clara D. Bloomfield HemaSphere vol 3 (Issue) 81–82 2019

Abstract Leukemia

https://journals.lww.com/hemasphere/Fulltext/2019/06001/PROGNOSTIC_AND_PREDICTIVE_IMPA

342 Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients treated within the RATIFY/CALGB 10603 (Alliance) Study

Konstanze Döhner, Christian Thiede, Richard A. Larson, Thomas W. Prior, Guido Marcucci, Jürgen Krauter, Michael Heuser, Francesco Lo-Coco, Josep F. Nomdedeu, Sumithra Mandrekar, Ben L. Sanford, Kristine Laumann, Susan Geyer, Rebecca B. Klisovic, Andrew Wei, Jorge Sierra, Miguel Sanz, Joseph M. Brandwein, Theo de Witte, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Yuan Cheng, Celine Pallaud, Richard M. Stone, Hartmut Döhner, Clara D. Bloomfield Blood vol 130 (Suppl 1) 467 2017

Abstract Leukemia http://www.bloodjournal.org/content/130/Suppl_1/467

343 Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma

Sandra P. D'Angelo, Michelle R. Mahoney, Brian A. Van Tine, Douglas R. Adkins, Maria T. Grosse Perdekamp, Mercedes M. Condy, Jason J. Luke, Eliza Woodward Hartley, Cristina R. Antonescu, William D. Tap, Gary K. Schwartz Cancer Chemother. Pharmacol. vol 75 (3) 629-638 2015

Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/25672915>

344 A non-comparative multi-center randomized phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401)

Sandra P. D'Angelo, Michelle R. Mahoney, Brian A. Van Tine, James Atkins, Mohammed M. Milhem, Balkrishna N. Jahagirdar, Cristina R. Antonescu, Elise Horvath, William D. Tap, Gary K. Schwartz, Howard Streicher Lancet Oncol. vol 19 (3) 416-426 2018

Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/29370992>

345 A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401)

Sandra P. D'Angelo, Michelle R. Mahoney, Brian Van Tine, James Atkins, Mohammed M Milhem, William D. Tap, Cristina A. Antonescu, Priya U. Kumthekar, Gary K. Schwartz, Howard Streicher J.

346 CALGB 90203 (Alliance): Radical Prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high risk prostate cancer.

J.A. Eastham, G. Heller, S. Halabi, J. P. Monk, H. Beltran, M. Gleave, C.P. Evans, Steven Clinton, Russell Szmulewitz, Jonathan Coleman, David Hillman, Colleen Watt, O. Hahn, M. E. Taplin, E.

Small, J. Mohler, M. J. Morris *Journal of Urology* vol 201 (Suppl 4) e997 2019

Abstract GU <https://www.auajournals.org/doi/abs/10.1097/01.JU.0000557504.00464.d6>

347 CALGB 90203 (Alliance): Radical Prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high risk prostate cancer

J.A. Eastham, G. Heller, S. Halabi, J. P. Monk, H. Beltran, M. Gleave, C.P. Evans, Steven Clinton, Russell Szmulewitz, Jonathan Coleman, David Hillman, Colleen Watt, O. Hahn, M. E. Taplin, E.

Small, J. Mohler, M. J. Morris *J. Clin. Oncol.* vol 37 (15_suppl) 5079 2019

Abstract GU https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.5079

348 Serum VEGF and COX-2/5LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304

M. J. Edelman, L. D. Hodgson, X. Wang, R. H. Christenson, E. E. Vokes, R. A. Kratzke *J. Clin. Oncol.* vol 28 (15s) abstr 7614 2010

Abstract Respiratory

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7614?sid=378de8b3-c266-4aa9-9277-0f441

349 Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203

M. J. Edelman, D. M. Watson, X. Wang, R. A. Kratzke, A. M. Mauer, M. R. Green, E. E. Vokes, S. L. Graziano, G. A. Masters, M. M. Bedor *J. Clin. Oncol.* vol 24 (18s) abstr 7025 2006

Abstract Respiratory

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=40&abstractID

350 CYFRA 21-1 as a prognostic and predictive marker in advanced non-small cell lung cancer in a prospective trial: CALGB 150304

Martin J. Edelman, Lydia Hodgson, Paula Y. Rosenblatt, Robert H. Christenson, Everett Vokes, Xiaofei Wang, Robert Kratzke *J Thorac Oncol* vol 7 (4) 649-654 2012

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/22425913>

351 Serum Vascular Endothelial Growth Factor and COX-2/5-LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and Leukemia Group B 150304

Martin J. Edelman, Lydia Hodgson, Xiaofei Wang, Robert Christenson, Scott Jewell, Everett Vokes, Robert Kratzke *J Thorac Oncol* vol 6 (11) 1902-1906 2011

Manuscript Respiratory CALGB-150304, CALGB-30203

<http://www.ncbi.nlm.nih.gov/pubmed/21964530>

352 Final Results of a phase III trial of celecoxib (C) in addition to standard chemotherapy for advanced NSCLC with COX- 2 overexpression: CALGB 30801 (Alliance)

Martin J. Edelman, Xiaofei Wang, Lydia Hodgson, Richard T. Cheney, Maria Q. Bagstrom, Thomas Sachdev, Ajeet Gajra, Erin Bertino, Karen L. Reckamp, Julian Molina, Joan Schiller, Kisha

Mitchell-Richards, Paula N. Friedman, Jon Ritter, Ginger Milne, Olwen Hahn, Thomas Stinchcombe, Everett E. Vokes *Int. J. Radiat. Oncol. Biol. Phys.* vol 98 (1) 220-1 2017

Abstract Respiratory [http://www.redjournal.org/article/S0360-3016\(17\)30057-3/abstract](http://www.redjournal.org/article/S0360-3016(17)30057-3/abstract)

353 Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2

Overexpression: CALGB 30801 (Alliance)

Martin J. Edelman, Xiaofei Wang, Lydia Hodgson, Richard T. Cheney, Maria Q. Bagstrom, Sachdev P. Thomas, Ajeet Gajra, Erin Bertino, Karen L. Reckamp, Julian Molina, Joan H. Schiller, Kisha Mitchell-Richards, Paula N. Friedman, Jon Ritter, Ginger Milne, Olwen M. Hahn, Thomas E. Stinchcombe, Everett E. Vokes *J. Clin. Oncol* vol 35 (19) 2184-2192 2017
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/28489511>

354 Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

Martin J Edelman, Dee Watson, Xiaofei Wang, Carl Morrison, Robert A Kratzke, Scott Jewell, Lydia Hodgson, Ann M Mauer, Ajeet Gajra, Gregory A Masters, Michelle Bedor, Everett E Vokes, Mark J Green *J. Clin. Oncol.* vol 26 (6) 848-55 2008
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18281656>

355 Cytogenetic, Molecular and Clinical Features Associated with Rare CBFβ-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16)

C. G. Edwards, K. Maharry, K. Mrozek, S. Schwind, P. Paschka, D. Nicolet, J. Kohlschmidt, T. W. Prior, Y.-Z. Wu, J. E. Kolitz, W. Blum, M. J. Pettenati, P. D. Cin, A. J. Carroll, M. A. Caligiuri, R. A. Larson, G. Marcucci, C. D. Bloomfield *Blood* vol 118 (21) 2514 2011
Abstract *Leuk Corr Sci* CALGB-10503, CALGB-19808, CALGB-9621
<http://www.bloodjournal.org/content/118/21/2514>

356 Long-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial

D. Eiger, N. F. Ponde, D. Agbor-Tarh, Alvaro Moreno-Aspitia, Martine Piccart, Richard Rodeheffer, Michael Ewers, Thomas Suter, E. de Azambuja *Annals of Oncology* vol 30 (Supplement_3) iii65–iii71 2019
Abstract *Breast* https://academic.oup.com/annonc/article/30/Supplement_3/mdz101/5488368

357 The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia

A-K Eifeld, K Mrózek, J Kohlschmidt, D Nicolet, S Orwick, C J Walker, K W Kroll, J S Blachly, A J Carroll, J E Kolitz, B L Powell, E S Wang, R M Stone, A de la Chapelle, J C Byrd, C D Bloomfield *Leukemia* vol 31 (10) 2211-18 2017
Manuscript *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/28321123>

358 Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2

Ann-Kathrin Eifeld, Jessica Kohlschmidt, Krzysztof Mrózek, James S. Blachly, Deedra Nicolet, Karl Kroll, Shelley Orwick, Andrew J. Carroll, Richard M. Stone, Albert de la Chapelle, John C. Byrd, Clara D. Bloomfield *Leukemia* vol 30 (11) 2254-2258 2016
Manuscript *Leuk Corr Sci* CALGB-20202, CALGB-8461
<http://www.ncbi.nlm.nih.gov/pubmed/27435003>

359 Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies

Ann-Kathrin Eifeld, Jessica Kohlschmidt, Krzysztof Mrózek, James S. Blachly, Christopher J. Walker, Deedra Nicolet, Shelley Orwick, Sophia E. Maharry, Andrew J. Carroll, Richard M. Stone, Albert de la Chapelle, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, John C. Byrd, Clara D. Bloomfield *Leukemia* vol 32 (6) 1338-48 2018
Manuscript *Leuk Corr Sci* C8461, C8525, C8821, C9665, CALGB-10201, CALGB-10502, CALGB-11001, CALGB-11002, CALGB-20202, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/29563537>

- 360 NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome**
Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, Alice Mims, Christopher J. Walker, James S. Blachly, Deedra Nicolet, Shelley Orwick, Sophia E. Maharry, Andrew J. Carroll, Bayard L. Powell, Jonathan E. Kolitz, Eunice S. Wang, Richard M. Stone, Albert de la Chapelle, John C. Byrd, Clara D. Bloomfield *Leukemia* vol 32 2536–45 2018
Manuscript *Leuk Corr Sci* C8525, C8821, C9022, C9621, C9720, CALGB-10201, CALGB-10502, CALGB-10503, CALGB-10603, CALGB-19808, CALGB-8923
<http://www.ncbi.nlm.nih.gov/pubmed/29872168>
- 361 Additional gene mutations refine the 2017 European Leukemianet (ELN) classification of adult patients (pts) with de novo acute myeloid leukemia (AML) aged <60 years: An analysis of Alliance studies**
Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, Alice Mims, Christopher J. Walker, Deedra Nicolet, James S. Blachly, Andrew J. Carroll, Jonathan E. Kolitz, Bayard E. Powell, Richard M. Stone, Albert de la Chapelle, John C. Byrd, Clara D. Bloomfield *Blood* vol 132 (Suppl 1) 2740 2018
Abstract *Leuk Corr Sci* C8461, CALGB-20202
http://www.bloodjournal.org/content/132/Suppl_1/2740
- 362 Mutations in genes associated with familial predisposition to myeloid neoplasms: their frequency and associations with pretreatment characteristics in adult patients (pts) with presumably sporadic de novo acute myeloid leukemia (AML) (Alliance)**
Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, Alice Mims, Christopher J. Walker, Deedra Nicolet, James S. Blachly, Luke Genutis, Andrew J. Carroll, Bayard L. Powell, Jonathan E. Kolitz, Richard M. Stone, Albert de la Chapelle, John C. Byrd, Clara D. Bloomfield *Blood* vol 132 (Suppl 1) 1478 2018
Abstract *Leuk Corr Sci* C8461, CALGB-20202
http://www.bloodjournal.org/content/132/Suppl_1/1478
- 363 Mutational landscape and gene-expression patterns in adult acute myeloid leukemias with monosomy 7 as a sole abnormality**
Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, Stefano Volinia, James S. Blachly, Deedra Nicolet, Christopher Oakes, Karl Kroll, Shelley Orwick, Andrew J. Carroll, Richard M. Stone, John C. Byrd, Albert de la Chapelle, Clara D. Bloomfield *Cancer Res.* vol 77 (1) 207-218 2017
Manuscript *Leuk Corr Sci* CALGB-10201, CALGB-10503, CALGB-10603, CALGB-11002, CALGB-19808, CALGB-20202, CALGB-8461, CALGB-8525, CALGB-9222, CALGB-9420, CALGB-9621 <http://www.ncbi.nlm.nih.gov/pubmed/27784745>
- 364 Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia**
Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Sebastian Schwind, Deedra Nicolet, James S. Blachly, Shelley Orwick, Chandni Shah, Maryam Bainazar, Karl W. Kroll, Christopher J. Walker, Andrew J. Carroll, Bayard L. Powell, Richard M. Stone, Jonathan E. Kolitz, Maria R. Baer, Albert de la Chapelle, Krzysztof Mrózek, John C. Byrd, Clara D. Bloomfield *Leukemia* vol 31 (6) 1278-1285 2017
Manuscript *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/27843138>
- 365 Heritable polymorphism predisposes to high expression of BAALC in cytogenetically normal acute myeloid leukemia (CN-AML)**
Ann-Kathrin Eisfeld, G. Marcucci, S. Liyanarachchi, K. Döhner, S. Schwind, K. Maharry, D. Nicolet, M. D. Radmacher, H. Döhner, S. M. Tanner, C. D. Bloomfield, A. De La Chapelle *AACR Annual Meeting abstr* 1307 2012

366 MiR-3151, a novel microRNA embedded in BAALC, is only weakly co-expressed with its host gene and independently impacts on the clinical outcome of older patients (pts) with de novo cytogenetically normal acute myeloid leukemia (CN-AML)

Ann-Kathrin Eisfeld, G. Marcucci, K. Maharry, S. Schwind, M. D. Radmacher, D. Nicolet, H. Becker, S. P. Whitman, K. H. Metzeler, K. Mrozek, Y.-Z. Wu, M. R. Baer, B. L. Powell, T. H. Carter, J. O. Moore, J. E. Kolitz, M. Wetzler, M. A. Caligiuri, R. A. Larson, S. M. Tanner, A. De La Chapelle, C. D. Bloomfield *Blood* vol 118 (21) 1462 2011

Abstract Leuk Corr Sci C8525, CALGB-10201, CALGB-8923, CALGB-9420, CALGB-9720

<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/1462>

367 Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia

Ann-Kathrin Eisfeld, Guido Marcucci, Sandya Liyanarachchi, Konstanze Döhner, Sebastian Schwind, Kati Maharry, Benjamin Leffel, Hartmut Döhner, Michael D. Radmacher, Clara D. Bloomfield, Stephan M. Tanner, Albert de la Chapelle *Proc. Natl. Acad. Sci. U.S.A* vol 109 (17) 6668-6673 2012
Manuscript Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pubmed/22493267>

368 miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia

Ann-Kathrin Eisfeld, Guido Marcucci, Kati Maharry, Sebastian Schwind, Michael D. Radmacher, Deedra Nicolet, Heiko Becker, Krzysztof Mrózek, Susan P. Whitman, Klaus H. Metzeler, Jason H. Mender, Yue-Zhong Wu, Sandya Liyanarachchi, Ravi Patel, Maria R. Baer, Bayard L. Powell, Thomas H. Carter, Joseph O. Moore, Jonathan E. Kolitz, Meir Wetzler, Michael A. Caligiuri, Richard A. Larson, Stephan M. Tanner, Albert de la Chapelle, Clara D. Bloomfield *Blood* vol 120 (2) 249-258 2012

Manuscript Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pubmed/22529287>

369 Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma

Benjamin M Ellingson, Lauren E Abrey, Sarah J Nelson, Timothy J Kaufmann, Josep Garcia, Olivier Chinot, Frank Saran, Ryo Nishikawa, Roger Henriksson, Warren P Mason, Wolfgang Wick, Nicholas Butowski, Keith L Ligon, Elizabeth R Gerstner, Howard Colman, John de Groot, Susan Chang, Ingo Mellinghoff, Robert J Young, Brian M Alexander, Rivka Colen, Jennie W Taylor, Isabel Arrillaga-Romany, Arnav Mehta, Raymond Y Huang, Whitney B Pope, David Reardon, Tracy Batchelor, Michael Prados, Evanthia Galanis, Patrick Y Wen, Timothy F Cloughesy *Neuro-oncology* vol 20 (9) 1240-50 2018

Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/29660006>

370 ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer

M. J. Ellis, A. U. Buzdar, G. W. Unzeitig, L. J. Esserman, A. M. Leitch, K. Deshryver, D. C. Allred, V. Suman, K. K. Hunt, J. Olson *J. Clin. Oncol.* vol 28 (18s) abstr LBA513 2010

Abstract Breast

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

371 Whole-genome analysis informs breast cancer response to aromatase inhibition

M. J. Ellis, L. Ding, D. Shen, J. Q. Luo, V. J. Suman, J. W. Wallis, B. A. Van Tine, J. Hoog, R. J. Goiffon, T. C. Goldstein, S. Ng, L. Lin, R. Crowder, J. Snider, K. Ballman, J. Weber, K. Chen, D. C. Koboldt, C. Kandoth, W. S. Schierding, J. F. McMichael, C. A. Miller, C. Lu, C. C. Harris, M. D. McLellan, M. C. Wendl, K. Deschryver, D. C. Allred, L. Esserman, G. Unzeitig, J. Margenthaler, G. V. Babiera, P. K. Marcom, J. M. Guenther, M. Leitch, K. Hunt, J. Olson, Y. Tao, C. A. Maher, L. L.

Fulton, R. S. Fulton, M. Harrison, B. Oberkfell, F. Y. Du, R. Demeter, T. L. Vickery, A. Elhammali, H. Piwnica-Worms, S. McDonald, M. Watson, D. J. Dooling, D. Ota, L. W. Chang, R. Bose, T. J. Ley, D. Piwnica-Worms, J. M. Stuart, R. K. Wilson, E. R. Mardis Nature vol 486 (7403) 353-360 2012
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/22722193>

372 Z1031B neoadjuvant aromatase inhibitor trial: A Phase 2 study of triage to chemotherapy based on 2 to 4 week Ki67 level >10%

M. J. Ellis, V Suman, L. McCall, R. Luo, J. Hoog, A. Brink, M. Watson, C. Ma, G. Unzeitig, T. Pluard, P. Whitworth, G. Babiera, M. Guenther, Z. Dayao, M. Leitch, D. Ota, J. Olson, K. Hunt, C. Allred
Cancer Res. vol 72 (24 suppl) PD07-01 2012
Abstract Breast http://cancerres.aacrjournals.org/content/72/24_Supplement/PD07-01.short

373 Tumor Ki67 Proliferation Index within 4 Weeks of Initiating Neoadjuvant Endocrine Therapy for Early Identification of Non-Responders

M. Ellis, J. Luo, Y. Tao, J. Hoog, J. Snider, K. DeSchryver, C. Allred, S. Davies, K. Hunt, J. Olson, V. Suman, C. Perou, T. Nielsen, M. Cheang, I. Smith, R. A'Hern and M. Dowsett Cancer Research vol 69 (24) 2009
Abstract Correl Sci NOS http://cancerres.aacrjournals.org/content/69/24_Supplement/78

374 Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Rodrigo Goncalves, Souzan Sanati, Chad J. Creighton, Katherine DeSchryver, Erika Crouch, Amy Brink, Mark Watson, Jingqin Luo, Yu Tao, Michael Barnes, Mitchell Dowsett, G. Thomas Budd, Eric Winer, Paula Silverman, Laura Esserman, Lisa Carey, Cynthia X. Ma, Gary Unzeitig, Timothy Pluard, Pat Whitworth, Gildy Babiera, J. Michael Guenther, Zoneddy Dayao, David Ota, Marilyn Leitch, John A. Olson, D. Craig Allred, Kelly Hunt J. Clin. Oncol vol 35 (10) 1061-1069 2017
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/28045625>

375 Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Li Lin, Jacqueline Snider, Aleix Prat, Joel S. Parker, Jingqin Luo, Katherine DeSchryver, D. Craig Allred, Laura J. Esserman, Gary W. Unzeitig, Julie Margenthaler, Gildy V. Babiera, P. Kelly Marcom, Joseph M. Guenther, Mark A. Watson, Marilyn Leitch, Kelly Hunt, John A. Olson J. Clin. Oncol. vol 29 (17) 2342-2349 2011
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/21555689>

376 Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

Matthew J Ellis, Li Lin, Robert Crowder, Yu Tao, Jeremy Hoog, Jacqueline Snider, Sherri Davies, Katherine DeSchryver, Dean B Evans, Jutta Steinseifer, Raj Bandaru, WeiHua Liu, Humphrey Gardner, Vladimir Semiglazov, Mark Watson, Kelly Hunt, John Olson, José Baselga Breast Cancer Res Treat vol 119 (2) 379-390 2010
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/19844788>

377 CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer

P. C. Enzinger, B. Burtness, D. R. Hollis, D. Niedzwiecki, D. H. Ilson, A. B. 3rd Benson, R. J. Mayer, R. M. Goldberg J. Clin. Oncol. vol 28 (15s) abstr 4006 2010
Abstract GI <http://meetinglibrary.asco.org/content/44487-74>

- 378 CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers**
Peter C. Enzinger, Barbara Ann Burtness, Donna Niedzwiecki, Xing Ye, Kathe Douglas, David H. Ilson, Victoria Meucci Villaflor, Steven J. Cohen, Robert J. Mayer, Alan Venook, Al Bowen Benson, Richard M. Goldberg J. Clin. Oncol vol 34 (23) 2736-2742 2016
Manuscript GI CALGB-80403, ECOG-1206 <http://www.ncbi.nlm.nih.gov/pubmed/27382098>
- 379 Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657**
L. J. Esserman, D. A. Berry, A. Demichele, L. Carey, S. E. Davis, M. Buxton, C. Hudis, J. W. Gray, C. Perou, C. Yau, C. Livasy, H. Krontiras, L. Montgomery, D. Tripathy, C. Lehman, M. C. Liu, O. I. Olopade, H. S. Rugo, J. T. Carpenter, L. Dressler, D. Chhieng, B. Singh, C. Mies, J. Rabban, Y. Y. Chen, D. Giri, L. Van't Veer, N. Hylton J. Clin. Oncol. vol 30 (26) 3242-3249 2012
Manuscript Correl Sci NOS CALGB-150007, CALGB-150012, ACRIN-6657
<http://www.ncbi.nlm.nih.gov/pubmed/22649152>
- 380 Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY Trial (CALGB 150007/150012, ACRIN 6657)**
L. J. Esserman, C. M. Perou, M. Cheang, A. Demichele, L. A. Carey, L. J. Van't Veer, J. W. Gray, E. Petricoin, K. M. Conway, D. A. Berry J. Clin. Oncol. vol 27 (18s) abstr LBA515 2009
Abstract Correl Sci NOS ACRIN-6657, CALGB-150007
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID
- 381 Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)**
Laura J. Esserman, Donald A. Berry, Maggie C. U. Cheang, Christina Yau, Charles M. Perou, Lisa Carey, Angela DeMichele, Joe W. Gray, Kathleen Conway-Dorsey, Marc E. Lenburg, Meredith B. Buxton, Sarah E. Davis, Laura J. van't Veer, Clifford Hudis, Koei Chin, Denise Wolf, Helen Krontiras, Leslie Montgomery, Debu Tripathy, Constance Lehman, Minetta C. Liu, Olufunmilayo I. Olopade, Hope S. Rugo, John T. Carpenter, Chad Livasy, Lynn Dressler, David Chhieng, Baljit Singh, Carolyn Mies, Joseph Rabban, Yunni-Yi Chen, Dilip Giri, Alfred Au, Nola Hylton Breast Cancer Res. Treat vol 132 (3) 1049-1062 2012
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/22198468>
- 382 Nut Consumption and Survival in Stage III Colon Cancer Patients: Results from CALGB 89803 (Alliance)**
Temidayo Fadelu, Sui Zhang, Donna Niedzwiecki, Xing Ye, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Kimmie Ng, Edward L. Giovannucci, Jeffrey A. Meyerhardt, Ying Bao, Charles S. Fuchs J. Clin. Oncol. vol 35 (15 suppl) abstr 3517 2017
Abstract GI http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3517
- 383 Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance)**
Temidayo Fadelu, Sui Zhang, Donna Niedzwiecki, Xing Ye, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al B. Benson, Daniel M. Atienza, Michael Messino, Hedy L. Kindler, Alan Venook, Shuji Ogino, Kimmie Ng, Kana Wu, Walter Willett, Edward Giovannucci, Jeffrey Meyerhardt, Ying Bao, Charles S. Fuchs J. Clin. Oncol vol 36 (11) 1112-20 2018
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/29489429>
- 384 A Prospective Multicenter Phase II Trial of Pentostatin in Adult Patients with**

Steroid-Refractory Chronic Graft-Versus-Host Disease (cGvHD): A Cancer and Leukemia Group B/Eastern Cooperative Oncology Group Study

S. Farag, K. Owzar, V. Hars, H. M. Lazarus, E. A. Stadtmauer, S. M. Devine, K. V. Besien, C. Linker
Blood vol 114 (22) 2238 2009

Abstract Transplant <http://www.bloodjournal.org/content/114/22/2238?sso-checked=true>

385 Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Aged 60–70 Years with Acute Myeloid Leukemia in First Remission

Sherif S. Farag, Kati Maharry, Mei-Jie Zhang, Waleska S. Pérez, Stephen L. George, Krzysztof Mrózek, John DiPersio, Donald W. Bunjes, Guido Marcucci, Maria R. Baer, Mitchell Cairo, Edward Copelan, Corey S. Cutler, Luis Isola, Hillard M. Lazarus, Mark R. Litzow, David I. Marks, Olle Ringdén, David A. Rizzieri, Robert Soiffer, Richard A. Larson, Martin S. Tallman, Clara D. Bloomfield, Daniel J. Weisdorf Biol. Blood Marrow Transplant. vol 17 (12) 2011

Manuscript Leukemia CALGB-9720, CALGB-10201

<http://www.ncbi.nlm.nih.gov/pubmed/21699879>

386 Lymphatic Drainage Patterns in Oral Squamous Cell Carcinoma: Findings of the ACOSOG Z0360 (Alliance) Study

Roger W. Farmer, Linda McCall, Francisco J. Civantos, Jeffrey N. Myers, Wendell G. Yarbrough, Barbara Murphy, Miriam O’Leary, Robert Zitsch, Barry A. Siegel Otolaryngol Head Neck Surg vol 152 (4) 673-677 2015

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/25749001>

387 Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901

Leigh Anne Faul, Gheorghe Luta, Vanessa Sheppard, Claudine Isaacs, Harvey J. Cohen, Hyman B. Muss, Rachel Yung, Jonathan D. Clapp, Eric Winer, Clifford Hudis, Michelle Tallarico, Julhy Wang, William T. Barry, Jeanne S. Mandelblatt J Cancer Surviv vol 8 (4) 627-637 2014

Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/24917307>

388 Causal modeling of CALGB 80405 (Alliance) identifies network drivers of metastatic colorectal cancer (CRC)

Federico Innocenti, Heinz-Josef Lenz, Jeffrey Meyerhardt, Donna Niedzwiecki, Andrew Nixon, Eileen O’Reilly, Fang-Shu Ou, Alan Venook, Rahul K. Das, Leon Furchtgott, Daniel Cunha, Kelly Rich, Jeanne Latourelle, Diane Wuest, Boris Hayete, Iya Khalil J Clin Oncol vol 36 (Suppl) abstr 3570 2018

Abstract GU <https://meetinglibrary.asco.org/record/158938/abstract>

389 ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203)

D Feldman, M Feuilly, J Meng, J Lister, F Marteau, MJ Morris, D George, T Choueiri J Clin Oncol vol 36 (Suppl) abstr e18690 2018

Abstract GU <https://meetinglibrary.asco.org/record/159636/abstract>

390 Do Older Patients with Metastatic Non-Small Cell Lung Cancer Also Benefit from First-Line Platinum-Based Doublet Chemotherapy?

Josephine L. Feliciano, Jennifer G. Le-Rademacher, Ajeet Gajra, Martin J. Edelman, Tyler Zemla, Ryan McMurray, Hongbin Chen, Arti Hurria, Hyman Muss, Harvey J. Cohen, Rogerio Lilenbaum, Aminah Jatoi J Geriatr Oncol vol 9 (5) 501-6 2018

Manuscript Older Adult CALGB-30203, A151622, CALGB-30801, CALGB-9730

<http://www.ncbi.nlm.nih.gov/pubmed/29848457>

391 Genomic predictive biomarkers to anti-HER2 targeted therapies: a combined analysis of

CALGB 40601 (Alliance) and PAMELA clinical trials

Aranzazu Fernandez-Martinez, Maki Tanioka, Cheng Fan, Joel S. Parker, Katherine A. Hoadley, Ian Krop, Javier Cortes, Antonio Llombart-Cussac, Paolo Nuciforo, Patricia Galván, Tomás Pascual, Ann Patridge, Aleix Prat, Charles Perou, Lisa Carey J. Clin. Oncol. vol 37 (15_suppl) 571-571 2019
Abstract Breast https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.571

392 Thirty and Ninety Day Outcomes After Sublobar Resection of High-risk Patients with Non-small cell lung cancer (NSCLC); Results from a multicenter phase III study

H. C. Fernando, R. J. Landreneau, S. Mandraker, S. Hillman, F. Nichols, T. A. Dipetrillo, D. E. Heron, B. F. Meyers, D. R. Jones, S. Starnes, J. B. Putnam Jr American Association of Thoracic Surgery 91st Annual Meeting abstr 2011
Abstract Respiratory <http://www.aats.org/annualmeeting/Abstracts/2011/55.cgi>

393 The Impact of Adjuvant Brachytherapy with Sublobar Resection on Pulmonary Function and Dyspnea: Preliminary Results from ACOSOG Z4032 Trial

H. C. Fernando, R. Landreneau, S. Mandraker, S. Hillman, F. Nichols, B. Meyers, T. A. Dipetrillo, D. E. Heron, J. B. Jr Putnam American Association of Thoracic Surgery 90th Annual Meeting abstr 2010
Abstract Respiratory <http://aats.org/annualmeeting/Abstracts/2010/15.cgi>

394 Impact of brachytherapy on local recurrence after sublobar resection: Results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small cell lung cancer (NSCLC)

H. Fernando, R. Landreneau, S. Mandrekar, F. Nichols, S. Hillman, D. Heron, B. Meyers, T. Dipetrillo, D. Jones, S. Starnes, A. Tan, B. Daly, J. Putnam J. Clin. Oncol. vol 31 (15 suppl) abstr 7502 2013
Abstract Respiratory
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7502?sid=40c2cbc2-3313-4c9e-8f07-89c7f

395 Impact of Brachytherapy on Local Recurrence Rates After Sublobar Resection: Results From ACOSOG Z4032 (Alliance), a Phase III Randomized Trial for High-Risk Operable Non-Small-Cell Lung Cancer

Hiran C. Fernando, Rodney J. Landreneau, Sumithra J. Mandrekar, Francis C. Nichols, Shauna L. Hillman, Dwight E. Heron, Bryan F. Meyers, Thomas A. DiPetrillo, David R. Jones, Sandra L. Starnes, Angelina D. Tan, Benedict D.T. Daly, Joe B. Putnam J. Clin. Oncol vol 32 (23) 2456-2462 2014
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/24982457>

396 American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021: A randomized study of sublobar resection compared with stereotactic body radiotherapy for high-risk stage I non-small cell lung cancer

Hiran C. Fernando, Robert Timmerman J. Thorac. Cardiovasc. Surg. vol 144 (3) S35-S38 2012
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/22795435>

397 The Impact of Adjuvant Brachytherapy with Sublobar Resection on Pulmonary Function and Dyspnea in High-risk Operable Patients; Preliminary results from the ACOSOG Z4032 Trial

Hiran C Fernando, Rodney J Landreneau, Sumithra J Mandrekar, Shauna L Hillman, Francis C Nichols, Bryan Meyers, Thomas A DiPetrillo, Dwight Heron, David R Jones, Benedict D T Daly, Sandra L Starnes, Jeffrey E Hatter, Joe B Putnam J Thorac Cardiovasc Surg vol 142 (3) 554-562 2011
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21724195>

398 Analysis of longitudinal quality of life data in high-risk operable patients with lung cancer: Results from ACOSOG Z4032 (Alliance) a multicenter randomized trial

Hiran C Fernando, Rodney J Landreneau, Sumithra J Mandrekar, Francis C Nichols, Thomas A

DiPetrillo, Bryan F Meyers, Dwight E Heron, Shauna Hillman, David R Jones, Sandra L Starnes, Angelina D Tan, Benedict D T Daly, Joe B Putnam J. Thorac. Cardiovasc. Surg. vol 149 (3) 718-726 2015

Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/25500100>

399 Factors contributing to cancer screening in African Americans

C. E. Ferrans, C. Ryan, L. E. Archer, S. Freels, L. Lan, E. Paskett, R. Molokie, D. D. Hurd, A. B. Kornblith J. Clin. Oncol. vol 26 (May 20 suppl) abstr 6514 2008

Abstract Health Outcome

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

400 Dose intensified daunorubicin induction and consolidation plus combined modality maintenance therapy for children with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup study C9710

J. Feusner, J. Gregory, B. K. Moser, V. Hars, B. L. Powell, R. A. Larson J. Clin. Oncol. vol 25 (15s) abstr 9510 2010

Abstract Leukemia

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

401 Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030)

J. J. Fibla, S. D. Cassivi, P. A. Decker, M. S. Allen, G. E. Darling, R. J. Landreneau, R. W. McKenna, D. R. Jones, R. I. Inculet, J. B. Putnam Jr J. Clin. Oncol. vol 28 (15s) abstr 7021 2010

Abstract Respiratory <http://meetinglibrary.asco.org/content/54130-74>

402 Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set

Juan J. Fibla, Stephen D. Cassivi, Alessandro Brunelli, Paul A. Decker, Mark S. Allen, Gail E. Darling, Rodney J. Landreneau, Joe B. Putnam Lung Cancer vol 78 (3) 259-262 2012

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/23040416>

403 Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030)

Juan J. Fibla, Stephen D. Cassivi, Paul A. Decker, Mark S. Allen, Gail E. Darling, Rodney J.

Landreneau, Robert J. McKenna, Joe B. Putnam Eur J Cardiothorac Surg vol 43 (5) 911-914 2013

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/23014970>

404 Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial

Gini F Fleming, Prudence A Francis, István Láng, Eva M Ciruelos, Meritxell Bellet, Hervé R Bonnefoi, Miguel A Climent, Lorenzo Pavesi, Harold J Burstein, Silvana Martino, Nancy E Davidson, Charles E Geyer, Jr, Barbara A Walley, Robert E Coleman, Pierre Kerbrat, Stefan Buchholz, James N Ingle, Manuela Rabaglio-Poretti, Marco Colleoni, Meredith M Regan Ann. Oncol. vol 28 (9) 2225-2232 2017

Abstract Breast <https://academic.oup.com/annonc/article/28/9/2225/4080725>

405 Five year results from the COST trial testing laparoscopic versus open colectomy for colon cancer

J. Fleshman, D. Sargent, E. Green, M. Anvari, S. Stryker, R. Beart, M. Hellinger, R. Flanagan, W. Peters, H. Nelson EJC Supplement vol 5 (4) 12 abstr 31 2007

Abstract GI

<http://download.journals.elsevierhealth.com/pdfs/journals/1359-6349/PIIS1359634907701453.pdf>

406 Disease Free Survival and Local Recurrence for Laparoscopic Resection Compared to Open Resection of Stage II-III Rectal Cancer: Follow up Results of the ACOSOG Z6051 Randomized Controlled Trial

J Fleshman, ME Branda, DJ Sargent, AM Boller, VV George, MA Abbas, WR Jr Peters, DC Maun, GJ Chang, A Herline, A Fichera, MG Mutch, SD Wexner, MH Whiteford, J Marks, E Birnbaum, DA Margolin, DW Larson, PW Marcello, MC Posner, TE Read, JRT Monson, SM Wren, PWT Pisters, H Nelson Ann. Surg. vol 269 (4) 589-95 2019
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/30080730>

407 Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes

James Fleshman, Megan Branda, Daniel J. Sargent, Anne Marie Boller, Virgilio George, Maher Abbas, Walter R. Peters, Dipen Maun, George Chang, Alan Herline, Alessandro Fichera, Matthew Mutch, Steven Wexner, Mark Whiteford, John Marks, Elisa Birnbaum, David Margolin, David Larson, Peter Marcello, Mitchell Posner, Thomas Read, John Monson, Sherry M. Wren, Peter W. T. Pisters, Heidi Nelson JAMA vol 314 (13) 1346-1355 2015
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/26441179>

408 Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial.

James Fleshman, Daniel J Sargent, Erin Green, Mehran Anvari, Steven J Stryker, Robert W Beart, Michael Hellinger, Richard Flanagan, Walter Peters, Heidi Nelson Ann. Surg. vol 246 (4) 655-62; discussion 662-4 2007
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17893502>

409 Comparative nocebo findings in older patients enrolled in cancer therapeutic trials: observations from a 446-patient cohort (Alliance A151602)

Jared C. Foster, Jennifer G. Le-Rademacher, Josephine L. Feliciano, Ajeet Gajra, Drew K. Seisler, Ronald DeMatteo, Jacqueline M. Lafky, Arti Hurria, Hyman B. Muss, Harvey J. Cohen, Aminah Jatoi J. Clin. Oncol. vol 35 (15 suppl) e21545 2017
Abstract Older Adult A151602, ACOSOG-Z9001, NCCTG-97-24-51
http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e21545

410 Comparative “Nocebo Effects” in Older Patients Enrolled in Cancer Therapeutic Trials: Observations From a 446-Patient Cohort

Jared C. Foster, Jennifer G. Le-Rademacher, Josephine L. Feliciano, Ajeet Gajra, Drew K. Seisler, Ronald DeMatteo, Jacqueline M. Lafky, Arti Hurria, Hyman B. Muss, Harvey J. Cohen, Aminah Jatoi Cancer vol 123 (21) 4193-98 2017
Manuscript Older Adult ACOSOG-Z9001, A151602, NCCTG-97-24-51
<http://www.ncbi.nlm.nih.gov/pubmed/28700816>

411 Age, Gender, Performance Status and Stage Outperformed Stage alone in Predicting Overall Survival (OS) in Patients with Small Cell Lung Cancer: A Pooled Analysis of 1623 patients from the North Central Cancer Treatment Group.

N. R. Foster, S. J. Mandrekar, S. E. Schild, G. D. Nelson, J. R. Jett, A. A. Adjei J. Clin. Oncol. vol 25 (18s) abstr 7223 2007
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

412 Prognostic importance of performance status (PS) in small cell lung cancer (SCLC): A North Central Cancer Treatment Group (NCCTG) investigation.

N. R. Foster, S. J. Mandrekar, S. E. Schild, G. D. Nelson, K. M. Rowland Jr, R. L. Deming, T. F.

Kozelsky, J. R. Jett, R. S. Marks, A. A. Adjei J. Clin. Oncol. vol 26 (18s) 19041 2008
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

413 Comparison of progression-free survival (PFS) and tumor response as endpoints for predicting overall survival (OS) in untreated extensive-stage small cell lung cancer (ED-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials.

N. R. Foster, Y. Qi, J. E. Krook, J. W. Kugler, S. A. Kuross, J. R. Jett, J. R. Molina, S. E. Schild, A. A. Adjei, S. J. Mandrekar J. Clin. Oncol. vol 27 (15s) abstr 8085 2009
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

414 Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials.

N. R. Foster, Y. Qi, Q. Shi, J. E. Krook, J. W. Kugler, J. R. Jett, J. R. Molina, S. E. Schild, A. A. Adjei, S. J. Mandrekar J. Clin. Oncol. vol 28 (15 (May 20 Supplement)) 7637 2010
Abstract Respiratory http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7637

415 Multitrial evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in previously untreated extensive-stage small cell lung cancer (ES-SCLC): An Alliance-led analysis

N. R. Foster, L. A. Renfro, S. E. Schild, M. W. Redman, X. F. Wang, S. E. Dahlberg, K. Ding, P. A. Bradbury, S. S. Ramalingam, D. R. Gandara, E. E. Vokes, A. A. Adjei, S. J. Mandrekar J. Clin. Oncol. vol 31 (15 suppl) abstr 7510 2013
Abstract Respiratory Comprehensive, CALGB-9033, CALGB-9732, CALGB-30103, NCCTG-862051, NCCTG-892051, NCCTG-932053, ECOG-1500, ECOG-7593, JCOG-9511, NCIC-BR4, NCIC-BR8, SWOG-S0124
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7510?sid=af1f40b1-fe3e-4dff-9005-91e48c

416 Body mass index (BMI) and DNA mismatch repair status in colon cancers from patients treated in adjuvant therapy trials.

N. R. Foster, F. Sinicrope, G. Yothers, C. Allegra, D. Sargent J. Clin. Oncol. vol 29 (suppl) abstr 10590 2011
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

417 Prognostic factors differ by tumor stage for Small Cell Lung Cancer: A Pooled Analysis of North Central Cancer Treatment Group (NCCTG) Trials

Nathan R. Foster, Sumithra J. Mandrekar, Steven E. Schild, Garth D. Nelson, Kendrith M. Rowland, Richard L. Deming, Timothy F. Kozelsky, Randolph S. Marks, James R. Jett, Alex A. Adjei Cancer vol 115 (12) 2721-2731 2009
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/19402175>

418 Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Findings Based on North Central Cancer Treatment Group (NCCTG) Trials

Nathan R. Foster, Yingwei Qi, Qian Shi, James E. Krook, John W. Kugler, James R. Jett, Julian R. Molina, Steven E. Schild, Alex A. Adjei, Sumithra J. Mandrekar Cancer vol 117 (6) 1262-1271 2011
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20960500>

419 Multi-Trial Evaluation of Progression-Free Survival (PFS) as a Surrogate Endpoint for Overall Survival (OS) in First-Line Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Nathan R. Foster, Lindsay A. Renfro, Steven E. Schild, Mary W. Redman, Xiaofei F. Wang, Suzanne E. Dahlberg, Keyue Ding, Penelope A. Bradbury, Suresh S. Ramalingam, David R. Gandara, Taro Shibata, Nagahiro Saijo, Everett E. Vokes, Alex A. Adjei, Sumithra J. Mandrekar J Thorac Oncol vol 10 (7) 1099-1106 2015

Manuscript Respiratory CALGB-30103, N0424, NCCTG-932053
<http://www.ncbi.nlm.nih.gov/pubmed/26134227>

420 Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

P. A. Francis, O. Pagani, G. F. Fleming, B. A. Walley, M. Colleoni, I. Láng, H. L. Gómez, C. Tondini, E. Ciruelos, H. J. Burstein, H. R. Bonnefoi, M. Bellet, S. Martino, C. E. Jr Geyer, M. P. Goetz, V. Stearns, G. Pinotti, F. Puglisi, S. Spazzapan, M. A Climent, L. Pavesi, T. Ruhstaller, N. E. Davidson, R. Coleman, M. Debled, S. Buchholz, J. N. Ingle, E. P. Winer, R. Maibach, M. RabaglioPoretti, B. Ruepp, A. Di Leo, A. S. Coates, R. D. Gelber, A. Goldhirsch, M.M. Regan N. Engl. J. Med. vol 379 (2) 122-37 2018

Manuscript Breast IBCSG-24-02 (SOFT-TEXT), IBCSG-25-02 (TEXT), S0002
<http://www.ncbi.nlm.nih.gov/pubmed/29863451>

421 Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

Prudence A. Francis, Meredith M. Regan, Gini F. Fleming, István Láng, Eva Ciruelos, Meritxell Bellet, Hervé R. Bonnefoi, Miguel A. Climent, Gian Antonio Da Prada, Harold J. Burstein, Silvana Martino, Nancy E. Davidson, Charles E. Geyer, Barbara A. Walley, Robert Coleman, Pierre Kerbrat, Stefan Buchholz, James N. Ingle, Eric P. Winer, Manuela Rabaglio-Poretti, Rudolf Maibach, Barbara Ruepp, Anita Giobbie-Hurder, Karen N. Price, Marco Colleoni, Giuseppe Viale, Alan S. Coates, Aron Goldhirsch, Richard D. Gelber N. Engl. J. Med. vol 372 (5) 436-46 2015

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25495490>

422 Long-Term Follow-Up of TEXT and SOFT Trials of Adjuvant Endocrine Therapies for Premenopausal Women with HR+ Early Breast Cancer

Prue Francis, Gini Fleming, Meredith Regan, Olivia Pagani, Barb Walley Cancer Res vol 77 (4 Suppl) Abstract nr OT3-02-0 2017

Abstract Breast http://cancerres.aacrjournals.org/content/77/4_Supplement/OT3-02-03

423 Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of NCCTGs phase III trials N9741 and N9841.

J. Franko, Q. Shi, C. D. Goldman, B. A. Pockaj, G. D. Nelson, R. M. Goldberg, H. C. Pitot, A. Grothey, S. R. Alberts, D. J. Sargent J. Clin. Oncol. vol 29 (suppl) abstr 3571 2011

Abstract GI N9841, N9741

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

424 Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841

Jan Franko, Qian Shi, Charles D. Goldman, Barbara A. Pockaj, Garth D. Nelson, Richard M. Goldberg, Henry C. Pitot, Axel Grothey, Steven R. Alberts, Daniel J. Sargent J Clin Oncol vol 30 (3) 263-267 2012

Manuscript GI N9841, N9741 <http://www.ncbi.nlm.nih.gov/pubmed/22162570>

425 Changes in Cognitive Function in Older Women With Breast Cancer Treated with Standard Chemotherapy and Capecitabine within CALGB 49907

R. Freedman, B. Pitcher, N. Keating, W. Barry, K. Ballman, A. Kornblith, J. Mandelblatt, G. Kimmick, A. Hurria, E. Winer, C. Hudis, H. Cohen, H. Muss Cancer Res. vol 72 (24 suppl) Abstract nr P6-08-05 2012

Abstract Older Adult

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/P6-08-05

- 426 Promoting Accrual of Older Patients with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology Member Survey (A171602)**
Rachel A. Freedman, Travis J. Dockter, Jacqueline M. Lafky, Arti Hurria, Hyman J. Muss, Harvey J. Cohen, Aminah Jatoi, M. Margaret Kemeny, Kathryn J. Ruddy *Oncologist* vol 23 (9) 1016-23 2018
Manuscript *Older Adult* <http://www.ncbi.nlm.nih.gov/pubmed/29674441>
- 427 Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527**
Rachel A. Freedman, Jared C. Foster, Drew K. Seisler, Jacqueline M. Lafky, Hyman B. Muss, Harvey J. Cohen, Jeanne Mandelblatt, Eric P. Winer, Clifford A. Hudis, Ann H. Partridge, Lisa A. Carey, Constance Cirrincione, Alvaro Moreno-Aspitia, Gretchen Kimmick, Aminah Jatoi, Arti Hurria *J. Clin. Oncol* vol 35 (4) 421-431 2017
Manuscript *Older Adult* A151527, ACOSOG-Z1031, ACOSOG-Z1041, C8541, C9344, C9741, CALGB-40101, CALGB-40302, CALGB-40502, CALGB-40503, CALGB-40601, CALGB-40603, CALGB-49907, CALGB-9342, CALGB-9840, N89-30-52, N9831
<http://www.ncbi.nlm.nih.gov/pubmed/27992272>
- 428 Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907**
Rachel A. Freedman, Brandelyn Pitcher, Nancy L. Keating, Karla V. Ballman, Jeanne Mandelblatt, Alice B. Kornblith, Gretchen G. Kimmick, Arti Hurria, Eric P. Winer, Clifford A. Hudis, Harvey Jay Cohen, Hyman B. Muss *Breast Cancer Res. Treat.* vol 139 (2) 607-616 2013
Manuscript *Older Adult* CALGB-49907, CALGB-361002
<http://www.ncbi.nlm.nih.gov/pubmed/23681403>
- 429 Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)**
Rachel A. Freedman, D. K. Seisler, J. C. Foster, J. A. Sloan, J. M. Lafky, G. G. Kimmick, A. Hurria, H. J. Cohen, E. P. Winer, C. A. Hudis, A. H. Partridge, L. A. Carey, A. Jatoi, H. D. Klepin, M. Citron, D. A. Berry, L. N. Shulman, A. U. Buzdar, V. J. Suman, H. B. Muss *Breast Cancer Res. Treat.* vol 161 (2) 363-373 2017
Manuscript *Older Adult* CALGB-40101, A151511, CALGB-49907, CALGB-9344, CALGB-9741
<http://www.ncbi.nlm.nih.gov/pubmed/27866278>
- 430 Accrual of Older Breast Cancer Patients to Alliance Systemic Therapy Protocols over Time: Alliance A151527 (Multiple)**
Rachel A Freedman, Drew K. Seisler, Jared C. Foster, Jacqueline Lafky, Gretchen Kimmick, Aminah Jatoi, Hyman B. Muss, Harvey J. Cohen, Eric P. Winer, Clifford A. Hudis, Arti Hurria *J. Clin. Oncol.* vol 34 (suppl) abstr 1024 2016
Abstract *Older Adult* A151527, ACOSOG-Z1031, ACOSOG-Z1041, C8541, C9344, C9741, CALGB-40101, CALGB-40302, CALGB-40502, CALGB-40503, CALGB-40601, CALGB-40603, CALGB-49907, CALGB-9342, CALGB-9840, N89-30-52, N9831
http://abstract.asco.org/176/AbstView_176_163808.html
- 431 Model-based prediction of defective DNA mismatch repair using clinicopathological variables in stage II and III colon cancers.**
A. French, F. Sinicrope, N. Foster, S. Thibodeau, D. Sargent, M. O'Connell *J. Clin. Oncol.* vol 27 (15s) 11093 2009
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

- 432 Prognostic Significance of Defective Mismatch Repair and BRAF-V600E in Patients with Colon Cancer**
Amy J. French, Daniel J. Sargent, Lawrence J. Burgart, Nathan R. Foster, Brian F. Kabat, Richard Goldberg, Lois Shepherd, Harold E. Windschitl, Stephen N. Thibodeau Clin Cancer Res vol 14 (11) 3408-3415 2008
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/18519771>
- 433 Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma multiforme: a north central cancer treatment group study.**
B. B. Friday, J. Buckner, S. K. Anderson, C. Giannini, J. Kugler, M. Mazurczak, P. Flynn, H. Gross, E. Pajon, K. Jaeckle, E. Galanis 15th Annual Meeting of the Society for Neuro-Oncology (SNO) vol 12 (suppl 4) 70 2010
Abstract Neuro-Onc
http://neuro-oncology.oxfordjournals.org/content/12/suppl_4/iv69.full.pdf+html
- 434 Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study**
Bret B. Friday, S. Keith Anderson, Jan Buckner, Chunrong Yu, Caterina Giannini, Francois Geoffroy, John Schwerkoske, Mirosław Mazurczak, Howard Gross, Eduardo Pajon, Kurt Jaeckle, Evanthia Galanis Neuro Oncol vol 14 (2) 215-221 2012
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/22090453>
- 435 Dietary and lifestyle determinants of colon cancer recurrence and survival**
C. S. Fuchs, J. A. Meyerhardt, K. Ng, D. Niedzwiecki, D. R. Hollis, S. Ogino, A. T. Chan, B. M. Wolpin, M. M. Bertagnolli, E. Giovannucci, R. M. Goldberg 2008
Abstract GI
- 436 KRAS mutation, cancer recurrence and patient survival in stage III colon cancer: Findings from CALGB 89803**
C. S. Fuchs, S. Ogino, J. A. Meyerhardt, N. Irahara, D. Niedzwiecki, D. R. Hollis, L. B. Saltz, R. J. Mayer, M. M. Bertagnolli J. Clin. Oncol. vol 27 (15s) abstr 4037 2009
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID
- 437 Postoperative adjuvant chemoradiation for gastric or gastroesophageal (GE) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): Results from Intergroup trial CALGB 80101**
C. S. Fuchs, J. E. Tepper, D. Niedzwiecki, D. R. Hollis, H. Mamon, R. S. Swanson, D. G. Haller, T. Dragovich, S. Alberts, G. A. Bjarnason, C. Willett, R. M. Goldberg, A. P. Venook, R. J. Mayer J. Clin. Oncol. vol 29 (15s) abstr 4003 2011
Abstract GI
http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/4003?sid=9616a22c-422f-42c7-8a99-d222
- 438 Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741**
Charles S. Fuchs, Richard M. Goldberg, Daniel J. Sargent, Jeffrey A. Meyerhardt, Brian M. Wolpin, Erin M. Green, Henry C. Pitot, Michael Pollak Clin Cancer Res vol 14 (24) 8263-8269 2008
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19073970>
- 439 Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance)**
Charles S. Fuchs, Donna Niedzwiecki, Harvey J. Mamon, Joel E. Tepper, Xing Ye, Richard S.

Swanson, Peter C. Enzinger, Daniel G. Haller, Tomislav Dragovich, Steven R. Alberts, Georg A. Bjarnason, Christopher G. Willett, Leonard L. Gunderson, Richard M. Goldberg, Alan P. Venook, David Ilson, Eileen O'Reilly, Kristen Ciombor, David J. Berg, Jeffrey Meyerhardt, Robert J. Mayer J. Clin. Oncol vol 35 (32) 3671-77 2017
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/28976791>

440 Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance)

M. A. Fuchs, C. Yuan, K. Sato, D. Niedzwiecki, X. Ye, L. B. Saltz, R. J. Mayer, R. B. Mowat, R. Whittom, A. Hantel, A. Benson, D. Atienza, M. Messino, H. Kindler, A. Venook, F. Innocenti, R. S. Warren, M. M. Bertagnolli, S. Ogino, E. L. Giovannucci, E. Horvath, J. A. Meyerhardt, K. Ng Ann. Oncol vol 28 (6) 1359-67 2017
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/28327908>

441 Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance)

Michael A. Fuchs, Kaori Sato, Donna Niedzwiecki, Xing Ye, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Kana Wu, Walter C. Willett, Edward L. Giovannucci, Jeffrey A. Meyerhardt PLoS ONE vol 9 (6) e99816 2014
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24937507>

442 Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

Noreen Fulton, Jeffrey Johnson, Lawrence D. Kaplan, Greg Koval, Greg Malnassy, Sin-Ho Jung, Steve Devine, Thomas C. Shea, John P. Leonard, Bruce D. Cheson, Wendy Stock Blood vol 122 (21) Abstract 3002 2013
Abstract Lymphoma <http://bloodjournal.hematologylibrary.org/content/122/21/3002.abstract>

443 Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary tumor side.

Leon Furchtgott, David Swanson, Boris Hayete, Iya Khalil, Diane Wuest, Kelly Rich, Andrew B. Nixon, Donna Niedzwiecki, Jeffrey A. Meyerhardt, Eileen Mary O'Reilly, Fang-Shu Ou, Heinz-Josef Lenz, Federico Innocenti, Alan P. Venook J. Clin. Oncol. vol 35 (15 suppl) abstr 3528 2017
Abstract GI http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3528

444 A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254

Richard R. Furman, Michael L. Grossbard, Jeffrey L. Johnson, Andrew L. Pecora, Peter A. Cassileth, Sin-Ho Jung, Bruce A. Peterson, Lee M. Nadler, Arnold Freedman, Ruthee-Lu Bayer, Nancy L. Bartlett, David D. Hurd, Bruce D. Cheson Leuk. Lymphoma vol 52 (4) 587-596 2011
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/21275630>

445 Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

T. F. Gajewski, A. K. Salama, D. Niedzwiecki, J. Johnson, G. Linette, C. Bucher, M. A. Blaskovich, S. M. Sebt, F. Haluska J Transl Med vol 10 246 2012
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/23228035>

446 Association of patient preference for adjuvant chemotherapy (chemo) at baseline (BL) with toxicity, mental health, function, quality of life (QoL) and survival in older women with early stage breast cancer (ESBC) [CALGB 49907 Alliance]

Ajeet Gajra, Linda McCall, Hyman B. Muss, Harvey J. Cohen, A Jatoi, Karla V. Ballman, AH

Partridge, L. Sutton, BA Parker, G. Magrinat, JM Lafky, Arti Hurria Cancer Res. vol 75 (9 Supplement) abstr P5-15-07 2015
Abstract Breast http://cancerres.aacrjournals.org/content/75/9_Supplement/P5-15-07.short?rss=1

447 The Preference to Receive Chemotherapy and Cancer-related Outcomes in Older Adults with Breast Cancer CALGB 49907 (Alliance)

Ajeet Gajra, Linda McCall, Hyman B. Muss, Harvey J Cohen, Aminah Jatoui, Karla V Ballman, Ann H Partridge, Linda Sutton, Barbara A Parker, Gustav Magrinat, Heidi D Klepin, Jacqueline M Lafky, Arti Hurria J Geriatr Oncol vol 9 (3) 221-7 2018
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/29602735>

448 Time-to-Treatment-Failure and Related Outcomes among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711)

Ajeet Gajra, Tyler J. Zemla, Aminah Jatoui, Josephine L. Feliciano, Melisa L. Wong, Hongbin Chen, Ronald Maggiore, Ryan P. McMurray, Arti Hurria, Hyman B. Muss, Harvey J. Cohen, Jacqueline Lafky, Martin J. Edelman, Rogerio Lilenbaum, Jennifer G. Le-Rademacher J Thorac Oncol vol 13 (7) 996-1003 2018
Manuscript Older Adult A151711, CALGB-30203, CALGB-30801, CALGB-9730
<http://www.ncbi.nlm.nih.gov/pubmed/29608967>

449 NCCTG phase II trial of bevacizumab in combination with sorafenib (BEV/SOR) in recurrent glioblastoma (RGBM).

E. Galanis, S. K. Anderson, J. M. Lafky, T. J. Kaufmann, J. H. Uhm, C. Giannini, S. K. Kumar, D. W. Northfelt, P. J. Flynn, K. A. Jaeckle, J. C. Buckner Neuro-oncology vol 13 (3) 62 Abstract NO-93 2011
Abstract Neuro-Onc
http://neuro-oncology.oxfordjournals.org/content/13/suppl_3/iii41.full.pdf+html

450 Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

E. Galanis, S. K. Anderson, J. M. Lafky, J. Uhm, C. Giannini, S. K. Kumar, T. Kimlinger, D. W. Northfelt, P. J. Flynn, K. Jaeckle, T. J. Kaufmann, J. C. Buckner Clin. Cancer Res. vol 19 (17) 4816-23 2013
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/23833308>

451 N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM)

E. Galanis, K. A. Jaeckle, M. J. Maurer, J. M. Reid, M. M. Ames, C. Giannini, J. S. Hardwick, D. F. Jr Moore, J. A. Zwiebel, J. C. Buckner J. Clin. Oncol. vol 25 (18s) abstr 2004 2007
Abstract Neuro-Onc http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/2004

452 NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM.

E. Galanis, K. Jaeckle, S. Anderson, T. Kaufmann, J. Uhm, C. Giannini, S. Kumar, D. Northfelt, P. Flynn, J. Buckner J. Clin. Oncol. vol 28 (15s) abstr 2018 2010
Abstract Neuro-Onc <http://meetinglibrary.asco.org/content/42461-74>

453 Vorinostat in glioblastoma multiforme (Gbm): updated results from phase I and II trials provide the rationale for further clinical development.

E. Galanis, K. Jaeckle, J. Buckner, M. Maurer, J. Hardwick, V. Puduvalli, K. Lamborn, J. Kuhn, M. Prados, P. Wen Ann. Oncol. vol 19 (Suppl 8) 249-250 abstr 806PD 2008
Abstract Neuro-Onc http://annonc.oxfordjournals.org/content/19/suppl_8/viii249.full.pdf+html

454 Phase I/II trial of vorinostat combined with temozolomide (TMZ) and radiation therapy (RT)

for newly diagnosed glioblastoma (GBM) (N0874-ABTC0902, Alliance): Final results of the phase I trial

E. Galanis, J. Sarkaria, K. Anderson, W. Wu, K. Jaeckle, C. Giannini, J. Buckner, P. Wen *J. Clin. Oncol.* vol 31 (15 suppl) abstr 2046 2013
Abstract Neuro-Onc <http://meetinglibrary.asco.org/content/112936-132>

455 Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02

Evanthia Galanis, S Keith Anderson, C Ryan Miller, Jann N Sarkaria, Kurt Jaeckle, Jan C Buckner, Keith L Ligon, Karla V Ballman, Dennis F Moore, Michael Nebozhyn, Andrey Loboda, David Schiff, Manmeet Singh Ahluwalia, Eudocia Q Lee, Elizabeth R Gerstner, Glenn J Lesser, Michael Prados, Stuart A Grossman, Jane Cerhan, Caterina Giannini, Patrick Y Wen *Neuro-oncology* vol 20 (4) 546-56 2018
Manuscript Neuro-Onc ABTC-0902, N0874 <http://www.ncbi.nlm.nih.gov/pubmed/29016887>

456 A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.

Evanthia Galanis, S Keith Anderson, Erin L Twohy, Xiomara W Carrero, Jesse G Dixon, David Dinh Tran, Suriya A Jeyapalan, Daniel M Anderson, Timothy J Kaufmann, Ryan W Feathers, Caterina Giannini, Jan C Buckner, Panos Z Anastasiadis, David Schiff *Cancer* 2019
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/31290996>

457 NCCTG N0872 (Alliance): A Randomized Placebo-Controlled Phase II Trial of Bevacizumab Plus Dasatinib in Patients with Recurrent Glioblastoma (GBM)

Evanthia Galanis, S. Keith Anderson, Panagiotis Z. Anastasiadis, David Tran, Suriya A. Jeyapalan, Daniel M. Anderson, Tim Kaufmann, Caterina Giannini, Jan C. Buckner, David Schiff *J. Clin. Oncol.* vol 33 (suppl) abstr 2004 2015
Abstract Neuro-Onc
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2004?sid=163ebdc1-978e-4e50-b1e8-e2b1:

458 NCCTG N1174: Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme (Alliance)

Evanthia Galanis, S. Keith Anderson, Nicholas Butowski, Adilia MV Hormingo, David Schiff, David D. Tran, Antonio M. Omuro, Kurt A. Jaeckle, Shaji Kumar, Timothy Kaufmann, Caterina Giannini, Erin Twohy, Patrick Y. Wen *J. Clin. Oncol.* vol 35 (15 suppl) abstr 2023 2017
Abstract Neuro-Onc http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2023

459 Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902)

Evanthia Galanis, S. Keith Anderson, C. Ryan Miller, Jann Nagina Sarkaria, Kurt A. Jaeckle, Jan C. Buckner, Keith L. Ligon, Karla V. Ballman, Dennis Frederic Moore, Manmeet Singh Ahluwalia, Eudocia Quant Lee, Elizabeth Robins Gerstner, Glenn Jay Lesser, Michael Prados, Stuart A. Grossman, Caterina Giannini, Patrick Y. Wen *J. Clin. Oncol.* vol 32 (5s) (suppl); abstr 2030 2014
Abstract Neuro-Onc http://abstracts.asco.org/144/AbstView_144_133770.html

460 Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

Evanthia Galanis, Kurt A. Jaeckle, Matthew J. Maurer, Joel M. Reid, Matthew M. Ames, James S. Hardwick, John F. Reilly, Andrey Loboda, Michael Nebozhyn, Valeria R. Fantin, Victoria M. Richon, Bernd Scheithauer, Caterina Giannini, Patrick J. Flynn, Dennis F. Moore, James Zwiebel, Jan C. Buckner *J Clin Oncol* vol 27 (12) 2052-2058 2009
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/19307505>

461 Treatment-influenced associations of PML-RARalpha mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia

R. E. Gallagher, B. K. Moser, J. Racevskis, X. Poire, C. D. Bloomfield, A. J. Carroll, R. P. Ketterling, D. Roulston, E. Schachter-Tokarz, D. C. Zhou, I. M. Chen, R. Harvey, G. Koval, D. A. Sher, J. H. Feusner, M. S. Tallman, R. A. Larson, B. L. Powell, F. R. Appelbaum, E. Paietta, C. L. Willman, W. Stock *Blood* vol 120 (10) 2098-2108 2012
Manuscript *Leuk Corr Sci* <http://www.ncbi.nlm.nih.gov/pubmed/22734072>

462 Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710

R. E. Gallagher, B. K. Moser, J. Racevskis, X. Poire, C. D. Bloomfield, A. J. Carroll, R. Ketterling, D. Ralston, E. Schachter-Tokarz, D. Zhou, I.-M. L. Chen, R. Harvey, G. Koval, D. A. Sher, J. H. Feusner, M. S. Tallman, F. R. Appelbaum, R. A. Larson, B. L. Powell, E. Paietta, C. L. Willman, W. Stock *Blood* vol 116 (21) 1038 2010
Abstract *Leuk Corr Sci* <http://www.bloodjournal.org/content/116/21/1038>

463 Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer

Judy E. Garber, Susan Halabi, Sara M. Tolaney, Ellen Kaplan, Laura Archer, James N. Atkins, Stephen Edge, Charles L. Shapiro, Lynn Dressler, Electra M. Paskett, Gretchen Kimmick, James Orcutt, Anthony Scalzo, Eric Winer, Ellis Levine, Nasir Shahab, Nancy Berliner *J Natl Cancer Inst* vol 102 (13) 942-949 2010
Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/20554945>

464 Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.

Yolanda I Garces, Scott H Okuno, Steven E Schild, Sumithra J Mandrekar, Brian M Bot, John M Martens, Donald B Wender, Gamini S Soori, Dennis F Moore, Timothy F Kozelsky, James R Jett *Int. J. Radiat. Oncol. Biol. Phys.* vol 67 (4) 995-1001 2007
Manuscript *Respiratory* <http://www.ncbi.nlm.nih.gov/pubmed/17336213>

465 Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) and local excision (LE) for uT2uN0 rectal cancer (RC): results of the ACOSOG Z6041 trial

J. Garcia-Aguilar, Q. Shi, C. R. J. Thomas, E. Chan, P. Cataldo, J. Marcet, D. Medich, A. Pigazzi, S. Oommen, M. C. Posner *J. Clin. Oncol.* vol 28 (15s) abstr 3510 2010
Abstract *GI*
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

466 Organ preservation for clinical t2n0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision: results of a multicenter phase 2 study

Julio Garcia-Aguilar, Lindsay A. Renfro, Oliver S. Chow, Qian Shi, Xiomara W. Carrero, Patricio B. Lynn, Charles R. Thomas, Emily Chan, Peter A. Cataldo, Jorge E. Marcet, David S. Medich, Craig S. Johnson, Samuel C. Oommen, Bruce G. Wolff, Alessio Pigazzi, Shane M. McNevin, Roger K. Pons, Ronald Bleday *Lancet Oncol.* vol 16 (15) 1537-1546 2015
Manuscript *GI* <http://www.ncbi.nlm.nih.gov/pubmed/26474521>

467 A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial

Julio Garcia-Aguilar, Qian Shi, Charles R. Thomas, Emily Chan, Peter Cataldo, Jorge Marcet, David Medich, Alessio Pigazzi, Samuel Oommen, Mitchell C. Posner *Ann. Surg. Oncol.* vol 19 (2) 384-391

- 468 Expression and prognostic impact of lncRNAs in acute myeloid leukemia**
 Ramiro Garzon, Stefano Volinia, Dimitrios Papaioannou, Deedra Nicolet, Jessica Kohlschmidt, Pearly S. Yan, Krzysztof Mrózek, Donna Bucci, Andrew J. Carroll, Maria R. Baer, Meir Wetzler, Thomas H. Carter, Bayard L. Powell, Jonathan E. Kolitz, Joseph O. Moore, Ann-Kathrin Einfeld, James S. Blachly, William Blum, Michael A. Caligiuri, Richard M. Stone, Guido Marcucci, Carlo M. Croce, John C. Byrd, Clara D. Bloomfield *Proc. Natl. Acad. Sci. U.S.A* vol 111 (52) 18679-18684 2014
 Manuscript Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pubmed/25512507>
- 469 RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.**
 Oghenekevwe M Gbenedio, Caroline Bonnans, Delphine Grun, Chih-Yang Wang, Ace J Hatch, Michelle R Mahoney, David Barras, Mary Matli, Yi Miao, K Christopher Garcia, Sabine Tejpar, Mauro Delorenzi, Alan P Venook, Andrew B Nixon, Robert S Warren, Jeroen P Roose, Philippe Depeille *JCI Insight* vol 5 2019
 Manuscript GI CALGB-80203, CALGB-80405 <http://www.ncbi.nlm.nih.gov/pubmed/31237864>
- 470 Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: subgroup analysis of the Alliance A031203 CABOSUN trial**
 Daniel J. George, Colin Hessel, Susan Halabi, M. Dror Michaelson, Olwen Hahn, Meghara Walsh, Joel Picus, Eric J. Small, Shaker Dakhil, Darren R. Feldman, Milan Mangeshkar, Christian Scheffold, Michael J. Morris, Toni K. Choueiri *Oncologist* 2019
 Manuscript GU
- 471 The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from Cancer and Leukemia Group B 9480.**
 Daniel J George, Susan Halabi, Timothy F Shepard, Ben Sanford, Nicholas J Vogelzang, Eric J Small, Philip W Kantoff *Clin. Cancer Res.* vol 11 (5) 1815-20 2005
 Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/15756004>
- 472 Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance)**
 Daniel.J. George, Susan Halabi, Andrew B. Nixon, Mark D. Starr, J.Chris Brady, Herbert I. Hurwitz, Ian Barak, M. Morris, Brian.I. Rini, Eric Small, Won Kim, Mary-Ellen Taplin *J. Clin. Oncol.* vol 35 (15 suppl) abstr 4522 2017
 Abstract Correl Sci NOS http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.4522
- 473 Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial**
 Daniel George, Colin Hessel, Susan Halabi, Ben Sanford, M. Dror Michaelson, Olwen Hahn, Meghara Walsh, Thomas Olencki, Joel Picus, Eric J. Small, Shaker Dakhil, Darren Feldman, Milan Mangeshkar, Christian Scheffold, Michael J. Morris, Toni K. Choueiri *J Clin Oncol* vol 36 (suppl 6S) abstr 582 2018
 Abstract GU <https://meetinglibrary.asco.org/record/156873/abstract>
- 474 Central Pathology Review by Whole Slide Imaging in Glioblastoma Clinical Trials**
 Caterina Giannini, Ryan Miller, Keith Ligon, Helen Tollefson, Mark Korinek, Justin Koepplin, David Holmes, Sarah Jenkins, Jan Buckner *J Neuropathol Expl Neurol* vol 74 (6) 595, abstr 26 2015
 Abstract Neuro-Onc N0872, N0877
<https://academic.oup.com/jnen/article/74/6/588/2614402#46637304>

- 475 Analysis of prognostic (prog) Web-based models for stage II and III colon cancer (CC): A population-based validation of Numeracy (NUM) and ADJUVANT! Online (ADJ!).**
S. Gill, C. Loprinzi, H. Kennecke, A. Grothey, G. Nelson, R. Woods, C. Speers, S. Alberts, A. Bardia, D. Sargent *J. Clin. Oncol.* vol 27 (15s) 4044 2009
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID
- 476 Prognostic Web-based Models for Stage II and III Colon Cancer: a Population and Clinical Trials-based Validation of Numeracy and Adjuvant! Online**
Sharlene Gill, Charles Loprinzi, Hagen Kennecke, Axel Grothey, Garth Nelson, Ryan Woods, Caroline Speers, Steven R. Alberts, Aditya Bardia, Michael J. O'Connell, Daniel J. Sargent *Cancer* vol 117 (18) 4155-4165 2011
Manuscript GI NCCTG-89-46-51, NCCTG-914653 <http://www.ncbi.nlm.nih.gov/pubmed/21365628>
- 477 Local and Regional Control in Breast Cancer after Sentinel Node Biopsy without Axillary Lymph Node Dissection: Results from a Randomized Trial**
A. E. Giuliano, L. Mccall, P. Beitsch, P. W. Whitworth, P. Blumencranz, A. M. Leitch, S. Saha, K. K. Hunt, M. Morrow, K. V. Ballman *American Surgical Association 130th Annual Meeting* 43-44 2010
Abstract Breast <http://www.americansurgical.info/files/2010/ASA10-Program-Book-for-Web.pdf>
- 478 ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1 - 2 N0 M0 breast Cancer who have a positive sentinel node**
A. E. Giuliano, L. Mccall, P. Beitsch, P. Whitworth, M. Morrow, P. Blumencranz, A. M. Leitch, S. Saha, K. K. Hunt, K. V. Ballman *J. Clin. Oncol.* vol 28 (18s) abstr CRA506 2010
Abstract Breast <http://meetinglibrary.asco.org/content/47842-74>
- 479 Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis**
Armando E. Giuliano, Karla V. Ballman, Linda McCall, Peter D. Beitsch, Meghan B. Brennan, Pond R. Kelemen, David W. Ollila, Nora M. Hansen, Pat W. Whitworth, Peter W. Blumencranz, A. Marilyn Leitch, Sukamal Saha, Kelly K. Hunt, Monica Morrow *JAMA* vol 318 (10) 918-26 2017
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/28898379>
- 480 Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: Long-Term Follow-Up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial**
Armando E. Giuliano, Karla Ballman, Linda McCall, Peter Beitsch, Pat W. Whitworth, Peter Blumencranz, A. Marilyn Leitch, Sukamal Saha, Monica Morrow, Kelly K. Hunt *Ann. Surg.* vol 264 (3) 413-420 2016
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/27513155>
- 481 Association of occult metastases in sentinel lymph nodes and bone marrow with survival of women with early-stage invasive breast cancer**
Armando E. Giuliano, Debra Hawes, Karla V. Ballman, Pat W. Whitworth, Peter W. Blumencranz, Douglas S. Reintgen, Monica Morrow, A. Marilyn Leitch, Kelly K. Hunt, Linda M. McCall, Andrea Abati, Richard Cote *JAMA* vol 306 (4) 385-393 2011
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/21791687>
- 482 Ten-Year Survival Results of ACOSOG Z0011 (Alliance)**
Armando E. Giuliano, Kelly K. Hunt, Karla. V. Ballman, Peter D. Beitsch, Pat W. Whitworth, Peter W. Blumencranz, A. Marilyn Leitch, Sukamal Saha, Linda M. McCall, Monica Morrow *J. Clin. Oncol.* vol 34 (suppl) abstr 1007 2016

483 Sentinel Lymph Node Dissection With and Without Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial

Armando E. Giuliano, Kelly K. Hunt, Karla V. Ballman, Peter D. Beitsch, Pat W. Whitworth, Peter W. Blumencranz, A. Marilyn Leitch, Sukamal Saha, Linda M. McCall, Monica Morrow JAMA vol 305 (6) 569-575 2011

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/21304082>

484 Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: The American College of Surgeons Oncology Group Z0011 Randomized Trial

Armando E Giuliano, Linda McCall, Peter Beitsch, Pat W Whitworth, Peter Blumencranz, A. Marilyn Leitch, Sukamal Saha, Kelly K Hunt, Monica Morrow, Karla Ballman Ann. Surg. vol 252 (3) 426-433 2010

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/20739842>

485 Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: Long-term follow-up from the American College of Surgeons Oncology Group (Alliance) Z0011 Randomized Trial

Armando E Giuliano, Linda McCall, Peter Beitsch, Pat W Whitworth, Peter Blumencranz, A. Marilyn Leitch, Sukamal Saha, Kelly K Hunt, Monica Morrow, Karla Ballman 2016

Abstract Breast <http://meeting.americansurgical.org/abstracts/2016/1.cgi>

486 The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.

Ajay Goel, Takeshi Nagasaka, Christian N Arnold, Toru Inoue, Cody Hamilton, Donna Niedzwiecki, Carolyn Compton, Robert J Mayer, Richard Goldberg, Monica M Bertagnolli, C Richard Boland Gastroenterology vol 132 (1) 127-38 2007

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17087942>

487 Role of SULT1A1 copy number in tamoxifen treated breast cancer: findings from the North Central Cancer Treatment Group (NCCTG) adjuvant trial 89-30-52.

M. P. Goetz, A. M. Moyer, R. M. Weinshilboum, V. A. Suman, S. J. Hebbbring, M. M. Ames, J. C. Berg, C. Reynolds, E. A. Perez, J. N. Ingle J. Clin. Oncol. vol 26 (15s) 22041 2008

Abstract PPP http://hwmain.maint.meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/22041

488 Use of gene expression profiling to identify responsive patients treated with carboplatin (Carb), paclitaxel (Pac), and everolimus as first-line treatment for cancer of unknown primary (CUP): NCCTG N0871 (Alliance)

M. Goetz, N. Foster, J. Meyers, P. Steen, D. Visscher, H. Yoon, R. Pillai, D. Prow, C. Reynolds, B. Marchello, R. Mowat, B. Mattar, C. Erlichman J. Clin. Oncol. vol 31 (15 suppl) abstr 2562 2013

Abstract Experimental <http://meetinglibrary.asco.org/content/113055-132>

489 Tamoxifen Pharmacogenetics of CYP2D6, CYP2C19, and SULT1A1: Long Term Follow-up of the North Central Cancer Treatment Group 89-30-52 Adjuvant Trial.

M. Goetz, V. Suman, M. Ames, J. Black, S. Safgren, M. Kuffel, R. Avula, A. Moyer, R. Weinshilboum, C. Reynolds, E. Perez, J. Ingle Cancer Res. vol 69 (2, suppl 1) abstr SABCS-6037 2009

Abstract PPP

http://cancerres.aacrjournals.org/content/69/2_Supplement/6037.abstract?sid=d7929468-5cd6-4de4-8cfa

490 CYP2D6 and HOXB13/IL17BR: Combining inherited and tumor gene markers for prediction of

tamoxifen resistance

Matthew P. Goetz, Vera J. Suman, Fergus J. Couch, Matthew M. Ames, James M. Rae, Mark G. Erlander, Xiao-Jun Ma, Dennis C. Sgroi, Carol A. Reynolds, Wilma L. Lingle, Richard M. Weinshilboum, David A. Flockhart, Zeruesenay Desta, Edith A. Perez, James N. Ingle *Clin Cancer Res* vol 14 (18) 5864-5868 2008
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/18794098>

491 Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies

Matthew P. Goetz, James X. Sun, Vera J. Suman, Grace O. Silva, Charles M. Perou, Yusuke Nakamura, Nancy J. Cox, Philip J. Stephens, Vincent A. Miller, Jeffrey S. Ross, David Chen, Stephanie L. Safgren, Mary J. Kuffel, Matthew M. Ames, Krishna R. Kalari, Henry L. Gomez, Ana M. Gonzalez-Angulo, Octavio Burgues, Hiltrud B. Brauch, James N. Ingle, Mark J. Ratain, Roman Yelensky *J. Natl. Cancer Inst* vol 107 (2) 2014
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/25490892>

492 The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.

Matthew P Goetz, Stacey K Knox, Vera J Suman, James M Rae, Stephanie L Safgren, Matthew M Ames, Daniel W Visscher, Carol Reynolds, Fergus J Couch, Wilma L Lingle, Richard M Weinshilboum, Emily G Barr Fritcher, Andrea M Nibbe, Zeruesenay Desta, Anne Nguyen, David A Flockhart, Edith A Perez, James N Ingle *Breast Cancer Res. Treat.* vol 101 (1) 113-21 2007
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/17115111>

493 A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in 9 first line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC).

R. M. Goldberg, C. H. Kohne, M. T. Seymour, A. De Gramont, R. Porschen, L. Saltz, P. Rougier, C. Tournigand, A. Grothey, D. J. Sargent *J. Clin. Oncol.* vol 25 (18s) abstr 4011 2007
Abstract GI N0545, N9741
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

494 Adjuvant mFOLFOX6 +/- Cetuximab in Patients With KRAS Mutant Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147.

R. Goldberg, D. Sargent, S. Thibodeau, M. Mahoney, A. Shields, E. Chan, S. Gill, M. Kahlenberg, S. Nair, S. Alberts *J. Clin. Oncol.* vol 28 (15s) abstr 3508 2010
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

495 A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Richard M Goldberg, Daniel J Sargent, Roscoe F Morton, Charles S Fuchs, Ramesh K Ramanathan, Stephen K Williamson, Brian P Findlay, Henry C Pitot, Steven R Alberts *J. Clin. Oncol.* vol 22 (1) 23-30 2004
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/14665611>

496 Variability of Pelvic MRI Performance in a Prospective Multicenter Rectal Cancer Trial NCCTG N1048 (Alliance)

Marc J. Gollub, Qian Shi, Stephanie Nougaret, Preethi Subramanian, Jun Zhang, Michael Knopp, Deborah Schrag, Gregory Nyman, Lawrence Schwartz *J Clin Oncol* vol 36 (Suppl) abstr e18783 2018
Abstract GI <https://meetinglibrary.asco.org/record/159550/abstract>

497 Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant paclitaxel followed by

doxorubicin and cyclophosphamide on breast conservation rates: Surgical results from CALGB 40603 (Alliance).

Mehra Golshan, Constance T. Cirrincione, Donald A. Berry, William M. Sikov, Sara Jasinski, Tracey F. Weisberg, George Somlo, Eric P. Winer, Clifford Hudis, David W. Ollila 2015
Abstract Breast <http://meeting.americansurgical.org/abstracts/2015/3.cgi>

498 Impact of Neoadjuvant Therapy on Breast Conservation Rates in Triple- Negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance)

Mehra Golshan, Constance T. Cirrincione, Donald Berry, Lisa Carey⁴, William Sikov, Norah Henry, George Somlo, Elisa Port, Eric Winer, Clifford A. Hudis, David Ollila J. Clin. Oncol. vol 33 (suppl) abstr 1007 2015
Abstract Breast CALGB-40601, CALGB-40603
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1007?sid=dea30587-a124-4651-a1b8-66b0

499 Impact of Neoadjuvant Chemotherapy in Stage II–III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates

Mehra Golshan, Constance T. Cirrincione, William M. Sikov, Donald A. Berry, Sara Jasinski, Tracey F. Weisberg, George Somlo, Clifford Hudis, Eric Winer, David W. Ollila Ann. Surg. vol 262 (3) 434-439 2015
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26222764>

500 Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

Mehra Golshan, Constance T. Cirrincione, William M. Sikov, Lisa A. Carey, Donald A. Berry, Beth Overmoyer, Nora L. Henry, George Somlo, Elisa Port, Harold J. Burstein, Clifford Hudis, Eric Winer, David W. Ollila Breast Cancer Res. Treat. vol 160 (2) 297-304 2016
Manuscript Breast CALGB-40601, CALGB-40603 <http://www.ncbi.nlm.nih.gov/pubmed/27704226>

501 Sentinel node biopsy performed in the neoadjuvant setting for Breast Cancer: Results from the CALGB 150007 & 150012/ACRIN 6657 I-SPY TRIAL

R. Gomez, J. Zakhireh, D. Moore, A. Demichelle, J. Przewoznik, D. W. Ollila, J. Frank, H. Krontiras, L. L. Montgomery, V. Sarode, G. Broadwater, L. J. Esserman Cancer Res. vol 69 (2 suppl 1) 202 2009
Abstract Correl Sci NOS ACRIN-6657, CALGB-150007
http://cancerres.aacrjournals.org/content/69/2_Supplement/202

502 Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147

Wilson I. Gonsalves, Michelle R. Mahoney, Daniel J. Sargent, Garth D. Nelson, Steven R. Alberts, Frank A. Sinicrope, Richard M. Goldberg, Paul J. Limburg, Stephen N. Thibodeau, Axel Grothey, Joleen M. Hubbard, Emily Chan, Suresh Nair, Jeffrey L. Berenberg, Robert R. McWilliams J. Natl. Cancer Inst vol 106 (7) 2014
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24925349>

503 Survival Outcomes from CALGB 80803 (Alliance): A Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy for Esophageal Cancer

Karyn A. Goodman, Nathan Hall, Tanios Bekaii-Saab, Fang-Shu Ou, Erin Twohy, Michael Meyers, Daniel Boffa, Kristen Ciombor, Wendy Frankel, Alan Venook, Eileen O'Reilly, David Ilson J. Clin. Oncol. vol 36 (15_suppl) 4012-4012 2018
Abstract GI https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.4012

504 Initial results of CALGB 80803: A randomized phase II trial of pet scan-directed combined modality therapy for esophageal cancer (Alliance)

Karyn A. Goodman, Donna Niedzwiecki, Nathan Hall, Tanios Bekaii-Saab, Xing Ye, Michael Meyers, Daniel Boffa, Wendy Frankel, Alan Venook, Howard Hochster, Christopher Crane, Eileen O'Reilly, David Ilson J Clin Oncol vol 35 (suppl 4S) abstr 1 2017
Abstract GI http://abstracts.asco.org/195/AbstView_195_176998.html

505 Predictors of accrual success for cooperative group trials: The Cancer and Leukemia Group B (Alliance) experience

David Gordon, Qianying Liu, Benjamin Kleinman, Theodore Karrison, Michael Kelly, Gini Fleming J. Clin. Oncol. vol 31 (15) abstr TPS6645 2013
Abstract Health Outcome
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/TPS6645?sid=68c9c943-2214-43b1-863e-

506 New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials

Thierry Gorlia, Wenting Wu, Meihua Wang, Brigitta G. Baumert, Minesh Mehta, Jan C. Buckner, Edward Shaw, Paul Brown, Roger Stupp, Evanthia Galanis, Denis Lacombe, Martin J. van den Bent Neuro-oncology vol 15 (11) 1568-1579 2013
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/24049111>

507 Sorafenib for Advanced and Refractory Desmoid Tumors

Mrinal M. Gounder, Michelle R. Mahoney, Brian A. Van Tine, Vinod Ravi, Steven Attia, Hari A. Deshpande, Abha A. Gupta, Mohammed M. Milhem, Robert M. Conry, Sujana Movva, Michael J. Pishvaian, Richard F. Riedel, Tarek Sabagh, William D. Tap, Natally Horvat, Ethan Basch, Lawrence H. Schwartz, Robert G. Maki, Narasimhan P. Agaram, Robert A. Lefkowitz, Yousef Mazaheri, Rikiya Yamashita, John J. Wright, Amylou C. Dueck, Gary K. Schwartz N. Engl. J. Med. vol 379 (25) 2417-28 2018
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/30575484>

508 Phase III, randomized, double blind, placebo (P)-controlled trial of sorafenib (S) in desmoid tumor, (DT) (ALLIANCE A091105)

Mrinal M. Gounder, Michelle R. Mahoney, Brian Andrew Van Tine, Vinod Ravi, Steven Attia, Hari Anant Deshpande, Abha A. Gupta, Mohammed M. Milhem, Robert Martin Conry, Sujana Movva, Michael J. Pishvaian, Jeffrey Crawford, Tarek Sabagh, Robert G. Maki, William D. Tap, Robert A Lefkowitz, Narasimhan P Agaram, John Joseph Wright, Amylou C. Dueck, Gary K. Schwartz J Clin Oncol vol 36 (no. 15_suppl) 11500-11500 2018
Abstract Experimental https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.11500

509 Phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407

R. Govindan, J. A. Bogart, X. Wang, L. D. Hodgson, R. A. Kratzke, E. E. Vokes J. Clin. Oncol. vol 27 (15s) abstr 7505 2009
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

510 A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non small cell lung cancer: CALGB 30407 early evaluation of feasibility and toxicity

R. Govindan, J. A. Bogart, X. Wang, D. Liu, R. A. Kratzke, E. E. Vokes J. Clin. Oncol. vol 26 (May 20 suppl) abstr 7518 2008
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

- 511 Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407**
Ramaswamy Govindan, Jeffrey Bogart, Thomas Stinchcombe, Xiaofei Wang, Lydia Hodgson, Robert Kratzke, Jennifer Garst, Timothy Brotherton, Everett E. Vokes J Clin Oncol vol 29 (23) 3120-3125 2011
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21747084>
- 512 ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early Stage Non–Small Cell Lung Cancer**
Ramaswamy Govindan, Sumithra J. Mandrekar, David E. Gerber, Geoffrey R. Oxnard, Suzanne E. Dahlberg, Shakun Malik, Margaret Mooney, Jeffrey S. Abrams, Pasi A. Jänne, David R. Gandara, Suresh S. Ramalingam, Everett E. Vokes Clin. Cancer Res. vol 21 (24) 5439-5444 2015
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/26672084>
- 513 A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104.**
Ramaswamy Govindan, Xiaofei Wang, Maria Q Baggstrom, Susan Burdette-Radoux, Lydia Hodgson, Everett E Vokes, Mark R Green J Thorac Oncol vol 4 (2) 220-6 2009
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/19179900>
- 514 Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20)**
B. Grant, J. P. Leonard, J. L. Johnson, L. Kostakoglu, E. Hsi, J. C. Byrd, J. A. Jones, S.-H. Jung, B. D. Cheson Blood vol 116 (21) -427 2010
Abstract Lymphoma <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;116/21/427>
- 515 A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.**
Barbara W Grant, Sin-Ho Jung, Jeffrey L Johnson, Lale Kostakoglu, Eric Hsi, John C Byrd, Jeffrey Jones, John P Leonard, S Eric Martin, Bruce D Cheson Cancer vol 119 (21) 3797-804 2013
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/23922187>
- 516 Menstrual Cycle and Surgical Treatment of Breast Cancer: Findings From the NCCTG N9431 Study**
Clive S. Grant, James N. Ingle, Vera J. Suman, Daniel A. Dumesic, D. Lawrence Wickerham, Richard D. Gelber, Patrick J. Flynn, Lorna M. Weir, Mattia Intra, Wayne O. Jones, Edith A. Perez, Lynn C. Hartmann J Clin Oncol vol 27 (22) 3620-3626 2009
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/19487378>
- 517 Prognostic significance of molecular markers and clinical factors in stage IB non-small cell lung cancer (NSCLC): A laboratory companion study to CALGB 9633**
S. L. Graziano, L. Gu, X. Wang, A. Tatum, R. T. Vollmer, G. M. Strauss, R. A. Kratzke, M. R. Green, E. E. Vokes J Thorac Oncol vol 2 (8) S403 2007
Abstract Correl Sci NOS CALGB-159802, CALGB-9633
http://journals.lww.com/jto/Fulltext/2007/08001/Prognostic_significance_of_molecular_markers_and.36
- 518 Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer (NSCLC) treated with adjuvant chemotherapy: Results from IALT, JBR.10 and ANITA**
S. L. Graziano, J. P. Pignon, R. T. Vollmer, R. A. Kratzke, V. Soriano, M. Tsao, R. Rosell J Thorac Oncol vol 4 (9 suppl 1) abstr PD7.3.2 2009

519 Dose-dense weekly paclitaxel (P) in extensive stage small cell lung cancer (ES-SCLC): Cancer and Leukemia Group B (CALGB) 39901

S. L. Graziano, M. A. Socinski, J. E. Herndon 2nd, D. M. Watson, M. R. Green Proc Am Soc Clin Oncol vol 22 Abstr 2598 2003

Abstract Respiratory

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=23&abstractID

520 LACE-Bio pooled analysis of the prognostic and predictive value of p53 mutations and expression by Immunohistochemistry (IHC) in patients with resected Non-Small Cell Lung Cancer (NSCLC).

S. Graziano, E. Paris, X. Ma, J. Pignon, P. Hainaut, M. Taron, M. Tsao, B. Brambilla, J. Soria Ann. Oncol. vol 21 ((suppl 8): viii122-viii161) abstract 389P 2010

Abstract Respiratory http://annonc.oxfordjournals.org/content/21/suppl_8/viii122.full.pdf+html

521 Prognostic Significance of Mucin and p53 Expression in Stage IB Non-Small Cell Lung Cancer: A Laboratory Companion Study to CALGB 9633

Stephen L. Graziano, Lin Gu, Xiaofei Wang, Arthur H. Tatum, Robin T. Vollmer, Gary M. Strauss, Robert Kratzke, Arkadiusz Z. Dudek, Everett E Vokes, Mark R. Green J Thorac Oncol vol 5 (6) 810-817 2010

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20521348>

522 Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA

Stephen L. Graziano, Benjamin Lacas, Robin Vollmer, Robert Kratzke, Helmut Popper, Martin Filipits, Lesley Seymour, Frances A. Shepherd, Rafael Rosell, Anne Sophie Veillard, Miquel Taron, Jean-Pierre Pignon Lung Cancer vol 82 (1) 149-155 2013

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/23920379>

523 Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.

Stephen L Graziano, James E Herndon, Mark A Socinski, Xiaofei Wang, Dorothy Watson, Everett Vokes, Mark R Green J Thorac Oncol vol 3 (2) 158-62 2008

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18303437>

524 Phase II randomized study of dose-dense docetaxel (Doc) and cisplatin (Cis) every two weeks with pegfilgrastim (Pfil) and darbepoetin alfa (Darb) with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (NSCLC)

M. R. Green, A. A. Miller, X. Wang, L. Gu, E. E. Vokes J. Clin. Oncol. vol 25 (18s) abstr 7617 2007

Abstract Respiratory

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

525 Local excision of distal rectal cancer: An update of Cancer and Leukemia Group B 8984

J. A. Greenberg, D. Shibata, J. E. 2nd Herndon, G. D. Steele Jr, R. J. Mayer, R. Bleday Am Soc Colon Rectal Surg vol 51 (8) abstr 8984 2008

Abstract GI

http://journals.lww.com/dcrjournal/Abstract/2008/51080/Local_Excision_of_Distal_Rectal_Cancer__An

526 Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984.

Jacob A Greenberg, David Shibata, James E Herndon, Glenn D Steele, Robert Mayer, Ronald Bleday

- 527 Treatment of Myelodysplastic Syndrome with Two Schedules and Doses of Oral Topotecan: A Randomized Phase II Trial by the Cancer and Leukemia Group B (CALGB 19803)**
David L. Grinblatt, Daohai Yu, Vera Hars, James W. Vardiman, Bayard L. Powell, Sreenivasa Nattam, Lewis R. Silverman, Carlos de Castro, Richard M. Stone, Clara D. Bloomfield, Richard A. Larson
Cancer vol 115 (1) 84-93 2009
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/19025972>
- 528 Accuracy of FDG-PET to diagnose lung cancer in the ACOSOG Z4031 trial**
E. Grogan, S. Deppen, K. Ballman, G. Andrade, F. Verdail, M. Aldrich, H. Chen, P. Decker, D. Harpole, R. Cerfolio, R. Keenan, D. Jones, T. D'Amico, J. Shrager, B. Meyers, J. Putnam J. Clin. Oncol. vol 30 (suppl) abstr 7008 2012
Abstract Respiratory <https://meetinglibrary.asco.org/content/94453-114>
- 529 Accuracy of FDG-PET within the clinical practice of the ACOSOG Z4031 trial to diagnose clinical stage I NSCLC**
Eric L. Grogan, Stephen A. Deppen, Karla V. Ballman, Gabriela M. Andrade, Francys C. Verdial, Melinda C. Aldrich, Chiu L. Chen, Paul A. Decker, David H. Harpole, Rrobert J. Cerfolio, Robert J. Keenan, David R. Jones, Thomas A. D'Amico, Joseph B. Shrager, Bryan F. Meyers, Joe B. Putnam
Ann. Thorac. Surg. vol 97 (4) 1142-1148 2014
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/24576597>
- 530 New lesions vs. growth of existing disease: does it impact prognosis?**
A. Grothey, J. M. Heun, M. Branda, R. M. Goldberg, D. J. Sargent J. Clin. Oncol. vol 29 (suppl) abstr 2579 2011
Abstract GI <http://meetinglibrary.asco.org/content/82873-102>
- 531 Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): results of the phase II North Central Cancer Treatment Group Study N054C**
A. Grothey, J. M. Lafky, B. W. Morlan, P. J. Stella, S. R. Dakhil, P. D. Steen, W. S. Loui, B. M. Bot, S. R. Alberts, J. T. Reynolds J. Clin. Oncol. vol 28 (15s) abstr 3549 2010
Abstract GI <http://meetinglibrary.asco.org/content/51133-74>
- 532 Baseline quality of life (QOL) is a strong and performance status (PS)-independent prognostic factor for overall survival (OS) in patients with metastatic colorectal cancer (mCRC)**
A. Grothey, D. J. Sargent, W. Szydlo, X. Zhao, M. Campbell, R. M. Goldberg, J. Sloan
Gastrointestinal Cancers Symposium abstr 334 2008
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=53&abstractID
- 533 Duration of Adjuvant Chemotherapy for Stage III Colon Cancer**
A. Grothey, A.F. Sobrero, A.F. Shields, T. Yoshino, J. Paul, J. Taieb, J. Souglakos, Q. Shi, R. Kerr, R. Labianca, J.A. Meyerhardt, D. Vernerey, T. Yamanaka, I. Boukovinas, J.P. Meyers, L.A. Renfro, D. Niedzwiecki, T. Watanabe, V. Torri, M. Saunders, D.J. Sargent, T. Andre, T. Iveson N. Engl. J. Med. vol 378 (13) 1177-1188 2018
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/29590544>
- 534 Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.**
Axel Grothey, Eric E Hedrick, Robert D Mass, Somnath Sarkar, Sam Suzuki, Ramesh K Ramanathan,

535 Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7

Axel Grothey, Daniel A. Nikcevich, Jeff A. Sloan, John W. Kugler, Peter T. Silberstein, Todor Dentchev, Donald B. Wender, Paul J. Novotny, Umesh Chitale, Steven R. Alberts, Charles L. Loprinzi J Clin Oncol vol 29 (4) 421-427 2011

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/21189381>

536 Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration

Axel Grothey, Alberto F. Sobrero, Jeffrey A. Meyerhardt, Takayuki Yoshino, James Paul, Julien Taieb, Ioannis Sougklakos, Rachel Kerr, Roberto Labianca, Anthony F. Shields, Franck Bonnetain, Toshiaki Watanabe, Ioannis Boukovinas, Qian Shi, Lindsay A. Renfro, Donna Niedzwiecki, Valter Torri, Daniel J. Sargent, Thierry Andre, Timothy Iveson Annals of Oncology vol 28 (suppl_5) v605-v649 2017

Abstract GI

<http://oncologypro.esmo.org/Meeting-Resources/ESMO-2017-Congress/Prospective-pooled-analysis-of->

537 Determination of Utility Scores for Control of Chemotherapy-Induced Nausea or Vomiting—CALGB 309801

S. M. Grunberg, J. Weeks, W. F. Magnan, J. 2nd Herndon, M. L. Naughton, K. L. Blackwell, M. E. Wood, D. L. Christian, M. C. Perry, E. C. Dees, E. Reed, M. E. Marshall J Support Oncol vol 7 (5) W17 - W22 2009

Manuscript Disparities

538 Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance)

Brendan J. Guercio, Kaori Sato, Donna Niedzwiecki, Xing Ye, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Frank B. Hu, Shuji Ogino, Kana Wu, Walter C. Willett, Edward L.

Giovannucci, Jeffrey A. Meyerhardt, Charles S. Fuchs J. Clin. Oncol vol 33 (31) 3598-3607 2015

Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/26282659>

539 Associations of Physical Activity with Survival and Progression in Metastatic Colorectal Cancer: Results from CALGB 80405 (Alliance)

Brendan J. Guercio, Alan P. Venook, Donna Niedzwiecki, Sui Zhang, Kaori Sato, Charles Fuchs, Heinz-Josef Lenz, Federico Innocenti, Michelle R. Mahoney, Bert H. O'Neil, James Edward Shaw, Blase N. Polite, Howard S. Hochster, James Norman Atkins, Richard M. Goldberg, Robert J. Mayer, Monica M. Bertagnolli, Charles D. Blanke, Jeffrey A. Meyerhardt J Clin Oncol vol 35 (suppl 4S) abstr 659 2017

Abstract GI http://abstracts.asco.org/195/AbstView_195_175855.html

540 Associations of Insulin-Like Growth Factor Binding Proteins and Adiponectin with Disease Progression and Mortality in Metastatic Colorectal Cancer: Results from CALGB/SWOG 80405 (Alliance)

Brendan J. Guercio, Alan P. Venook, Sui Zhang, Fang-Shu Ou, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Michael Pollak, Andrew Nixon, Michelle R. Mahoney, Bert H. O'Neil, James E. Shaw, Blase N. Polite, Crystal Denlinger, James N. Atkins, Richard M. Goldberg, Robert J. Mayer, Charles D. Blanke, Charles S. Fuchs, Jeffrey A. Meyerhardt J. Clin. Oncol. vol 37 (15_suppl) 3035-3035 2019

Abstract GI https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3035

- 541 Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance)**
Brendan J. Guercio, Sui Zhang, Donna Niedzwiecki, Yanping Li, Ana Babic, Vicente Morales-Oyarvide, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Emilie S. Zoltick, Meir Stampfer, Kimmie Ng, Kana Wu, Walter C. Willett, Edward L. Giovannucci, Jeffrey A. Meyerhardt, Charles S. Fuchs PLoS ONE vol 13 (7) e0199244 2018
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/30024889>
- 542 Body mass index, weight loss, and progression and mortality in metastatic colorectal cancer (Alliance)**
Brendan J. Guercio, Sui Zhang, Alan P. Venook, Fang-Shu Ou, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Michelle R. Mahoney, Bert H. O'Neil, James E. Shaw, Blase N. Polite, Howard S. Hochster, James N. Atkins, Richard M. Goldberg, Robert J. Mayer, Charles D. Blanke, Charles S. Fuchs, Jeffrey A. Meyerhardt 2019
Abstract GI <https://www.abstractsonline.com/pp8/#!/6812/presentation/1801>
- 543 Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.**
Brendan J Guercio, Sui Zhang, Fang-Shu Ou, Alan P Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Bert H O'Neil, James E Shaw, Blase N Polite, Howard S Hochster, James N Atkins, Richard M Goldberg, Kaori Sato, Kimmie Ng, Erin Van Blarigan, Robert J Mayer, Charles D Blanke, Eileen M O'Reilly, Charles S Fuchs, Jeffrey A Meyerhardt J. Clin. Oncol. JCO1901019 2019
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/31408415>
- 544 A Phase II Study of the Oral VEGF Receptor Tyrosine Kinase Inhibitor Vatalanib (PTK787/ZK222584) in Myelodysplastic Syndrome: Cancer and Leukemia Group B Study 10105 (Alliance)**
Pankaj Gupta, Flora Mulkey, Robert P. Hasserjian, Ben L. Sanford, Ravi Vij, David D. Hurd, Olatoyosi M. Odenike, Clara D. Bloomfield, Kouros Owzar, Richard M. Stone, Richard A. Larson Invest New Drugs vol 31 (5) 1311-1320 2013
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/23700288>
- 545 Dual Epigenetic Control of CCAAT/Enhancer Binding Protein {alpha} (C/EBP{alpha}) Expression in Acute Myeloid Leukemia**
B. Hackanson, K. L. Bennett, R. M. Brena, J. Jiang, K. Maharry, S. P. Whitman, T. D. Schmittgen, M. Luebbert, G. Marcucci, C. D. Bloomfield, C. Plass Blood vol 110 (11) 2116 2007
Abstract Leuk Corr Sci CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://www.bloodjournal.org/content/110/11/2116>
- 546 Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia.**
Björn Hackanson, Kristi L Bennett, Romulo M Brena, Jinmai Jiang, Rainer Claus, Shih-Shih Chen, Nadya Blagitko-Dorfs, Katie Maharry, Susan P Whitman, Thomas D Schmittgen, Michael Lübbert, Guido Marcucci, Clara D Bloomfield, Christoph Plass Cancer Res. vol 68 (9) 3142-51 2008
Manuscript Leuk Corr Sci CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/18451139>
- 547 Persistent Fatigue in Hematopoietic Stem Cell Transplantation Survivors**
Eileen Danaher Hacker, Anne M. Fink, Tara Peters, Chang Park, Giamila Fantuzzi, Damiano Rondelli Cancer Nurs vol 40 (3) 174-183 2017

- 548 Persistent Fatigue in Stem Cell Transplant Survivors: A Biobehavioral Perspective**
Eileen Danaher Hacker, Anne Fink, Tara Peters, Chang Park, Giamila Fantuzzi, Damiano Rondelli
Biol. Blood Marrow Transplant. vol 21 (2) S126 2015
Abstract Symptom Inter [http://www.bbmt.org/article/S1083-8791\(14\)00875-1/pdf](http://www.bbmt.org/article/S1083-8791(14)00875-1/pdf)
- 549 Real-Time Fatigue and Free-Living Physical Activity in Hematopoietic Stem Cell Transplantation Cancer Survivors and Healthy Controls: A Preliminary Examination of the Temporal, Dynamic Relationship**
Eileen Danaher Hacker, Inah Kim, Chang Park, Tara Peters Cancer Nurs vol 40 (4) 259-268 2017
Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/27922918>
- 550 Phase II study of oxaliplatin, 5-FU and RT followed by gemcitabine in patients with unresectable pancreatic cancer.**
M. Haddock, G. Kim, N. Foster, J. Bollinger, P. Stella, J. Kugler, S. Dakhil, S. Alberts
Gastrointestinal Cancers Symposium abstr 176 2007
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=45&abstractID
- 551 Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.**
Michael G Haddock, Revathi Swaminathan, Nathan R Foster, Mark D Hauge, James A Martenson, John K Camoriano, Philip J Stella, Richard C Tenglin, Paul L Schaefer, Dennis F Moore, Steven R Alberts J. Clin. Oncol. vol 25 (18) 2567-72 2007
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17577035>
- 552 Radiation use and field design in women with node positive breast cancer treated with preoperative systemic therapy and breast surgery including axillary dissection on a prospective clinical trial ACOSOG Z1071 [Alliance]**
Bruce G. Haffty, Linda M. McCall, Karla V. Ballman, Kelly K. Hunt, Thomas A. Buchholz, Judy C. Boughey Int J Radiation Biol Physics vol 93 (3) abstr S136 2015
Abstract Breast <http://www.redjournal.org/article/S0360-3016%2815%2901055-X/abstract>
- 553 Patterns of local-regional management following neoadjuvant chemotherapy in breast cancer: Results from ACOSOG Z1071 (Alliance)**
Bruce G. Haffty, Linda M. McCall, Karla V. Ballman, Sarah McLaughlin, Reshma Jagsi, David W. Ollila, Kelly K. Hunt, Thomas A. Buchholz, Judy C. Boughey Int. J. Radiat. Oncol. Biol. Phys. vol 94 (3) 493-502 2016
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26867878>
- 554 Impact of radiation on local regional control in women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary lymph node dissection: Results from ACOSOG 1071 Clinical Trial.**
Bruce G Haffty, Linda M McCall, Karla V Ballman, Thomas A Buchholz, Kelly K Hunt, Judy C Boughey Int. J. Radiat. Oncol. Biol. Phys. 2019
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/31085287>
- 555 Impact of radiation on local regional control in women with node positive breast cancer treated with neoadjuvant chemotherapy (NAC) and axillary lymph node dissection (ALND); results from ACOSOG Z1071 (Alliance)**
Bruce Haffty, Karla Ballman, Kelly Hunt, Linda McCall, Judy C. Boughey Int. J. Radiat. Oncol. Biol. Phys. vol 96 (2 suppl) S144 2016

556 Optimal Two-Stage Dynamic Treatment Regimes from a Classification Perspective with Censored Survival Data

Rebecca Hager, Anastasios A. Tsiatis, Marie Davidian Biometrics vol 74 (4) 1180-92 2018
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/29775203>

557 LACE-Bio Pooled Analysis of the Prognostic and Predictive Value of TP53 mutations in Completely Resected Non Small Cell Lung Cancer (NSCLC)

P. Hainaut, X. Ma, B. Lacas, M. Tsao, J.-Y. Douillard, V. Rousseau, A. Dunant, L. Seymour, M. Filipits, S. Graziano 2012
Abstract Respiratory

558 Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

S. Halabi, W. K. Kelly, E. B. Kaplan, E. J. Small J. Clin. Oncol. vol 30 (suppl 5) abstr 200 2012
Abstract GU http://meeting.ascopubs.org/cgi/content/abstract/30/5_suppl/200

559 A novel intermediate endpoint for predicting overall survival in men with metastatic castration-recurrent prostate cancer (CRPC)

S. Halabi, S. Ou, N. J. Vogelzang, H. I. Scher, E. J. Small J. Clin. Oncol. vol 25 (18s) 5113 2007
Abstract GU
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=46&abstractID

560 Is progression free survival a predictor of overall survival in men with castration recurrent prostate cancer (CRPC)?

S. Halabi, S. Ou, N. J. Vogelzang, E. J. Small 2008
Abstract GU C9181, C9182, CALGB-90004, CALGB-90006, CALGB-9583, CALGB-9680, CALGB-9780, CALGB-99813, INT-0159

561 Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

S. Halabi, B. I. Rini, W. M. Stadler, L. E. Archer, E. J. Small J. Clin. Oncol. vol 28 (15s) abstr 4525 2010
Abstract GU
http://jco.ascopubs.org/gca?gca=ascomtg%3B28%2F15_suppl%2F4525&allch=&submit=Go

562 Pain interference scores at 6-weeks from baseline and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC)

S. Halabi, N. J. Vogelzang, A. B. Kornblith, L. E. Archer, P. W. Kantoff, N. A. Dawson, E. J. Small Genitourinary Cancers Symposium abstr 168 2009
Abstract GU C9181, C9182, INT-0159
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=64&abstractID

563 Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

Susan Halabi, William Kevin Kelly, Hua Ma, Haojin Zhou, Nicole C. Solomon, Karim Fizazi, Catherine M. Tangen, Mark Rosenthal, Daniel P. Petrylak, Maha Hussain, Nicholas J. Vogelzang, Ian M. Thompson, Kim N. Chi, Johann de Bono, Andrew J. Armstrong, Mario A. Eisenberger, Abderrahim Fandi, Shaoyi Li, John C. Araujo, Christopher J. Logothetis, David I. Quinn, Michael J. Morris, Celestia S. Higano, Ian F. Tannock, Eric J. Small J. Clin. Oncol vol 34 (14) 1652-1659 2016
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/26951312>

- 564 The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.**
Susan Halabi, William Kevin Kelly, Haojin Zhou, Andrew J. Armstrong, David Quinn, Karim Fizazi, Nicole C Solomon, Ian Tannock, Daniel Peter Petrylak, Michael J. Morris, Eric Jay Small J. Clin. Oncol. vol 32 (5s) (suppl; abstr 5002) 2014
Abstract GU CALGB-90401, S9916 http://abstracts.asco.org/144/AbstView_144_129874.html
- 565 Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer**
Susan Halabi, Chen-Yen Lin, W. Kevin Kelly, Karim S. Fizazi, Judd W. Moul, Ellen B. Kaplan, Michael J. Morris, Eric J. Small J. Clin. Oncol vol 32 (7) 671-677 2014
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/24449231>
- 566 A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy**
Susan Halabi, Chen-Yen Lin, Eric J. Small, . Andrew J. Armstrong, Ellen B. Kaplan, Daniel P. Petrylak, Cora N. Sternberg, Liji Shen, Stephane Oudard, Johann S. De Bono, Sartor A. Oliver J. Clin. Oncol. vol 31 (suppl, abstr 5011) 2013
Abstract GU <http://meetinglibrary.asco.org/content/110602-132>
- 567 Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer.**
Susan Halabi, San-San Ou, Nicholas J Vogelzang, Eric J Small Cancer vol 110 (7) 1478-84 2007
Manuscript GU C9181, C9182, CALGB-90004, CALGB-90006, CALGB-9583, CALGB-9680, CALGB-9780, CALGB-99813 <http://www.ncbi.nlm.nih.gov/pubmed/17665494>
- 568 Progression-Free Survival (PFS) as a Surrogate Endpoint of Overall Survival (OS) in Patients with Metastatic Renal Cell Carcinoma (mRCC)**
Susan Halabi, Brian Rini, Bernard Escudier, Walter M. Stadler, Eric J. Small Cancer vol 120 (1) 2014
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/24347384>
- 569 Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer**
Susan Halabi, Nicholas J. Vogelzang, San-San Ou, Kouros Owzar, Laura Archer, Eric J. Small J Clin Oncol vol 27 (17) 2766-2771 2009
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/19380448>
- 570 Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.**
Susan Halabi, Nicholas J Vogelzang, Alice B Kornblith, San-San Ou, Philip W Kantoff, Nancy A Dawson, Eric J Small J. Clin. Oncol. vol 26 (15) 2544-9 2008
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/18487572>
- 571 The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials.**
Susan Halabi, Nicholas J Vogelzang, San-San Ou, Eric J Small J. Urol. vol 177 (2) 531-4 2007
Manuscript GU C9181, C9182, CALGB-90004, CALGB-9000, CALGB-9583, CALGB-9680, CALGB-9780, CALGB-99813, INT-0159 <http://www.ncbi.nlm.nih.gov/pubmed/17222627>
- 572 A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)**
Thorvardur R. Halfdanarson, Nathan R. Foster, George P. Kim, Jeffrey P. Meyers, Thomas C. Smyrk,

573 N0733: Phase II trial of capecitabine and lapatinib +/- cixutumumab in HER2 positive breast cancer

P. Haluska, M. M. Reinholz, A. C. Dueck, H. M. Linden, W. L. Lingle, A. M. Jr Bernath, M. C. Arbushites, H. Youssoufian, H. X. Chen, E. A. Perez J. Clin. Oncol. vol 28 (15s) abstr TPS129 2010
Abstract Breast
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

574 Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance).

Paul Haluska, Albert M. Bernath, Karla V. Ballman, Amylou C. Dueck, Hannah M. Linden, Matthew P. Goetz, Donald W. Northfelt, Xiaonan Hou, Kathleen S. Tenner, Piyawan Tienchaiananda, Lynn M. Flickinger, Beiyun Chen, Helen X. Chen, Wilma L. Lingle, Christine M. Pellegrino, Robert W. Sponzo, Monica Madden Reinholz, Edith A. Perez J. Clin. Oncol. vol 32 (5s) suppl; abstr 632) 2014
Abstract Breast <http://meetinglibrary.asco.org/content/132004-144>

575 Impact of Adjuvant Trastuzumab on Local Regional Recurrence; Data from the NCCTG N9831 study.

M. Y. Halyard, A. C. Dueck, T. M. Pisansky, S. A. Mclaughlin, L. J. Pierce, L. B. Marks, L. J. Solon, B. A. Pockaj, E. A. Perez Cancer Res. vol 70 (24) abstr P5-13-02 2010
Abstract Breast http://cancerres.aacrjournals.org/content/70/24_Supplement/P5-13-02

576 Assessing the clinical significance of real-time Quality of Life (QOL) data in cancer patients treated with radiation therapy

M. Y. Halyard, A. D. Tan, M. D. Callister, J. B. Ashman, S. A. Vora, W. Wong, S. E. Schild, P. J. Atherton, J. A. Sloan J. Clin. Oncol. vol 28 (15s) abstr 9107 2010
Abstract Health Outcome <http://meetinglibrary.asco.org/content/53556-74>

577 Changes in left ventricular function after radiation therapy and trastuzumab: analysis of North Central Cancer Treatment Group Phase III Trial N9831.

M. Halyard, T. M. Pisansky, L. J. Pierce, L. J. Solin, L. B. Marks, K. S. Tenner, A. C. Dueck, E. A. Perez Int. J. Radiat. Oncol. Biol. Phys. vol 75 (3s) S50 2009
Abstract Breast [http://www.redjournal.org/article/S0360-3016\(09\)01178-X/abstract](http://www.redjournal.org/article/S0360-3016(09)01178-X/abstract)

578 Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831

Michele Y. Halyard, Thomas M. Pisansky, Amylou C. Dueck, Vera Suman, Lori Pierce, Larry Solin, Larry Marks, Nancy Davidson, Silvana Martino, Peter Kaufman, Leila Kutteh, Shaker R. Dakhil, Edith A. Perez J Clin Oncol vol 27 (16) 2638-2644 2009
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/19349549>

579 Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.

Svasti Haricharan, Nindo Punturi, Purba Singh, Kimberly R Holloway, Meenakshi Anurag, Jacob Schmelz, Cheryl Schmidt, Jonathan T Lei, Vera Suman, Kelly Hunt, John A Olson, Jeremy Hoog, Shunqiang Li, Shixia Huang, Dean P Edwards, Shyam M Kavuri, Matthew N Bainbridge, Cynthia X Ma, Matthew J Ellis Cancer Discov vol 7 (10) 1168-83 2017
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/28801307>

- 580 Proteomic analysis for detection of NSCLC: Results of ACOSOG Z4031**
D. Harpole, K. V. Ballman, A. L. Oberg, G. Whiteley, R. Cerfolio, R. Keenan, D. R. Jones, T. A. D'Amico, J. Shrager, J. B. Putnam Jr, American College of Surgeons Oncology Group J. Clin. Oncol. vol 29 (15_suppl) 7003 2011
Abstract Respiratory http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/7003
- 581 Genome-wide profiling of archived material from CALGB 9840 and 9342 for paclitaxel (P) and trastuzumab (T) response biomarkers using gene expression and copy number analysis**
L. N. Harris, J. R. Parker, G. Broadwater, V. Schulz, K. T. Halligan, K. Geyda, A. D. Seidman, D. A. Berry, E. P. Winer, C. A. Hudis, M. J. Ellis, A. Kraznitz, J. Hicks, D. Tuck, C. M. Perou Cancer Res. vol 69 (24, suppl 3) abstr SABCS-09-4032 2009
Abstract PPP CALGB-9342, CALGB-9840, CALGB-159806
http://cancerres.aacrjournals.org/cgi/content/abstract/69/24_MeetingAbstracts/4032
- 582 Topoisomerase II Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013**
Lyndsay N. Harris, Gloria Broadwater, Maysa Abu-Khalaf, David Cowan, Ann D. Thor, Daniel Budman, Constance T. Cirrincione, Donald A. Berry, Eric P. Winer, Clifford A. Hudis, Daniel F. Hayes, Paula Friedman, Matthew Ellis, Lynn Dressler J. Clin. Oncol vol 27 (21) 3430-3436 2009
Manuscript Correl Sci NOS C8541, CALGB-150013
<http://www.ncbi.nlm.nih.gov/pubmed/19470942>
- 583 Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy**
A. L. Harzstark, S. Halabi, W. K. Kelly, M. J. Morris, P. G. Febbo, E. J. Small J. Clin. Oncol. vol 30 (suppl 5) abstr 129 2012
Abstract GU
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=116&abstractID
- 584 Hypertension is associated with clinical outcome for patients (Pts) with metastatic renal cell carcinoma (RCC) treated with interferon and bevacizumab on CALGB 90206**
A. L. Harzstark, S. Halabi, W. M. Stadler, D. A. Vaena, J. N. Atkins, J. Picus, P. Czakowski, J. Dutcher, B. I. Rini, E. J. Small Genitourinary Cancers Symposium abstr 351 2010
Abstract GU
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID
- 585 Application of 2008 WHO classification criteria for myelodysplastic syndromes (MDS) without excess blasts: Observations from Cancer and Leukemia Group B Study 10105**
R. Hasserjian, P. Gupta, K. A. Donohue, K. Owzar, R. A. Larson, F. K. Racke, C. D. Bloomfield United States and Canadian Academy of Pathology Annual Meeting vol 22 (suppl 1) abstr 1208 2009
Abstract Leuk Corr Sci http://www.abstracts2view.com/uscap09/view.php?nu=USCAP09L_1208
- 586 A comparison of two methodologies to quantify Thymidylate synthase for predicting survival in patients with colorectal cancer treated on CALGB 89803**
R. M. Hasson, D. Niedzwiecki, M. M. Bertagnoli Cancer Res. vol 72 (8, Supplement 1) Abstract 4514 2012
Abstract GI http://cancerres.aacrjournals.org/content/72/8_Supplement/4514.short
- 587 On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance)**
Ace J. Hatch, Fang-Shu Ou, Tyler Zemla, Liu, Mark D. Star, J. Chris Brady, Yingmiao, Federico Innocenti, MD, Jeffrey A. Meyerhardt, Eileen O'Reilly, Heinz-Josef Lenz, Herbert I. Hurwitz, Alan Venook, Andrew B. Nixon J. Clin. Oncol vol 37 (4 suppl) 588 2019
Abstract GI https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.4_suppl.588

- 588 Bloodbased markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)**
Ace J. Hatch, Alexander B. Sibley, Mark D. Starr, J. Chris Brady, Chen Jiang, Jingquan Jia, Daniel L. Bowers, Herbert Pang, Kouros Owzar, Donna Niedzwiecki, Federico Innocenti, Alan P. Venook, Herbert I. Hurwitz, Andrew B. Nixon *Cancer Med* vol 5 (9) 2249-2260 2016
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/27465221>
- 589 Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).**
Ace Joseph Hatch, Herbert Pang, Mark D. Starr, John C. Brady, Jingquan Jia, Chen Jiang, Alexander Sibley, Kouros Owzar, Donna Niedzwiecki, Alan P. Venook, Stephanie M. Cushman, Herbert Hurwitz, Andrew B. Nixon *J. Clin. Oncol.* vol 32 (5s) (suppl; abstr 11022) 2014
Abstract GI http://abstracts.asco.org/144/AbstView_144_129964.html
- 590 Genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer**
Christos Hatzis, Lajos Pusztai, Vicente Valero, Daniel J. Booser, Laura Esserman, Ana Lluch, Tatiana Vidaurre, Frankie Holmes, Eduardo Souchon, Miguel Martin, José Cotrina, Henry Gomez, Rebekah Hubbard, J. Ignacio Chacón, Jaime Ferrer-Lozano, Richard Dyer, Meredith Buxton, Yun Gong, Yun Wu, Nuhad Ibrahim, Eleni Andreopoulou, Naoto T. Ueno, Kelly Hunt, Wei Yang, Arlene Nazario, Angela DeMichele, Joyce O'Shaughnessy, Gabriel N. Hortobagyi, W. Fraser Symmans *JAMA* vol 305 (18) 1873-1881 2011
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/21558518>
- 591 Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML**
Violaine Havelange, Parvathi Ranganathan, Susan Geyer, Deedra Nicolet, Xiaomeng Huang, Xueyan Yu, Stefano Volinia, Steven M. Kornblau, Michael Andreeff, Carlo M. Croce, Guido Marcucci, Clara D. Bloomfield, Ramiro Garzon *Blood* vol 123 (15) 2412-2415 2014
Manuscript *Leuk Corr Sci* C8525, C9720, CALGB-10201, CALGB-8923, CALGB-9420
<http://www.ncbi.nlm.nih.gov/pubmed/24596420>
- 592 HER2 and response to paclitaxel in node-positive breast cancer.**
Daniel F Hayes, Ann D Thor, Lynn G Dressler, Donald Weaver, Susan Edgerton, David Cowan, Gloria Broadwater, Lori J Goldstein, Silvana Martino, James N Ingle, I Craig Henderson, Larry Norton, Eric P Winer, Clifford A Hudis, Matthew J Ellis, Donald A Berry *N. Engl. J. Med.* vol 357 (15) 1496-506 2007
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/17928597>
- 593 Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405**
Volker Heinemann, Donna Niedzwiecki, Rachel Pearline, Heinz-Josef Lenz, Federico Innocenti, Howard S. Hochster, Axel Grothey, Richard M. Goldberg, Robert J. Mayer, Richard L. Schilsky, Monica M. Bertagnolli, Charles D. Blanke, Alan P. Venook, Sebastian Stinzing, Bert H. O'Neil *J. Clin. Oncol.* vol 33 (suppl) abstr 3585 2015
Abstract GI <http://meetinglibrary.asco.org/content/150067-156>
- 594 Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group**
Michael C. Heinrich, Kouros Owzar, Christopher L. Corless, Donna Hollis, Ernest C. Borden, Christopher D.M. Fletcher, Christopher W. Ryan, Margaret von Mehren, Charles D. Blanke, Cathryn

Rankin, Robert S. Benjamin, Vivien H. Bramwell, George D. Demetri, Monica M. Bertagnolli, Jonathan A. Fletcher J Clin Oncol vol 26 (33) 5360-5367 2008
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/18955451>

595 CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC)

R. C. Suk Heist, X. Wang, L. D. Hodgson, G. A. Otterson, T. E. Stinchcombe, M. A. Socinski J. Clin. Oncol. vol 30 (suppl) abstr 7513 2012
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID

596 A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Rebecca S. Heist, Xiaofei Wang, Lydia Hodgson, Gregory A. Otterson, Thomas E. Stinchcombe, Leena Gandhi, Miguel A. Villalona-Calero, Peter Watson, Everett E. Vokes, Mark A. Socinski J Thorac Oncol vol 9 (2) 214-221 2014
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/24419419>

597 Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

I Craig Henderson, Donald A Berry, George D Demetri, Constance T Cirrincione, Lori J Goldstein, Silvana Martino, James N Ingle, M Robert Cooper, Daniel F Hayes, Katherine H Tkaczuk, Gini Fleming, James F Holland, David B Duggan, John T Carpenter, Emil Frei, Richard L Schilsky, William C Wood, Hyman B Muss, Larry Norton J. Clin. Oncol. vol 21 (6) 976-83 2003
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/12637460>

598 Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (ppembro) and standard platinum-based chemotherapy (chemo) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) AFT-09 (Alliance)

Thomas Hensing, Xiaofei Wang, David Kozono, Arkadius Dudek, Stephen Graziano, Jyoti Patel, Bryan Faller, Konstantin Dragnev, Everett Vokes, Thomas Stinchcombe J. Clin. Oncol. vol 37 (15_suppl) 2019
Abstract Respiratory https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9088

599 Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials

J. E. Herndon, A. B. Kornblith, J. C. Holland, E. D. Paskett Psycho-Oncology vol 22 (2) 315-323 2013
Manuscript Disparities <http://www.ncbi.nlm.nih.gov/pubmed/22021121>

600 Patient Education Level As a Predictor of Survival In Lung Cancer Clinical Trials

James E. Herndon, Alice B. Kornblith, Jimmie C. Holland, Electra D. Paskett J Clin Oncol vol 26 (25) 4116-4123 2008
Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/18757325>

601 A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance)

D. L. Hertz, K. Owzar, S. Halabi, W. K. Kelly, H. Zembutsu, C. Jiang, J. Patel, D. Watson, I. Shterev, D. L. Kroetz, P. N. Friedman, J. F. Mahoney, M. A. Carducci, M. L. J. Kelley, E. J. Small, P. G. Febbo, Y. Nakamura, M. Kubo, M. J. Ratain, H. L. Mcleod J. Clin. Oncol. vol 31 (15 suppl) abstr 11053 2013
Abstract PPP C90401, CALGB-60404

602 Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism That Increases Risk of Docetaxel-Induced Neuropathy

Daniel L. Hertz, Kouros Owzar, Sherrie Lessans, Claudia Wing, Chen Jiang, William Kevin Kelly, Jai Patel, Susan Halabi, Yoichi Furukawa, Heather E. Wheeler, Alexander B. Sibley, Cameron Lassiter, Lois Weisman, Dorothy Watson, Stefanie D. Krens, Flora Mulkey, Cynthia L. Renn, Eric J. Small, Phillip G. Febbo, Ivo Shterev, Deanna L. Kroetz, Paula N. Friedman, John F. Mahoney, Michael A. Carducci, Michael J Kelley, Yusuke Nakamura, Michiaki Kubo, Susan G. Dorsey, M. Eileen Dolan, Michael J. Morris, Mark J. Ratain, Howard L. McLeod Clin. Cancer Res. vol 22 (19) 4890-4900 2016

Manuscript PPP CALGB-60404, CALGB-90401 <http://www.ncbi.nlm.nih.gov/pubmed/27143689>

603 A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).

Daniel Louis Hertz, Chen Jiang, Kouros Owzar, Susan Halabi, William Kevin Kelly, Flora Mulkey, Jai Narendra Patel, Michael Anthony Carducci, Michael J. Kelley, Walter Michael Stadler, Mohamed K. Mohamed, Michael J. Morris, Yusuke Nakamura, Hitoshi Zembutsu, Mark J. Ratain, Howard L. McLeod J. Clin. Oncol. vol 32 (15_suppl) 9612 2014

Abstract PPP CALGB-60404, CALGB-90401 <http://meetinglibrary.asco.org/content/126788-144>

604 Tumor Status at 12 Weeks Predicts Survival in Advanced Colorectal Cancer: Findings from NCCTG N9741

James M. Heun, Axel Grothey, Megan E. Branda, Richard M. Goldberg, Daniel J. Sargent Oncologist vol 16 (6) 859-867 2011

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21632455>

605 Lenalidomide-mediated enhanced translation of C/EBP-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia

Christopher J. Hickey, Sebastian Schwind, Hanna S. Radomska, Adrienne M. Dorrance, Ramasamy Santhanam, Anjali Mishra, Yue-Zhong Wu, Houda Alachkar, Kati Maharry, Deedra Nicolet, Krzysztof Mrózek, Alison Walker, Anna M. Eiring, Susan P. Whitman, Heiko Becker, Danilo Perrotti, Lai-Chu Wu, Xi Zhao, Todd A. Fehniger, Ravi Vij, John C. Byrd, William Blum, L. James Lee, Michael A. Caligiuri, Clara D. Bloomfield, Ramiro Garzon, Guido Marcucci Blood vol 121 (1) 159-169 2013

Manuscript Leuk Corr Sci CALGB-9621, CALGB-19808

<http://www.ncbi.nlm.nih.gov/pubmed/23100311>

606 Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation

S. L. Hillman, S. J. Mandrekar, B. Bot, R. P. Dematteo, E. A. Perez, K. V. Ballman, H. Nelson, J. C. Buckner, D. J. Sargent J. Clin. Oncol. vol 28 (18) 3002-3007 2010

Manuscript Respiratory ACOSOG-Z9001, NCCTG-97-24-51

<http://www.ncbi.nlm.nih.gov/pubmed/20479400>

607 Evaluation of the Optimal Number of Lesions Needed for Tumor Evaluation Using the Response Evaluation Criteria in Solid Tumors: A North Central Cancer Treatment Group Investigation

Shauna L. Hillman, An Ming-Wen, Michael J. O'Connell, Richard M. Goldberg, Paul Schaefer, Jan C. Buckner, Daniel J. Sargent J Clin Oncol vol 27 (19) 3205-3210 2009

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19414682>

608 Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases

Andrew L. Himmelstein, Jared C. Foster, James L. Khatcheressian, John D. Roberts, Drew K. Seisler,

Paul J. Novotny, Rui Qin, Ronald S. Go, Stephen S. Grubbs, Tracey O'Connor, Mario R. Velasco, Douglas Weckstein, Ann O'Mara, Charles L. Loprinzi, Charles L. Shapiro JAMA vol 317 (1) 48-58 2017

Manuscript Symptom Inter CALGB-70604, CALGB-150804
<http://www.ncbi.nlm.nih.gov/pubmed/28030702>

609 CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer

Andrew L. Himmelstein, Rui Qin, Paul J. Novotny, Drew K. Seisler, James L. Khatcheressian, John D. Roberts, Stephen S. Grubbs, Tracey O'Connor, Douglas Weckstein, Charles L. Loprinzi, Charles L. Shapiro J. Clin. Oncol. vol 33 (suppl) abstr 9501 2015
Abstract Symptom Inter http://meeting.ascopubs.org/cgi/content/short/33/15_suppl/6011?rss=1

610 Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC

Stephanie L. Hines, Betty Mincey, Todor Dentchev, Jeff A. Sloan, Edith A. Perez, David B. Johnson, Paul L. Schaefer, Steve Alberts, Heshan Liu, Stephen Kahanic, Mirosław A. Mazurczak, Daniel A. Nikcevich, Charles L. Loprinzi Breast Cancer Res. Treat. vol 117 (3) 603-609 2009
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/19214743>

611 Alliance A091104: A Phase II Trial of MK-2206 in patients with progressive, recurrent/metastatic adenoid cystic carcinoma

Alan L Ho, Nathan R. Foster, Jeffrey P. Meyers, Shyamprasad Deraje Vasudeva, Nora Katabi, Cristina R. Antonescu, L. Elise Horvath, Charles Erlichman, Gary K. Schwartz J. Clin. Oncol. vol 33 (suppl) abstr 6039 2015
Abstract Experimental http://hwmain.meeeting.ascopubs.org/cgi/content/abstract/33/15_suppl/6039

612 Alliance A091404: a phase II study of enzalutamide (nsc# 766085) for patients with androgen receptor positive salivary cancers

Alan Loh Ho, Nathan R. Foster, Alex J. Zoroufy, Francis Worden, Katharine Price, Douglas Adkins, Daniel W. Bowles, Hyunseok Kang, Barbara Burtness, Eric Sherman, Roscoe Morton, Nora Katabi, Pamela Munster, Gary K. Schwartz J. Clin. Oncol. vol 37 (15_suppl) 6020-6020 2019
Abstract Experimental https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.6020

613 Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without +/- lapatinib (L) for HER2-positive breast cancer

Katherine A. Hoadley, William T. Barry, Brandelyn N. Pitcher, Joel S. Parker, Matthew D. Wilkerson, William Irvin, N. Lynn Henry, Sara M. Tolaney, Chau Dang, Ian E. Krop, Donald A. Berry, Elaine R. Mardis, Charles M. Perou, Eric P. Winer, Clifford A. Hudis, Lisa A. Carey Cancer Res vol 75 (9 Supplement) abstr S3-06 2015
Abstract Breast http://cancerres.aacrjournals.org/content/75/9_Supplement/S3-06

614 Multivariate Analysis of Subtype and Gene Expression Signatures Predictive of Pathologic Complete Response (pCR) in Triple-Negative Breast Cancer (TNBC): CALGB 40603 (Alliance)

Katherine A. Hoadley, Terry Hyslop, Cheng Fan, Donald A. Berry, Olwen Hahn, Sara Tolaney, William M. Sikov, Charles M. Perou, Lisa Carey Cancer Res vol 77 (4 suppl) Abstract nr PD1-03 2017
Abstract Correl Sci NOS http://cancerres.aacrjournals.org/content/77/4_Supplement/PD1-03

615 N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy

T. J. Hobday, P. J. Stella, T. R. Fitch, A. Jaslowski, B. Laplant, M. M. Ames, M. P. Goetz, E. A. Perez J. Clin. Oncol. vol 26 (May 20 suppl; abstr 1081) General Poster Session, Breast Cancer - Metastatic

Abstract 1081 2008

Abstract Breast

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

616 A North Central Cancer Treatment Group (NCCTG) Phase II Trial of VEGF Trap in Patients With Metastatic Breast Cancer (MBC) Previously Treated with an Anthracycline and/or a Taxane.

T. Hobday, K. Rowland Jr, A. Dueck, D. Northfelt, W. Lingle, R. Morton, T. Fitch, D. Nikcevich, E. Perez Breast Cancer Symposium abstr 164 2008

Abstract Breast

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=58&abstractID

617 Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma

Sarah A. Holstein, Sin-Ho Jung, Paul G. Richardson, Craig C. Hofmeister, David D. Hurd, Hani Hassoun, Sergio Giralt, Edward A. Stadtmauer, Daniel J. Weisdorf, Ravi Vij, Jan S. Moreb, Natalie S. Callander, Koen van Besien, Teresa G. Gentile, Luis Isola, Richard T Maziarz, Asad Bashey, Heather Landau, Thomas Martin, Muzaffar H Qazilbash, Cesar Rodriguez, Brian McClune, Robert L. Schlossman, Scott E. Smith, Vera Hars, Kouros Owzar, Chen Jiang, Molly Boyd, Chelsea Schultz, Marcia Wilson, Parameswaran Hari, Marcelo C. Pasquini, Mary M. Horowitz, Thomas C. Shea, Steven M. Devine, Charles Linker, Kenneth C. Anderson, Philip L. McCarthy Lancet Haematol vol 4 (9) e431-e442 2017

Manuscript Myeloma <http://www.ncbi.nlm.nih.gov/pubmed/28826616>

618 Updated analysis of CALGB 100104: lenalidomide (Len) vs. placebo maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM).

Sarah A. Holstein, Kouros Owzar, Paul G. Richardson, Chen Jiang, Craig C. Hofmeister, Hani Hassoun, David D. Hurd, Edward A. Stadtmauer, Sergio Giralt, Steven M. Devine, Vera Hars, John Postiglione, Daniel J. Weisdorf, Ravi Vij, Jan S. Moreb, Natalie S. Callander, Marcelo C. Pasquini, Thomas C. Shea, Kenneth Anderson, Philip L. McCarthy J. Clin. Oncol. vol 33 (suppl) abstr 8523 2015

Abstract Myeloma http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8523

619 Gemcitabine (G) and irinotecan (CPT-11) as first-line therapy for carcinoma (ca) of unknown primary (CUP): An NCCTG phase II trial

S. G. Holtan, N. R. Foster, C. E. Erlichman, M. Aubry, M. M. Ames, S. Safgren, P. D. Steen, R. F. Morton, D. Graham, M. P. Goetz J. Clin. Oncol. vol 26 (suppl) abstr 13525 2008

Abstract Experimental

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

620 Gemcitabine and Irinotecan as First-Line Therapy for Carcinoma of Unknown Primary: Results of a Multicenter Phase II Trial

Shernan G. Holtan, Preston D. Steen, Nathan R. Foster, Charles Erlichman, Fabiola Medeiros, Matthew M. Ames, Stephanie L. Safgren, David L. Graham, Robert J. Behrens, Matthew P. Goetz PLoS ONE vol 7 (7) e39285 2012

Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/22815703>

621 Public Health and Cooperative Group Partnership: A Colorectal Cancer Educational Intervention for Breast Cancer Survivors

Homan, Sherri G Semin Oncol Nurs vol 30 (1) 61-73 2014

Manuscript Onc Nursing <http://www.ncbi.nlm.nih.gov/pubmed/24559782>

622 Lymphedema, Musculoskeletal Events and Arm Function in Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer (Alliance A171302)

Judith O. Hopkins, Jake Allred, Arti Hurria, Aminah Jatoi, Jacqueline M. Lafky, Harvey Cohen, Clifford Hudis, Eric Winer, Jeanne Mandelblatt, Ann Partridge, Lisa Carey, Hyman B. Muss Breast Cancer Res. Treat. vol 166 (3) 793-808 2017
Manuscript Older Adult CALGB-49907, A171302 <http://www.ncbi.nlm.nih.gov/pubmed/28825227>

623 Irinotecan-induced neutropenia and UGT1A1*28: Does dose matter?

J. M. Hoskins, R. M. Goldberg, H. L. McLeod J. Clin. Oncol. vol 25 (18s) abstr 4023 2007

Abstract PPP

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

624 UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.

Janelle M Hoskins, Richard M Goldberg, Pingping Qu, Joseph G Ibrahim, Howard L McLeod J. Natl. Cancer Inst. vol 99 (17) 1290-5 2007

Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/17728214>

625 Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study

E. D. Hsi, J. Said, J. L. Johnson, S. Jung, R. Lai, D. Jones, A. Chadburn, B. D. Cheson, W. H. Wilson Blood vol 112 (11) abstr 476 2008

Abstract Correl Sci NOS <http://www.bloodjournal.org/content/112/11/476>

626 Ki67 and PIM1 expression in aggressively treated mantle cell lymphoma (MCL): A Cancer and Leukemia Group B (CALGB) 59909 correlative science study

E. Hsi, S. Jung, R. Lai, J. Johnson, J. Cook, D. Jones, S. Devos, B. D. Cheson, L. E. Damon, J. Said J. Clin. Oncol. vol 26 (May 20 suppl) abstr 8560 2008

Abstract Lymphoma

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

627 Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study

Eric D. Hsi, Sin-Ho Jung, Raymond Lai, Jeffrey L. Johnson, James R. Cook, Dan Jones, Sven Devos, Bruce D. Cheson, Lloyd E. Damon, Jonathan Said Leuk. Lymphoma vol 49 (11) 2081-2090 2008

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/19021050>

628 Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147

J. Huang, D. J. Sargent, M. R. Mahoney, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S.

Kahlenberg, J. T. Quesenberry, T. C. Smyrk, A. Grothey, F. Sinicrope, S. G. Nair, S. R. Alberts J. Clin. Oncol. vol 29 (Suppl 1) abstr 3522 2011

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

629 Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147

J. Huang, D. J. Sargent, M. R. Mahoney, S. N. Thibodeau, T. C. Smyrk, F. Sinicrope, G. D. Alberts, S. R. Nelson J Clin Oncol 29, No 4_suppl (February vol 29 (4s) abstr 363 2011

Abstract GI N0147, NCCTG-N0147

http://meeting.ascopubs.org/cgi/content/abstract/29/4_suppl/363

630 Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147

Jocelin Huang, Suresh G. Nair, Michelle R. Mahoney, Garth D. Nelson, Anthony F. Shields, Emily

Chan, Richard M. Goldberg, Sharlene Gill, Morton S. Kahlenberg, James T. Quesenberry, Stephen N. Thibodeau, Thomas C. Smyrk, Axel Grothey, Frank A. Sinicrope, Thomas A. Webb, Gist H. Farr, Barbara A. Pockaj, Jeffrey L. Berenberg, Margaret Mooney, Daniel J. Sargent, Steven R. Alberts Clin Colorectal Cancer vol 13 (2) 100-109 2014
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24512953>

631 Phase I evaluation of sorafenib (SOR) & bevacizumab (BEV) in first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group Trial N0745

J. Hubbard, S. Alberts, W. Loui, M. Mahoney, L. Roberts, T. Smyrk, Z. Gatalica, S. Kumar, S. Dakhil, P. Flynn, M. Bury J. Clin. Oncol. vol 29 (suppl) abstr 4116 2011

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

632 Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group trial N0745 (Alliance)

Joleen M. Hubbard, Michelle R. Mahoney, William S. Loui, Lewis R. Roberts, Thomas C. Smyrk, Zoran Gatalica, Mitesh Borad, Shaji Kumar, Steven R. Alberts Target Oncol vol 12 (2) 201-209 2017

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/27943153>

633 Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set

Joleen Hubbard, David M. Thomas, Greg Yothers, Erin Green, Charles Blanke, Michael J. O'Connell, Roberto Labianca, Qian Shi, Archie Bleyer, Aimery de Gramont, Daniel Sargent J. Clin. Oncol vol 30 (19) 2334-2339 2012

Manuscript GI ACCENT, CALGB-89803 <http://www.ncbi.nlm.nih.gov/pubmed/22614981>

634 Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer

K. S. Hughes, L. Schnaper, C. T. Cirrincione, D. A. Berry, B. McCormick, C. A. Hudis, E. P. Winer J. Clin. Oncol. vol 28 (15s) abstr 507 2010

Abstract Breast

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

635 Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343

Kevin S. Hughes, Lauren A. Schnaper, Jennifer R. Bellon, Constance T. Cirrincione, Donald A. Berry, Beryl McCormick, Hyman B. Muss, Barbara L. Smith, Clifford A. Hudis, Eric P. Winer, William C. Wood J. Clin. Oncol. vol 31 (19) 2382-2387 2013

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/23690420>

636 Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.

Kevin S Hughes, Lauren A Schnaper, Donald Berry, Constance Cirrincione, Beryl McCormick, Brenda Shank, Judith Wheeler, Lorraine A Champion, Thomas J Smith, Barbara L Smith, Charles Shapiro, Hyman B Muss, Eric Winer, Clifford Hudis, William Wood, David Sugarbaker, I Craig Henderson, Larry Norton N. Engl. J. Med. vol 351 (10) 971-7 2004

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/15342805>

637 Safety and tolerability of lapatinib ditosylate given concurrently with docetaxel, carboplatin, and trastuzumab (TCHL) as part of adjuvant therapy for patients with HER2+ breast cancer: Pilot data from the North Central Cancer Treatment Group Trial N083E.

C. Bueno Hume, A. Moreno-Aspitia, D. Hillman, B. Chen, A. Perez, R. Jenkins, A. C. Dueck, D. B. Johnson, R. Carolla, E. Perez J. Clin. Oncol. vol 28 (15s) abstr 565 2010
Abstract Breast
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

638 A phase II study evaluating the role of sentinel lymph node surgery and axillary lymph node dissection following preoperative chemotherapy in women with node-positive breast cancer (T1-4, N1-2, M0) at initial diagnosis: ACOSOG Z1071

K. Hunt, H. T. Le-Petross, V. Suman, B. G. Haffty, A. M. Leitch, D. Ollila, D. R. Byrd, T. A. Bucholz, W. F. Symmans, J. C. Boughey J. Clin. Oncol. vol 28 (15s) abstr TPS118 2010
Abstract Breast
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

639 Factors Associated with Local-Regional Recurrence Following a Negative Sentinel Node Dissection: Results of the ACOSOG Z0010 Trial

Kelly K. Hunt, Karla V. Ballman, Linda M. McCall, Judy C. Boughey, Elizabeth A. Mittendorf, Charles E. Cox, Pat W. Whitworth, Peter D. Beitsch, A. Marilyn Leitch, Thomas A. Buchholz, Monica A. Morrow, Armando E. Giuliano Ann. Surg. vol 256 (3) 428-436 2012
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/22868365>

640 Local-Regional Recurrence (LRR) Data from the American College of Surgeons Oncology Group (ACOSOG) Z1041 (Alliance): A Randomized Neoadjuvant Trial of Sequential Versus Concurrent Anthracycline with Trastuzumab and Paclitaxel Plus Trastuzumab in HER2-Positive (HER2+) Breast Cancer (BC)

Kelly K. Hunt, Vera J. Suman, Funda Meric-Bernstam, Ann M. Leitch, Matthew J. Ellis, Judy C. Boughey, Gary W. Unzeitig, Melanie E. Royce, Aman U. Buzdar 2019
Abstract Breast <http://expo.jspargo.com/exhibitor/web/SSO2019ASOAbstractSupplement.pdf>

641 Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401

Arti Hurria, Constance T. Cirrincione, Hyman B. Muss, Alice B. Kornblith, William Barry, Andrew S. Artz, Linda Schmieder, Rafat Ansari, William P. Tew, Douglas Weckstein, Jeffrey Kirshner, Kayo Togawa, Kurt Hansen, Vani Katheria, Richard Stone, Ilene Galinsky, John Postiglione, Harvey Jay Cohen J Clin Oncol vol 29 (10) 1290-1296 2011
Manuscript GU CALGB-99809, CALGB-360401 <http://www.ncbi.nlm.nih.gov/pubmed/21357782>

642 Functional Decline and Resilience among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer

Arti Hurria, Enrique Soto-Perez-de-Celis, Jacob B. Allred, Harvey Jay Cohen, Anait Arsenyan, Karla Ballman, Jennifer Le-Rademacher, Aminah Jatoi, Julie Filo, Jeanne Mandelblatt, Jacqueline M. Lafky, Gretchen Kimmick, Heidi D. Klepin, Rachel A. Freedman, Harold Burstein, Julie Gralow, Antonio C. Wolff, Gustav Magrinat, Myra Barginear, Hyman Muss J Am Geriatr Soc vol 67 (5) 920-7 2019
Manuscript Older Adult CALGB-361007, CALGB-49907
<http://www.ncbi.nlm.nih.gov/pubmed/30146695>

643 Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance)

H. Hurwitz, S. Cushman, C. Jiang, I. Shterev, M. R. Mahoney, D. Niedzwiecki, R. J. Mayer, A. P. Venook, K. Owzar, A. B. Nixon J. Clin. Oncol. vol 31 (15 suppl) abstr 11011 2013
Abstract GI
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/11011?sid=8da84e74-5d65-4c40-a3e7-7ac

644 Combination external beam radiation and brachytherapy boost with androgen deprivation for

treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809

M. D. Hurwitz, S. Halabi, L. Archer, L. S. McGinnis, M. R. Kuettel, S. J. Dibiase, E. J. Small *Cancer* vol 117 (24) 5579-5588 2011

Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/22535500>

645 Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.

Mark D Hurwitz, Susan Halabi, San-San Ou, Lamar S McGinnis, Michael R Keuttel, Steven J Dibiase, Eric J Small *Int. J. Radiat. Oncol. Biol. Phys.* vol 72 (3) 814-9 2008

Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/18407435>

646 A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials.

Mashele M Huschka, Sumithra J Mandrekar, Paul L Schaefer, James R Jett, Jeff A Sloan *Cancer* vol 109 (4) 787-95 2007

Manuscript Respiratory N0021, N0022, NCCTG-95-20-53, NCCTG-95-24-51, NCCTG-95-24-52, NCCTG-97-24-51, NCCTG-98-24-52 <http://www.ncbi.nlm.nih.gov/pubmed/17211864>

647 The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS)

E Shelley Hwang, Terry Hyslop, Thomas Lynch, Elizabeth Frank, Donna Pinto, Desiree Basila, Deborah Collyar, Antonia Bennett, Celia Kaplan, Shoshana Rosenberg, Alastair Thompson, Anna Weiss, Ann Partridge *BMJ Open* vol 9 (3) e026797 2019

Manuscript ACS CCDRC <http://www.ncbi.nlm.nih.gov/pubmed/30862637>

648 Primary endocrine therapy for ER-positive ductal carcinoma in situ (DCIS) (Alliance) CALGB 40903

E. Shelley Hwang, Stephanie Duong, Isabelle Bedrosian, Jacob Allred, Dorota Wisner, Terry Hyslop, Abigail Caudle, Tina Hieken, Joseph Guenther, Laura Esserman, Nola Hylton *Cancer Res* vol 78 (4 Supplement) GS5-05 2017

Abstract Breast http://cancerres.aacrjournals.org/content/78/4_Supplement/GS5-05

649 Comparison of MRI endpoints for assessing breast cancer response to neoadjuvant treatment: preliminary findings of the American College of Radiology Imaging Network (ACRIN) trial 6657

N. M. Hylton, J. Blume, W. Bernreuter, E. Pisano, M. Rosen, E. Morris, P. Weatherall, C. Lehman, S. Polin, G. Newstead, H. Marques, M. Schnall, L. J. Esserman *Cancer Res.* vol 69 (2 Suppl) Abstr 6043 2009

Abstract Breast

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6043?sid=004eb34

650 MRI Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy: Preliminary Findings of the American College of Radiology Imaging Network (ACRIN) Trial 6657

N. M. Hylton, J. Blume, W. Bernreuter, E. Pisano, M. Rosen, E. Morris, P. Weatherall, C. Lehman, S. Polin, G. Newstead, H. Marques, M. Schnall, L. J. Esserman *Radiological Society of North America 94th Scientific Assembly and Annual Meeting* abstr 6006524 2008

Abstract Breast http://rsna2008.rsna.org/event_display.cfm?em_id=6006524

651 MRI tumor volume for predicting response to neoadjuvant chemotherapy in locally advanced breast cancer: Findings from ACRIN trial 6657/CALGB 150007

N. M. Hylton, J. Blume, C. Gastonis, R. Gomez, W. Bernreuter, E. Pisano, M. Rosen, H. Marques, L. J. Esserman, M. Schnall *J. Clin. Oncol.* vol 27 (15s) abstr 529 2009

Abstract Breast ACRIN-6657, CALGB-150007

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

- 652 Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL**
Nola M. Hylton, Jeffrey D. Blume, Wanda K. Bernreuter, Etta D. Pisano, Mark A. Rosen, Elizabeth A. Morris, Paul T. Weatherall, Constance D. Lehman, Gillian M. Newstead, Sandra Polin, Helga S. Marques, Laura J. Esserman, Mitchell D. Schnall *Radiology* vol 263 (3) 663-672 2012
Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/22623692>
- 653 Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival—Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL**
Nola M. Hylton, Constantine A. Gatsonis, Mark A. Rosen, Constance D. Lehman, David C. Newitt, Savannah C. Partridge, Wanda K. Bernreuter, Etta D. Pisano, Elizabeth A. Morris, Paul T. Weatherall, Sandra M. Polin, Gillian M. Newstead, Helga S. Marques, Laura J. Esserman, Mitchell D. Schnall *Radiology* vol 279 (1) 44-55 2016
Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/26624971>
- 654 Reproducibility of Random Periareolar Fine Needle Aspiration in a Multi-Institutional Cancer and Leukemia Group B (CALGB) Cross-Sectional Study**
Catherine Ibarra-Drendall, Lee G. Wilke, Carola Zalles, Victoria Scott, Laura E. Archer, Siya Lem, Lisa D. Yee, Joanne Lester, Swati Kulkarni, Christine Murekeyisoni, Marie Wood, Karen Wilson, Judy Garber, Carleen Gentry, April Stouder, Gloria Broadwater, Joseph C. Baker, Shauna N. Vasilatos, Elizabeth Owens, Sarah Rabiner, Abbey C. Barron, Victoria L. Seewaldt *Cancer Epidemiol. Biomarkers Prev.* vol 18 (5) 1379-1385 2009
Manuscript *Prevention* <http://www.ncbi.nlm.nih.gov/pubmed/19383884>
- 655 Impact of Tumor-Infiltrating B-Cell Clonal Diversity on Response to Neoadjuvant Therapy in Triple Negative and HER2+ Breast Cancer Treated on CALGB (Alliance) 40601 and 40603**
Michael D. Iglesia, Benjamin G. Vincent, Jonathan S. Serody, Lisa A. Carey, William T. Barry, William M. Sikov, Clifford Hudis, Eric M. Winer, Charles M. Perou *Cancer Res.* vol 75 (9_supplement) abstr PD1-2 2014
Abstract *Breast CALGB-40601, CALGB-40603*
http://cancerres.aacrjournals.org/content/75/9_Supplement/PD1-2.short
- 656 Can a Gastric Cancer Risk Survey Identify High-Risk Patients for Endoscopic Screening? A Pilot Study**
Haejin In, Marisa Langdon-Embry, Lauren Gordon, Clyde B. Schechter, Judith Wylie-Rosett, Philip E. Castle, M. Margaret Kemeny, Bruce D. Rapkin *J. Surg. Res.* vol 227 246-56 2018
Manuscript *Health Outcome* <http://www.ncbi.nlm.nih.gov/pubmed/29622399>
- 657 A Pilot Case Control Study: Could a Gastric Cancer Risk Screening Tool Help Identify High Risk Patients for Endoscopic Screening in the US?**
Haejin In, Marisa Langdon-Embry, Lauren Gordon, Clyde Schechter, Judith Wylie-Rosett, Philip Castle, Margaret Kemeny, Bruce Rapkin *J Clin Oncol* vol 36 (supple 4S) abstr 64 2018
Abstract *Disparities* http://abstracts.asco.org/210/AbstView_210_201627.html
- 658 A Pilot Case Control Study: Could a Gastric Cancer Risk Screening Tool Help Identify High Risk Patients for Endoscopic Screening in the US?**
Haejin In, Marisa Langdon-Embry, Lauren Gordon, Clyde Schechter, Judith Wylie-Rosett, Philip Castle, Margaret Kemeny, Bruce Rapkin *Ann. Surg. Oncol.* vol 25 (Suppl 1) S200 2018
Abstract *Disparities* <http://expo.jspargo.com/exhibitor/web/Abstracts18.pdf>
- 659 Heritable interleukin-17F (IL17F) gene variation is associated with overall survival (OS) in pancreatic cancer patients: Results from a genome-wide association study (GWAS) in CALGB 80303**

F. Innocenti, K. Owzar, N. J. Cox, P. Evans, M. Kubo, D. R. Hollis, T. Mushiroda, H. L. Kindler, Y. Nakamura, M. J. Ratain *J. Clin. Oncol.* vol 27 (15s) abstr 4531 2009

Abstract PPP

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

- 660 A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients**
F Innocenti, C Jiang, A B Sibley, S Denning, A S Etheridge, D Watson, D Niedzwiecki, A J Hatch, H Hurwitz, A Nixon, Y Furukawa, M Kubo, D J Crona, H Kindler, H L McLeod, M J Ratain, K Owzar
Ann Oncol vol 29 (suppl_8) abstr 1868P 2018
Abstract PPP https://academic.oup.com/annonc/article/29/suppl_8/mdy303.038/5140563
- 661 An Initial Genetic Analysis of Gemcitabine-Induced High-Grade Neutropenia in Pancreatic Cancer Patients in CALGB 80303 (Alliance)**
Federico Innocenti, Chen Jiang, Alexander B. Sibley, Stefanie Denning, Amy S. Etheridge, Dorothy Watson, Donna Niedzwiecki, Ace J. Hatch, Herbert I. Hurwitz, Andrew B. Nixon, Yoichi Furukawa, Michiaki Kubo, Daniel J. Crona, Hedy L. Kindler, Howard L. McLeod, Mark J. Ratain, Kouros Owzar
Pharmacogenet. Genomics vol 29 (6) 123-31 2019
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/30889042>
- 662 Genetic variation determines VEGF-A plasma levels in cancer patients**
Federico Innocenti, Chen Jiang, Alexander B. Sibley, Amy S. Etheridge, Ace J. Hatch, Stefanie Denning, Donna Niedzwiecki, Ivo D. Shterev, Jiaying Lin, Yoichi Furukawa, Michiaki Kubo, Hedy L. Kindler, J. Todd Auman, Alan P. Venook, Herbert I. Hurwitz, Howard L. McLeod, Mark J. Ratain, Raluca Gordan, Andrew B. Nixon, Kouros Owzar *Sci Rep* vol 8 16332 2018
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/30397360>
- 663 Genetic prediction of VEGF-A plasma levels in cancer patients CALGB 80303 (Alliance)**
Federico Innocenti, Chen Jiang, Alexander Sibley, Amy S Etheridge, Yoichi Furukawa, Michiaki Kubo, Hedy L Kindler, Alan P Venook, Herbert Hurwitz, Andrew Nixon, Kouros Owzar *Cancer Res* vol 76 (14 suppl) abstr 3388 2016
Abstract PPP http://cancerres.aacrjournals.org/content/76/14_Supplement/3388
- 664 Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome**
Federico Innocenti, Fang-Shu Ou, Xueping Qu, Tyler J. Zemla, Donna Niedzwiecki, Rachel Tam, Shilpi Mahajan, Richard M. Goldberg, Monica M. Bertagnolli, Charles D. Blanke, Hanna Sanoff, James Atkins, Blasé Polite, Alan P. Venook, Heinz-Josef Lenz, Omar Kabbarah *J. Clin. Oncol* vol 37 (14) 1217-27 2019
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/30865548>
- 665 Somatic DNA mutations, mutational load (ML), and MSI status: association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance)**
Federico Innocenti, Fang-Shu Ou, Tyler Zemla, Donna Niedzwiecki, Xueping Qu, Rachel Tam, Shilpi Mahajan, Richard Goldberg, Robert Mayer, Monica Bertagnolli, Howard S. Hochster, Charles David Blanke, Alan P. Venook, Heinz-Josef Lenz, Hanna Sanoff, Omar Kabbarah *J. Clin. Oncol.* vol 35 (15 suppl) abstr 3504 2017
Abstract Correl Sci NOS http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3504
- 666 A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303**
Federico Innocenti, Kouros Owzar, Nancy L. Cox, Patrick Evans, Michiaki Kubo, Hitoshi Zembutsu, Chen Jiang, Donna Hollis, Taisei Mushiroda, Liang Li, Paula Friedman, Liewei Wang, Dylan Glubb,

Herbert Hurwitz, Kathleen M. Giacomini, Howard L. McLeod, Richard M. Goldberg, Richard L. Schilsky, Hedy L. Kindler, Yusuke Nakamura, Mark J. Ratain Clin. Cancer Res. vol 18 (2) 577-584 2012

Manuscript PPP CALGB-80303, C151006 <http://www.ncbi.nlm.nih.gov/pubmed/22142827>

667 The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients:

Genomic analysis and experimental validation

Federico Innocenti, Kouros Owzar, Chen Jiang, Amy S. Etheridge, Raluca Gordân, Alexander B. Sibley, Flora Mulkey, Donna Niedzwiecki, Dylan Glubb, Nicole Neel, Mark S. Talamonti, David J. Bentrem, Eric Seiser, Jen Jen Yeh, Katherine Van Loon, Howard McLeod, Mark J. Ratain, Hedy L. Kindler, Alan P. Venook, Yusuke Nakamura, Michiaki Kubo, Gloria M. Petersen, William R. Bamlet, Robert R. McWilliams PLoS ONE vol 13 (8) e0202272 2018

Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/30107003>

668 The vitamin D receptor gene is a determinant of survival in advanced pancreatic cancer patients

Federico Innocenti, Kouros Owzar, Chen Jiang, Eric Seiser, Amy Etheridge, Raluca Gordan, Dylan Glubb, Katherine Van Loon, Hedy L Kindler, Alan P Venook, Yusuke Nakamura, Michiaki Kubo, Gloria M Petersen, William R Bamlet, Robert R McWilliams 2015

Abstract GI [http](http://www.ncbi.nlm.nih.gov/pubmed/25511111)

669 A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405

Federico Innocenti, Kouros Owzar, Chen Jiang, Alexander B. Sibley, Donna Niedzwiecki, Heinz-Josef Lenz, Monica M. Bertagnolli, Paula N. Friedman, Yoichi Furukawa, Michiaki Kubo, Mark J. Ratain, Charles David Blanke, Alan P. Venook, Howard McLeod J. Clin. Oncol. vol 33 (suppl) abstr 3599 2015

Abstract PPP <http://meetinglibrary.asco.org/content/151613-156>

670 A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405

Federico Innocenti, Kouros Owzar, Chen Jiang, Alexander B. Sibley, Donna Niedzwiecki, Heinz-Josef Lenz, Monica M. Bertagnolli, Yoichi Furukawa, Michiaki Kubo, Mark J. Ratain, Alan P. Venook, Howard McLeod Eur J Cancer vol 41 (suppl 3) S329–S330 2015

Abstract PPP [http://www.ejccancer.com/article/S0959-8049\(16\)30932-7/abstract](http://www.ejccancer.com/article/S0959-8049(16)30932-7/abstract)

671 A Genome-Wide Association Study (GWAS) Of Survival In Metastatic Breast Cancer (MBC) Patients Treated With Letrozole (L) With Or Without Bevacizumab (B) In CALGB 40503 (Alliance)

Federico Innocenti, Kouros Owzar, Chen Jiang, Alexander B Sibley, Flora Mulkey, Lisa Carey, Debu Tripathy, Bryan Schneider, William T Barry, Eric P Winer, Clifford A Hudis, Howard L McLeod, Maura N Dickler J. Clin. Oncol. vol 34 (suppl) abstr 538 2016

Abstract PPP <http://meetinglibrary.asco.org/content/166252-176>

672 Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma.

D J Inwards, P A Fishkin, B R LaPlant, M T Drake, P J Kurtin, D A Nikcevich, D B Wender, B S Lair, T E Witzig Ann. Oncol. vol 25 (10) 2020-4 2014

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/25057177>

673 Phase I Trial of Rituximab, Cladribine and Temsirolimus (RCT) for Initial Therapy of Mantle Cell Lymphoma

D. J. Inwards, P. Fishkin, B. R. Laplant, M. T. Drake, P. Kurtin, D. Nikcevich, D. Wender, B. Lair, T. E. Witzig ASH Annual Meeting Abstracts vol 120 (21) -3661 2012

Abstract Lymphoma <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/3661>

- 674 Long-term Results of the Treatment of Patients With Mantle Cell Lymphoma With Cladribine (2-CDA) Alone (95-80-53) or 2-CDA and Rituximab (N0189) in the North Central Cancer Treatment Group**
David J. Inwards, Paul A. S. Fishkin, David W. Hillman, David W. Brown, Stephen M. Ansell, Paul J. Kurtin, Rafael Fonseca, Roscoe F. Morton, Michael H. Veeder, Thomas E. Witzig *Cancer* vol 113 (1) 108-116 2008
Manuscript Lymphoma N0189, NCCTG-95-80-53 <http://www.ncbi.nlm.nih.gov/pubmed/18470909>
- 675 The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803**
N. A. Jackson, C. S. Fuchs, D. Niedzwiecki, D. R. Hollis, L. B. Saltz, R. J. Mayer, J. A. Meyerhardt *J. Clin. Oncol.* vol 26 (May 20 suppl) abstr 4039 2008
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID
- 676 Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis.**
K A Jaeckle, P A Decker, K V Ballman, P J Flynn, C Giannini, B W Scheithauer, R B Jenkins, J C Buckner *J. Neurooncol.* vol 104 (1) 253-9 2011
Manuscript Experimental Comprehensive, NCCTG-85-72-51, NCCTG-86-03-51, NCCTG-88-72-02, NCCTG-88-72-52, NCCTG-90-72-01, NCCTG-91-72-01, NCCTG-92-72-03, NCCTG-93-72-02, NCCTG-93-72-52, NCCTG-88-72-51, NCCTG-89-72-51, NCCTG-89-72-52, NCCTG-91-72-51, NCCTG-92-72-51, NCCTG-93-72-51, NCCTG-95-72-53, NCCTG-98-72-54, N997B, NCCTG-84-72-51, NCCTG-86-72-02, NCCTG-86-72-53, N0074, N0272, NCCTG-98-72-52, NCCTG-86-72-51, NCCTG-98-72-51, NCCTG-96-72-51
<http://www.ncbi.nlm.nih.gov/pubmed/21153680>
- 677 NCCTG N0272: phase II trial of imatinib mesylate; (gleevec; sti571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma: a north central cancer treatment group study.**
K. A. Jaeckle, S. K. Anderson, M. Kosel, J. Sarkaria, P. Brown, P. J. Flynn, J. C. Buckner, E. Galanis *Neuro-oncology* vol 13 (3) 89 2011
Abstract Neuro-Onc http://neuro-oncology.oxfordjournals.org/content/13/suppl_3/iii85.abstract
- 678 NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study**
K. A. Jaeckle, D. Schiff, S. K. Anderson, E. Galanis, P. J. Stella, P. J. Flynn, J. N. Sarkaria, B. W. Scheithauer, B. J. Erickson, J. C. Buckner *J. Clin. Oncol.* vol 29 (suppl) abstr 2033 2011
Abstract Neuro-Onc <http://meetinglibrary.asco.org/content/80655-102>
- 679 Correlation of response with survival endpoints in patients with newly diagnosed and recurrent glioblastoma (GBM) treated on prospective North Central Cancer Treatment Group (NCCTG) clinical trials**
K. A. Jaeckle, W. Wu, M. Kosel, P. J. Flynn, J. C. Buckner *J. Clin. Oncol.* vol 26 (15s, pt I) 95s abstr 2024 2008
Abstract Neuro-Onc
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID
- 680 Phase I/II trial of sorafenib and CCI-779 in patients with recurrent glioblastoma (GBM)**
K. Jaeckle, K. Anderson, J. Sarkaria, P. Decker, J. Buckner, E. Galanis, J. Dancey, C. Giannini, P. Brown, M. Wiesenfeld, D. Schiff 2008
Abstract Neuro-Onc

- 681 Results of a phase II trial of vorinostat in patients with recurrent glioblastoma: Evidence of post-treatment histone acetylation in tumor tissue and pharmacokinetic analysis: North Central Cancer Treatment Group (NCCTG) study N047B**
K. Jaeckle, M. Maurer, J. Reid, M. Ames, C. Giannini, D. Moore, J. Zwiebel, J. Buckner, E. Galanis
2007
Abstract Neuro-Onc
- 682 NCCTG (Alliance) N0572: A phase II trial of sorafenib and temsirolimus in recurrent glioblastoma (GBM) patients who progress following prior RT/temozolomide (TMZ) and VEGF inhibitors (VEGFi)**
K. Jaeckle, D. Schiff, S. Anderson, E. Galanis, P. Stella, P. Flynn, J. Sarkaria, C. Giannini, B. Erickson, J. Buckner J. Clin. Oncol. vol 31 (15 suppl) abstr 2014 2013
Abstract Neuro-Onc
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2014?sid=165fe81a-424a-4104-aacf-b90d5
- 683 Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma**
Kurt A. Jaeckle, Karla Ballman, Alfred Furth, Jan C. Buckner Neurology vol 73 (15) 1207-1213
2009
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/19822870>
- 684 Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).**
Kurt A Jaeckle, S K Anderson, Erin L Twohy, Jesse G Dixon, Caterina Giannini, Robert Jenkins, Merrill J Egorin, Jann N Sarkaria, Paul D Brown, P J Flynn, John Schwerkoske, Jan C Buckner, Evanthea Galanis J. Neurooncol. vol 143 (3) 573-81 2019
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/31119479>
- 685 CODEL (Alliance-N0577; EORTC-26081/22086; NRG-1071; NCIC-CEC-2): Phase III randomized study of RT vs. RT+TMZ vs. TMZ for newly diagnosed 1p/19q-codeleted anaplastic glioma. Analysis of patients treated on the original protocol design**
Kurt Jaeckle, Michael Vogelbaum, Karla Ballman, S. Keith Anderson, Caterina Giannini, Kenneth Aldape, Jane Cerhan, Jeffrey Wefel, Donald Nordstrom, Robert Jenkins, Martin Klein, Jeffrey Raizer, Martin van den Bent, Wolfgang Wick, Patrick Flynn, Frederick Dhermain, Gregory Cairncross, Paul Brown Neurology vol 86 (16 suppl) abstr PL02.005 2016
Abstract Neuro-Onc
http://www.neurology.org/content/86/16_Supplement/PL02.005.short?sid=e537ffeb-b9f7-4182-beb0-68
- 686 CODEL (Alliance N0577; EORTC 26081/22086 ; NRG 1071; NCIC CEC-2): A Phase III Randomized Intergroup Study for patients (pts) with newly diagnosed 1p/19q codeleted anaplastic glioma. Preliminary analysis of patients treated on the original protocol design with RT vs. RT + concomitant/adjuvant TMZ vs. TMZ alone**
Kurt Jaeckle, Michael Voglebaum, Karla Ballman, Caterina Giannini, Ken Aldape, Jane Cerhan, Jeffrey Wefel, Donald Nordstrom, Robert Jenkins, Martin Klein, Jeffrey Raizer, Martin van den Bent, Wolfgang Wick, Patrick Flynn, Frederick Dhermain, Gregory Cairncross, Paul Brown Neuro Oncol vol 17 (suppl 5) v4-v5 abstr ATCT-16 2015
Abstract Neuro-Onc
http://neuro-oncology.oxfordjournals.org/content/17/suppl_5/v4.4.full?sid=5a186658-2b60-4272-94f5-31
- 687 Radiation field design on the ACOSOG Z0011 trial**
R. Jagsi, K. Ballman, M. Chadha, J. Moni, F. Laurie, T. A. Buchholz, B. G. Haffty, A. Giuliano
Cancer Res. vol 73 (24 Suppl) Abstract P5-14-19 2013
Abstract Breast http://cancerres.aacrjournals.org/content/73/24_Supplement/P5-14-19

- 688 Radiation Field Design in the ACOSOG Z0011 (Alliance) Trial**
Reshma Jagsi, Manjeet Chadha, Janaki Moni, Karla Ballman, Fran Laurie, Thomas A. Buchholz, Armando Giuliano, Bruce G. Haffty J. Clin. Oncol vol 32 (32) 3600-3606 2014
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25135994>
- 689 Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).**
Thierry Jahan, Lin Gu, Robert Kratzke, Arkadiusz Dudek, Gregory A Otterson, Xiaofei Wang, Mark Green, Everett E Vokes, Hedy Lee Kindler Lung Cancer vol 76 (3) 393-6 2012
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/22197613>
- 690 Comprehensive molecular profiling of FLT3-mutated acute myeloid leukemia (AML) patients treated within the RATIFY trial (Alliance)**
Nikolaus Jahn, Ekaterina Panina, Lars Bullinger, Anna Dolnik, Julia Herzig, Tamara J. Blätte, Axel Benner, Julia Krzykalla, Insa Gathmann, Richard A. Larson, Francesco Lo-Coco, Sergio Amadori, Thomas W. Prior, Joseph M. Brandwein, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Eva Tiecke, Celine Pallaud, Gerhard Ehninger, Michael Heuser, Arnold Ganser, Richard M. Stone, Christian Thiede, Hartmut Döhner, Clara D. Bloomfield, Konstanze Döhner Blood vol 132 (Suppl 1) 1534 2018
Abstract Leukemia http://www.bloodjournal.org/content/132/Suppl_1/1534
- 691 Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: Results of CALGB Protocol 39803**
M. T. Jaklitsch, L. Gu, T. Demmy, D. H. Harpole, T. A. D'Amico, R. J. Mckenna Jr, M. J. Krasna, L. J. Kohman, S. J. Swanson, M. M. Decamp, X. Wang, S. Barry, D. J. Sugarbaker J Thorac Cardiovasc Surg vol 146 (1) 9-16 2013
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/23768804>
- 692 Prospective Phase II Trial of Pre-Resection Thoracoscopic (VATS) Restaging Following Neoadjuvant Therapy For IIIA(N2) Non-small Cell Lung Cancer (NSCLC): Results of CALGB 39803**
M. T. Jaklitsch, L. Gu, D. H. Harpole, T. A. D'Amico, R. J. Mckenna Jr, M. J. Krasna, L. J. Kohman, S. J. Swanson, M. M. Decamp, D. J. Sugarbaker J. Clin. Oncol. vol 23 (16s) abstr 7065 2005
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=34&abstractID
- 693 Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406**
P. A. Janne, V. A. Miller, X. Wang, M. A. Socinski, J. Crawford, M. Capelletti, M. J. Edelman, M. A. Villalona-Calero, R. A. Kratzke, E. E. Vokes J. Clin. Oncol. vol 28 (15s) abstr 7503 2010
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID
- 694 Sorafenib in malignant mesothelioma (MM): A phase II trial of the Cancer and Leukemia Group B (CALGB 30307)**
P. A. Janne, X. F. Wang, L. M. Krug, L. Hodgson, E. E. Vokes, H. L. Kindler J. Clin. Oncol. vol 25 (18s) abstr 7707 2007
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID
- 695 Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial**

P. A. Janne, X. F. Wang, M. A. Socinski, J. Crawford, T. E. Stinchcombe, L. Gu, M. Capelletti, M. J. Edelman, M. A. Villalona-Calero, R. Kratzke, E. E. Vokes, V. A. Miller J. Clin. Oncol. vol 30 (17) 2063-2069 2012
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/22547605>

696 Outcome of advanced NSCLC patients with EGFR exon 19 and 21 mutations treated with erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in CALGB 30406

P. A. Janne, X. Wang, M. A. Socinski, J. Crawford, L. Gu, M. Capelletti, M. J. Edelman, M. A. Villalona-Calero, R. A. Kratzke, E. E. Vokes, V. A. Miller J Thorac Oncol vol 6 (suppl 2) abstr O39.01 2011
Abstract Respiratory <http://journals.lww.com/jto/toc/2011/06001#1986296615>

697 Prognostic and Predictive Values of KRAS in EGFR-based Subgroups and Combined with P53 in Completely Resected Non-Small Cell Lung Cancer (NSCLC): a LACE-Bio Study

P. Janne, F. Shepherd, C. Domerg, G. Le Teuff, R. Kratzke, P. Hainaut, J. Pignon, R. Rosell, J. Soria, M. Tsao Ann. Oncol. vol 23 ((suppl 9): ix73-ix94.) abstract 1670 2012
Abstract Respiratory http://annonc.oxfordjournals.org/content/23/suppl_9/ix73.abstract?sid=f3d4d421-30a0-497a-8e9e-bb1b9

698 Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance)

Claire L. Jansson-Knodell, Nathan R. Foster, Daniel J. Sargent, Paul J. Limburg, Stephen N. Thibodeau, Thomas C. Smyrk, Frank A. Sinicrope, Balkrishna Jahagirdar, Richard M. Goldberg, Steven R. Alberts J Gastrointest Oncol vol 8 (1) 1-11 2017
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/28280603>

699 Elderly patients with metastatic esophageal/gastric cancer: a pooled analysis of age-based outcomes from 8 consecutive North Central Cancer Treatment Group (NCCTG) therapeutic trials

A. Jatoi, N. R. Foster, J. Egner, P. Burch, P. J. Stella, J. Rubin, S. R. Dakhil, D. J. Sargent, B. Murphy, S. R. Alberts J. Clin. Oncol. vol 26 (15s abstr 9507) 503s 2008
Abstract GI http://ascopubs.org/doi/abs/10.1200/jco.2008.26.15_suppl.9507

700 A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422)

A. Jatoi, S. E. Schild, N. Foster, G. T. Henning, K. J. Dornfeld, P. J. Flynn, T. R. Fitch, S. R. Dakhil, K. M. Jr Rowland, P. J. Stella, G. S. Soori, A. A. Adjei Ann Oncol vol 21 (10) 2040-4 2010
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20570832>

701 A double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trial.

A Jatoi, P D Steen, P J Atherton, D F Moore, K M Rowland, N A Le-Lindqwister, C S Adonizio, A J Jaslowski, J Sloan, C Loprinzi Ann. Oncol. vol 28 (8) 1957-63 2017
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/28475678>

702 A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group.

Aminah Jatoi, Patrick Burch, David Hillman, Joanne M Vanyo, Shaker Dakhil, Daniel Nikceovich, Kendrith Rowland, Roscoe Morton, Patrick J Flynn, Charles Young, Winston Tan Urology vol 69 (2) 289-94 2007
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/17320666>

703 Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer

Treatment Group (N044B)1

Aminah Jatoi, Shaker R. Dakhil, Nathan R. Foster, Cynthia Ma, Kendrith M. Rowland, Dennis F. Moore, Anthony J. Jaslowski, Sachdev P. Thomas, Mark D. Hauge, Patrick J. Flynn, Philip J. Stella, Steven R. Alberts J Thorac Oncol vol 3 (5) 516-520 2008
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/18449005>

704 Prophylactic Tetracycline Does Not Diminish the Severity of Epidermal Growth Factor Receptor (EGFR) Inhibitor Induced Rash: Results from the North Central Cancer Treatment Group (Supplementary N03CB)1

Aminah Jatoi, Shaker R. Dakhil, Jeff A. Sloan, John W. Kugler, Kendrith M. Rowland, Paul L. Schaefer, Paul J. Novotny, Donald B. Wender, Howard M. Gross, Charles L. Loprinzi Support Care Cancer vol 19 (10) 1601-1607 2011
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/20820817>

705 Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: A pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials

Aminah Jatoi, Nathan R. Foster, James R. Egner, Patrick A. Burch, Philip J. Stella, Joseph Rubin, Shaker R. Dakhil, Daniel J. Sargent, Brian R. Murphy, Steven R. Alberts Int. J. Oncol. vol 36 (3) 601-606 2010
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/20126980>

706 Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147

Aminah Jatoi, Erin M. Green, Jr. Kendrith M. Rowland, Daniel J. Sargent, Steven R. Alberts Oncology vol 77 (2) 120-123 2009
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19622902>

707 Is social support associated with improved clinical outcomes in geriatric lung cancer patients? Observations from North Central Cancer Treatment Group Studies N9921 and N0222

Aminah Jatoi, Shauna L Hillman, Katie L Allen Ziegler, Philip J Stella, Gamini S Soori, Kendrith M Rowland Cancer Manag Res vol 1 61-8 2009
Manuscript Respiratory N0222, N9921 <http://www.ncbi.nlm.nih.gov/pubmed/21188124>

708 Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044).

Aminah Jatoi, James A Martenson, Nathan R Foster, Howard L McLeod, Bradley S Lair, Frank Nichols, Loren K Tschetter, Dennis F Moore, Tom R Fitch, Steven R Alberts Am. J. Clin. Oncol. vol 30 (5) 507-13 2007
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17921712>

709 Social Support and Its Implications in Older, Early-Stage Breast Cancer Patients in CALGB 49907 (Alliance A171301)

Aminah Jatoi, Hyman Muss, Jake B. Allred, Harvey J. Cohen, Karla Ballman, Judith O. Hopkins, Ajeet Gajra, Jacqueline Lafky, Antonio Wolff, Lisa Kottschade, Julie Gralow, Arti Hurria Psychooncology vol 25 (4) 441-446 2016
Manuscript Older Adult CALGB-49907, A171301 <http://www.ncbi.nlm.nih.gov/pubmed/25994447>

710 Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinoma.

Aminah Jatoi, Phuong L Nguyen, Nathan Foster, David Sun, Philip J Stella, Megan Campbell, Loren K Tschetter, Shaker R Dakhil, James A Mailliard, Daniel A Nikcevich J Support Oncol vol 5 (1) 41-6

2007

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17265786>

- 711 A Pilot Study of Long-Acting Octreotide for Symptomatic Malignant Ascites (N04C2)**
Aminah Jatoi, Jorge J. Nieva, Rui Qin, Charles L. Loprinzi, Edward J. Wos, Paul J. Novotny, Dennis F. Moore, Rex B. Mowat, Naftali Bechar, Eduardo R. Pajon, Lynn C. Hartmann *Oncology* vol 82 (6) 315-320 2012
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/22572824>
- 712 A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9).**
Aminah Jatoi, Howard L Ritter, Amylou Dueck, Phuong L Nguyen, Daniel A Nikcevich, Ronnie F Luyun, Bassam I Mattar, Charles L Loprinzi *Lung Cancer* vol 68 (2) 234-9 2010
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/19665818>
- 713 Tetracycline to Prevent Epidermal Growth Factor Receptor Inhibitor-Induced Skin Rashes: Results of a Placebo-Controlled Trial from the North Central Cancer Treatment Group (N03CB)1**
Aminah Jatoi, Kendrith Rowland, Jeff A. Sloan, Howard M. Gross, Paul A. Fishkin, Stephen P. Kahanic, Paul J. Novotny, Paul L. Schaefer, David B. Johnson, Loren K. Tschetter, Charles L. Loprinzi *Cancer* vol 113 (4) 847-853 2008
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/18543329>
- 714 Phase II Study of Preoperative Pemetrexed, Carboplatin, and Radiation Followed by Surgery for Locally Advanced Esophageal Cancer and Gastroesophageal Junction Tumors**
Aminah Jatoi, Gamini Soori, Nathan R. Foster, Bradley Hiatt, James A. Knost, Tom R. Fitch, Matthew D. Callister, Francis C. Nichols, Tim M. Husted, Steven R. Alberts *J Thorac Oncol* vol 5 (12) 1994-1998 2010
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20975604>
- 715 Does Sunscreen Prevent Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash? Results of a Placebo-Controlled Trial from the North Central Cancer Treatment Group (N05C4)**
Aminah Jatoi, Abby Thrower, Jeff A. Sloan, Patrick J. Flynn, Nicole Lea Wentworth-Hartung, Shaker R. Dakhil, Bassam I. Mattar, Daniel A. Nikcevich, Paul Novotny, Aleksandar Sekulic, Charles L. Loprinzi *Oncologist* vol 15 (9) 1016-1022 2010
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/20798191>
- 716 A phase I/II trial adding the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel in patients with locoregionally advanced squamous cell carcinoma of the head and neck (HNSCC) Alliance A091101**
Michael J. Jelinek, Nathan R. Foster, Alex J. Zoroufy, Jonas A. DeSouza, Gary K. Schwartz, Pamela Munster, Tanguy Seiwert, Everett E. Vokes *J Clin Oncol* vol 36 (15 suppl) 6031 2018
Abstract Experimental https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.6031
- 717 Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803 / ALLIANCE**
Justin Jeon, Kaori Sato, Donna Niedzwiecki, Xing Ye, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Devin S. Wigler, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Charles S. Fuchs, Jeffrey A. Meyerhardt *Clin Colorectal Cancer* vol 12 (4) 2013
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/24035029>
- 718 Phase II trial of pemetrexed (P) and carboplatin (C) in previously untreated extensive stage disease small cell lung cancer (ED-SCLC): A NCCTG Study**

J. R. Jett, A. Jr Bernath, N. Foster, J. Molina, D. Nikcevich, P. Steen, P. Flynn, K. Rowland Jr, T. Fitch, A. Adjei J. Clin. Oncol. vol 26 (suppl) abstr 8066 2008
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

719 The Effect of Atorvastatin on Breast Cancer Biomarkers in High-Risk Women

YongLi Ji, Tiffany Rounds, Abigail Crocker, Betsy Sussman, Russell C. Hovey, Fonda Kingsley, Hyman B. Muss, Judy E. Garber, Marie E. Wood Cancer Prev Res (Phila) vol 9 (5) 379-384 2016
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/26908565>

720 Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Jörg T Hartmann, Daniel Pink, Jochen Schütte, Giuliano Ramadori, Peter Hohenberger, Justus Duyster, Salah-Eddin Al-Batran, Marcus Schlemmer, Sebastian Bauer, Eva Wardelmann, Maarit Sarlomo-Rikala, Bengt Nilsson, Harri Sihto, Karla V Ballman, Mika Leinonen, Ronald P DeMatteo, Peter Reichardt Cancer vol 120 (15) 2325-2333 2014
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24737415>

721 Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).

Elizabeth A Johnson, Randolph S Marks, Sumithra J Mandrekar, Shauna L Hillman, Mark D Hauge, Mitchel D Bauman, Edward J Wos, Dennis F Moore, John W Kugler, Harold E Windschitl, David L Graham, Albert M Bernath, Tom R Fitch, Gamini S Soori, James R Jett, Alex A Adjei, Edith A Perez Lung Cancer vol 60 (2) 200-7 2008
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18045731>

722 Everolimus plus R-CHOP-21 is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG N1085 (Alliance)

Patrick B. Johnston, Betsy R. LaPlant, Ellen D. McPhail, Thomas M. Habermann, David J. Inwards, Ivana Micallef, Joseph Colgan, Grzegorz Nowakowski, Stephen M. Ansell, Thomas E. Witzig Blood vol 126 (23) abstr 813 2015
Abstract Lymphoma <http://www.bloodjournal.org/content/126/23/813>

723 Combination of everolimus with R-CHOP (ever R-CHOP) as an initial therapy for diffuse large B cell lymphoma (DLBCL): NCCTG N1085 (Alliance) phase I and feasibility study

Patrick B. Johnston, Betsy R. LaPlant, Grzegorz S. Nowakowski, Ivana N.M. Micallef, Stephen M. Ansell, Thomas H. Habermann, Joseph, P. Colgan, Thomas E. Witzig J. Clin. Oncol. vol 33 (suppl) abstr 8518 2015
Abstract Lymphoma <http://meetinglibrary.asco.org/content/147348-156>

724 Everolimus plus R--CHOP as initial therapy for DLBCL: a phase I/feasibility study (NCCTG N1085 [Alliance])

Patrick B. Johnston, Betsy R. LaPlant, Grzegorz S. Nowakowski, Ivana N.M. Micallef, Stephen M. Ansell, Thomas H. Habermann, Joseph, P. Colgan1, Thomas E. Witzig Hematol Oncol vol 33 (suppl S2) p 241, abstr 282 2015
Abstract Lymphoma <http://onlinelibrary.wiley.com/doi/10.1002/hon.2228/epdf>

725 The mTORC1 Inhibitor Everolimus Combined with R-CHOP-21 for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Safety and Efficacy Results of a Phase I and Feasibility Trial NCCTG 1085 (Alliance)

Patrick B. Johnston, Betsy LaPlant, Ellen McPhail, Thomas M. Habermann, David J. Inwards, Ivana N. Micallef, Joseph P. Colgan, Grzegorz S. Nowakowski, Stephen M. Ansell, Thomas E. Witzig Lancet Haematol vol 3 (7) e309-e316 2016

726 Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101

J. A. Jones, A. S. Ruppert, W. Zhao, T. S. Lin, K. Rai, B. Peterson, R. A. Larson, G. Marcucci, N. A. Heerema, J. C. Byrd *Leuk. Lymphoma* vol 54 (12) 2654-9 2013

Manuscript Leukemia CALGB-19901, CALGB-10101

<http://www.ncbi.nlm.nih.gov/pubmed/23547837>

727 Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials

J. A. Jones, A. Stark, W. Zhao, T. S. Lin, K. R. Rai, G. Marcucci, B. Peterson, R. A. Larson, N. A. Heerema, J. C. Byrd *Blood* vol 118 (21) -1791 2011

Abstract Leukemia CALGB-10101, CALGB-19901

<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/1791>

728 Peak Oxygen Consumption and Long-Term All-Cause Mortality in Non-Small Cell Lung Cancer

Lee W. Jones, Dorothy Watson, James E. Herndon, Neil D. Eves, Benjamin E. Haithcock, Gregory Loewen, Leslie Kohman *Cancer* vol 116 (20) 4825-4832 2010

Manuscript Respiratory CALGB-140803, CALGB-9238

<http://www.ncbi.nlm.nih.gov/pubmed/20597134>

729 Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study.

P W Kantoff, S Halabi, M Conaway, J Picus, J Kirshner, V Hars, D Trump, E P Winer, N J Vogelzang *J. Clin. Oncol.* vol 17 (8) 2506-13 1999

Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/10561316>

730 Bortezomib maintenance (BM) vs consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell (MCL): CALGB 50403 (Alliance).

L. D. Kaplan, S. H. Jung, N. C. Bartlett, J. Johnson, J. Byrd, K. Blum, W. Stock, A. S. Lacasce, E. Hsi, D. Hurd, M. S. Czuczman, B. D. Cheson *Hematol Oncol* vol 31 (suppl 1) abstr 089 2013

Abstract Lymphoma <http://onlinelibrary.wiley.com/doi/10.1002/hon.2057/pdf>

731 A randomized phase II trial of maintenance vs consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma (MCL): CALGB 50403

L. D. Kaplan, S. Jung, J. L. Johnson, C. Linker, J. C. Byrd, W. Stock, B. D. Cheson *J. Clin. Oncol.* vol 28 (15s) abstr TPS306 2010

Abstract Lymphoma <http://meetinglibrary.asco.org/content/41656-74>

732 Bortezomib maintenance (BM) or consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): 8-year follow-up of CALGB 50403 (Alliance)

Lawrence D. Kaplan, Matthew Maurer, Wendy Stock, Noreen Fulton, Nancy Bartlett, Adam Pettinger, John Byrd, Kristie A. Blum, Anne S. LaCasce, Eric D. Hsi, David Hurd, Amy Ruppert, John P.

Leonard, Bruce. D. Cheson *Blood* vol 132 (suppl 1) 146 2018

Abstract Lymphoma http://www.bloodjournal.org/content/132/Suppl_1/146

733 Bortezomib Maintenance (Bm) Versus Consolidation (Bc) Following Aggressive

Immunochemotherapy and Autologous Stem Cell Transplant (Asct) For Untreated Mantle Cell Lymphoma (Mcl): CALGB 50403

Lawrence D. Kaplan, Wendy Stock, Sin-Ho Jung, Nancy Bartlett, Brandy Pitcher, John Byrd, Kristie A. Blum, Ann S. LaCasce, Eric D. Hsi, David Hurd, Myron Czuczman, John P. Leonard, Bruce D. Cheson Blood vol 126 (23) abstr 337 2015
Abstract Lymphoma <http://www.bloodjournal.org/content/126/23/337.abstract?sso-checked=true>

734 Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E

Rajini Katipamula, Aminah Jatoi, Nathan R. Foster, Francis Nichols, Joseph Rubin, Matthew Callister, Leonard Gunderson, Steven Alberts Clin Med Oncol vol 2 223-225 2008
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21892283>

735 Standardization and documentation of surgical and pathologic variables in a multi-institutional trial of adjuvant therapy for pancreatic cancer: Results from ACOSOG Z5031

M. H. Katz, N. B. Merchant, S. Brower, M. Campbell, M. C. Posner, L. W. Traverso, R. A. Abrams, V. J. Picozzi, P. W. Pisters SSO Annual Meeting abstr Z5031 2010
Abstract GI
http://www.surgonc.org/media/88503/sso_annual_cancer_symposium_abstract_supplement_to_annals_o

736 The role of patient advocates in clinical trials: Perspectives from investigators and advocates in the Cancer and Leukemia Group B (CALGB)

M. L. Katz, L. E. Archer, J. M. Peppercorn, S. Kereakoglow, D. Collyar, H. J. Burstein, R. L. Schilsky, A. H. Partridge J. Clin. Oncol. vol 28 (15s) abstr 6148 2010
Abstract Patient Adv
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

737 Standardization of Surgical and Pathologic Variables is Needed in Multicenter Trials of Adjuvant Therapy for Pancreatic Cancer: Results from the ACOSOG Z5031 Trial

Matthew H. G. Katz, Nipun B. Merchant, Steven Brower, Megan Branda, Mitchell C. Posner, L. William Traverso, Ross A. Abrams, Vincent J. Picozzi, Peter W. T. Pisters Ann. Surg. Oncol. vol 18 (2) 337-344 2011
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20811779>

738 Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas

Matthew H. G. Katz, Fang-Shu Ou, Joseph M. Herman, Syed A. Ahmad, Brian Wolpin, Robert Marsh, Spencer Behr, Qian Shi, Michael Chuong, Lawrence H. Schwartz, Wendy Frankel, Eric Collisson, Eugene J. Koay, JoLeen M. Hubbard, James L. Leenstra, Jeffrey Meyerhardt, Eileen O'Reilly BMC Cancer vol 17 505 2017
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/28750659>

739 Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer

Matthew H. G. Katz, Qian Shi, Syed A. Ahmad, Joseph M. Herman, Robert de W. Marsh, Eric Collisson, Lawrence Schwartz, Wendy Frankel, Robert Martin, William Conway, Mark Truty, Hedy Kindler, Andrew M. Lowy, Tanios Bekaii-Saab, Philip Philip, Mark Talamonti, Dana Cardin, Noelle LoConte, Perry Shen, John P. Hoffman, Alan P. Venook JAMA Surg vol 151 (8) e161137 2016
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/27275632>

740 Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for

borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101.

Matthew H.G. Katz, Qian Shi, Syed Ahmad, Joseph Herman, Robert Marsh, Eric Collisson, Lawrence Schwartz, Robert Martin, William Conway, Mark Truty, Hedy Kindler, Andrew M. Lowy, Tanios Bekaii-Saab, Dana Cardin, Noelle LoConte, Alan P. Venook *J. Clin. Oncol.* vol 33 (suppl) abstr 4008 2015

Abstract GI <http://meetinglibrary.asco.org/content/147695-156>

741 Borderline resectable pancreatic cancer: Need for Standardization and Methods for Optimal Clinical Trial Design

Matthew HG Katz, Robert Marsh, Joseph M. Herman, Qian Shi, Eric Collison, Alan Venook, Hedy Kindler, Steven Alberts, Philip Philip, Andrew M. Lowy, Peter Pisters, Mitchell Posner, Jordan Berlin, Syed A. Ahmad *Ann. Surg. Oncol.* vol 20 (8) 2787-2795 2013

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/23435609>

742 Nomogram-Based Estimate of Axillary Nodal Involvement in ACOSOG Z0011 (Alliance): Validation and Association with Radiation Protocol Variations and Outcomes

Matthew S. Katz, Linda McCall, Karla Ballman, Bruce G. Haffty, Reshma Jagsi, Armando E. Giuliano *Int J Radiat Oncol Biol Phys* vol 102 (3 suppl) S228-9 2018

Abstract Breast [https://www.redjournal.org/article/S0360-3016\(18\)31566-9/fulltext](https://www.redjournal.org/article/S0360-3016(18)31566-9/fulltext)

743 Alliance for clinical trials in oncology trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas

Matthew Katz, Joseph M. Herman, Fang-Shu Ou, Robert Marsh, Michael Chuong, Brian Wolpin, Lawrence H. Schwarz, James L. Leenstra, Eileen O'Reilly, Jeffrey Meyerhardt, Syed Ahmad *J. Clin. Oncol.* vol 35 (15 suppl) TPS4151 2017

Abstract GI http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS4151

744 Cancer Surveillance Behaviors and Psychosocial Factors Among Long-Term Survivors of Breast Cancer

Mira L. Katz, Kathleen A. Donohue, Catherine M. Alfano, Jeannette M. Day, James E. Herndon, Electra D. Paskett *Cancer* vol 115 (3) 480-488 2009

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/19133656>

745 CALGB 150002: Correlation of HER-2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840: Paclitaxel (P) +/-T in HER-2(+) and (-) metastatic breast cancer (MBC)

P. A. Kaufman, G. Broadwater, K. A. Lezon-Geyda, L. G. Dressler, M. J. Ellis, E. P. Winer, C. A. Hudis, A. D. Seidman, L. N. Harris *J. Clin. Oncol.* vol 25 (18s) abstr 1009 2007

Abstract Correl Sci NOS

http://jco.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B25%2F18_suppl%2F1009

746 Improved outcome in recurrent glioblastoma (RGBM) patients treated with bevacizumab (BEV) and sorafenib (SOR) is predicted by a greater drop in apparent diffusion coefficient (ADC) on MRI imaging.

T. J. Kaufmann, S. K. Anderson, K. A. Jaeckle, J. H. Uhm, D. W. Northfelt, P. J. Flynn, J. C. Buckner, E. Galanis 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors vol 13 (suppl 3) 138 2011

Abstract Neuro-Onc http://neuro-oncology.oxfordjournals.org/content/13/suppl_3/iii136.abstract

747 Regional Differences In Breast Cancer Biomarkers In American Indian And Alaska Native Women

Judith S Kaur, Robert A. Vierkant, Timothy Hobday, Daniel Visscher *Cancer Epidemiol. Biomarkers*

748 Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8

Ann E. Kearns, Donald W. Northfelt, Amylou C. Dueck, Pamela J. Atherton, Shaker R. Dakhil, Kendrith M. Rowland, Jyotsna Fuloria, Patrick J. Flynn, Todor Dentchev, Charles L. Loprinzi
Support Care Cancer vol 18 (3) 321-328 2010

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/19468757>

749 Phase II Study of Induction Cisplatin and Irinotecan Followed by Concurrent Carboplatin, Etoposide, and Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer, CALGB 30206

M. J. Kelley, J. A. Bogart, L. D. Hodgson, R. H. Ansari, J. N. Atkins, H. Pang, M. R. Green, E. E. Vokes
J Thorac Oncol vol 8 (1) 102-108 2013

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/23196276>

750 CALGB 30206: Phase II study of induction cisplatin (P) and irinotecan (I) followed by combination carboplatin (C), etoposide (E), and thoracic radiotherapy for limited stage small cell lung cancer

M. J. Kelley, J. A. Bogart, L. D. Hodgson, R. H. Ansari, J. N. Atkins, X. Wang, M. R. Green, E. E. Vokes
J. Clin. Oncol. vol 25 (18s) abstr 7565 2007

Abstract Respiratory http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/7565

751 Five-year follow-up of a multicenter phase II study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin (TEC) plus androgen-deprivation therapy (ADT) prior to radiation therapy in patients with unfavorable-risk localized prostate cancer: CALGB 99811

W. K. Kelly, S. Halabi, L. E. Archer, J. A. Bogart, M. J. Zelefsky, E. J. Small
Genitourinary Cancers Symposium abstr 123 2010

Abstract GU

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID

752 Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)

W. K. Kelly, S. Halabi, M. A. Carducci, D. J. George, J. F. Mahoney, W. M. Stadler, M. J. Morris, P. W. Kantoff, J. P. Monk, E. J. Small
J. Clin. Oncol. vol 30 (Supplement) abstr 4655 2012

Abstract GU http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/4655

753 A randomized double-blind placebo controlled phase III trial comparing docetaxel, prednisone and placebo with docetaxel prednisone and bevacizumab in men with metastatic castrate resistant prostate cancer (metCRPC): Survival results of CALGB 90401

W. K. Kelly, S. Halabi, D. J. George, W. M. Stadler, P. W. Kantoff, M. J. Morris, P. J. Monk, E. H. Leung, E. J. Small
J. Clin. Oncol. vol 28 (15s) abstr 4511 2010

Abstract GU

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

754 Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

William Kevin Kelly, Susan Halabi, Michael Carducci, Daniel George, John F. Mahoney, Walter M. Stadler, Michael Morris, Philip Kantoff, J. Paul Monk, Ellen Kaplan, Nicholas J. Vogelzang, Eric J. Small
J. Clin. Oncol vol 30 (13) 1534-1540 2012

Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/22454414>

- 755 Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.**
William Kevin Kelly, Susan Halabi, Aymen Elfiky, San-San Ou, Jeff Bogart, Michael Zelefsky, Eric Small *Cancer* vol 113 (11) 3137-45 2008
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/18989865>
- 756 Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).**
Nancy E Kemeny, Donna Niedzwiecki, Donna R Hollis, Heinz-Josef Lenz, Robert S Warren, Michelle J Naughton, Jane C Weeks, Elin R Sigurdson, James E Herndon, Chunfeng Zhang, Robert J Mayer *J. Clin. Oncol.* vol 24 (9) 1395-403 2006
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/16505413>
- 757 Factors impacting oncologic outcomes after sublobar pulmonary resection: Results from ACOSOG Z4032 (Alliance), a randomized trial for high-risk operable non-small cell lung cancer (NSCLC)**
M. Kent, R. Landreneau, S. Mandrekar, F. Nichols, T. Dipetrillo, B. Meyers, D. Heron, J. Putnam, D. Jones, S. Starnes, B. Daly, A. Tan, H. Fernando *J. Clin. Oncol.* vol 31 (15 suppl) abstr 7524 2013
Abstract Respiratory
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7524?sid=468ed2a2-4b64-4195-a8fd-8ef48
- 758 Impact of Sublobar Resection on Pulmonary Function: Long-term Results from ACOSOG Z4032 (Alliance)**
Michael S. Kent, Sumithra J. Mandrekar, Rodney Landreneau, Francis Nichols, Thomas A. DiPetrillo, Bryan Meyers, Dwight E. Heron, David R. Jones, Angelina D. Tan, Sandra Starnes, Joe B. Putnam, Hiran C. Fernando *Ann. Thorac. Surg.* vol 102 (1) 230-238 2016
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/27101728>
- 759 A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032)**
Michael S. Kent, Sumithra J. Mandrekar, Rodney Landreneau, Francis Nichols, Nathan R. Foster, Thomas A. DiPetrillo, Bryan Meyers, Dwight E. Heron, David R. Jones, Angelina D. Tan, Sandra Starnes, Joe B. Putnam, Hiran C Fernando *Ann. Thorac. Surg.* vol 102 (1) 239-246 2016
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/27101729>
- 760 Impact of Sublobar Resection on pulmonary function; Long-term results from Z4032 (Alliance), a randomized phase III trial**
Michael Kent, Hiran C Fernando, Sumithra Mandrekar, Rodney Landreneau, Francis Nichols, Thomas A DiPetrillo, Bryan Meyers, Dwight Heron, David R Jones, Angelina D Tan, Sandra Starnes, Joe B Putnam *Ann Thoracic Surg* vol 102 (1) 230-238 2016
Abstract Respiratory [http://www.annalsthoracicsurgery.org/article/S0003-4975\(16\)00082-5/abstract](http://www.annalsthoracicsurgery.org/article/S0003-4975(16)00082-5/abstract)
- 761 Development of a Nomogram for Predicting Outcomes after Sublobar Resection for lung cancer; An Analysis from ACOSOG Z4032 (Alliance) a Randomized Trial**
Michael Kent, Sumithra Mandrekar, Rodney Landreneau, Francis Nichols, Nathan Foster, Thomas A DiPetrillo, Bryan Meyers, Dwight Heron, David R Jones, Angelina D Tan, Sandra Starnes, Joe B Putnam, Hiran C Fernando 2015
Abstract Respiratory <http://aats.org/annualmeeting/program-books/2015/70.cgi>
- 762 A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia**
C. Khandanpour, C. Thiede, P. J. Valk, E. Sharif-Askari, H. Nuckel, D. Lohmann, B. Horsthemke, W.

Siffert, A. Neubauer, K. H. Grzeschik, C. D. Bloomfield, G. Marcucci, K. Maharry, M. L. Slovak, B. A. Van Der Reijden, J. H. Jansen, H. K. Schackert, K. Afshar, S. Schnittger, J. K. Peeters, F. Kroschinsky, G. Ehninger, B. Lowenberg, U. Duhrsen, T. Moroy *Blood* vol 115 (12) 2462-2472 2010
Manuscript *Leuk Corr Sci* C9665, C8461 <http://www.ncbi.nlm.nih.gov/pubmed/20075157>

763 North Central Cancer Treatment Group phase II study of panitumumab (Pmab), chemotherapy, and external beam radiation (Chemo-RT) in patients with locally advanced (LA) pancreatic cancer

G. P. Kim, N. R. Foster, M. G. Haddock, S. R. Dakhil, R. J. Behrens, P. J. Flynn, S. R. Alberts *J. Clin. Oncol.* vol 30 (suppl 4) abstr 271 2012
Abstract GI http://meeting.ascopubs.org/cgi/content/abstract/30/4_suppl/271

764 Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma

G. P. Kim, N. R. Foster, M. Salim, P. J. Flynn, D. F. Jr Moore, R. Zon, R. B. Mowat, M. Wiesenfeld, A. E. McCullough, S. R. Alberts *J. Clin. Oncol.* vol 29 (suppl 4) abstr 238 2011
Abstract GI <http://meetinglibrary.asco.org/content/71370-103>

765 Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU) and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer

G. P. Kim, M. G. Haddock, N. Foster, J. Bollinger, P. Stella, J. Kugler, S. Alberts, J. Martenson *Gastrointestinal Cancers Symposium* abstr 144 2008
Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=53&abstractID

766 Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU), and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer

G. P. Kim, M. Haddock, N. R. Foster, J. Bollinger, P. J. Stella, J. W. Kugler, S. R. Alberts, J. Martenson *J. Clin. Oncol.* vol 26 (15s) abstr 15553 2008
Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

767 Analysis of time-dependent patterns of treatment effect and failure to explain the predictive role of deficient mismatch repair (dMMR) in stage II and III colon cancer (CC)

G. P. Kim, S. Marsoni, G. Monges, C. J. Allegra, S. N. Thibodeau, S. R. Hamilton, B. Kabat, G. A. Yothers, S. Gallinger, D. J. Sargent *J. Clin. Oncol.* vol 28 (15s) abstr 3518 2010
Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

768 Phase II of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma

G. P. Kim, A. L. Oberg, N. R. Foster, A. Jaslowski, P. J. Flynn, D. Campbell, E. Hedrick, L. Gray, A. Grothey, S. Alberts *J. Clin. Oncol.* vol 25 (18s) abstr 4553 2007
Abstract GI http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/4553

769 Time-dependent patterns of treatment effect and failure as an explanation for the predictive role of deficient mismatch repair (dMMR) in colon cancer.

G. Kim, S. Marsoni, G. Monges, C. Allegra, S. N. Thibodeau, S. Hamilton, B. F. Kabat, G. Yothers, S. Gallinger, D. Sargent *Gastrointestinal Cancers Symposium* abstr 342 2010
Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID

- 770 Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841**
George P. Kim, Daniel J. Sargent, Michelle R. Mahoney, Kendrith M. Rowland, Philip A. Philip, Edith Mitchell, Abraham P. Mathews, Tom R. Fitch, Richard M. Goldberg, Steven R. Alberts, Henry C. Pitot
J Clin Oncol vol 27 (17) 2848-2854 2009
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19380443>
- 771 A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance)**
Hyung L. Kim, Susan Halabi, Ping Li, Greg Mayhew, Jeff Simko, Andrew B. Nixon, Eric J. Small, Brian Rini, Michael J. Morris, Mary-Ellen Taplin, Daniel George
EBioMedicine vol 2 (11) 1814-1820 2015
Manuscript GU CALGB-150603, CALGB-90206 <http://www.ncbi.nlm.nih.gov/pubmed/26870806>
- 772 A prognostic model for overall survival in patients with metastatic clear cell renal carcinoma: Results from CALGB 90206 (Alliance)**
Hyung L. Kim, Susan Halabi, Ping Li, Greg Mayhew, Jeff Simko, Andrew Nixon, Eric Small, Brian Rini, Michael Morris, Mary-Ellen Taplin, Daniel George
J Urol vol 193 (4S) abstr MP44-01 2015
Abstract GU <http://www.jurology.com/article/S0022-5347%2815%2901854-6/abstract>
- 773 Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS**
Kyu-pyo Kim, Robert A. Parise, Julianne L. Holleran, Lionel D. Lewis, Leonard Appleman, Nielka van Erp, Michael J. Morris, Jan H. Beumer
J Pharm Biomed Anal vol 138 197-205 2017
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/28219796>
- 774 Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)**
G. G. Kimmick, C. Cirrincione, D. B. Duggan, K. Bhalla, N. Robert, D. Berry, L. Norton, S. Lemke, I. C. Henderson, C. Hudis, E. Winer
Breast Cancer Res. Treat. vol 113 (3) 479-490 2009
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/18306034>
- 775 Using ePrognosis to Estimate 2-year All-Cause Mortality in Older Women with Breast Cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503)**
Gretchen G Kimmick, Brittany Major, Jonathan Clapp, Jeff Sloan, Brandelyn Pitcher, Karla Ballman, Myra Barginear, Rachel A Freedman, Andrew Artz, Heidi D Klepin, Jacqueline M Lafky, Judith Hopkins, Eric Winer, Clifford Hudis, Hyman Muss, Harvey Cohen, Aminah Jatoui, Arti Hurria, Jeanne Mandelblatt
Breast Cancer Res. Treat. vol 163 (2) 391-398 2017
Manuscript Older Adult A151503, CALGB-369901, CALGB-49907
<http://www.ncbi.nlm.nih.gov/pubmed/28283904>
- 776 Determining All-Cause Survival Estimates using ePrognosis in Older Women with Breast Cancer in CALGB 49907 and 369901 (Alliance A151503)**
Gretchen Kimmick, Brandelyn Pitcher, Jeanne Mandelblatt, Jonathan Clapp, Myra Barginear, Rachel Freedman, Heidi Klepin, Jacqueline Lafky, Eric Winer, Clifford Hudis, Hyman Muss, Harvey Cohen, Aminah Jatoui, Arti Hurria
Cancer Res. vol 76 (4 Suppl) P6-09-10 2016
Abstract Older Adult A151503, CALGB-369901, CALGB-49907
http://cancerres.aacrjournals.org/content/76/4_Supplement/P6-09-10.short?rss=1
- 777 A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer**

(PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB)

H. L. Kindler, D. Niedzwiecki, D. R. Hollis, E. A. Oraefo, D. Schrag, H. I. Hurwitz, H. L. Mcleod, M. Mulcahy, R. L. Schilsky, R. M. Goldberg J. Clin. Oncol. vol 25 (18s) abstr 4508 2007
Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

778 Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

Hedy Lee Kindler, Donna Niedzwiecki, Donna Hollis, Susan Sutherland, Deborah Schrag, Herbert Hurwitz, Federico Innocenti, Mary Frances Mulcahy, Eileen O'Reilly, Timothy F. Wozniak, Joel Picus, Pankaj Bhargava, Robert J. Mayer, Richard L. Schilsky, Richard M. Goldberg J Clin Oncol vol 28 (22) 3617-3622 2010

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20606091>

779 Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer (BC)

H. D. Klepin, B. Pitcher, K. V. Ballman, G. G. Kimmick, A. B. Kornblith, H. J. Cohen, A. Hurria, E. P. Winer, C. Hudis, H. B. Muss J. Clin. Oncol. vol 30 (Supplement May) abstr 6015 2012

Abstract Older Adult CALGB-70103, CALGB-49907

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID

780 Comorbidity, Chemotherapy Toxicity, and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 and CALGB 361004 (Alliance)

Heidi D. Klepin, Brandelyn N. Pitcher, Karla V. Ballman, Alice B. Kornblith, Arti Hurria, Eric P. Winer, Clifford Hudis, Harvey J. Cohen, Hyman B. Muss, Gretchen G. Kimmick J Oncol Pract vol 10 (5) e285-e292 2014

Manuscript Older Adult CALGB-49907, CALGB-361004

<http://www.ncbi.nlm.nih.gov/pubmed/25074878>

781 Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance).

Heidi D. Klepin, Ellen K. Ritchie, Ben L. Sanford, Guido Marcucci, Weiqiang Zhao, Susan Michelle Geyer, Karla V. Ballman, Bayard L. Powell, Maria R. Baer, Wendy Stock, Harvey Jay Cohen, Richard M. Stone, Richard A. Larson, Geoffrey L. Uy J. Clin. Oncol. vol 32 (15_suppl) 7102 2014

Abstract Older Adult http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7102

782 Nursing contributions in Community Clinical Oncology Research Programs.

Kathy Klinger, Cesar Figueras, Kathleen M Beney, Jane M Armer, Sharon Levy Semin Oncol Nurs vol 30 (1) 38-43 2014

Manuscript Onc Nursing <http://www.ncbi.nlm.nih.gov/pubmed/24559779>

783 Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206

Harriet M. Kluger, Susan Halabi, Nicole C Solomon, Lucia Jilaveanu, Christopher Zito, Joshua Sznol, Andrew B. Nixon, Brian I. Rini, Eric Jay Small, Daniel J. George J. Clin. Oncol. vol 32 (5s) (suppl; abstr 4532) 2014

Abstract GU http://abstracts.asco.org/144/AbstView_144_132556.html

784 Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study N9831

K. L. Knutson, E. A. Perez, K. Ballman, C. L. Erskine, N. Fox, C.-A. Mccarl, N. Norton, S. V.

Sumrall, D. Northfelt, W. Tan, C. Calfa, M. Pegram, R. Clynes J. Clin. Oncol. vol 31 (15 suppl) abstr

- 785 Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain**
Keith L. Knutson, Raphael Clynes, Barath Shreeder, Patrick Yeramian, Kathleen P. Kemp, Karla Ballman, Kathleen S. Tenner, Courtney L. Erskine, Nadine Norton, Donald Northfelt, Winston Tan, Carmen Calfa, Mark Pegram, Elizabeth A. Mittendorf, Edith A. Perez *Cancer Res.* vol 76 (13) 3702-3710 2016
Manuscript Breast N0337, N98-32-52, N0938 <http://www.ncbi.nlm.nih.gov/pubmed/27197192>
- 786 Associations of HER2-Specific Immunity with Survival During Treatment with Trastuzumab and Chemotherapy in Breast Cancer**
Keith L. Knutson, Raphael Clynes, Patrick Yeramian, Kathleen P. Kemp, Barath Shreeder, Karla Ballman, Kathleen S. Tenner, Courtney L. Erskine, Nadine Norton, Donald Northfelt, Winston Tan, Mark Pegram, Carmen Calfa, Elizabeth A. Mittendorf, Edith A. Perez *J. Clin. Oncol.* vol 33 (suppl) abstr 587 2015
Abstract Breast N0337, N98-32-52, N0938 <http://meetinglibrary.asco.org/content/143678-156>
- 787 Association between cardiorespiratory fitness and overall survival in operable lung cancer patients: Ancillary analysis of protocol 9238**
L. J. Kohman, D. M. Watson, J. E. Herndon 2nd, N. Eves, B. E. Haithcock, G. M. Loewen, L. W. Jones *J. Clin. Oncol.* vol 27 (15s) abstr 7518 2009
Abstract Respiratory CALGB-140803, CALGB-9238
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID
- 788 Biopsy first: Lessons learned from CALGB 140503**
Leslie J. Kohman, Lin Gu, Nasser Altorki, Ernest Scalzetti, Linda J. Veit, Jason M. Wallen, Xiaofei Wang *J. Thorac. Cardiovasc. Surg.* vol 153 (6) 1592-1597 2017
Manuscript Respiratory CALGB-140503, A081202, CALGB-580602
<http://www.ncbi.nlm.nih.gov/pubmed/28274562>
- 789 Surgeon Error In Predicting Stage I Non-Small Cell Lung Cancer (NSCLC) Is A Major Factor Precluding Randomization In CALGB 140503 (Alliance)**
Leslie J. Kohman, Lin Gu, Nasser Altorki, Linda J. Veit, Xiaofei Wang 2016
Abstract Respiratory
http://aats.org/aatsimis/AATS/Meetings/Past_AATS_Meetings/2016/AATS_96th_Annual_Meeting_.asp
- 790 Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808**
J. E. Kolitz, V. Hars, D. J. Deangelo, S. L. Allen, T. C. Shea, R. Vij, E. Hoke, C. D. Bloomfield, M. A. Caligiuri, S. L. George, R. A. Larson *Blood* vol 110 (11) 157 2007
Abstract Leukemia CALGB-19808, CALGB-8461, CALGB-9665
<http://www.bloodjournal.org/content/110/11/157>
- 791 Recombinant Interleukin-2 in Patients Aged Younger Than 60 Years With Acute Myeloid Leukemia in First Complete Remission**
Jonathan E. Kolitz, Stephen L. George, Don M. Benson, Kati Maharry, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. DeAngelo, Thomas C. Shea, Wendy Stock, Courtney E. Bakan, Vera Hars, Eva Hoke, Clara D. Bloomfield, Michael A. Caligiuri, Richard A. Larson *Cancer* vol 120 (7) 1010-1017 2014
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/24382782>

- 792 P-glycoprotein inhibition using valsopodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808**
Jonathan E. Kolitz, Stephen L. George, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. DeAngelo, Thomas C. Shea, Wendy Stock, Maria R. Baer, Vera Hars, Kati Maharry, Eva Hoke, James W. Vardiman, Clara D. Bloomfield, Richard A. Larson *Blood* vol 116 (9) 1413-1421 2010
Manuscript *Leukemia* CALGB-19808, CALGB-8461
<http://www.ncbi.nlm.nih.gov/pubmed/20522709>
- 793 Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.**
Edward L Korn, Ping-Yu Liu, Sandra J Lee, Judith-Anne W Chapman, Donna Niedzwiecki, Vera J Suman, James Moon, Vernon K Sondak, Michael B Atkins, Elizabeth A Eisenhauer, Wendy Parulekar, Svetomir N Markovic, Scott Saxman, John M Kirkwood *J. Clin. Oncol.* vol 26 (4) 527-34 2008
Manuscript *Experimental* <http://www.ncbi.nlm.nih.gov/pubmed/18235113>
- 794 Quality of life of early stage breast cancer patients 65 years old or older randomized to standard chemotherapy or capecitabine (CALGB 49907)**
A. B. Kornblith, L. E. Archer, L. Lan, G. G. Kimmick, A. H. Partridge, R. A. Casey, S. Bennett, C. A. Hudis, E. P. Winer, H. J. Cohen, H. B. Muss *Cancer Res.* vol 69 (24, suppl 3) abstr SABCS-09-5035 2009
Abstract *Breast* http://cancerres.aacrjournals.org/cgi/content/abstract/69/24_MeetingAbstracts/5035
- 795 Quality of Life of Older Patients With Early-Stage Breast Cancer Receiving Adjuvant Chemotherapy: A Companion Study to Cancer and Leukemia Group B 49907**
Alice B. Kornblith, Lan Lan, Laura Archer, Ann Partridge, Gretchen Kimmick, Clifford Hudis, Eric Winer, Rebecca Casey, Samantha Bennett, Harvey Jay Cohen, Hyman B. Muss *J Clin Oncol* vol 29 (8) 1022-1028 2011
Manuscript *Health Outcome* C70103, CALGB-49907
<http://www.ncbi.nlm.nih.gov/pubmed/21300923>
- 796 Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?**
L. Kostakoglu, H. Schoder, N. C. Hall, D. J. Straus, J. L. Johnson, L. Schwartz, A. S. Lacasce, S. Jung, N. L. Bartlett, G. P. Canellos, B. D. Cheson *ASH Annual Meeting Abstracts* vol 118 (21) abstr 3644 2011
Abstract *Lymphoma* <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/3644>
- 797 Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results**
L. Kostakoglu, D. J. Straus, H. Schoder, A. S. Lacasce, N. L. Bartlett, N. C. Hall, J. L. Johnson, S. Jung, G. P. Canellos, L. H. Schwartz, B. D. Cheson *ASH Annual Meeting Abstracts* vol 112 (11) abstr 1460 2008
Abstract *Lymphoma* <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;112/11/1460>
- 798 Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?**
Lale Kostakoglu, Heiko Schöder, Jeffrey L Johnson, Nathan C Hall, Lawrence H Schwartz, David J

Straus, Ann S LaCasce, Sin-Ho Jung, Nancy L Bartlett, George P Canellos, Bruce D Cheson Leuk. Lymphoma vol 53 (11) 2143-50 2012
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/22421007>

799 Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: results from two prospective cohorts and CALGB 89803 Alliance) trial
Keisuke Kosumi, Tsuyoshi Hamada, Sui Zhang, Li Liu, Annacarolina da Silva, Hideo Koh, Tyler S. Twombly, Kosuke Mima, Teppei Morikawa, Mingyang Song, Jonathan A. Nowak, Reiko Nishihara, Leonard B. Saltz, Donna Niedzwiecki, Fang-Shu Ou, Tyler Zemla, Robert J. Mayer, Hideo Baba, Kimmie Ng, Marios Giannakis, Xuehong Zhang, Kana Wu, Edward L. Giovannucci, Andrew T. Chan, Charles S. Fuchs, Jeffrey A. Meyerhardt, Shuji Ogino Eur. J. Cancer vol 111 82-93 2019
Manuscript Correl Sci NOS CALGB-89803 <http://www.ncbi.nlm.nih.gov/pubmed/30826660>

800 A phase II trial of carboplatin and ABI-007 in patients with unresectable stage IV melanoma, N057E.
L. Kottschade, V. Suman, T. Amatruda, R. McWilliams, S. Dakhil, D. Nikcevich, R. Morton, T. Fitch, A. Jaslowski, S. Markovic J. Clin. Oncol. vol 26 (May 20 suppl) abstr 9044 2008
Abstract Experimental
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

801 A randomized phase II trial of temozolomide (TMZ) and bevacizumab (BEV) or nab-paclitaxel (nab-P)/carboplatin (CBDCA) and bevacizumab (BEV) in patients with unresectable stage IV metastatic melanoma: A North Central Cancer Treatment Group Study (N0775)
L. Kottschade, V. Suman, D. Perez, R. McWilliams, J. Kaur, T. Amatruda, F. Geoffroy, H. Gross, T. Fitch, A. Jaslowski, M. Kosel, S. Markovic J. Clin. Oncol. vol 29 (suppl) abstr 8532 2011
Abstract Experimental <http://meetinglibrary.asco.org/content/77235-102>

802 The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial
Lisa A. Kottschade, Jeff A. Sloan, Mirosław A. Mazurczak, David B. Johnson, Bronagh P. Murphy, Kendrieth M. Rowland, DeAnne A. Smith, Alan R. Berg, Philip J. Stella, Charles L. Loprinzi Support Care Cancer vol 19 (11) 1769-1777 2011
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/20936417>

803 A randomized phase II study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: A North Central Cancer Treatment Group Study, N0775
Lisa A. Kottschade, Vera J. Suman, Domingo G. Perez, Robert R. McWilliams, Judith S. Kaur, Thomas T. Amatruda, Francois J. Geoffroy, Howard M. Gross, Peter A. Cohen, Anthony J. Jaslowski, Matthew L. Kosel, Svetomir N. Markovic Cancer vol 119 (3) 586-592 2013
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/22915053>

804 Nursing's presence in the changing cooperative group setting.
Lisa A Kottschade, Jennifer Bell, Kathy Klinger, Ellen M Lavoie Smith Semin Oncol Nurs vol 30 (1) 32-7 2014
Manuscript Onc Nursing <http://www.ncbi.nlm.nih.gov/pubmed/24559778>

805 A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma- A North Central Cancer Treatment Group Study, N057E1
Lisa A Kottschade, Vera J. Suman, Thomas Amatruda, Robert R. McWilliams, Bassam I. Mattar, Daniel A Nikcevich, Robert Behrens, Tom R Fitch, Anthony J Jaslowski, Svetomir N Markovic Cancer vol 117 (8) 2011
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/21472717>

806 A randomized phase II study of paclitaxel (P), carboplatin (C), bevacizumab (B) +/- everolimus (E) in metastatic melanoma (MM): secondary analysis of outcomes in patients who harbor an NRAS mutation NCCTG N0879 (Alliance).

Lisa Kottschade, Jacob Allred, K. Rumila, Svetomir Markovic, Matthew McWilliams Robert Block
2017

Abstract Experimental

<https://www.professionalabstracts.com/melanoma2017/programme-melanoma2017.pdf>

807 Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance)

Lisa Kottschade, Paul Novotny, Alan Lyss, Mirosław Mazurczak, Charles Loprinzi, Debra Barton
Support Care Cancer vol 24 (6) 2661-2667 2016

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/26768436>

808 Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001

G. Koval, M. Wetzler, D. Watson, K. Owzar, C. D. Bloomfield, G. Malnassy, D. A. Sher, R. A. Larson, W. Stock Blood vol 118 (21) 2541 2011

Abstract Leuk Corr Sci <http://www.bloodjournal.org/content/118/21/2541>

809 Tolerability of veliparib (V) in combination with carboplatin (C)/paclitaxel (P) - based chemoradiotherapy (CRT) in subjects with stage III non-small cell lung cancer (NSCLC).

David E. Kozono, Joseph Kamel Salama, Tom Stinchcombe, Jeffrey Bogart, William J. Petty, Michael J. Guarino, Lyudmila Bazhenova, James Mitchell Larner, Jared Weiss, Thomas A. DiPetrillo, Steven J. Feigenberg, Tu Xu, Beibei Hu, Silpa Nuthalapati, Lindsey Rosenwinkel, Lindsey Bensman, Eric Feral Johnson, Mark D. McKee, Everett E. Vokes J. Clin. Oncol. vol 35 (15 suppl) abstr 8546 2017

Abstract Respiratory http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.8546

810 Veliparib (Vel) in Combination with Chemoradiotherapy (CRT) of Carboplatin/Paclitaxel (C/P) Plus Radiation in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) (AFT-07).

David E. Kozono, Thomas Stinchcombe, Joseph K. Salama, Jeffery Bogart, William J. Petty, Michael J. Guarino, Lyudmila Bazhenova, James M. Larner, Jared Weiss, Thomas A. Di Petrillo, Steven J. Feigenberg, Beibei Hu, Silpa Nuthalapati, Yan Luo, Everett E. Vokes J. Clin. Oncol. vol 37 (15_suppl) 8510-8510 2019

Abstract Respiratory https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.8510

811 Does positron emission tomography prevent nontherapeutic pulmonary resections for clinical stage IA lung cancer?

Benjamin D Kozower, Bryan F Meyers, Carolyn E Reed, David R Jones, Paul A Decker, Joe B Putnam
Ann. Thorac. Surg. vol 85 (4) 1166-9; discussion 1169-70 2008

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18355490>

812 Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.

Robert A Kratzke, Xiaofei Wang, Long Wong, Marian G Kratzke, Mark R Green, Everett E Vokes, Nicholas J Vogelzang, Hedy L Kindler, Jeffrey A Kern J Thorac Oncol vol 3 (4) 417-21 2008

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18379362>

813 Inherited genetic variation in EPHA5, FGD4 and NRDG1 and paclitaxel (P) induced peripheral neuropathy (PN): Results from a genome-wide association study (GWAS) in CALGB 40101

D. L. Kroetz, R. Baldwin, K. Owzar, C. Jiang, H. Zembutsu, M. Kubo, C. A. Hudis, E. P. Winer, E.

Nakamura, L. N. Shulman, M. J. Ratain J. Clin. Oncol. vol 28 (15s) abstr 3021 2010
Abstract PPP C60202, CALGB-40101
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

814 Increasing Adherence to Adjuvant Hormone Therapy among Breast Cancer Patients: A Smart Phone App-Based Pilot Study

Jessica L. Krok-Schoen, Michelle J. Naughton, Gregory S. Young, Jennifer Moon, Electra D. Paskett, Douglas M. Post J Clin Oncol vol 36 (Suppl) abstr e12523 2018
Abstract Health Outcome <https://meetinglibrary.asco.org/record/163105/abstract>

815 Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab

Ian E. Krop, David Hillman, Mei Polley, Maki Tanioka, Joel S. Parker, Lucas Huebner, N. Lynn Henry, Sara Tolaney, Chau Dang, Lyndsay Harris, Donald A. Berry, Charles M. Perou, Ann Partridge, Lisa A. Carey Cancer Res vol 78 (4 Supplement) GS3-02 2018
Abstract Breast http://cancerres.aacrjournals.org/content/78/4_Supplement/GS3-02

816 RWDD3 and TECTA variants not linked to paclitaxel induced peripheral neuropathy in North American trial N08C1

Amit A. Kulkarni, Ganesh Boora, Rahul Kanwar, Kathryn J. Ruddy, Michaela S. Banck, Nguyet Le-Lindqwister, Terry M. Therneau, Charles L. Loprinzi, Andreas S. Beutler Acta Oncol vol 54 (8) 1227-1229 2015
Manuscript Symptom Inter N08C1, N08CA <http://www.ncbi.nlm.nih.gov/pubmed/25549536>

817 Randomized Phase II Study of Everolimus (E) versus Everolimus plus Bevacizumab (E+B) in Patients (Pts) with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET), CALGB 80701 (Alliance)

Matthew H. Kulke, Donna Niedzwiecki, Nathan R. Foster, Briant Fruth, Pamela L. Kunz, Hagen Kennecke, Edward M. Woli, Alan P. Venook Pancreas vol 45 (3) abstr C23 2016
Abstract GI https://www.nanets.net/nanets_cd/2015/Browse_NET_Abstracts.html

818 Randomized Phase II Study of Everolimus Alone (E) versus Everolimus plus Bevacizumab (E+B) in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors, CALGB 80701 (Alliance)

Matthew H. Kulke, Donna Niedzwiecki, Nathan R. Foster, Bryant Fruth, Pamela L. Kunz, Hagen Kennecke, Edward M. Wolin, Alan P. Venook J. Clin. Oncol. vol 33 (suppl) abstr 4005 2015
Abstract GI <http://meetinglibrary.asco.org/content/150169-156>

819 Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination With Cisplatin, Docetaxel, or Irinotecan in Patients With Metastatic Pancreatic Cancer: CALGB 89904

Matthew H. Kulke, Margaret A. Tempero, Donna Niedzwiecki, Donna R. Hollis, Hedy L. Kindler, Michael Cusnir, Peter C. Enzinger, Stefan M. Gorsch, Richard M. Goldberg, Robert J. Mayer J Clin Oncol vol 27 (33) 5506-5512 2009
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19858396>

820 Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51.

David M Kurtz, Loren K Tschetter, Jacob B Allred, Susan M Geyer, Paul J Kurtin, Wesley D Putnam, Kendrith M Rowland, Martin Wiesenfeld, Gamini S Soori, Richard C Tenglin, Albert M Bernath, Thomas E Witzig Leuk. Lymphoma vol 48 (7) 1290-8 2007
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/17613756>

- 821 FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group**
M. A. Kutny, B. K. Moser, K. Laumann, J. H. Feusner, A. Gamis, J. Gregory, R. A. Larson, B. L. Powell, W. Stock, C. L. Willman, W. G. Woods, S. Meshinchi *Pediatr Blood Cancer* vol 59 (4) 662-667 2012
Manuscript *Leuk Corr Sci* <http://www.ncbi.nlm.nih.gov/pubmed/22378655>
- 822 A Comparison of Outcomes between Adolescents and Young Adults (AYA) and Children with Acute Promyelocytic Leukemia: North American Intergroup Study CALGB 9710 (Alliance)**
Matthew A. Kutny, Susan Geyer, Kristina M Laumann, John Gregory, Cheryl L. Willman, Wendy Stock, Richard A. Larson, Bayard L. Powell, James H. Feusner *Blood* vol 124 (21) 2306 2014
Abstract *Leukemia* <http://www.bloodjournal.org/content/124/21/2306?sso-checked=true>
- 823 Outcome for Pediatric Acute Promyelocytic Leukemia Patients at Children's Oncology Group Sites on the Leukemia Intergroup Study CALGB 9710 (Alliance)**
Matthew A. Kutny, Susan Geyer, Kristina M Laumann, John Gregory, Cheryl L. Willman, Wendy Stock, Richard A. Larson, Bayard L. Powell, James H. Feusner *Pediatr Blood Cancer* vol 66 (3) e27542 2019
Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/30393935>
- 824 Effect of young Age on Outcomes in Pediatric Acute Promyelocytic Leukemia: North American Intergroup Study CALGB 9710 (Alliance)**
Matthew A. Kutny, John Gregory, Susan Geyer, Kristina Laumann, Cheryl L. Willman, Wendy Stock, Richard A. Larson, Bayard L. Powell, James H. Feusner *Blood* vol 124 (21) 2301 2014
Abstract *Leukemia* <http://www.bloodjournal.org/content/124/21/2301?sso-checked=true>
- 825 A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2 positive breast cancer**
L.A. Kutteh, T. J. Hobday, A. S. Jaffe, B. R. Laplant, D. W. Hillman, P. Kaufman, N. Davidson, S. Martino, A. Moreno, E. A. Perez *J. Clin. Oncol.* vol 25 (18s) abstr 579 2007
Abstract *Breast* http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/579
- 826 High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia**
Andrea Kühnl, Martin Kaiser, Martin Neumann, Lars Fransecky, Sandra Heesch, Michael Radmacher, Guido Marcucci, Clara D Bloomfield, Wolf-Karsten Hofmann, Eckhard Thiel, Claudia D Baldus *Leuk. Res.* vol 35 (12) 1585-1590 2011
Manuscript *Leuk Corr Sci* C9665, C20202, C9621, C8461
<http://www.ncbi.nlm.nih.gov/pubmed/21899885>
- 827 Phase I randomized phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM): Final results of phase I study**
N. N. Laack, E. Galanis, C. Leinweber, J. C. Buckner, C. Giannini, F. J. Geoffroy, K. A. Jaeckle, J. N. Sarkaria *J. Clin. Oncol.* vol 30 (15 suppl) abstr 2032 2012
Abstract *Neuro-Onc*
http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/2032?sid=2b49f5ee-cb83-4a46-8d0a-2505c
- 828 CHOD/BVAM Chemotherapy and Whole-Brain Radiotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma**
Nadia N. Laack, Brian Patrick O'Neill, Karla V. Ballman, Judith Rich O'Fallon, Xiomara W. Carrero, Paul J. Kurtin, Bernd W. Scheithauer, Paul D. Brown, Thomas M. Habermann, Joseph P. Colgan, Mark

R. Gilbert, Roland B. Hawkins, Roscoe F. Morton, Harry E. Windschitl, Tom R. Fitch, Eduardo R. Pajon *Int. J. Radiat. Oncol. Biol. Phys.* vol 81 (2) 476-482 2011
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/20800387>

829 Randomized Placebo-Controlled Phase II Study of Dasatinib with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma (GBM), N0877

Nadia Laack, Eva Galanis, S. Keith Anderson, Clinton Leinweber, Jan Buckner, Caterina Giannini, Francois Geoffroy, Derek R. Johnson, Glenn J. Lesser, Kurt Jaeckle, Jann Sarkaria *J. Clin. Oncol.* vol 33 (suppl) abstr 2013 2015
Abstract Neuro-Onc <http://meetinglibrary.asco.org/content/151649-156>

830 Utility of circulating biomarkers as outcome predictors in metastatic colorectal cancer and recurrent glioblastoma multiforme patients treated with bevacizumab/sorafenib

J. M. Lafky, S. K. Anderson, B. W. Morlan, G. D. Nelson, X. W. Carrero, S. Kumar, J. T. Reynolds, P. J. Stella, S. R. Dakhil, W. S. Loui, S. R. Alberts, P. J. Flynn, H. M. Gross, K. A. Jaeckle, J. C. Buckner, E. Galanis, A. Grothey *Cancer Res.* vol 72 (8) abstr 5562 2012
Abstract GI http://cancerres.aacrjournals.org/content/72/8_Supplement/5562.short

831 Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BEV) and sorafenib

J. M. Lafky, B. M. Bot, B. W. Morlan, S. K. Anderson, S. K. Kumar, T. K. Kimlinger, J. T. Reynolds, P. J. Stella, S. R. Dakhil, W. S. Loui, S. R. Alberts, A. Grothey *J. Clin. Oncol.* vol 29 (suppl) abstr e 14063 2011
Abstract GI <http://meetinglibrary.asco.org/content/83471-102>

832 Genetic variant associations with treatment outcome and safety in metastatic colorectal cancer patients treated with sorafenib and bevacizumab (BEV) as salvage therapy

J. Lafky, B. Bot, B. Morlan, A. Grothey *Proc Am Assoc Can Res* vol 71 (8 Suppl) 382, abstr nr 4131 2011
Abstract GI http://cancerres.aacrjournals.org/content/71/8_Supplement/4131.short

833 High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study.

Raymond Lai, Nancy L Bartlett, John R Mackey, Sin-Ho Jung, Jeffrey L Johnson, James R Cook, Dan Jones, Carol E Cass, James D Young, Jonathan Said, Bruce Cheson, Eric D Hsi *Leuk. Lymphoma* vol 49 (6) 1202-5 2008
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/18452103>

834 Utilization of receptor targeted technetium Tc 99m Tilmanocept (lymphoseek injection) to identify and evaluate the pathological status of sentinel lymph nodes vs. elective neck dissection in patients with intraoral squamous cell carcinoma: A preliminary performance evaluation against technetium Tc 99m sulfur colloid in the ACOSOG-Z0360 study

S. Y. Lai, A. Agrawal, F. J. Civantos *Ann. Surg. Oncol.* vol 20 (1 suppl) abstr P226-S108 2013
Abstract GI <http://link.springer.com/article/10.1245/s10434-013-2877-x>

835 Joint NABTC + NCCTG prognostic factors analysis for high grade recurrent glioma

K. Lamborn, W. Wu, M. Prados, K. Jaeckle, S. Chang, P. Novotny, J. Buckner *J. Clin. Oncol.* vol 25 (18S) abstr 2075 2007
Abstract Neuro-Onc
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

836 Differences in clinical trial patient attributes and outcomes according to trial enrollment setting:

Analyses from 10 CALGB lung cancer trials

E. B. Lamont, L. E. Archer, L. Lan, E. E. Vokes, B. J. Mcneil, N. L. Keating, M. Landrum J. Clin. Oncol. vol 26 (May 20 suppl) abstr 6517 2008

Abstract Disparities

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

837 Survival of clinical trial subjects vs elderly Medicare patients with extensive stage small cell lung cancer following treatment with cisplatin and etoposide

E. B. Lamont, Y. He, L. Lan, S. Joffe J Geriatr Oncol vol 2 (S u p p l e m e n t 1) S24 2011

Abstract Disparities

http://ac.els-cdn.com/S1879406811000683/1-s2.0-S1879406811000683-main.pdf?_tid=71e546da-26be-

838 Measuring clinically significant chemotherapy-related toxicities using Medicare claims from CALGB breast and lung cancer trial participants

E. B. Lamont, J. E. 2nd Herndon, J. C. Weeks, I. C. Henderson, R. C. Lilenbaum, R. L. Schilsky, N. A. Christakis J. Clin. Oncol. vol 25 (18s) abstr 6595 2007

Abstract Breast CALGB-70101, CALGB-9730, INT-0148

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&c

839 Sensitivity of Medicare Claims Data for Measuring Use of Standard Multiagent Chemotherapy Regimens

E. B. Lamont, L. Lan Med Care vol 52 (3) e15-20 2014

Manuscript Health Outcome CALGB-9344, CALGB-9730, CALGB-9235, CALGB-9732,

CALGB-80203, CALGB-89803 <http://www.ncbi.nlm.nih.gov/pubmed/22410411>

840 Measuring Clinically Significant Chemotherapy-Related Toxicities Using Medicare Claims From Cancer and Leukemia Group B (CALGB) Trial Participants

Elizabeth B. Lamont, James E. Herndon, Jane C. Weeks, I. Craig Henderson, Rogerio Lilenbaum,

Richard L. Schilsky, Nicholas A. Christakis Med Care vol 46 (3) 303-308 2008

Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/18388845>

841 Differences in Clinical Trial Patient Attributes and Outcomes According to Enrollment Setting

Elizabeth B. Lamont, Mary Beth Landrum, Nancy L. Keating, Laura Archer, Lan Lan, Gary M.

Strauss, Rogerio Lilenbaum, Harvey B. Niell, L. Herbert Maurer, Michael P. Kosty, Antonius A.

Miller, Gerald H. Clamon, Anthony D. Elias, Edward F. McClay, Everett E. Vokes, Barbara J. McNeil

J Clin Oncol vol 28 (2) 215-221 2010

Manuscript Disparities <http://www.ncbi.nlm.nih.gov/pubmed/19933919>

842 Generalizability of Trial Results to Elderly Medicare Patients with Advanced Solid Tumors (Alliance 70802)

Elizabeth B. Lamont, Richard L. Schilsky, Yulei He, Hyman Muss, Harvey Jay Cohen, Arti Hurria,

Ashley Meilleur, Hedy L. Kindler, Alan Venook, Rogerio Lilenbaum, Harvey Niell, Richard M.

Goldberg, Steven Joffe J. Natl. Cancer Inst vol 107 (1) 2014

Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/25432408>

843 Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802)

Elizabeth B. Lamont, Menggang Yu, Yulei He, Leonard Saltz, Hyman Muss, Alan M. Zaslavsky J

Geriatr Oncol vol 5 (3) 230-237 2014

Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/24594119>

844 Multicenter I-SPY 1 TRIAL (CALGB 150007/150012): Breast cancer stem cells are associated with intrinsic chemoresistance and worse survival

M. Landis, C. Yau, V. Neumeister, D. Rimm, L. Esserman, J. Chang *Cancer Res.* vol 72 (24 suppl) Abstract nr P2-10-06 2012
Abstract Correl Sci NOS CALGB-150007, CALGB-150012
http://cancerres.aacrjournals.org/cgi/content/short/72/24_MeetingAbstracts/P2-10-06?rss=1

- 845 Low Meningioma 1 (MN1) gene expression to predict outcome in cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study**
C. Langer, K. S. Maharry, K. A. Mrozek, P. Paschka, S. P. Whitman, J. E. Kolitz, R. A. Larson, G. Marcucci, C. D. Bloomfield *J. Clin. Oncol.* vol 26 (May 20 suppl) abstr 7011 2008
Abstract Leuk Corr Sci CALGB-19808, CALGB-20502, CALGB-9621
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID
- 846 High BAALC expression associates with other molecular prognostic markers, poor outcome and a distinct gene expression signature in cytogenetically normal acute myeloid leukemia (CN AML): A Cancer and Leukemia Group B (CALGB) study**
C. Langer, A. S. Ruppert, M. D. Radmacher, S. P. Whitman, P. Paschka, C. Baldus, K. A. Mrozek, J. E. Kolitz, G. Marcucci, C. D. Bloomfield *J. Clin. Oncol.* vol 25 (18s) abstr 7013 2007
Abstract Leuk Corr Sci CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID
- 847 Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study**
Christian Langer, Guido Marcucci, Kelsi B. Holland, Michael D. Radmacher, Kati Maharry, Peter Paschka, Susan P. Whitman, Krzysztof Mrózek, Claudia D. Baldus, Ravi Vij, Bayard L. Powell, Andrew J. Carroll, Jonathan E. Kolitz, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield *J Clin Oncol* vol 27 (19) 3198-3204 2009
Manuscript Leuk Corr Sci CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://www.ncbi.nlm.nih.gov/pubmed/19451432>
- 848 High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study**
Christian Langer, Michael D. Radmacher, Amy S. Ruppert, Susan P. Whitman, Peter Paschka, Krzysztof Mrózek, Claudia D. Baldus, Tamara Vukosavljevic, Chang-Gong Liu, Mary E. Ross, Bayard L. Powell, Albert de la Chapelle, Jonathan E. Kolitz, Richard A. Larson, Guido Marcucci, Clara D. Bloomfield *Blood* vol 111 (11) 5371-5379 2008
Manuscript Leuk Corr Sci CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://www.ncbi.nlm.nih.gov/pubmed/18378853>
- 849 Early relapse of follicular lymphoma after rituximab-based biologic doublet upfront therapy is associated with increased risk of death: a combined analysis from CALGB/Alliance Studies 50402, 50701 and 50803**
Frederick Lansigan, Ian Barak, Brandelyn Pitcher, Sin-Ho Jung, Bruce Cheson, Myron Czuczman, Barbara Grant, Peter Martin, Eric Hsi, Heiko Schroder, Nancy Bartlett, John P. Leonard, Kristie A. Blum *Blood* vol 128 (22) abstr 2953 2016
Abstract Lymphoma CALGB-50402, CALGB-50701, CALGB-50803
<http://www.bloodjournal.org/content/128/22/2953>
- 850 The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials**
Frederick Lansigan, Ian Barak, Brandelyn Pitcher, SinHo Jung, Bruce D. Cheson, Myron Czuczman,

Peter Martin, Eric Hsi, Heiko Schöder, Scott Smith, Nancy L. Bartlett, John P. Leonard, Kristie A. Blum *Cancer Med* vol 8 (1) 165-73 2018
Manuscript Lymphoma CALGB-50402, CALGB-50701, CALGB-50803
<http://www.ncbi.nlm.nih.gov/pubmed/30575311>

851 p53 Expression in Node Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B (CALGB) 9344 Trial (159905)

Jonathan F. Lara, Ann D. Thor, Lynn G. Dressler, Gloria Broadwater, Ira J. Bleiweiss, Susan Edgerton, David Cowan, Lori J. Goldstein, Silvana Martino, James N. Ingle, I. Craig Henderson, Larry Norton, Eric P. Winer, Clifford A. Hudis, Matthew J. Ellis, Donald A. Berry, Daniel F. Hayes *Clin Cancer Res* vol 17 (15) 5170-5178 2011
Manuscript Correl Sci NOS CALGB-9344, CALGB-159905
<http://www.ncbi.nlm.nih.gov/pubmed/21693655>

852 What Determines the Outcome for Adolescents and Young Adults With Acute Lymphoblastic Leukemia?

R. A. Larson, W. Stock *Ann Hematol* vol 87 (Suppl 1) S67-S69 2008
Abstract Leukemia C8811, C9331, CALGB-19802, CALGB-8461
<http://www.springerlink.com/content/u34p00527070m826/>

853 An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Richard A. Larson, Sumithra Mandrekar, Ben L Sanford, Kristine Laumann, Susan Geyer, Clara D. Bloomfield, Christian Thiede, T W Prior, Konstanze Dohner, Guido Marcucci, Francesco Lo-Coco, Rebecca B. Klisovic, Andrew Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, Theo de Witte, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S Tallman, Jurgen Krauter, *Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Hartmut Dohner, Richard M. Stone *Blood* vol 130 (Suppl 1) 145 2017
Abstract Leukemia http://www.bloodjournal.org/content/130/Suppl_1/145

854 Psychometric Testing of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization (CI-PeriNomS) and Alliance for Clinical Trials in Oncology (Alliance) A151408 Study Data

Ellen M. Lavoie Smith, Tanima Banerjee, James J. Yang, Celia M. Bridges, Paola Alberti, Jeff A. Sloan, Charles Loprinzi *Cancer Nurs* vol 42 (3) 179-89 2019
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/29649081>

855 Central review versus local review of axillary ultrasound prior to and after neoadjuvant chemotherapy: Results from the American College of Surgeons Oncology Group Z1071 trial (Alliance)

H. Carisa Le-Petross, Linda M. McCall, Kelly K. Hunt, Karla V. Ballman, Judy C. Boughey 2019
Abstract Breast

856 Role of axillary ultrasound after neoadjuvant chemotherapy in women with node-positive breast cancer (T1-4, N1-2, M0) at initial diagnosis (ACOSOG Z1071)

H. T. Le-Petross, L. Mccall, K. Hunt, E. A. Mittendorf, G. Ahrendt, L. Wilke, M. Leitch, B. Taback, J. C. Boughey *J. Clin. Oncol.* vol 30 (15 suppl) abstr 1107 2012
Abstract Breast
http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/1107?sid=09cfdcb8-739c-4acc-849e-43718

857 Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance)

Huong T. Le-Petross, Linda M. McCall, Kelly K. Hunt, Elizabeth A. Mittendorf, Gretchen M. Ahrendt, Lee G. Wilke, Karla V. Ballman, Judy C. Boughey AJR Am J Roentgenol vol 210 (3) 669-76 2018
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/29381381>

- 858 Comparison of results from three different density assessment methods on mammographic density (MD) in a screening patients receiving vitamin D (Vit D): Results of CALGB 70806 (Alliance)**
Huong T. Le-Petross, Drew K. Seisler, Despina Kontos, Sin-Ho Jung, Jayne Charlamb, James Marshall, Marie Wood 2018
Abstract Prevention <http://archive.rsna.org/2018/18004859.pdf>
- 859 Application of multi-state models in cancer clinical trials**
Jennifer G Le-Rademacher, Ryan A Peterson, Terry M Therneau, Ben L Sanford, Richard M Stone, Sumithra J Mandrekar Clin Trials vol 15 (5) 489-98 2018
Manuscript Leukemia CALGB-10603, A151732 <http://www.ncbi.nlm.nih.gov/pubmed/30035644>
- 860 Association Between Patient Perception of Oncology Clinical Trial Participation and Survival: NCCTG N0392 (Alliance)**
Jennifer Le-Rademacher, Dueck Amylou, Cynthia Chauhan, Daniel Satele, Jeff Sloan J. Clin. Oncol. vol 34 (suppl) abstr e18122 2016
Abstract Health Outcome <http://meetinglibrary.asco.org/content/168067-176>
- 861 Association Between Patient Perception of Oncology Clinical Trial Participation and Survival: NCCTG N0392 (Alliance)**
Jennifer Le-Rademacher, Amylou Dueck, Cynthia Chauhan, Daniel Satele, Jeff Sloan 2016
Abstract Health Outcome
<http://mascc2016.kenes.com/PublishingImages/scientific-information/abstract-journal/MASCC%202016>
- 862 Patient-Reported (EORTC QLQ-CIPN20) Versus Physician-Reported (CTCAE) Quantification of Oxaliplatin- and Paclitaxel/Carboplatin-Induced Peripheral Neuropathy in NCCTG/Alliance Clinical Trials**
Jennifer Le-Rademacher, Rahul Kanwar, Drew Seisler, Deirdre R. Pachman, Rui Qin, Alexej Abyzov, Kathryn J. Ruddy, Michaela S. Banck, Ellen M. Lavoie Smith, Susan G. Dorsey, Neil K. Aaronson, Jeff Sloan, Charles L. Loprinzi, Andreas S. Beutler Support Care Cancer vol 25 (11) 3537-44 2017
Manuscript Symptom Inter N08CA, N08CB <http://www.ncbi.nlm.nih.gov/pubmed/28634656>
- 863 NCCTG N08CA (Alliance): The use of Glutathione for Prevention of Paclitaxel/Carboplatin Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo-Controlled Study**
Alexis D. Leal, Rui Qin, Pamela J. Atherton, Paul Haluska, Robert J. Behrens, Charles Tiber, Patanit Watanaboonyakhet, Matthias Weiss, Paul T. Adams, Travis Dockter, Charles L. Loprinzi Cancer vol 120 (12) 1890-1897 2014
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/24619793>
- 864 Validation of DPYD variants DPYD*2A, I560S, and D949V as predictors of 5-fluorouracil (5-FU)-related toxicity in stage III colon cancer (CC) patients from adjuvant trial NCCTG N0147**
A. Lee, Q. Shi, E. Pavey, D. J. Sargent, S. R. Alberts, F. A. Sinicrope, J. Berenberg, R. Goldberg, R. B. Diasio J. Clin. Oncol. vol 31 (15 suppl) abstr 3510 2013
Abstract Correl Sci NOS
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/3510?sid=2f408d27-7862-4e30-bca6-bee5t
- 865 HapB3 and the deep intronic variant c.1129-5923 C>G of the dihydropyrimidine dehydrogenase gene (DPYD) as predictors of toxicity in Stage III colon cancer (CC) patients (pts) (NCCTG N0147) (Alliance)**
Adam M. Lee, Qian Shi, Steven R. Alberts, Daniel J. Sargent, Frank A. Sinicrope, Jeffrey L.

Berenberg, Richard M. Goldberg, Robert B. Diasio J. Clin. Oncol. vol 33 (3 suppl) 508 2015
Abstract Correl Sci NOS
http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/508?sid=32dbef88-d682-4247-8ef8-39e3a68

866 Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Adam M. Lee, Qian Shi, Steven R. Alberts, Daniel J. Sargent, Frank A. Sinicrope, Jeffrey L. Berenberg, Axel Grothey, Blase Polite, Emily Chan, Sharlene Gill, Morton S. Kahlenberg, Suresh G. Nair, Anthony F. Shields, Richard M. Goldberg, Robert B. Diasio Pharmacogenet. Genomics vol 26 (3) 133-137 2016
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/26658227>

867 DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147)

Adam M. Lee, Qian Shi, Emily Pavey, Steven R. Alberts, Daniel J. Sargent, Frank A. Sinicrope, Jeffrey L. Berenberg, Richard M. Goldberg, Robert B. Diasio J. Natl. Cancer Inst vol 106 (12) 2014
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/25381393>

868 Association of micropapillary architecture and high tumor budding with prognosis in patients with stage III colon cancer from a FOLFOX-based adjuvant chemotherapy trial: NCCTG N0147 (Alliance)

Hee Eun Lee, Qian Shi, Nate Foster, Emily Chan, Sharlene Gill, Monrton Kahlenberg, Suresh Nair, Anthony F Shields, Richard M Goldberg, Steven R. Alberts, Frank A. Sinicrope, Thomas C. Smyrk Mod Pathol vol 30 (S2) 181A 2017
Abstract Correl Sci NOS
<https://www.nature.com/modpathol/journal/v30/n2s/pdf/modpathol2016249a.pdf>

869 Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Head and Neck Radiotherapy With or Without Chemotherapy: A Phase III, Randomized, Double-Blind Trial (NCCTG-N09C6 [Alliance])

James L. Leenstra, Robert C. Miller, Rui Qin, James A. Martenson, Kenneth J. Dornfeld, James D. Bearden, Dev R. Puri, Philip J. Stella, Miroslaw A. Mazurczak, Marie D. Klish, Paul J. Novotny, Robert L. Foote, Charles L. Loprinzi J. Clin. Oncol vol 32 (15) 1571-1577 2014
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/24733799>

870 CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon

H. Lenz, D. Niedzwiecki, F. Innocenti, C. Blanke, M. Mahoney, B. O'Neil, J. Shaw, B. Polite, H. Hochster, J. Atkins, R. Goldberg, R. Mayer, R. Schilsky, M. Bertagnolli, A. Venook Ann. Oncol. vol 25 (suppl 4) 5010 2014
Abstract GI http://annonc.oxfordjournals.org/content/25/suppl_4/mdu438.13

871 Impact of Consensus Molecular Subtyping (CMS) on overall survival (OS) and Progression Free Survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).

Heinz-Josef Lenz, Fang-Shu Ou, Alan P. Venook, Howard S. Hochster, Donna Niedzwiecki, Richard Goldberg, Robert Mayer, Monica Bertagnolli, Charles David Blanke, Tyler Zemla, Xueping Qu, Omar Kabbarah, Federico Innocenti J. Clin. Oncol. vol 35 (15 suppl) abstr 3511 2017
Abstract Correl Sci NOS http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3511

872 Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).

Heinz-Josef Lenz, Fang-Shu Ou, Alan P Venook, Howard S Hochster, Donna Niedzwiecki, Richard M Goldberg, Robert J Mayer, Monica M Bertagnoli, Charles D Blanke, Tyler Zemla, Xueping Qu, Pratyaksha Wirapati, Sabine Tejpar, Federico Innocenti, Omar Kabbarah *J. Clin. Oncol.* vol 37 (22) 1876-1885 2019
Manuscript Correl Sci NOS CALGB-80405, A151425
<http://www.ncbi.nlm.nih.gov/pubmed/31042420>

873 A randomized, double-blind, placebo-controlled trial of testosterone (T) for aromatase inhibitor-induced arthralgias (AIA) in postmenopausal women: Alliance study A221102

Roberto A. Leon-Ferre, Paul Novotny, Shelby Terstriep, Rebecca Glaser, Debra L. Barton, Jennifer Le-Rademacher, Armando Giuliano, Sibel Blau, Cheryl Jones, Seth PageWilliam Mitchell, Stephen N. Birrell, Charles L. Loprinzi *Cancer Res* vol 79 (4 suppl) abstr P4-16-01 2019
Abstract Symptom Inter http://cancerres.aacrjournals.org/content/79/4_Supplement/P4-16-01

874 CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma.

J. Leonard, S.-H. Jung, J. L. Johnson, N. L. Bartlett, K. A. Blum, B. D. Cheson *J. Clin. Oncol.* vol 30 (15 suppl) abstr 80000 2012
Abstract Lymphoma <http://meetinglibrary.asco.org/content/93509-114>

875 Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)

John P. Leonard, Sin-Ho Jung, Jeffrey Johnson, Brandelyn N. Pitcher, Nancy L. Bartlett, Kristie A. Blum, Myron Czuczman, Jeffrey K. Giguere, Bruce D. Cheson *J. Clin. Oncol* vol 33 (31) 3635-3640 2015
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/26304886>

876 Alliance A051202: A Phase I Trial of Lenalidomide, Rituximab and GS-1101 (Idelalisib) in recurrent follicular lymphoma

John P. Leonard, Sin-ho Jung, Bruce D. Cheson *Hematol Oncol* vol 31 (51) 271-278 (abstr 563) 2013
Abstract Lymphoma <http://onlinelibrary.wiley.com/doi/10.1002/hon.2084/full>

877 A mentored cooperative group pilot study: atrophic vaginitis.

Joanne L Lester, Chandler Jarvis, Deborah Bartholomew, Lisa Yee *Semin Oncol Nurs* vol 30 (1) 53-60 2014
Manuscript Onc Nursing <http://www.ncbi.nlm.nih.gov/pubmed/24559781>

878 Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial

R. Lesurf, O. L. Griffith, M. Griffith, J. Hundal, L. Trani, M. A. Watson, R. Aft, M. J. Ellis, D. Ota, V. J. Suman, F. Meric-Bernstam, A. M. Leitch, J. C. Boughey, G. Unzeitig, A. U. Buzdar, K. K. Hunt, E. R. Mardis *Ann. Oncol* vol 28 (5) 1070-77 2017
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/28453704>

879 The genomics of response to neoadjuvant trastuzumab in HER2-positive breast cancer – results from the ACOSOG Z1041 (Alliance) trial

Robert Lesurf, Malachi Griffith, Obi Griffith, Mark A. Watson, Jeremy Hoog, Matthew J. Ellis, David Ota, Vera J. Suman, Funda Meric-Bernstam, A. Marilyn Leitch, Judy C. Boughey, Gary Unzeitig, Aman U. Buzdar, Kelly K. Hunt, Elaine R. Mardis *Cancer Res.* vol 76 (4 Suppl) PD6-02 2016
Abstract PPP http://cancerres.aacrjournals.org/content/76/4_Supplement/PD6-02.short

880 The genomics of response to neoadjuvant trastuzumab and chemotherapy in HER2-positive

breast cancer - results from the ACOSOG Z1041 (Alliance) trial

Robert Lesurf, Obi Griffith, Malachi Griffith, Lee Trani, Mark A. Watson, Matthew J. Ellis, David Ota, Vera J. Suman, Funda Meric-Bernstam, A. Marilyn Leitch, Judy C. Boughey, Gary Unzeitig, Aman U. Buzdar, Kelly K. Hunt, Elaine R. Mardis 2016

Abstract PPP

http://pccradiumhospital.org/content/text_8ef111f1-5736-4092-8487-6601340066bb/1456755424010/pc

881 The nurse liaison role in the cooperative group setting.

Sharon Levy, Kathy Klinger, Ilene Galinsky, Wanda DeKrey, Joanne Lester Semin Oncol Nurs vol 30 (1) 11-6 2014

Manuscript Onc Nursing <http://www.ncbi.nlm.nih.gov/pubmed/24559775>

882 The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance)

L. D. Lewis, A. A. Miller, K. Owzar, R. R. Bies, S. Markova, C. Jiang, D. L. Kroetz, M. J. Egorin, H. L. Mcleod, M. J. Ratain Pharmacogenet Genomics vol 23 (1) 29-33 2013

Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/23188068>

883 The pharmacokinetics and pharmacodynamics of docetaxel (DCTX) in caucasian and African American patients with solid tumors

L. D. Lewis, G. L. Rosner, A. A. Miller, M. J. Egorin, M. V. Relling, H. Kastrissios, R. Bies, M. J. Ratain J. Clin. Oncol. vol 22 (14s) abstr 2043 2004

Abstract PPP

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=26&abstractID

884 A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.

Lionel D Lewis, Antonius A Miller, Gary L Rosner, Jonathan E Dowell, Manuel Valdivieso, Mary V Relling, Merrill J Egorin, Robert R Bies, Donna R Hollis, Ellis G Levine, Gregory A Otterson, Frederick Millard, Mark J Ratain Clin. Cancer Res. vol 13 (11) 3302-11 2007

Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/17545536>

885 DNMT3A mutations in acute myeloid leukemia

T. J. Ley, L. Ding, M. J. Walter, M. D. Mclellan, T. Lamprecht, D. E. Larson, C. Kandoth, J. E. Payton, J. Baty, J. Welch, C. C. Harris, C. F. Lichti, R. R. Townsend, R. S. Fulton, D. J. Dooling, D. C. Koboldt, H. Schmidt, Q. Zhang, J. R. Osborne, L. Lin, M. O'Laughlin, J. F. McMichael, K. D.

Delehaunty, S. D. Mcgrath, L. A. Fulton, V. J. Magrini, T. L. Vickery, J. Hundal, L. L. Cook, J. J. Conyers, G. W. Swift, J. P. Reed, P. A. Alldredge, T. Wylie, J. Walker, J. Kalicki, M. A. Watson, S. Heath, W. D. Shannon, N. Varghese, R. Nagarajan, P. Westervelt, M. H. Tomasson, D. C. Link, T. A. Graubert, J. F. Dipersio, E. R. Mardis, R. K. Wilson N. Engl. J. Med. vol 363 (25) 2424-2433 2010

Manuscript Leuk Corr Sci C9665, C8461 <http://www.ncbi.nlm.nih.gov/pubmed/21067377>

886 DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

T. J. Ley, E. R. Mardis, L. Ding, B. Fulton, M. D. Mclellan, K. Chen, D. Dooling, B. H. Dunford-Shore, S. Mcgrath, M. Hickenbotham, L. Cook, R. Abbott, D. E. Larson, D. C. Koboldt, C. Pohl, S. Smith, A. Hawkins, S. Abbott, D. Locke, L. W. Hillier, T. Miner, L. Fulton, V. Magrini, T. Wylie, J. Glasscock, J. Conyers, N. Sander, X. Shi, J. R. Osborne, P. Minx, D. Gordon, A. Chinwalla, Y. Zhao, R. E. Ries, J. E. Payton, P. Westervelt, M. H. Tomasson, M. Watson, J. Baty, J. Ivanovich, S. Heath, W. D. Shannon, R. Nagarajan, M. J. Walter, D. C. Link, T. A. Graubert, J. F. Dipersio, R. K. Wilson Nature vol 456 (7218) 66-72 2008

Manuscript Leuk Corr Sci C9665, C8461 <http://www.ncbi.nlm.nih.gov/pubmed/18987736>

887 Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth

Kinetics Modeling

CH Li, RR Bies, Y Wang, MR Sharma, S Karovic, L Werk, MJ Edelman, AA Miller, EE Vokes, A Oto, MJ Ratain, LH Schwartz, ML Maitland Clin Transl Sci vol 9 (1) 43-50 2016
Manuscript PPP CALGB-30203, CALGB-30303, CALGB-9730
<http://www.ncbi.nlm.nih.gov/pubmed/26790562>

888 Identifying Risk Factors For Toxicity In Patients With Hormone-Receptor Positive Advanced Breast Cancer Treated With Bevacizumab Plus Letrozole: A CALGB 40503 (Alliance) Correlative Study

Daneng Li, Maura N. Dickler, Linda M. McCall, Olwen M Hahn, Clifford A. Hudis, Harvey J. Cohen, Hyman B. Muss, Karla V. Ballman, Eric P. Winer, Debu Tripathy, Bryan Schneider, Constance Cirrincione, William Barry, Arti Hurria J. Clin. Oncol. vol 34 (suppl) abstr 10047 2016
Abstract Older Adult <http://meetinglibrary.asco.org/content/168148-176>

889 Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) correlative study.

Daneng Li, Linda M. McCall, Olwen M Hahn, Clifford A. Hudis, Harvey J. Cohen, Hyman B. Muss, Aminah Jatoi, Jacqueline M. Lafky, Karla V. Ballman, Eric P. Winer, Debu Tripathy, Bryan Schneider, William Barry, Maura N. Dickler, Arti Hurria Breast Cancer Res. Treat. vol 171 (2) 325-34 2018
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/29789969>

890 RANK expression in primary tumor tissue at the time of diagnosis correlates with risk of subsequent bone metastases in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657)

J. Li, C. Yau, M. Campbell, J. W. Park, H. S. Rugo Cancer Res. vol 71 (24, suppl 3) abstr SABC11-P15-14-04 2011
Abstract Correl Sci NOS ACRIN-6657, CALGB-150007
http://cancerres.aacrjournals.org/content/71/24_Supplement/P5-14-04

891 Identification of a Genomic Region Between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)

Megan Li, Flora Mulkey, Chen Jiang, Bert H. O'Neil, Bryan P. Schneider, Fei Shen, Paula N. Friedman, Yukihide Momozawa, Michiaki Kubo, Donna Niedzwiecki, Howard S. Hochster, Heinz-Josef Lenz, James N. Atkins, Hope S. Rugo, Susan Halabi, William Kevin Kelly, Howard L. McLeod, Federico Innocenti, Mark J. Ratain, Alan P. Venook, Kouros Owzar, Deanna L. Kroetz Clin. Cancer Res. vol 24 (19) 4734-44 2018
Manuscript PPP CALGB-40502, CALGB-80405, CALGB-90401, E5103
<http://www.ncbi.nlm.nih.gov/pubmed/29871907>

892 Association of Variants with Bevacizumab-Induced Hypertension Identified by Exome Sequencing CALGB-80405 (Alliance)

Megan Li, Flora Mulkey, Chen Jiang, Alan P. Venook, Kouros Owzar, Deanna L. Kroetz 2016
Abstract GI
<http://www.ascp.org/Portals/8/docs/Meetings/2016%20Annual%20Meeting/Final%20Program.pdf>

893 Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL

Wen Li, Vignesh Arasu, David C. Newitt, Ella F. Jones, Lisa Wilmes, Jessica Gibbs, John Kornak, Bonnie N. Joe, Laura J. Esserman, Nola M. Hylton Tomography vol 2 (4) 378-387 2016
Manuscript Breast ACRIN 6657, CALGB-150007 <http://www.ncbi.nlm.nih.gov/pubmed/28066808>

894 Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML

Z. Li, H. Huang, Y. Li, X. Jiang, P. Chen, S. Arnovitz, M. D. Radmacher, K. Maharry, A. Elkahlon,

X. Yang, C. He, M. He, Z. Zhang, K. Dohner, M. B. Neilly, C. Price, Y. A. Lussier, Y. Zhang, R. A. Larson, M. M. Le Beau, M. A. Caligiuri, L. Bullinger, P. J. Valk, R. Delwel, B. Lowenberg, P. P. Liu, G. Marcucci, C. D. Bloomfield, J. D. Rowley, J. Chen *Blood* vol 119 (10) 2314-2324 2012
Manuscript *Leuk Corr Sci* <http://www.ncbi.nlm.nih.gov/pubmed/22251480>

895 Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia

Z. Li, H. Huang, Y. Li, X. Jiang, P. Chen, S. Arnovitz, M. D. Radmacher, K. Maharry, A. Elkahlon, X. Yang, C. He, C. O. Price, K. Dohner, Z. Zhang, C. Shen, M. B. Neilly, Y. A. Lussier, Y. Zhang, R. A. Larson, M. M. Le Beau, M. A. Caligiuri, L. Bullinger, P. Valk, R. Delwel, B. Lowenberg, P. P. Liu, G. Marcucci, C. D. Bloomfield, J. D. Rowley, J. Chen *ASH Annual Meeting Abstracts* vol 118 (21) 236 2011
Abstract *Leuk Corr Sci*
<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/236>

896 Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study

Zejuan Li, Tobias Herold, Chunjiang He, Peter J.M. Valk, Ping Chen, Vindi Jurinovic, Ulrich Mansmann, Michael D. Radmacher, Kati S. Maharry, Miao Sun, Xinan Yang, Hao Huang, Xi Jiang, Maria-Cristina Sauerland, Thomas Büchner, Wolfgang Hiddemann, Abdel Elkahlon, Mary Beth Neilly, Yanming Zhang, Richard A. Larson, Michelle M. Le Beau, Michael A. Caligiuri, Konstanze Döhner, Lars Bullinger, Paul P. Liu, Ruud Delwel, Guido Marcucci, Bob Lowenberg, Clara D. Bloomfield, Janet D. Rowley, Stefan K. Bohlander, Jianjun Chen *J. Clin. Oncol* vol 31 (9) 1172-1181 2013
Manuscript *Leukemia* CALGB-19808, CALGB-9222, CALGB-9621, CALGB-9710, CALGB-9720
<http://www.ncbi.nlm.nih.gov/pubmed/23382473>

897 Effect of renal function (RF) on outcomes in the adjuvant treatment of older women with breast cancer (>65 years): CALGB/CTSUS 49907 (CC) ancillary data study

S. M. Lichtman, C. Cirrincione, A. Hurria, A. Jatoi, M. Theodoulou, A. C. Wolff, J. Gralow, D. Morganstern, G. Magrinat, H. J. Cohen, H. B. Muss *J. Clin. Oncol.* vol 31 (15 suppl) abstr 9515 2013
Abstract *Older Adult* CALGB-49907, A171201
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/9515?sid=959c7a05-11ee-43ff-be27-1377e

898 Paclitaxel in older women with breast cancer. Combined analysis of CALGB 9342 and 9840 with a focus on age

S. M. Lichtman, A. Hurria, C. T. Cirrincione, A. D. Seidman, E. Winer, C. Hudis, H. J. Cohen, H. B. Muss *Cancer Res.* vol 69 (2 (supplement)) 6112 2009
Abstract *Older Adult* CALGB-360701, CALGB-9342, CALGB-9840
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6112

899 Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840

S. M. Lichtman, A. Hurria, C. T. Cirrincione, A. D. Seidman, E. Winer, C. Hudis, H. J. Cohen, H. B. Muss *Ann. Oncol* vol 23 (3) 632-638 2012
Manuscript *Breast* CALGB-9342, CALGB-9840 <http://www.ncbi.nlm.nih.gov/pubmed/21693770>

900 Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSUS 49907

Stuart M. Lichtman, Constance T. Cirrincione, Arti Hurria, Aminah Jatoi, Maria Theodoulou, Antonio C. Wolff, Julie Gralow, Daniel E. Morganstern, Gustav Magrinat, Harvey Jay Cohen, Hyman B. Muss

901 Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).

Stuart M Lichtman, Donna Hollis, Antonius A Miller, Gary L Rosner, Chris A Rhoades, Eric P Lester, Frederick Millard, John Byrd, Stephen A Cullinan, D Marc Rosen, Robert A Parise, Mark J Ratain, Merrill J Egorin J. Clin. Oncol. vol 24 (12) 1846-51 2006

Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/16567769>

902 Body mass index (BMI), tumor subtype, and relapse-free survival (RFS) in CALGB 9741 (Alliance)

J. A. Ligibel, C. Cirricione, M. Liu, M. Citron, J. Ingle, W. Gradishar, S. Martino, W. M. Sikov, R. A. Michaelson, C. Hudis, E. Winer, W. Barry J. Clin. Oncol. vol 31 (15 suppl) abstr 1032 2013

Abstract Disparities

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/1032?sid=c5d6e4ba-d61c-4dcd-ae36-d571

903 The Breast Cancer Weight Loss (BWEL) Trial: Randomized Phase III Trial Evaluating The Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer (Alliance A011401)

Jennifer A. Ligibel, William T. Barry, Catherine Alfano, Dawn L. Hershman, Melinda Irwin, Marian Neuhaus, Cynthia A. Thomson, Linda Delahanty, Elizabeth Frank, Patty Spears, Electra D. Paskett, Judith Hopkins, Vanessa Bernstein, Vered Stearns, Julia White, The BWEL Investigators Group, Thomas A. Wadden, Pamela J. Goodwin, Lisa A. Carey, Ann H. Partridge, Eric P. Winer J Clin Oncol vol 36 (Suppl) abstr TPS598 2018

Abstract Breast <https://meetinglibrary.asco.org/record/165229/abstract>

904 Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design

Jennifer A. Ligibel, William T. Barry, Catherine Alfano, Dawn L. Hershman, Melinda Irwin, Marian Neuhaus, Cynthia A. Thomson, Linda Delahanty, Elizabeth Frank, Patty Spears, Electra D. Paskett, Judith Hopkins, Vanessa Bernstein, Vered Stearns, Julia White, Olwen Hahn, Clifford Hudis, Eric P. Winer, Thomas A. Wadden, Pamela J. Goodwin NPJ Breast Cancer vol 3 37 2017

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/28948213>

905 Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)

Jennifer A. Ligibel, Constance T. Cirricione, Minetta Liu, Marc Citron, James N. Ingle, William Gradishar, Silvana Martino, William Sikov, Richard Michaelson, Elaine Mardis, Charles M. Perou, Matthew Ellis, Eric Winer, Clifford A. Hudis, Donald Berry, William T. Barry J. Natl. Cancer Inst vol 107 (9) 2015

Manuscript Breast C9741, CALGB-40902 <http://www.ncbi.nlm.nih.gov/pubmed/26113580>

906 Impact of a Telephone-Based Physical Activity Intervention upon Exercise Behaviors and Fitness in Cancer Survivors Enrolled in a Cooperative Group Setting

Jennifer A. Ligibel, Jeffrey Meyerhardt, John P. Pierce, Julie Najita, Laura Shockro, Nancy Campbell, Vicky A. Newman, Leslie Barbier, Eileen Hacker, Marie Wood, James Marshall, Electra Paskett, Charles Shapiro Breast Cancer Res. Treat. vol 132 (1) 205-13 2012

Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/22113257>

907 Physical Activity, Weight and Outcomes in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from CALGB 40502 (Alliance)

LJ Ligibel, JA Heubner, HS Rugo, H Burstein, DL Toppmeyer, CK Anders, C Ma, CA Hudis, EP

- 908 Phase II randomized trial of docetaxel plus cetuximab or bortezomib in patients with advanced NSCLC and performance status (PS) 2: CALGB 30402**
R. C. Lilenbaum, X. Wang, L. Gu, J. Kirshner, E. E. Vokes J. Clin. Oncol. vol 25 (18s) abstr 7595 2007
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID
- 909 A Phase II Study Of Induction Chemotherapy Followed By Thoracic Radiotherapy (TRT) And Erlotinib In Poor-risk Stage III Non-small Cell Lung Cancer (NSCLC): Initial Results Of CALGB 30605 And RTOG 0972**
R. Lilenbaum, M. Samuels, F. Kong, X. Wang, P. Janne, G. Masters, J. Bogart, J. Bradley, E. Vokes J Thorac Oncol vol 7 (15) abstract 153 2012
Abstract Respiratory <http://journals.lww.com/jto/Fulltext/2012/09004/Abstracts.5.aspx>
- 910 Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730).**
Rogerio C Lilenbaum, James E Herndon, Marcy A List, Chris Desch, Dorothy M Watson, Antonius A Miller, Stephen L Graziano, Michael C Perry, Wayne Saville, Philippe Chahinian, Jane C Weeks, Jimmie C Holland, Mark R Green J. Clin. Oncol. vol 23 (1) 190-6 2005
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/15625373>
- 911 A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor risk stage III non-small cell lung cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)**
Rogerio Lilenbaum, Michael Samuels, Xiaofei Wang, Feng Ming Kong, Pasi A. Jänne, Gregory Masters, Sreedhar Katragadda, Lydia Hodgson, Jeffrey Bogart, Jeffrey Bradley, Everett Vokes J Thorac Oncol vol 10 (1) 143-147 2015
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/25384173>
- 912 Randomized Phase II Trial of Docetaxel Plus Cetuximab or Docetaxel Plus Bortezomib in Patients With Advanced Non-Small-Cell Lung Cancer and a Performance Status of 2: CALGB 30402**
Rogerio Lilenbaum, Xiaofei Wang, Lin Gu, Jeffrey Kirshner, Keith Lerro, Everett Vokes J Clin Oncol vol 27 (27) 4487-4491 2009
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/19704058>
- 913 Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening**
C. Lin, D. Moore, A. Demichele, D. W. Ollila, L. L. Montgomery, M. C. Liu, H. Krontiras, R. Gomez, L. J. Esserman J. Clin. Oncol. vol 27 (15s) abstr 1503 2009
Abstract Correl Sci NOS
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID
- 914 Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial)**
Cheryl Lin, Meredith Becker Buxton, Dan Moore, Helen Krontiras, Lisa Carey, Angela DeMichele, Leslie Montgomery, Debasish Tripathy, Constance Lehman, Minetta Liu, Olufunmilayo Olapade, Christina Yau, Donald Berry, Laura J. Esserman Breast Cancer Res. Treat. vol 132 (3) 871-879 2012
Manuscript Breast CALGB-150007, CALGB-150012
<http://www.ncbi.nlm.nih.gov/pubmed/21796368>
- 915 Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and**

Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101

T. S. Lin, K. A. Donohue, J. C. Byrd, M. S. Lucas, E. Hoke, E. M. Bengtson, J. N. Atkins, B. K. Link, K. R. Rai, R. A. Larson *Blood* vol 114 (22) -210 2009
Abstract *Leukemia* <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;114/22/210>

916 Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101

T. S. Lin, K. A. Donohue, M. S. Lucas, J. C. Byrd, E. M. Bengtson, B. L. Peterson, R. A. Larson *Blood* vol 110 (11) 755 2007
Abstract *Leukemia* <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;110/11/755>

917 Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101

Thomas S. Lin, Kathleen A. Donohue, John C. Byrd, Margaret S. Lucas, Eva E. Hoke, Elizabeth M. Bengtson, Kanti R. Rai, James N. Atkins, Brian K. Link, Richard A. Larson *J Clin Oncol* vol 28 (29) 4500-4506 2010
Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/20697069>

918 Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia

Daniel C. Link, Ghada Kunter, Yumi Kasai, Yu Zhao, Tracie Miner, Michael D. McLellan, Rhonda E. Ries, Deepak Kapur, Rakesh Nagarajan, David C. Dale, Audrey Anna Bolyard, Laurence A. Boxer, Karl Welte, Cornelia Zeidler, Jean Donadieu, Christine Bellanné-Chantelot, James W. Vardiman, Michael A. Caligiuri, Clara D. Bloomfield, John F. DiPersio, Michael H. Tomasson, Timothy A. Graubert, Peter Westervelt, Mark Watson, William Shannon, Jack Baty, Elaine R. Mardis, Richard K. Wilson, Timothy J. Ley *Blood* vol 110 (5) 1648-1655 2007
Manuscript *Leuk Corr Sci CALGB-8461, CALGB-9665*
<http://www.ncbi.nlm.nih.gov/pubmed/17494858>

919 Auto-SCT for AML in second remission: CALGB study 9620.

C A Linker, K Owzar, B Powell, D Hurd, L E Damon, L E Archer, R A Larson *Bone Marrow Transplant.* vol 44 (6) 353-9 2009
Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/19289999>

920 Semi-quantitative protein analysis of HER2 and ER levels in human breast cancer reveals broad expression ranges within HER2+ and ER+ phenotypes

L. Liotta, M. Pierobon, J. Wulfkuhle, J. Laird, C. Livasy, V. Espina, L. J. Esserman, E. Petricoin *J. Clin. Oncol.* vol 27 (15s) abstr 11014 2009
Abstract *Correl Sci NOS* <http://meetinglibrary.asco.org/content/35157-65>

921 Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer

Esther H. Lips, Rita A. Mukhtar, Christina Yau, Jorma J. de Ronde, Chad Livasy, Lisa A. Carey, Claudette E. Loo, Marie-Jeanne T.F.D. Vrancken-Peeters, Gabe S. Sonke, Donald A. Berry, Laura J. van 't Veer, Laura J. Esserman, Jelle Wesseling, Sjoerd Rodenhuis, E. Shelley Hwang *Breast Cancer Res. Treat.* vol 136 (1) 35-43 2012
Manuscript *Correl Sci NOS* <http://www.ncbi.nlm.nih.gov/pubmed/22961065>

922 Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB

140203 multicenter phase II trial.

Michael J Liptay, Thomas A D'amico, Chumy Nwogu, Todd L Demmy, Xiaofei F Wang, Lin Gu, Virginia R Litle, Scott J Swanson, Leslie J Kohman J Thorac Oncol vol 4 (2) 198-202 2009
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/19179896>

923 Comparing and validating simple measures of patient-reported peripheral neuropathy (PRPN) for NCCTG Clinical Trials: A pooled analysis of 2,440 patients (pts)

H. Liu, A. D. Tan, A. Grothey, P. L. Schaefer, J. C. Buckner, C. L. Loprinzi, R. F. Morton, J. A. Sloan
J. Clin. Oncol. vol 26 (May 20 supplement) abstr 9534 2008
Abstract Symptom Inter
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

924 Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients

Heshan Liu, Angelina D. Tan, Rui Qin, Daniel J. Sargent, Axel Grothey, Jan C. Buckner, Paul L. Schaefer, Jeff A. Sloan SOJ Anesthesiol Pain Manag vol 2 (2) 2015
Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/26526218>

925 Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909

Hongtao Liu, Jeffrey L. Johnson, Greg Koval, Greg Malnassy, Dorie Sher, Lloyd E. Damon, Eric D. Hsi, Donna Marie Bucci, Charles A. Linker, Bruce D. Cheson, Wendy Stock Haematologica vol 97 (4) 579-585 2012
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/22102709>

926 PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy

M. Liu, B. Pitcher, E. Mardis, S. Davies, J. Snider, T. Vickery, J. Reed, K. Deschryver, B. Singh, P. Friedman, W. Gradishar, E. Perez, S. Martino, M. Citron, L. Norton, E. Winer, C. Hudis, C. Perou, M. Ellis, W. Barry Cancer Res. vol 72 (24 supplement) abstract P2-10-01 2012
Abstract Correl Sci NOS
http://cancerres.aacrjournals.org/content/72/24_Supplement/P2-10-01?cited-by=yes&legid=canres;72/24

927 Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTO (BIG 2-06, Alliance N063D) Trial

M.C. Liu, B. Rack, A.C. Dueck, D.W. Hillman, M.B. Campion, M.M. Reinholz, K.C. Halling, C. Sotiriou, F. Rothé, M. Maetens, G. Rouas, W. Janni, A.C. Wolff, L.N. Harris, J.R. Gralow, K.I. Pritchard, S. Ellard, N.A. Le-Lindqwister, F. Boyle, E. de Azambuja, M.J. Piccart-Gebhart, M. Ignatiadis, E.A. Perez Cancer Res. vol 75 (9_Supplement) abstr P4-01-01 2014
Abstract Breast http://cancerres.aacrjournals.org/content/75/9_Supplement/P4-01-01.short

928 Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel

Minetta C. Liu, George D. Demetri, Donald A. Berry, Larry Norton, Gloria Broadwater, Nicholas J. Robert, David Duggan, Daniel F. Hayes, I. Craig Henderson, Alan Lyss, Judith Hopkins, Peter A. Kaufman, P. Kelly Marcom, Jerry Younger, Nancy Lin, Katherine Tkaczuk, Eric P. Winer, Clifford A. Hudis Cancer Treat Rev vol 34 (3) 223-230 2008
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/18234424>

929 PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)

Minetta C Liu, Brandelyn N Pitcher, Elaine R Mardis, Sherri R Davies, Paula N Friedman, Jacqueline

E Snider, Tammi L Vickery, Jerry P Reed, Katherine DeSchryver, Baljit Singh, William J Gradishar, Edith A Perez, Silvana Martino, Marc L Citron, Larry Norton, Eric P Winer, Clifford A Hudis, Lisa A Carey, Philip S Bernard, Torsten O Nielsen, Charles M Perou, Matthew J Ellis, William T Barry NPJ Breast Cancer vol 2 15023- 2016
Manuscript Correl Sci NOS C9741, CALGB-159905
<http://www.ncbi.nlm.nih.gov/pubmed/28691057>

- 930 Sp1/NFB/HDAC/miR-29b Regulatory Network in KIT-driven Myeloid Leukemia**
Shujun Liu, Lai-Chu Wu, Jiuxia Pang, Ramasamy Santhanam, Sebastian Schwind, Yue-Zhong Wu, Christopher Hickey, Jianhua Yu, Heiko Becker, Kati Maharry, Michael D Radmacher, Chenglong Li, Susan P. Whitman, Anjali Mishra, Nicole Stauffer, Anna M. Eiring, Roger Briesewitz, Robert A. Baiocchi, Kenneth K. Chan, Peter Paschka, Michael A. Caligiuri, John C. Byrd, Carlo M Croce, Clara D. Bloomfield, Danilo Perrotti, Ramiro Garzon, Guido Marcucci Cancer Cell vol 17 (4) 333-347 2010
Manuscript Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pubmed/20385359>
- 931 Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.**
Ting Xi Liu, Michael W Becker, Jaroslav Jelinek, Wen-Shu Wu, Min Deng, Natallia Mikhalkovich, Karl Hsu, Clara D Bloomfield, Richard M Stone, Daniel J DeAngelo, Ilene A Galinsky, Jean-Pierre Issa, Michael F Clarke, A Thomas Look Nat. Med. vol 13 (1) 78-83 2007
Manuscript Leuk Corr Sci CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/17159988>
- 932 Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab**
Y. Liu, M. D. Starr, A. Bulusu, H. Pang, N. S. Wong, W. Honeycutt, A. Amara, H. I. Hurwitz, A. B. Nixon Cancer Med vol 2 (2) 234-242 2013
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/23634291>
- 933 Validation of Single-Item Linear Analog Scale Assessment of Quality of Life in Neuro-Oncology Patients**
Dona E.C. Locke, Paul A. Decker, Jeff A. Sloan, Paul D. Brown, James F. Malec, Matthew M. Clark, Teresa A. Rummans, Karla V. Ballman, Paul L. Schaefer, Jan C. Buckner J Pain Symptom Manage vol 34 (6) 628-638 2007
Manuscript Neuro-Onc N0074, NCCTG-98-72-51, NCCTG-98-72-52
<http://www.ncbi.nlm.nih.gov/pubmed/17703910>
- 934 Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051).**
A C Lockhart, C E Reed, P A Decker, B F Meyers, M K Ferguson, A R Oeltjen, J B Putnam, S D Cassivi, A J Montero, T E Schefter Ann. Oncol. vol 25 (5) 1039-44 2014
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24562448>
- 935 Preoperative exercise VO2 measurement for lung resection candidates: results of Cancer and Leukemia Group B Protocol 9238.**
Gregory M Loewen, Dorothy Watson, Leslie Kohman, James E Herndon, Hani Shennib, Kemp Kernstine, Jemi Olak, M Jeffery Mador, David Harpole, David Sugarbaker, Mark Green J Thorac Oncol vol 2 (7) 619-25 2007
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/17607117>
- 936 A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal**

dryness: NCCTG study N04CA

C. L. Loprinzi, E. P. Balcueva, H. Liu, L. A. Kottschade, P. J. Stella, M. D. Carlson, D. F. Jr Moore, R. Zon, R. Levitt, J. A. Sloan J. Clin. Oncol. vol 28 (15s) abstr 9024 2010

Abstract Symptom Inter

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

937 A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: North Central Cancer Treatment group study N04CA

C. L. Loprinzi, E. P. Balcueva, H. Liu, J. A. Sloan, L. A. Kottschade, P. J. Stella, M. D. Carlson, D. F. Jr Moore, R. T. Zon, R. Levitt, A. J. Jaslawski J Support Oncol vol 9 (3) 105-112 2011

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/21702402>

938 Gabapentin for hot flashes in men: NCCTG trial N00CB

C. L. Loprinzi, B. S. Khoiratty, A. Dueck, D. L. Barton, S. Jafar, K. M. Rowland Jr, P. J. Atherton, G. W. Marsa, J. Krook, L. Kottschade J. Clin. Oncol. vol 25 (June 20 Supplement) abstr 9005 2007

Abstract Symptom Inter

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

939 Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An Alliance for Clinical Trials in Oncology study

C. L. Loprinzi, R. Qin, S. R. Dakhil, L. Fehrenbacher, P. J. Stella, P. Atherton, D. Seisler, R. Qamar, G. C. Lewis, A. Grothey J. Clin. Oncol. vol 31 (15 suppl) abstr 3501 2013

Abstract Symptom Inter

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/3501?sid=afb15112-3f62-4e22-9fb1-e2c23

940 Pregabalin for hot flashes in women: NCCTG trial N07C1

C. L. Loprinzi, R. Qin, P. J. Stella, K. M. Rowland Jr, D. L. Graham, N. Erwin, S. R. Dakhil, D. J. Jurgens, K. N. Burger J. Clin. Oncol. vol 27 (15s) abstr 9513 2009

Abstract Symptom Inter

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

941 Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1

C. L. Loprinzi, B. N. Reeves, S. R. Dakhil, J. A. Sloan, S. L. Wolf, K. N. Burger, A. Kamal, N. A. Le-Lindqwister, G. S. Soori, A. J. Jaslawski, P. J. Novotny, D. H. Lachance J. Clin. Oncol. vol 29 (11) 1472-1478 2011

Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/21383290>

942 Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes, N07C1

Charles L. Loprinzi, Rui Qin, Ernie P. Baclueva, Kathleen A. Flynn, Kendrith M. Rowland, David L. Graham, Nancy K. Erwin, Shaker R. Dakhil, Donald J. Jurgens, Kelli N. Burger J Clin Oncol vol 28 (4) 641-647 2010

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/19901102>

943 Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance)

Charles L. Loprinzi, Rui Qin, Shaker R. Dakhil, Louis Fehrenbacher, Kathleen A. Flynn, Pamela Atherton, Drew Seisler, Rubina Qamar, Grant C. Lewis, Axel Grothey J. Clin. Oncol vol 32 (10) 997-1005 2014

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/24297951>

944 Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5.

Charles L Loprinzi, John W Kugler, Debra L Barton, Amylou C Dueck, Loren K Tschetter, Robert A Nelimark, Ernie Porteza Balcueva, Kelli N Burger, Paul J Novotny, Mark D Carlson, Steven Fletcher Duane, Steven W Corso, David B Johnson, Anthony J Jaslowski J. Clin. Oncol. vol 25 (3) 308-12 2007

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/17146104>

945 The genetic landscape of mutations in Burkitt lymphoma

Cassandra Love, Zhen Sun, Dereje Jima, Guojie Li, Jenny Zhang, Rodney Miles, Kristy L Richards, Cherie H Dunphy, William W L Choi, Gopesh Srivastava, Patricia L Lugar, David A Rizzieri, Anand S Lagoo, Leon Bernal-Mizrachi, Karen P Mann, Christopher R Flowers, Kikkeri N Naresh, Andrew M Evens, Amy Chadburn, Leo I Gordon, Magdalena B Czader, Javed I Gill, Eric D Hsi, Adrienne Greenough, Andrea B Moffitt, Matthew McKinney, Anjishnu Banerjee, Vladimir Grubor, Shawn Levy, David B Dunson, Sandeep S Dave Nat. Genet. vol 44 (12) 1321-1325 2012

Manuscript Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pubmed/23143597>

946 Quantitative Measurement of CD52 Expression and Alemtuzumab Binding in Adult Acute Lymphoblastic Leukemia (ALL): Correlation with Immunophenotype and Cytogenetics in Patients (Pts) Enrolled on a Phase I/II Trial from the Cancer and Leukemia Group B (CALGB 10102)

G. Lozanski, B. Sanford, K. Mrozek, C. Edwards, R. Pearson, C. D. Bloomfield, R. A. Larson, W. Stock Blood vol 110 (11) 2386 2007

Abstract Leuk Corr Sci CALGB-10102, CALGB-8461, CALGB-9665, CALGB-9862

<http://www.bloodjournal.org/content/110/11/2386?sso-checked=true>

947 Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study

Gerard Lozanski, Amy S. Ruppert, Nyla A. Heerema, Arletta Lozanski, David M. Lucas, Amber Gordon, John G. Gribben, Vicki A. Morrison, Kanti M. Rai, Guido Marcucci, Richard A. Larson, John C. Byrd Leuk. Lymphoma vol 53 (9) 1743-1748 2012

Manuscript Leuk Corr Sci CALGB-9712, CALGB-9665

<http://www.ncbi.nlm.nih.gov/pubmed/22369572>

948 Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.

Anthony Lucci, Linda Mackie McCall, Peter D Beitsch, Patrick W Whitworth, Douglas S Reintgen, Peter W Blumencranz, A Marilyn Leitch, Sukumal Saha, Kelly K Hunt, Armando E Giuliano J. Clin. Oncol. vol 25 (24) 3657-63 2007

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/17485711>

949 Randomized phase II study comparing the met inhibitor cabozantinib to temozolomide (tmz) or dacarbazine (dtic) in ocular melanoma - A091201

Jason J. Luke, Jacob B. Allred, Laura E. Horvath, Bruno R. Bastos, Charles Erlichman, Gary K. Schwartz J. Clin. Oncol. vol 33 (suppl) abstr TPS9087 2015

Abstract Experimental <http://meetinglibrary.asco.org/content/149141-156>

950 A randomized phase ii study of anti-PD-1 antibody [MK-3475 (pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance A091605)

Jason Luke, Steven Chmura, Joseph Salama, Hania Al-Hallaq, Charles Hsu, Sue Yom, Mark Kozloff, Jacob Allred, Pamela Munster, Gary Schwartz J Clin Oncol vol 36 (15_suppl) TPS9599-TPS9599

2018

Abstract Experimental

951 An mRNA Gene Expression–Based Signature to Identify FGFR1-Amplified Estrogen Receptor–Positive Breast Tumors

Jingqin Luo, Shuzhen Liu, Samuel Leung, Alejandro A. Gru, Yu Tao, Jeremy Hoog, Julie Ho, Sherri R. Davies, D. Craig Allred, Andrea L. Salavaggione, Jacqueline Snider, Elaine R. Mardis, Torsten O. Nielsen, Matthew J. Ellis *J Mol Diagn* vol 19 (1) 147-161 2017

Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/27993329>

952 Prevention of aromatase Inhibitor (AI)-induced joint symptoms with omega-3 fatty acid supplementation: A randomized placebo-controlled pilot study

M.B. Lustberg, T. Orchard, X. Pan, R. Reinbolt, A. Logan, J. Lester, R.M. Layman, E. Macrae, E. Mrozek, B. Ramaswamy, R. Wesolowski, M. Berger, M. Knopp, C. Loprinzi, C.L. Shapiro, L. Yee *Cancer Res* vol 75 (suppl 9) abstr P1-09-03 2015

Abstract Symptom Inter http://cancerres.aacrjournals.org/content/75/9_Supplement/P1-09-03

953 Randomized Placebo-Controlled Pilot Trial of Omega 3 Fatty Acids for Prevention of Aromatase Inhibitor-Induced Musculoskeletal Pain

Maryam B Lustberg, Tonya S. Orchard, Raquel Reinbolt, Rebecca Andridge, Xueliang Pan, Martha Belury, Rachel Cole, Amanda Logan, Rachel Layman, Bhuvanewari Ramaswamy, Robert Wesolowski, Michael Berger, Elaine Patterson, Charles Loprinzi, Charles L. Shapiro, Lisa Yee *Breast Cancer Res. Treat.* vol 167 (3) 709-18 2018

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/29101597>

954 Alliance A011106: ALternate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study

Cynthia X. Ma, Vera Suman, A. Marilyn Leitch, Souzan Sanati, Katherine DeSchryver, Gary W. Unzeitig, Paul Haluska, Mark Watson, Olwen Hahn, Jo Anne Zujewski, Kelly Hunt, Eric P. Winer, Clifford A. Hudis, Matthew J. Ellis *Cancer Res.* vol 75 (9 Supplement) abstr OT2-1-04 2015

Abstract Breast http://cancerres.aacrjournals.org/content/75/9_Supplement/OT2-1-04.short

955 NCCTG N057K phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: A North Central Cancer Treatment Group trial.

D. Ma, E. Galanis, D. Schiff, W. Wu, P. J. Peller, C. Giannini, P. D. Brown, J. H. Uhm, S. McGraw, K. A. Jaeckle, P. J. Flynn, J. C. Buckner, J. N. Sarkaria *J. Clin. Oncol.* vol 30 (15 suppl) abstr 2031 2012

Abstract Neuro-Onc <http://meetinglibrary.asco.org/content/100091-114>

956 A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K

Daniel J. Ma, Evanthia Galanis, S. Keith Anderson, David Schiff, Timothy J. Kaufmann, Patrick J. Peller, Caterina Giannini, Paul D. Brown, Joon H. Uhm, Steven McGraw, Kurt A. Jaeckle, Patrick J. Flynn, Keith L. Ligon, Jan C. Buckner, Jann N. Sarkaria *Neuro-oncology* vol 17 (9) 1261-1269 2015

Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/25526733>

957 Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.

Xiaoli Ma, Gwénaél Le Teuff, Benjamin Lacas, Ming Sound Tsao, Stephen Graziano, Jean-Pierre Pignon, Jean-Yves Douillard, Thierry Le Chevalier, Lesley Seymour, Martin Filipits, Robert Pirker, Pasi A Jänne, Frances A Shepherd, Elisabeth Brambilla, Jean-Charles Soria, Pierre Hainaut *J Thorac Oncol* vol 11 (6) 850-61 2016

Manuscript Respiratory CALGB-150802, CALGB-9633

<http://www.ncbi.nlm.nih.gov/pubmed/26899019>

958 Genome-wide copy number analysis of circulating tumor cells from patients (pts) with metastatic breast cancer (MBC)

M. M. Magbanua, E. V. Sosa, L. E. Eisenbud, J. Scott, A. Olshen, D. Pinkel, H. S. Rugo, J. W. Park J. Clin. Oncol. vol 29 (suppl 27) abstr 9 2011
Abstract PPP
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=111&abstractID

959 Trajectory patterns of circulating tumor cells (CTC) in chemotherapy-treated metastatic breast cancer (MBC) patients predict poor clinical outcomes: CALGB 40502 / NCCTG N063H (Alliance)

Mark Jesus M. Magbanua, Laura Hendrix, Terry Hyslop, William Barry, Eric P. Winer, Clifford Hudis, Deborah Toppmeyer, Harold Burstein, Misbah Qadir, Cynthia Ma, Janet H. Scott, John W. Park, Hope S. Rugo Cancer Res vol 78 (4 Supplement) P2-01-01 2017
Abstract Correl Sci NOS CALGB-40502, NCCTG-N063H
http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-01-01

960 Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time (CALGB 40502 and CALGB 40503, Alliance)

Mark Jesus M. Magbanua, Hope S. Rugo, Denise M. Wolf, Louai Hauranieh, Ritu Roy, Praveen Pendyala, Eduardo V. Sosa, Janet H. Scott, Jin Sun Lee, Brandelyn Pitcher, Terry Hyslop, William T. Barry, Steven J. Isakoff, Maura Dickler, Laura van't Veer, John W. Park Clin. Cancer Res. vol 24 (6) 1486-1499 2018
Manuscript Correl Sci NOS CALGB-40502, CALGB-40503
<http://www.ncbi.nlm.nih.gov/pubmed/29311117>

961 Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients

Mark Jesus M. Magbanua, Eduardo V. Sosa, Ritu Roy, Lauren E. Eisenbud, Janet H. Scott, Adam Olshen, Dan Pinkel, Hope Rugo, John W. Park Cancer Res. vol 73 (1) 30-40 2013
Manuscript PPP CALGB-40502, CALGB-40503 <http://www.ncbi.nlm.nih.gov/pubmed/23135909>

962 Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response

Mark Jesus M. Magbanua, Denise M. Wolf, Christina Yau, Sarah E. Davis, Julia Crothers, Alfred Au, Christopher M. Haqq, Chad Livasy, Hope S. Rugo, Laura Esserman, John W. Park, Laura J. van 't Veer Breast Cancer Res vol 17 (1) 2015
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/26021444>

963 Endpoints for validation of tumor markers for recurrence risk: Recurrence-free interval (RFI), disease-free survival (DFS), overall survival (OS), and colon-cancer specific survival (CCSS) in CALGB 9581

N. N. Mahmoud, M. Lopatin, M. Lee, K. Clark-Langone, D. Niedzwiecki, A. P. Venook Eur. J. Cancer vol 47 (Suppl 1) S172 2011
Abstract GI
<http://www.ejcaancer.info/article/abstracts?terms1=CALGB+9581&terms2=&terms3=&terms4=>

964 Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples

D. W. Mahoney, T. M. Therneau, S. K. Anderson, J. Jen, J. P. Kocher, M. M. Reinholz, E. A. Perez, J. E. Eckel-Passow BMC Res Notes vol 6 33 2013
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/23360712>

965 Quality of life (QOL) for patients treated with FOLFOX+/-cetuximab (Cmab) following

complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) Phase III Trial N0147

M. R. Mahoney, J. A. Sloan, J. M. Hubbard, H. Liu, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, S. G. Nair, D. J. Sargent, S. R. Alberts J. Clin. Oncol. vol 29 (suppl) abstr 3541 2011

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

966 Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance)

Brittney T. Major-Elechi, Paul J. Novotny, Jasvinder A. Singh, James A. Bonner, Amylou C. Dueck, Daniel J. Sargent, Axel Grothey, Jeff A. Sloan Int J Stat Med Res vol 7 (4) 137-46 2018

Manuscript Health Outcome NCCTG-89-20-52 <http://www.ncbi.nlm.nih.gov/pubmed/31396297>

967 Comparison Of Deep Sequencing and Allele-Specific Oligonucleotide PCR Methods For MRD Quantitation In Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma: CALGB 10403 and CALGB 59909 (Alliance)

Greg Malnassy, Susan Geyer, Noreen Fulton, Greg Koval, Donna Niedzwiecki, Victoria Carlton, Li Weng, Lawrence D. Kaplan, Guido Marcucci, Lloyd E. Damon, Richard A. Larson, Richard M. Stone, Bruce D. Cheson, Malek Faham, Wendy Stock Blood vol 122 (21) 2547 2013

Abstract Leuk Corr Sci CALGB-10403, CALGB-59909

<http://bloodjournal.hematologylibrary.org/content/122/21/2547.abstract?sid=ae1b6fda-d137-4533-b41c-c>

968 Preliminary Analysis of Cancer and Leukemia Group B (CALGB) 80003: A Phase II Trial of Gemcitabine, 5-Fluorouracil (5FU), and Radiation Therapy (RT) in Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma

H. J. Mamon, D. Niedzwiecki, D. R. Hollis, B. Tan, J. Smith, A. W. Blackstock, J. E. Tepper, R. M. Goldberg, R. J. Mayer, C. S. Fuchs Int. J. Radiat. Oncol. Biol. Phys. vol 63 (S13) 0360-3016 2005

Abstract GI <http://linkinghub.elsevier.com/retrieve/pii/S0360301605011958?showall=true>

969 A Phase II Trial of Gemcitabine, 5-Fluorouracil, and Radiation Therapy in Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma: Cancer and Leukemia Group B (CALGB) 80003

Harvey J. Mamon, Donna Niedzwiecki, Donna Hollis, Benjamin R. Tan, Robert J. Mayer, Joel E. Tepper, Richard M. Goldberg, A. William Blackstock, Charles S. Fuchs Cancer vol 117 (12) 2620-2628 2011

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21656739>

970 Patient and physician decision styles and breast cancer chemotherapy use in older women: Cancer and Leukemia Group B protocol 369901

J. S. Mandelblatt, L. A. Faul, G. Luta, S. B. Makgoeng, C. Isaacs, K. Taylor, V. B. Sheppard, M. Tallarico, W. T. Barry, H. J. Cohen J. Clin. Oncol. vol 30 (21) 2609-2614 2012

Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/22614985>

971 Patient preference as a determinant of breast cancer adjuvant chemotherapy use in older women: CALGB 369901

J. Mandelblatt, V. Sheppard, A. Hurria, G. G. Kimmick, C. Isaacs, K. Taylor, G. Luta, A. Noone, A. B. Kornblith, W. T. Barry J. Clin. Oncol. vol 27 (15s) abstr 9544 2009

Abstract Older Adult

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

972 Frailty and Long-term Mortality Of Older Breast Cancer Patients: CALGB 369901 (Alliance)

Jeanne S. Mandelblatt, Ling Cai, George Luta, Gretchen Kimmick, Jonathan Clapp, Claudine Isaacs, Brandeyln Pitcher, William Barry, Eric Winer, Stephen Sugarman, Clifford Hudis, Hyman Muss, Harvey J. Cohen, Arti Hurria Breast Cancer Res. Treat. vol 164 (1) 107-117 2017

973 Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance)

Jeanne S. Mandelblatt, Jonathan D. Clapp, Gheorghe Luta, Leigh Anne Faul, Michelle D. Tallarico, Trina D. McClendon, Jessica A. Whitley, Ling Cai, Tim A. Ahles, Robert A. Stern, Paul B. Jacobsen, Brent J. Small, Brandelyn N. Pitcher, Estrella Dura-Fernandis, Hyman B. Muss, Arti Hurria, Harvey J. Cohen, Claudine Isaacs *Cancer* 2016

Abstract Older Adult <http://onlinelibrary.wiley.com/doi/10.1002/cncr.30208/pdf>

974 Longterm trajectories of selfreported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance)

Jeanne S. Mandelblatt, Jonathan D. Clapp, Gheorghe Luta, Leigh Anne Faul, Michelle D. Tallarico, Trina D. McClendon, Jessica A. Whitley, Ling Cai, Tim A. Ahles, Robert A. Stern, Paul B. Jacobsen, Brent J. Small, Brandelyn N. Pitcher, Estrella DuraFernandis, Hyman B. Muss, Arti Hurria, Harvey J. Cohen, Claudine Isaacs *Cancer* vol 122 (22) 3555-63 2016

Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/27447359>

975 A planned, prospective comparison of short-term quality of life outcomes among older breast cancer patients treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB 49907 and 369901

Jeanne S. Mandelblatt, Solomon B. Makgoeng, Gheorghe Luta, Arti Hurria, Gretchen Kimmick, Claudine Isaacs, Michelle Tallarico, William T. Barry, Brandy Pitcher, Eric P. Winer, Clifford Hudis, Harvey J. Cohen, Hyman B. Muss *J Geriatr Oncol* vol 4 (4) 353-361 2013

Manuscript Older Adult CALGB-49907, CALGB-369901

<http://www.ncbi.nlm.nih.gov/pubmed/24472479>

976 Breast Cancer Adjuvant Chemotherapy Decisions in Older Women: The Role of Patient Preference and Interactions With Physicians

Jeanne S. Mandelblatt, Vanessa B. Sheppard, Arti Hurria, Gretchen Kimmick, Claudine Isaacs, Kathryn L. Taylor, Alice B. Kornblith, Anne-Michelle Noone, Gheorghe Luta, Michelle Tallarico, William T. Barry, Lisa Hunegs, Robin Zon, Michael Naughton, Eric Winer, Clifford Hudis, Stephen B. Edge, Harvey Jay Cohen, Hyman Muss *J Clin Oncol* vol 28 (19) 3146-3153 2010

Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/20516438>

977 Are actual tumor measurements or categorical tumor response status better at predicting overall survival in cancer clinical trials?

M. D. Mandrekar, S. L. Hillman, M. E. Campbell, B. Hobbs, R. M. Goldberg, A. Adjei, D. J. Sargent *J. Clin. Oncol.* vol 26 (15s) abstr 6520 2008

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

978 Comparison of progression-free survival (PFS) with best or confirmed response (BR, CR) as an endpoint for overall survival (OS) in advanced non small cell lung cancer (A-NSCLC): A North Central Cancer Treatment Group (NCCTG) investigation

S. J. Mandrekar, S. L. Hillman, K. L. Allen Ziegler, N. F. Reuter, K. M. Rowland Jr, R. S. Marks, S. E. Schild, A. A. Adjei *J. Clin. Oncol.* vol 26 (15s) abstr 8021 2008

Abstract Respiratory

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

979 Systematic evaluation of the impact of disease progression (DP) date determination on progression-free survival (PFS) in advanced lung cancer: a joint North Center Cancer Treatment Group (NCCTG) and Southwest Oncology Group (SWOG) investigation

S. J. Mandrekar, Y. Qi, K. Allen-Ziegler, S. L. Hillman, M. W. Redman, S. E. Schild, D. R. Gandara, A. A. Adjei *J. Clin. Oncol.* vol 29 (suppl) abstr 7005 2011
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

980 Impact of the Algorithm for Declaring Exact Progression Data on Progression-Free Survival Estimates in Advanced Lung Cancer

S. Mandrekar, S. Hillman, A. Jatoi, J. Jett, S. Schild, A. Adjei, K. Allen-Ziegler *J. Clin. Oncol.* vol 28 (15s) abstr 7629 2010
Abstract Respiratory http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.7629

981 Impact of disease progression (DP) date determination method on post progression survival (PPS) and DP metrics in advanced lung cancer

Sumithra J. Mandrekar, Nathan R. Foster, Yingwei Qi, Grace K. Dy, Aminah Jatoi, Julian R. Molina, James R. Jett, Philip J. Stella, Steven E. Schild, Alex A. Adjei *J. Clin. Oncol.* vol 30 (suppl) abstr 7605 2012
Abstract Respiratory
http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/7605?sid=3a6df366-f524-429a-860c-c83e9

982 Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era

Simon Mantha, Debra A. Goldman, Sean M. Devlin, Ju-Whei Lee, Diana Zannino, Marnie Collins, Dan Douer, Harry J. Iland, Mark R. Litzow, Eytan M. Stein, Frederick R. Appelbaum, Richard A. Larson, Richard Stone, Bayard L. Powell, Susan Geyer, Kristina Laumann, Jacob M. Rowe, Harry Erba, Steven Coutre, Megan Othus, Jae H. Park, Peter H. Wiernik, Martin S. Tallman *Blood* vol 129 (13) 1763-1767 2017
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/28082441>

983 Improving the molecular risk classification for younger (<60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts)

G. Marcucci, K. S. Maharry, S. P. Whitman, P. Paschka, C. D. Baldus, C. Langer, K. A. Mrozek, J. E. Kolitz, R. A. Larson, C. D. Bloomfield *J. Clin. Oncol.* vol 27 (15s) abstr 7002 2009
Abstract *Leuk Corr Sci* CALGB-19808, CALGB-20202, CALGB-9621
<http://meetinglibrary.asco.org/content/34742-65>

984 High ERG expression levels predict adverse outcome and refine molecular risk-based classification of cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study

G. Marcucci, K. S. Maharry, S. P. Whitman, T. Vukosavljevic, P. Paschka, C. Langer, K. A. Mrozek, C. Baldus, A. J. Carroll, B. L. Powell, J. E. Kolitz, R. A. Larson, C. D. Bloomfield *AACR Annual Meeting* vol 45 (580) abstr 2440 2007
Abstract *Leuk Corr Sci* CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665
<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={602C556E-A3FC-41BE->

985 IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study

G. Marcucci, K. S. Maharry, Y. Wu, M. D. Radmacher, K. A. Mrozek, D. Margeson, K. B. Holland, S. P. Whitman, H. P. Becker, S. Schwind, K. Metzeler, B. L. Powell, T. H. Carter, J. E. Kolitz, M. Wetzler, M. R. Baer, A. J. Carroll, M. A. Caligiuri, R. A. Larson, C. D. Bloomfield *Haematologica* vol 95 (suppl 2) 456, abstr 1107 2010
Abstract *Leuk Corr Sci* C8525, CALGB-10201, CALGB-19808, CALGB-20202, CALGB-20502, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720

<http://online.haematologica.org/EHA15/browserecord.php?-action=browse&-recid=7179>

986 Gene and microRNA (miRNA) Expression Signatures and Prognostic Significance of CEBPA Mutations in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML) with High-Risk Molecular Features: A Cancer and Leukemia Group B (CALGB) Study

G. Marcucci, K. Maharry, M. D. Radmacher, K. Mrozek, T. Vukosavljevic, P. Paschka, S. P. Whitman, C. Langer, C. D. Baldus, A. S. Ruppert, B. L. Powell, A. J. Carroll, M. A. Caligiuri, J. E. Kolitz, R. A. Larson, C. D. Bloomfield *Blood* vol 110 (11) -104 2007

Abstract *Leuk Corr Sci* CALGB-19808, CALGB-20205, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665

<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;110/11/104>

987 A phase III randomized trial of intensive induction and consolidation chemotherapy +/- oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old

G. Marcucci, B. K. Moser, W. G. Blum, W. Stock, M. Wetzler, J. E. Kolitz, M. C. Thakuri, T. H. Carter, R. K. Stuart, R. A. Larson *J. Clin. Oncol.* vol 25 (18s) abstr 7012 2007

Abstract *Leukemia*

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

988 Adding the KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB study 10801 (Alliance)

Guido Marcucci, Susan Geyer, John Zhao, Andrew J Carroll, Donna Bucci, Geoffrey L Uy, William Blum, Timothy Pardee, Meir Wetzler, Wendy Stock, Jonathan E. Kolitz, Ann-Kathrin Eisfeld, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson *Blood* vol 124 (21) abstr 8 2014

Abstract *Leukemia* <http://www.bloodjournal.org/content/124/21/8?rss=1&ss-checked=true>

989 Adding The KIT Inhibitor Dasatinib (DAS) To Standard Induction and Consolidation Therapy For Newly Diagnosed Patients (pts) With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial Results Of The CALGB 10801 (Alliance) Study

Guido Marcucci, Susan Geyer, John Zhao, Andrew J Carroll, Donna Bucci, Ravi Vij, William Blum, Timothy Pardee, Meir Wetzler, Wendy Stock, Clara D. Bloomfield, Richard A. Larson, Richard M. Stone *Blood* vol 122 (21) Abstract 357 2013

Abstract *Leuk Corr Sci* <http://www.bloodjournal.org/content/122/21/357.short>

990 Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients

Guido Marcucci, Kati S. Maharry, Klaus H. Metzeler, Stefano Volinia, Yue-Zhong Wu, Krzysztof Mrózek, Deedra Nicolet, Jessica Kohlschmidt, Susan P. Whitman, Jason H. Mender, Sebastian Schwind, Heiko Becker, Ann-Kathrin Eisfeld, Andrew J. Carroll, Bayard L. Powell, Jonathan E. Kolitz, Ramiro Garzon, Michael A. Caligiuri, Richard M. Stone, Clara D. Bloomfield *J. Clin. Oncol.* vol 31 (17) 2086-2093 2013

Manuscript *Leuk Corr Sci* CALGB-8461, CALGB-9665, CALGB-20202

<http://www.ncbi.nlm.nih.gov/pubmed/23650424>

991 Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study

Guido Marcucci, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Tamara Vukosavljevic, Peter Paschka, Susan P. Whitman, Christian Langer, Claudia D. Baldus, Chang-Gong Liu, Amy S. Ruppert, Bayard L. Powell, Andrew J. Carroll, Michael A. Caligiuri, Jonathan E. Kolitz, Richard A. Larson, Clara D. Bloomfield *J Clin Oncol* vol 26 (31) 5078-5087 2008

Manuscript Leuk Corr Sci CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://www.ncbi.nlm.nih.gov/pubmed/18809607>

992 High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.

Guido Marcucci, Kati Maharry, Susan P Whitman, Tamara Vukosavljevic, Peter Paschka, Christian Langer, Krzysztof Mrózek, Claudia D Baldus, Andrew J Carroll, Bayard L Powell, Jonathan E Kolitz, Richard A Larson, Clara D Bloomfield J. Clin. Oncol. vol 25 (22) 3337-43 2007
Manuscript Leuk Corr Sci CALGB-19808, CALGB-20205, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://www.ncbi.nlm.nih.gov/pubmed/17577018>

993 IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Guido Marcucci, Kati Maharry, Yue-Zhong Wu, Michael D. Radmacher, Krzysztof Mrózek, Dean Margeson, Kelsi B. Holland, Susan P. Whitman, Heiko Becker, Sebastian Schwind, Klaus H. Metzeler, Bayard L. Powell, Thomas H. Carter, Jonathan E. Kolitz, Meir Wetzler, Andrew J. Carroll, Maria R. Baer, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield J Clin Oncol vol 28 (14) 2348-2355 2010
Manuscript Leuk Corr Sci C8421, C8525, CALGB-10201, CALGB-19808, CALGB-20202, CALGB-20502, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/20368543>

994 Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia

Guido Marcucci, Klaus H. Metzeler, Sebastian Schwind, Heiko Becker, Kati Maharry, Krzysztof Mrózek, Michael D. Radmacher, Jessica Kohlschmidt, Deedra Nicolet, Susan P. Whitman, Yue-Zhong Wu, Bayard L. Powell, Thomas H. Carter, Jonathan E. Kolitz, Meir Wetzler, Andrew J. Carroll, Maria R. Baer, Joseph O. Moore, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield J. Clin. Oncol. vol 30 (7) 742-750 2012
Manuscript Leuk Corr Sci CALGB-9621, CALGB-19808 <http://www.ncbi.nlm.nih.gov/pubmed/22291079>

995 MicroRNA expression in cytogenetically normal acute myeloid leukemia.

Guido Marcucci, Michael D Radmacher, Kati Maharry, Krzysztof Mrózek, Amy S Ruppert, Peter Paschka, Tamara Vukosavljevic, Susan P Whitman, Claudia D Baldus, Christian Langer, Chang-Gong Liu, Andrew J Carroll, Bayard L Powell, Ramiro Garzon, Carlo M Croce, Jonathan E Kolitz, Michael A Caligiuri, Richard A Larson, Clara D Bloomfield N. Engl. J. Med. vol 358 (18) 1919-28 2008
Manuscript Leuk Corr Sci CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://www.ncbi.nlm.nih.gov/pubmed/18450603>

996 Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score

Guido Marcucci, Pearly Yan, Kati Maharry, David Frankhouser, Deedra Nicolet, Klaus H. Metzeler, Jessica Kohlschmidt, Krzysztof Mrózek, Yue-Zhong Wu, Donna Bucci, John P. Curfman, Susan P. Whitman, Ann-Kathrin Eifeld, Jason H. Mendler, Sebastian Schwind, Heiko Becker, Constance Bär, Andrew J. Carroll, Maria R. Baer, Meir Wetzler, Thomas H. Carter, Bayard L. Powell, Jonathan E. Kolitz, John C. Byrd, Christoph Plass, Ramiro Garzon, Michael A. Caligiuri, Richard M. Stone, Stefano Volinia, Ralf Bundschuh, Clara D. Bloomfield J. Clin. Oncol vol 32 (6) 548-556 2014
Manuscript Leuk Corr Sci CALGB-10201, CALGB-9420, CALGB-9720, CALGB-9621, CALGB-19808 <http://www.ncbi.nlm.nih.gov/pubmed/24378410>

997 Recurring mutations found by sequencing an acute myeloid leukemia genome

E. R. Mardis, L. Ding, D. J. Dooling, D. E. Larson, M. D. Mclellan, K. Chen, D. C. Koboldt, R. S. Fulton, K. D. Delehaunty, S. D. Mcgrath, L. A. Fulton, D. P. Locke, V. J. Magrini, R. M. Abbott, T. L. Vickery, J. S. Reed, J. S. Robinson, T. Wylie, S. M. Smith, L. Carmichael, J. M. Eldred, C. C. Harris, J. Walker, J. B. Peck, F. Du, A. F. Dukes, G. E. Sanderson, A. M. Brummett, E. Clark, J. F. Mcmichael, R. J. Meyer, J. K. Schindler, C. S. Pohl, J. W. Wallis, X. Shi, L. Lin, H. Schmidt, Y. Tang, C. Haipek, M. E. Wiechert, J. V. Ivy, J. Kalicki, G. Elliott, R. E. Ries, J. E. Payton, P. Westervelt, M. H. Tomasson, M. A. Watson, J. Baty, S. Heath, W. D. Shannon, R. Nagarajan, D. C. Link, M. J. Walter, T. A. Graubert, J. F. Dipersio, R. K. Wilson, T. J. Ley N. Engl. J. Med. vol 361 (11) 1058-1066 2009
Manuscript Leuk Corr Sci C9665, C8461 <http://www.ncbi.nlm.nih.gov/pubmed/19657110>

998 A phase II trial of carboplatin (C) and nab-paclitaxel (ABI-007-nab-P) in patients with unresectable stage IV melanoma: Final data from N057E

S. N. Markovic, V. J. Suman, L. A. Kottschade, T. Amatruda, R. R. Mcwilliams, S. R. Dakhil, D. A. Nikcevich, R. F. Morton, T. R. Fitch, A. J. Jaslowski J. Clin. Oncol. vol 27 (15s) abstr 9055 2009
Abstract Experimental
<http://jco.ascopubs.org/gca?gca=ascomtg%3B27%2F15S%2F9055&allch=&submit=Go>

999 Aerosolized sargramostim for the treatment of metastatic melanoma to the lungs

S. Markovic, V. Suman, P. Schaefer, K. Rowland Jr, R. Morton J. Clin. Oncol. vol 25 (18s (June 20 Supplement)) abstr 2004 2007
Abstract Experimental
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1000 Tumor SPARC Microenvironment Signature and Plasma Levels in a Phase II Trial of Unresectable Stage IV Melanoma Treated With nab-Paclitaxel and Carboplatin: A Translational Study of NCCTG Trial N057E

S. Markovic, V. Suman, V. Treiu, X. Liu, W. Yeh, L. Hwang, T. Treece, K. Motamed, P. Pramanik, N. Desai J. Clin. Oncol. vol 28 (15s) abstr 8578 2010
Abstract Correl Sci NOS
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8578?sid=47f729d6-2db7-45ec-b759-2228

1001 A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG study1

Svetomir N. Markovic, Vera J. Suman, Wendy K. Nevala, Louis Geeraerts, Edward T. Creagan, Lori A. Erickson, Kendrith M. Rowland, Roscoe F. Morton, William L. Horvath, Mark R. Pittelkow Am J Clin Oncol vol 31 (6) 573-579 2008
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/19060590>

1002 Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082

L. B. Marks, C. Cirrincione, T. J. Fitzgerald, F. Laurie, A. S. Glicksman, J. Vredenburgh, L. R. Prosnitz, E. J. Shpall, M. Crump, P. G. Richardson, M. W. Schuster, J. Ma, B. L. Peterson, L. Norton, S. Seagren, I. C. Henderson, D. D. Hurd, W. P. Peters Int. J. Radiat. Oncol. Biol. Phys. vol 76 (5) 1305-1313 2010
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/19747781>

1003 Phase III, Double-Blind Study of Depot Octreotide Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy: Results of North Central Cancer Treatment Group N00CA

James A. Martenson, Michele Y. Halyard, Jeff A. Sloan, Gary M. Proulx, Robert C. Miller, Richard L. Deming, Stephen J. Dick, Harold A. Johnson, T.H. Patricia Tai, Angela W. Zhu, Joan Keit, Kathy J. Stien, Pamela J. Atherton J Clin Oncol vol 26 (32) 5248-5253 2008

1004 Detection of Occult Micrometastases in Patients With Clinical Stage I Non–Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance)

Linda W. Martin, Jonathan D’Cunha, Xiaofei Wang, Debra Herzan, Lin Gu, Naif Abraham, Todd L. Demmy, Frank C. Detterbeck, Shawn S. Groth, David H. Harpole, Mark J. Krasna, Kemp Kernstine, Leslie J. Kohman, G. Alexander Patterson, David J. Sugarbaker, Robin T. Vollmer, Michael A. Maddaus, Robert A. Kratzke *J. Clin. Oncol* vol 34 (13) 1484-1491 2016
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/26926677>

1005 PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

M. Martin, A. Prat, A. Rodriguez-Lescure, R. Caballero, M. T. Ebbert, B. Munarriz, M. Ruiz-Borrego, R. R. Bastien, C. Crespo, C. Davis, C. A. Rodriguez, J. M. Lopez-Vega, V. Furio, A. M. Garcia, M. Casas, M. J. Ellis, D. A. Berry, B. N. Pitcher, L. Harris, A. Ruiz, E. Winer, C. Hudis, I. J. Stijleman, D. P. Tuck, E. Carrasco, C. M. Perou, P. S. Bernard *Breast Cancer Res. Treat.* vol 138 (2) 457-466 2013
Manuscript Correl Sci NOS CALGB-9342, CALGB-9840
<http://www.ncbi.nlm.nih.gov/pubmed/23423445>

1006 Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.

Miguel Martin, Sibylle Loibl, Terry Hyslop, Juan de la Haba-Rodriguez, Bahriye Aktas, Constance Cirrincione, Eva Maria Carrasco, Keyur Mehta, William Thomas Barry, Serafin Morales, Lisa A. Carey, Jose Angel Garcia Saenz, Ann Partridge, Noelia Martinez, Olwen Mary Hahn, Eric P. Winer, Angel Guerrero, Cliff Hudis, Maribel Casas, Maura N. Dickler *J. Clin. Oncol.* vol 35 (15 suppl) abstr 1012 2017
Abstract Breast http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.1012

1007 CALGB 50803 (Alliance): A phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma

P. Martin, S.-H. Jung, J. Johnson, R. Elstrom, N. L. Bartlett, K. Blum, T. Shea, J. Leonard, B. Cheson *Hematol Oncol* vol 31 (suppl 1) abstr 063 2013
Abstract Lymphoma <http://onlinelibrary.wiley.com/doi/10.1002/hon.2057/pdf>

1008 A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance)

P Martin, S -H Jung, B Pitcher, N L Bartlett, K A Blum, T Shea, E D Hsi, J Ruan, S E Smith, J P Leonard, B D Cheson *Ann. Oncol* vol 28 (11) 2806-12 2017
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/28945884>

1009 A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

Peter Martin, Nancy L. Bartlett, Kristie A. Blum, Steven Park, Kami Maddocks, Jia Ruan, LeAnn Ridling, Christopher Dittus, Zhengming Chen, Xiangao Huang, Giorgio Inghirami, Maurizio DiLiberto, Selina Chen-Kiang, John P. Leonard *Blood* vol 133 (11) 1201-4 2019
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/30692121>

1010 Oral Azacitidine (CC-486) Plus R-CHOP in Patients With High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)

Peter Martin, Nancy L. Bartlett, Julio C. Chavez, John L. Reagan, Sonali M. Smith, Ann LaCasce, Maria Revuelta, Jeffrey Jones, James Drew, Chengqing Wu, Leandro Cerchietti, John P. Leonard *Blood* vol 132 (Suppl 1) 2964 2018

1011 A phase I, open-label, multicenter trial of oral azacitidine (CC-486) plus R-CHOP in patients with high-risk, previously untreated diffuse large B-cell lymphoma, grade 3b follicular lymphoma, or transformed lymphoma (AFT-08)

Peter Martin, Nancy L. Bartlett, Ildefonso Ismael Rodriguez-Rivera, Maria Revuelta, Julio C. Chavez, John Reagan, Sonali M. Smith, Ann LaCasce, Lei Zhang, Merry Zhai, Chengqing Wu, John Leonard, Leandro Cerchietti *Blood* vol 130 (Suppl 1) 192 2017
Abstract Lymphoma NCT02343536, AFT-08 http://www.bloodjournal.org/content/130/Suppl_1/192

1012 CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma

Peter Martin, Sin-Ho Jung, Jeffrey L. Johnson, Brandy Pitcher, Rebecca L. Elstrom, Nancy Bartlett, Kristie A. Blum, Kristy L. Richards, John Leonard, Bruce D. Cheson *J. Clin. Oncol.* vol 32 (15 suppl) abstr 8521 2014
Abstract Lymphoma http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8521

1013 Final results of CALGB 50803 (Alliance): A phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma

Peter Martin, Sin-Ho Jung, Brandy Pitcher, Nancy Bartlett, Kristy Blum, Thomas Shea, Jia Ruan, Scott Smith, John Leonard, Bruce Cheson *Hemato Oncol* vol 35 (suppl S2) 51 2017
Abstract Lymphoma http://onlinelibrary.wiley.com/doi/10.1002/hon.2437_34/epdf

1014 Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.

M Martín, S Loibl, T Hyslop, J De la Haba-Rodríguez, B Aktas, C T Cirrincione, K Mehta, W T Barry, S Morales, L A Carey, J A Garcia-Saenz, A Partridge, N Martinez-Jañez, O Hahn, E Winer, A Guerrero-Zotano, C Hudis, M Casas, C Rodriguez-Martin, J Furlanetto, E Carrasco, M N Dickler *Eur. J. Cancer* vol 117 91-8 2019
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/31276981>

1015 A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531

Gregory A. Masters, Xiaofei Wang, Lydia Hodgson, Thomas Shea, Everett Vokes, Mark Green *Lung Cancer* vol 74 (2) 258-263 2011
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21529989>

1016 Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

A. Mauguén, J. P. Pignon, S. Burdett, C. Domerg, D. Fisher, R. Paulus, S. J. Mandrekar, C. P. Belani, F. A. Shepherd, T. Eisen, H. Pang, L. Collette, W. T. Sause, S. E. Dahlberg, J. Crawford, M. O'Brien, S. E. Schild, M. Parmar, J. F. Tierney, C. Le Pechoux, S. Michiels *Lancet Oncol.* vol 14 (7) 619-626 2013
Manuscript Respiratory CALGB-8831, CALGB-9310, CALGB-9633, NCCTG-892052, NCCTG-902451, NCCTG-942452 <http://www.ncbi.nlm.nih.gov/pubmed/23680111>

1017 Elevated Pre-Treatment Serum Immunoglobulin Free Light Chains (FLC) Are Associated with Poor Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL)

M. J. Maurer, I. N. Micalef, J. A. Katzmann, D. Nikcevic, T. E. Witzig *ASH Annual Meeting Abstracts* vol 114 (22) abstr 136 2009

1018 Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

Matthew J. Maurer, Hervé Ghesquières, Jean-Philippe Jais, Thomas E. Witzig, Corinne Haioun, Carrie A. Thompson, Richard Delarue, Ivana N. Micallef, Frédéric Peyrade, William R. Macon, Thierry Jo Molina, Nicolas Ketterer, Sergei I. Syrbu, Olivier Fitoussi, Paul J. Kurtin, Cristine Allmer, Emmanuelle Nicolas-Virelizier, Susan L. Slager, Thomas M. Habermann, Brian K. Link, Gilles Salles, Hervé Tilly, James R. Cerhan *J. Clin. Oncol* vol 32 (10) 1066-1073 2014
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/24550425>

1019 Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma

Matthew J. Maurer, Ivana N.M. Micallef, James R. Cerhan, Jerry A. Katzmman, Brian K. Link, Joseph P. Colgan, Thomas M. Habermann, David J. Inwards, Svetomir N. Markovic, Stephen M. Ansell, Luis F. Porrata, Patrick B. Johnston, Grzegorz S. Nowakowski, Carrie A. Thompson, Mamta Gupta, Sergei I. Syrbu, Paul J. Kurtin, William R. Macon, Daniel A. Nikcevich, Thomas E. Witzig *J Clin Oncol* vol 29 (12) 1620-1626 2011
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/21383282>

1020 Diagnosis to treatment interval (DTI) is associated with adverse outcome in newly diagnosed patients with mantle cell lymphoma, a MER/LEO and Alliance collaboration

Matthew J. Maurer, Amy S. Ruppert, Brian K. Link, Lawrence D. Kaplan, David Inwards, Andrew Feldman, Eric D. Hsi, Adam Pettinger, Jonathon Cohen, Peter Martin, Brad Kahl, Nancy Bartlett, James R. Cerhan, John P. Leonard, Thomas M. Habermann *Blood* vol 132 (suppl 1) 2878 2018
Abstract Lymphoma http://www.bloodjournal.org/content/132/Suppl_1/2878

1021 How Much Missing Data is Too Much? Monte Carlo Simulations to Develop SISAQOL Guidelines for Missing Data Handling.

Gina L. Mazza, Corneel Coens, Madeline Pe, Lien Dorme, Kathy Oliver, Andrew Bottomley, Jeff A. Sloan, Amylou C. Dueck *Qual Life Res* vol 27 (suppl 1) abstr 2018.1 2018
Abstract Health Outcome <https://link.springer.com/content/pdf/10.1007%2Fs11136-018-1946-9.pdf>

1022 Exploring Therapeutic Decisions in Elderly Patients with Non-Small Cell Lung Cancer: Results and Conclusions from North Central Cancer Treatment Group Study N0222

Heidi Mc Kean, Philip J. Stella, Shauna L. Hillman, Kendrith M. Rowland, Michael W. Cannon, Robert J. Behrens, Gerald G. Gross, Mark D. Sborov, Eliot L. Friedman, Aminah Jatoi *Cancer Invest.* vol 29 (4) 266-271 2011
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21345074>

1023 CALGB/ECOG 100104 (Alliance) Study: Lenalidomide (LEN) vs Placebo (PBO) Maintenance (Maint) After Stem Cell Transplant (SCT) for Patients (Pts) With Multiple Myeloma: Overall Survival (OS) and Progression-Free Survival (PFS) Adjusted for Treatment (Tx) Crossover (XO)

Philip L. McCarthy, Sarah A. Holstein, Sin-Ho Jung, Miranda Cooper, Craig J. Gibson, Edward A. Stadtmauer, Benjamin Winograd, Paul Richardson *J. Clin. Oncol.* vol 35 (15 suppl) abstr 8037 2017
Abstract Myeloma http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.8037

1024 Overall and Progression-Free Survival Adjusted for Treatment Crossover in the CALGB 100104 Study of Lenalidomide Versus Placebo Maintenance After Stem Cell Transplant for Patients With Newly Diagnosed Multiple Myeloma (Alliance)

Philip L. McCarthy, Sarah A. Holstein, Sin-Ho Jung, Miranda Cooper, Craig J. Gibson, Edward A. Stadtmauer, Benjamin Winograd, Paul Richardson 2017
Abstract Myeloma

1025 Lenalidomide vs Placebo Maintenance After Stem Cell Transplant for Patients With Multiple Myeloma: Overall Survival and Progression-Free Survival After Adjusting for Treatment Crossover in CALGB

Philip L. McCarthy, Sarah A. Holstein, Sin-Ho Jung, Miranda Cooper, Craig J. Gibson, Edward A. Stadtmauer, Benjamin Winograd, Paul Richardson *Haematologica* vol 102 (S2) p 108, abstr p332 2017

Abstract Myeloma <http://www.haematologica.org/content/102/s2/1.full.pdf+html>

1026 Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

Philip L. McCarthy, Sarah A. Holstein, Maria Teresa Petrucci, Paul G. Richardson, Cyrille Hulin, Patrizia Tosi, Sara Brinthen, Pellegrino Musto, Kenneth C. Anderson, Denis Caillot, Francesca Gay, Philippe Moreau, Gerald Marit, Sin-Ho Jung, Zhinuan Yu, Benjamin Winograd, Robert D. Knight, Antonio Palumbo, Michel Attal *J. Clin. Oncol* vol 35 (29) 3279-89 2017

Manuscript Myeloma <http://www.ncbi.nlm.nih.gov/pubmed/28742454>

1027 Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Philip L. McCarthy, Kouros Owzar, Craig C. Hofmeister, David D. Hurd, Hani Hassoun, Paul G. Richardson, Sergio Giralt, Edward A. Stadtmauer, Daniel J. Weisdorf, Ravi Vij, Jan S. Moreb, Natalie Scott Callander, Koen Van Besien, Teresa Gentile, Luis Isola, Richard T. Maziarz, Don A. Gabriel, Asad Bashey, Heather Landau, Thomas Martin, Muzaffar H. Qazilbash, Denise Levitan, Brian McClune, Robert Schlossman, Vera Hars, John Postiglione, Chen Jiang, Elizabeth Bennett, Susan Barry, Linda Bressler, Michael Kelly, Michele Seiler, Cara Rosenbaum, Parameswaran Hari, Marcelo C. Pasquini, Mary M. Horowitz, Thomas C. Shea, Steven M. Devine, Kenneth C. Anderson, Charles Linker *N. Engl. J. Med.* vol 366 (19) 1770-1781 2012

Manuscript Myeloma <http://www.ncbi.nlm.nih.gov/pubmed/22571201>

1028 Survival analysis from the CALGB trial of lenalidomide (LEN) maintenance therapy in newly diagnosed multiple myeloma (NDMM) post-autologous stem cell transplant (ASCT), adjusting for crossover (Alliance)

Philip L. McCarthy, Vera Suman, Miranda Cooper, Owain Saunders, Paul Richardson, Sujith Dhanasiri, Sergio Giralt, Ken Anderson, Ed Stadtmauer, Sarah A. Holstein *Blood* vol 132 (Suppl 1) 4737 2018

Abstract Myeloma http://www.bloodjournal.org/content/132/Suppl_1/4737?sso-checked=true

1029 A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235).

Edward F McClay, Jeff Bogart, James E Herndon, Dee Watson, Lisa Evans, Steven L Seagren, Mark R Green *Am. J. Clin. Oncol.* vol 28 (1) 81-90 2005

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/15685040>

1030 Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database

Nadine J. McCleary, Jeffrey A. Meyerhardt, Erin Green, Greg Yothers, Aimery de Gramont, Eric Van Cutsem, Michael O'Connell, Christopher J. Twelves, Leonard B. Saltz, Daniel G. Haller, Daniel J. Sargent *J. Clin. Oncol* vol 31 (20) 2600-2606 2013

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/23733765>

1031 Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (Alliance)

Nadine J McCleary, Joleen Hubbard, Michelle R Mahoney, Jeffrey A Meyerhardt, Daniel Sargent, Alan Venook, Axel Grothey J Geriatr Oncol vol 9 (1) 24-31 2018
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/28917648>

1032 Impact of smoking on patients with stage III colon cancer: Results from CALGB 89803

Nadine Jackson McCleary, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Paul Schaefer, Renaud Whittom, Alexander Hantel, Al Benson, Richard Goldberg, Jeffrey A. Meyerhardt Cancer vol 116 (4) 957-966 2010
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20052723>

1033 Concordance of HER2 Central Assessment by Two International Central Laboratories: a ring study within the framework of the Adjuvant HER2-Positive ALTTO Trial (BIG2-06/N063D/EGF106708).

AE McCullough, P Dell'Orto, MM Reinholz, RD Gelber, AC Dueck, L Russo, RB Jenkins, S Andrighetto, B Chen, WL Lingle, C Jackisch, EA Perez, MJ Piccart-Gebhart, G. Viale Cancer Res. vol 70 (24, suppl 2) abstr P3-10-36 2010
Abstract Breast http://cancerres.aacrjournals.org/content/70/24_Supplement/P3-10-36.abstract

1034 Central Pathology Laboratory Review of HER2 and ER in Early Breast Cancer: An ALTTO Trial [BIG 2-06 / NCCTG N063D (Alliance)] Ring Study

Ann E. McCullough, Patrizia Dell'Orto, Monica M. Reinholz, Richard D. Gelber, Amylou C. Dueck, Leila Russo, Robert B. Jenkins, Stefania Andrighetto, Beiyun Chen, Christian Jackisch, Michael Untch, Edith A. Perez, Martine J. Piccart-Gebhart Breast Cancer Res. Treat. vol 143 (3) 485-492 2014
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/24395109>

1035 Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741

Howard L. McLeod, Daniel J. Sargent, Sharon Marsh, Erin M. Green, Cristi R. King, Charles S. Fuchs, Ramesh K. Ramanathan, Stephen K. Williamson, Brian P. Findlay, Stephen N. Thibodeau, Axel Grothey, Roscoe F. Morton, Richard M. Goldberg J Clin Oncol vol 28 (20) 3227-3233 2010
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/20530282>

1036 Influence of 6q22-23 on overall survival in primary central nervous system lymphoma. Analysis of North Central Cancer Treatment Group trials 86 72 52, 93 73 51 and 96 73 51

Ellen R. McPhail, Mark E. Law, Paul A. Decker, Brian P. O'Neill Br. J. Haematol. vol 154 (1) 146-150 2011
Manuscript Leuk Corr Sci NCCTG-86-72-52, 93-73-51, 96-73-51
<http://www.ncbi.nlm.nih.gov/pubmed/21275973>

1037 NCCTG N0879 (Alliance): A randomized phase II trial of carboplatin, paclitaxel, bevacizumab, with or without everolimus for therapy of metastatic malignant melanoma

Robert R. McWilliams, Jake Allred, Lisa Kottschade, Lori Erickson, Kandelaria Rumilla, Mamta Gupta, Roxana S. Dronca, Rajini Katipamula, Svetomir N. Markovic Eur. J. Cancer vol 51 (S672) abstr 3324 2015
Abstract Experimental
<http://www.ejcancer.com/action/doSearch?searchType=quick&searchText=McWilliams&occurrences=a>

1038 NCCTG N0543 (Alliance): A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma

Robert R. McWilliams, Nathan R. Foster, Michelle R. Mahoney, Thomas C. Smyrk, Joseph A. Murray, Matthew M. Ames, Elise Horvath, Daniel Schneider, Timothy J. Hobday, Aminah Jatoi, Jeffrey P. Meyers, Matthew P. Goetz Cancer vol 123 (18) 3494-501 2017

1039 NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab±everolimus for metastatic melanoma.

Robert R McWilliams, Jacob B Allred, Jessica A Slostad, Rajini Katipamula, Roxana S Dronca, Kandelaria M Rumilla, Lori A Erickson, Alan H Bryce, Richard W Joseph, Lisa A Kottschade, David M King, John M Leitch, Svetomir N Markovic *Cancer* vol 124 (3) 537-45 2018
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/29044496>

1040 Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.

Robert R McWilliams, Matthew P Goetz, Bruce W Morlan, Muhammad Salim, Kendrith M Rowland, James E Krook, Matthew M Ames, Charles Erlichman *Clin Colorectal Cancer* vol 6 (7) 516-21 2007
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17553200>

1041 Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence

M. D. Mccarter, C. R. Antonescu, K. V. Ballman, R. G. Maki, P. W. Pisters, G. D. Demetri, C. D. Blanke, M. Von Mehren, M. F. Brennan, L. Mccall, D. M. Ota, R. P. Dematteo *J. Am. Coll. Surg.* vol 215 (1) 53-59; discussion 59-60 2012
Manuscript GI ACOSOG-Z9000, ACOSOG-Z9001 <http://www.ncbi.nlm.nih.gov/pubmed/22726733>

1042 Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma (CALGB 100104): Initial report of patient accrual and adverse events

P. L. Mccarthy, C. Linker, C. C. Hofmeister, K. Owzar, E. Stadtmauer, K. C. Anderson, P. Richardson, D. D. Hurd, D. J. Weisdorf *J. Clin. Oncol.* vol 28 (15s) Poster Board III-353 2010
Abstract Transplant <https://ash.confex.com/ash/2009/webprogram/Paper22181.html>

1043 Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

P. L. Mccarthy, K. Owzar, K. C. Anderson, C. C. Hofmeister, D. D. Hurd, H. Hassoun, S. Giralt, E. A. Stadtmauer, P. G. Richardson, D. J. Weisdorf, R. Vij, J. S. Moreb, N. S. Callander, K. Van Besien, T. Gentile, L. Isola, R. T. Maziarz, D. A. Gabriel, A. Bashey, H. Landau, T. Martin, M. H. Qazilbash, D. Levitan, B. Mcclune, V. Hars, J. Postiglione, C. Jiang, E. Bennett, S. S. Barry, L. Bressler, M. Kelly, M. Sexton, C. Rosenbaum, H. Parameswaran, M. C. Pasquini, M. M. Horowitz, T. C. Shea, S. M. Devine, C. Linker *Blood* vol 116 (21) -37 2010
Abstract Transplant <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;116/21/37>

1044 Analysis Of Overall Survival (OS) In The Context Of Cross-Over From Placebo To Lenalidomide And The Incidence Of Second Primary Malignancies (SPM) In The Phase III Study Of Lenalidomide Versus Placebo Maintenance Therapy Following Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) CALGB (Alliance) ECOG BMT-CTN 100104

P. Mccarthy, K. Owzar, C. Hofmeister, P. Richardson, H. Hassoun, E. Stadtmauer, S. Giralt, D. Hurd, M. Qazilbash, B. Mcclune, M. Pasquini, V. Hars, C. Jiang, J. Postiglione, M. Kelly, L. Bressler, S. Devine, K. Anderson, C. Linker *Clin Lymphoma Myeloma Leuk* vol 13 (suppl 1) S28 2013
Abstract Myeloma
<http://www.sciencedirect.com/science/article/pii/S2152265013000372/pdf?md5=87528f83cd37541b24>

1045 Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database

N. A. J. Mccleary, J. Meyerhardt, E. Green, G. Yothers, A. Degramont, E. Van Cutsem, M. O'Connell,

C. Twelves, L. Saltz, D. Sargent, T. a. C. Group J. Clin. Oncol. vol 27 (15s, (suppl)) abstr 4010 2009
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

1046 100% Concordance between IHC and FISH HER2 Testing Cannot Be Achieved Using N9831 Cohort

A. E. Mccullough, B. Chen, D. W. Hillman, K. S. Tenner, R. B. Jenkins, M. M. Reinholz, W. L. Lingle, A. C. Dueck, E. A. Perez Lab Invest vol 90 (Suppl 1) 62A, abstr 267 2010
Abstract Breast <http://www.nature.com/labinvest/journal/v90/n1s/pdf/labinvest201011a.pdf>

1047 Cellular transporter pharmacogenetics in metastatic colorectal cancer: Initial analysis of C80203

H. L. Mcleod, K. Owzar, D. L. Kroetz, F. Innocenti, S. Das, P. N. Friedman, K. Giacomini, R. M. Goldberg, A. P. Venook, M. J. Ratain J. Clin. Oncol. vol 26 (May 20 suppl) abstr 3513 2008
Abstract PPP
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1048 NCCTG phase I/II trial (N9943) of gemcitabine and pemetrexed in patients with biliary tract or gallbladder carcinoma: phase II results

R. R. Mcwilliams, N. R. Foster, F. J. Quevedo, R. F. Marschke, J. W. Kugler, E. L. Friedman, A. J. Jaslowski, J. R. Sande, S. R. Alberts J. Clin. Oncol. vol 25 (18S) abstr 4578 2007
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1049 Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial

R. R. Mcwilliams, M. R. Mahoney, B. T. Marchello, A. Jatoi, K. D. Krewer, M. M. Ames, D. J. Schneider, G. R. Seeger, R. B. Mowat, S. R. Alberts, M. P. Goetz J. Clin. Oncol. vol 30 (4 suppl) abstr 314 2012
Abstract GI
http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/7605?sid=3a6df366-f524-429a-860c-c83e9

1050 A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147.

R. R. Mcwilliams, M. R. Mahoney, D. J. Sargent, G. D. Nelson, F. Sinicrope, P. J. Limburg, S. N. Thibodeau, A. Grothey, J. M. Hubbard, S. R. Alberts J. Clin. Oncol. vol 30 (Suppl 4) abstr 446 2012
Abstract GI
http://meeting.ascopubs.org/cgi/content/abstract/30/4_suppl/446?sid=76670aad-765f-40ab-ba01-b192e0c

1051 Phase II trial of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin for metastatic colorectal cancer

R. Mcwilliams, M. Goetz, B. Morlan, M. Salim, K. Rowland Jr, J. Krook, M. Ames, C. Erlichman
Gastrointestinal Cancers Symposium abstr 383 2007
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=45&abstractID

1052 Kinetic-Pharmacodynamic Model of Chemotherapy Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel or Ixabepilone: CALGB 40502 (Alliance)

Shailly Mehrotra, Manish R. Sharma, Elizabeth Gray, Kehua Wu, William T. Barry, Clifford Hudis, Eric P. Winer, Alan P. Lyss, Deborah L. Toppmeyer, Alvaro Moreno-Aspitia, Thomas E. Lad, Mario Valasco, Beth Overmoyer, Hope Rugo, Mark J. Ratain, Jogarao V. Gobburu AAPS J vol 19 (5) 1411-23 2017

1053 Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures

J. H. Mendler, K. Maharry, M. D. Radmacher, K. Mrozek, J. Kohlschmidt, D. Nicolet, H. Becker, K. H. Metzeler, S. Schwind, S. P. Whitman, W. Blum, B. L. Powell, J. E. Kolitz, T. H. Carter, M. Wetzler, J. O. Moore, A. J. Carroll, M. R. Baer, R. A. Larson, M. A. Caligiuri, G. Marcucci, C. D. Bloomfield *Blood* vol 118 (21) -3454 2011
Abstract *Leuk Corr Sci* C8525, CALGB-10201, CALGB-19808, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9720
<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/3454>

1054 RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures

Jason H. Mendler, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Heiko Becker, Klaus H. Metzeler, Sebastian Schwind, Susan P. Whitman, Jihane Khalife, Jessica Kohlschmidt, Deedra Nicolet, Bayard L. Powell, Thomas H. Carter, Meir Wetzler, Joseph O. Moore, Jonathan E. Kolitz, Maria R. Baer, Andrew J. Carroll, Richard A. Larson, Michael A. Caligiuri, Guido Marcucci, Clara D. Bloomfield *J. Clin. Oncol.* vol 30 (25) 3109-3118 2012
Manuscript *Leuk Corr Sci* C8525, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720, CALGB-10201, CALGB-19808, CALGB-20202
<http://www.ncbi.nlm.nih.gov/pubmed/22753902>

1055 Combined-modality therapy of poor prognosis anal canal carcinoma: a phase II study of the Cancer and Leukemia Group B (CALGB)

N. J. Meropol, D. Niedzwiecki, B. Shank, T. Colacchio, J. Ellerton, F. Valone, D. Hollis, S. Budinger, J. M. Dowell, R. J. Mayer *Gastrointestinal Cancers Symposium abstr* 238 2005
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=36&abstractID

1056 Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the Cancer and Leukemia Group B (CALGB 9281).

Neal J Meropol, Donna Niedzwiecki, Brenda Shank, Thomas A Colacchio, John Ellerton, Frank Valone, Susan Budinger, Jeannette M Day, Judy Hopkins, Joel Tepper, Richard M Goldberg, Robert J Mayer *J. Clin. Oncol.* vol 26 (19) 3229-34 2008
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/18490648>

1057 ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet 'Favorable' Genetic Category

K. H. Metzeler, H. Becker, K. Maharry, M. D. Radmacher, J. Kohlschmidt, K. Mrozek, D. Nicolet, S. P. Whitman, Y.-Z. Wu, S. Schwind, B. L. Powell, T. H. Carter, M. Wetzler, J. O. Moore, J. E. Kolitz, M. R. Baer, A. J. Carroll, R. A. Larson, M. A. Caligiuri, G. Marcucci, C. D. Bloomfield *Blood* vol 118 (21) -417 2011
Abstract *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665
<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/417>

1058 An 86-Probe Gene Expression Signature Can Predict Survival in AML with Normal Karyotype Independently of FLT3 ITD and NPM1 Mutation Status - A Collaborative Study from the AMLCG and CALGB Study Groups

K. H. Metzeler, M. Hummel, C. D. Bloomfield, K. Spiekermann, M. C. Sauerland, A. Heinecke, M.

Radmacher, G. Marcucci, S. P. Whitman, K. Maharry, P. Paschka, R. A. Larson, W. E. Berdel, T. Buchner, B. Wormann, U. Mansmann, W. Hiddemann, S. K. Bohlander, C. Buske *Blood* vol 110 (11) -596 2007

Abstract *Leuk Corr Sci* CALGB-8461, CALGB-9621, CALGB-9665

<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;110/11/596>

1059 TET2 mutations occur in over 20% of adults with de novo cytogenetically normal AML, and their prevalence increases with age: A Cancer and Leukemia Group B study.

K. H. Metzeler, K. Maharry, D. Margeson, J. Curfman, H. Becker, M. D. Radmacher, K. Mrózek, K. Holland, S. P. Whitman, Y.-Z. Wu, S. Schwind, W. Blum, B. L. Powell, T. H. Carter, M. R. Baer, A. J. Carroll, J. O. Moore, J. E. Kolitz, R. A. Larson, M. A. Caligiuri, G. Marcucci, C. D. Bloomfield *Haematologica* vol 95 (Supplement) 2010

Abstract *Leuk Corr Sci* C8525, CALGB-10201, CALGB-19808, CALGB-20202, CALGB-20502, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720

http://www.haematologica.org/content/95/supplement_2/1.full.pdf

1060 Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study

K. H. Metzeler, K. Maharry, M. D. Radmacher, K. Mrozek, D. Margeson, H. Becker, J. Curfman, K. B. Holland, S. Schwind, S. P. Whitman, Y.-Z. Wu, W. Blum, B. L. Powell, T. H. Carter, M. Wetzler, J. O. Moore, J. E. Kolitz, M. R. Baer, A. J. Carroll, R. A. Larson, M. A. Caligiuri, G. Marcucci, C. D. Bloomfield *Blood* vol 116 (21) -98 2010

Abstract *Leuk Corr Sci* C8525, C8641, CALGB-10201, CALGB-19808, CALGB-20202, CALGB-20502, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720

<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;116/21/98>

1061 A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia

KH Metzeler, K Maharry, J Kohlschmidt, S Volinia, K Mrózek, H Becker, D Nicolet, SP Whitman, JH Mendler, S Schwind, A-K Eisfeld, Y-Z Wu, BL Powell, TH Carter, M Wetzler, JE Kolitz, MR Baer, AJ Carroll, RM Stone, MA Caligiuri, G Marcucci, CD Bloomfield *Leukemia* vol 27 (10) 2023-2031 2013

Manuscript *Leuk Corr Sci* CALGB-8461, CALGB-9665, CALGB-20202

<http://www.ncbi.nlm.nih.gov/pubmed/23765227>

1062 ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

Klaus H. Metzeler, Heiko Becker, Kati Maharry, Michael D. Radmacher, Jessica Kohlschmidt, Krzysztof Mrózek, Deedra Nicolet, Susan P. Whitman, Yue-Zhong Wu, Sebastian Schwind, Bayard L. Powell, Thomas H. Carter, Meir Wetzler, Joseph O. Moore, Jonathan E. Kolitz, Maria R. Baer, Andrew J. Carroll, Richard A. Larson, Michael A. Caligiuri, Guido Marcucci, Clara D. Bloomfield *Blood* vol 118 (26) 6920-6929 2011

Manuscript *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665

<http://www.ncbi.nlm.nih.gov/pubmed/22031865>

1063 An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia

Klaus H. Metzeler, Manuela Hummel, Clara D. Bloomfield, Karsten Spiekermann, Jan Braess, Maria-Cristina Sauerland, Achim Heinecke, Michael Radmacher, Guido Marcucci, Susan P. Whitman, Kati Maharry, Peter Paschka, Richard A. Larson, Wolfgang E. Berdel, Thomas Büchner, Bernhard Wörmann, Ulrich Mansmann, Wolfgang Hiddemann, Stefan K. Bohlander, Christian Buske *Blood* vol 112 (10) 4193-4201 2008

1064 TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Klaus H. Metzeler, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Dean Margeson, Heiko Becker, John Curfman, Kelsi B. Holland, Sebastian Schwind, Susan P. Whitman, Yue-Zhong Wu, William Blum, Bayard L. Powell, Thomas H. Carter, Meir Wetzler, Joseph O. Moore, Jonathan E. Kolitz, Maria R. Baer, Andrew J. Carroll, Richard A. Larson, Michael A. Caligiuri, Guido Marcucci, Clara D. Bloomfield J Clin Oncol vol 29 (10) 1373-1381 2011

Manuscript Leuk Corr Sci C8525, CALGB-10201, CALGB-19808, CALGB-20202, CALGB-20502, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720
<http://www.ncbi.nlm.nih.gov/pubmed/21343549>

1065 Impact of age and comorbidities on treatment effect, tolerance and toxicity in metastatic colorectal cancer (mCRC) patients treated on CALGB 80203

J. A. Meyerhardt, N. A. Jackson, D. Niedzwiecki, D. R. Hollis, A. P. Venook, R. J. Mayer, R. M. Goldberg J. Clin. Oncol. vol 27 (15s) abstr 4038 2009

Abstract GI <http://meetinglibrary.asco.org/content/33181-65>

1066 The impact of dietary patterns on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803

J. A. Meyerhardt, D. Niedzwiecki, D. R. Hollis, L. B. Saltz, W. C. Willett, R. J. Mayer, C. S. Fuchs J. Clin. Oncol. vol 25 (18s) abstr 4019 2007

Abstract GI

http://meeting.ascopubs.org/gca?gca=ascomtg%3B25%2F18_suppl%2F4019&allch=&submit=Go

1067 Dietary Glycemic Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings From CALGB 89803

J. A. Meyerhardt, K. Sato, D. Niedzwiecki, C. Ye, L. B. Saltz, R. J. Mayer, R. B. Mowat, R. Whittom, A. Hantel, A. Benson, D. S. Wigler, A. Venook, C. S. Fuchs J Natl Cancer Inst vol 104 (22) 1702-1711 2012

Manuscript Prevention CALGB-89803, CALGB-159806

<http://www.ncbi.nlm.nih.gov/pubmed/23136358>

1068 Impact of Body Mass Index and Weight Change After Treatment on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From Cancer and Leukemia Group B 89803

Jeffrey A. Meyerhardt, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, Heidi Nelson, Renaud Whittom, Alexander Hantel, James Thomas, Charles S. Fuchs J Clin Oncol vol 26 (25) 4109-4115 2008

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/18757324>

1069 Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.

Jeffrey A Meyerhardt, Denise Heseltine, Donna Niedzwiecki, Donna Hollis, Leonard B Saltz, Robert J Mayer, James Thomas, Heidi Nelson, Renaud Whittom, Alexander Hantel, Richard L Schilsky, Charles S Fuchs J. Clin. Oncol. vol 24 (22) 3535-41 2006

Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/16822843>

1070 Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.

Jeffrey A Meyerhardt, Donna Niedzwiecki, Donna Hollis, Leonard B Saltz, Frank B Hu, Robert J

Mayer, Heidi Nelson, Renaud Whittom, Alexander Hantel, James Thomas, Charles S Fuchs JAMA
vol 298 (7) 754-64 2007

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17699009>

1071 The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial.

Bryan F Meyers, Robert J Downey, Paul A Decker, Robert J Keenan, Barry A Siegel, Robert J Cerfolio, Rodney J Landreneau, Carolyn E Reed, Dennis M Balfe, Farrokh Dehdashti, Karla V Ballman, Valerie W Rusch, Joe B Putnam J. Thorac. Cardiovasc. Surg. vol 133 (3) 738-45 2007
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/17320575>

1072 Ratio of metastatic to examined lymph nodes is a powerful predictor of overall survival in rectal cancer: An analysis of Intergroup 0114

M. O. Meyers, D. R. Hollis, R. J. Mayer, A. B. 3rd Benson, R. M. Goldberg, B. Cummings, L. Gunderson, J. Martenson, J. S. Macdonald, M. J. O'Connell, J. E. Tepper J. Clin. Oncol. vol 25 (18s) abstr 4006 2007
Abstract GI http://ascopubs.org/doi/abs/10.1200/jco.2007.25.18_suppl.4006

1073 Use of the ratio of metastatic to examined lymph nodes to predict local recurrence in rectal cancer: Analysis of data from intergroup trial 0114.

M. O. Meyers, D. R. Hollis, R. J. Mayer, R. M. Goldberg, A. B. Benson 3rd, B. Cummings, L. L. Gunderson, J. A. Jr Martenson, J. S. Macdonald, M. O'Connell, J. E. Tepper Gastrointestinal Cancers Symposium abstr 384 2009
Abstract GI <http://meetinglibrary.asco.org/content/10558-63>

1074 Ratio of Metastatic to Examined Lymph Nodes is Predictive of Local Recurrence in Rectal Cancer: Analysis of Data From Intergroup Trial 0114

M.O. Meyers, D.R. Hollis, R.J. Mayer, R.M. Goldberg, Benson A.B. III, B. Cummings, L.L. Gunderson, J.A. Martenson, J.S. Macdonald, M. O'Connell, J.E. Tepper Ann. Surg. Oncol. vol 16 (1) 90 2009
Abstract GI
<http://download.springer.com/static/pdf/854/art%253A10.1245%252Fs10434-008-0291-6.pdf?originUrl=>

1075 Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma

I. N. Micallef, M. J. Maurer, D. A. Nikcevich, M. W. Cannon, E. W. Schaefer, D. F. Jr Moore, P. Kurtin, T. E. Witzig J. Clin. Oncol. vol 27 (15s) abstr 8508 2009
Abstract Lymphoma
<http://www.asco.org/ASCOv2/Meethttp://meeting.ascopubs.org/cgi/content/abstract/27/15S/8508ings/At>

1076 A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma

I. N. Micallef, M. J. Maurer, D. A. Nikcevich, M. Cannon, D. F. Moore Jr, P. Kurtin, T. E. Witzig J. Clin. Oncol. vol 86 (15s) abstr 8500 2008
Abstract Lymphoma
http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/8500?sid=be945ed9-b3b0-417d-8c78-410b

1077 PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

I. N. Micallef, M. J. Maurer, T. E. Witzig, D. Nikcevich, P. Kurtin, M. W. Cannon, P. J. Flynn, G. S.

Soori, V. Lowe, G. Wiseman ASH Annual Meeting Abstracts vol 114 (22) abstr 137 2009
Abstract Lymphoma <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;114/22/137>

1078 Promising results of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma.

I. N. Micallef, M. Maurer, D. Nikcevich, M. Cannon, D. Moore, P. Kurtin, E. Schaefer, T. Witzig
Ann. Oncol. vol 19 (Suppl 4) 161 abstr 257 2008

Abstract Lymphoma http://annonc.oxfordjournals.org/content/19/suppl_4/iv158.full.pdf+html

1079 Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

Ivana N. M. Micallef, Matthew J. Maurer, Gregory A. Wiseman, Daniel A. Nikcevich, Paul J. Kurtin, Michael W. Cannon, Domingo G. Perez, Gamini S. Soori, Brian K. Link, Thomas M. Habermann, Thomas E. Witzig
Blood vol 118 (15) 4053-4061 2011

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/21673350>

1080 Phase II trial of paclitaxel-topotecan-etoposide (PTE) followed by consolidation chemoradiotherapy for limited stage small cell lung cancer (LS-SCLC): CALGB 30002

A. A. Miller, J. A. Bogart, D. M. Watson, X. F. Wang, C. M. Rocha Lima, E. E. Vokes, M. R. Green
J. Clin. Oncol. vol 23 (16s) abstract 7170 2005

Abstract Respiratory

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=34&abstractID

1081 Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301

A. A. Miller, D. J. Murry, K. Owzar, D. R. Hollis, G. K. Abou-Alfa, A. Desai, J. J. Hwang, M. A. Villalona-Calero, E. C. Dees, M. J. Ratain
J. Clin. Oncol. vol 25 (18s) abstr 2007

Abstract Experimental

http://meeting.ascopubs.org/gca?gca=ascomtg%3B25%2F18_suppl%2F3538&allch=&submit=Go

1082 Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301

Antonius A. Miller, Daryl J. Murry, Kouros Owzar, Donna R. Hollis, Erin B. Kennedy, Ghassan Abou-Alfa, Apurva Desai, Jimmy Hwang, Miguel A. Villalona-Calero, E. Claire Dees, Lionel D. Lewis, Marwan G. Fakih, Martin J. Edelman, Fred Millard, Richard C. Frank, Raymond J. Hohl, Mark J. Ratain
J. Clin. Oncol vol 27 (11) 1800-1805 2009

Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/19255312>

1083 A Phase II Study of Dasatinib in Patients with Chemo-sensitive Relapsed Small Cell Lung Cancer (CALGB 30602)

Antonius A. Miller, Herbert Pang, Lydia Hodgson, Nithya Ramnath, Gregory A. Otterson, Michael J. Kelley, Robert A. Kratzke, Everett E. Vokes
J Thorac Oncol vol 5 (3) 380-384 2010

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20087228>

1084 A Phase II Study of Dasatinib in Patients with Chemo-sensitive Relapsed Small Cell Lung Cancer (CALGB 30602)

Antonius A. Miller, Herbert Pang, Lydia Hodgson, Nithya Ramnath, Gregory A. Otterson, Michael J. Kelley, Robert A. Kratzke, Everett E. Vokes
J Thorac Oncol vol 4 (9, suppl 1) S816, abstract P2.212 2009

Abstract Respiratory <http://journals.lww.com/jto/toc/2009/09001>

1085 Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or

renal dysfunction: CALGB 60101.

Antonius A Miller, Daryl J Murry, Kouros Owzar, Donna R Hollis, Lionel D Lewis, Hedy L Kindler, John L Marshall, Miguel A Villalona-Calero, Martin J Edelman, Raymond J Hohl, Stuart M Lichtman, Mark J Ratain J. Clin. Oncol. vol 25 (21) 3055-60 2007
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/17634483>

1086 Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.

Antonius A Miller, Xiaofei F Wang, Jeffrey A Bogart, Lydia D Hodgson, Caio M S Rocha Lima, James E Radford, Everett E Vokes, Mark R Green J Thorac Oncol vol 2 (7) 645-51 2007
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/17607121>

1087 Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).

Antonius A Miller, Xiaofei F Wang, Lin Gu, Philip Hoffman, Jamil Khatri, Frank Dunphy, Martin J Edelman, Michael Bolger, Everett E Vokes, Mark R Green J Thorac Oncol vol 3 (10) 1159-65 2008
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18827613>

1088 Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers

Christopher A. Miller, Yevgeniy Gindin, Charles Lu, Obi L Griffith, Malachi Griffith, Dong Shen, Jeremy Hoog, Tiandao Li, David E. Larson, Mark Watson, Sherri R Davies, Kelly Hunt, Vera J. Suman, Jacqueline Snider, Thomas Walsh, Graham A. Colditz, Katherine DeSchryver, Richard K. Wilson, Elaine R. Mardis, Matthew J. Ellis Nat Commun vol 7 2016
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/27502118>

1089 Primary and Secondary Endpoint Analysis of N08C9 (Alliance)- A Phase III Randomized Trial of Sulfasalazine versus Placebo in the Prevention of Acute Radiation Enteritis

R. C. Miller, D. G. Petereit, J. A. Sloan, H. Liu, J. A. Jr Martenson, J. D. 3rd Bearden, R. Sapiante, G. R. Seeger, R. B. Mowat, B. Liem, M. J. Iott, C. L. Loprinzi INT J RADIAT BIOL vol 90 (1 supplement) S86 2014
Abstract Symptom Inter <http://www.sciencedirect.com/science/article/pii/S0360301614011274>

1090 Primary and Secondary Endpoint Analysis of N08C9 (Alliance)- A Phase III Randomized Trial of Sulfasalazine versus Placebo in the Prevention of Acute Radiation Enteritis

R. C. Miller, D. G. Petereit, J. A. Sloan, H. Liu, J. A. Jr Martenson, J. D. 3rd Bearden, R. Sapiante, G. R. Seeger, R. B. Mowat, B. Liem, M. J. Iott, C. L. Loprinzi J. Clin. Oncol. vol 33 (3 suppl) 562 2015
Abstract Symptom Inter http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/562

1091 N08C9 (Alliance) - A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy

R. C. Miller, D. G. Petereit, J. A. Sloan, H. Liu, J. A. Martenson Jr, J. D. Bearden 3rd, R. Sapiante, G. R. Seeger, M. J. Iott, C. L. Loprinzi Int. J. Radiat. Oncol. Biol. Phys. vol 87 (5) 1186 2013
Abstract Symptom Inter <http://www.redjournal.org/article/S0360-3016%2813%2903204-5/fulltext>

1092 N09C6 (Alliance) -A phase III, randomized double-blind study of N09C6 rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy

R. Miller, J. Leenstra, R. Qun, J. Martenson, J. Dornfeld, J. Bearden, D. Puri, P. Stella, R. Foote, C. Loprinzi Int. J. Radiat. Oncol. Biol. Phys. vol 85 (1) abstr LBA1-21 2013
Abstract Symptom Inter <http://www.redjournal.org/article/S0360-3016%2812%2903772-8/fulltext#sec4>

- 1093 A Phase III, Randomized Double-Blind Study of Doxepin Rinse versus “Magic Mouthwash” versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Head and Neck Radiotherapy with or without Chemotherapy (Alliance A221304)**
Robert C. Miller, Jennifer Le-Rademacher, Terence Sio, James L. Leenstra, Grant Rine, Amy Curtis, Anurag K. Singh, James A. Martenson, Paul J. Novotny, Angelina D. Tan, Paul Reiter, Charles L. Loprinzi *Int. J. Radiat. Oncol. Biol. Phys.* vol 96 (5) 938 2016
Abstract Symptom Inter
<http://pm6mt7vg3j.scholar.serialssolutions.com/?sid=google&auinit=RC&aulast=Miller&atitle=A+Phase>
- 1094 N09C6 (Alliance) - A Phase III, Randomized Double-Blind Study of Doxepin Rinse versus Placebo in the Treatment of Acute Oral Mucositis Pain: Secondary analysis of the continuation phase**
Robert C. Miller, James L. Leenstra, Rui Qin, James A. Martenson, Kenneth J. Dornfeld, James D. Bearden, Dev Puri, Philip J. Stella, Robert L. Foote, C. L. Loprinzi *European Journal of Cancer* vol 49 S759 2013
Abstract Symptom Inter
<https://www.clinicalkey.com/ui/service/content/url?eid=1-s2.0-S0959804913700650>
- 1095 N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine vs Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy**
Robert C. Miller, Daniel G. Peterit, Jeff A. Sloan, Heshan Liu, James A. Martenson, James D. Bearden, Ronald Sapiante, Grant R. Seeger, Rex B. Mowat, Ben Liem, Matthew J. Iott, Charles L. Loprinzi *Int. J. Radiat. Oncol. Biol. Phys.* vol 95 (4) 1168-1174 2016
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/27354129>
- 1096 Mometasone Furoate Effect on Acute Skin Toxicity in Breast Cancer Patients Receiving Radiotherapy: A Phase 3 Double-Blind, Randomized Trial from the North Central Cancer Treatment Group N06C4**
Robert C. Miller, David J. Schwartz, Jeff A. Sloan, Patricia C. Griffin, Richard L. Deming, Jon C. Anders, Thomas J. Stoffel, Robert E. Haselow, Paul L. Schaefer, James D. Bearden, Pamela J. Atherton, Charles L. Loprinzi, James A. Martenson *Int J Radiat Oncol Biol Phys* vol 79 (5) 1460-1466 2011
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/20800381>
- 1097 Development and Validation of a Dominant Clone Precision Medicine Classification for Treatment of Elderly Acute Myeloid Leukemia (Alliance)**
Alice S. Mims, Uma Borate, Jessica Kohlschmidt, Brianna Norris, Taylor Bucy, James S. Blachly, Shelley Orwick, Ann-Kathrin Einfeld, Deedra Nicolet, Krzysztof Mrzek, Bhavana Bhatnagar, Eytan Stein, Richard M. Stone, Jonathan E. Kolitz, Eunice S. Wang, Bayard L. Powell, Amy Burd, Ross Levine, Brian Druker, Clara D. Bloomfield and John C. Byrd *Blood* vol 132 (Suppl 1) 1489 2018
Abstract *Leuk Corr Sci* C8461, CALGB-20202
http://www.bloodjournal.org/content/132/Suppl_1/1489
- 1098 Comparisons between TP53 mutations and TP73 mutations in adult acute myeloid leukemia (AML) (Alliance)**
Alice S. Mims, Jessica Kohlschmidt, Ann-Kathrin Einfeld, Krzysztof Mrzek, James S. Blachly, Shelley Orwick, Deedra Nicolet, Deepa Sampath, Richard M. Stone, Bayard L. Powell, Jonathan E. Kolitz, John C. Byrd, Clara D. Bloomfield *Blood* vol 132 (Suppl 1) 1488 2018
Abstract *Leuk Corr Sci* C8461, CALGB-20202
http://www.bloodjournal.org/content/132/Suppl_1/1488?sso-checked=true
- 1099 Evaluation of the stage IB designation of the 7th edition of the AJCC staging system: Biologic factors are more important**

E. Mittendorf, K. Ballman, L. McCall, N. Hansen, A. Lucci, S. Gabram, M. Urist, J. Crow, T. Hurd, K. Hunt, A. Giuliano *Cancer Res.* vol 72 (24 suppl) Abstract nr P1-01-06 2012
Abstract Breast http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/1130

1100 Evaluation of the Stage IB Designation of the American Joint Committee on Cancer Staging System in Breast Cancer

Elizabeth A. Mittendorf, Karla V. Ballman, Linda M. McCall, Min Yi, Aysegul A. Sahin, Isabelle Bedrosian, Nora Hansen, Sheryl Gabram, Thelma Hurd, Armando E. Giuliano, Kelly K. Hunt *J. Clin. Oncol* vol 33 (10) 1119-1127 2015
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25488970>

1101 MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer

Jinsei Miyoshi, Shusuke Toden, Kazuhiro Yoshida, Yuji Toiyama, Steven R. Alberts, Masato Kusunoki, Frank A. Sinicrope, Ajay Goel *Sci Rep* vol 7 2017
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/28262692>

1102 Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series

James L. Mohler, Susan Halabi, Stephen T. Ryan, Ali Al-Daghmin, Mitchell H. Sokoloff, Gary D. Steinberg, Ben L. Sanford, James A. Eastham, Philip J. Walther, Michael J. Morris, Eric J. Small *Prostate Cancer Prostatic Dis.* vol 22 (2) 309-16 2019
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/30385835>

1103 A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second line therapy in advanced non-small cell lung cancer (NSCLC) of non-squamous histology: NCCTG N0626 study

J. R. Molina, G. K. Dy, N. R. Foster, Allen Ziegler, A. A. Adjei, K. M. Jr Rowland, M. C. Aurby, P. J. Flynn, S. J. Mandrekar, S. E. Schild *J. Clin. Oncol.* vol 29 (suppl) abstr 7513 2011
Abstract Respiratory http://ascopubs.org/doi/abs/10.1200/jco.2011.29.15_suppl.7513

1104 A randomized double-blinded phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG N0923 (Alliance) Study

J. R. Molina, S. J. Mandrekar, G. Dy, M. C. Aubry, K. A. Ziegler, S. R. Dakhil, B. A. Sachs, J. J. Nieva, S. E. Schild, K. Burroughs, A. Williams, C. M. Rudin, A. A. Adjei *J. Clin. Oncol.* vol 31 (15 suppl) abstr 7509 2013
Abstract Respiratory <http://meetinglibrary.asco.org/content/115112-132>

1105 A phase II study of the VEGFR inhibitor pazopanib (P) in patients with newly diagnosed or relapsed malignant pleural mesothelioma (MPM): an NCCTG study

J. R. Molina, S. J. Mandrekar, K. L. Allen Ziegler, G. S. Soori, K. M. Rowland Jr, S. E. Schild, P. Ivy, A. A. Adjei *J Thorac Oncol* vol 4 (4, Supplement 1) PD4.1.2, S456 2009
Abstract Respiratory <http://journals.lww.com/jto/toc/2009/09001>

1106 NCCTG Phase II Trial (N0621) of the SRC inhibitor AZD0530 after 4 cycles of cytoreductive chemotherapy for patients with Extensive Stage Small Cell Lung Cancer (ED-SCLC)

Julian R. Molina, Nathan R. Foster, Garth D. Nelson, Andrew V. Grain ger, Preston D. Steen, Daniel A. Nikcevich, Steven E. Schild, John Wright, Alex A. Adjei *J Thorac Oncol* vol 4 (9) abstr PD4.3.4 2009
Abstract Respiratory [http://www.jto.org/article/S1556-0864\(15\)33608-X/fulltext](http://www.jto.org/article/S1556-0864(15)33608-X/fulltext)

1107 A phase II trial of the Src-kinase inhibitor saracatinib after 4 cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621

Julian R. Molina, Nathan R. Foster, Thanyanan Reungwetwattana, Garth D. Nelson, Andrew V. Grainger, Preston D. Steen, Philip J. Stella, Randolph Marks, John Wright, Alex A. Adjei Lung Cancer vol 85 (2) 245-250 2014
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/24957683>

1108 Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: Results of Cancer and Leukemia Group B (CALGB) 9782

J.P. Monk, S. Halabi, J. Picus, A. Hussain, G. Philips, E. Kaplan, T. Ahles, Lin Gu, N. Vogelzang, W.K. Kelly, E.J. Small Cancer vol 118 (17) 4139-4147 2012
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/22180287>

1109 Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222

Joseph O. Moore, Stephen L. George, Richard K. Dodge, Philip C. Amrein, Bayard L. Powell, Jonathan E. Kolitz, Maria R. Baer, Frederick R. Davey, Clara D. Bloomfield, Richard A. Larson, Charles A. Schiffer Blood vol 105 (9) 3420-3427 2005
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/15572587>

1110 Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).

Vicente Morales-Oyarvide, Chen Yuan, Ana Babic, Sui Zhang, Donna Niedzwiecki, Jennie C Brand-Miller, Laura Sampson-Kent, Xing Ye, Yanping Li, Leonard B Saltz, Robert J Mayer, Rex B Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Kana Wu, Walter C Willett, Edward L Giovannucci, Brian M Wolpin, Jeffrey A Meyerhardt, Charles S Fuchs, Kimmie Ng J. Natl. Cancer Inst. vol 111 (2) 170-9 2019
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/30726946>

1111 Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB

A. R. Moraska, P. J. Atherton, D. W. Szydlo, D. L. Barton, P. J. Stella, K. M. Jr Rowland, P. L. Schaefer, J. Krook, J. D. 3rd Bearden, C. L. Loprinzi J Support Oncol vol 8 (3) 128-132 2010
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/20552926>

1112 Gabapentin for the management of hot flashes in prostate cancer survivors: A longitudinal continuation study—NCCTG trial N00CB

A. R. Moraska, P. J. Atherton, D. W. Szydlo, D. L. Barton, P. J. Stella, K. M. Rowland Jr, P. L. Schaefer, J. E. Krook, J. Bearden, C. L. Loprinzi J. Clin. Oncol. vol 28 (15s) abstr 9139 2010
Abstract Symptom Inter
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

1113 Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial

A. R. Moraska, A. Sood, S. R. Dakhil, J. A. Sloan, D. Barton, P. J. Atherton, J. J. Suh, P. C. Griffin, D. B. Johnson, A. Ali, P. T. Silberstein, S. F. Duane, C. L. Loprinzi J. Clin. Oncol. vol 28 (23) 3673-3679 2010
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/20625123>

1114 Serum Biomarker Analysis in a Phase II Study of Irinotecan in Refractory Metastatic Breast Cancer

A. Moreno-Aspitia, S. Anderson, M. Reinholz, A. Dueck, J. Lafky, D. Hillman, E. Perez Cancer Res. vol 69 (2, suppl 1) abstr 6074 2009

1115 Serum HER2 (sHER2) levels in early-stage HER2 neu (+) breast cancer (HER2 + BC): Results from the NCCTG adjuvant intergroup trial N9831

A. Moreno-Aspitia, A. Dueck, W. Lingle, L. Kutteh, K. Tenner, N. Davidson, S. Martino, P. Kaufman, W. Carney, E. Perez *J. Clin. Oncol.* vol 26 (15s) abstr 529 2008

Abstract Breast http://meeting.ascpubs.org/cgi/content/abstract/26/15_suppl/529

1116 Paclitaxel-Related Peripheral Neuropathy Associated with Improved Outcome of Patients with Early Stage HER2+ Breast Cancer Who Did Not Receive Trastuzumab in the N9831 Clinical Trial

A. Moreno-Aspitia, A. Dueck, T. Patel, D. Hillman, K. Tenner, S. Dakhil, K. Jr Rowland, S.

Mclaughlin, E. Perez, Tbc Breast Cancer Intergroup of North America *Cancer Res.* vol 69 (24 Supplement) abstr 2100 2009

Abstract Breast http://cancerres.aacrjournals.org/cgi/content/abstract/69/24_MeetingAbstracts/2100

1117 Baseline and recurrence levels of soluble HER2 (sHER2) in early-stage HER2-neu positive breast cancer (HER2+BC) from the NCCTG adjuvant Intergroup trial N9831

A. Moreno-Aspitia, D. W. Hillman, A. C. Dueck, W. P. Carney, W. L. Lingle, K. S. Tenner, J. M.

Lafky, M. M. Reinholz, L. A. Kutteh, E. A. Perez *J. Clin. Oncol.* vol 27 (15s) abstr 539 2009

Abstract Breast <http://meetinglibrary.asco.org/content/33967-65>

1118 Soluble HER2 (sHER2) levels in HER2-positive breast cancer patients receiving chemotherapy with or without trastuzumab: Results from the NCCTG adjuvant trial N9831

A. Moreno-Aspitia, D. W. Hillman, S. H. Dyar, K. S. Tenner, J. Gralow, P. A. Kaufman, N. E.

Davidson, J. M. Lafky, M. M. Reinholz, W. L. Lingle, L. A. Kutteh, W. P. Carney, A. C. Dueck, E. A. Perez *Cancer* vol 119 (15) 2675-2682 2013

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/23744760>

1119 N0937 (Alliance): Final clinical results and correlative data from the phase II trial of cisplatin (C) and the novel agent brostallicin (B) in patients with metastatic triple-negative breast cancer (mTNBC)

A. Moreno-Aspitia, H. Liu, D. Hillman, K. M. Jr Rowland, X. Geiger, P. J. Stella, P. Kourlas, H. M. Gross, N. Karlin, M. J. Bury, G. S. Soori, A. Nassar, E. A. Perez *J. Clin. Oncol.* vol 31 (15 suppl) abstr 1059 2013

Abstract Breast <http://meetinglibrary.asco.org/content/115710-132>

1120 N0937 (Alliance): Preliminary results of a phase II clinical trial of cisplatin and the novel agent brostallicin in patients with metastatic triple negative breast cancer (mTNBC)

A. Moreno-Aspitia, K. M. Jr Rowland, J. B. Allred, H. Liu, P. J. Stella, H. M. Gross, G. S. Soori, N. Karlin, E. A. Perez *Cancer Res.* vol 72 (24 Suppl) P1-12-06 2012

Abstract Breast http://cancerres.aacrjournals.org/content/72/24_Supplement/P1-12-06.short

1121 Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer

Alvaro Moreno-Aspitia, Eileen Holmes, Christian Jackisch, Evandro de Azambuja, Frances Boyle, David W. Hillman, Larissa Korde, Debora Fumagalli, Miguel Izquierdo, Ann McCullough, Antonio C. Wolff, Kathleen Pritchard, Michael Untch, Istvan Lang, Binghe Xu, Ian Smith, Carlos H. Barrios, Rich Gelber, Jose Baselga, Martine Piccart-Gebhart *J. Clin. Oncol.* vol 35 (15 suppl) abstr 502 2017

Abstract Breast http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.502

1122 Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to

- Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336**
Alvaro Moreno-Aspitia, Roscoe F. Morton, David W. Hillman, Wilma L. Lingle, Kendrith M. Rowland, Martin Wiesenfeld, Patrick J. Flynn, Tom R. Fitch, Edith A. Perez J Clin Oncol vol 27 (1) 11-15 2009
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/19047293>
- 1123 A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis.**
V. A. Morrison, J. L. Johnson, S. Jung, J. P. Leonard, B. D. Cheson J. Clin. Oncol. vol 28 (15s) abstr 8106 2010
Abstract Lymphoma <http://meetinglibrary.asco.org/content/47551-74>
- 1124 Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)**
V. A. Morrison, S.-H. Jung, J. Johnson, A. Lacasce, K. A. Blum, N. L. Bartlett, B. D. Cheson ASH Annual Meeting Abstracts vol 120 (21) -3696 2012
Abstract Lymphoma <https://ash.confex.com/ash/2012/webprogram/Paper51222.html>
- 1125 Therapy with bortezomib plus lenalidomide is tolerable in patients (pts) with relapsed/refractory mantle cell lymphoma (MCL): Interim results of CALGB 50501**
V. A. Morrison, S. Jung, J. Johnson, J. Leonard, B. Cheson Ann. Oncol. vol 22 (Iv221-222) abstr 436 2011
Abstract Lymphoma
http://annonc.oxfordjournals.org/content/22/suppl_4/iv220.full.pdf+html?sid=3b797230-91b6-427e-a6e4
- 1126 A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501)**
V. A. Morrison, S. Jung, J. Leonard, B. D. Cheson J. Clin. Oncol. vol 29 (suppl) abstr TPS223 2011
Abstract Lymphoma <http://meetinglibrary.asco.org/content/47551-74>
- 1127 Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901)**
V. A. Morrison, B. L. Peterson, K. R. Rai, J. C. Byrd, R. A. Larson Blood vol 110 (11) 756 2007
Abstract Leukemia C9011, CALGB-19901, CALGB-9712
<http://www.bloodjournal.org/content/110/11/756.full>
- 1128 Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501)**
Vicki A. Morrison, Sin-Ho Jung, Jeffrey Johnson, Ann LaCasce, Kristie A. Blum, Nancy L. Bartlett, Brandelyn N. Pitcher, Bruce D. Cheson Leuk. Lymphoma vol 56 (4) 958-964 2015
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/24996441>
- 1129 The Impact of Actual Body Weight-Based Chemotherapy Dosing and Body Size on Adverse Events and Outcome in Older Patients with Breast Cancer: Results from Cancer and Leukemia Group B (CALGB) Trial 49907 (Alliance A151436)**
Vicki A. Morrison, Linda McCall, Hyman B. Muss, Aminah Jatoui, Harvey J. Cohen, Constance T. Cirrincione, Jennifer A. Ligibel, Jacqueline M. Lafky, Arti Hurria J Geriatr Oncol vol 9 (3) 228-34 2018
Manuscript Older Adult CALGB-49907, A151436 <http://www.ncbi.nlm.nih.gov/pubmed/29233548>
- 1130 Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim**

J. Moukharskaya, D.M. Abrams, T. Ashikaga, F. Khan, J. Schwartz, K. Wilson, C. Verschraegen, T. Openshaw, J. Valentine, J. Eneman, P. Unger, S. Ades. Support Care Cancer vol 24 (7) 3085-3093 2016

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/26894485>

1131 Randomized phase II pilot study of loratadine for the prevention of bone pain caused by pegfilgrastim.

Julia Moukharskaya, Deborah Michelle Abrams, Farrah B. Khan, Joanna Schwartz, Steven Ades, Takamaru Ashikaga, Thomas H. Openshaw, Claire F. Verschraegen, Steven M. Grunberg J. Clin. Oncol. vol 32 (5s) abstr 9628 2014

Abstract Symptom Inter http://abstracts.asco.org/144/AbstView_144_130880.html

1132 SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen

Ann M Moyer, Vera J Suman, Richard M Weinshilboum, Rajeswari Avula, John L Black, Stephanie L Safgren, Mary J Kuffel, Matthew M Ames, James N Ingle, Matthew P Goetz Pharmacogenomics vol 12 (11) 1535-1543 2011

Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/21961651>

1133 Prognostic Significance of Unbalanced Chromosome Abnormalities Used by 2008 World Health Organization (WHO) Classification to Define Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes in Adults: a Cancer and Leukemia Group B (CALGB) Study

K. Mrozek, K. B. Holland, M. J. Pettenati, K. Maharry, G. Marcucci, M. R. Baer, J. E. Kolitz, D. Margeson, C. G. Edwards, A. J. Carroll, R. A. Larson, C. D. Bloomfield Blood vol 114 (22) abstr 2602 2009

Abstract Leuk Corr Sci <http://www.bloodjournal.org/content/114/22/2602>

1134 Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts)

K. Mrozek, G. Marcucci, K. Maharry, D. Nicolet, H. Becker, S. P. Whitman, K. H. Metzeler, S. Schwind, Y.-Z. Wu, J. Kohlschmidt, M. J. Pettenati, P. R. K. Koduru, N. A. Heerema, A. W. Block, S. R. Patil, M. R. Baer, J. E. Kolitz, J. O. Moore, A. J. Carroll, R. A. Larson, C. D. Bloomfield Blood vol 118 (21) -414 2011

Abstract Leuk Corr Sci C8525, CALGB-10201, CALGB-19808, CALGB-20202, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720

<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/414>

1135 Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: The Cancer and Leukemia Group B experience

Krzysztof Mrózek, Andrew J. Carroll, Kati Maharry, Kathleen W. Rao, Shivanand R. Patil, Mark J. Pettenati, Michael S. Watson, Diane C. Arthur, Ramana Tantravahi, Nyla A. Heerema, Prasad R. K. Koduru, AnneMarie W. Block, Mazin B. Qumsiyeh, Colin G. Edwards, Lisa J. Sterling, Kelsi B. Holland, Clara D. Bloomfield Int. J. Oncol. vol 33 (2) 239-244 2008

Manuscript Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pubmed/18636143>

1136 Molecular landscape and clinical features of acute myeloid leukemia (AML) with complex karyotype (CK) CALGB 20202 and 8461 (Alliance)

Krzysztof Mrózek, Ann-Kathrin Einfeld, Jessica Kohlschmidt, Andrew J. Carroll, Deedra Nicolet, James S. Blachly, Christopher J. Walker, Eunice S. Wang, Geoffrey L. Uy, Jonathan E. Kolitz, Bayard L. Powell, William Blum, Richard M. Stone, John C. Byrd, Clara D. Bloomfield Blood vol 130 (Suppl 1) 1404 2017

Abstract Leuk Corr Sci CALGB-20202, CALGB-8461

http://www.bloodjournal.org/content/130/Suppl_1/1404

1137 Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically

Krzysztof Mrózek, Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Andrew J. Carroll, Christopher J. Walker, Deedra Nicolet, James S. Blachly, Marius Bill, Dimitrios Papaioannou, Eunice S. Wang, Geoffrey L. Uy, Jonathan E. Kolitz, Bayard L. Powell, William Blum, Richard M. Stone, John C. Byrd, Clara D. Bloomfield *Leukemia* vol 33 (7) 1620-34 2019
Manuscript *Leuk Corr Sci* C8461, C9665, CALGB-20202
<http://www.ncbi.nlm.nih.gov/pubmed/30737482>

1138 Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

Krzysztof Mrózek, Guido Marcucci, Deedra Nicolet, Kati S. Maharry, Heiko Becker, Susan P. Whitman, Klaus H. Metzeler, Sebastian Schwind, Yue-Zhong Wu, Jessica Kohlschmidt, Mark J. Pettenati, Nyla A. Heerema, AnneMarie W. Block, Shivanand R. Patil, Maria R. Baer, Jonathan E. Kolitz, Joseph O. Moore, Andrew J. Carroll, Richard M. Stone, Richard A. Larson, Clara D. Bloomfield *J. Clin. Oncol.* vol 30 (36) 4515-4523 2012
Manuscript *Leuk Corr Sci* CALGB-10201, CALGB-19808, CALGB-8461, CALGB-8525, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9720
<http://www.ncbi.nlm.nih.gov/pubmed/22987078>

1139 Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

Krzysztof Mrózek, Guido Marcucci, Peter Paschka, Susan P. Whitman, Clara D. Bloomfield *Blood* vol 109 (2) 431-448 2007
Manuscript *Leuk Corr Sci* <http://www.ncbi.nlm.nih.gov/pubmed/16960150>

1140 Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL)

L. S. Muffly, W. Stock, K. Breitenbach, F. Mulkey, S. Luger, A. Advani, E. Parker, M. C. Foster, M. Liedtke, R. Garcia, K. Coffan, J. Sipin-Sayno, J. Mcneer, M. S. Tallman, F. R. Appelbaum, R. M. Stone, R. A. Larson *Blood* vol 120 (21) 3535 2012
Abstract *Disparities* CALGB-10403, C10403 <http://www.bloodjournal.org/content/120/21/3535>

1141 MRI phenotype and tumor subtype affect breast conservation eligibility and MRI accuracy in the I-SPY 1 trial

R. A. Mukhtar, N. M. Hylton, M. Rosen *Cancer Res.* vol 71 (24, suppl 3) abstr SABCS11-PD02-05 2011
Abstract *Breast* http://cancerres.aacrjournals.org/content/71/24_Supplement/PD02-05

1142 Lobular breast cancer and NAC: Combined results from the NKI and I-SPY 1 trial

R. A. Mukhtar, E. Lips, J. Wesseling, C. Livasy, C. Yau, D. A. Berry, L. Van't Veer, L. A. Carey, L. J. Esserman, S. Rodenhuis, E. S. Hwang *Cancer Res.* vol 71 (24, suppl 3) abstr 11-P11-06-10 2011
Abstract *Correl Sci NOS* ACRIN-6657, CALGB-150007
http://cancerres.aacrjournals.org/content/71/24_Supplement/P1-06-10

1143 PCNA+ tumor associated macrophages are associated with M1 and M2 gene expression, and confer poor prognosis in the absence of anti-tumor immune environment

R. A. Mukhtar, D. Wolf, V. Tandon, J. Zhu, M. Lenburg, L. Van't Veer, M. Campbell, L. J. Esserman *Cancer Res.* vol 71 (24, suppl 3) abstr SABCS11-P14-09-19 2011
Abstract *Correl Sci NOS* ACRIN-6657, CALGB-150007
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/71/24_MeetingAbstracts/P4-09-19

- 1144 Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)**
Rita A. Mukhtar, Christina Yau, Mark Rosen, Vickram J. Tandon, Nola Hylton, Laura J. Esserman
Ann. Surg. Oncol vol 20 (12) 3823-3830 2013
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/23780381>
- 1145 Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907**
H. B. Muss, D. A. Berry, C. T. Cirincione, M. Theodoulou, A. M. Mauer, H. J. Cohen, A. H. Partridge, L. Norton, C. A. Hudis, E. P. Winer J. Clin. Oncol. vol 26 (May 20 suppl) abstr 507 2008
Abstract Older Adult
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID
- 1146 Standard chemotherapy vs capecitabine for older women with early-stage breast cancer: Long-term results of CALGB 49907 (Alliance)**
Hyman B. Muss, Donald A. Berry, Constance T. Cirincione, Maria Theodoulou, Arti Hurria, Harvey J. Cohen, Ann H. Partridge, Larry Norton, Clifford A. Hudis, Eric P. Winer J. Clin. Oncol. vol 33 (suppl) abstr 1022 2015
Abstract Breast <http://meetinglibrary.asco.org/content/143212-156>
- 1147 Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer**
Hyman B. Muss, Donald A. Berry, Constance T. Cirincione, Maria Theodoulou, Ann M. Mauer, Alice B. Kornblith, Ann H. Partridge, Lynn G. Dressler, Harvey J. Cohen, Heather P. Becker, Patricia A. Kartcheske, Judith D. Wheeler, Edith A. Perez, Antonio C. Wolff, Julie R. Gralow, Harold J. Burstein, Ahmad A. Mahmood, Gustav Magrinat, Barbara A. Parker, Ronald D. Hart, Debjani Grenier, Larry Norton, Clifford A. Hudis, Eric P. Winer N Engl J Med vol 360 (20) 2055-2065 2009
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/19439741>
- 1148 Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.**
Hyman B. Muss, Donald A. Berry, Constance Cirincione, Daniel R. Budman, I. Craig Henderson, Marc L. Citron, Larry Norton, Eric P. Winer, Clifford A. Hudis J. Clin. Oncol. vol 25 (24) 3699-704 2007
Manuscript Breast C8541, C9741 <http://www.ncbi.nlm.nih.gov/pubmed/17704418>
- 1149 Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.**
Hyman B. Muss, Mei-Yin C. Polley, Donald A. Berry, Heshan Liu, Constance T. Cirincione, Maria Theodoulou, Ann M. Mauer, Alice B. Kornblith, Ann H. Partridge, Lynn G. Dressler, Harvey J. Cohen, Patricia A. Kartcheske, Edith A. Perez, Antonio C. Wolff, Julie R. Gralow, Harold J. Burstein, Ahmad A. Mahmood, Linda M. Sutton, Gustav Magrinat, Barbara A. Parker, Ronald D. Hart, Debjani Grenier, Arti Hurria, Aminah Jatoi, Larry Norton, Clifford A. Hudis, Eric P. Winer, Lisa Carey J. Clin. Oncol. JCO1900647 2019
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/31339827>
- 1150 Quality of life (QOL) and toxicity among patients in CALGB 80405**
M. J. Naughton, D. Schrag, A. P. Venook, D. Niedzwiecki, R. T. Anderson, H.-J. Lenz, S. S. Grubbs
J. Clin. Oncol. vol 31 (15 suppl) abstr 3611 2013
Abstract Health Outcome
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/3611?sid=c1634dd9-82ab-4bf4-bb6f-25af4
- 1151 Health-related quality of life outcomes for the LEAP Study - Alliance 70305: a lymphedema prevention intervention trial for newly-diagnosed breast cancer patients**

MJ Naughton, DK Seisler, JA Sloan, H Liu, J Le-Rademacher, J Oliveri, JM Armer, G Unzeitig, M Schwartz, M Melnik, JR Taylor, ED Paskett Qual Life Res vol 27 (suppl 1) abstr 2019 2018
Abstract Health Outcome

1152 Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Rudolph M. Navari, Rui Qin, Kathryn J. Ruddy, Heshan Liu, Steven F. Powell, Madhuri Bajaj, Leah Dietrich, David Biggs, Jacqueline M. Lafky, Charles L. Loprinzi N. Engl. J. Med. vol 375 (2) 134-142 2016
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/27410922>

1153 Olanzapine For The Prevention Of Chemotherapy Induced Nausea And Vomiting (CINV) In Patients Receiving Highly Emetogenic Chemotherapy (HEC): Alliance A221301 A Randomized, Double-Blind, Placebo-Controlled Trial
Rudolph M. Navari, Rui Qin, Kathryn J. Ruddy, Heshan Liu, Steven Powell, Charles L. Loprinzi J. Clin. Oncol. vol 33 (suppl 29S) abstr 176 2015
Abstract Symptom Inter <http://meetinglibrary.asco.org/content/155048-165>

1154 Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4)
Michelle A. Neben-Wittich, Pamela J. Atherton, David J. Schwartz, Jeff A. Sloan, Patricia C. Griffin, Richard L. Deming, Jon C. Anders, Charles L. Loprinzi, Kelli N. Burger, James A. Martenson, Robert C. Miller Int. J. Radiat. Oncol. Biol. Phys. vol 81 (2) 397-402 2011
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/20888137>

1155 Cancer and Aging: Reflections for Elders (CARE): A pilot randomized controlled trial of a psychotherapy intervention for older adults with cancer
Christian J. Nelson, Rebecca M. Saracino, Andrew J. Roth, Elizabeth Harvey, Anne Martin, Mark Moore, Dana Marcone, Shannon R. Poppito, Jimmie Holland Psychooncology vol 28 (1) 39-47 2019
Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/30296337>

1156 Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study
Andreas Neubauer, Kati Maharry, Krzysztof Mrózek, Christian Thiede, Guido Marcucci, Peter Paschka, Robert J. Mayer, Richard A. Larson, Edison T. Liu, Clara D. Bloomfield J Clin Oncol vol 26 (28) 4603-4609 2008
Manuscript Leuk Corr Sci C8525, C8765, CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/18559876>

1157 FTY720, a new and alternative strategy for treating blast crisis CML and Ph1 ALL patients
P. Neviani, R. Santhanam, J. Oaks, A. Eiring, M. Notari, B. W. Blaser, S. Liu, R. Trotta, N. Muthusamy, C. Gambacorti, B. J. Druker, J. Cortes, G. Marcucci, C. Chen, D. C. Roy, M. A. Caligiuri, C. D. Bloomfield, J. C. Byrd, D. Perrotti AACR Annual Meeting abstr 1638 2007
Abstract Leuk Corr Sci CALGB-8461, CALGB-9665
<http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={6D254926-C351-44CF-8>

1158 FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia
Paolo Neviani, Ramasamy Santhanam, Joshua J. Oaks, Anna M. Eiring, Mario Notari, Bradley W. Blaser, Shujun Liu, Rossana Trotta, Natarajan Muthusamy, Carlo Gambacorti-Passerini, Brian J. Druker, Jorge Cortes, Guido Marcucci, Ching-Shih Chen, Nicole M. Verrills, Denis C. Roy, Michael A. Caligiuri, Clara D. Bloomfield, John C. Byrd, Danilo Perrotti J Clin Invest vol 117 (9) 2408-2421 2007

1159 Genetic correlates of therapeutic toxicities of stage III colon cancer (CC) patients treated with adjuvant FOLFOX+/-cetuximab (Alliance NCCTG N0147)

Polly A. Newcomb, Wei Sun, Xinwei Hua, Barbara Banbury, Amanda I. Phipps, Jonathan M. Kocarnik, Tabitha A. Harrison, Qian Shi, Frank Sinicrope, Steve Thibodeau, Emily Chan, Sharlene Gill, Richard M. Goldberg, Morton Kahlenberg, Suresh Nair, Anthony Shields, Ulrike Peters, Steve R. Alberts, Andrew T. Chan J. Clin. Oncol. vol 35 (15 suppl) abstr 3604 2017
Abstract PPP http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3604

1160 Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer

Kimmie Ng, Jeffrey A. Meyerhardt, Andrew T. Chan, Kaori Sato, Jennifer A. Chan, Donna Niedzwiecki, Leonard B. Saltz, Robert J. Mayer, Al B. Benson, Paul L. Schaefer, Renaud Whittom, Alexander Hantel, Richard M. Goldberg, Alan P. Venook, Shuji Ogino, Edward L. Giovannucci, Charles S. Fuchs J. Natl. Cancer Inst vol 107 (1) 2014
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/25432409>

1161 Multivitamin Use Is Not Associated With Cancer Recurrence or Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803

Kimmie Ng, Jeffrey A. Meyerhardt, Jennifer A. Chan, Donna Niedzwiecki, Donna R. Hollis, Leonard B. Saltz, Robert J. Mayer, Al B. Benson, Paul L. Schaefer, Renaud Whittom, Alexander Hantel, Richard M. Goldberg, Charles S. Fuchs J Clin Oncol vol 28 (28) 4354-4363 2010
Manuscript GI CALGB-8461, CALGB-9665 <http://www.ncbi.nlm.nih.gov/pubmed/20805450>

1162 Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803

Kimmie Ng, Shuji Ogino, Jeffrey A. Meyerhardt, Jennifer A. Chan, Andrew T. Chan, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, Al B. Benson, Paul L. Schaefer, Renaud Whittom, Alexander Hantel, Richard M. Goldberg, Monica M. Bertagnolli, Alan P. Venook, Charles S. Fuchs J Natl Cancer Inst vol 103 (20) 1540-1551 2011
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21849660>

1163 Vitamin D Status in Patients With Stage IV Colorectal Cancer: Findings From Intergroup Trial N9741

Kimmie Ng, Daniel J. Sargent, Richard M. Goldberg, Jeffrey A. Meyerhardt, Erin M. Green, Henry C. Pitot, Bruce W. Hollis, Michael N. Pollak, Charles S. Fuchs J Clin Oncol vol 29 (12) 1599-1606 2011
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/21422438>

1164 Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB 80405 (Alliance)

Kimmie Ng, Alan P. Venook, Kaori Sato, Bruce W. Hollis, Donna Niedzwiecki, Cynthia Ye, I-Wen Chang, Bert H. O'Neil, Federico Innocenti, Heinz-Josef Lenz, Charles David Blanke, Robert J. Mayer, Charles S. Fuchs, Jeffrey A. Meyerhardt J. Clin. Oncol. vol 33 (suppl 3) abstr 507 2015
Abstract GI <http://meetinglibrary.asco.org/content/139861-158>

1165 Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance)

Kimmie Ng, Alan P. Venook, Kaori Sato, Chen Yuan, Bruce W. Hollis, Donna Niedzwiecki, Cynthia Ye, I-Wen Chang, Bert H. O'Neil, Federico Innocenti, Heinz-Josef Lenz, Charles David Blanke, Robert J. Mayer, Charles S. Fuchs, Jeffrey A. Meyerhardt J. Clin. Oncol. vol 33 (suppl) abstr 3503 2015

1166 High expression of DNMT3B negatively impacts on clinical outcome of older patients (pts) with primary cytogenetically normal (CN) acute myeloid leukemia (AML) [CALGB 20202 (Alliance)].

C. Niederwieser, J. Kohlschmidt, K. Maharry, K. Mrózek, K. H. Metzeler, S. Volinia, P. Yan, D. Frankhouser, S. P. Whitman, H. Becker, Ann-Kathrin Einfeld, S. Schwind, J. Curfman, Y.-Z. Wu, M. R. Baer, B. L. Powell, J. E. Kolitz, J. O. Moore, T. H. Carter, G. Marcucci, C. D. Bloomfield
European Hematology Association Congress abstr S1168 2013
Abstract Leuk Corr Sci <https://b-com.mci-group.com/EventProgramme/EHA18.aspx>

1167 Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia

Christian Niederwieser, Jessica Kohlschmidt, Stefano Volinia, Susan P. Whitman, Klaus H. Metzeler, Ann-Kathrin Einfeld, Kati Maharry, Pearly Yan, David Frankhouser, Heiko Becker, Sebastian Schwind, Andrew J. Carroll, Deedra Nicolet, Jason H. Mendler, John P. Curfman, Yue-Zhong Wu, Maria R. Baer, Bayard L. Powell, Jonathan E. Kolitz, Joseph O. Moore, Thomas H. Carter, Ralf Bundschuh, Richard A. Larson, Richard M. Stone, Krzysztof Mrózek, Guido Marcucci, Clara D. Bloomfield
Leukemia vol 29 (3) 567-575 2015
Manuscript Leuk Corr Sci C8461, C9665, CALGB-10201, CALGB-20202, CALGB-8525, CALGB-8923, CALGB-9420, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/25204569>

1168 Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance)

Christian Niederwieser, Deedra Nicolet, Andrew J. Carroll, Jonathan E. Kolitz, Bayard L. Powell, Jessica Kohlschmidt, Richard M. Stone, John C. Byrd, Krzysztof Mrózek, Clara D. Bloomfield
Haematologica vol 101 (12) 1516-1523 2016
Manuscript Leuk Corr Sci CALGB-10201, CALGB-10502, CALGB-10503, CALGB-10603, CALGB-10801, CALGB-11002, CALGB-19808, CALGB-8461, CALGB-8525, CALGB-8923, CALGB-9022, CALGB-9621, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/27470602>

1169 Documenting the Natural History of Patients With Resected Stage II Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observation: Results From CALGB 9581

Donna Niedzwiecki, Monica M. Bertagnolli, Robert S. Warren, Carolyn C. Compton, Nancy E. Kemeny, Al Bowen Benson, S. Gail Eckhardt, Steven Alberts, Gity N. Porjosh, David J. Kerr, Anthony Fields, Philippe Rougier, J. Marc Pipas, Joel H. Schwartz, James Atkins, Mark O'Rourke, Michael C. Perry, Richard M. Goldberg, Robert J. Mayer, Thomas A. Colacchio
J Clin Oncol vol 29 (23) 3146-3152 2011
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21747085>

1170 Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)

Donna Niedzwiecki, Wendy L. Frankel, Alan P. Venook, Xing Ye, Paula N. Friedman, Richard M. Goldberg, Robert J. Mayer, Thomas Anthony Colacchio, Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, Peter Kerr, Patrick G. Johnston, Richard D. Kennedy, D. Paul Harkin, Richard L. Schilsky, Monica M. Bertagnolli, Robert S. Warren, Federico Innocenti
J. Clin. Oncol vol 34 (25) 3047-3053 2016
Manuscript Correl Sci NOS C9581, CALGB-150705
<http://www.ncbi.nlm.nih.gov/pubmed/27432924>

1171 A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803

Donna Niedzwiecki, Rian M. Hasson, HeinzJosef Lenz, Cynthia Ye, Mark Redston, Shuji Ogino, Charles S. Fuchs, Carolyn C. Compton, Robert J. Mayer, Richard M. Goldberg, Thomas A. Colacchio, Leonard B. Saltz, Robert S. Warren, Monica M. Bertagnolli *Oncologist* vol 22 (1) 107-114 2017
Manuscript GI C89803, C9581 <http://www.ncbi.nlm.nih.gov/pubmed/27821793>

1172 Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.

Harvey B Niell, James E Herndon, Antonius A Miller, Dorothy M Watson, Alan B Sandler, Karen Kelly, Randolph S Marks, Micheal C Perry, Rafat H Ansari, Grefory Otterson, John Ellerton, Everett E Vokes, Mark R Green *J. Clin. Oncol.* vol 23 (16) 3752-9 2005
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/15923572>

1173 Intrinsic subtype and response to paclitaxel in CALGB 9344 tissue microarrays

T. O. Nielsen, S. D. Jewell, A. D. Thor, D. Gao, C. M. Perou, G. Broadwater, L. N. Harris, D. F. Hayes, D. A. Berry, M. J. Ellis *Breast Cancer Symposium abstr* 23 2009
Abstract Correl Sci NOS C159905, C9344 <http://meetinglibrary.asco.org/content/40158-70>

1174 A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer

Torsten O. Nielsen, Joel S Parker, Samuel Leung, David Voduc, Mark Ebbert, Tammi Vickery, Sherri R. Davies, Jacqueline Snider, Inge J. Stijleman, Jerry Reed, Maggie C.U. Cheang, Elaine R. Mardis, Charles M. Perou, Philip S. Bernard, Matthew J. Ellis *Clin Cancer Res* vol 16 (21) 5222-5232 2010
Manuscript Correl Sci NOS CALGB-159905, CALGB-9344
<http://www.ncbi.nlm.nih.gov/pubmed/20837693>

1175 Electronic Patient-Reported Outcomes and Toxicities During Radiotherapy for Head and Neck Cancer

Joshua R. Niska, Michele Y. Halyard, Angelina D. Tan, Pamela J. Atherton, Samir H. Patel, Jeff A. Sloan *Qual Life Res* vol 26 (7) 1721-31 2017
Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/28247313>

1176 Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance)

A. B. Nixon, S. Halabi, I. Shterev, M. D. Starr, J. C. Brady, J. P. Dutcher, J. O. Hopkins, H. I. Hurwitz, E. Small, B. Rini, P. G. Febbo, D. George *J. Clin. Oncol.* vol 31 (15 suppl) abstr 4520 2013
Abstract GU <http://meetinglibrary.asco.org/content/112878-132>

1177 Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303

A. B. Nixon, H. Pang, M. D. Starr, D. R. Hollis, M. M. Bertagnolli, H. L. Kindler, R. M. Goldberg, A. P. Venook, H. I. Hurwitz *J. Clin. Oncol.* vol 29 (suppl) abstr 10508 2011
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

1178 Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)

Andrew B. Nixon, Herbert Pang, Mark D. Starr, Paula N. Friedman, Monica M. Bertagnolli, Hedy L. Kindler, Richard M. Goldberg, Alan P. Venook, Herbert I. Hurwitz *Clin. Cancer Res.* vol 19 (24) 6957-6966 2013
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24097873>

- 1179 Blood-based biomarkers (BMs) in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI + bevacizumab (Bev), cetuximab (Cetux) or Bev + Cetux: Results from CALGB 80405**
Andrew B. Nixon, Alexander B. Sibley, Ace J. Hatch, Yingmiao Liu, Chen Jiang, Flora Mulkey, Mark D. Starr, John C. Brady, Donna Niedzwiecki, Federico Innocenti, Alan P. Venook, Howard Hochster, Heinz-Josef Lenz, Kouros Owzar, Herbert I. Hurwitz *J. Clin. Oncol.* vol 34 (suppl) abstr 3597 2016
Abstract Correl Sci NOS <http://meetinglibrary.asco.org/content/169258-176>
- 1180 Feasibility of a text-based smoking cessation intervention in rural older adults**
D Noonan, S Silva, J Njuru, T Bishop, L J Fish, L A Simmons, S H Choi, K I Pollak *Health Educ Res* vol 33 (1) 81-88 2018
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/29309599>
- 1181 Addressing Tobacco Use Disparities in Rural Older Adults through a Mobile Phone Intervention: Project Wise**
Devon Noonan, Susan Silva, Laura Fish, Leigh Ann Simmons, Kathryn Pollak 2017
Abstract Prevention http://www.memphis.edu/sph/rural_cancer_pdfs/rcc_posterabstracts.pdf
- 1182 Addressing Tobacco Use Disparities in Rural Older Adults through a Mobile Phone Intervention: Project Wise**
Devon Noonan, Susan Silva, J. Njuru, T. Bishop, Laura J. Fish, Leigh Ann Simmons, Seung Hee Choi, Kathryn I. Pollak 2017
Abstract Prevention
- 1183 Phase II trial combining nab-paclitaxel (NP), gemcitabine (G) and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735**
D. W. Northfelt, A. C. Dueck, T. P. Flynn, P. J. Stella, P. J. Zander, M. K. Melnik, E. S. Pavey, E. A. Perez *J. Clin. Oncol.* vol 29 (suppl) abstr 1126 2011
Abstract Breast
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID
- 1184 Phase II trial of polyglutamated paclitaxel (PPX) with capecitabine for metastatic breast cancer**
D. Northfelt, J. Allred, H. Liu, T. Hobday, M. Rodacker, A. Lyss, T. Fitch, E. Perez *J. Clin. Oncol.* vol 26 (May 20 suppl) abstr 1063 2008
Abstract Breast
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID
- 1185 Phase 2 Trial of Paclitaxel Polyglumex with Capecitabine for Metastatic Breast Cancer**
DW Northfelt, JB Allred, H Liu, TJ Hobday, MW Rodacker, AP Lyss, TR Fitch, EA Perez *Am. J. Clin. Oncol.* vol 37 (2) 167-171 2014
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/23211220>
- 1186 Association Studies of Fc Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831**
Nadine Norton, Rebecca M. Olson, Mark Pegram, Kathleen Tenner, Karla V. Ballman, Raphael Clynes, Keith L. Knutson, Edith A. Perez *Cancer Immunol Res* vol 2 (10) 962-969 2014
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/24989892>
- 1187 Bendamustine and rituximab and lenalidomide (BRR) in the treatment of relapsed and refractory low grade non-Hodgkin lymphoma (NHL): Final results of phase 1 study NCCTG N1088/Alliance**
Grzegorz S. Nowakowski, Betsy LaPlant, William R. Macon, Morie A. Gertz, Thomas M. Habermann, David J. Inwards, Ivana N. Micallef, Donald B. Wender, John P. Leonard, Thomas E. Witzig *J. Clin.*

1188 VATS Lobectomy Has Better Peri-operative Outcomes than Open Lobectomy: Ancillary Analysis of CALGB 140202 (Alliance)

C. E. Nwogu, J. D'cunha, H. Pang, L. Gu, X. Wang, W. G. Richards, L. J. Veit, T. L. Demmy, D. J. Sugarbaker, L. J. Kohman, S. J. Swanson 2014
Abstract Respiratory
<http://www.sts.org/search/google?cx=014846217445771685953%3Aindljwu5dcc&cof=FORID%3A11&>

1189 VATS Lobectomy Has Better Peri-operative Outcomes than open Lobectomy: CALGB 31001, an Ancillary Analysis of CALGB 140202 (Alliance)

Chukwumere E. Nwogu, Jonathan D'Cunha, Herbert Pang, Lin Gu, Xiaofei Wang, William G. Richards, Linda J. Veit, Todd L. Demmy, David J. Sugarbaker, Leslie J. Kohman, Scott J. Swanson
Ann. Thorac. Surg. vol 99 (2) 399-405 2015
Manuscript Respiratory CALGB-140202, CALGB-31001
<http://www.ncbi.nlm.nih.gov/pubmed/25499481>

1190 A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603

E. M. O'Reilly, L. F. Gilman-Rosen, D. Niedzwiecki, D. R. Hollis, S. L. Sutherland, F. M. Overcash, R. M. Goldberg J. Clin. Oncol. vol 26 (May 20 suppl) abstr 4515 2008
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1191 A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603)

Eileen M. O'Reilly, Donna Niedzwiecki, Margaret Hall, Donna Hollis, Tanios Bekaii-Saab, Timothy Pluard, Kathe Douglas, Ghassan K. Abou-Alfa, Hedy L. Kindler, Richard L. Schilsky, Richard M. Goldberg Oncologist vol 15 (12) 1310-1319 2010
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21148613>

1192 LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin CALGB 80402

A. J. Ocean, D. Niedzwiecki, J. N. Atkins, B. A. Parker, B. O'Neil, J. W. Lee, S. Wadler, R. M. Goldberg J. Clin. Oncol. vol 26 (May 20 suppl) abstr 4109 2008
Abstract GI http://meeting.ascopubs.org/cgi/content/short/26/15_suppl/4109

1193 KRAS mutation is not associated with recurrence or survival in 508 stage III colon cancers: Findings from multicenter adjuvant trial CALGB 89803

S. Ogino, J. A. Meyerhardt, N. Irahara, D. Niedzwiecki, D. R. Hollis, L. B. Saltz, R. J. Mayer, P. Schaefer, R. Whittom, A. Hantel, A. B. Benson 3rd, R. M. Goldberg, M. M. Bertagnolli, C. S. Fuchs
Annual Meeting Association of Molecular Pathology STO2 2009
Abstract GI http://www.amp.org/meetings/past_meetings.cfm

1194 Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial

Shuji Ogino, Xiaoyun Liao, Yu Imamura, Mai Yamauchi, Nadine J. McCleary, Kimmie Ng, Donna Niedzwiecki, Leonard B. Saltz, Robert J. Mayer, Renaud Whittom, Alexander Hantel, Al B. Benson, Rex B. Mowat, Donna Spiegelman, Richard M. Goldberg, Monica M. Bertagnolli, Jeffrey A. Meyerhardt, Charles S. Fuchs J. Natl. Cancer Inst vol 105 (23) 1789-1798 2013
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24231454>

1195 KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial

CALGB 89803

Shuji Ogino, Jeffrey A. Meyerhardt, Natsumi Irahara, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, Paul Schaefer, Renaud Whittom, Alexander Hantel, Al B. Benson, Richard M. Goldberg, Monica M. Bertagnolli, Charles S. Fuchs *Clin Cancer Res* vol 15 (23) 7322-7329 2009
Manuscript GI CALGB-89803, C150705 <http://www.ncbi.nlm.nih.gov/pubmed/19934290>

1196 Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803

Shuji Ogino, Kaori Shima, Jeffrey A. Meyerhardt, Nadine J. McCleary, Kimmie Ng, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, Paul Schaefer, Renaud Whittom, Alexander Hantel, Al B. Benson, Donna Spiegelman, Richard M. Goldberg, Monica M. Bertagnolli, Charles S. Fuchs *Clin Cancer Res* vol 18 (3) 890-900 2012
Manuscript GI C89803, C150705 <http://www.ncbi.nlm.nih.gov/pubmed/22147942>

1197 A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.

Scott H Okuno, Robert Delaune, Jeff A Sloan, Nathan R Foster, Matthew J Maurer, Marie-Christine Aubry, Kendrith M Rowland, Gamini S Soori, Daniel A Nikcevich, Carl G Kardinal, Donald W Northfelt, Alex A Adjei *Cancer* vol 112 (8) 1772-9 2008
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18224661>

1198 Arm swelling and psychological well-being among long-term breast cancer survivors

J. M. Oliveri, J. Day, C. M. Alfano, J. E. 2nd Herndon, M. L. Katz, M. L. Bittoni, E. D. Paskett *American Public Health Association Annual Meeting* vol 135 abstr 163789 2007
Abstract Health Outcome http://apha.confex.com/apha/135am/techprogram/paper_163789.htm

1199 Arm/Hand Swelling and Perceived Functioning among Breast Cancer Survivors 12 Years Post-diagnosis: CALGB 79804

Jill M. Oliveri, Jeannette M. Day, Catherine M. Alfano, James E. Herndon, Mira L. Katz, Marisa A. Bittoni, Kathleen Donohue, Electra D. Paskett *J Cancer Surviv* vol 2 (4) 233-242 2008
Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/18792786>

1200 Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance)

D. Ollila, D. Berry, C. Cirrincione, L. Carey, K. Amos, N. L. Henry, E. Winer, C. Hudis, M. Golshan *J. Clin. Oncol.* vol 31 (15 suppl) abstr 501 2013
Abstract Breast
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/501?sid=211d90d6-54e6-40ec-951b-49deb

1201 Axillary Management of Stage II/III Breast Cancer Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-positive) and CALGB 40603 (Triple-negative)

David W Ollila, Constance T Cirrincione, Donald A Berry, Lisa A Carey, William M Sikov, Clifford A Hudis, Eric P Winer, Mehra Golshan *J. Am. Coll. Surg.* vol 224 (4) 688-694 2017
Manuscript Breast CALGB-40601, CALGB-40603 <http://www.ncbi.nlm.nih.gov/pubmed/28089784>

1202 Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL

Adam Olshen, Denise Wolf, Ella F. Jones, David Newitt, Laura J. van 't Veer, Christina Yau, Laura Esserman, Julia D. Wulfschlegel, Rosa I. Gallagher, Lisa Singer, Emanuel F. Petricoin, Nola Hylton, Catherine C. Park *J Med Imaging (Bellingham)* vol 5 (1) 011014 2018
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/29296631>

1203 ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole and

anastrozole in postmenopausal women with clinical stage II/III estrogen receptor positive breast cancer

J. A. Jr Olson, G. V. Babiera, G. Unzeitig, P. K. Marcom, J. M. Guenther, K. Deschryver, C. Allred, V. Suman, K. Hunt, M. J. Ellis Breast Cancer Symposium abstr 91 2010
Abstract Breast http://ascopubs.org/doi/abs/10.1200/jco.2010.28.18_suppl.lba513

1204 Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011.

John A Olson, Linda M McCall, Peter Beitsch, Pat W Whitworth, Douglas S Reintgen, Peter W Blumencranz, A Marilyn Leitch, Sukamal Saha, Kelly K Hunt, Armando E Giuliano J. Clin. Oncol. vol 26 (21) 3530-5 2008
Manuscript Breast ACOSOG-Z0010, ACOSOG-Z0011
<http://www.ncbi.nlm.nih.gov/pubmed/18640934>

1205 Relationship of dietary and red blood cell (RBC) polyunsaturated fatty acids (PUFAs) to inflammatory markers in breast cancer survivors taking Aromatase Inhibitors (AI)

TS Orchard, X Pan, Lester. J, A Logan, CL Shapiro, RD Jackson, MA Belury, L Yee, MB Lustberg Cancer Res. vol 75 (9 suppl) abstr P1-09-30 2015
Abstract Symptom Inter http://cancerres.aacrjournals.org/content/75/9_Supplement/P1-09-30

1206 Testing a Mixture of Fats and Oils for Use as a Placebo in Clinical Trials.

Tonya S. Orchard, Martha A. Belury, Rachel Cole, Rebecca Andridge, Xueliang Pan, Joanne Lester, Amanda Logan, Lisa Yee, Maryam B. Lustberg 2015
Abstract Symptom Inter
<http://www.aocs.org/attend-meetings/archives/106th-aocs-annual-meeting-and-short-courses>

1207 Diet Quality, Inflammation and Quality of Life in Breast Cancer Survivors; a Cross-Sectional Analysis of Pilot Study Data

Tonya Orchard, Rebecca R. Andridge, Lisa D. Yee, Maryam B. Lustberg J Acad Nutr Diet vol 118 (4) 578-88 2018
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/29233615>

1208 Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301

R. Z. Orlowski, B. L. Peterson, B. Sanford, A. A. Chanan-Khan, L. M. Zehngebot, P. R. Watson, M. A. Caligiuri, R. A. Larson, The Cancer Leukemia Group B ASH Annual Meeting Abstracts vol 108 (11) 797 2006
Abstract Leukemia <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;108/11/797>

1209 Survival implications of variation in the thoroughness of pathologic lymph node examination in American College of Surgeons Oncology Group Z0030 (Alliance)

Raymond U. Osarogiagbon, Paul A. Decker, Karla Ballman, Dennis Wigle, Mark S. Allen, Gail E. Darling Ann. Thorac. Surg. vol 102 (2) 363-369 2016
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/27262908>

1210 Survival implications of variation in the lymph node (LN) count in ACOSOG Z0030 (Alliance)

Raymond U. Osarogiagbon, Paul Decker, Karla Ballman, Dennis Wigle, Mark Allen, Gail Darling J Thorac Oncol vol 10 (9) suppl 2, abstr 34-05 2015
Abstract Respiratory [http://www.jto.org/article/S1556-0864\(16\)30010-7/fulltext](http://www.jto.org/article/S1556-0864(16)30010-7/fulltext)

1211 Phase II Study of the HDAC Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (CALGB 30304)

G.A. Otterson, L. Hodgson, H. Pang, E.E. Vokes J Thorac Oncol vol 5 (10) 1644-1648 2010
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20871263>

1212 Milestone prediction for time-to-event endpoint monitoring in clinical trials.

Fang-Shu Ou, Martin Heller, Qian Shi Pharm Stat 2019

Manuscript GI A151730 <http://www.ncbi.nlm.nih.gov/pubmed/30806485>

1213 Concomitant use of midostaurin with Strong CYP3A4 inhibitors: An analysis from the CALGB 10603/RATIFY Trial (Alliance)

Taoufik Ouatas, Vincent Duval, Karen Sinclair, Noah Berkowitz Blood vol 130 (Suppl 1) 3814 2017
Abstract Leukemia http://www.bloodjournal.org/content/130/Suppl_1/3814

1214 Adjuvant targeted therapy following standard adjuvant therapy for resected NSCLC: An initial report from ALCHEMIST (Alliance A151216)

Geoffrey R. Oxnard, Sumithra Mandrekar, Shauna Hillman, Angelina Tan, Ramaswamy Govindan, Dennis Wigle, Shakun Malik, Colleen Watt, David Gerber, Jamie Chaft, Suzanne Dahlberg, Karen Kelly, David R. Gandara, Meredith Faggen, TBD, Philip Stella, Karim Tazi, Suresh Ramalingam, Thomas E. Stinchcombe J Thorac Oncol vol 13 (10) S646-47, abstr P1.16-47 2018
Abstract Respiratory [https://www.jto.org/article/S1556-0864\(18\)31974-9/fulltext](https://www.jto.org/article/S1556-0864(18)31974-9/fulltext)

1215 Randomized Clinical Trial of Imiquimod: An Adjunct to Treating Cervical Dysplasia

Deirdre R. Pachman, Debra L. Barton, Amy H. Clayton, Renee M. McGovern, John A. Jefferies, Paul J. Novotny, Jeff A. Sloan, Charles L. Loprinzi, Bobbie S. Gostout Am J Obstet Gynecol vol 206 (1) 42.e1-42.e7 2012

Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/21907959>

1216 Clinical course of patients with oxaliplatin-associated neuropathy: N08CB (Alliance)

Deirdre R. Pachman, Rui Qin, Drew K. Seisler, Ellen M. Lavoie Smith, Andreas S. Beutler, Lauren E. Ta, Jacqueline M. Lafky, Nina Wagner-Johnston, Kathryn Jean Ruddy, Shaker R. Dakhil, Axel Grothey, Charles L. Loprinzi J. Clin. Oncol. vol 32 (15_suppl) 3595 2014

Abstract Symptom Inter http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3595

1217 Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance)

Deirdre R. Pachman, Rui Qin, Drew K. Seisler, Ellen M.L. Smith, Andreas S. Beutler, Lauren E. Ta, Jacqueline M. Lafky, Nina D. Wagner-Johnston, Kathryn J. Ruddy, Shaker Dakhil, Nathan P. Staff, Axel Grothey, Charles L. Loprinzi J. Clin. Oncol vol 33 (30) 3416-3422 2015

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/26282635>

1218 Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505)

Deirdre R. Pachman, Rui Qin, Drew Seisler, Ellen M. Lavoie Smith, Suneetha Kaggal, Paul Novotny, Kathryn J. Ruddy, Jacqueline M. Lafky, Lauren E. Ta, Andreas S. Beutler, Nina D. Wagner-Johnston, Nathan P. Staff, Axel Grothey, Patrick M. Dougherty, Guido Cavaletti, Charles L. Loprinzi Support Care Cancer vol 24 (12) 5059-5068 2016

Manuscript Symptom Inter N08C1, N08CB <http://www.ncbi.nlm.nih.gov/pubmed/27534963>

1219 The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD

Joel E. Pacyna, Simon Kim, Kathleen Yost, Hillary Sedlacek, Daniel Petereit, Judith Kaur, Bruce Rapkin, Robert Grubb, Electra Paskett, George J. Chang, Jeff Sloan, Ethan Basch, Brittany Major, Paul Novotny, John Taylor, Jan Buckner, J. Kellogg Parsons, Michael Morris, Jon C. Tilburt BMC Cancer vol 18 (1) 788 2018

1220 Lessons learned from implementing the first Alliance NCORP Research Base Cancer Care Delivery Research (CCDR) trial A191402CD

Joel E. Pacyna, Jeff Sloan, Simon Kim, Hillary Sedlacek, Jon Tilburt J Clin Oncol vol 36 (30_suppl) abstr 175 2018

Abstract Disparities http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.30_suppl.175?af=R

1221 Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials

Olivia Pagani, Meredith M. Regan, Gini F. Fleming, Barbara A. Walley, Marco Colleoni, István Láng, Henry L. Gomez, Carlo Tondini, Harold J. Brustein, Matthew P. Goetz, Eva M. Ciruelos, Vered Stearns, Hervé R. Bonefoi, Silvana Martino, Charles E. Geyer Jr., Graziella Pinotti, Alan S. Coates, Aron Goldhirsch, Richard D. Gelber, Prudence A. Francis Cancer Res vol 78 (4 Supplement) GS4-02 2018

Abstract Breast IBCSG-24-02 (SOFT-TEXT), IBCSG-25-02 (TEXT)

http://cancerres.aacrjournals.org/content/78/4_Supplement/GS4-02

1222 Validation of survival prognostic models for non-small-cell lung cancer instage- and age-specific groups

H. Pang, L. Gu, W. Richards, J. Crawford, M. Green, E. Vokes, X. Wang Cancer Res. vol 73 (8 (suppl)) abstr 4707 2013

Abstract Respiratory

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/73/8_MeetingAbstracts/4707

1223 Validation of the CALGB and EORTC Prognostic Models for Mesothelioma Based on Multiple CALGB Trials (Alliance)

Herbert Pang, Lydia Hodgson, Robert Kratzke, Jeffrey Crawford, Hedy Kindler, Everett Vokes, Xiaofei Wang J Thoracic Oncol vol 8 (2) 933, abstract P2.14-002 2013

Abstract Respiratory CALGB-8435, CALGB-8638, CALGB-8833, CALGB-8933, CALGB-9031, CALGB-9131, CALGB-9234, CALGB-9530, CALGB-9631, CALGB-9733, CALGB-30101, CALGB-30107, CALGB-30307, CALGB-30601, CALGB-39807

http://library.iaslc.org/search-speaker?search_speaker=20847

1224 Prognostic Model for Mesothelioma Based on Cancer and Leukemia Group B (CALGB) Trials (Alliance)

Herbert Pang, Kang Yan, Robert Kratzke, Thomas Stinchcombe, Jeffrey Crawford, Hedy Kindler, Everett Vokes, Xiaofei Wang J Thorac Oncol vol 12 (1) Suppl, pg S1367 2017

Abstract Respiratory CALGB-30101, CALGB-30107, CALGB-30307, CALGB-30601, CALGB-39807, CALGB-8435, CALGB-8638, CALGB-8833, CALGB-8933, CALGB-9031, CALGB-9131, CALGB-9234, CALGB-9530, CALGB-9631, CALGB-9733

[http://www.jto.org/article/S1556-0864\(16\)33176-8/abstract](http://www.jto.org/article/S1556-0864(16)33176-8/abstract)

1225 Differential Clinical Impact Of Gene Mutations and Their Combinations In Primary Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Dimitrios Papaioannou, Kati Maharry, Krzysztof Mrózek, Heiko Becker, Klaus H. Metzeler, Jason H. Mender, Susan P. Whitman, Ann-Kathrin Eisfeld, Sebastian Schwind, Yue-Zhong Wu, Deedra Nicolet, Jonathan E. Kolitz, Maria R. Baer, Bayard L. Powell, Donna Bucci, Michael A. Caligiuri, Andrew J. Carroll, Stefano Volinia, Richard M. Stone, Guido Marcucci, Clara D. Bloomfield Blood vol 122 (21) Abstract 2540 2013

Abstract Leuk Corr Sci CALGB-20202, CALGB-9665, CALGB-8461

<http://www.bloodjournal.org/content/122/21/2540.abstract?sso-checked=true>

1226 Prognostic and Biologic Relevance of Clinically Applicable Long Non-Coding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia

Dimitrios Papaioannou, Deedra Nicolet, Hatice G. Ozer, Krzysztof Mrózek, Stefano Volinia, Paolo Fadda, Andrew J. Carroll, Jessica Kohlschmidt, Jonathan E. Kolitz, Eunice S. Wang, Richard M. Stone, John C. Byrd, Ramiro Garzon, Clara D. Bloomfield Mol. Cancer Ther. vol 18 (8) 1451-9 2019

Manuscript Leuk Corr Sci C8525, C8621, C9720, CALGB-10201, CALGB-10502, CALGB-10801, CALGB-11001, CALGB-8923 <http://www.ncbi.nlm.nih.gov/pubmed/31164409>

1227 Prognostic and biologic significance of long non-coding RNA (lncRNA) profiling in cytogenetically abnormal acute myeloid leukemia (CA-AML)

Dimitrios Papaioannou, Deedra Nicolet, Xiaoqing Rong-Mullins, Krzysztof Mrózek, Jessica Kohlschmidt, Andrew J. Carroll, John C. Byrd, Kellie J. Archer, Jonathan E. Kolitz, Bayard L. Powell, Richard M. Stone, Geoffrey L. Uy, Eunice S. Wang, Wendy Stock, Ramiro Garzon, Clara D. Bloomfield Blood vol 132 abstr 2767 2018

Abstract Leuk Corr Sci C8461, C9665, CALGB-20202
http://www.bloodjournal.org/content/132/Suppl_1/2767

1228 Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia

Dimitrios Papaioannou, Deedra Nicolet, Stefano Volinia, Krzysztof Mrózek, Pearly Yan, Ralf Bundschuh, Andrew J. Carroll, Jessica Kohlschmidt, William Blum, Bayard L. Powell, Geoffrey L. Uy, Jonathan E. Kolitz, Eunice S. Wang, Ann-Kathrin Einfeld, Shelley J. Orwick, David M. Lucas, Michael A. Caligiuri, Richard M. Stone, John C. Byrd, Ramiro Garzon, Clara D. Bloomfield Haematologica vol 102 (8) 1391-1400 2017

Manuscript Leuk Corr Sci CALGB-10503, CALGB-10603, CALGB-19808, CALGB-20202, CALGB-8461, CALGB-8525, CALGB-9022, CALGB-9222, CALGB-9621, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/28473620>

1229 Long non-coding RNA profiling provides important prognostic information and biologic insights in younger patients (pts) with cytogenetically normal acute myeloid leukemia (CN-AML) (Alliance) CALGB 8461, 9665, and 20202.

Dimitrios Papaioannou, Deedra Nicoleta, Stefano Volinia, Krzysztof Mrózek, Pearly Yan, Andrew J. Carroll, Jessica Kohlschmidt, William Bluma, Bayard L. Powell, Geoffrey L. Uy, Jonathan E. Kolitz, Eunice S. Wang, Ann-Kathrin Einfeld, David M. Lucas, Michael A. Caligiuri, Richard M. Stone, John C. Byrd, Ramiro Garzon, Clara D. Bloomfield 2016

Abstract Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665

<http://learningcenter.ehaweb.org/eha/2016/21st/135304/dimitrios.papaioannou.long.non-coding.rna.profi>

1230 Recurrent Genetic Variants of Long Non-Coding RNAs Independently Associate with Clinical Outcome of Younger Adults with Cytogenetically Normal Acute Myeloid Leukemia (ALLIANCE/CALGB 8461, 9665, 20202)

Dimitrios Papaioannou, Gulcin H. Ozer, Deedra Nicolet, Krzysztof Mrózek, Stefano Volinia, Andrew J. Carroll, Jessica Kohlschmidt, William Blum, Bayard L. Powell, Geoffrey L. Uy, Eunice S. Wang, Jonathan E. Kolitz, Ann-Kathrin Einfeld, Richard M. Stone, John C. Byrd, Ramiro Garzon, Clara D. Bloomfield Blood vol 130 (Suppl 1) 1401 2017

Abstract Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665

http://www.bloodjournal.org/content/130/Suppl_1/1401

1231 Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia

Dimitrios Papaioannou, Changxian Shen, Deedra Nicolet, Betina McNeil, Marius Bill, Malith

Karunasiri, Matthew H. Burke, Hatice Gulcin Ozer, Selen A. Yilmaz, Nina Zitzer, Gregory K. Behbehani, Christopher C. Oakes, Damian J. Steiner, Guido Marcucci, Bayard L. Powell, Jonathan E. Kolitz, Thomas H. Carter, Eunice S. Wang, Krzysztof Mrózek, Carlo M. Croce, Michael A. Caligiuri, Clara D. Bloomfield, Ramiro Garzon, Adrienne M. Dorrance Proc. Natl. Acad. Sci. U.S.A vol 114 (23) E4641-E4647 2017

Manuscript Leuk Corr Sci CALGB-10201, CALGB-10503, CALGB-10603, CALGB-19808, CALGB-20202, CALGB-8461, CALGB-8525, CALGB-8923, CALGB-9022, CALGB-9120, CALGB-9222, CALGB-9420, CALGB-9665, CALGB-9720
<http://www.ncbi.nlm.nih.gov/pubmed/28533390>

1232 Prognostic and biologic significance of circular RNA profiling in younger adult patients with cytogenetically normal acute myeloid leukemia (CN-AML) (CALGB/Alliance 8461, 9665, 20202)

Dimitrios Papaioannou, Stefano Volinia, Deedra Nicolet, Michal Swierniak, Andreas Petrie, Krzysztof Mrózek, Andrew J. Carroll, Jessica Kohlschmidt, Bayard L. Powell, Geoffrey L. Uy, Jonathan E. Kolitz, Eunice S. Wang, Sakari Kauppinen, Richard M. Stone, Ramiro Garzon, Clara D. Bloomfield 2018

Abstract Leuk Corr Sci CALGB-20202, CALGB-8461, CALGB-9665

<https://learningcenter.ehaweb.org/eha/2018/stockholm/214594/dimitrios.papaioannou.prognostic.and.bio>

1233 NCCTG N10C2 (Alliance) – A Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes

Haeseong Park, Rui Qin, Thomas J. Smith, Pamela J. Atherton, Debra L. Barton, Keren Sturtz, Shaker R. Dakhil, Daniel M. Anderson, Kathleen Flynn, Suneetha Puttabasavaiah, Nguyet Anh

Le-Lindqwister, Gilbert D.A. Padula, Charles L. Loprinzi Menopause vol 22 (6) 627-632 2015

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/25423327>

1234 NCCTG N10C2 (Alliance): A double-blind, placebo-controlled study of magnesium supplements to reduce menopausal hot flashes

Haeseong Park, Rui Qin, Thomas J. Smith, Pamela J. Atherton, Debra L. Barton, Keren Sturtz, Shaker R. Dakhil, Daniel M. Anderson, Philip J. Stella, Suneetha Puttabasavaiah, Nguyet A Le-Lindqwister, Gilbert D. A. Padula, Charles L. Loprinzi J. Clin. Oncol. vol 32 (15 suppl) 9508 2014

Abstract Symptom Inter

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9508?sid=22c46b74-3a55-4f00-a2d2-5a10

1235 Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.

H L Parnes, C Cirrincione, J Aisner, D A Berry, S L Allen, J Abrams, E Chuang, M R Cooper, M C Perry, D B Duggan, T P Szatrowski, I C Henderson, L Norton J. Clin. Oncol. vol 21 (9) 1819-24 2003

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/12721259>

1236 Dietary modification in patients with prostate cancer on active surveillance: a randomized, multicentre feasibility study.

J Kellogg Parsons, Vicky A Newman, James L Mohler, John P Pierce, Shirley Flatt, James Marshall BJU Int. vol 101 (10) 1227-31 2008

Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/18218061>

1237 The Men's Eating and Living (MEAL) study: a Cancer and Leukemia Group B pilot trial of dietary intervention for the treatment of prostate cancer.

J Kellogg Parsons, Vicky Newman, James L Mohler, John P Pierce, Electra Paskett, James Marshall Urology vol 72 (3) 633-7 2008

Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/18280560>

- 1238 A Randomized Trial of Diet in Men with Early Stage Prostate Cancer on Active Surveillance: Rationale and Design of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance])**
J. Kellogg Parsons, John P. Pierce, James Mohler, Electra Paskett, Sin-Ho Jung, Peter Humphrey, John R. Taylor, Vicky A. Newman, Leslie Barbier, Cheryl L. Rock, James Marshall *Contemp Clin Trials* vol 38 (2) 198-203 2014
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/24837543>
- 1239 The Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): Recruitment Feasibility and Baseline Demographics of a Randomized Trial of Diet in Men on Active Surveillance for Prostate Cancer**
J. Kellogg Parsons, John P. Pierce, James Mohler, Electra Paskett, Sin-Ho Jung, Michael J. Morris, Eric Small, Olwen Hahn, Peter Humphrey, John Taylor, James Marshall *BJU Int.* vol 121 (4) 534-9 2018
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/28437029>
- 1240 A Randomized Pilot Trial of Dietary Modification for the Chemoprevention of Non-invasive Bladder Cancer: The Dietary Intervention in Bladder Cancer Study (DIBS)**
J. Kellogg Parsons, John P. Pierce, Loki Natarajan, Vicky A. Newman, Leslie Barbier, James Mohler, Cheryl L. Rock, Dennis D. Heath, Khurshid Guru, Michael B. Jameson, Hongying Li, Hossein Mirheydar, Michael A. Holmes, James Marshall *Cancer Prev Res (Phila)* vol 6 (9) 2013
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/23867158>
- 1241 The Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): A Randomized Clinical Trial of a Diet Intervention in Men on Active Surveillance for Prostate Cancer**
J. Kellogg Parsons, David Zariwih, John P. Pierce, James Mohler, Electra Paskett, Donna Hansel, Adam Kibel, Olwen Hahn, John Taylor, Robert Grubb, Sean Stroup, Eric Small, Peter Van Veldhuizen, Michael J. Morris, James Marshall *J Urol* vol 199 (4S) p. e1077 2018
Abstract Prevention [https://www.auajournals.org/article/S0022-5347\(18\)42733-4/fulltext](https://www.auajournals.org/article/S0022-5347(18)42733-4/fulltext)
- 1242 CALGB 60104: Adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907**
A. H. Partridge, L. E. Archer, A. B. Kornblith, J. Gralow, D. Grenier, H. B. Muss, E. Perez, A. C. Wolff, C. A. Hudis, E. P. Winer *J. Clin. Oncol.* vol 26 (May 20 suppl) abstr 6542 2008
Abstract Experimental
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID
- 1243 Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104**
Ann H. Partridge, Laura Archer, Alice B. Kornblith, Julie Gralow, Debjani Grenier, Edith Perez, Antonio C. Wolff, Xiaofei Wang, Helen Kastrissios, Donald Berry, Clifford Hudis, Eric Winer, Hyman Muss *J Clin Oncol* vol 28 (14) 2418-2422 2010
Manuscript Experimental CALGB-49907, C60104 <http://www.ncbi.nlm.nih.gov/pubmed/20368559>
- 1244 Prognostic impact of NPM1 mutations in cytogenetically normal (CN) acute myeloid leukemia (AML) is adversely affected by high expression of the ERG gene: A Cancer and Leukemia Group B (CALGB) study**
P. Paschka, G. Marcucci, K. S. Maharry, S. P. Whitman, A. S. Ruppert, T. Vukosavljevic, K. A. Mrozek, B. L. Powell, J. E. Kolitz, R. A. Larson, C. D. Bloomfield *Haematol-Hematol J* vol 92 (suppl 1) 145, abstr 396 2007
Abstract *Leuk Corr Sci* CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 http://www.haematologica.org/content/92/supplement_1/1.full.pdf
- 1245 Wilms Tumor 1 (WT1) Gene Mutations Predict Poor Outcome in Adults with Cytogenetically**

Normal (CN) Acute Myeloid Leukemia (AML): A Cancer and Leukemia Group B (CALGB) Study

P. Paschka, G. Marcucci, A. S. Ruppert, K. Mrozek, S. P. Whitman, K. Maharry, C. Langer, C. D. Baldus, B. L. Powell, M. R. Baer, A. J. Carroll, M. A. Caligiuri, J. E. Kolitz, R. A. Larson, C. D. Bloomfield *Blood* vol 110 (11) -362 2007
Abstract *Leuk Corr Sci* CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;110/11/362>

1246 Outcome prediction in adult core binding factor (CBF) acute myeloid leukemia (AML) with gene expression profiling: A Cancer and Leukemia Group B (CALGB) study

P. Paschka, M. D. Radmacher, G. Marcucci, A. S. Ruppert, T. Vukosavljevic, S. P. Whitman, K. A. Mrozek, C. Liu, R. A. Larson, C. D. Bloomfield *J. Clin. Oncol.* vol 25 (18S) abstr 7011 2007
Abstract *Leuk Corr Sci* C8525, C9022, CALGB-19808, CALGB-8461, CALGB-9222, CALGB-9621, CALGB-9665
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1247 Wilms' Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Peter Paschka, Guido Marcucci, Amy S. Ruppert, Susan P. Whitman, Krzysztof Mrózek, Kati Maharry, Christian Langer, Claudia D. Baldus, Weiqiang Zhao, Bayard L. Powell, Maria R. Baer, Andrew J. Carroll, Michael A. Caligiuri, Jonathan E. Kolitz, Richard A. Larson, Clara D. Bloomfield *J Clin Oncol* vol 26 (28) 4595-4602 2008
Manuscript *Leuk Corr Sci* CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://www.ncbi.nlm.nih.gov/pubmed/18559874>

1248 Independent validation of the PAM50-based Chemo-Endocrine Score (CES) in hormonal receptor positive (HR+)/HER2+ breast cancer (BC) treated with neoadjuvant anti-HER2-based therapy.

Tomás Pascual, Maki Tanioka, M. Vittoria Dieci, Sonia Pernas, Joaquin Gavila, Valentina Guarnieri, Javier Cortes, Antonio Llombart, Mafalda Oliveira, Laia Paré, Donald Berry, Patricia Galvan, Steven Isakoff, Charles M. Perou, Aleix Prat, Lisa Carey *Cancer Res* vol 78 (4 Supplement) P2-09-05 2018
Abstract *Breast* http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-09-05

1249 Applying a Conceptual Model for Examining Health-Related Quality of Life in Long-Term Breast Cancer Survivors: CALGB Study 79804

Electra D. Paskett, James E. Herndon, Jeannette M. Day, Nancy N. Stark, Eric P. Winer, Stephen S. Grubbs, Michael D. Pavy, Charles L. Shapiro, Marcy A. List, Martee L. Hensley, Michelle A. Naughton, Alice B. Kornblith, Karleen R. Habin, Gini F. Fleming, Marisa A. Bittoni *Psychooncology* vol 17 (11) 1108-1120 2008
Manuscript *Health Outcome* C8541, CALGB-79804
<http://www.ncbi.nlm.nih.gov/pubmed/18314912>

1250 Health-Related Quality of Life in Long-Term Breast Cancer Survivors: Differences by Adjuvant Chemotherapy Dose in CALGB Study 8541

Electra Paskett, James Herndon, Kathleen Donohue, Michelle Naughton, Stephen Grubbs, Michael Pavy, Martee Hensley, Nancy Stark, Alice Kornblith, Marisa Bittoni *Cancer* vol 115 (5) 1109-1120 2009
Manuscript *Health Outcome* C8541, CALGB-79804
<http://www.ncbi.nlm.nih.gov/pubmed/19170232>

1251 Prevention of Lymphedema in Women with Breast Cancer: Results of CALGB 70305 (Alliance)

Electra Paskett, Jill Oliveri, Jennifer Le-Rademacher, Heshan Liu, Drew Seisler, Jeffrey Sloan, Jane Armer, Michelle Naughton, Karen Hock, Michael Schwartz, Gary Unzeitig, Gilbert Padula, Stephen

Grubbs, Lisa Yee, Lisa Bailey, Shawna Willey, Thomas Sunnenberg, Lisa Baddi, Gini Fleming J. Clin. Oncol. vol 35 (5 suppl) 104 2017
Abstract Symptom Inter http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.5_suppl.104

1252 Bevacizumab and risk of arterial and venous thromboembolism in metastatic castration-resistant prostate cancer patients treated on Cancer and Leukemia Group B (CALGB 90401 (Alliance))

Jai N. Patel, Chen Jiang, Daniel L. Hertz, Flora A. Mulkey, Kouros Owzar, Susan Halabi, Mark J. Ratain, Paula N. Friedman, Eric J. Small, Michael A. Carducci, John F. Mahoney, Michael J. Kelley, Michael J. Morris, William K. Kelly, Howard L. McLeod Cancer vol 121 (7) 1025-1031 2015
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/25417775>

1253 A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance)

Jai N. Patel, Chen Jiang, Kouros Owzar, Daniel L. Hertz, Flora A. Mulkey, William K. Kelly, Susan Halabi, Yoichi Furukawa, Cameron Lassiter, Susan G. Dorsey, Paula N. Friedman, Eric J. Small, Phillip G. Febbo, Deanna L. Kroetz, Michael A. Carducci, John F. Mahoney, Michael J. Kelley, Yusuke Nakamura, Michiaki Kubo, Mark J. Ratain, Michael J. Morris, Howard L. McLeod Cancer Res. vol 76 (14 suppl) abstr 2037 2016
Abstract PPP http://cancerres.aacrjournals.org/content/76/14_Supplement/2037

1254 Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE).

Jai Narendra Patel, Chen Jiang, Daniel Louis Hertz, Flora Mulkey, Paula N. Friedman, Susan Halabi, Mark J. Ratain, Michael J. Morris, Eric Jay Small, Kouros Owzar, William Kevin Kelly, Howard L. McLeod J. Clin. Oncol. vol 32 (15_suppl) e16061 2014
Abstract GU CALGB-90401, CALGB-60404
http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e16061

1255 Oral Cancer Chemotherapy Adherence and Adherence Assessment Tools: A Report from North Central Cancer Group Trial N0747 and a Systematic Review of the Literature

Krishna Patel, Nathan R. Foster, Ann Farrell, Nguyet Anh Le-Lindqwister, Josy Mathew, Brian Costello, John Reynolds, Jeffrey P. Meyers, Aminah Jatoi J Cancer Educ vol 28 (4) 2013
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/23872949>

1256 MRE11-Deficiency Associated with Improved Long-Term Disease Free Survival and Overall Survival in a Subset of Stage III Colon Cancer Patients in Randomized CALGB 89803 Trial

Thomas Pavelitz, Lindsay Renfro, Nathan R. Foster, Amber Caracol, Piri Welsch, Victoria Valinluck Lao, William B. Grady, Donna Niedzwiecki, Leonard B. Saltz, Monica M. Bertagnolli, Richard M. Goldberg, Peter S. Rabinovitch, Mary Emond, Raymond J. Monnat, Nancy Maizels PLoS ONE vol 9 (10) 2014
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/25310185>

1257 Multiplexed Digital Quantification of mRNA Abundance: a Highly Reproducible, PCR-independent Assessment of BAALC, ERG, and MN1 mRNA Levels in Acute Myeloid Leukemia (AML) Bone Marrow (BM) and Peripheral Blood (PB) Samples

J. E. Payton, G. Marcucci, M. D. Radmacher, K. Maharry, C. Langer, C. D. Baldus, C. D. Bloomfield, T. J. Ley ASH Annual Meeting Abstracts vol 114 (22) abstr 1599 2009
Abstract Leuk Corr Sci C9665, C8461
<http://www.bloodjournal.org/content/114/22/1599?sso-checked=true>

1258 High throughput digital quantification of mRNA abundance in primary human acute myeloid

leukemia samples

Jacqueline E. Payton, Nicole R. Grieselhuber, Li-Wei Chang, Mark Murakami, Gary K. Geiss, Daniel C. Link, Rakesh Nagarajan, Mark A. Watson, Timothy J. Ley J Clin Invest vol 119 (6) 1714-1726 2009

Manuscript Leuk Corr Sci CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/19451695>

1259 Improving standards of patient reported outcomes analysis: developing a consensus taxonomy of key research objectives – a SISAQOL initiative

Pe, M., Dorme L., Coens C., Basch E., Calvert Melanie, Campbell A., Cleeland C., Cocks K., Collette L., Devlin N., Dueck A., Flechtner H.-H., Gotay C., Greimel E., Griebisch I., Groenvold M., Hamel J.-F., L. Johnson L., King M., Kluetz P., Koller M., Malone D., Martinelli F., Mitchell S., Musoro J., O. Connor D., Oliver K., Piau-Louis E., Piccart M., Pimentel F., Quinten C., Reijneveld J., Schurmann C., Sloan J., W. Smith A., Soltys K., Sridhara R., Taphoorn M., Velikova and A. Bottomley G. Qual Life Res vol 27 (suppl 1) abst 203.4 2018

Abstract Health Outcome <https://link.springer.com/content/pdf/10.1007%2Fs11136-018-1946-9.pdf>

1260 Analysis of the associations of FC gamma receptor polymorphisms (FCGR3A, FCGR2A, and FCGR2B) with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) trial N9831

Mark Pegram, Nadine Norton, Kathleen Tenner, Karla L. Ballman, Raphael Clynes, Keith L. Knutson, Edith A. Perez Mol Cancer Res vol 11 (10 Suppl) B123 2013

Abstract Breast http://mcr.aacrjournals.org/content/11/10_Supplement/B123.abstract

1261 Genome-wide association with survival in stage II-III colon cancer (CC) clinical trials (NCCTG N0147, Alliance for Clinical Trials in Oncology; NSABP C-08, NRG Oncology)

Kathryn Penney, Barbara L. Banbury, Qian Shi, Carmen J. Allegra, Steven R. Alberts, Ulrike Peters, Greg Yothers, Frank A. Sinicrope, Wei Sun, Norman Wolmark, Suresh G. Nair, Tabitha Harrison, Richard M. Goldberg, Peter Lucas, Thomas J. George, Linda H Colangelo, James Atkins, Polly A. Newcomb, Andrew T. Chan J Clin Oncol vol 36 (suppl) 3582 2018

Abstract GI <https://meetinglibrary.asco.org/record/158813/abstract>

1262 Ethics of Mandatory Research Biopsy for Correlative End Points Within Clinical Trials in Oncology

Jeffrey Peppercorn, Iuliana Shapira, Deborah Collyar, Teresa Deshields, Nancy Lin, Ian Krop, Hans Grunwald, Paula Friedman, Ann H. Partridge, Richard L. Schilsky, Monica M. Bertagnolli J. Clin. Oncol vol 28 (15) 2635-2640 2010

Manuscript Ethics <http://www.ncbi.nlm.nih.gov/pubmed/20406927>

1263 Phase II trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma

D. Perez, V. Suman, T. Amatruda, M. Gornet, R. Morton, S. Jilani, C. Constantinou, J. Egner, S. Markovic J. Clin. Oncol. vol 25 (18s) abstr 8560 2007

Abstract Experimental http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/8560

1264 Phase II Trial of Carboplatin, Weekly Paclitaxel and Biweekly Bevacizumab in Patients with Unresectable Stage IV Melanoma – A North Central Cancer Treatment Group (NCCTG) Study, N047A1

Domingo G. Perez, Vera J. Suman, Tom R. Fitch, Thomas Amatruda, Roscoe F. Morton, Shamim Z. Jilani, Costas L. Constantinou, James R. Egner, Lisa A. Kottschade, Svetomir N. Markovic Cancer vol 115 (1) 119-127 2009

Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/19090009>

- 1265 Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer.**
E. A. Perez, A. C. Dueck, M. F. Press, B. Chen, R. B. Jenkins, S. Paik, C. Kim, A. E. Wiktor, R. G. Meyer, R. P. Ketterling, I. Villalobos, M. Finnigan, M. Buyse, J. Zujewski, M. Shing, H. Stern, W. L. Lingle, M. M. Reinholz, D. J. Slamon *Cancer Res.* vol 70 (24 supplement) PD10-02 2010
Abstract Breast http://cancerres.aacrjournals.org/cgi/content/abstract/69/24_MeetingAbstracts/2100
- 1266 North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer**
E. A. Perez, D. W. Hillman, T. Dentchev, N. A. Le-Lindqwister, L. H. Geeraerts, T. R. Fitch, H. Liu, D. L. Graham, S. P. Kahanic, H. M. Gross, T. A. Patel, F. M. Palmieri, A. C. Dueck *Ann Oncol* vol 21 (2) 269-274 2010
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/19901014>
- 1267 Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)**
E. A. Perez, M. F. Press, A. C. Dueck, R. B. Jenkins, C. Kim, B. Chen, I. Villalobos, S. Paik, M. Buyse, A. E. Wiktor, R. Meyer, M. Finnigan, J. Zujewski, M. Shing, H. M. Stern, W. L. Lingle, M. M. Reinholz, D. J. Slamon *Breast Cancer Res. Treat.* vol 138 (1) 99-108 2013
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/23420271>
- 1268 Do the ASCO/CAP 2007 HER2 testing guidelines improve prediction of benefit to adjuvant trastuzumab?: Data from North Central Cancer Treatment Group N9831 Adjuvant trial.**
E. A. Perez, M. M. Reinholz, A. C. Dueck, K. S. Tenner, N. E. Davidson, J. R. Gralow, L. N. Harris, L. A. Kutteh, R. B. Jenkins, B. Chen *Cancer Res.* vol 69 (24 Suppl 3) abstr 701 2009
Abstract Breast http://cancerres.aacrjournals.org/cgi/content/abstract/69/24_MeetingAbstracts/701
- 1269 Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with or without trastuzumab (H) in patients (pts) with HER2-positive breast cancer**
E. A. Perez, E. H. Romond, V. J. Suman, J. Jeong, N. E. Davidson, C. E. Geyer Jr, S. Martino, E. P. Mamounas, P. A. Kauffman, N. Wolmark, Ncctg/Nsabp *J. Clin. Oncol.* vol 25 (18S) abstr 512 2007
Abstract Breast
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID
- 1270 The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831**
E. Perez, S. Butler, A. Dueck, F. Baehner, F. Jamshidian, D. Cherbavaz, E. Thompson, S. Shak, P. Kaufman, N. Davidson, J. Gralow, Y. Asmann, K. Ballman *J. Clin. Oncol.* vol 31 (15 suppl) abstr 520 2013
Abstract Breast
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/520?sid=02ec31c3-4740-487b-98f2-9de29
- 1271 Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831**
E. Perez, A. L. Dueck, M. M. Reinholz, B. Chen, X. Geiger, R. B. Jenkins, W. Lingle, C. Andorfer, N. E. Davidson, S. Martino, P. Kaufman, L. A. Kutteh, G. W. Sledge, L. N. Harris, J. R. Gralow, A. E. McCullough *J. Clin. Oncol.* vol 29 (suppl) abstr 10504 2011
Abstract Breast http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/10504
- 1272 Predictive genomic markers to chemotherapy and adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 adjuvant study**
E. Perez, J. Eckel-Passow, K. Ballman, S. Anderson, E. Thompson, Y. Asmann, J. Jen, A. Dueck, W. Lingle, G. Sledge, E. Winer, J. Gralow, R. Jenkins, M. Reinholz *Cancer Res.* vol 72 (24 supplement) PD10-04 2012

1273 c-MYC (MYC) Amplification and Correlation With Patient Outcome in Early Stage HER2 + Breast Cancer (BC) From the NCCTG Adjuvant Intergroup Trial N9831

E. Perez, M. Reinholz, A. Dueck, A. Wiktor, W. Lingle, N. Davidson, S. Martino, P. Kaufman, L. Kutteh, R. Jenkins Cancer Res. vol 69 (2, suppl 1) abstr SABCS-56 2009
Abstract Breast http://cancerres.aacrjournals.org/content/69/2_Supplement/56.short

1274 The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831

Edith A. Perez, Frederick L. Baehner, Steven M. Butler, E. Aubrey Thompson, Amylou C. Dueck, Farid Jamshidian, Diana Cherbavaz, Carl Yoshizawa, Steven Shak, Peter A. Kaufman, Nancy E. Davidson, Julie Gralow, Yan W. Asmann, Karla V. Ballman Breast Cancer Res vol 17 2015
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26429296>

1275 Stromal tumor infiltrating lymphocytes: In the Alliance N9831 trial STILS are prognostic of chemotherapy benefit but not predictive of trastuzumab benefit

Edith A. Perez, Karla V. Ballman, S. Keith Anderson, E. Aubrey Thompson, S.S. Badve, H. Bailey, F.L. Baehner Cancer Res. vol 75 (9 Supplement) abstr S1-06 2015
Abstract Breast http://cancerres.aacrjournals.org/content/75/9_Supplement/S1-06.abstract?sid=b0d523ff-b595-47a8-8352

1276 Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial

Edith A. Perez, Karla V. Ballman, Afshin Mashadi-Hosseini, Kathleen S. Tenner, Jennifer M. Kachergus, Nadine Norton, Brian M. Necela, Jennifer M. Carr, Sean Ferree, Charles M. Perou, Frederick Baehner, Maggie Chon U. Cheang, E. Aubrey Thompson J. Natl. Cancer Inst vol 109 (2) 2016
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/27794124>

1277 Intrinsic subtype and therapeutic response among early stage HER2-positive breast tumors from the North Central Cancer Treatment Group (Alliance) N9831 trial

Edith A. Perez, Karla V. Ballman, Afshin Mashadi-Hosseini, Kathleen S. Tenner, Jennifer M. Kachergus, Nadine Norton, Brian M. Necela, Jennifer M. Carr, Sean Ferree, Charles M. Perou, Maggie Chon U. Cheang, E. Aubrey Thompson Cancer Res. vol 76 (4 Suppl) P3-07-04 2016
Abstract Breast http://cancerres.aacrjournals.org/content/76/4_Supplement/P3-07-04

1278 Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer

Edith A. Perez, Karla V. Ballman, Kathy S. Tenner, E. Aubrey Thompson, Sunil S. Badve, Helen Bailey, Frederick L. Baehner JAMA Oncol vol 2 (1) 56-64 2016
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26469139>

1279 Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial

Edith A. Perez, Amylou C. Dueck, Ann E. McCullough, Beiyun Chen, Xochiquetzal J. Geiger, Robert B. Jenkins, Wilma L. Lingle, Nancy E. Davidson, Silvana Martino, Peter A. Kaufman, Leila A. Kutteh, George W. Sledge, Lyndsay N. Harris, Julie R. Gralow, Monica M. Reinholz J. Clin. Oncol. vol 31 (17) 2115-2122 2013
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/23650412>

1280 Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria

Edith A. Perez, Amylou C. Dueck, Ann E. McCullough, Monica M. Reinholz, Kathleen S. Tenner, Nancy E. Davidson, Julie Gralow, Lyndsay N. Harris, Leila A. Kutteh, David W. Hillman, Robert B. Jenkins, Beiyun Chen J Natl Cancer Inst vol 104 (2) 159-162 2012
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/22138096>

1281 Disease-free survival (DFS) and treatment effect estimates of the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance]; N063D) in the adjuvant treatment of HER2-positive early breast cancer (EBC) patients according to hormone receptor status

Edith A. Perez, Eileen Holmes, José Baselga, Evandro de Azambuja, Amylou C. Dueck, Giuseppe Viale, Jo Anne Zujewski, Aron Goldhirsch, Rocco Crescenzo, Kathleen I. Pritchard, Antonio C. Wolff, Christian Jackisch, Istvan Lang, Michael Untch, Ian Smith, Frances Boyle, Binghe Xu, Henry Gomez, Richard D. Gelber, Martine Piccart-Gebhart Ann. Oncol. vol 25 (suppl 4) 2014
Abstract Breast http://annonc.oxfordjournals.org/content/25/suppl_4/mdu438.2

1282 C-MYC Alterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

Edith A. Perez, Robert B. Jenkins, Amylou C. Dueck, Anne E. Wiktor, Patrick P. Bedroske, S. Keith Anderson, Rhett P. Ketterling, William R. Sukov, Kazunori Kanehira, Beiyun Chen, Xochiquetzal J. Geiger, Cathy A. Andorfer, Ann E. McCullough, Nancy E. Davidson, Silvana Martino, George W. Sledge, Peter A. Kaufman, Leila A. Kutteh, Julie R. Gralow, Lyndsay N. Harris, James N. Ingle, Wilma L. Lingle, Monica M. Reinholz J Clin Oncol vol 29 (6) 651-659 2011
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/21245420>

1283 HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial

Edith A. Perez, Monica M. Reinholz, David W. Hillman, Kathleen S. Tenner, Matthew J. Schroeder, Nancy E. Davidson, Silvana Martino, George W. Sledge, Lyndsay N. Harris, Julie R. Gralow, Amylou C. Dueck, Rhett P. Ketterling, James N. Ingle, Wilma L. Lingle, Peter A. Kaufman, Daniel W. Visscher, Robert B. Jenkins J Clin Oncol vol 28 (28) 4307-4315 2010
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/20697084>

1284 Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

Edith A. Perez, Edward H. Romond, Vera J. Suman, Jong-Hyeon Jeong, Nancy E. Davidson, Charles E. Geyer, Silvana Martino, Eleftherios P. Mamounas, Peter A. Kaufman, Norman Wolmark J Clin Oncol vol 29 (25) 3366-3373 2011
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/21768458>

1285 Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

Edith A. Perez, Edward H. Romond, Vera J. Suman, Jong-Hyeon Jeong, George Sledge, Charles E. Geyer, Silvana Martino, Priya Rastogi, Julie Gralow, Sandra M. Swain, Eric P. Winer, Gerardo Colon-Otero, Nancy E. Davidson, Eleftherios Mamounas, Jo Anne Zujewski, Norman Wolmark J. Clin. Oncol vol 32 (33) 3744-3752 2014
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25332249>

1286 Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer

Edith A. Perez, Vera J. Suman, Nancy E. Davidson, Julie R. Gralow, Peter A. Kaufman, Daniel W. Visscher, Beiyun Chen, James N. Ingle, Shaker R. Dakhil, JoAnne Zujewski, Alvaro Moreno-Aspitia,

1287 Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.

Edith A. Perez, E. Aubrey Thompson, S. Keith Anderson, Yan W. Asmann, Krishna R. Kalari, Jeanette Eckel-Passow, Amylou C. Dueck, Kathleen S. Tenner, Jin Jen, Jian-Bing Fan, Xochiquetzal Geiger, Ann E. McCullough, Beiyun Chen, Michael Zschunke, Robert B. Jenkins, George W. Sledge, Eric P. Winer, Julie Gralow, Monica Madden Reinholz, Karla V. Ballman J. Clin. Oncol. vol 32 (15_suppl) 509 2014
Abstract Breast meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/509

1288 Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

Edith A. Perez, E. Aubrey Thompson, Karla V. Ballman, S. Keith Anderson, Yan W. Asmann, Krishna R. Kalari, Jeanette E. Eckel-Passow, Amylou C. Dueck, Kathleen S. Tenner, Jin Jen, Jian-Bing Fan, Xochiquetzal J. Geiger, Ann E. McCullough, Beiyun Chen, Robert B. Jenkins, George W. Sledge, Eric P. Winer, Julie R. Gralow, Monica M. Reinholz J. Clin. Oncol vol 33 (7) 701-708 2015
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25605861>

1289 Updated analysis of a Phase III study of surgical resection and chemotherapy (paclitaxel/carboplatin) (CT) with or without adjuvant radiation therapy (RT) for resected stage III non-small cell lung cancer (NSCLC) CALGB 9734

M. C. Perry, L. Kohman, J. Bonner, L. Gu, X. Wang, E. Vokes, M. R. Green J. Clin. Oncol. vol 23 (16s) abstr 7145 2005
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=34&abstractID

1290 A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734.

Michael C Perry, Leslie J Kohman, James A Bonner, Lin Gu, Xiaofei Wang, Everett E Vokes, Mark R Green Clin Lung Cancer vol 8 (4) 268-72 2007
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/17311692>

1291 Tobacco Assessment in Completed Lung Cancer Treatment Trials

Erica N. Peters, Graham W. Warren, Jeff A. Sloan, James R. Marshall Cancer vol 122 (21) 3260-3262 2016
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/27459400>

1292 Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.

William P Peters, Gary L Rosner, James J Vredenburgh, Elizabeth J Shpall, Michael Crump, Paul G Richardson, Michael W Schuster, Lawrence B Marks, Constance Cirrincione, Larry Norton, I C Henderson, Richard L Schilsky, David D Hurd J. Clin. Oncol. vol 23 (10) 2191-200 2005
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/15767638>

1293 High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.

Bruce A Peterson, Jeffrey Johnson, Margaret A Shipp, Maurice Barcos, Jon P Gockerman, George P Canellos Leuk. Lymphoma vol 48 (5) 870-80 2007
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/17487729>

- 1294 A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102**
G. K. Philips, S. Halabi, B. L. Sanford, D. Bajorin, E. J. Small *Ann Oncol* vol 20 (6) 1074-1079 2009
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/19168670>
- 1295 Adjuvant ovarian function suppression and cognitive function in women with breast cancer**
Kelly-Anne Phillips, Meredith M Regan, Karin Ribbi, Prudence A Francis, Fabio Puglisi, Meritxell Bellet, Simon Spazzapan, Per Karlsson, Daniel R Budman, Khalil Zaman, Ehtesham A Abdi, Susan M Domchek, Yang Feng, Karen N Price, Alan S Coates, Richard D Gelber, Paul Maruff, Frances Boyle, John F Forbes, Tim Ahles, Gini F Fleming, Jürg Bernhard *Br. J. Cancer* vol 114 (9) 956-964 2016
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/27092785>
- 1296 Smoking status and prognosis in patients with stage III colon cancer: A correlative analysis of NCCTG phase III trial N0147**
A. I. Phipps, Q. Shi, P. L. J. Limburg, G. D. Nelson, D. J. Sargent, P. A. Newcomb, S. R. Alberts *J. Clin. Oncol.* vol 30 (15 suppl) abstr 3526 2012
Abstract GI
http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/3526?sid=0392af30-b7db-4da1-8d41-cf8cc
- 1297 Associations Between Cigarette Smoking Status and Colon Cancer Prognosis Among Participants in North Central Cancer Treatment Group Phase III Trial N0147**
A. I. Phipps, Q. Shi, P. A. Newcomb, G. D. Nelson, D. J. Sargent, S. R. Alberts, P. J. Limburg *J. Clin. Oncol.* vol 31 (16) 2016-2023 2013
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/23547084>
- 1298 Pre-diagnostic physical activity and outcomes in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance)**
Amanda I. Phipps, Qian Shi, Emily Chan, Sharlene Gill, Richard M. Goldberg, Sheetal Hardikar, Paul J. Limburg, Polly A. Newcomb, Frank A. Sinicrope, Tyler J. Zemla, Balkrishna Jahagirdar, Crystal S. Denlinger, Daniel J. Sargent, Steven R. Alberts 2017
Abstract GI
- 1299 Alcohol consumption and prognosis in patients with stage III colon cancer: a correlative analysis of NCCTG phase III trial N0147**
Amanda I. Phipps, Qian Shi, Paul J. Limburg, Garth D. Nelson, Daniel J. Sargent, Frank A. Sinicrope, Emily Chan, Sharlene Gill, Richard M. Goldberg, Morton Kahlenberg, Suresh Nair, Anthony F. Shields, Polly A. Newcomb, Steven R. Alberts *J. Clin. Oncol.* vol 33 (suppl) abstr 1508 2015
Abstract GI http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1508
- 1300 Alcohol consumption and colon cancer prognosis among participants in North Central Cancer Treatment Group phase III trial N0147**
Amanda I. Phipps, Qian Shi, Paul J. Limburg, Garth D. Nelson, Daniel J. Sargent, Frank A. Sinicrope, Emily Chan, Sharlene Gill, Richard M. Goldberg, Morton Kahlenberg, Suresh Nair, Anthony F. Shields, Polly A. Newcomb, Steven R. Alberts *Int. J. Cancer* vol 139 (5) 986-995 2016
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/27060850>
- 1301 Physical activity and outcomes in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance)**
Amanda I. Phipps, Qian Shi, Tyler J. Zemla, Efrat Dotan, Sharlene Gill, Richard M. Goldberg, Sheetal Hardikar, Balkrishna Jahagirdar, Paul J. Limburg, Polly A. Newcomb, Anthony Shields, Frank A. Sinicrope, Daniel J. Sargent, Steven R. Alberts *Cancer Epidemiol. Biomarkers Prev.* vol 27 (6)

1302 First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).

Martine J. Piccart-Gebhart, Andrew Peter Holmes, Jose Baselga, Evandro de Azambuja, Amylou C. Dueck, Giuseppe Viale, Jo Anne Zujewski, Aron Goldhirsch, Sergio Santillana, Kathleen I. Pritchard, Antonio C. Wolff, Christian Jackisch, Istvan Lang, Michael Untch, Ian E. Smith, Frances Boyle, Binghe Xu, Henry Leonidas Gomez, Richard D. Gelber, Edith A. Perez *J. Clin. Oncol.* vol 32 (15_suppl) LBA4 2014

Abstract Breast http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/LBA4

1303 Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Martine Piccart-Gebhart, Eileen Holmes, José Baselga, Evandro de Azambuja, Amylou C. Dueck, Giuseppe Viale, Jo Anne Zujewski, Aron Goldhirsch, Alison Armour, Kathleen I. Pritchard, Ann E. McCullough, Stella Dolci, Eleanor McFadden, Andrew P. Holmes, Liu Tonghua, Holger Eidtmann, Phuong Dinh, Serena Di Cosimo, Nadia Harbeck, Sergei Tjulandin, Young-Hyuck Im, Chiun-Sheng Huang, Véronique Diéras, David W. Hillman, Antonio C. Wolff, Christian Jackisch, Istvan Lang, Michael Untch, Ian Smith, Frances Boyle, Binghe Xu, Henry Gomez, Thomas Suter, Richard D. Gelber, Edith A. Perez *J. Clin. Oncol* vol 34 (10) 1034-1042 2016

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26598744>

1304 Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031

V. J. Picozzi, R. A. Abrams, P. A. Decker, W. Traverso, E. M. O'Reilly, E. Greeno, R. C. Martin, L. S. Wilfong, M. L. Rothenberg, M. C. Posner, P. W. T. Pisters *Ann Oncol* vol 22 (2) 348-354 2011

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20670978>

1305 Report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5-FU, and alpha-interferon

V. J. Picozzi, R. A. Abrams, L. W. Traverso, E. M. O'Reilly, E. Greeno, R. C. Martin, L. S. Wilfong, P. A. Decker, P. W. Pisters, M. C. Posner *J. Clin. Oncol.* vol 26 (May 20 suppl) abstr 4505 2008

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1306 Long term efficacy of peripheral androgen blockade on prostate cancer: CALGB 9782.

J. Picus, S. Halabi, E. Small, A. Hussain, G. Philips, E. Kaplan, N. Vogelzang *J. Clin. Oncol.* vol 24 (18s) abstr 4573 2006

Abstract GU

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=40&abstractID

1307 A Phase II Study Of Estramustine, Docetaxel, And Bevacizumab In Men With Castrate Resistant Prostate Cancer: Results Of Cancer And Leukemia Group B (CALGB) 90006

Joel Picus, Susan Halabi, W. Kevin Kelly, Nicholas J. Vogelzang, Young E. Whang, Ellen B. Kaplan, Walter M. Stadler, Eric J. Small *Cancer* vol 117 (3) 526-533 2011

Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/20862750>

1308 LACE-Bio: Cross-validation and Pooled Analyses of the Putative Prognostic/Predictive Biomarkers p27, p16 and cyclin E in IALT, ANITA, JBR10 and CALGB 9633

R. Pirker, V. Rousseau, E. Paris, M. S. Tsao, S. Aviel-Ronen, M. Taron, R. Kratzke, E. Brambilla, L.

Seymour, M. Filipits J Thorac Oncol vol 5 (12) S503 2010
Abstract Respiratory <http://journals.lww.com/jto/Citation/2010/12003/Abstracts.5.aspx>

1309 Impact of poor prognostic features on the surgical treatment of breast cancer in an intergroup adjuvant chemotherapeutic trial

B. A. Pockaj, A. Dueck, K. Tenner, E. Perez J. Clin. Oncol. vol 25 (18s) abstr 612 2007
Abstract Breast http://ascopubs.org/doi/abs/10.1200/jco.2007.25.18_suppl.612

1310 Effect of Docetaxel and Carboplatin on VEGF, PGE2, and Immune cells in Patients With Stage II or III Breast Cancer

B. Pockaj, T. Tinder, C. Klosterman, J. Allred, V. Roy, E. Perez, P. Mukherjee Cancer Res. vol 69 (2, suppl 1) abstr 5110 2009
Abstract Breast http://cancerres.aacrjournals.org/content/69/2_Supplement/5110

1311 Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype

Xavier Poiré, Barry K. Moser, Robert E. Gallagher, Kristina Laumann, Clara D. Bloomfield, Bayard L. Powell, Gregory Koval, Kabir Gulati, Nicholas Holowka, Richard A. Larson, Martin S. Tallman, Frederick R. Appelbaum, Dorie Sher, Cheryl Willman, Elisabeth Paietta, Wendy Stock Leuk. Lymphoma vol 55 (7) 1523-1532 2014
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/24160850>

1312 Differences in psychosocial factors among diverse women enrolled in a phase III cooperative group metastatic breast cancer trial (CALGB 40502/Alliance)

B. N. Polite, J. B. Allred, H. S. Rugo, T. Cipriano, C. Cirrincione, S. J. Gehlert, E. D. Paskett, C. Hudis, E. P. Winer J. Clin. Oncol. vol 31 (15 suppl) abstr 9581 2013
Abstract Disparities
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/9581?sid=985b67e7-cc5b-40f4-bf45-2f2c3

1313 Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840—Cancer and Leukemia Group B

Blase N. Polite, Constance Cirrincione, Gini F. Fleming, Donald A. Berry, Andrew Seidman, Hyman Muss, Larry Norton, Charles Shapiro, Kamal Bakri, Kelly Marcom, Diana Lake, Joel H. Schwartz, Clifford Hudis, Eric P. Winer J. Clin. Oncol. vol 26 (16) 2659-2665 2008
Manuscript Breast CALGB-40501, CALGB-9342, CALGB-9840
<http://www.ncbi.nlm.nih.gov/pubmed/18509177>

1314 A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.

Mitchell C Posner, Donna Niedzwiecki, Alan P Venook, Donna R Hollis, Hedy L Kindler, Edward W Martin, Richard L Schilsky, Richard M Goldberg, Robert J Mayer Ann. Surg. Oncol. vol 15 (1) 158-64 2008
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/18008108>

1315 Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710

B. L. Powell, B. K. Moser, W. Stock, R. E. Gallagher, C. L. Willman, R. M. Stone, J. M. Rowe, S. E. Coutre, J. H. Feusner, J. Gregory, S. Couban, F. R. Appelbaum, M. S. Tallman, R. A. Larson Blood vol 118 (21) -258 2011
Abstract Leukemia <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/258>

- 1316 Effect of consolidation with arsenic trioxide (As₂O₃) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710.**
B. L. Powell, B. Moser, W. Stock, R. E. Gallagher, C. Willman, S. Coutre, J. H. Feusner, F. R. Appelbaum, M. S. Tallman, R. A. Larson *J. Clin. Oncol.* vol 25 (18S, June 20 Supplement) 2 2007
Abstract Leukemia
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID
- 1317 Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710**
Bayard L. Powell, Barry Moser, Wendy Stock, Robert E. Gallagher, Cheryl L. Willman, Richard M. Stone, Jacob M. Rowe, Steven Coutre, James H. Feusner, John Gregory, Stephen Couban, Frederick R. Appelbaum, Martin S. Tallman, Richard A. Larson *Blood* vol 116 (19) 3751-3757 2010
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/20705755>
- 1318 Predicting response and survival in chemotherapy-treated triple-negative breast cancer**
A Prat, A Lluch, J Albanell, W T Barry, C Fan, J I Chacón, J S Parker, L Calvo, A Plazaola, A Arcusa, M A Seguí-Palmer, O Burgues, N Ribelles, A Rodriguez-Lescure, A Guerrero, M Ruiz-Borrego, B Munarriz, J A López, B Adamo, M C U Cheang, Y Li, Z Hu, M L Gulley, M J Vidal, B N Pitcher, M C Liu, M L Citron, M J Ellis, E Mardis, T Vickery, C A Hudis, E P Winer, L A Carey, R Caballero, E Carrasco, M Martín, C M Perou, E Alba *Br. J. Cancer* vol 111 (8) 1532-1541 2014
Manuscript Breast C9741, CALGB-159905 <http://www.ncbi.nlm.nih.gov/pubmed/25101563>
- 1319 The evaluation of flaxseed for hot flashes: Results of a randomized, controlled trial, NCCTG study N08C7**
S. Pruthi, R. Qin, S. A. Terstriepe, H. Liu, C. L. Loprinzi, T. R. C. Shah, K. F. Tucker, S. R. Dakhil, M. J. Bury, R. L. Carolla, P. D. Steen, J. Vuky, D. L. Barton *J. Clin. Oncol.* vol 29 (supplement) abstr CRA9015 2011
Abstract Symptom Inter
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID
- 1320 A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Flaxseed for the Treatment of Hot Flashes1:NCCTG N08C7**
Sandhya Pruthi, Rui Qin, Shelby A. Terstriepe, Heshan Liu, Charles L. Loprinzi, Tushar R. C. Shah, Kenneth F. Tucker, Shaker R. Dakhil, Martin J. Bury, Robert L. Carolla, Preston D. Steen, Jacqueline Vuky, Debra L. Barton *Menopause* vol 19 (1) 48-53 2012
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/21900849>
- 1321 Incidence of bleeding and thrombosis among elderly patients undergoing systemic chemotherapy in advanced non-small cell lung cancer: An analysis of North Central Cancer Treatment Group trials**
Y. Qi, G. K. Dy, G. D. Nelson, S. E. Schild, S. J. Mandrekar, A. A. Adjei *J. Clin. Oncol.* vol 28 (15s) abstr e18093 2010
Abstract Respiratory <http://meetinglibrary.asco.org/content/53472-74>
- 1322 Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer**
Y. Qi, K. L. Allen Ziegler, S. L. Hillman, M. W. Redman, S. E. Schild, D. R. Gandara, A. A. Adjei, S. J. Mandrekar *Cancer* vol 118 (21) 5358-5365 2012
Manuscript Respiratory N0022, N0026, N0222, N0323, N0326, N0426, N0528, N0626, N0821, N9921 <http://www.ncbi.nlm.nih.gov/pubmed/22434489>
- 1323 Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in**

Patients with Advanced Stage Non-small Cell Lung Cancer

Yingwei Qi, Steven E. Schild, Sumithra J. Mandrekar, Angelina D. Tan, James E. Krook, Kendrith M. Rowland, Yolanda I. Garces, Gamini S. Soori, Alex A. Adjei, Jeff A. Sloan J Thorac Oncol vol 4 (9) 1075-1082 2009

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/19546817>

1324 Quality of Life Analysis of N0877 (Alliance): Phase II Trial of Either Dasatinib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)

Rui Qin, Angelina D. Tan, Jeff A. Sloan, Derek Richard Johnson, Glenn Jay Lesser, S. Keith Anderson, Nadia N. Laack J. Clin. Oncol. vol 33 (suppl) abstr e17715 2015

Abstract Health Outcome <http://meetinglibrary.asco.org/content/146850-156>

1325 MicroRNA (miR) expression signatures in molecular subsets of cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study

M. D. Radmacher, G. Marcucci, P. Paschka, T. Vukosavljevic, S. P. Whitman, A. S. Ruppert, K. A. Mrozek, J. E. Kolitz, R. A. Larson, C. D. Bloomfield J. Clin. Oncol. vol 25 (18s) abstr 7010 2007
Abstract Leuk Corr Sci CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1326 Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

K. R. Rai, B. L. Peterson, F. R. Appelbaum, M. S. Tallman, A. Belch, V. A. Morrison, R. A. Larson Blood vol 114 (22) abstr 536 2009

Abstract Leukemia <http://www.bloodjournal.org/content/114/22/536>

1327 Results of NCCTG phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma

R. D. Rao, J. B. Allred, H. E. Windschitl, W. J. Maples, R. R. McWilliams, E. T. Creagan, J. S. Kaur, M. K. Gornet, B. A. Pockaj, S. N. Markovic J. Clin. Oncol. vol 25 (18s) abstr 8530 2007

Abstract Experimental

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1328 A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance)

Sara R. Rashkin, Katherina C. Chua, Carol Ho, Flora Mulkey, Chen Jiang, Tasei Mushiroda, Michiaki Kubo, Paula N. Friedman, Hope S. Rugo, Howard L. McLeod, Mark J. Ratain, Francisco Castillos, Michael Naughton, Beth Overmoyer, Deborah Toppmeyer, John S. Witte, Kouros Owzar, Deanna L. Kroetz Clin. Pharmacol. Ther. vol 105 (3) 738-45 2019

Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/30260474>

1329 A phase II study of cisplatin(C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC)

N. E. Ready, A. Z. Dudek, X. Wang, S. L. Graziano, M. R. Green, E. E. Vokes J. Clin. Oncol. vol 25 (18s) abstr 7563 2007

Abstract Respiratory

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1330 Combination chemotherapy with sunitinib (IND 74019; NSC 736511) for untreated extensive stage small cell lung cancer (SCLC): CALGB 30504 phase IB safety results

N. E. Ready, F. R. Dunphy, H. Pang, R. V. Heinze, J. Crawford, E. E. Vokes J. Clin. Oncol. vol 28 (15s) abstr 7056 2010

Abstract Respiratory

1331 Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small cell lung cancer: A randomized, placebo controlled phase II study CALGB 30504 (ALLIANCE)

N. E. Ready, H. H. Pang, L. Gu, G. A. Otterson, S. P. Thomas, A. A. Miller, M. Q. Baggstrom, G. A. Masters, S. L. Graziano, J. Crawford, J. Bogart, E. E. Vokes J. Clin. Oncol. vol 31 (15 suppl) abstr 7506 2013

Abstract Respiratory

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7506?sid=3204ebb7-e5d3-4684-ab2e-9ed3

1332 Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study

Neal E. Ready, Arkadiusz Z. Dudek, Herbert H. Pang, Lydia D. Hodgson, Stephen L. Graziano, Mark R. Green, Everett E. Vokes J Clin Oncol vol 29 (33) 4436-4441 2011

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21969504>

1333 Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study—CALGB 30504 (Alliance)

Neal E. Ready, Herbert H. Pang, Lin Gu, Gregory A. Otterson, Sachdev P. Thomas, Antonius A. Miller, Maria Baggstrom, Gregory A. Masters, Stephen L. Graziano, Jeffrey Crawford, Jeffrey Bogart, Everett E. Vokes J. Clin. Oncol vol 33 (15) 1660-1665 2015

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/25732163>

1334 Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: Cancer and Leukemia group B (CALGB) 30106, a CALGB-stratified phase II trial.

Neal Ready, Pasi A Jänne, Jeffrey Bogart, Thomas Dipetrillo, Jennifer Garst, Stephen Graziano, Lin Gu, Xiaofei Wang, Mark R Green, Everett E Vokes J Thorac Oncol vol 5 (9) 1382-90 2010

Manuscript Respiratory CALGB-150508, CALGB-30106

<http://www.ncbi.nlm.nih.gov/pubmed/20686428>

1335 A phase II study of neoadjuvant therapy with cisplatin, docetaxel, panitumumab plus radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051)

C. Reed, P. Decker, T. Schefter, B. Meyers, M. Ferguson, A. Oeltjen, J. Putnam, S. Cassivi, A. Lockhart J. Clin. Oncol. vol 30 (suppl) abstr 4062 2012

Abstract GI <https://meetinglibrary.asco.org/content/92693-114>

1336 Natural history of paclitaxel-associated acute pain syndrome (P-APS): NCCTG trial N08C1

B. Reeves, S. R. Dakhil, J. A. Sloan, A. Kamal, S. L. Wolf, K. N. Burger, N. Lelindqwister, G. S. Soori, A. J. Jaslowski, C. L. Loprinzi J. Clin. Oncol. vol 28 (15s) abstr 9135 2010

Abstract Health Outcome

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

1337 Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1.

Brandi N Reeves, Shaker R Dakhil, Jeff A Sloan, Sherry L Wolf, Kelli N Burger, Arif Kamal, Nguyet A Le-Lindqwister, Gamini S Soori, Anthony J Jaslowski, Joseph Kelaghan, Paul J Novotny, Daniel H Lachance, Charles L Loprinzi Cancer vol 118 (20) 5171-8 2012

Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/22415454>

1338 Efficacy of carboplatin–taxane combinations in the management of castration-resistant

prostate cancer: a pooled analysis of seven prospective clinical trials

M. M. Regan, E. K. O'Donnell, W. K. Kelly, S. Halabi, W. Berry, S. Urakami, N. Kikuno, W. K. Oh
Ann Oncol vol 21 (2) 312-318 2010
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/19633053>

1339 Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT

M. M. Regan, B. A. Walley, P. A. Francis, G. F. Fleming, I. Láng, H. L. Gómez, M. Colleoni, C. Tondini, G. Pinotti, M. Salim, S. Spazzapan, V. Parmar, T. Ruhstaller, E. A. Abdi, R. D. Gelber, A. S. Coates, A. Goldhirsch, O. Pagani Ann. Oncol vol 28 (9) 2225-32 2017
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/28911092>

1340 Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials

Meredith M. Regan, Prudence A. Francis, Olivia Pagani, Gini F. Fleming, Barbara A. Walley, Giuseppe Viale, Marco Colleoni, István Láng, Henry L. Gómez, Carlo Tondini, Graziella Pinotti, Karen N. Price, Alan S. Coates, Aron Goldhirsch, Richard D. Gelber J. Clin. Oncol vol 34 (19) 2221-2231 2016
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/27044936>

1341 Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials

Meredith M. Regan, Olivia Pagani, Gini F. Fleming, Barbara A. Walley, Karen N. Price, Manuela Rabaglio, Rudolf Maibach, Barbara Ruepp, Alan S. Coates, Aron Goldhirschi, Marco Colleoni, Richard D. Gelber, Prudence A. Francis Breast vol 22 (6) 1094-100 2013
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/24095609>

1342 Predictive value and clinical utility of centrally-assessed ER, PgR and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials

Meredith M. Regan, Olivia Pagani, Prudence A. Francis, Gini F. Fleming, Barbara A. Walley, Roswitha Kammler, Patrizia Dell'Orto, Leila Russo, János Szke, Franco Doimi, Laura Villani, Stefano Pizzolitto, Christian Öhlschlegel, Fausto Sessa, Vicente Peg Cámara, José Luis Rodríguez Peralto, Gaëtan MacGrogan, Marco Colleoni, Aron Goldhirsch, Karen N. Price, Alan S. Coates, Richard D. Gelber, Giuseppe Viale Breast Cancer Res. Treat. vol 154 (2) 275-286 2015
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26493064>

1343 Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status

R L Rego, N R Foster, T C Smyrk, M Le, M J O'Connell, D J Sargent, H Windschitl, F A Sinicrope Br J Cancer vol 102 (1) 165-172 2010
Manuscript Correl Sci NOS NCCTG-894651, NCCTG-91-46-53
<http://www.ncbi.nlm.nih.gov/pubmed/19997103>

1344 EGFR expression is associated with increased cell turnover and poor histologic grade in human colon carcinomas.

R. L. Rego, T. C. Smyrk, N. R. Foster, D. J. Sargent, B. F. Kabat, A. J. French, S. N. Thibodeau, H. Windschitl, M. J. O'Connell, F. A. Sinicrope J. Clin. Oncol. vol 25 (18s) abstr 21046 2007
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1345 Activated EGFR as a prognostic marker in human colon cancer

R. L. Rego, T. C. Smyrk, N. R. Foster, D. J. Sargent, S. N. Thibodeau, S. R. Alberts, H. E. Windschitl, F. A. Sinicropo J. Clin. Oncol. vol 26 (15s) abstr 22119 2008

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1346 Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials

T. Reiman, R. Lai, A. S. Veillard, E. Paris, J. C. Soria, R. Rosell, M. Taron, S. Graziano, R. Kratzke, L. Seymour, F. A. Shepherd, J. P. Pignon, P. Seve, L.-B. Grp Ann. Oncol. vol 23 (1) 86-93 2012

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21471564>

1347 Prognostic value of Class III B-Tubulin (TUBB3) in operable non-small cell lung cancer (NSCLC) and predictive value for adjuvant cisplatin based chemotherapy (CT): A validation study on 3 randomized trials

T. Reiman, P. Seve, A. Vataire, A. Dunant, R. Rosell, S. L. Graziano, L. Seymour, R. Pirker, R. Lai J. Clin. Oncol. vol 26 (May 20 suppl) abstr 7506 2008

Abstract Respiratory

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1348 Validation of the prognostic and predictive value of class III beta tubulin (TUBB3) for adjuvant chemotherapy (ACT) in completely resected non-small cell lung cancer (R-NSCLC): Results from four randomized trials

Tony Reiman, Pascal Seve, Anne-Sophie Veillard, Jean-Charles Soria, Rafael Rosell, Miquel Taron, Stephen Graziano, Robert Kratzke, Lesley Seymour, Frances Shepherd, Jean-Pierre Pignon, Raymond Lai J Thorac Oncol vol 4 (9 suppl 1) abstr A4.2 2009

Abstract Respiratory [http://www.jto.org/article/S1556-0864\(15\)33608-X/fulltext](http://www.jto.org/article/S1556-0864(15)33608-X/fulltext)

1349 Effect of IGFIR protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial

M. M. Reinholz, A. L. Dueck, B. Chen, X. Geiger, A. Mccullough, R. Jenkins, W. Lingle, C. Andorfer, N. Davidson, S. Martino, P. Kaufman, L. Kutteh, G. Sledge, L. Harris, J. Gralow, E. Perez J. Clin. Oncol. vol 29 (suppl) abstr 10503 2011

Abstract Breast <http://meetinglibrary.asco.org/content/81832-102>

1350 MYC protein expression and copy number anomalies in early-stage HER2+ breast cancer in context of the NCCTG adjuvant trial, N9831.

M. M. Reinholz, X. Geiger, A. C. Dueck, A. E. Wiktor, W. L. Lingle, C. Andorfer, W. R. Sukov, R. P. Ketterling, R. B. Jenkins, E. A. Perez, N. E. Davidson, S. Martino, P. A. Kaufman, L. A. Kutteh, G. W. Sledge, L. N. Harris, J. R. Gralow Molecular Markers in Cancer abstr 66 2010

Abstract Breast <http://meetinglibrary.asco.org/content/60958-101>

1351 The concordance between NCCTGs and NSABPs C-myc FISH assays

M. Reinholz, A. Dueck, W. Lingle, A. Ziegler, A. Wiktor, S. Paik, R. Jenkins, E. Perez J. Clin. Oncol. vol 26 (May 20 suppl) abstr 22110 2008

Abstract Correl Sci NOS http://meeting.ascopubs.org/cgi/content/short/26/15_suppl/22110

1352 Cytokeratin-19 (CK19) and mammaglobin (MGB1) gene expression in circulating tumor cells (CTCs) from metastatic breast cancer patients enrolled in the NCCTG trials, N0436 and N0437

M. Reinholz, K. Kitzmann, T. Hobday, D. Northfelt, B. Laplant, J. Allred, A. Dueck, P. Stella, W. Lingle, E. Perez J. Clin. Oncol. vol 27 (15s) abstr 11095 2009

Abstract Breast N0436, N0437 <http://meetinglibrary.asco.org/content/33733-65>

- 1353 Circulating tumor cells in North Central Cancer Treatment Group breast clinical trials**
M. Reinholz, K. Kitzmann, K. Tenner, D. Hillman, T. Hobday, V. Roy, A. Moreno-Aspitia, D. Northfelt, J. Allred, B. Laplant, A. Dueck, E. Perez, W. Lingle 7th International Symposium on Minimal Residual Cancer abstr O24 2009
Abstract Breast N0234, N0336, N0338, N0436, N0437
<http://www.erasmus.gr/en/congresses/athens/2009/7th-international-symposium-on-minimal-residual-car>
- 1354 c-MYC (MYC) Protein Expression and Associations with Trastuzumab Benefit in Early-Stage, HER2+ Breast Cancer in Context of the NCCTG Adjuvant Trial, N9831**
MM Reinholz, AC Dueck, AE Wiktor, WL Lingle, RB Jenkins, NE Davidson, S Martino, PA Kaufman, LA Kutteh, GW Sledge, LN Harris, JR Gralow, X Geiger, EA. Perez Cancer Res. vol 70 (24, suppl 2) abstr P2-09-08 2010
Abstract Breast http://cancerres.aacrjournals.org/content/70/24_Supplement/P2-09-08.short
- 1355 IGF1R Protein Expression is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2-positive Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831**
Monica M. Reinholz, Beiyun Chen, Amylou C. Dueck, Kathleen Tenner, Karla Ballman, Darren Riehle, Robert B. Jenkins, Xochiquetzal J. Geiger, Ann E McCullough, Edith A. Perez Clin. Cancer Res. vol 23 (15) 4203-11 2017
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/28533226>
- 1356 Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group (NCCTG) trials, N0234/336/436/437**
Monica M. Reinholz, Kathleen A. Kitzmann, Kathleen Tenner, David Hillman, Amylou C. Dueck, Timothy J. Hobday, Donald W. Northfelt, Alvaro Moreno-Aspitia, Vivek Roy, Betsy LaPlant, Jake B. Allred, Philip J. Stella, Wilma L. Lingle, Edith A. Perez Clin. Cancer Res. vol 17 (22) 7183-7193 2011
Manuscript Breast N0336, N0234, N0338, N0436, N0437
<http://www.ncbi.nlm.nih.gov/pubmed/21976532>
- 1357 Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trials.**
Lindsay A Renfro, Daniel J Sargent Chin Clin Oncol vol 5 (6) 80 2016
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/28061544>
- 1358 Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.**
Thanyanan Reungwetwattana, Julian R Molina, Sumithra J Mandrekar, Katie Allen-Ziegler, Kendrith M Rowland, Nicholas F Reuter, Ronnie F Luyun, Grace K Dy, Randolph S Marks, Steven E Schild, James R Jett, Alex A Adjei J Thorac Oncol vol 7 (5) 919-22 2012
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/22722792>
- 1359 Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial**
Karin Ribi, Weixiu Luo, Jürg Bernhard, Prudence A. Francis, Harold J. Burstein, Eva Ciruelos, Meritxell Bellet, Lorenzo Pavesi, Ana Lluch, Marilena Visini, Vani Parmar, Carlo Tondini, Pierre Kerbrat, Antonia Perelló, Patrick Neven, Roberto Torres, Davide Lombardi, Fabio Puglisi, Per Karlsson, Thomas Ruhstaller, Marco Colleoni, Alan S. Coates, Aron Goldhirsch, Karen N. Price, Richard D. Gelber, Meredith M. Regan, Gini F. Fleming J. Clin. Oncol vol 34 (14) 1601-1610 2016
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/27022111>

1360 The effects of treatment-induced symptoms, depression and age on sexuality in premenopausal women with early breast cancer receiving adjuvant endocrine therapy

Karin Ribí, Weixiu Luo, Harold J. Burstein, Michael J. Naughton, Jacquie Chirgwin, Rafat H. Ansari, Barbara A. Walley, Muhammed Salim, Andre van der Westhuizen, Ehtesham Abdi, Prudence A. Francis, Daniel R. Budman, Hagen Kennecke, Vernon J. Harvey, Anita Giobbie-Hurder, Gini F. Fleming, Olivia Pagani, Meredith M. Regan, Jürg Bernhard *Cancer Research* vol 77 (7) Suppl-4 2017

Abstract Breast http://cancerres.aacrjournals.org/content/77/4_Supplement/P2-09-09

1361 EGFR expression measured by quantitative immunofluorescence is associated with decreased benefit from trastuzumab in the adjuvant setting in the NCCTG (Alliance) N9831 trial.

D. L. Rimm, K. Ballman, H. Cheng, M. Vassilakopoulou, B. Chen, J. Gralow, C. Hudis, N. E. Davidson, G. Fountzilas, A. Psyrri, E. A. Perez *Cancer Res.* vol 72 (24) abstr S5-4 2012

Abstract Correl Sci NOS http://cancerres.aacrjournals.org/content/72/24_Supplement/S5-4.short

1362 Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840

D. L. Rimm, G. Broadwater, P. N. Friedman, D. A. Berry, A. D. Seidman, C. A. Hudis, E. P. Winer, L. N. Harris, A. D. Thor *Cancer Res.* vol 69 (2 Suppl 1) abstr 6046 2009

Abstract Breast http://cancerres.aacrjournals.org/content/69/2_Supplement/6046

1363 Cancer and Leukemia Group B Pathology Committee Guidelines for Tissue Microarray Construction Representing Multicenter Prospective Clinical Trial Tissues

David L. Rimm, Torsten O. Nielsen, Scott D. Jewell, Daniel C. Rohrer, Gloria Broadwater, Frederic Waldman, Kisha A. Mitchell, Baljit Singh, Gregory J. Tsongalis, Wendy L. Frankel, Anthony M. Magliocco, Jonathan F. Lara, Eric D. Hsi, Ira J. Bleiweiss, Sunil S. Badve, Beiyun Chen, Peter M. Ravdin, Richard L. Schilsky, Ann Thor, Donald A. Berry *J Clin Oncol* vol 29 (16) 2282-2290 2011
Manuscript Pathology C9741, CALGB-9840 <http://www.ncbi.nlm.nih.gov/pubmed/21519016>

1364 CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma

B. I. Rini, S. Halabi, J. E. Rosenberg, W. M. Stadler, J. Picus, J. N. Atkins, S. Ou, J. Tanguay, J. Dutcher, E. J. Small *Genitourinary Cancers Symposium* abstr 350 2008

Abstract GU

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=54&abstractID

1365 Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206

B. I. Rini, S. Halabi, J. E. Rosenberg, W. M. Stadler, D. A. Vaena, J. N. Atkins, J. Picus, P. Czaykowski, J. Dutcher, E. J. Small *J. Clin. Oncol.* vol 27 (15s) abstr LBA5019 2009

Abstract GU

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

1366 Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

Brian I. Rini, Susan Halabi, Jonathan E. Rosenberg, Walter M. Stadler, Daniel A. Vaena, Laura Archer, James N. Atkins, Joel Picus, Piotr Czaykowski, Janice Dutcher, Eric J. Small *J Clin Oncol* vol 28 (13) 2137-2143 2010

Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/20368558>

1367 Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Brian I. Rini, Susan Halabi, Jonathan E. Rosenberg, Walter M. Stadler, Daniel A. Vaena, San-San Ou, Laura Archer, James N. Atkins, Joel Picus, Piotr Czaykowski, Janice Dutcher, Eric J. Small J Clin Oncol vol 26 (33) 5422-5428 2008
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/18936475>

1368 Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt - Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002

D. A. Rizzieri, J. L. Johnson, J. C. Byrd, G. Lozanski, B. L. Powell, T. C. Shea, S. Nattom, E. Hoke, B. D. Cheson, R. Larson Blood vol 116 (21) -858 2010
Abstract Leukemia <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;116/21/858>

1369 Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10002

David A. Rizzieri, Jeffrey L. Johnson, John C. Byrd, Gerard Lozanski, Kristie A. Blum, Bayard L. Powell, Thomas C. Shea, Sreenivasa Nattam, Eva Hoke, Bruce D. Cheson, Richard A. Larson Br. J. Haematol. vol 165 (1) 102-111 2014
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/24428673>

1370 N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group): Phase III Trial of Post-Operative Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease: Cognitive function of long-term survivors

David Roberge, Karla V. Ballman, Jane H. Cerhan, S. Keith Anderson, Xiomara W. Carrero, Anthony C. Whitton, Jeffrey Greenspoon, Ian F., Nadia N.I. Laack, Jonathan B. Ashman, Jean-Paul Bahary, Costas G. Hadjipanayis, James J. Urbanic, Fred G. Barker II, Elana Farace, Deepak Khuntia, Yolanda Garces, Caterina Giannini, Jan C. Buckner, Evanthia Galanis, Paul D. Brown Neuro-Oncology vol 19 (suppl 6) abstr NCOG-06. 2017
Abstract Neuro-Onc
https://watermark.silverchair.com/nox168.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9

1371 Identification of Potential Prognostic Biomarkers in Patients with Untreated, Advanced Pancreatic Cancer from a Phase III Trial (CALGB 80303)

Andrew S. Roberts, Michael J. Campa, Elizabeth B. Gottlin, Chen Jiang, Kouros Owzar, Hedy L. Kindler, Alan P. Venook, Richard M. Goldberg, Eileen M. O'Reilly, Edward F. Patz Cancer vol 118 (2) 571-578 2012
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/21713765>

1372 Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)

Gail J. Roboz, Sumithra J. Mandrekar, Pinkal Desai, Kristina Laumann, Alison R. Walker, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, Eyal C. Attar, Wendy Stock, Clara D. Bloomfield, Jessica Kohlschmidt, Krzysztof Mrózek, Duane C. Hassane, Levi Garraway, Judit Jané-Valbuena, Michele Baltay, Adam Tracy, Guido Marcucci, Richard M. Stone, Richard A. Larson Blood Adv vol 2 (24) 3608-17 2018
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/30567725>

1373 Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.

C M Rocha-Lima, J E Herndon, M E Lee, J N Atkins, A Mauer, E Vokes, M R Green Ann. Oncol. vol 18 (2) 331-7 2007
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/17065590>

- 1374 Comparison of performance status with peak oxygen consumption in operable patients with non-small-cell lung cancer**
Michael A. Roman, Graeme J. Koelwyn, Neil D. Eves, Whitney E. Hornsby, Dorothy Watson, James E. Herndon, Leslie Kohman, Gregory Loewen, Lee W. Jones *Respirology* vol 19 (1) 105-108 2014
Manuscript *Respiratory* <http://www.ncbi.nlm.nih.gov/pubmed/23890224>
- 1375 Does health-related quality of life (HRQL) improve for patients who respond to chemotherapy? Analysis of patients with advanced pancreas cancer (APC) receiving gemcitabine on Cancer and Leukemia Group B (CALGB) study 80303**
D. Romanus, L. E. Archer, X. Wang, R. M. Goldberg, M. Mulcahy, H. L. Kindler, D. Schrag *J. Clin. Oncol.* vol 25 (18s) abstr 9008 2007
Abstract *GI*
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID
- 1376 Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303).**
Dorothy Romanus, Hedy L Kindler, Laura Archer, Ethan Basch, Donna Niedzwiecki, Jane Weeks, Deborah Schrag *J Pain Symptom Manage* vol 43 (2) 205-17 2012
Manuscript *Health Outcome* <http://www.ncbi.nlm.nih.gov/pubmed/22104618>
- 1377 Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831**
E. H. Romond, V. J. Suman, J.-H. Jeong, G. Sledge, C. E. Jr Geyer, S. Martino, P. Rastogi, J. Gralow, S. M. Swain, E. Winer, G. Colon-Otero, C. Hudis, S. Paik, N. E. Davidson, E. Mamounas, J. Zujewski, N. Wolmark, E. A. Perez *Cancer Res.* vol 72 (24 supplement) S5 2012
Abstract *Breast*
http://cancerres.aacrjournals.org/cgi/content/short/72/24_MeetingAbstracts/S5-5?rss=1
- 1378 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.**
Edward H Romond, Edith A Perez, John Bryant, Vera J Suman, Charles E Geyer, Nancy E Davidson, Elizabeth Tan-Chiu, Silvana Martino, Soonmyung Paik, Peter A Kaufman, Sandra M Swain, Thomas M Pisansky, Louis Fehrenbacher, Leila A Kutteh, Victor G Vogel, Daniel W Visscher, Greg Yothers, Robert B Jenkins, Ann M Brown, Shaker R Dakhil, Eleftherios P Mamounas, Wilma L Lingle, Pamela M Klein, James N Ingle, Norman Wolmark *N. Engl. J. Med.* vol 353 (16) 1673-84 2005
Manuscript *Breast* <http://www.ncbi.nlm.nih.gov/pubmed/16236738>
- 1379 Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance)**
Cara A. Rosenbaum, Brandelyn Pitcher, Nancy L Bartlett, Sonali Smith, Kristie Blum, Eric Hsi, Sin-Ho Jung, John P. Leonard, Bruce D. Cheson *Blood* vol 126 (23) abstr 2741 2015
Abstract *Lymphoma* <http://www.bloodjournal.org/content/126/23/2741>
- 1380 Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).**
Cara A Rosenbaum, Sin-Ho Jung, Brandelyn Pitcher, Nancy L Bartlett, Sonali M Smith, Eric Hsi, Nina Wagner-Johnston, Sachdev P Thomas, John P Leonard, Bruce D Cheson *Br. J. Haematol.* vol 185 (1) 53-64 2019
Manuscript *Lymphoma* <http://www.ncbi.nlm.nih.gov/pubmed/30723894>
- 1381 Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207**
J. E. Rosenberg, S. Halabi, B. L. Sanford, A. L. Himmelstein, J. N. Atkins, R. J. Hohl, F. Millard, D. F.

Bajorin, E. J. Small Ann. Oncol vol 19 (5) 946-950 2008
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/18272914>

1382 The feasibility of breast-conserving surgery for multiple ipsilateral breast cancer: An initial report from ACOSOG Z11102 (Alliance) trial

Kari M. Rosenkranz, Karla Ballman, Linda McCall, Charlotte Kubicky, Laurie Cuttino, Huong Le-Petross, Kelly K. Hunt, Armando Giuliano, Kimberly J. Van Zee, Bruce Haffty, Judy C. Boughey
Ann. Surg. Oncol. vol 25 (10) 2858-66 2018
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/29987605>

1383 The feasibility of breast conserving surgery for multiple ipsilateral breast cancer: an initial report from ACOSOG Z11102 (Alliance) trial

Kari Rosenkranz, Linda McCall, Karla Ballman, Charlotte Kubicky, Laurie Cuttino, Huong T. Le-Petross, Kelly Hunt, Judy C. Boughey Ann. Surg. Oncol. vol 25 (Suppl 2) 257 2018
Abstract Breast <https://link.springer.com/content/pdf/10.1245%2Fs10434-018-6534-2.pdf>

1384 Phase II Trial of Atezolizumab Before and After Definitive Chemoradiation for Patients with Unresectable Stage III NSCLC

Helen J. Ross, David Kozono, James Urbanic, Terence Williams, Carter DuFrane, Ilze Bara, Mayank Gandhi, Katja Schulze, J. Michelle Brockman, Xiaofei Wang, Everett E. Vokes, Thomas E. Stinchcombe J Thorac Oncol vol 12 (11, suppl 2) S2285-86 2017
Abstract Respiratory [http://www.jto.org/article/S1556-0864\(17\)32396-1/fulltext](http://www.jto.org/article/S1556-0864(17)32396-1/fulltext)

1385 Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531)

V. Roy, B. R. LaPlant, G. G. Gross, C. L. Bane, F. M. Palmieri Ann Oncol vol 20 (3) 449-453 2009
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/19087987>

1386 NCCTG phase II trial N0531 of weekly nab-paclitaxel (nab-p) in combination with gemcitabine (gem) in patients with metastatic breast cancer (MBC)

V. Roy, B. Laplant, G. Gross, F. Palmieri, E. Perez J. Clin. Oncol. vol 25 (18S) abstr 1048 2007
Abstract Breast
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1387 N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer

V. Roy, B. Pockaj, D. Northfelt, J. Allred, H. Liu, D. Nikcevich, B. Mattar, E. Perez J. Clin. Oncol. vol 26 (May 20 suppl) abstr 563 2008
Abstract Breast
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1388 A Phase II trial of docetaxel and carboplatin administered every two weeks as preoperative therapy for stage II or III breast cancer: NCCTG Study N0338

Vivek Roy, Barbara A. Pockaj, Jacob B. Allred, Heidi Apsey, Donald W. Northfelt, Daniel Nikcevich, Bassam Mattar, Edith A. Perez Am. J. Clin. Oncol. vol 36 (6) 2013
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/22868240>

1389 BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance)

J. L. Rubenstein, E. D. Hsi, J. L. Johnson, S.-H. Jung, B. Grant, B. D. Cheson, L. D. Kaplan ASH Annual Meeting Abstracts vol 120 (21) -301 2012
Abstract Lymphoma <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/301>

1390 Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)

J. L. Rubenstein, E. D. Hsi, J. L. Johnson, S.-H. Jung, M. O. Nakashima, B. Grant, B. D. Cheson, L. D. Kaplan J. Clin. Oncol. vol 31 (25) 3061-8 2013

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/23569323>

1391 Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma: Results of CALGB 50202

J. L. Rubenstein, J. L. Johnson, S.-H. Jung, B. D. Cheson, L. D. Kaplan Blood vol 116 (21) -763 2010

Abstract Lymphoma <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;116/21/763>

1392 Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907)

K. J. Ruddy, B. N. Pitcher, L. E. Archer, H. J. Cohen, E. P. Winer, C. A. Hudis, H. B. Muss, A. H. Partridge Ann. Oncol. vol 23 (12) 3075-3081 2012

Manuscript Experimental CALGB-49907, CALGB-60104

<http://www.ncbi.nlm.nih.gov/pubmed/22767584>

1393 Adherence, persistence and toxicity with oral CMF in older women with early stage breast cancer in CALGB 49907 (adherence companion study 60104)

K. Ruddy, L. E. Archer, H. J. Cohen, E. P. Winer, C. A. Hudis, H. B. Muss, A. H. Partridge Cancer Res. vol 70 (24, suppl 2) abstr P5-10-12 2010

Abstract Health Outcome

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/70/24_MeetingAbstracts/P5-10-12

1394 A Comparison of the Natural History of Oxaliplatin- and Paclitaxel-Induced Neuropathy (NCCTG N08C1, N08CB/Alliance)

Kathryn Jean Ruddy, Dierdre Pachman, Rui Qin, Drew K. Seisler, Ellen M. Lavoie Smith, Suneetha Puttabasavaiah, Paul J. Novotny, Lauren E. Ta, Andreas S. Beutler, Nina D. Wagner-Johnston, Nathan Staff, Axel Grothey, Shaker R. Dakhil, Charles L. Loprinzi J. Clin. Oncol. vol 33 (suppl) abstr 9564 2015

Abstract Symptom Inter N08C1, A151505, N08CB

<http://meetinglibrary.asco.org/content/145135-156>

1395 CALGB 30103: A randomized phase II study of carboplatin and etoposide (CE) with or without G3139 in patients with extensive stage small cell lung cancer (ES-SCLC).

C. M. Rudin, R. Salgia, X. F. Wang, M. R. Green, E. E. Vokes J. Clin. Oncol. vol 23 (16s) abstract 7168 2005

Abstract Respiratory

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=34&abstractID

1396 Randomized Phase II Study of Carboplatin and Etoposide With or Without the bcl-2 Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103

Charles M. Rudin, Ravi Salgia, Xiaofei Wang, Lydia D. Hodgson, Gregory A. Masters, Mark Green, Everett E. Vokes J. Clin. Oncol. vol 26 (6) 870-876 2008

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18281659>

1397 CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC)

H. S. Rugo, W. T. Barry, A. Moreno-Aspitia, A. P. Lyss, C. Cirrincione, E. L. Mayer, M. Naughton, R. M. Layman, L. A. Carey, R. A. Somer, E. A. Perez, C. Hudis, E. P. Winer J. Clin. Oncol. vol 30 (18

suppl) abstr CRA1002 2012

Abstract Breast CALGB-40502, NCCTG-N063H

http://meeting.ascopubs.org/cgi/content/abstract/30/18_suppl/CRA1002?sid=9319c70d-f68e-40ab-8ad4-l

1398 Long-term follow-up (fu) of (Alliance) CALGB 40502/NCCTG N063H: a randomized phase iii trial of weekly paclitaxel (p) compared to weekly nanoparticle albumin bound nab-paclitaxel (np) or ixabepilone (ix) +/- bevacizumab (b) as first-line therapy for locally recurrent or metastatic breast cancer (MBC)

Hope S. Rugo, William T. Barry, Alvaro Moreno-Aspitia, Lyss Alan, Lucas Huebner, Erica L. Mayer, Michael Naughton, RM Layman, Lisa A. Carey, RA Somer, D Toppmeyer, M Velasco, Edith A. Perez, Clifford Hudis, Eric Winer *Cancer Res* vol 78 (4 Supplement) P1-09-01 2018

Abstract Breast CALGB-40502, NCCTG-N063H

http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-09-01

1399 Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)

Hope S. Rugo, William T. Barry, Alvaro Moreno-Aspitia, Alan P. Lyss, Constance Cirrincione, Eleanor Leung, Erica L. Mayer, Michael Naughton, Deborah Toppmeyer, Lisa A. Carey, Edith A. Perez, Clifford Hudis, Eric P. Winer *J. Clin. Oncol* vol 33 (21) 2361-2369 2015

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26056183>

1400 Prophylactic Cranial Irradiation in Elderly Patients with Small Cell Lung Cancer: Findings from a North Central Cancer Treatment Group Pooled Analysis

W. G. Rule, N. R. Foster, J. P. Meyers, J. B. Ashman, S. A. Vora, T. F. Kozelsky, Y. I. Garces, J. J. Urbanic, J. K. Salama, S. E. Schild *J Geriatr Oncol* vol 6 (2) 119-126 2015

Manuscript Respiratory NCCTG-86-20-51, NCCTG-89-20-51, NCCTG-89-20-52, NCCTG-95-20-53 <http://www.ncbi.nlm.nih.gov/pubmed/25482023>

1401 Results of NCCTG N0275 (Alliance) – a phase II trial evaluating resection followed by adjuvant radiation therapy for patients with desmoplastic melanoma

William G. Rule, Jacob B. Allred, Barbara A. Pockaj, Svetomir N. Markovic, David J. DiCaudo, Lori A. Erickson, Richard L. Deming, Steven E. Schild *Cancer Med* vol 5 (8) 1890-1896 2016

Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/27368067>

1402 Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia.

A S Ruppert, J Yin, M Davidian, A A Tsiatis, J C Byrd, J A Woyach, S J Mandrekar *Ann. Oncol.* vol 30 (4) 542-50 2019

Manuscript Leukemia A041202 <http://www.ncbi.nlm.nih.gov/pubmed/30799502>

1403 A Genetic Risk-Stratified, Phase II Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated Chronic Lymphocytic Leukemia (CLL): Final Results of Cancer and Leukemia Group B (CALGB) 10404 (Alliance)

Amy S. Ruppert, John C. Byrd, Nyla A. Heerema, Mitchell Smith, John Godwin, Stephen Couban, Todd A. Fehniger, Michael Thirman, Alese E. Halvorson, Bercedis L. Peterson, Martin S. Tallman, Frederick R. Appelbaum, Richard M. Stone, Sue Robinson, Julie E. Chang, Sumithra J. Mandrekar, Richard A. Larson *J. Clin. Oncol.* vol 35 (15 suppl) abstr 7503 2017

Abstract Leukemia http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.7503

1404 Occult Metastases in Lymph Nodes Predict Survival in Resectable Non-Small-Cell Lung Cancer: Report of the ACOSOG Z0040 Trial

V. W. Rusch, D. Hawes, P. A. Decker, S. E. Martin, A. Abati, R. J. Landreneau, G. A. Patterson, R. I. Incullet, D. R. Jones, R. A. Malthaner, R. G. Cohen, K. Ballman, J. B. Putnam Jr, R. J. Cote J. Clin. Oncol. vol 29 (32) 4313-4319 2011
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21990404>

1405 Serum Androgens and Survival in metastatic Castration Resistant Prostate Cancer (mCRPC) Patients Treated with Docetaxel and Prednisone: Results from CALGB 90401 (Alliance)

Charles J Ryan, Sandipan Dutta, William K Kelly, Rob Middleberg, Carly Russell, Eric J. Small, Michael J. Morris, Mary-Ellen Taplin, Susan Halabi J. Clin. Oncol. vol 35 (15 suppl) abstr 5067 2017
Abstract GU http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.5067

1406 Decline in serum androgens and survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with docetaxel and prednisone: results from CALGB 90401 (Alliance)

Charles J Ryan, Sandipan Dutta, William K Kelly, Carly Russell, Eric J. Small, Michael J. Morris, Mary-Ellen Taplin, Susan Halabi Eur Urol vol 17 (2) e1073 2018
Abstract GU
[https://www.eusupplements.europeanurology.com/article/S1569-9056\(18\)31580-X/pdf](https://www.eusupplements.europeanurology.com/article/S1569-9056(18)31580-X/pdf)

1407 Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).

Charles J Ryan, Sandipan Dutta, William K Kelly, Carly Russell, Eric J Small, Michael J Morris, Mary-Ellen Taplin, Susan Halabi Prostate Cancer Prostatic Dis. 2019
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/31053766>

1408 Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.

Charles J Ryan, Susan Halabi, San-San Ou, Nicholas J Vogelzang, Philip Kantoff, Eric J Small Clin. Cancer Res. vol 13 (7) 2030-7 2007
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/17404083>

1409 Prognostic impact of insertion site in acute myeloid leukemia with FLT3 internal tandem duplication: results from the RATIFY study (Alliance)

Frank G. Rücker, Ling Du, Tamara J. Blätte, Axel Benner, Julia Krzykalla, Insa Gathmann, Richard A. Larson, Francesco Lo-Coco, Sergio Amadori, Thomas W. Prior, Joseph M. Brandwein, Frederick R. Appelbaum, Bruno C. Medeiros, Michelle Geddes, Jorge Sierra, Eva Tiecke, Celine Pallaud, Miguel Sanz, Theo de Witte, Dietger Niederwieser, Gerhard Ehninger, Michael Heuser, Arnold Ganser, Lars Bullinger, Clara D. Bloomfield, Richard M. Stone, Hartmut Döhner, Christian Thiede, Konstanze Döhner Blood vol 132 (Suppl 1) 435 2018
Abstract Leukemia http://www.bloodjournal.org/content/132/Suppl_1/435.abstract

1410 Questionable value of attribution when interpreting adverse event data: A joint evaluation by North Central Cancer Treatment Group (NCCTG) and American College of Surgeons Oncology Group (ACOSOG).

Hillman SL, Sargent DJ, Bot BM, DeMatteo RP, Perez EA, Ballman KV, Mandrekar SJ: J Clin Oncol vol 25 (18S) abst 6511 2007
Abstract GI

1411 Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial – CALGB/alliance 170601

E.M.L. SMITH, H. PANG, C. YE, C. CIRINCIONE, S. FLEISHMAN, E.D. PASKETT, T. AHLES, L.R. BRESSLER, N. LE-LINDQWISTER, C.E. FADUL, C. LOPRINZI, C.L. SHAPIRO Eur J

1412 Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.

Everardo D Saad, Pierre Squifflet, Tomasz Burzykowski, Emmanuel Quinaux, Suzette Delalogue, Dimitris Mavroudis, Edith Perez, Martine Piccart-Gebhart, Bryan P Schneider, Dennis Slamon, Norman Wolmark, Marc Buyse *Lancet Oncol.* vol 20 (3) 361-70 2019
Manuscript Breast N9831, NSABP B-31 <http://www.ncbi.nlm.nih.gov/pubmed/30709633>

1413 Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials

Poornima Saha, Meredith M. Regan, Olivia Pagani, Prudence A. Francis, Barbara A. Walley, Karin Ribí, Jürg Bernhard, Weixiu Luo, Henry L. Gómez, Harold J. Burstein, Vani Parmar, Roberto Torres, Josephine Stewart, Meritxell Bellet, Antonia Perelló, Faysal Dane, Antonio Moreira, Daniel Vorobiof, Michelle Nottage, Karen N. Price, Alan S. Coates, Aron Goldhirsch, Richard D. Gelber, Marco Colleoni, Gini F. Fleming *J. Clin. Oncol* vol 35 (27) 3113-22 2017
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/28654365>

1414 Interim analysis of CALGB 150607: A pilot project to study the expression of MET and p53 in resected lung adenocarcinoma specimens

A. K. Salama, R. A. Kratzke, W. Richards, H. Pang, E. E. Vokes, R. Salgia *J. Clin. Oncol.* vol 28 (15s) abstr 10633 2010
Abstract Correl Sci NOS
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

1415 Predictors of pulmonary toxicity in limited stage (LS) small cell lung cancer (SCLC) patients treated with concurrent chemotherapy (CTX) and high dose (70 Gy) daily radiotherapy (RT), a pooled analysis of three CALGB studies

J. K. Salama, L. D. Hodgson, H. Pang, M. R. Green, J. J. Urbanic, A. W. Blackstock, J. Crawford, J. A. Bogart, E. E. Vokes *J. Clin. Oncol.* vol 29 (suppl) abstr 7078 2011
Abstract Respiratory CALGB-30002, C30904, CALGB-30206, CALGB-30904, CALGB-39808
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

1416 A Pooled Analysis of Limited-Stage Small-Cell Lung Cancer Patients Treated with Induction Chemotherapy Followed by Concurrent Platinum-Based Chemotherapy and 70 Gy Daily Radiotherapy: CALGB 30904

J. K. Salama, L. Hodgson, H. Pang, J. J. Urbanic, A. W. Blackstock, S. E. Schild, J. Crawford, J. A. Bogart, E. E. Vokes *J Thorac Oncol* vol 8 (8) 1043-9 2013
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/23715301>

1417 Positive Interaction Between Prophylactic Cranial Irradiation And Maintenance Sunitinib For Untreated Extensive Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis Of CALGB 30504 (Alliance)

Joseph K. Salama, Lin Gu, Xiaofei Wang, Herbert H. Pang, Jeffrey A. Bogart, Jeffrey Crawford, Steven E. Schild, Everett E. Vokes, Neal E. Ready *J Thorac Oncol* vol 11 (3) 361-369 2016
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/26723241>

1418 Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904

Joseph K. Salama, Herbert Pang, Jeffrey A. Bogart, A. William Blackstock, James J. Urbanic, Lydia

Hodgson, Jeffery Crawford, Everett E. Vokes Lung Cancer vol 82 (3) 436-440 2013
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/24396884>

1419 Pulmonary toxicity in stage III non-small cell lung cancer patients treated with high dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: A secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105

Joseph K. Salama, Thomas E. Stinchcombe, Lin Gu, Xiaofei Wang, Karen Morano, Jeffrey A. Bogart, Jeffrey C. Crawford, Mark A. Socinski, A. William Blackstock, Everett E. Vokes Int J Radiat Oncol Biol Phys vol 81 (4) e269-e274 2011
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21477940>

1420 PCI Survival Improvement for Extensive Stage SCLC Limited to Patients on Maintenance Systemic Therapy: A Secondary Analysis of CALGB 30504 (Alliance)

Joseph K. Salama, Lin Gu, Xiaofei Wang, Jeffrey Bogart, Jeffrey Crawford, Steven Schild, Neil Ready, Everett E Vokes J Thorac Oncol vol 10 (9) suppl 2, abstr MINI37.07 2015
Abstract Respiratory [http://www.jto.org/article/S1556-0864\(16\)30011-9/fulltext](http://www.jto.org/article/S1556-0864(16)30011-9/fulltext)

1421 An Interim Analysis Of CALGB 150607: Expression And Mutational Status Of c-MET, HGF, EGFR, KRAS, p53, c-CBL, And E-cadherin In Resected Lung Adenocarcinoma Specimens

R. Salgia, V. Nallasura, H. Pang, C. Rolle, W. Richards, L. Hodgson, Q. Arif, A. Husain, R. Kratzke, E. Vokes Clin. Cancer Res. vol 18 abstr A37 2012
Abstract Correl Sci NOS
http://clincancerres.aacrjournals.org/content/18/3_Supplement/A37.abstract

1422 Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.

Leonard B Saltz, Donna Niedzwiecki, Donna Hollis, Richard M Goldberg, Alexander Hantel, James P Thomas, Anthony L A Fields, Robert J Mayer J. Clin. Oncol. vol 25 (23) 3456-61 2007
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17687149>

1423 Validation of the Preoperative Endocrine Prognostic Index in the ACOSOG (Alliance) Z1031 Neoadjuvant Aromatase Inhibitor Trial

Souzan Sanati, Vera J. Suman, R. Goncalves, K. DeSchryver, C.X. Ma, J. Hoog, E. Crouch, M. Barnes, G. Unzeitig, A.M. Leitch, Kelly K. Hunt, Matthew J. Ellis Cancer Res. vol 75 (suppl 9) abstr P4-11-13 2015
Abstract Breast http://cancerres.aacrjournals.org/content/75/9_Supplement/P4-11-13.short?rss=1

1424 A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.

Robert S Sandler, Susan Halabi, John A Baron, Susan Budinger, Electra Paskett, Roger Keresztes, Nicholas Petrelli, J Marc Pipas, Daniel D Karp, Charles L Loprinzi, Gideon Steinbach, Richard Schilsky N. Engl. J. Med. vol 348 (10) 883-90 2003
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/12621132>

1425 Risk stratified analysis improves prediction of treatment (Rx) benefit over subgroup analysis: Findings from Intergroup N9741

H. K. Sanoff, M. E. Campbell, H. C. Pitot, R. M. Goldberg, D. J. Sargent J. Clin. Oncol. vol 26 (suppl) abstr 4018 2008
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1426 N9741: Survival update and prognostic factor analysis of oxaliplatin (Ox) and irinotecan (Iri) combinations for metastatic colorectal cancer (MCRC)

H. K. Sanoff, D. J. Sargent, M. E. Campbell, R. Morton, C. S. Fuchs, R. Ramanathan, S. Williamson, B. Findlay, H. Pitot, R. M. Goldberg J. Clin. Oncol. vol 25 (18s) abstr 4067 2007
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1427 Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741

Hanna K. Sanoff, Daniel J. Sargent, Megan E. Campbell, Roscoe F. Morton, Charles S. Fuchs, Ramesh K. Ramanathan, Stephen K. Williamson, Brian P. Findlay, Henry C. Pitot, Richard M. Goldberg J Clin Oncol vol 26 (35) 5721-5727 2008
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19001325>

1428 Racial Differences in Advanced Colorectal Cancer Outcomes and Pharmacogenetics: A Subgroup Analysis of a Large Randomized Clinical Trial

Hanna K. Sanoff, Daniel J. Sargent, Erin M. Green, Howard L. McLeod, Richard M. Goldberg J Clin Oncol vol 27 (25) 4109-4115 2009
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19636001>

1429 Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results

Marta Santisteban, Jan C. Buckner, Joel M. Reid, Wenting Wu, Bernd W. Scheithauer, Matthew M. Ames, Sara J. Felten, Daniel A. Nikcevich, Martin Wiesenfeld, Kurt A. Jaeckle, Evanthia Galanis J Neurooncol vol 92 (2) 165-175 2009
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/19066728>

1430 Overall and 12 week tumor response versus actual tumor measurements as predictors of overall survival (OS) in advanced colorectal cancer (ACRC): Findings from NCCTG N9741.

D. J. Sargent, M. E. Campbell, A. Grothey, R. M. Goldberg Gastrointestinal Cancers Symposium abstr 446 2008
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=53&abstractID

1431 Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803.

D. J. Sargent, G. Yothers, E. Van Cutsem, J. Cassidy, L. Saltz, N. Wolmark, Q. Shi, M. Buyse, A. De Gramont, A. Grp J. Clin. Oncol. vol 27 (15) abstr 4011 2009
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

1432 Benefits and adverse events in younger (age<50) vs. older patients receiving adjuvant chemotherapy for colon cancer: Findings From the 33,574 pt ACCENT dataset.

D. Sargent, G. Yothers, E. Green, C. Blanke, M. O'Connell, R. Labianca, A. Bleyer, A. Degramont, D. Thomas J. Clin. Oncol. vol 28 (15s) abstr 3523 2010
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

1433 Two or Three Year Disease Free Survival (DFS) as a Primary Endpoint in Stage III Adjuvant Colon Cancer Trials with fluoropyrimidines with or without Oxaliplatin or Irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07, and C89803

D Sargent, Q Shi, G Yothers, E Van Cutsem, J Cassidy, L Saltz, N Wolmark, B Bot, A Grothey, M Buyse, A de Gramont Eur J Cancer vol 47 (7) 990-996 2011
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21257306>

1434 Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer

Daniel J. Sargent, Claus Henning Köhne, Hanna Kelly Sanoff, Brian M. Bot, Matthew T. Seymour, Aimery de Gramont, Ranier Porschen, Leonard B. Saltz, Philippe Rougier, Christopher Tournigand, Jean-Yves Douillard, Richard J. Stephens, Axel Grothey, Richard M. Goldberg J Clin Oncol vol 27 (12) 1948-1955 2009

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19255311>

1435 Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

Daniel J. Sargent, Silvia Marsoni, Genevieve Monges, Stephen N. Thibodeau, Roberto Labianca, Stanley R. Hamilton, Amy J. French, Brian Kabat, Nathan R. Foster, Valter Torri, Christine Ribic, Axel Grothey, Malcolm Moore, Alberto Zaniboni, Jean-Francois Seitz, Frank Sinicrope, Steven Gallinger J Clin Oncol vol 28 (20) 3219-3226 2010

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20498393>

1436 End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Daniel J Sargent, Smitha Patiyil, Greg Yothers, Daniel G Haller, Richard Gray, Jacqueline Benedetti, Marc Buyse, Roberto Labianca, Jean Francois Seitz, Christopher J O'Callaghan, Guido Francini, Axel Grothey, Michael O'Connell, Paul J Catalano, David Kerr, Erin Green, Harry S Wieand, Richard M Goldberg, Aimery de Gramont J. Clin. Oncol. vol 25 (29) 4569-74 2007

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/17876008>

1437 Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: Lessons from the 20,800 patient ACCENT dataset

Sargent, D. J. J. Clin. Oncol. vol 25 (18s) abstr 4008 2007

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=45&abstractID

1438 NCCTG phase I trial of Everolimus (RAD001) and Temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients (N057K).

J. N. Sarkaria, E. Galanis, P. J. Peller, P. D. Brown, W. Wu, S. J. Felten, J. H. Uhm, C. Giannini, K. A. Jaeckle, J. C. Buckner Mol Cancer Ther vol 8 (12s) abstr C56 2009

Abstract Neuro-Onc

http://mct.aacrjournals.org/cgi/content/meeting_abstract/8/12_MeetingAbstracts/C56?sid=1123373f-30d

1439 NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients

J. N. Sarkaria, E. Galanis, W. Wu, C. Giannini, K. A. Jaeckle, L. Doyle, J. Uhm, P. Brown, A. B. Dietz, J. Buckner J. Clin. Oncol. vol 27 (15) abstr 2019 2009

Abstract Neuro-Onc

<http://meeting.ascopubs.org/gca?gca=ascomtg%3B27%2F15S%2F2019&allch=&submit=Go>

1440 Effect of combined therapy with temsirolimus (CCI-779), temozolomide (TMZ), and radiation (RT) in newly diagnosed glioblastoma multiforme (GBM) patients on immune suppression: results from NCCTG N027D

J. Sarkaria, E. Galanis, M. Gustafson, A. Dietz, W. Wu, P. Brown, J. H. Uhm, C. Giannini, K. Jaeckle, J. Buckner J. Clin. Oncol. vol 28 (15s) 183s abstr 2016 2010

Abstract Neuro-Onc

1441 FLT-PET analysis of early response to everolimus in newly diagnosed glioblastoma patients enrolled on NCCTG N057K

J. Sarkaria, P. Peller, E. Galanis, M. Jacobson, W. Wu, K. Jaeckle, J. Buckner J. Clin. Oncol. vol 29 (15s) abstr e12501 2011
Abstract Neuro-Onc
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B29%2F15_suppl%2Fe12501

1442 Combination of temsirolimus (CCI-779) with chemo-radiation in newly diagnosed GBM (NCCTG trial N027D) is associated with increased infectious risks¹

Jann N. Sarkaria, Eva Galanis, Wenting Wu, Allan B. Dietz, Timothy J. Kaufmann, Michael P. Gustafson, Paul D. Brown, Joon H. Uhm, Ravi D. Rao, Laurence Doyle, Caterina Giannini, Kurt A. Jaeckle, Jan C. Buckner Clin Cancer Res vol 16 (22) 5573-5580 2010
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/20921209>

1443 NCCTG Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination with Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme Patients¹

Jann N. Sarkaria, Evanthia Galanis, Wenting Wu, Patrick J. Peller, Caterina Giannini, Paul D. Brown, Joon H. Uhm, Steven McGraw, Kurt A. Jaeckle, Jan C. Buckner Int J Radiat Oncol Biol Phys vol 81 (2) 468-475 2011
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/20864273>

1444 A Phase II Study of Neoadjuvant Therapy with Cisplatin, Docetaxel, Panitumumab Plus Radiation Therapy Followed by Surgery in Patients with Locally Advanced Adenocarcinoma of the Distal Esophagus. (Results of ACOSOG Z4051 (Alliance))

T. Schefter, P. Decker, B. Meyers, M. Ferguson, A. Oeltjen, J. B. Jr Putnam, S. Cassivi, C. E. Reed, C. A. Lockhart Int. J. Radiat. Oncol. Biol. Phys. vol 87 (2 Supplement) S85-S86 2013
Abstract GI <http://www.sciencedirect.com/science/article/pii/S0360301613008924>

1445 Phase I study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North central cancer treatment group (NCCTG) N0572

D. Schiff, J. Sarkaria, P. Decker, J. Buckner, E. Galanis, J. Dancy, C. Giannini, P. Brown, M. Wiesenfeld, K. Jaeckle Neuro-oncology vol 9 (4) 518-518 2007
Abstract Neuro-Onc <http://neuro-oncology.oxfordjournals.org/content/9/4/467.full.pdf+html>

1446 Feasibility/tolerability results from a phase I/II study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North Central Cancer Treatment Group (NCCTG) N0572

D. Schiff, J. Sarkaria, P. Decker, J. Buckner, E. Galanis, J. Dancy, C. Giannini, P. Brown, M. Wiesenfeld, K. Jaeckle Neuro-oncology vol 11 (2) 232-232 2009
Abstract Neuro-Onc <http://neuro-oncology.oxfordjournals.org/content/11/2/217.full.pdf+html>

1447 Phase I/II Trial of Temsirolimus and Sorafenib in Treatment of Patients with Recurrent Glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572

David Schiff, Kurt A Jaeckle, S. Keith Anderson, Evanthia Galanis, Caterina Giannini, Jan C. Buckner, Phillip Stella, Patrick J Flynn, Bradley J Erickson, John F Schwerkoske, Vesna Kaluza, Erin Twohy, Janet Dancy, John Wright, Jann N. Sarkaria Cancer vol 124 (7) 1455-1463 2018
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/29313954>

1448 Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis

S. E. Schild, N. R. Foster, J. P. Meyers, H. J. Ross, P. J. Stella, Y. I. Garces, K. R. Olivier, J. R. Molina, L. R. Past, A. A. Adjei Ann. Oncol. vol 23 (11) 2919-2924 2012

- 1449 N0321: A phase II study of bortezomib, paclitaxel, carboplatin, and radiotherapy for locally advanced non-small cell lung cancer**
S. E. Schild, J. R. Molina, G. K. Dy, K. M. Rowland Jr, J. N. Sarkaria, S. P. Thomas, D. W. Northfelt, J. W. Kugler, N. R. Foster, A. A. Adjei J. Clin. Oncol. vol 30 (15 suppl) abstr 7073 2012
Abstract Respiratory
http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/7073?sid=1d518509-b067-40df-8465-669d
- 1450 Baseline quality of life (QOL) as a prognostic factor for overall survival (OS) in patients (Pts) with advanced stage non-small cell lung cancer (A-NSCLC): An analysis of NCCTG studies.**
S. E. Schild, Y. Qi, A. D. Tan, S. J. Mandrekar, A. A. Adjei, J. E. Krook, K. M. Rowland Jr, Y. I. Garces, G. S. Soori, J. A. Sloan J. Clin. Oncol. vol 26 (15s) abstr 8076 2008
Abstract Respiratory
http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/8076?sid=d8821ba2-45c3-45ae-af7d-b823t
- 1451 Prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC): Findings from a North Central Cancer Treatment Group (NCCTG) pooled analysis.**
S. Schild, N. Foster, J. Meyers, K. Olivier, H. Ross, J. Molina, P. Stella, L. Past, Y. Garces, A. Adjei J. Clin. Oncol. vol 29 (15s) abstr 7074 2011
Abstract Respiratory NCCTG-89-20-51, NCCTG-89-20-52, NCCTG-892052, NCCTG-95-20-53
http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/7074
- 1452 Survival of patients (pts) treated with high-dose radiotherapy (RT) and concurrent chemotherapy for unresectable non-small cell lung cancer (NSCLC).**
S. Schild, D. Graham, S. Hillman, S. Vora, G. Yolanda, J. Molina, H. Shahidi, J. Kugler, A. Adjei J. Clin. Oncol. vol 27 (15S) 7544 2009
Abstract Respiratory
<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/7544?sid=85d951d9-44ea-49c0-b15d-2bc919a6t>
- 1453 Long-term Survival of Patients (pts) Treated with High-dose Radiotherapy(rt) and Concurrent Chemotherapy for Unresectable Non-small Cell Lung Cancer (nslc)**
S. Schild, S. Hillman, D. Graham, S. Vora, Y. Garces, K. Olivier, J. Kugler, H. Ross, J. Molina, A. Adjei J Thorac Oncol vol 7 (15 (suppl 4)) 234, Abstract 158 2012
Abstract Respiratory <http://www.jto.org/article/S1556-0864%2815%2933009-4/fulltext>
- 1454 The value of combined modality therapy in elderly patients with stage III non-small cell lung cancer (NSCLC)**
S. Schild, S. Mandrekar, A. Jatoi, W. McGinnis, P. Stella, R. Deming, J. Jett, Y. Garces, K. Allen, A. Adjei J. Clin. Oncol. vol 28 (18s) 19503 2007
Abstract Respiratory NCCTG-94-24-52, NCCTG-90-24-51
http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/19503?sid=144cd6d1-2a9a-428d-8e31-041
- 1455 N0321: A Phase I Study of bortezomib, Paclitaxel, Carboplatin (CBDCA) & Radiotherapy (RT) for Locally-Advanced Non-Small Cell Lung Cancer (NSCLC)**
S. Schild, J. Molina, G. Dy, K. Rowland Jr, J. Sarkaria, S. Thomas, D. Northfelt, J. Kugler, N. Foster, A. Adjei J. Clin. Oncol. vol 28 (15s) abstr 7085 2010
Abstract Respiratory
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7085?sid=1d518509-b067-40df-8465-669d
- 1456 Brain Metastases From Melanoma**
Steven E. Schild, Deepti Behl, Svetomir N. Markovic, Paul D. Brown, Jonathan R. Sande, Richard L.

Deming, Kendrith M. Rowland, James D. Bearden Am. J. Clin. Oncol. vol 33 (6) 633-636 2010
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/20042969>

1457 Long-terms results of a trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small cell lung cancer: NCCTG N0028 (Alliance)

Steven E. Schild, Shauna L. Hillman, Angelina D. Tan, Helen J. Ross, William L. McGinnis, Yolanda A. Garces, David L. Graham, Alex A. Adjei, James R. Jett J Thorac Oncol vol 12 (4) 697-703 2017
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/28089762>

1458 Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).

Steven E Schild, James A Bonner, Shauna Hillman, Timothy F Kozelsky, Antonio P G Vigliotti, Randolph S Marks, David L Graham, Gamini S Soori, John W Kugler, Richard C Tenglin, Donald B Wender, Alex Adjei J. Clin. Oncol. vol 25 (21) 3124-9 2007
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/17634491>

1459 The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer.

Steven E Schild, Sumithra J Mandrekar, Aminah Jatoi, William L McGinnis, Phillip J Stella, Richard L Deming, James R Jett, Yolanda I Garces, Katie L Allen, Alex A Adjei Cancer vol 110 (2) 363-8 2007
Manuscript Respiratory NCCTG-90-24-51, NCCTG-94-24-52
<http://www.ncbi.nlm.nih.gov/pubmed/17542000>

1460 Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer.

Steven E Schild, William L McGinnis, David Graham, Shauna Hillman, Tom R Fitch, Donald Northfelt, Yolanda I Garces, Homayoon Shahidi, Loren K Tschetter, Paul L Schaefer, Alex Adjei, James Jett Int. J. Radiat. Oncol. Biol. Phys. vol 65 (4) 1106-11 2006
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/16730134>

1461 A patterns-of-care study of post-progression treatment (Rx) among patients (pts) with advanced pancreas cancer (APC) after gemcitabine therapy on Cancer and Leukemia Group B (CALGB) study 80303

D. Schrag, L. E. Archer, X. Wang, D. Romanus, M. Mulcahy, R. M. Goldberg, H. L. Kindler J. Clin. Oncol. vol 25 (18S) abstr 4524 2007
Abstract Health Outcome
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1462 Clinical trial participants' strategies for coping with prescription drug costs: A companion study to CALGB 80405

D. Schrag, M. J. Naughton, A. Kesselheim, L. E. Archer, D. Niedzwiecki, D. Romanus, R. M. Goldberg, A. P. Venook J. Clin. Oncol. vol 27 (15s) abstr 9503 2009
Abstract Health Outcome <http://meetinglibrary.asco.org/content/34985-65>

1463 Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405.

Deborah Schrag, Amylou C. Dueck, Michelle Joy Naughton, Donna Niedzwiecki, Craig Earle, James Edward Shaw, Axel Grothey, Howard S. Hochster, Charles David Blanke, Alan P. Venook J. Clin. Oncol. vol 33 (suppl) abstr 6504 2015
Abstract Health Outcome CALGB-80405, CALGB-70502
<http://meetinglibrary.asco.org/content/152903-156>

1464 Challenges and Solutions in the Design and Execution of the PROSPECT Phase II/III Neoadjuvant Rectal Cancer Trial (NCCTG N1048/Alliance)

Deborah Schrag, Martin Weiser, Leonard Saltz, Harvey Mamon, Marc Gollub, Ethan Basch, Alan Venook, Qian Shi Clin Trials vol 16 (2) 165-75 2019
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/30688523>

1465 Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

Werner Schroth, Matthew P. Goetz, Ute Hamann, Peter A. Fasching, Marcus Schmidt, Stefan Winter, Peter Fritz, Wolfgang Simon, Vera J. Suman, Matthew M. Ames, Stephanie L. Safgren, Mary J. Kuffel, Hans Ulrich Ulmer, Julia Boländer, Reiner Strick, Matthias W. Beckmann, Heinz Koelbl, Richard M. Weinshilboum, James N. Ingle, Michel Eichelbaum, Matthias Schwab, Hiltrud Brauch JAMA vol 302 (13) 1429-1436 2009
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/19809024>

1466 Higher MN1 expression is an unfavorable prognosticator in older patients (Pts) with cytogenetically normal acute myeloid leukemia (CN-AML): A CALGB study

S. Schwind, G. Marcucci, K. B. Holland, K. Mrózek, M. D. Radmacher, K. Maharry, H. Becker, S. P. Whitman, Y.-Z. Wu, T. H. Carter, B. L. Powell, M. A. Caligiuri, M. R. Baer, R. A. Larson, C. D. Bloomfield AACR Annual Meeting abstr 2717 2010
Abstract Leuk Corr Sci C20502, C9665, C8461, C9621, C19808
<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=3a98c08e-5100-427d-b077-f6c5984fe48>

1467 MicroRNA 181a (miR-181a) expression as a prognosticator in cytogenetically normal acute myeloid leukemia (CN AML)

S. Schwind, G. Marcucci, K. S. Maharry, M. D. Radmacher, S. P. Whitman, P. Paschka, K. A. Mrozek, J. E. Kolitz, R. A. Larson, C. D. Bloomfield J. Clin. Oncol. vol 27 (15s) abstr 7001 2009
Abstract Leuk Corr Sci C9621, CALGB-19808
<http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B27%2F15S%2F7001>

1468 Aberrant Gene Expression of BAALC and ERG in Older \geq 60 Years (y) De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study

S. Schwind, G. Marcucci, K. Maharry, K. Mrozek, M. D. Radmacher, K. B. Holland, H. Becker, S. P. Whitman, Y. Z. Wu, M. R. Baer, B. L. Powell, A. J. Carroll, M. A. Caligiuri, R. A. Larson, C. D. Bloomfield Blood vol 114 (22) 93-94 2009
Abstract Leuk Corr Sci CALGB-10201, CALGB-20202, CALGB-8461, CALGB-9720
<https://ash.confex.com/ash/2009/webprogram/Paper22613.html>

1469 *inv*(16)/*t*(16;16) acute myeloid leukemia with non-type A CBF β -MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations

Sebastian Schwind, Colin G. Edwards, Deedra Nicolet, Krzysztof Mrózek, Kati Maharry, Yue-Zhong Wu, Peter Paschka, Ann-Kathrin Einfeld, Pia Hoellerbauer, Heiko Becker, Klaus H. Metzeler, John Curfman, Jessica Kohlschmidt, Thomas W. Prior, Jonathan E. Kolitz, William Blum, Mark J. Pettenati, Paola Dal Cin, Andrew J. Carroll, Michael A. Caligiuri, Richard A. Larson, Stefano Volinia, Guido Marcucci, Clara D. Bloomfield Blood vol 121 (2) 385-391 2013
Manuscript Leuk Corr Sci CALGB-8461, CALGB-8525, CALGB-8821, CALGB-8923, CALGB-9022, CALGB-9120, CALGB-9222, CALGB-9621, CALGB-9720, CALGB-19808, CALGB-10201, CALGB-10502, CALGB-10503, CALGB-10603
<http://www.ncbi.nlm.nih.gov/pubmed/23160462>

1470 Prognostic Significance of Expression of a Single MicroRNA, miR-181a, in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Sebastian Schwind, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Kelsi B. Holland, Dean Margeson, Susan P. Whitman, Christopher Hickey, Heiko Becker, Klaus H. Metzeler, Peter Paschka, Claudia D. Baldus, Shujun Liu, Ramiro Garzon, Bayard L. Powell, Jonathan E. Kolitz, Andrew J. Carroll, Michael A. Caligiuri, Richard A. Larson, Guido Marcucci, Clara D. Bloomfield *J Clin Oncol* vol 28 (36) 5257-5264 2010
Manuscript *Leuk Corr Sci* CALGB-19808, CALGB-20202, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://www.ncbi.nlm.nih.gov/pubmed/21079133>

1471 Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia

Sebastian Schwind, Guido Marcucci, Jessica Kohlschmidt, Michael D. Radmacher, Krzysztof Mrózek, Kati Maharry, Heiko Becker, Klaus H. Metzeler, Susan P. Whitman, Yue-Zhong Wu, Bayard L. Powell, Maria R. Baer, Jonathan E. Kolitz, Andrew J. Carroll, Richard A. Larson, Michael A. Caligiuri, Clara D. Bloomfield *Blood* vol 118 (15) 4188-4198 2011
Manuscript *Leuk Corr Sci* C8525, CALGB-10201, CALGB-20202, CALGB-8461, CALGB-8923, CALGB-9420, CALGB-9665, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/21828125>

1472 BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Sebastian Schwind, Guido Marcucci, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Kelsi B. Holland, Dean Margeson, Heiko Becker, Susan P. Whitman, Yue-Zhong Wu, Klaus H. Metzeler, Bayard L. Powell, Jonathan E. Kolitz, Thomas H. Carter, Joseph O. Moore, Maria R. Baer, Andrew J. Carroll, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield *Blood* vol 116 (25) 5660-5669 2010
Manuscript *Leuk Corr Sci* C8525, CALGB-10201, CALGB-20202, CALGB-8923, CALGB-9420, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/20841507>

1473 High proliferation by the MCL35 assay is associated with inferior outcomes in patients treated with intensive regimens – a correlative study from the Alliance 50403 trial.

David W. Scott, Brandelyn Pitcher, Yi Tian Liu, Merrill Boyle, Anja Mottok, Jonathan Said, Amy Chadburn, Raymond Lai, Sin-Ho Jung, John P. Leonard, Lawrence D. Kaplan, Eric D. Hsi *Hematol Oncol* vol 35 (suppl S2) 152-2 2017
Abstract *Correl Sci NOS* http://onlinelibrary.wiley.com/doi/10.1002/hon.2438_5/abstract

1474 Perioperative Outcomes of Video-Assisted (VATS) Lobectomy for Lung Cancer Compared to Open Thoracotomy and Lobectomy, An Analysis of Data from the American College of Surgeons Oncology Group (ACOSOG) Z0030 Clinical Trials

W. J. Scott, M. Allen, G. Darling, B. F. Meyers, P. A. Decker, J. B. Putnam Jr, R. W. McKenna, R. J. Landreneau, J. R. David, R. I. Inculet, R. A. Malthaner 2009
Abstract *Respiratory*
<http://westernthoracic.org/search.cgi?cx=009762188130679964917%3Aq202knjprxc&cof=FORID%3A>

1475 Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial.

Walter J Scott, Mark S Allen, Gail Darling, Bryan Meyers, Paul A Decker, Joe B Putnam, Robert W McKenna, Rodney J Landreneau, David R Jones, Richard I Inculet, Richard A Malthaner *J. Thorac. Cardiovasc. Surg.* vol 139 (4) 976-81; discussion 981-3 2010
Manuscript *Respiratory* <http://www.ncbi.nlm.nih.gov/pubmed/20172539>

1476 The Complicated ‘Yes’: Decision -Making Processes and Receptivity to Lung Cancer Screening Among Head and Neck Cancer Survivors

Aaron T. Seaman, Kimberly Dukes, Richard M. Hoffman, Alan J. Christensen, Nicholas Kendell,

Andrew L. Sussman, Miriam Veléz-Bermúdez, Robert J. Volk, Nitin A. Pagedar Patient Educ Couns
vol 101 (10) 1741-7 2018
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/29709410>

1477 Association of RAS mutations with race in metastatic colorectal cancer CALGB 80405 (Alliance)

Amikar Sehdev, Donna Niedzwiecki, Alan P. Venook, Heinz-Josef Lenz, Federico Innocenti, Michelle R. Mahoney, James Edward Shaw, Blase N. Polite, Howard S. Hochster, James Norman Atkins, Richard M. Goldberg, Robert J. Mayer, Richard L. Schilsky, Monica M. Bertagnolli, Charles David Blanke, Bert O'Neil J Clin Oncol vol 36 (supple 4S) abstr 638 2018
Abstract Correl Sci NOS <https://meetinglibrary.asco.org/record/155707/abstract>

1478 Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.

Andrew D Seidman, Donald Berry, Constance Cirrincione, Lyndsay Harris, Hyman Muss, P Kelly Marcom, Grandella Gipson, Harold Burstein, Diana Lake, Charles L Shapiro, Peter Ungaro, Larry Norton, Eric Winer, Clifford Hudis J. Clin. Oncol. vol 26 (10) 1642-9 2008
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/18375893>

1479 Genome-wide association study of cardiotoxicity in NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial

DJ Serie, JE Crook, BM Necela, TJ Dockter, X Wang, YW Asmann, D Fairweather, KA Bruno, G Colon-Otero, EA Perez, EA Thompson, N Norton Pharmacogenet. Genomics vol 27 (10) 378-85 2017
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/28763429>

1480 Prognostic and Predictive Biomarkers for ACT (Adjuvant Chemotherapy) in Resected Non-Small Cell Lung Cancer (R-NSCLC): LACE-Bio

L. K. Seymour, G. Le Teuff, M. Tsao, E. Brambilla, F. Shepherd, J-C. Soria, R. Kratzke, S. Graziano, J. Y. Douillard, R. Rosell, A. Reiman, B. Lacas, A. Bourredjem, T. LeChavalier, R. Pirker, M. Filipits, P. Hainaut, P. A. Janne, J. P. Pignon Ann. Oncol. vol 25 (suppl. 4) iv58-iv84 2014
Abstract Respiratory CALGB-150802, CALGB-9633
<http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Biomarkers/Prognostic-and-predictive-bio>

1481 LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer.

Lesley Seymour, Gwénaél Le Teuff, Elisabeth Brambilla, Frances A Shepherd, Jean-Charles Soria, Robert Kratzke, Stephen Graziano, Jean-Yves Douillard, Rafael Rosell, Anthony Reiman, Benjamin Lacas, Beranger Lueza, Sarit Aviel-Ronen, Anne McLeer, Thierry Le Chevalier, Robert Pirker, Martin Filipits, Ariane Dunant, Jean-Pierre Pignon, Ming-Sound Tsao Clin Lung Cancer vol 20 (2) 66-73.e6 2019
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/30414783>

1482 Association study of the let-7 microRNA-binding site polymorphism in 3-untranslated region (UTR) of the KRAS gene in stage III colon cancers from adjuvant trial NCCTG N0147

D. Sha, A. Lee, Q. Shi, A. R. Steven, D. J. Sargent, F. A. Sinicrope, R. B. Diasio J. Clin. Oncol. vol 30 (15 suppl) abstr 3564 2012
Abstract GI
http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/3564?sid=04f1c8ab-3735-446f-9b9d-c6e61

1483 Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 clinical trial)

Dan Sha, Adam Lee, Qian Shi, Steven R. Alberts, Daniel J. Sargent, Frank A. Sinicrope, Robert B. Diasio Clin. Cancer Res. vol 20 (12) 3319-3327 2014
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24727325>

1484 Changing pattern for HER2 positivity due to updated ASCO/CAP guidelines for HER2 testing and its impact.

Mithun Vinod Shah, Anne E. Wiktor, Reid G. Meyer, Kathleen S. Tenner, Karla V. Ballman, Rhett P. Ketterling, Edith A. Perez, Robert B. Jenkins J. Clin. Oncol. vol 32 (5s) (suppl; abstr 523) 2014
Abstract Breast http://abstracts.asco.org/144/AbstView_144_126631.html

1485 Phase II Trials of Single Agent Anti-VEGF Therapy for Patients with Chronic Lymphocytic Leukemia (CLL)

Tait Shanafelt, Clive Zent, John Byrd, Charles Erlichman, Betsy LaPlant, Asish Ghosh, Timothy Call, Miguel Villalona-Calero, Diane Jelinek, Deborah Bowen, Kristina Laumann, Wenting Wu, Curtis Hanson, Neil Kay Leuk. Lymphoma vol 51 (12) 2222-2229 2010
Manuscript Leukemia N048F, N0683 <http://www.ncbi.nlm.nih.gov/pubmed/21054149>

1486 Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 79809

C. L. Shapiro, S. Halabi, G. Gibson, R. J. Friedlander, J. Kirshner, W. Sikov, E. P. Winer, C. A. Hudis, C. Issac J. Clin. Oncol. vol 26 (suppl) abstr 512 2008
Abstract Symptom Inter http://www.abstract.asco.org/AbstView_55_31982.html

1487 Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809

C. L. Shapiro, S. Halabi, V. Hars, L. Archer, D. Weckstein, J. Kirshner, W. Sikov, E. Winer, H.J. Burstein, C. Hudis, C. Isaacs, R. Schilsky, E. Paskett Eur. J. Cancer vol 47 (5) 683-689 2011
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/21324674>

1488 Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance)

Charles L. Shapiro, James P. Moriarty, Stacie Dusetzina, Andrew L. Himmelstein, Jared C. Foster, Stephen S. Grubbs, Paul J. Novotny, Bijan J. Borah J. Clin. Oncol vol 35 (35) 3949-55 2017
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/29023215>

1489 Resampling the N9741 Trial to Compare Tumor Dynamic Versus Conventional End Points in Randomized Phase II Trials

Manish R. Sharma, Elizabeth Gray, Richard M. Goldberg, Daniel J. Sargent, Theodore G. Karrison J. Clin. Oncol vol 33 (1) 36-41 2015
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/25349295>

1490 A model-based approach to dose optimization of neurotoxic chemotherapy drugs for metastatic breast cancer (MBC)

Manish Sharma, Elizabeth Gray, Shailly Mehrotra, Kehua Wu, William Thomas Barry, Clifford A. Hudis, Eric P. Winer, Alan P. Lyss, Deborah Toppmeyer, Alvaro Moreno-Aspitia, Hope S. Rugo, Mark J. Ratain, Jogarao Gobburu J. Clin. Oncol. vol 33 (suppl) abstr 1041 2015
Abstract Breast <http://meetinglibrary.asco.org/content/151093-156>

1491 Reduced intensity allogeneic transplantation provides high disease-free and overall survival in patients (Pts) with advanced indolent NHL and CLL: CALGB 109901

T. C. Shea, J. Johnston, W. Walsh, S. Farag, J. Mccarty, A. Bashey, L. Isola, M. Stewart, M. Kelly, K.

Owzar, C. Linker *Blood* vol 110 (11) 150A-150A 2007
Abstract Transplant http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_1208

1492 Reduced Intensity Allogeneic Transplantation Provides High Event-Free And Overall Survival In Patients With Advanced Indolent B Cell Malignancies: CALGB 109901

Thomas Shea, Jeffrey Johnson, Peter Westervelt, Sherif Farag, John McCarty, Asad Bashey, Luis Isola, Lee-Anne Baxter-Lowe, Michael Kelly, Kouros Owzar, Charles Linker *Biol Blood Marrow Transplant* vol 17 (9) 1395-1403 2011

Manuscript Transplant <http://www.ncbi.nlm.nih.gov/pubmed/21296675>

1493 Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study

K. Shedden, J. M. Taylor, S. A. Enkemann, M. S. Tsao, T. J. Yeatman, W. L. Gerald, S. Eschrich, I. Jurisica, T. J. Giordano, D. E. Misek, A. C. Chang, C. Q. Zhu, D. Strumpf, S. Hanash, F. A. Shepherd, K. Ding, L. Seymour, K. Naoki, N. Pennell, B. Weir, R. Verhaak, C. Ladd-Acosta, T. Golub, M. Gruidl, A. Sharma, J. Szoke, M. Zakowski, V. Rusch, M. Kris, A. Viale, N. Motoi, W. Travis, B. Conley, V. E. Seshan, M. Meyerson, R. Kuick, K. K. Dobbin, T. Lively, J. W. Jacobson, D. G. Beer *Nat. Med.* vol 14 (8) 822-827 2008

Manuscript Respiratory C9761, C150302, CALGB-9761
<http://www.ncbi.nlm.nih.gov/pubmed/18641660>

1494 Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study.

F. A. Shepherd, A. Bourredjem, E. Brambilla, C. Domerg, J.-Y. Douillard, M. Filipits, S. L. Graziano, P. Hainaut, P. A. Janne, T. Le Chevalier, G. Le Teuff, J.-P. Pignon, R. Pirker, L. Seymour, J.-C. Soria, M. Taron, M. S. Tsao, L.-B. C. R. Group *J. Clin. Oncol.* vol 30 (Supplement) abstr 7007 2012

Abstract Respiratory

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID

1495 Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy

Frances A. Shepherd, Caroline Domerg, Pierre Hainaut, Pasi A. Jänne, Jean-Pierre Pignon, Stephen Graziano, Jean-Yves Douillard, Elizabeth Brambilla, Thierry Le Chevalier, Lesley Seymour, Abderrahmane Bourredjem, Gwénaél Le Teuff, Robert Pirker, Martin Filipits, Rafael Rosell, Robert Kratzke, Bizhan Bandarchi, Xiaoli Ma, Marzia Capelletti, Jean-Charles Soria, Ming-Sound Tsao *J. Clin. Oncol* vol 31 (17) 2173-2181 2013

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/23630215>

1496 Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901

Vanessa B. Sheppard, Leigh Anne Faul, George Luta, Jonathan D. Clapp, Rachel L. Yung, Judy Huei-yu Wang, Gretchen Kimmick, Claudine Isaacs, Michelle Tallarico, William T. Barry, Brandelyn N. Pitcher, Clifford Hudis, Eric P. Winer, Harvey J. Cohen, Hyman B. Muss, Arti Hurria, Jeanne S. Mandelblatt *J. Clin. Oncol* vol 32 (22) 2318-2327 2014

Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/24934786>

1497 Lymph node (LN) ratio (LNR) risk classification (RC) in stage III colon cancer (CC): A pooled analysis of 16,425 patients from the ACCENT database.

Q. Shi, J. M. Hubbard, G. A. Yothers, T. Andre, L. Saltz, G. Francini, B. M. Bot, C. Twelves, M. E. Buyse, A. Grothey, D. J. Sargent *J. Clin. Oncol.* vol 29 (suppl) abstr 3556 2011

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

1498 Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database

Qian Shi, Thierry Andre, Axel Grothey, Greg Yothers, Stanley R. Hamilton, Brian M. Bot, Daniel G. Haller, Eric Van Cutsem, Chris Twelves, Jacqueline K. Benedetti, Michael J. O'Connell, Daniel J. Sargent *J. Clin. Oncol.* vol 31 (29) 3656-3663 2013
Manuscript GI CALGB-89803, NCCTG-784852, NCCTG-874651, NCCTG-894651, NCCTG-914653 <http://www.ncbi.nlm.nih.gov/pubmed/23980089>

1499 Prospective pooled analysis of six phase III trials investigating duration of adjuvant oxaliplatin-based therapy (3 versus 6 months) for patients with stage III colon cancer: The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration (Alliance)

Qian Shi, Alberto Sobrero, Anthony Shields, Takayuki Yoshino, TBN5, Julien Taieb, Ioannis Souglakos, Roberto Labianca, Jeffrey Meyerhardt, Franck Bonnetain, Toshiaki Watanabe, Ioannis Mpoukovanas, Lindsay Renfro, Axel Grothey, Donna Niedzwiecki, Valter Torri, Thierry Andre, Dan Sargent *J. Clin. Oncol.* vol 35 (18 suppl) abstr LBA1 2017
Abstract GI http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.18_suppl.LBA1

1500 Cancer registries: a novel alternative to long-term clinical trial follow-up based on results of a comparative study

Qian Shi, Y Nancy You, Heidi Nelson, Mark S Allen, David Winchester, Andrew Stewart, Tonia Young-Fadok, Paul A Decker, Erin M Green, Sara J Holton, Karla V Ballman *Clin Trials* vol 7 (6) 686-695 2010
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/20729254>

1501 Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: the IDEA collaboration

Anthony F. Shields, Fang-Shu Ou, James Paul, Alberto F. Sobrero, Takayuki Yoshino, Julien Taieb, John Souglakos, Qian Shi, Rachel Kerr, Roberto Labianca, Takeharu Yamanaka, J Dewi Vernerey, Ioannis Boukovinas, Takeshi Kato, Valter Torri, Stylianos Kakolyris, Thierry Andre, Axel Grothey, Jeffrey A. Meyerhardt, Timothy Iveson *J Clin Oncol* vol 36 (Suppl) abstr 3599 2018
Abstract GI <https://meetinglibrary.asco.org/record/158923/abstract>

1502 CpG Island Methylator Phenotype is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage 3 Colon Cancer

Stacey Shiovitz, Monica M. Bertagnolli, Lindsay A. Renfro, Eunmi Nam, Nathan R. Foster, Slavomir Dzieciatkowski, Yanxin Luo, Victoria Valinluck Lao, Raymond J. Monnat, Mary J. Emond, Nancy Maizels, Donna Niedzwiecki, Richard M. Goldberg, Leonard B. Saltz, Alan Venook, Robert S. Warren, William M. Grady *Gastroenterology* vol 147 (3) 637-645 2014
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24859205>

1503 Feasibility of using an epigenetic marker of risk for lung cancer, methylation of p16, to promote smoking cessation among US veterans

Scott Shofer, Matthew Beyea, Sufeng Li, Lori A Bastian, Momen M Wahidi, Michael Kelley, Isaac M Lipkus *BMJ Open Respir Res* vol 1 (1) 2014
Manuscript Prevention <http://www.ncbi.nlm.nih.gov/pubmed/25478181>

1504 Six cycles of Doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: cancer and leukemia group B 40101

L. N. Shulman, C. T. Cirrincione, D. A. Berry, H. P. Becker, E. A. Perez, R. O'Regan, S. Martino, J. N. Atkins, E. Mayer, C. J. Schneider, G. Kimmick, L. Norton, H. Muss, E. P. Winer, C. Hudis *J. Clin.*

1505 Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes: CALGB 40101 A 2x2 Factorial Phase III Trial: First Results Comparing 4 vs 6 Cycles of Therapy.

L. N. Shulman, C. T. Cirrincione, D. A. Berry, H. P. Becker, E. Perez, R. O'Regan, S. Martino, J. N. Atkins, C. Hudis, E. Winer 2010
Abstract Breast

1506 Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101

L. Shulman, D. Berry, C. Cirrincione, H. Becker, E. Perez, R. O'Regan, S. Martino, C. L. Shapiro, S. J. Atkin, C. Schneider, G. Kimmick, H. Burstein, L. Norton, H. Muss, C. Hudis, E. Winer J. Clin. Oncol. vol 31 (15 suppl) abstr 1007 2013
Abstract Breast
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/1007?sid=9be34414-e040-4be0-b71e-0184

1507 Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)

Lawrence N. Shulman, Donald A. Berry, Constance T. Cirrincione, Heather P. Becker, Edith A. Perez, Ruth O'Regan, Silvana Martino, Charles L. Shapiro, Charles J. Schneider, Gretchen Kimmick, Harold J. Burstein, Larry Norton, Hyman Muss, Clifford A. Hudis, Eric P. Winer J. Clin. Oncol vol 32 (22) 2311-2317 2014
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/24934787>

1508 Randomized phase II study of two doses of pixantrone in patients with metastatic breast cancer, N1031 Alliance.

K. Sideras, A. Moreno-Aspitia, R. C. Tenglin, H. Liu, W. L. Lingle, M. M. Reinholz, K. C. Halling, B. Chen, G. Gross, R. B. Mowat, S. R. Dakhil, E. A. Perez J. Clin. Oncol. vol 30 (15 suppl) abstr 1083 2012
Abstract Breast <http://meetinglibrary.asco.org/content/96940-114>

1509 North Central Cancer Treatment Group (NCCTG) N0537: Phase II Trial of VEGF-Trap in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and/or a Taxane

Kostandinos Sideras, Amylou C. Dueck, Timothy J. Hobday, Kendrith M. Rowland, Jacob B. Allred, Donald W. Northfelt, Wilma L. Lingle, Robert J. Behrens, Tom R. Fitch, Daniel A. Nikcevich, Edith A. Perez Clin. Breast Cancer vol 12 (6) 387-391 2012
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/23083501>

1510 Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)

W. Sikov, D. Berry, C. Perou, B. Singh, C. Cirrincione, H. Burstein, C. Kuzma, T. Pluard, G. Somlo, E. Port, M. Golshan, J. Bellon, D. Collyar, O. Hahn, C. Hudis, E. Winer Cancer Res. vol 73 (24 Suppl) Abstract nr S5-01 2013
Abstract Breast http://www.abstracts2view.com/sabcs13/view.php?nu=SABCS13L_458&terms=

1511 Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer

W. Sikov, C. M. Perou, M. Golshan, D. Collyar, D. A. Berry, O. M. Hahn, B. Singh, C. A. Hudis, E. P. Winer J. Clin. Oncol. vol 28 (15s) abstr TPS110 2010

1512 Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Alliance)

William M. Sikov, William T. Barry, Katherine A. Hoadley, Brandelyn N. Pitcher, Baljit Singh, Sara M Tolaney, Charles S Kuzma, Timothy J Pluard, George Somlo, Elisa R Port, Mehra Golshan, Donald A Berry, Olwen M Hahn, Lisa A Carey, Charles M. Perou, Clifford A Hudis, Eric P Winer *Cancer Res.* vol 75 (suppl 9) S4-5 2015

Abstract Breast http://cancerres.aacrjournals.org/content/75/9_Supplement/S4-05

1513 Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

William M. Sikov, Donald A. Berry, Charles M. Perou, Baljit Singh, Constance T. Cirrincione, Sara M. Tolaney, Charles S. Kuzma, Timothy J. Pluard, George Somlo, Elisa R. Port, Mehra Golshan, Jennifer R. Bellon, Deborah Collyar, Olwen M. Hahn, Lisa A. Carey, Clifford A. Hudis, Eric P. Winer *J. Clin. Oncol* vol 33 (1) 13-21 2015

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/25092775>

1514 Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance)

William M Sikov, Donald A Berry, Charles M Perou, Baljit Singh, Constance T Cirrincione, Sara M Tolaney, Charles S Kuzma, Timothy J Pluard, George Somlo, Elisa R Port, Mehra Golshan, Jennifer R Bellon, Deborah Collyar, Olwen M Hahn, Lisa A Carey, Clifford A Hudis, Eric P Winer *Cancer Res.* vol 76 (4 Suppl) S2-05 2016

Abstract Breast http://cancerres.aacrjournals.org/content/76/4_Supplement/S2-05.short

1515 Executive function in rural older adult smokers: influence of depression and nicotine dependence (NCT02510716)

Nikolas J. Silva, Cherie Conley, Shawn McClintock, Devon Noonan *Annals of Behavioral Medicine* vol 52 (Supplement 1) 377 (B321) 2018

Abstract Disparities

https://watermark.silverchair.com/kay013.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9

1516 Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B.

Lewis R Silverman, Erin P Demakos, Bercedis L Peterson, Alice B Kornblith, Jimmie C Holland, Rosalie Odchimar-Reissig, Richard M Stone, Douglas Nelson, Bayard L Powell, Carlos M DeCastro, John Ellerton, Richard A Larson, Charles A Schiffer, James F Holland *J. Clin. Oncol.* vol 20 (10) 2429-40 2002

Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/12011120>

1517 A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072

Rache M. Simmons, Karla V. Ballman, Charles Cox, Ned Carp, Jennifer Sabol, Rosa F. Hwang, Deanna Attai, Michael Sabel, David Nathanson, Andrew Kenler, Linsey Gold, Cary Kaufman, Linda Han, Aaron Bleznak, J. Stanley Smith, Dennis Holmes, Bruno Fornage, Carisa Le-Petross, Syed Hoda, Linda McCall, Kelly K. Hunt *Ann. Surg. Oncol.* vol 23 (8) 2438-2445 2016

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/27221361>

1518 A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results From ACOSOG (Alliance) Z1072

Rache Simmons, Karla Ballman, Charles Cox, Ned Carp, Jennifer Sabol, Rosa Hwang, Deanna Attai, Michael Sabel, David Nathanson, Andrew Kenler, Linsey Gold, Cary Kaufman, Linda Han, Aaron Bleznak, J. Stanley Smith, Dennis Holmes, Lorraine Tafra, Marla Dudak, Susan Weinberg, Michael Kinney, Bruno Fornage, Carisa Le-Petross, Syed Hoda, Thomas Buchholz, Janice Cormier, Wendy Lindeman, Linda McCall, Mark Watson, Bettye Green, Kelly Hunt *Ann. Surg. Oncol.* vol 21 (2, suppl) 6 2014

Abstract Breast https://www.breastsurgeons.org/docs2014/2014_Official_Proceedings.pdf

1519 Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales.

Jasvinder A Singh, Dona E Locke, Daniel Satele, Suneetha Puttabasavaiah, Jan C. Buckner, Jeff A. Sloan *J. Clin. Oncol.* vol 32 (suppl; abstr e17619) 2014

Abstract Health Outcome 954651, NCCTG-95-20-53, NCCTG-95-24-52, 959204, NCCTG-964251, 979202, NCCTG-98-24-52, NCCTG-98-72-51, NCCTG-98-72-52, NCCTG-959257, NCCTG-989251, NCCTG-969256, NCCTG-971151, NCCTG-979251, NCCTG-979253

http://abstracts.asco.org/144/AbstView_144_129911.html

1520 Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales

Jasvinder A Singh, Daniel Satele, Suneetha Pattabasavaiah, Jan C Buckner, Jeff A Sloan *Health Qual Life Outcomes* vol 12 2014

Manuscript Health Outcome NCCTG-95-20-53, 954651, 959204, NCCTG-95-24-52, NCCTG-964251, 979202, NCCTG-97-24-51, NCCTG-98-24-52, NCCTG-98-72-51, NCCTG-959257, NCCTG-98-72-52, NCCTG-989251, NCCTG-969256, NCCTG-971151, NCCTG-979251, NCCTG-979253 <http://www.ncbi.nlm.nih.gov/pubmed/25519478>

1521 Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)

Preet Paul Singh, Qian Shi, Nathan R. Foster, Axel Grothey, Suresh G. Nair, Emily Chan, Anthony F. Shields, Richard M. Goldberg, Sharlene Gill, Morton S. Kahlenberg, Frank A. Sinicrope, Daniel J.

Sargent, Steven R. Alberts *Oncologist* vol 21 (12) 1509-1521 2016

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/27881709>

1522 Relationship between Metformin use and Recurrence and Survival in Patients (pts) with Resected Stage III Colon Cancer (CC) Receiving Adjuvant Chemotherapy: Results from NCCTG N0147 (Alliance)

Preet Paul Singh, Qian Shi, Nathan Foster, Axel Grothey, Suresh Nair, Emily Chan, Anthony Frank Shields, Richard M. Goldberg, Sharlene Gill, Morton S. Kahlenberg, Frank A. Sinicrope, Daniel J.

Sargent, Steven R. Alberts *J. Clin. Oncol.* vol 33 (suppl) abstr 3531 2015

Abstract GI <http://meetinglibrary.asco.org/content/144132-156>

1523 Randomized Trial of FOLFOX Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability (ATOMIC, Alliance A021502)

Sinicrope FA, F-S Ou, Q Shi, A Nixon, Kabir Mody, Alex LeVasseur, Amylou Dueck, Asha Dhanarajan, Christopher Lie, Deirdre Cohen, Federico Innocenti, Robert Behrens, Walter Peters, DJ Sargent, N Sommers, E O'Reilly, J Meyerhardt *J. Clin. Oncol.* vol 35 (15 suppl) abstr TPS3630 2017

Abstract GI http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS3630

1524 Prognostic impact of KRAS and BRAFV600E mutations stratified by tumor site in resected stage III colon cancer patients treated with adjuvant mFOLFOX6 with or without cetuximab: NCCTG N0147 (Alliance)

F. A. Sinicrope, M. R. Mahoney, T. C. Smyrk, S. N. Thibodeau, R. M. Goldberg, G. D. Nelson, D. J. Sargent, S. R. Alberts J. Clin. Oncol. vol 31 (15_suppl) 3523 2013
Abstract GI http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/3523

1525 Prognostic impact of BRAF and KRAS mutations and their relationship to DNA mismatch repair (MMR) status in 2,686 stage III colon cancer patients (pts) treated in a phase III study of adjuvant FOLFOX +/- cetuximab: NCCTG N0147.

F. A. Sinicrope, M. R. Mahoney, T. C. Smyrk, S. N. Thibodeau, R. M. Goldberg, G. Nelson, D. J. Sargent, S. R. Alberts J. Clin. Oncol. vol 30 (suppl) abstr 3514 2012
Abstract GI
http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/3514?sid=0055954a-dce9-4db0-b477-d76e

1526 Association of reduced intraepithelial CD3+/regulatory T-cell ratio with poor outcome in human colon cancers

F. A. Sinicrope, R. L. Rego, N. R. Foster, D. J. Sargent, S. M. Ansell, E. D. Kwon J. Clin. Oncol. vol 26 (15s) abstr 11023 2008
Abstract GI http://hwmain.meeeting.ascopubs.org/cgi/content/abstract/26/15_suppl/11023

1527 Mutations in the proapoptotic BAX gene are associated with defective DNA mismatch repair and altered tumor growth rates in human colon cancers

F. A. Sinicrope, R. L. Rego, A. J. French, N. R. Foster, D. J. Sargent, H. Windschitl, M. J. O'Connell, S. N. Thibodeau J. Clin. Oncol. vol 25 (18s) abstr 10529 2007
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID

1528 Prognostic impact of body-mass index upon cancer recurrence and survival in stage III colon cancer patients treated in adjuvant therapy trials

F. Sinicrope, N. R. Foster, D. J. Sargent, S. Alberts, M. O'Connell J. Clin. Oncol. vol 27 (15s) abstr 11088 2009
Abstract GI
<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/11088?sid=a57ac56b-2d39-4d5d-9c63-a772322a>

1529 Evaluation of recurrence rate,time-to-recurrence, and hepatic metastases in patients with colon cancers with defective DNA mismatch repair.

F. Sinicrope, N. R. Foster, D. J. Sargent, S. N. Thibodeau, S. Galliger, M. J. Moore, D. Tu
Gastrointestinal Cancers Symposium abstr 330 2010
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID

1530 DNA Mismatch Repair Status and Site of Tumor Recurrence in Stage II and III Colon Cancers Treated in 5-Fluorouracil-Based Adjuvant Therapy Trials.

F. Sinicrope, N. Foster, D. Sargent, S. Gallinger, P. Benatti, S. Marsoni, G. Monges, R. Labianca, M. O'Connell, C. Allegra J. Clin. Oncol. vol 28 (15s) abstr 3519 2010
Abstract GI
http://meeting.ascopubs.org/gca?gca=ascomtg%3B28%2F15_suppl%2F3519&allch=&submit=Go

1531 Body mass index (BMI) as a prognostic and predictive factor in stage II/III colon cancer: An analysis of the ACCENT database

F. Sinicrope, N. Foster, G. Yothers, A. Benson, D. Haller, J. Seitz, R. Labianca, J. Benedetti, R. Goldberg, A. De Gramont, D. Sargent J. Clin. Oncol. vol 29 (15s) abstr e21126 2011

Abstract GI

http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B29%2F15_suppl%2Fe21126

1532 Obesity Is an Independent Prognostic Variable in Colon Cancer Survivors

Frank A. Sinicrope, Nathan R. Foster, Daniel J. Sargent, Michael J. O'Connell, Cathryn Rankin Clin Cancer Res vol 16 (6) 1884-1893 2010

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20215553>

1533 DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy

Frank A. Sinicrope, Nathan R. Foster, Stephen N. Thibodeau, Silvia Marsoni, Genevieve Monges, Roberto Labianca, Greg Yothers, Carmen Allegra, Malcolm J. Moore, Steven Gallinger, Daniel J. Sargent J Natl Cancer Inst vol 103 (11) 863-875 2011

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21597022>

1534 Association of Obesity With DNA Mismatch Repair Status and Clinical Outcome in Patients With Stage II or III Colon Carcinoma Participating in NCCTG and NSABP Adjuvant Chemotherapy Trials

Frank A. Sinicrope, Nathan R. Foster, Harry H. Yoon, Thomas C. Smyrk, George P. Kim, Carmen J. Allegra, Greg Yothers, Daniel A. Nikcevic, Daniel J. Sargent J Clin Oncol vol 30 (4) 406-412 2012

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/22203756>

1535 Body Mass Index at Diagnosis and Survival Among Colon Cancer Patients Enrolled in Clinical Trials of Adjuvant Chemotherapy

Frank A. Sinicrope, Nathan R. Foster, Greg Yothers, Al Benson, Jean Francois Seitz, Roberto Labianca, Richard M. Goldberg, Aimery DeGramont, Michael J. O'Connell, Daniel J. Sargent Cancer vol 119 (8) 1528-1536 2013

Manuscript GI N0441, NCCTG-78-48-52, NCCTG-87-46-51, NCCTG-89-46-51, NCCTG-91-46-53, NCCTG-N0441 <http://www.ncbi.nlm.nih.gov/pubmed/23310947>

1536 Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy

Frank A. Sinicrope, Michelle R. Mahoney, Thomas C. Smyrk, Stephen N. Thibodeau, Robert S. Warren, Monica M. Bertagnolli, Garth D. Nelson, Richard M. Goldberg, Daniel J. Sargent, Steven R. Alberts J. Clin. Oncol vol 31 (29) 3664-3672 2013

Manuscript GI CALGB-89803, N0147 <http://www.ncbi.nlm.nih.gov/pubmed/24019539>

1537 Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)

Frank A. Sinicrope, Michelle R. Mahoney, Harry H. Yoon, Thomas C. Smyrk, Stephen N. Thibodeau, Richard M. Goldberg, Garth D. Nelson, Daniel J. Sargent, Steven R. Alberts Clin. Cancer Res. vol 21 (23) 5294-5304 2015

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/26187617>

1538 Prognostic Impact of Bim, Puma, and Noxa Expression in Human Colon Carcinomas

Frank A. Sinicrope, Rafaela L. Rego, Kenji Okumura, Nathan R. Foster, Michael J. O'Connell, Daniel J. Sargent, Harold E. Windschitl Clin Cancer Res vol 14 (18) 5810-5818 2008

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/18794091>

1539 Association of DNA Mismatch Repair and Mutations in BRAF and KRAS with Survival after Recurrence in Stage III Colon Cancers from Phase III Adjuvant Chemotherapy Trials

Frank A. Sinicrope, Qian Shi, Carmen J. Allegra, Thomas C. Smyrk, Stephen N. Thibodeau, Richard M. Goldberg, Jeffrey P. Meyers, Kay L. Pogue-Geile, Greg Yothers, Daniel J. Sargent, Steven R.

1540 Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials

Frank A. Sinicrope, Qian Shi, Carmen Joseph Allegra, Thomas C. Smyrk, Stephen N. Thibodeau, Richard M. Goldberg, Jeffrey P. Meyers, Greg Yothers, Daniel J. Sargent, Steven R. Alberts J. Clin. Oncol. vol 34 (suppl) abstr 3600 2016

Abstract GI N0147, NCCTG-N0147 <http://meetinglibrary.asco.org/content/169815-176>

1541 Immunoscore provides prognostic information in low (T1-3N1) and high risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)

Frank A. Sinicrope, Qian Shi, Fabienne Hermitte, Erica N. Heying, Al B. Benson, Sharlene Gill, Richard M. Goldberg, Morton S. Kahlenberg, Suresh G. Nair, Anthony F. Shields, Daniel J. Sargent, Jérôme Galon, Steven R. Alberts J Clin Oncol vol 36 (suppl 4S) abstr 614 2018

Abstract Correl Sci NOS <https://meetinglibrary.asco.org/record/155684/abstract>

1542 Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)

Frank A. Sinicrope, Qian Shi, Fabienne Hermitte, Erica N. Heying, Al B. Benson, Sharlene Gill, Richard M. Goldberg, Morton S. Kahlenberg, Suresh G. Nair, Anthony F. Shields, Daniel J. Sargent, Jérôme Galon, Steven R. Alberts Annals of Oncology vol 28 (suppl_3) 153 2017

Abstract GI <https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdx302.009>

1543 Association of an immunoscore with survival of stage III colon cancer (CC) patients treated with adjuvant FOLFOX (Alliance N0147)

Frank A. Sinicrope, Qian Shi, Fabienne Hermitte, Erica Heying, Al Bowen Benson III, Sharlene Gill, Richard M. Goldberg, Morton Kahlenberg, Suresh Nair, Anthony Shields, Dan Sargent, Jerome Galon, Steven R. Alberts J. Clin. Oncol. vol 35 (15 suppl) abstr 3579 2017

Abstract Correl Sci NOS http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3579

1544 Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adjuvant therapy trial: NCCTG N0147 (Alliance)

Frank A. Sinicrope, Qian Shi, Hee Eun Lee, Nathan R. Foster, Steven R. Alberts, Thomas C. Smyrk J Clin Oncol vol 36 (suppl) abstr 3583 2018

Abstract Correl Sci NOS <https://meetinglibrary.asco.org/record/159055/abstract>

1545 Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy (NCCTG N0147) (Alliance)

Frank A. Sinicrope, Qian Shi, Thomas C. Smyrk, Richard M. Goldberg, Erica N Heying, Steven J. Cohen, Sharlene Gill, Morton S. Kahlenberg, Suresh Nair, Anthony Frank Shields, Daniel J. Sargent, Balkrishna N. Jahagirdar, Michael N. Pollak, Steven R. Alberts J. Clin. Oncol. vol 35 (15 suppl) abstr 3516 2017

Abstract Correl Sci NOS http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3516

1546 Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated with Patient Outcomes

Frank A. Sinicrope, Qian Shi, Thomas C. Smyrk, Stephen N. Thibodeau, Rodrigo Dienstmann, Justin Guinney, Brian M. Bot, Sabine Tejpar, Mauro Delorenzi, Richard M. Goldberg, Michelle Mahoney, Daniel J. Sargent, Steven R. Alberts Gastroenterology vol 148 (1) 88-99 2015

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/25305506>

1547 Molecular subtyping of colon cancers and distinct prognostic groups [NCCTG N0147 (Alliance)].

Frank A. Sinicrope, Qian Shi, Stephen N. Thibodeau, Richard M. Goldberg, Daniel J. Sargent, Steven R. Alberts J. Clin. Oncol. vol 32 (5s) (suppl; abstr 3512) 2014
Abstract GI http://abstracts.asco.org/144/AbstView_144_133603.html

1548 Association Of Tumor Infiltrating Lymphocytes (Tils) With Molecular Subtype And Prognosis In Stage III Colon Cancers From A FOLFOX-Based Adjuvant Chemotherapy Trial: NCCTG N0147 (Alliance)

Frank A. Sinicrope, Thomas C. Smyrk, Nathan R. Foster, Jeffrey P. Meyers, Stephen N. Thibodeau, Richard M. Goldberg, Qian Shi, Sargent Daniel J., Steven R. Alberts J. Clin. Oncol. vol 34 (suppl) abstr 3518 2016
Abstract GI <http://meetinglibrary.asco.org/content/170078-176>

1549 Mutation-Specific Antibody Detects Mutant BRAFV600E Protein Expression in Human Colon Carcinomas

Frank A. Sinicrope, Thomas C. Smyrk, David Tougeron, Stephen N. Thibodeau, Shalini Singh, Andrea Muranyi, Kandavel Shanmugam, Thomas M. Grogan, Steven R. Alberts, Qian Shi Cancer vol 119 (15) 2765-2770 2013
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/23657789>

1550 Overall survival result and outcomes by KRAS, BRAF, and DNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147.

Frank A. Sinicrope, Harry H. Yoon, Michelle R. Mahoney, Garth D. Nelson, Stephen N. Thibodeau, Richard M. Goldberg, Daniel J. Sargent, Steven R. Alberts J. Clin. Oncol. vol 32 (15_suppl) 3525 2014
Abstract GI
<http://meeting.ascopubs.org/cgi/content/abstrhttp://meetinglibrary.asco.org/content/133798-144>

1551 A low intraepithelial effector (CD3+):regulatory (FoxP3+) T-cell ratio predicts adverse outcome of human colon carcinoma

Frank A Sinicrope, Rafaela L Rego, Stephen M Ansell, Keith L Knutson, Nathan R Foster, Daniel J Sargent Gastroenterology vol 137 (4) 1270-1279 2009
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/19577568>

1552 Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients

Frank Sinicrope, N.R. Foster, D.J. Sargent, S.N. Thibodeau, T.C. Smyrk, M.J. O'Connell Cancer vol 116 (7) 1691-1698 2010
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/20186699>

1553 Repeated Measures Analyses of Dermatitis Symptom Evolution in Breast Cancer Patients Receiving Radiotherapy in a Phase 3 Randomized Trial of Mometasone Furoate vs Placebo (N06C4 [Alliance])

Terence T. Sio, Pamela J. Atherton, Brandon J Birckhead, David J. Schwartz, Jeff A. Sloan, Drew K. Seisler, James A. Martenson, Charles L. Loprinzi, Patricia C. Griffin, Roscoe F. Morton, Jon C. Anders, Thomas J. Stoffel, Robert E. Haselow, Rex B. Mowat, Michelle A. Neben Wittich, James D. Bearden, Robert C. Miller Support Care Cancer vol 24 (9) 3847-3855 2016
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/27075674>

1554 Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in

Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial

Terence T. Sio, Pamela J. Atherton, Levi D. Pederson, W. Ken Zhen, Robert W. Mutter, Yolanda I. Garces, Daniel J. Ma, James L. Leenstra, Jean-Claude M. Rwigema, Shaker Dakhil, James D. Bearden, Sonja J. van der Veen, Apar K. Ganti, Steven E. Schild, Robert C. Miller Int. J. Radiat. Oncol. Biol. Phys. vol 103 (3) 686-96 2019
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/30395904>

1555 Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain

Terence T. Sio, Jennifer G. Le-Rademacher, James L. Leenstra, Charles L. Loprinzi, Grant Rine, Amaranthia Curtis, Anurag K. Singh, James A. Martenson, Paul J. Novotny, Angelina D. Tan, Rui Qin, Stephen J. Ko, Paul L. Reiter, Robert C. Miller JAMA vol 321 (15) 1481-90 2019
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/30990550>

1556 Expansion of the Wilson & Cleary Theoretical Model to Incorporate Genetic Influences on Quality of Life

Sloan J, Sprangers M 2010
Abstract Health Outcome
<http://download.springer.com/static/pdf/235/art%253A10.1007%252Fs11136-010-9766-6.pdf?originUrl->

1557 A patient-level pooled analysis of the prognostic significance of baseline fatigue for overall survival (OS) among 3,915 patients participating in 43 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials.

J. A. Sloan, H. Liu, D. J. Sargent, D. Satele, P. L. Schaefer, M. Y. Halyard, A. Grothey, Y. I. Garces, P. D. Brown, C. L. Loprinzi, J. C. Buckner J. Clin. Oncol. vol 27 (15s) abstract 9599 2009
Abstract Health Outcome
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

1558 Was it worth it (WIWI)? patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) Phase III Trial N0147

J. A. Sloan, M. R. Mahoney, D. J. Sargent, J. M. Hubbard, H. Liu, E. M. Basch, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, S. R. Alberts J. Clin. Oncol. vol 29 (suppl) abstr 6122 2011
Abstract Health Outcome
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

1559 Calibration of Quality-Adjusted Life Years (QALYS) For Oncology Clinical Trials (OCT).

J. A. Sloan, P. J. Novotny, D. J. Sargent, P. Decker ISOQOL abstr 187/1783 2010
Abstract GI <http://www.springerlink.com/content/5203321j83123k3p/fulltext.pdf>

1560 Clinically Significant Effect Sizes for Survival and Response Endpoints Using the 1/2 Standard Deviation Rule.

J. A. Sloan, P. J. Novotny, D. J. Sargent, P. Decker, R. Qin Qual Life Res vol 19 (40) abstr 1772 2010
Abstract GI <http://www.springerlink.com/content/5203321j83123k3p/fulltext.pdf>

1561 Relationship between genetic markers and quality of life (QOL) in stage III colon cancer (CC) patients (pts) prior to adjuvant treatment (N0147).

J. A. Sloan, Q. Shi, A. Lee, R. B. Diasio, E. S. Pavey, D. J. Sargent, R. M. Goldberg, F. A. Sinicrope, M. R. Mahoney, S. R. Alberts J. Clin. Oncol. vol 30 (15 suppl) abstr 3617 2012
Abstract Health Outcome http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/3617

1562 Tumor burden is not related to quality of life in patients with metastatic colorectal cancer

J. Sloan, A. Grothey, E. Green, X. Zhao, M. Campbell, D. Szydlo, D. Sargent, R. Goldberg J. Clin. Oncol. vol 26 (suppl) abstr 4017 2008

Abstract GI

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1563 Calibration of quality-adjusted life years (QALYs) for oncology clinical trials (OCT)

J. Sloan, P. Novotny, D. Sargent, P. A. Decker, R. Marks, H. Nelson J. Clin. Oncol. vol 28 (15s) abstr 6108 2010

Abstract Respiratory

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

1564 Lessons from Large Scale Collection of Patient Reported Outcomes: Implications for Big Data Aggregation and Analytics

Jeff A. Sloan, Michele Halyard, Issam El Naqa, Charles Mayo Int. J. Radiat. Oncol. Biol. Phys. vol 95 (3) 922-929 2016

Manuscript Health Outcome N9741, NCCTG-89-20-52

<http://www.ncbi.nlm.nih.gov/pubmed/27302508>

1565 Prognostic significance of baseline fatigue for overall survival: A patient-level meta-analysis of 43 oncology clinical trials with 3915 patients

Jeff A. Sloan, H. Liu, D.V. Satele, S. Puttabasavaiah, J. S. Kaur, J. Hubbard, A. Dueck, P. J. Stella, Jasvinder A. Singh Trends Cancer Res vol 12 97-110 2017

Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/31213748>

1566 Combining survival and toxicity effect sizes from clinical trials into an interpretable, quality-adjusted survival effect size estimate of treatment efficacy.

Jeff A. Sloan, Brittny Major, Paul J. Novotny, Axel Grothey, Randolph Marks, Daniel J. Sargent, Amylou C. Dueck J. Clin. Oncol. vol 32 (15_suppl) 6630 2014

Abstract Symptom Inter http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/6630

1567 Calibration of Quality-Adjusted Life Years for Oncology Clinical Trials

Jeff A. Sloan, Daniel J. Sargent, Paul J. Novotny, Paul A. Decker, Randolph S. Marks, Heidi Nelson J Pain Symptom Manage vol 47 (6) 1091-1099.e3 2014

Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/24246787>

1568 The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401).

E. J. Small, S. Halabi, M. A. Carducci, C. J. Ryan, D. J. George, J. F. Mahoney, W. M. Stadler, M. J. Morris, P. Kantoff, J. P. Monk, W. K. Kelly J. Clin. Oncol. vol 30 (15 suppl) abstr 4667 2012

Abstract GU <http://meetinglibrary.asco.org/content/100283-114>

1569 Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

Eric J Small, Susan Halabi, Nancy A Dawson, Walter M Stadler, Brian I Rini, Joel Picus, Preston Gable, Frank M Torti, Ellen Kaplan, Nicholas J Vogelzang J. Clin. Oncol. vol 22 (6) 1025-33 2004

Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/15020604>

1570 The reliability, validity, and sensitivity of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-chemotherapy-induced Peripheral Neuropathy (QLQ-CIPN-20).

E. M. L. Smith, Yang, J., T. Banerjee, C. Loprinizi, G. Cavaletti, C. Bridges, R. Haupt, G. Kanzawa, R. Knoerl, D. Lee-Ekblad, N. Prasertsri 2016

1571 Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial

E. M. Smith, H. Pang, C. Cirrincione, S. Fleishman, E. D. Paskett, T. Ahles, L. R. Bressler, C. E. Fadul, C. Knox, N. Le-Lindqwister, P. B. Gilman, C. L. Shapiro JAMA vol 309 (13) 1359-1367 2013

Manuscript Onc Nursing <http://www.ncbi.nlm.nih.gov/pubmed/23549581>

1572 CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN)

Ellen M. Lavoie Smith, Herbert Pang, Constance Cirrincione, Stewart Barry Fleishman, Electra D. Paskett, Camilo E. Fadul, Chetaye Knox, Charles L. Shapiro, Paul Gilman J. Clin. Oncol. vol 30 (18 suppl) abstr CRA9013 2012

Abstract Onc Nursing

http://meeting.ascopubs.org/cgi/content/abstract/30/18_suppl/CRA9013?sid=4920c7ed-8051-473c-82f7-

1573 Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire–Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data

Ellen M. Lavoie Smith, Noah Zanzville, Grace Kanzawa-Lee, Clare Donohoe, Celia Bridges, Charles Loprinzi, Jennifer Le-Rademacher, James J. Yang Support Care Cancer vol 27 (7) 2599-2608 2019

Manuscript Symptom Inter N06CA, N08C1, N08CA, N08CB

<http://www.ncbi.nlm.nih.gov/pubmed/30460399>

1574 Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance)

M. R. Smith, S. Halabi, C. J. Ryan, W. M. Stadler, A. Hussain, N. J. Vogelzang, R. J. Hauke, B. L. Sanford, E. J. Small J. Clin. Oncol. vol 31 (suppl 6) abstr 27 2013

Abstract GU <http://meetinglibrary.asco.org/content/107592-134>

1575 Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)

Matthew R. Smith, Susan Halabi, Charles J. Ryan, Arif Hussain, Nicholas Vogelzang, Walter Stadler, Ralph J. Hauke, J. Paul Monk, Philip Saylor, Nirmala Bhoopalani, Fred Saad, Ben Sanford, W. Kevin Kelly, Michael Morris, Eric J. Small J. Clin. Oncol vol 32 (11) 1143-1150 2014

Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/24590644>

1576 Dosimetric evaluation of radiation exposure during I-125 vicryl mesh implants: implications for ACOSOG z4032.

Ryan P Smith, Matthew Schuchert, Krishna Komanduri, Steven Burton, Dwight E Heron, James D Luketich, Thomas d'Amato, Rodney Landreneau Ann. Surg. Oncol. vol 14 (12) 3610-3 2007

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/17909906>

1577 Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma (HL): Final results of CALGB 50602

S. M. Smith, N. L. Bartlett, J. L. Johnson, S. Jung, H. Schoder, K. T. Egan, B. D. Cheson J. Clin. Oncol. vol 28 (15s) abstr 8039 2010

Abstract Lymphoma

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8039?sid=d3b2c0e6-7ab7-420f-a807-6259f

1578 Recombinant interferon-2b added to oral cyclophosphamide either as induction or

maintenance in treatment-naive follicular lymphoma: Final Analysis of CALGB 8691

SM Smith, J Johnson, BD Cheson, G Canellos, G Petroni, M Oken, D Duggan, D Hurd, JP Gockerman, B Parker, J Prchal, BA Peterson Leuk. Lymphoma vol 50 (10) 1606-1617 2009
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/19626540>

1579 Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: ALLIANCE A051201 and A051202

Sonali M. Smith, Brandelyn N. Pitcher, Sin-Ho Jung, Nancy L. Bartlett, Nina Wagner-Johnston, Steven I. Park, Kristy L. Richards, Amanda F. Cashen, Bruce D. Cheson, John P. Leonard Blood vol 124 (21) Abstr 3091 2014
Abstract Lymphoma A051201, A051202 <http://www.bloodjournal.org/content/124/21/3091>

1580 Safety and Tolerability of Idelalisib, Lenalidomide, and Rituximab in Relapsed and Refractory Lymphoma: Alliance A051201 and A051202 Phase I Trials

Sonali M. Smith, Brandelyn N. Pitcher, Sin-Ho Jung, Nancy L. Bartlett, Nina Wagner-Johnston, Steven I. Park, Kristy L. Richards, Amanda F. Cashen, Anthony Jaslowski, Scott E. Smith, Bruce D. Cheson, Eric Hsi, John P. Leonard Lancet Haematol vol 4 (4) e176-e182 2017
Manuscript Lymphoma A051201, A051202 <http://www.ncbi.nlm.nih.gov/pubmed/28314699>

1581 The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)

Sonali M. Smith, Heiko Schöder, Jeffrey L. Johnson, Sin-Ho Jung, Nancy L. Bartlett, Bruce D. Cheson Leuk. Lymphoma vol 54 (7) 1405-1410 2013
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/23194022>

1582 Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.

Sonali M Smith, David Grinblatt, Jeffrey L Johnson, Donna Niedzwiecki, David Rizzieri, Nancy L Bartlett, Bruce D Cheson Br. J. Haematol. vol 140 (3) 313-9 2008
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/18217897>

1583 Detection of the BRAFV600E protein in human colon carcinomas by a mutation-specific antibody

T. C. Smyrk, D. Tougeron, S. N. Thibodeau, S. Singh, A. Muranyi, K. Shanmugam, T. M. Grogan, S. R. Alberts, Q. Shi, F. A. Sinicrope J. Clin. Oncol. vol 31 (15 suppl) abstr 3576 2013
Abstract GI <http://meetinglibrary.asco.org/content/112943-132>

1584 Sunitinib (S) switch maintenance in advanced non-small cell lung cancer (NSCLC): An ALLIANCE (CALGB 30607), randomized, placebo-controlled phase III trial.

Mark A. Socinski, Xiaofei F. Wang, Maria Quintos Baggstrom, Lin Gu, Thomas E. Stinchcombe, Martin J. Edelman, Sherman Baker JR, Heather Dorothy Mannuel, Jeffrey Crawford, Everett E. Vokes J. Clin. Oncol. vol 32 (5s) (suppl; abstr 8040) 2014
Abstract Respiratory http://abstracts.asco.org/144/AbstView_144_128285.html

1585 Switch Maintenance with Sunitinib (S) in Advanced Non-Small Cell Lung Cancer (NSCLC): An Alliance (CALGB 30607), Randomized, Placebo-controlled Phase III Trial

Mark A. Socinski, Xiaofei F. Wang, Maria Quintos Baggstrom, Lin Gu, Thomas E. Stinchcombe, Martin J. Edelman, Sherman Baker, Heather Dorothy Mannuel, Jeffrey Crawford, Everett E. Vokes Int. J. Radiat. Oncol. Biol. Phys. vol 90 (5) abstr S1 2014
Abstract Respiratory <http://www.redjournal.org/article/S0360-3016%2814%2903704-3/abstract>

1586 Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer:

CALGB 30105.

Mark A Socinski, A William Blackstock, Jeffrey A Bogart, Xiaofei Wang, Michael Munley, Julian Rosenman, Lin Gu, Gregory A Masters, Peter Ungaro, Arthur Sleeper, Mark Green, Antonius A Miller, Everett E Vokes *J. Clin. Oncol.* vol 26 (15) 2457-63 2008
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18487565>

1587 Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes as biologic risk factors in patients with previously untreated follicular lymphoma receiving rituximab-based biologic therapy: An Alliance correlative science study (CALGB 50901, 50402, 50701, 50803, 50401)

Aliyah R. Sohani, Brandy Pitcher, Amy Chadburn, Jonathan Said, Peter Martin, Myron S. Czuczman, Nancy Bartlett, Cara Rosenbaum, John P. Leonard, Bruce D. Cheson, Eric D. Hsi *Blood* vol 126 (23) abstr 334 2015

Abstract Correl Sci NOS CALGB-50401, CALGB-50402, CALGB-50701, CALGB-50803, CALGB-50901 <http://www.bloodjournal.org/content/126/23/334>

1588 Management of recurrent prostate cancer after radiotherapy: Results from CALGB 9687, a contemporary prospective multi-institutional salvage radical prostatectomy series

M. H. Sokoloff, G. D. Steinberg, S. Halabi, B. L. Sanford, J. A. Eastham, J. L. Mohler, P. J. Walther, P. R. Carroll, N. J. Vogelzang, E. J. Small *J Urol* vol 179 (4) 647 2008

Abstract GU

http://ac.els-cdn.com/S0022534708618923/1-s2.0-S0022534708618923-main.pdf?_tid=d5a3de1c-449a-1

1589 The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011).

Melhem Solh, Kanti R Rai, Bercedis L Peterson, Jonathan E Kolitz, Frederick R Appelbaum, Martin S Tallman, Andrew Belch, Richard A Larson, Vicki A Morrison *Leuk. Lymphoma* vol 54 (2) 252-4 2013

Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/22897733>

1590 Cultural and ethnic variables improve a survey's ability to identify individuals at high risk for gastric cancer

Ian Solsky, Michael Parides, Clyde Schechter, Bruce Rapkin, Haejin In 2019

Abstract Disparities <http://expo.jspargo.com/exhibitor/web/SSO2019ASOAbstractSupplement.pdf>

1591 Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance)

Mingyang Song, Fang-Shu Ou, Tyler J. Zemla, Mark A. Hull, Qian Shi, Paul J. Limburg, Steven R. Alberts, Frank A. Sinicrope, Edward L. Giovannucci, Erin L Van Blarigan, Jeffrey A. Meyerhardt, Andrew T. Chan *Int. J. Cancer* vol 145 (2) 380-9 2019

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/30623420>

1592 Postdiagnosis marine omega-3 fatty acid intake and survival of stage III colon cancer in North Central Cancer Treatment Group phase III trial N0147 (Alliance)

Mingyang Song, Fang-Shu Ou, Tyler J. Zemla, Qian Shi, Paul J. Limburg, Steven R. Alberts, Edward L. Giovannucci, Jeffrey A. Meyerhardt, Andrew T. Chan *Gastroenterology* vol 154 (6) S-787-S-788 2018

Abstract GI [https://www.gastrojournal.org/article/S0016-5085\(18\)32712-4/pdf](https://www.gastrojournal.org/article/S0016-5085(18)32712-4/pdf)

1593 Marine omega-3 polyunsaturated fatty acid intake and survival after colorectal cancer diagnosis

Mingyang Song, Xuehong Zhang, Jeffrey A. Meyerhardt, Edward L. Giovannucci, Shuji Ogino,

Charles S. Fuchs, Andrew T. Chan Gut vol 66 (10) 1790-96 2017
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/27436272>

1594 A Pooled Analysis to the Prognosis and Predictive value of EGFR mutation on Survival in Patients with KRAS wild-type Lung Adenocarcinoma.

Jean-Charles Soria, Elisabeth Brambilla, Gwénaél Le Teuff, Ming S. Tsao, Pasi A. Janne, Pierre Hainaut, Miquel Taron, Robert A. Kratzke, Frances A. Shepherd, Jean-Pierre Pignon J Thorac Oncol vol 6 (6) S617 2011

Abstract Respiratory <http://journals.lww.com/jto/Citation/2011/06001/Abstracts.1.aspx>

1595 Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population

Pamela R. Soulos, James B. Yu, Kenneth B. Roberts, Ann C. Raldow, Jeph Herrin, Jessica B. Long, Cary P. Gross J. Clin. Oncol vol 30 (14) 1601-1607 2012

Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/22393088>

1596 Effects of age, immune landscape, and response to trastuzumab (H) in HER-2 positive (HER2+) breast cancer in NCCTG (Alliance)-N9831.

Aixa Elena Soyano, Daniel Serie, Afshin Mashadi-Hosseini, Sarah Warren, Gerardo Colon-Otero, Keith L. Knutson, Edith A. Perez, Alvaro Moreno-Aspitia, E Aubrey Thompson, Saranya Chumsri JCO vol 35 (no. 15_suppl) 530 2017

Abstract Breast

http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.530#affiliationsContainer

1597 Which patient will feel down, which will be happy? The need to study the genetic disposition of emotional states

Mirjam A. G. Sprangers, Meike Bartels, Ruut Veenhoven, Frank Baas, Nicholas G. Martin, Miriam Mosing, Benjamin Movsas, Mary E. Ropka, Gen Shinozaki, Dick Swaab Qual Life Res vol 19 (10) 1429-1437 2010

Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/20419396>

1598 Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes

Mirjam A. G. Sprangers, Jeff A. Sloan, Andrea Barsevick, Cynthia Chauhan, Amylou C. Dueck, Hein Raat, Quiling Shi, Cornelis J. F. Van Noorden Qual Life Res vol 19 (10) 1395-403 2010

Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/20945161>

1599 A Survey of Survivors

Nancy Stark Appl Clin Trials vol 16 (7) 48-50,52,54. 2007

Manuscript Health Outcome

1600 Current Utilization and Surgical Efficacy of Laparoscopic Colectomy in Colon Cancer

Robert P Sticca, Steven R Alberts, Michelle R Mahoney, Daniel J Sargent, Lisa M Finstuen, Garth D Nelson, Timothy M Husted, Jan Franko, Charles D Goldman, Barbara A Pockaj J. Am. Coll. Surg. vol 217 (1) 56-63 2013

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/23623224>

1601 Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer

T. E. Stinchcombe, L. Hodgson, J. E. 2nd Herndon, M. J. Kelley, M. G. Cicchetti, N. Ramnath, H. B. Niell, J. N. Atkins, W. Akerley, M. R. Green, E. E. Vokes, Cancer, B. Leukemia Group J Thorac Oncol vol 4 (9) 1117-1125 2009

1602 Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801

T. E. Stinchcombe, L. Hodgson, J. E. Herndon 2nd, M. J. Kelley, M. Cicchetti, N. Ramnath, H. B. Niell, J. N. Atkins, M. R. Green, E. E. Vokes J. Clin. Oncol. vol 27 (15) abstr 7535 2009

Abstract Respiratory

<http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B27%2F15S%2F7535>

1603 An analysis of the prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC)

T. E. Stinchcombe, L. M. Sholl, X. Wang, L. Gu, M. A. Socinski, S. J. Rodig, M. Capelletti, J. Crawford, M. J. Edelman, M. L. A. Villalona-Calero, R. Kratzke, E. E. Vokes, V. A. Miller, P. A. Janne J. Clin. Oncol. vol 31 (15 suppl) abstr 8039 2013

Abstract Respiratory

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/8039?sid=7a0ce0eb-b5ee-4fdc-a77f-71be7

1604 Risk factors for distant recurrence and brain metastases observed on American College of Surgical Oncology Group trial Z0030: Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) Non- Small Cell Lung Cancer (NSCLC)

Thomas E. Stinchcombe, Paul A. Decker, Gail E. Darling, Mark S. Allen, Joe B. Putnam Jr J Thorac Oncol vol 4 (9 suppl 1) abstr PD12.11.16 2009

Abstract Respiratory [http://www.jto.org/article/S1556-0864\(15\)33608-X/fulltext](http://www.jto.org/article/S1556-0864(15)33608-X/fulltext)

1605 Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B trial 9430

Thomas E. Stinchcombe, Ann M. Mauer, Lydia D. Hodgson, James E. Herndon, Thomas J. Lynch, Mark. R. Green, Everett E. Vokes J Thorac Oncol vol 3 (11) 1301-1307 2008

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18978566>

1606 Prognostic significance of initial clinical and molecular genetic features of acute promyelocytic leukemia (APL): Results from the North American Intergroup Trial, C9710

W. Stock, B. K. Moser, B. L. Powell, F. Appelbaum, M. Tallman, R. A. Larson, J. Feusner, C. D. Bloomfield, C. Willman, R. Gallagher J. Clin. Oncol. vol 25 (18s) abstr 7016 2007

Abstract Leuk Corr Sci C9710, CALGB-8461, CALGB-9665

http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/7016

1607 High incidence of FLT3 mutations in adults with Acute Promyelocytic Leukemia (APL): Correlation with diagnostic features and treatment outcome (CALGB 9710)

W. Stock, K. Najib, B. K. Moser, N. Holowka, B. L. Powell, K. Gulati, C. D. Bloomfield, R. A. Larson, D. A. Sher J. Clin. Oncol. vol 26 (suppl) abstr 7002 2008

Abstract Leuk Corr Sci C9710, CALGB-9665

http://meeting.ascopubs.org/cgi/content/short/26/15_suppl/7002

1608 Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102)

W. Stock, B. Sanford, G. Lozanski, R. Vij, J. C. Byrd, B. L. Powell, M. Wetzler, D. Sher, C. Edwards, M. Kelly, S. Richards, C. Sung, G. Malnassy, E. Hoke, C. D. Bloomfield, R. A. Larson Blood vol 114 (22) 345-345 2009

Abstract Leukemia <http://www.bloodjournal.org/content/114/22/838.full>

1609 An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia

Wendy Stock, Barthelemy Diouf, Kristine R. Crews, Deqing Pei, Cheng Cheng, Kristina Laumann, Sumithra J. Mandrekar, Selina Luger, Anjali Advani, Richard M. Stone, Richard A. Larson, William E. Evans Clin. Pharmacol. Ther. vol 101 (3) 391-395 2017
Manuscript Leukemia CALGB-10102, CALGB-10403, CALGB-19802, CALGB-9862
<http://www.ncbi.nlm.nih.gov/pubmed/27618250>

1610 Dose Intensification of Daunorubicin and Cytarabine during Treatment of Adult Acute Lymphoblastic Leukemia: Results of Cancer and Leukemia Group B Study 19802

Wendy Stock, Jeffrey L. Johnson, Richard M. Stone, Jonathan E. Kolitz, Bayard L. Powell, Meir Wetzler, Peter Westervelt, Guido Marcucci, Daniel J. DeAngelo, James W. Vardiman, Diane McDonnell, Krzysztof Mrózek, Clara D. Bloomfield, Richard A. Larson Cancer vol 119 (1) 90-98 2013
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/22744771>

1611 What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

Wendy Stock, Mei La, Ben Sanford, Clara D. Bloomfield, James W. Vardiman, Paul Gaynon, Richard A. Larson, James Nachman Blood vol 112 (5) 1646-1654 2008
Manuscript Leukemia CALGB-8811, CALGB-9331, CALGB-19802, CALGB-8461, CALGB-9111, CALGB-9511 <http://www.ncbi.nlm.nih.gov/pubmed/18502832>

1612 A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

Wendy Stock, Selina M. Luger, Anjali S. Advani, Jun Yin, Richard C. Harvey, Charles G. Mullighan, Cheryl L. Willman, Noreen Fulton, Kristina M. Laumann, Greg Malnassy, Elisabeth Paietta, Edy Parker, Susan Geyer, Krzysztof Mrózek, Clara D. Bloomfield, Ben Sanford, Guido Marcucci, Michaela Liedtke, David F. Claxton, Matthew C. Foster, Jeffrey A. Bogart, John C. Grecula, Frederick R. Appelbaum, Harry Erba, Mark R. Litzow, Martin S. Tallman, Richard M. Stone, Richard A. Larson Blood vol 133 (14) 1548-59 2019
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/30658992>

1613 Favorable outcomes for adolescents and young adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early results of US Intergroup trial CALGB 10403 (Alliance)

Wendy Stock, Selina Luger, Anjali Advani, Susan Geyer, Richard Harvey, Charles Mullighan, Cheryl Willman, Edy Parker, Kristina Laumann, Ben Sanford, Guido Marcucci, Elizabeth Paietta, Martin S. Tallman, Frederick R. Appelbaum, Harry P. Erba, Mark Litzow, Richard M. Stone, Richard A. Larson Blood vol 124 (21) abstr 796 2014
Abstract Leukemia C10403, CALGB-10403 <http://www.bloodjournal.org/content/124/21/796>

1614 CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naïve patients with FLT3 mutated AML

R. M. Stone, H. Dohner, G. Ehninger, M. Villeneuve, T. Teasdale, J. D. Virkus, L. R. Bressler, M. M. Seiler, G. Marcucci, R. A. Larson J. Clin. Oncol. vol 29 (supplement) abstr TPS199 2011
Abstract Leukemia
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

1615 Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Richard M. Stone, Sumithra J. Mandrekar, Ben L. Sanford, Kristina Laumann, Susan Geyer, Clara D.

Bloomfield, Christian Thiede, Thomas W. Prior, Konstanze Döhner, Guido Marcucci, Francesco Lo-Coco, Rebecca B. Klisovic, Andrew Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, Theo de Witte, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Jürgen Krauter, Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Richard A. Larson, Hartmut Döhner N. Engl. J. Med. vol 377 (5) 454-464 2017
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/28644114>

1616 The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Richard M. Stone, Sumithra Mandrekar, Ben L Sanford, Susan Geyer, Clara D. Bloomfield, Konstanze Döhner, Christian Thiede, Guido Marcucci, Francesco Lo-Coco, Rebecca B. Klisovic, Andrew Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, Theo de Witte, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Jürgen Krauter, *Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Hartmut Döhner, Richard A. Larson Blood vol 130 (Suppl 1) 2580 2017
Abstract Leukemia http://www.bloodjournal.org/content/130/Suppl_1/2580

1617 Midostaurin v Placebo plus Daunorubicin/Cytarabine Induction, High-dose Cytarabine Consolidation and Maintenance Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) age 18-60 with FLT3 mutations: An International Prospective Randomized Placebo-Controlled Double-Blind Trial (CALGB 10603 [Alliance])

Richard M. Stone, Sumithra Mandrekar, Ben L Sanford, Susan Geyer, Clara D. Bloomfield, Konstanze Döhner, Christian Thiede, Guido Marcucci, Francesco Lo-Coco, Rebecca B. Klisovic, Andrew Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, Theo de Witte, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S Tallman, Jürgen Krauter, Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Richard A. Larson, Hartmut Döhner Blood vol 126 (23) 6 2015
Abstract Leukemia <http://www.bloodjournal.org/content/126/23/6.abstract>

1618 High Dose Cytarabine plus Gemtuzumab Ozogamicin for Patients with Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902

Richard M. Stone, Barry Moser, Ben Sanford, Philip Schulman, Jonathan E. Kolitz, Steven Allen, Wendy Stock, Ilene Galinsky, Ravi Vij, Guido Marcucci, David Hurd, Richard A. Larson Leuk Res vol 35 (3) 329-333 2011
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/20688393>

1619 A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.

Richard M Stone, Kathleen A Donohue, Wendy Stock, Vera Hars, Charles A Linker, Thomas Shea, Daniel J Deangelo, Guido Marcucci, Clara D Bloomfield, Richard A Larson Cancer Chemother. Pharmacol. vol 63 (5) 859-64 2009
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/18670778>

1620 Using Stakeholder Engagement to Overcome Barriers to Implementing Patient-reported Outcomes (PROs) in Cancer Care Delivery: Approaches From 3 Prospective Studies.

Angela M Stover, Carrie Tompkins Stricker, Karen Hammelef, Sydney Henson, Philip Carr, Jennifer Jansen, Allison M Deal, Antonia V Bennett, Ethan M Basch Med Care vol 57 Suppl 5 Suppl 1 S92-9 2019
Manuscript ACS CCDRC <http://www.ncbi.nlm.nih.gov/pubmed/30985602>

1621 Doxorubicin, vinblastine and gemcitabine (AVG), a novel regimen excluding bleomycin for the

treatment of early stage Hodgkin Lymphoma (HL): Results of CALGB 50203

D. J. Straus, A. S. Lacasce, M. E. Juweid, L. Kostakoglu, N. C. Hall, J. L. Johnson, S. Jung, G. P. Canellos, L. Schwartz, B. D. Cheson *Blood* vol 110 (11) abstr 214 2007
Abstract Lymphoma http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_1040&terms

1622 Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

David J. Straus, Jeffrey L. Johnson, Ann S. LaCasce, Nancy L. Bartlett, Lale Kostakoglu, Eric D. Hsi, Heiko Schöder, Nathan C. Hall, Sin-Ho Jung, George P. Canellos, Lawrence H. Schwartz, Ronald W. Takvorian, Malik E. Juweid, Bruce D. Cheson *Blood* vol 117 (20) 5314-5320 2011
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/21355087>

1623 CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

David J. Straus, Sin-Ho Jung, Brandelyn Pitcher, Lale Kostakoglu, John C. Greco, Eric D. Hsi, Heiko Schöder, Leslie L. Popplewell, Julie E. Chang, Craig H. Moskowitz, Nina Wagner-Johnston, John P. Leonard, Jonathan W. Friedberg, Brad S. Kahl, Bruce D. Cheson, Nancy L. Bartlett *Blood* vol 132 (10) 1013-21 2018
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/30049811>

1624 Results of US Intergroup Trial of Response-Adapted Chemotherapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

David J. Straus, Brandelyn N. Pitcher, Lale Kostakoglu, John C. Greco, Eric Hsi, Heiko Schöder, Sin-Ho Jung, Leslie L. Popplewell, John P. Leonard, Jonathan W. Friedberg, Brad S. Kahl, Bruce D. Cheson, Nancy L. Bartlett *Blood* vol 126 (23) abstr 578 2015
Abstract Lymphoma <http://www.bloodjournal.org/content/126/23/578?sso-checked=true>

1625 Adjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC): Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633

G. M. Strauss, X. Wang, M. A. Maddaus, D. W. Johnstone, E. A. Johnson, D. H. Harpole, H. Gillenwater, L. Gu, D. J. Sugarbaker, M. R. Green, S. L. Graziano, R. A. Kratzke, R. L. Schilsky, J. Crawford, E. E. Vokes *J. Clin. Oncol.* vol 29 (15s) abstr 7015 2011
Abstract Respiratory
http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/7015?sid=350a6f5a-3df6-4aa5-8dc3-8f6da

1626 Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

Gary M. Strauss, James E. Herndon, Michael A. Maddaus, David W. Johnstone, Elizabeth A. Johnson, David H. Harpole, Heidi H. Gillenwater, Dorothy M. Watson, David J. Sugarbaker, Richard L. Schilsky, Everett E. Vokes, Mark R. Green *J Clin Oncol* vol 26 (31) 5043-5051 2008
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18809614>

1627 Individual Item Analysis of Quality of Life Assessments Related to Laparoscopic-assisted Colectomy in the COST Trial 93-46-53 (INT 0146)

C. H. Stucky, B. A. Pockaj, P. A. Novotny, J. A. Sloan, D. J. Sargent, M. J. O'Connell, R. W. Beart Jr, J. Skibber, H. Nelson, J. C. Weeks *Ann. Surg. Oncol.* vol 17 (Supplement 1) S36 abstr 93 2010
Abstract GI <http://link.springer.com/content/pdf/10.1245%2Fs10434-009-0903-9>

1628 Long-Term Follow-Up and Individual Item Analysis of Quality of Life Assessments Related to Laparoscopic-Assisted Colectomy in the COST Trial 93-46-53 (INT 0146)

Chee-Chee H. Stucky, Barbara A. Pockaj, Paul J. Novotny, Jeff A. Sloan, Daniel J. Sargent, Michael J. O'Connell, Robert W. Beart, John M. Skibber, Heidi Nelson, Jane C. Weeks *Ann. Surg. Oncol.* vol

1629 Long-term surgical outcomes of 1018 patients with early stage NSCLC in ACOSOG Z0030 trial

S. Su, W. J. Scott, M. S. Allen, G. E. Darling, P. A. Decker, R. J. McKenna Jr, R. J. Landreneau, D. R. Jones, R. I. Incelet, B. F. Meyers 2013
Abstract Respiratory <http://www.aats.org/annualmeeting/Program-Books/2013/LB6.cgi>

1630 Patterns of survival and recurrence after surgical treatment of early stage non-small cell lung carcinoma in the ACOSOG Z0030 (Alliance) trial

Stacey Su, Walter J Scott, Mark S Allen, Gail E Darling, Paul A Decker, Robert J McKenna, Bryan F Meyers J. Thorac. Cardiovasc. Surg. vol 147 (2) 747-52: Discussion 752-3 2014
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/24290575>

1631 Genome-Wide Meta-Analyses Identifies Novel Taxane-Induced Peripheral Neuropathy Associated Loci

L E Sucheston-Campbell, A I Clay-Gilmour, W E Barlow, G T Budd, D O Stram, C A Haiman, X Sheng, L Yan, G Zirpoli, S Yao, C Jiang, K Owzar, D Hershman, K S Albain, D F Hayes, H C Moore, T J Hobday, J A Stewart, A Rizvi, C Isaacs, Muhammad Salim, J R Gralow, G N Hortobagyi, R B Livingston, D L Kroetz, C B Ambrosone Pharmacogenet. Genomics vol 28 (2) 49-55 2018
Manuscript Breast CALGB-40101, S0221 <http://www.ncbi.nlm.nih.gov/pubmed/29278617>

1632 Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial

W. R. Sukov, D. V. Miller, A. C. Dueck, K. S. Tenner, R. B. Jenkins, P. A. Kaufman, N. E. Davidson, S. R. Dakhil, S. Martino, V. Roy, E. A. Perez J. Clin. Oncol. vol 27 (15) abstr 520 2009
Abstract Breast
<http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B27%2F15S%2F520>

1633 The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2 invasive breast cancer

Vera Jean Suman, Matthew J. Ellis, Cynthia X. Ma Chin Clin Oncol vol 4 (3) 34 2015
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26408301>

1634 Results of CALGB 39802: feasibility of video-assisted thoracic surgery (VATS) lobectomy for early stage lung cancer

S. J. Swanson, J. Herndon 2nd, A. D'Amico, T. Demmy, R. McKenna, M. Green, D. Sugarbaker Proc Am Soc Clin Oncol vol 21 abstr 1158 2002
Abstract Respiratory
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=16&abstractID

1635 Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study.

Scott J Swanson, James E Herndon, Thomas A D'Amico, Todd L Demmy, Robert J McKenna, Mark R Green, David J Sugarbaker J. Clin. Oncol. vol 25 (31) 4993-7 2007
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/17971599>

1636 Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

Julien Taieb, Karine Le Malicot, Qian Shi, Frédérique Penault-Llorca, Olivier Bouché, Josep Taberero, Enrico Mini, Richard M. Goldberg, Gunnar Folprecht, Jean Luc Van Laethem, Daniel J. Sargent, Steven R. Alberts, Jean Francois Emile, Pierre Laurent Puig, Frank A. Sinicrope J. Natl. Cancer Inst vol 109 (5) 2016

1637 Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials

Julien Taieb, Karine Le Malicot, Frederique Madeleine Penault-Llorca, Olivier Bouche, Qian Shi, Stephen N. Thibodeau, Josep Taberero, Enrico Mini, Richard M. Goldberg, Gunnar Folprecht, Jean-Luc Van Laethem, Daniel J. Sargent, Steven R. Alberts, Pierre Laurent-Puig, Frank A. Sinicrope
J Clin Oncol vol 33 (suppl) abstr 3507 2015

Abstract GI http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.3507

1638 Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611)

Michael Tallarico, Jared C. Foster, Drew Seisler, Jacqueline M. Lafky, Arti Hurria, Aminah Jatoi, Harvey J. Cohen, Hyman B. Muss, Nancy Bartlett, Bruce D. Cheson, Sin-Ho Jung, John P. Leonard, John C. Byrd, Chadi Nabhan
J Geriatr Oncol vol 9 (4) 321-28 2018

Manuscript Older Adult <http://www.ncbi.nlm.nih.gov/pubmed/29673807>

1639 Toxicities and related outcomes of elderly patients (65 years) with hematologic malignancies in the contemporary era (Alliance A151611)

Michael Tallarico, Jared Foster, Drew Seisler, Jacqueline M. Lafky, Arti Hurria, Aminah Jatoi, Harvey J. Cohen, Hyman B. Muss, Nancy Bartlett, Bruce D. Cheson, Sin-Ho Chung, John Byrd, John P. Leonard, Chadi Nabhan
Blood vol 128 (22) abstr 536 2016

Abstract Older Adult CALGB-10101, A151611, CALGB-10404, CALGB-10501, CALGB-19805, CALGB-19901, CALGB-50002, CALGB-50103, CALGB-50201, CALGB-50401, CALGB-50402, CALGB-50501, CALGB-50602, CALGB-50701, CALGB-50803

<http://www.bloodjournal.org/content/128/22/536>

1640 Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

M. S. Tallman, H. T. Kim, P. Montesinos, F. R. Appelbaum, J. De La Serna, J. M. Bennett, G. Deben, C. D. Bloomfield, J. Gonzalez, J. H. Feusner, M. Gonzalez, R. Gallagher, J. D. Miguel, R. A. Larson, G. Milone, E. Paietta, C. Rayon, J. M. Rowe, C. Rivas, C. A. Schiffer, E. Vellenga, L. Shepherd, J. L. Slack, P. H. Wiernik, C. L. Willman, M. A. Sanz
Blood vol 116 (25) 5650-5659 2010

Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/20858857>

1641 QOL and Survival Comparisons by Race in Oncology Clinical Trials

AD Tan, PJ Novotny, JS Kaur, JC Buckner, RB Mowat, E Paskett, JA Sloan
J Cancer Clin Oncol vol 2 (1) 2016

Manuscript Disparities N0621, N0691 <http://www.ncbi.nlm.nih.gov/pubmed/28691116>

1642 N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.

W W Tan, D W Hillman, M Salim, D W Northfelt, D M Anderson, P J Stella, R Niedringhaus, A M Bernath, S S Gamini, F Palmieri, E A Perez
Ann. Oncol. vol 21 (3) 493-7 2010

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/19625343>

1643 N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial

W. W. Tan, A. C. Dueck, P. Flynn, P. Steen, D. Anderson, K. Jr Rowland, D. Northfelt, E. A. Perez
Ann. Oncol. vol 10 (24) 2548-54 2013

1644 N0539 Phase II Trial of Fulvestrant and Bevacizumab in Patients with Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor: A North Central Cancer Treatment Group Trial.

W. W. Tan, A. C. Dueck, P. Flynn, P. Steen, D. Anderson, K. Jr Rowland, D. Nothfeldt, W. Lingle, J. Copland, E. A. Perez *Cancer Res.* vol 69 (24 suppl 3) abstr 738S 2009
Abstract Breast http://cancerres.aacrjournals.org/content/69/24_Supplement/4096

1645 Phase I study of panobinostat (LBH589) and letrozole in post-menopausal women with metastatic breast cancer.

W. Tan, J. Allred, A. Moreno-Aspitia, D. Northfeld, J. Ingle, E. A. Perez *J. Clin. Oncol.* vol 30 (15 suppl) abstr e13501 2012
Abstract Breast <http://meetinglibrary.asco.org/content/95426-114>

1646 N0337: Phase II study of capecitabine in combination with vinorelbine and trastuzumab for the first or second treatment of HER2+metastatic breast cancer

W. Tan, J. Allred, M. Salim, P. Flynn, J. W. Kugler, P. J. Stella, M. Wiesenfeld, A. M. Bernath Jr, T. R. Fitch, E. A. Perez *J. Clin. Oncol.* vol 27 (15) abstr 120 2009
Abstract Breast
<http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B27%2F15S%2F1020>

1647 Phase I study of panobinostat (LBH589) and letrozole in post-menopausal metastatic breast cancer patients

Winston W. Tan, Jacob B. Allred, Alvaro Moreno-Aspitia, Donald W. Northfelt, James N. Ingle, Matthew P. Goetz, Edith A. Perez *Clin. Breast Cancer* vol 16 (2) 82-86 2016
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/26774555>

1648 Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial

Winston W. Tan, Jacob B. Allred, Muhammad Salim, Patrick Flynn, Paul A. S. Fishkin, Philip J. Stella, Martin Wiesenfeld, Albert M. Bernath, Tom R. Fitch, Edith A. Perez *Clin. Breast Cancer* vol 12 (2) 81-86 2012
Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/22444716>

1649 Integrated Analysis of Multidimensional Genomic Data on CALGB 40601 (Alliance), a Randomized Neoadjuvant Phase III Trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-Positive Breast Cancer

Maki Tanioka, Chen Fan, Lisa A. Carey, Terry Hyslop, Brandelyn Pitcher, Joel S. Parker, Katie Hoadley, N. Lynn Henry, Sara Tolaney, Chau Dang, Ian E. Krop, Lyndsay Harris, Donald A. Berry, Elaine Mardis, Charles M. Perou, Eric P Winer, Clifford A Hudis *Cancer Res* vol 77 (4 suppl) Abstract nr S3-05 2017
Abstract Sequencing http://cancerres.aacrjournals.org/content/77/4_Supplement/S3-05

1650 Integrated analysis of RNA and DNA from the phase III trial CALGB 40601 identifies predictors of response to trastuzumab-based neoadjuvant chemotherapy in HER2-positive breast cancer

Maki Tanioka, Cheng Fan, Joel S Parker, Katherine A Hoadley, Zhiyuan Hu, Yan Li, Terry M Hyslop, Brandelyn N Pitcher, Matthew G Soloway, Patricia A Spears, Lynn N Henry, Sara Tolaney, Chau T Dang, Ian E Krop, Lyndsay N Harris, Donald A Berry, Elaine R Mardis, Eric P Winer, Clifford A Hudis, Lisa A Carey, Charles M Perou *Clin. Cancer Res.* vol 24 (21) 5292-304 2018
Manuscript Sequencing <http://www.ncbi.nlm.nih.gov/pubmed/30037817>

1651 A prognostic model integrating clinical information and gene expression signatures in phase III neoadjuvant trial CALGB 40601(Alliance).

Maki Tanioka, Joel S Parker, Lynn N Henry, Sara Tolaney, Chau Dang, Ian E Krop, Lyndsay Harris, David Hillman, Mei Polley, Donald A Berry, Eric P Winer, Lisa A Carey, Charles M Perou Ann Oncol vol 29 (suppl_7) abstr SPS-3 2018
Abstract Sequencing

1652 Transient state change, but not permanent subtype change, after HER2-targeted therapy for HER2-positive breast cancer (Alliance)

Maki Tanioka, Joel S Parker, Lynn N Henry, Sara Tolaney, Chau Dang, Ian E Krop, Lyndsay Harris, David Hillman, Mei Polley, Donald A Berry, Eric P Winer, Lisa A Carey, Charles M Perou Cancer Res vol 79 (4 Suppl) Abstract nr P3-08-04 2019
Abstract Breast http://cancerres.aacrjournals.org/content/79/4_Supplement/P3-08-04

1653 A phase I/randomized phase II study of MLN0128 vs. Pazopanib in patients with locally advanced/unresectable and/or metastatic sarcoma: Alliance A091304

William Tap, Michelle Mahoney, Elise Horvath, Anthony Jazlowski, Gary Schwartz J. Clin. Oncol. vol 34 (suppl) abstr TPS11073 2016
Abstract Experimental <http://meetinglibrary.asco.org/content/170721-176>

1654 Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781

Joel Tepper, Mark J. Krasna, Donna Niedzwiecki, Donna Hollis, Carolyn E. Reed, Richard Goldberg, Krystyna Kiel, Christopher Willett, David Sugarbaker, Robert Mayer J. Clin. Oncol. vol 26 (7) 1086-1092 2008
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/18309943>

1655 A pilot, randomized trial of daily lisinopril vs placebo to prevent radiation-induced pulmonary distress (Alliance MC1221)

Terence T. Sio, Pamela J. Atherton, W. Ken Zhen, Yolanda I. Garces, Daniel J. Ma, Apar Ganti, Steven E. Schild, Robert C. Miller 2017
Abstract Symptom Inter https://library.iaslc.org/search-speaker?search_speaker=54829

1656 A novel approach of longitudinal adverse event evaluation in oncology clinical trials: the Toxicity over Time (ToxT) analysis of clinical trials N9741 and 979254 (Alliance)

Gita Thanarajasingam, Pamela J. Atherton, Paul J. Novotny, Charles L. Loprinzi, Jeff A. Sloan, Axel Grothey Lancet Oncol. vol 17 (5) 663-670 2016
Manuscript Health Outcome N9741, NCCTG-97-92-54
<http://www.ncbi.nlm.nih.gov/pubmed/27083333>

1657 Beyond maximum grade: A novel, longitudinal toxicity over time (ToxT) adverse event analysis of lenalidomide in follicular lymphoma in Alliance A151617

Gita Thanarajasingam, Amylou Dueck, Paul J. Novotny, Thomas E. Witzig, Thomas M. Habermann, Grzegorz S. Nowakowski, Christopher R. Flowers, Nancy L. Bartlett, Kristie A. Blum, Brandelyn N. Pitcher, Sin-Ho Jung, Pamela J. Atherton, Angelina Tan, Jeff A. Sloan, John P. Leonard Hematol Oncol vol 35 (S2) 213-5 2017
Abstract Health Outcome CALGB-50401, A151617
http://onlinelibrary.wiley.com/doi/10.1002/hon.2438_78/full

1658 The high prevalence of FLT3-ITD mutations is associated with the poor outcome in adult patients with t(6;9)(p23;q34) positive AML - Results of an international metaanalysis

C. Thiede, C. D. Bloomfield, F. Lo Coco, S. Frohling, W. Hiddemann, J. Krauter, M. Schaich, S. P. Whitman, G. Saglio, K. Dohner, K. Spiekermann, S. Schnittger, A. Ganser, G. Heil, T. Buchner, H.

Dohner, R. A. Larson, G. Ehninger Blood vol 110 (11) 234A-234A 2007
Abstract Leuk Corr Sci CALGB-19808, CALGB-8461, CALGB-9621, CALGB-9665
<http://www.bloodjournal.org/content/110/11/761?sso-checked=true>

1659 The high prevalence of FLT3-ITD mutations is associated with the poor outcome in adult patients with t(6;9)(p23;q34) positive AML: Results of an international metaanalysis

C. Thiede, C. D. Bloomfield, F. Lo Coco, S. Frohling, W. Hiddemann, J. Krauter, M. Schaich, S. P. Whitman, G. Saglio, K. Dohner, K. Spiekermann, S. Schnittger, A. Ganser, G. Heil, T. Büchner, H. Dohner, R. A. Larson, G. Ehninger Onkologie vol 30 (suppl 3) 113 (abstr 214) 2007
Abstract Leuk Corr Sci CALGB-8461, CALGB-9665
<http://content.karger.com/ProdukteDB/produkte.asp?Aktion=Ausgabe&Ausgabe=233773&ProduktNr=2>

1660 FLT3 mutation assay laboratory cross validation: results from the CALGB 10603/RATIFY(Alliance) trial in patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML)

Christian Thiede, Thomas Prior, Francesco Lo Coco, Jürgen Krauter, Eva Barragan, Josep Nomdedeu, Joop H. Jansen, Andrew Wei, Weiqiang Zhao, Xiaohong Li, Celine Pallaud, Eva Tiecke, Richard Larson, Clara D. Bloomfield, Hartmut Döhner, Gerhard Ehninger, Richard Stone, Konstanze Döhner Blood vol 132 (Suppl) 2800 2018
Abstract Leukemia
http://www.bloodjournal.org/content/132/Suppl_1/2800.abstract?sso-checked=true

1661 Translational correlates, including outcome for patients (pts) with ER-/PR-/HER2- (triple negative (TNeg)) disease from N0234, a phase II trial of gemcitabine and erlotinib for pts with previously treated metastatic breast cancer (MBC)

S. Thome, T. Hobday, D. Hillman, M. Aubry, W. Lingle, M. Reinholz, D. Graham, P. Flynn, A. Moreno, E. Perez J. Clin. Oncol. vol 25 (18s) abstr 1071 2007
Abstract Breast http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/1071

1662 Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia

Michael H. Tomasson, Zhifu Xiang, Richard Walgren, Yu Zhao, Yumi Kasai, Tracie Miner, Rhonda E. Ries, Olga Lubman, Daved H. Fremont, Michael D. McLellan, Jacqueline E. Payton, Peter Westervelt, John F. DiPersio, Daniel C. Link, Matthew J. Walter, Timothy A. Graubert, Mark Watson, Jack Baty, Sharon Heath, William D. Shannon, Rakesh Nagarajan, Clara D. Bloomfield, Elaine R. Mardis, Richard K. Wilson, Timothy J. Ley Blood vol 111 (9) 4797-4808 2008
Manuscript Leuk Corr Sci CALGB-19808, CALGB-9621, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/18270328>

1663 LACE-Bio Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation in Completely Resected Non-Small Cell Lung Cancer (NSCLC)

M. S. Tsao, P. Hainaut, A. Bourredjem, P. A. Janne, J.-P. Pignon, J.-Y. Douillard, J.-C. Soria, L. Seymour, F. A. Shepherd Ann. Oncol. vol 21 (supplement 8) viii63 2010
Abstract Respiratory
<http://oncologypro.esmo.org/meeting-resources/meeting-abstracts/european-society-for-medical-oncolog>

1664 PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer

M.-S. Tsao, G. Le Teuff, F. A. Shepherd, C. Landais, P. Hainaut, M. Filipits, R. Pirker, T. Le Chevalier, S. Graziano, R. Kratze, J.-C. Soria, J.-P. Pignon, L. Seymour, E. Brambilla Ann. Oncol vol 28 (4) 882-9 2017
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/28137741>

1665 Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection

Ming-Sound Tsao, Sophie Marguet, Gwénaél Le Teuff, Sylvie Lantuejoul, Frances A. Shepherd, Lesley Seymour, Robert Kratzke, Stephen L. Graziano, Helmut H. Popper, Rafael Rosell, Jean-Yves Douillard, Thierry Le-Chevalier, Jean-Pierre Pignon, Jean-Charles Soria, Elisabeth M. Brambilla J. Clin. Oncol vol 33 (30) 3439-3446 2015
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/25918286>

1666 Postoperative surveillance recommendations for early-stage colon cancer based on results from the clinical outcomes of surgical therapy trial

V. L. Tsikitis, K. Malireddy, E. A. Green, B. Christensen, R. Whelan, J. Hyder, D. Lauter, P. Marcello, S. Larach, D. Sargent, H. Nelson J. Clin. Oncol. vol 27 (15s Supplement) abstr 4013 2009
Abstract GI NCCTG-934651, CALGB-9396
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

1667 Postoperative Surveillance Recommendations for Early Stage Colon Cancer Based on Results From the Clinical Outcomes of Surgical Therapy Trial

Vassiliki L. Tsikitis, Kishore Malireddy, Erin A. Green, Brent Christensen, Richard Whelan, Jace Hyder, Peter Marcello, Sergio Larach, David Lauter, Daniel J. Sargent, Heidi Nelson J Clin Oncol vol 27 (22) 3671-3676 2009
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19564531>

1668 Use of baseline quality of life (QOL) as compared with performance status (PS) as prognostic factors for overall survival (OS) in patients with metastatic colorectal cancer (mCRC)

J. Turja, A. Grothey, D. Sargent, D. Szydlo, X. Zhao, M. Campbell, R. Goldberg, J. Sloan J. Clin. Oncol. vol 26 (suppl) abstr 4016 2008
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID

1669 Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group study N0074 1

Joon H. Uhm, Karla V. Ballman, Wenting Wu, Caterina Giannini, JC Krauss, Jan C. Buckner, C.D James, Bernd W. Scheithauer, Robert J. Behrens, Patrick J. Flynn, Paul L. Schaefer, Shaker R. Dakhil, Kurt A. Jaeckle Int. J. Radiat. Oncol. Biol. Phys. vol 80 (2) 347-353 2011
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/20510539>

1670 A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma

C. Ujjani, B. D. Cheson, S.-H. Jung Hematol Oncol vol 31 (S1) 271-278 2013
Abstract Lymphoma <http://onlinelibrary.wiley.com/doi/10.1002/hon.2084/full>

1671 Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

Chaitra S. Ujjani, Sin-Ho Jung, Brandelyn Pitcher, Peter Martin, Steven I. Park, Kristie A. Blum, Sonali M. Smith, Myron Czuczman, Matthew S. Davids, Ellis Levine, Lionel D. Lewis, Scott E. Smith, Nancy L. Bartlett, John P. Leonard, Bruce D. Cheson Blood vol 128 (21) 2510-2516 2016
Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/27697771>

1672 Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)

Chaitra Ujjani, Sin-Ho Jung, Brandelyn Pitcher, Peter Martin, Steven I. Park, Kristie Blum, Sonali Smith, Matthew S. Davids, Myron Czuczman, John P. Leonard, Bruce D. Cheson Blood vol 126 (23) abstr 471 2015

1673 Phase I Study of Accelerated Hypofractionated Radiotherapy with Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer: CALGB 31102 (Alliance)

James J. Urbanic, Xiaofei Wang, Jeffrey A. Bogart, Thomas E. Stinchcombe, Lydia Hodgson, Steven E. Schild, Lyudmila Bazhenova, Olwen Hahn, Ravi Salgia, Everett E. Vokes *Int. J. Radiat. Oncol. Biol. Phys.* vol 101 (1) 177-185 2018

Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/29487024>

1674 Phase I Study of Accelerated Hypofractionated Radiotherapy with Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer: CALGB 31102 (Alliance)

James J Urbanic, Jeffrey A Bogart, Thomas Stinchcombe, Xiaofei Wang, Lydia Hodgson, Steven Schild, Lyudmila Bahzenova, Ravi Salgia, Everett Vokes *Int. J. Radiat. Oncol. Biol. Phys.* vol 93 (3 suppl) S86 2015

Abstract Respiratory <http://www.redjournal.org/article/S0360-3016%2815%2900938-4/fulltext>

1675 Allogeneic Hematopoietic Cell Transplantation (HCT) vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG and CIBMTR Study

Celalettin Ustun, Jennifer G Le-Rademacher, Hailin Wang, Megan Othus, Zhuoxin Sun, Brittny Major, Mei-Jie Zhang, Jacqueline M. Lafky, Selina Chow, Krzysztof Mrozek, Eyal Attar, Clara D.

Bloomfield, Larry Cripe, Richard A. Larson, Guido Marcucci, Gail J. Roboz, Geoffrey Uy, Richard Stone, Aminah Jatoi, Thomas Shea, Marcos de Lima, James Foran, Brenda M. Sandmaier, Mark Litzow, Harry P Erba, Arti Hurria, Daniel Weisdorf, Andrew Artz *Blood* vol 132 (suppl 1) 2170 2018

Abstract Leukemia A151509, CALGB-100103

http://www.bloodjournal.org/content/132/Suppl_1/2170

1676 Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an Alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.

Celalettin Ustun, Jennifer Le-Rademacher, Hai-Lin Wang, Megan Othus, Zhuoxin Sun, Brittny Major, Mei-Jie Zhang, Elizabeth Storricks, Jacqueline M Lafky, Selina Chow, Krzysztof Mrózek, Eyal C Attar, Such Nand, Clara D Bloomfield, Larry D Cripe, Martin S Tallman, Frederick Appelbaum, Richard A Larson, Guido Marcucci, Gail J Roboz, Geoffrey L Uy, Richard M Stone, Aminah Jatoi, Thomas C Shea, Marcos de Lima, James M Foran, Brenda M Sandmaier, Mark R Litzow, Harry P Erba, Arti Hurria, Daniel J Weisdorf, Andrew S Artz *Leukemia* 2019

Manuscript Older Adult A151509, CALGB-10502, CALGB-100103, CALGB-10801, CALGB-11001, CALGB-11002, E3999, S0432, S0703

<http://www.ncbi.nlm.nih.gov/pubmed/31073153>

1677 A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001

Geoffrey L. Uy, Sumithra J. Mandrekar, Kristina Laumann, Guido Marcucci, Weiqiang Zhao, Mark J. Levis, Heidi D. Klepin, Maria R. Baer, Bayard L. Powell, Peter Westervelt, Daniel J. DeAngelo, Wendy Stock, Ben Sanford, William G. Blum, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson *Blood Adv* vol 1 (5) 331-340 2017

Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/29034366>

1678 Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults With FLT3-ITD Mutated AML (Alliance C11001).

Geoffrey L. Uy, Sumithra Mandrekar, Kristina Laumann, Ben Sanford, Guido Marcucci, Weiqiang Zhao, Mark Levis, Heidi D. Klepin, Bayard L. Powell, Maria R. Baer, Wendy Stock, John Byrd,

Richard M. Stone, Richard A. Larson Blood vol 126 (23) 319 2015
Abstract Leukemia <http://www.bloodjournal.org/content/126/23/319.abstract>

1679 Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001)

Geoffrey L. Uy, Ben Sanford, Guido Marcucci, Weiqiang Zhao, Susan Geyer, Heidi D. Klepin, Bayard L. Powell, Maria R. Baer, Wendy Stock, Richard M. Stone, Richard A. Larson Blood vol 122 (21) Abstract 2653 2013

Abstract Leukemia <http://www.bloodjournal.org/content/122/21/2653.abstract?sso-checked=true>

1680 Mammographic Breast Density Response to Aromatase Inhibition

Celine M. Vachon, Vera J. Suman, Kathleen R. Brandt, Matthew L. Kosel, Aman U. Buzdar, Janet E. Olson, Fang-Fang Wu, Lynn M. Flickinger, Giske Ursin, Catherine R. Elliott, Lois Shepherd, Richard M. Weinshilboum, Paul E. Goss, James N. Ingle Clin. Cancer Res. vol 19 (8) 2144-53 2013

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/23468058>

1681 Marine -3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance)

Erin L. Van Blarigan, Charles S. Fuchs, Donna Niedzwiecki, Xing Ye, Sui Zhang, Mingyang Song, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Edward L. Giovannucci, Jeffrey A. Meyerhardt Cancer Epidemiol. Biomarkers Prev. vol 27 (4) 438-45 2018

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/29358223>

1682 Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis

Erin L. Van Blarigan, Charles S. Fuchs, Donna Niedzwiecki, Sui Zhang, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Edward L. Giovannucci, Kimmie Ng, Jeffrey A. Meyerhardt JAMA Oncol vol 4 (6) 783-790 2018

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/29710284>

1683 Dietary fat intake after colon cancer diagnosis in relation to cancer recurrence and survival: CALGB 89803 (Alliance)

Erin L. Van Blarigan, Fang-Shu Ou, Donna Niedzwiecki, Sui Zhang, Charles S. Fuchs, Leonard Saltz, Robert J. Mayer, Alan Venook, Shuji Ogino, Mingyang Song, Al Benson, Alexander Hantel, James N. Atkins, Edward L. Giovannucci, Jeffrey A. Meyerhardt Cancer Epidemiol. Biomarkers Prev. vol 27 (10) 1227-30 2018

Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/30038051>

1684 Long-chain omega-3 fatty acid and fish intake after colon cancer diagnosis and disease-free, recurrence-free, and overall survival CALGB 89803 (Alliance)

Erin L. Van Blarigan, Charles S. Fuchs, Donna Niedzwiecki, Xing Ye, Sui Zhang, Mingyang Song, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Walter C. Willett, Edward L. Giovannucci, Jeffrey A. Meyerhardt J Clin Oncol vol 35 (suppl 4S) abstr 585 2017

Abstract GI http://abstracts.asco.org/195/AbstView_195_176704.html

1685 American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance)

Erin L. Van Blarigan, Charles S. Fuchs, Donna Niedzwiecki, Xing Ye, Sui Zhang, Mingyang Song, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Benson,

Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Walter C. Willett, Edward L. Giovannucci, Jeffrey A. Meyerhardt J. Clin. Oncol. vol 35 (15 suppl) 10006 2017
Abstract GI http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.10006

1686 25-hydroxyvitamin D levels and survival in patients with advanced pancreatic cancer (APC): Findings from CALGB 80303

K. Van Loon, K. Owzar, C. Jiang, H. L. Kindler, M. F. Mulcahy, D. Niedzwiecki, E. M. O'Reilly, C. S. Fuchs, F. Innocenti, A. P. Venook J. Clin. Oncol. vol 31 (15 suppl) abstr 4022 2013
Abstract GI
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/4022?sid=8c179369-c78a-4495-9e6b-4195

1687 Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients

K. Van Loon, D. S. Wigler, D. Niedzwiecki, D. R. Hollis, A. P. Venook, C. S. Fuchs, C. Blanke, L. B. Saltz, R. M. Goldberg, J. A. Meyerhardt J. Clin. Oncol. vol 29 (15s) abstr e14026 2011
Abstract GI C80405, C89803
http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/e14026?sid=4d819d7d-7fdb-4c16-9ecb-58

1688 Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic Colorectal Cancer Patients: Findings from CALGB 89803 and CALGB 80405

K. Van Loon, D. Wigler, D. Niedzwiecki, A. P. Venook, C. Fuchs, C. Blanke, L. Saltz, R. M. Goldberg, J. A. Meyerhardt Clin Colorectal Cancer vol 12 (2) 95-102 2013
Manuscript GI CALGB-89803, CALGB-80405 <http://www.ncbi.nlm.nih.gov/pubmed/23317558>

1689 Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer?: A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab

Katherine Van Loon, Anne M. Espinoza, David R. Fogelman, Robert A. Wolff, Milind M. Javle, Renuka V. Iyer, Vincent J. Picozzi, Ludmila Katherine Martin, Tanios Bekaii-Saab, Margaret A. Tempero, Nathan R. Foster, George P. Kim, Andrew H. Ko Pancreas vol 43 (3) 343-349 2014
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24622062>

1690 25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance)

Katherine Van Loon, Kouros Owzar, Chen Jiang, Hedy L. Kindler, Mary F. Mulcahy, Donna Niedzwiecki, Eileen M. O'Reilly, Charles Fuchs, Federico Innocenti, Alan P. Venook J. Natl. Cancer Inst vol 106 (8) 2014
Manuscript GI CALGB-151006, CALGB-80303 <http://www.ncbi.nlm.nih.gov/pubmed/25099612>

1691 Evaluation of the effect of screening on the detection of good and poor prognosis breast cancers

L. J. Van't Veer, L. J. Esserman, S. Linn, E. Rutgers, M. Knauer, V. Retel, S. E. Davis, C. Lin, I. S. Investigators J. Clin. Oncol. vol 27 (15) abstr 1525 2009
Abstract Correl Sci NOS
<http://meeting.ascopubs.org/gca?gca=ascomtg%3B27%2F15S%2F1525&allch=&submit=Go>

1692 Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission

Sumithira Vasu, Jessica Kohlschmidt, Krzysztof Mrózek, Ann-Kathrin Eisfeld, Deedra Nicolet, Lisa J. Sterling, Heiko Becker, Klaus H. Metzeler, Dimitrios Papaioannou, Bayard L. Powell, Jonathan E. Kolitz, Joseph O. Moore, Maria R. Baer, Gail J. Roboz, Richard M. Stone, John C. Byrd, Andrew J. Carroll, Clara D. Bloomfield Blood Adv vol 2 (13) 1645-50 2018
Manuscript Leukemia C8221, C8461, C8525, C8721, C8821, C9022, C9720, CALGB-19808, CALGB-8923, CALGB-9222, CALGB-9420, CALGB-9621, CALGB-9720

<http://www.ncbi.nlm.nih.gov/pubmed/29991495>

1693 Lymph node analysis in esophageal resection: American College of Surgeons Oncology Group Z0060 trial.

Nirmal K Veeramachaneni, Jennifer B Zoole, Paul A Decker, Joe B Putnam, Bryan F Meyers Ann. Thorac. Surg. vol 86 (2) 418-21; discussion 421 2008
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/18640307>

1694 Validation of a 12-gene colon cancer recurrence score (RS) in stage II colon cancer (CC) patients (pts) from CALGB 9581

A. P. Venook, D. Niedzwiecki, M. Lopatin, M. Lee, P. N. Friedman, W. L. Frankel, K. Clark-Langone, C. Yoshizawa, C. Millward, S. Shak, R. M. Goldberg, N. Mahmoud, R. L. Schilsky, M. M. Bertagnolli J. Clin. Oncol. vol 29 (suppl) abstr 3518 2011
Abstract GI
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID

1695 Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results

A. Venook, D. Niedzwiecki, D. Hollis, S. Sutherland, R. Goldberg, S. Alberts, A. Benson, J. Wade, R. Schilsky, R. Mayer J. Clin. Oncol. vol 24 (18s) abstr. 3509 2006
Abstract GI <http://www.ncbi.nlm.nih.gov/pubmed/27953330>

1696 CALGB/SWOG 80405: Analysis of patients undergoing surgery as part of treatment strategy

A. Venook, D. Niedzwiecki, H. Lenz, M. Mahoney, F. Innocenti, B. O'Neil, H. Hochster, R. Goldberg, R. Schilsky, R. Mayer, B. Polite, J. Atkins, J. Shaw, M. Bertagnolli, C. Blanke Ann. Oncol. vol 25 (suppl 4) abstr LBA10 2014
Abstract GI http://annonc.oxfordjournals.org/content/25/suppl_4/mdu438.8.short

1697 CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (mFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the colon

A. Venook, D. Niedzwiecki, H.J. Lenz, F. Innocenti, M.R. Mahoney, B. O'Neil, J. Shaw, B. Polite, H. Hochster, J. Atkins, R. Goldberg, R. Mayer, R. Schilsky, M. Bertagnolli, C. Blanke, Cancer and Leukemia Group B, SWOG, ECOG Ann. Oncol. vol 25 (supple 2) ii112-ii113 2014
Abstract GI http://annonc.oxfordjournals.org/content/25/suppl_2/ii112.2.full

1698 Impact of primary (1°) tumor location on overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)

Alan P. Venook, Donna Niedzwiecki, Federico Innocenti, Briant Fruth, Claire Greene, Bert H. O'Neil, James Edward Shaw, Blase N. Polite, Howard S. Hochster, Charles David Blanke, Richard M. Goldberg, Richard L. Schilsky, Robert J. Mayer, Monica M. Bertagnolli, Heinz-Josef Lenz J. Clin. Oncol. vol 34 (suppl) abstr 3504 2016
Abstract GI <http://meetinglibrary.asco.org/content/161936-176>

1699 Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer

Alan P. Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Briant Fruth, Jeffrey A. Meyerhardt, Deborah Schrag, Claire Greene, Bert H. O'Neil, James Norman Atkins, Scott Berry, Blase N. Polite, Eileen M. O'Reilly, Richard M. Goldberg, Howard S. Hochster, Richard L. Schilsky, Monica M. Bertagnolli, Anthony B. El-Khoueiry, Peter Watson, Al B. Benson, Daniel L. Mulkerin, Robert J. Mayer, Charles Blanke JAMA vol 317 (23) 2392-2401 2017
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/28632865>

1700 CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).

Alan P. Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Michelle R. Mahoney, Bert H. O'Neil, James Edward Shaw, Blase N. Polite, Howard S. Hochster, James Norman Atkins, Richard M. Goldberg, Robert J. Mayer, Richard L. Schilsky, Monica M. Bertagnolli, Charles David Blanke J. Clin. Oncol. vol 32 (15_suppl) LBA3 2014

Abstract GI http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/LBA3

1701 Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581

Alan P. Venook, Donna Niedzwiecki, Margarita Lopatin, Xing Ye, Mark Lee, Paula N. Friedman, Wendy Frankel, Kim Clark-Langone, Carl Millward, Steven Shak, Richard M. Goldberg, Najjia N. Mahmoud, Robert S. Warren, Richard L. Schilsky, Monica M. Bertagnolli J. Clin. Oncol. vol 31 (14) 1775-1781 2013

Manuscript GI C9581, C150705 <http://www.ncbi.nlm.nih.gov/pubmed/23530100>

1702 Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)

Alan P. Venook, Fang-Shu Ou, Federico Innocenti, Howard S. Hochster, Donna Niedzwiecki, Richard Goldberg, Robert Mayer, Monica Bertagnolli, Charles David Blanke Tyler Zemla, Xueping Qu, Omar Kabbarah, Heinz-Josef Lenz J. Clin. Oncol. vol 35 (15 suppl) abstr 3503 2017

Abstract GI http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3503

1703 Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTGN0377, Alliance)

Jesus Vera Aguilera, Ravi D. Rao, Jacob B. Allred, Vera J. Suman, Harold E. Windschitl, Judith S. Kaur, William J. Maples, Val J. Lowe, Edward T. Creagan, Lori A. Erickson, Svetomir Markovic Oncologist vol 23 (8) 887-e94 2018

Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/29666297>

1704 Receptor Activator of Nuclear Factor Kappa B (RANK) Expression in Primary Breast Cancer Correlates with Recurrence Free Survival and Development of Bone Metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657)

Neelima Vidula, Christina Yau, Jiali Li, Laura J. Esserman, Hope S. Rugo Breast Cancer Res. Treat. vol 165 (1) 129-38 2017

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/28577080>

1705 CALGB 100801 (Alliance): A phase II multi-center study of the addition of azacitidine (AZA) following allogeneic transplantation using a targeted busulfan based conditioning regimen for high risk myelodysplasia (MDS) and older patients with acute myeloid leukemia (AML)

Ravi Vij, Vera Hars, William Blum, Tsiporah Shore, Aaron Rapoport, Thomas Shea, Eva Hoke, Richard Stone, Paula Friedman, Kouros Owzar, Steven Devine Bone Marrow Transplantation vol 50 (S1) abstr P640 2015

Abstract Transplant <http://viewer.zmags.com/publication/b0929dae#/b0929dae/450>

1706 CALGB 100801 (Alliance): A phase II multi-center NCI cooperative group study of the addition of azacitidine (AZA) to reduced-intensity conditioning (RIC) allogeneic transplantation for high risk myelodysplasia (MDS) and older patients with acute myeloid leukemia (AML): Results of a busulfan test dose strategy

Ravi Vij, Vera Hars, Thomas Shea, Eva Hoke, William Blum, Richard Stone, Mark Ratain, Kouros Owzar, Steven Devine Blood vol 124 (21) abstr 543 2014

1707 A phase II multi-center study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplantation for high-risk myelodysplasia (and older patients with acute myeloid leukemia): CALGB 100801 (Alliance).

Ravi Vij, Jennifer Le-Rademacher, Kristina Laumann, Vera Hars, Kouros Owzar, Tsiporah Shore, Sumithira Vasu, Amanda Cashen, Luis Isola, Thomas Shea, Margarida DeMagalhaes-Silverman, David Hurd, Kenneth Meehan, Frank Beardell, Steven Devine Biol. Blood Marrow Transplant. 2019
Manuscript Transplant <http://www.ncbi.nlm.nih.gov/pubmed/31212080>

1708 Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

Everett E Vokes, James E Herndon, Michael J Kelley, M Giulia Cichetti, Nitya Ramnath, Harvey Neill, James N Atkins, Dorothy M Watson, Wallace Akerley, Mark R Green J. Clin. Oncol. vol 25 (13) 1698-704 2007
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/17404369>

1709 Interim safety analysis of a phase 2 randomized study of daratumumab (dara), lenalidomide (r), bortezomib (v), and dexamethasone (d; dararvd) vs. rvd in patients (pts) with newly diagnosed multiple myeloma (mm) eligible for highdose therapy (hdt) and autologous stem cell transplantation (asct)

Peter M. Voorhees, MD, Luciano J. Costa, PhD, Brandi Reeves, Nitya Nathwani, Cesar Rodriguez, Yana Lutska, Laura Hydutsky, Huiling Pei, Jon Ukropec, Ming Qi, Thomas Lin and Paul G Richardson Blood vol 130 (suppl 1) 1879 2017
Abstract Myeloma http://www.bloodjournal.org/content/130/Suppl_1/1879?sso-checked=true

1710 Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor based therapy: Phase I results.

Peter M. Voorhees, Flora Mulkey, Hani Hassoun, Claudia E. Paba-Prada, Yvonne Efebera, Eva Hoke, Guadalupe Aquino, Destin Carlisle, Vera Suman, Paul G. Richardson Blood vol 126 (23) abstr 375 2015
Abstract Myeloma <http://www.bloodjournal.org/content/126/23/375>

1711 Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study

Peter M. Voorhees, Robert Z. Orlowski, Flora Mulkey, Peter Watson, Susan Geyer, Ben L. Sanford, Elizabeth Bennett, Asher A. Chanan-Khan, Clara D. Bloomfield, Richard A. Larson Br. J. Haematol. vol 171 (3) 373-377 2015
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/26202857>

1712 Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; DaraVrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for HighDose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Peter M. Voorhees, Cesar Rodriguez, Brandi Reeves, Nitya Nathwani, Luciano J Costa, Yana Lutska, Daniela Hoehn, Huiling Pei, Jon Ukropec, Ming Qi, Thomas Lin, Paul Richardson Blood vol 132 (suppl 1) 151 2018
Abstract Myeloma http://www.bloodjournal.org/content/132/Suppl_1/151

1713 RATIFY: Prognostic impact of FLT3 tyrosine kinase domain (TKD) and NPM1 mutation

status in patients with newly diagnosed acute myeloid leukemia (AML) treated with midostaurin or placebo plus standard chemotherapy (Alliance)

Maria Teresa Voso, Richard A. Larson, Thomas W Prior, Guido Marcucci, Dan Jones, Jürgen Krauter, Michael Heuser, Serena Lavorgna, Josep Noedeu, Kristine Laumann, Susan M. Geyer, Rebecca B. Klisovic, Andrew Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, T. M. M de Witte, Joop H. Jansen, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Yuan Cheng, Insa Gathmann, Eva Tiecke, Christian Thiede, Konstanze Döhner, Hartmut Döhner, Richard M. Stone, Clara D. Bloomfield, Francesco Lo-Coco *Blood* vol 132 (Suppl 1) 2668 2018
Abstract *Leukemia* http://www.bloodjournal.org/content/132/Suppl_1/2668?sso-checked=true

1714 Ratify (Alliance 10603): Prognostic Impact of FLT3 Tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin Plus Standard Chemotherapy

Maria Teresa Voso, Richard A. Larson, Thomas W Prior, Guido Marcucci, Dan Jones, Jürgen Krauter, Michael Heuser, Serena Lavorgna, Josep Nomdedeu, Susan M. Geyer, Rebecca B. Klisovic, Andrew Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, T. M. M de Witte, Joop H. Jansen, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C Medeiros, Martin S. Tallman, Richard F. Schlenk MD, Arnold Ganser, Sergio Amadori, Yuan Cheng, YinMiao Chen, Eva Tiecke, Christian Thiede, Konstanze Döhner, Hartmut Döhner, Richard M. Stone, Clara D. Bloomfield, Francesco Lo-Coco. *HemaSphere* vol 3 (Issue) 79-80 2019
Abstract *Leukemia*
https://journals.lww.com/hemasphere/Fulltext/2019/06001/RATIFY__PROGNOSTIC_IMPACT_OF_FI

1715 5-year Follow-up of a Randomized Controlled Trial of Immediate versus Delayed Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women with Breast Cancer Starting Letrozole after Tamoxifen: N03CC (Alliance)

Nina D. Wagner-Johnston, Jeff A. Sloan, Heshan Liu, Ann E. Kearns, Stephanie L. Hines, Suneetha Puttabasavaiah, Shaker R. Dakhil, Jacqueline M. Lafky, Edith A. Perez, Charles L. Loprinzi *Cancer* vol 121 (15) 2537-2543 2015
Manuscript *Symptom Inter* <http://www.ncbi.nlm.nih.gov/pubmed/25930719>

1716 New Recurrent Balanced Translocations in Acute Myeloid Leukemia and Myelodysplastic Syndromes: Cancer and Leukemia Group B (CALGB) 8461

A. Walker, K. Mrózek, J. Kohlschmidt, K. W. Rao, M. J. Pettenati, L. J. Sterling, G. Marcucci, A. J. Carroll, C. D. Bloomfield *Genes Chromosomes Cancer* vol 52 (4) 385-401 2013
Manuscript *Leuk Corr Sci* <http://www.ncbi.nlm.nih.gov/pubmed/23225546>

1717 No evidence for microsatellite instability in acute myeloid leukemia

Christopher J. Walker, Ann-Kathrin Eisfeld, Luke K. Genutis, Maryam Bainazar, Jessica Kohlschmidt, Krzysztof Mrózek, Andrew J. Carroll, Jonathan E. Kolitz, Bayard L. Powell, Eunice S. Wang, Richard M. Stone, Ralf Bundschuh, Albert de la Chapelle, Clara D. Bloomfield *Leukemia* vol 31 (6) 1474-6 2017
Manuscript *Leuk Corr Sci* CALGB-20202, CALGB-8461, CALGB-9665
<http://www.ncbi.nlm.nih.gov/pubmed/28336936>

1718 Uniparental Disomies (UPD) of Chromosome 13q Is Associated with Shorter Disease-Free Survival in Adult Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Christopher J. Walker, Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, Deedra Nicolet, James S. Blachly, Christopher Oakes, Shelley Orwick, Bayard Powell, Jonathan Kolitz, Chi Song, Andrew J. Carroll, Richard M. Stone, Albert de la Chapelle, John C. Byrd, Clara D. Bloomfield *Blood* vol 132 (Suppl 1) 2777 2018

Abstract Leuk Corr Sci C8461, CALGB-20202
http://www.bloodjournal.org/content/132/Suppl_1/2777.abstract

1719 Genome-wide association study (GWAS) identifies a significant acute myeloid leukemia (AML) susceptibility locus near BICRA (Alliance)

Christopher J. Walker, Christopher C. Oakes, Luke K. Genutis, Brian Giacomelli, Sandya Liyanarachchi, Deedra Nicolet, Ann-Kathrin Einfeld, Markus Scholz, Pamela Brock, Jessica Kohlschmidt, Krzysztof Mrózek, Marius Bill, Andrew J. Carroll, Jonathan E. Kolitz, Bayard L. Powell, Eunice S. Wang, Dietger W. Niederwieser, Richard M. Stone, John C. Byrd, Sebastian Schwind, Albert de la Chapelle, Clara D. Bloomfield *Blood* vol 132 (Suppl 1) 85 2018
Abstract Leuk Corr Sci C8461, CALGB-20202
http://www.bloodjournal.org/content/132/Suppl_1/85.abstract?sso-checked=true

1720 Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA

Christopher J. Walker, Christopher C. Oakes, Luke K. Genutis, Brian Giacomelli, Sandya Liyanarachchi, Deedra Nicolet, Ann-Kathrin Einfeld, Markus Scholz, Pamela Brock, Jessica Kohlschmidt, Krzysztof Mrózek, Marius Bill, Andrew J. Carroll, Jonathan E. Kolitz, Bayard L. Powell, Eunice S. Wang, Dietger W. Niederwieser, Richard M. Stone, John C. Byrd, Sebastian Schwind, Albert de la Chapelle, Clara D. Bloomfield *Leukemia* vol 33 (3) 771-5 2019
Manuscript Leuk Corr Sci C8461, C9665, CALGB-20202
<http://www.ncbi.nlm.nih.gov/pubmed/30291333>

1721 Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial.

Kris Wallace, Neil Fleshner, Michael Jewett, Joan Basiuk, Juanita Crook *J. Clin. Oncol.* vol 24 (25) 4158-62 2006
Manuscript GU <http://www.ncbi.nlm.nih.gov/pubmed/16943531>

1722 High resolution array-based CGH and SNP studies of AML genomes

M. J. Walter, R. Ries, X. Li, W. Shannon, J. Payton, J. Books, C. Bloomfield, K. Mrozek, A. Ruppert, J. Dipersio, D. Link, M. Tomasson, T. Graubert, P. Westervelt, M. Watson, S. Heath, J. Baty, J. Armstrong, E. Mardis, R. Wilson, R. Selzer, T. Richmond, J. Kitzman, P. Eis, T. Ley *Blood* vol 110 (11) 40A-40A 2007
Abstract Leuk Corr Sci CALGB-8461, CALGB-9665
<http://www.bloodjournal.org/content/110/11/107.abstract>

1723 Acquired copy number alterations in adult acute myeloid leukemia genomes

M. Walter, J. Payton, R. Ries, W. Shannon, H. Deshmukh, Y. Zhao, J. Baty, S. Heath, P. Westervelt, M. Watson, M. H. Tomasson, R. Nagarajan, B. O'Gara, C. D. Bloomfield, K. A. Mrozek, R. Selzer, T. Richmond, J. Kitzman, J. Geoghegan, P. Eis, R. Maupin, R. Fulton, M. McLellan, R. Wilson, E. Mardis, D. Link, T. A. Graubert, J. F. Dipersio, T. J. Ley *P Natl Acad Sci USA* vol 4 (106) 12950-12955 2009
Abstract Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716381/?tool=pubmed>

1724 Acquired copy number alterations in adult acute myeloid leukemia genomes

Matthew J. Walter, Jacqueline E. Payton, Rhonda E. Ries, William D. Shannon, Hrishikesh Deshmukh, Yu Zhao, Jack Baty, Sharon Heath, Peter Westervelt, Mark A. Watson, Michael H. Tomasson, Rakesh Nagarajan, Brian P. O'Gara, Clara D. Bloomfield, Krzysztof Mrózek, Rebecca R. Selzer, Todd A. Richmond, Jacob Kitzman, Joel Geoghegan, Peggy S. Eis, Rachel Maupin, Robert S. Fulton, Michael McLellan, Richard K. Wilson, Elaine R. Mardis, Daniel C. Link, Timothy A. Graubert, John F. DiPersio, Timothy J. Ley *Proc Natl Acad Sci U S A* vol 106 (31) 12950-12955 2009
Manuscript Leuk Corr Sci <http://www.ncbi.nlm.nih.gov/pubmed/19651600>

1725 A Phase II Study of Carboplatin, Etoposide and Exisulind in Patients with Extensive Stage Small Cell Lung Cancer: CALGB 30104

X. F. Wang, R. Govindan, J. E. Herndon 2nd, R. C. Barrier, D. Watson, R. Florence, E. E. Vokes, M. R. Green J. Clin. Oncol. vol 23 (16s) abst 7161 2005

Abstract Respiratory

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=34&abstractID

1726 Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)

X. Wang, K. Owzar, P. Gupta, R. A. Larson, F. Mulkey, A. A. Miller, L. D. Lewis, D. Hurd, R. Vij, M. J. Ratain, D. Murry Clin Pharm Therapeut vol 93 (S82-S82) 2013

Abstract PPP <http://www.nature.com/clpt/journal/v93/n1s/index.html#Abstracts-of-Papers>

1727 Validation of Survival Prognostic Models for Non-Small-Cell Lung Cancer in Stage- and Age-specific Groups

Xiaofei Wang, Lin Gu, Ying Zhang, Daniel J. Sargent, William Richards, Apar Kishor Ganti, Jeffery Crawford, Harvey Jay Cohen, Thomas Stinchcombe, Everett Vokes, Herbert Pang Lung Cancer vol 90 (2) 281-287 2015

Manuscript Respiratory C8834, C8836, C8931, C8932, C9132, C9532, CALGB-140202, CALGB-140203, CALGB-30203, CALGB-30303, CALGB-30402, CALGB-30406, CALGB-30506, CALGB-30704, CALGB-39802, CALGB-39809, CALGB-39904, CALGB-9238, CALGB-9335, CALGB-9633, CALGB-9730, CALGB-9731, CALGB-9761, Comprehensive

<http://www.ncbi.nlm.nih.gov/pubmed/26319317>

1728 Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials

Xiaofei Wang, Xiaoyi Wang, Lydia Hodgson, Stephen L. George, Daniel J. Sargent, Nate R. Foster, Apar Kishor Ganti, Thomas E. Stinchcombe, Jeffrey Crawford, Robert Kratzke, Alex A. Adjei, Hedy L. Kindler, Everett E. Vokes, Herbert Pang Oncologist vol 22 (2) 189-198 2017

Manuscript Respiratory C8435, C8638, C8833, C8933, C9031, CALGB-30101, CALGB-30107, CALGB-30307, CALGB-30601, CALGB-39807, CALGB-9131, CALGB-9234, CALGB-9530, CALGB-9631, CALGB-9733, N0021, NCCTG-N0623

<http://www.ncbi.nlm.nih.gov/pubmed/28188257>

1729 Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)

Xiaofeng Wang, Kouros Owzar, Pankaj Gupta, Richard A Larson, Flora Mulkey, Antonius A Miller, Lionel D Lewis, David Hurd, Ravi Vij, Mark J Ratain, Daryl J Murry Br J Clin Pharmacol vol 78 (5) 1005-1013 2014

Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/24838014>

1730 Impact of Race, Ethnicity and BMI on Achievement of Pathologic Complete Response Following Neoadjuvant Chemotherapy for Breast Cancer: A Pooled Analysis of Four Prospective Alliance Clinical Trials (A151426)

Erica T. Warner, Karla V. Ballman, Carrie Strand, Judy Boughey, Aman U. Buzdar, Lisa A. Carey, William M. Sikov, H. Partridge Breast Cancer Res. Treat. vol 159 (1) 109-118 2016

Manuscript Disparities A151426, ACOSOG-Z1041, ACOSOG-Z1071, CALGB-40601, CALGB-40603 <http://www.ncbi.nlm.nih.gov/pubmed/27449492>

1731 Age, Race, BMI and Pathologic Complete Response Following Neoadjuvant Chemotherapy: An Analysis of Four Alliance Clinical Trials

Erica T. Warner, Karla V. Ballman, Carrie Strand, Ann H. Partridge J. Clin. Oncol. vol 33 (suppl 285) 33 2015

Abstract Disparities A151426, ACOSOG-Z1031, ACOSOG-Z1041, CALGB-40601, CALGB-40603 <http://meetinglibrary.asco.org/content/155240-163>

1732 A novel interaction of genotype, gender and adjuvant treatment in survival after resection of stage III colon cancer: Results of CALGB 89803

R. S. Warren, C. E. Atreya, D. Niedzwiecki, R. J. Mayer, R. M. Goldberg, C. C. Compton, V. K. Weinberg, M. M. Bertagnolli J. Clin. Oncol. vol 30 (4s) abstr 452 2012
Abstract GI <http://meetinglibrary.asco.org/content/88492-115>

1733 Association of TP53 Mutational Status and Gender with Survival After Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803

Robert S. Warren, Chloe E. Atreya, Donna Niedzwiecki, Vivian K. Weinberg, David B. Donner, Robert J. Mayer, Richard M. Goldberg, Carolyn C. Compton, Marlene B. Zuraek, Cynthia Ye, Leonard B. Saltz, Monica M. Bertagnolli Clin. Cancer Res. vol 19 (20) 5777-5787 2013
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/23983256>

1734 Economic analysis of the Clinical Outcomes of Surgical Therapy (COST) trial comparing laparoscopically-assisted colectomy (LAC) with open colectomy (OC) for colon cancer.

J. Weeks, H. Nelson, D. Romanus, K. Long, D. Sargent J. Clin. Oncol. vol 26 (15s) abstr 6502 2008
Abstract Health Outcome INT-0146, NCCTG-93-46-55, CALGB-9396
http://www.abstract.asco.org/AbstView_55_34994.html

1735 A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG/ Alliance Z5041 Trial

Alice Chia-chi Wei, Fang-Shu Ou, Qian Shi, Eileen Mary O'Reilly, Jeffrey A. Meyerhardt, Robert A. Wolff, Hedy L. Kindler, Douglas B. Evans, Vikram Deshpande, Joseph Misdraji, Eric P. Tamm, Dushyant Sahani, Malcolm J. Moore, Elliot Newman, Nipun B. Merchant, Jordan Berlin, Laura Williams Goff, Peter W. T. Pisters, Mitchell C. Posner J. Clin. Oncol vol 36 (15_suppl) 4112 2018
Abstract GI http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.4112

1736 Autologous stem cell transplantation (SCT) following sequential chemotherapy and imatinib for adults with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) - CALGB study 10001

M. Wetzler, W. Stock, K. A. Donohue, K. Owzar, D. A. Sher, E. E. Hoke, J. M. Mccarty, W. G. Blum, B. L. Powell, C. D. Bloomfield, C. A. Linker, R. A. Larson Blood vol 110 (11) 843A-844A 2007
Abstract Leukemia CALGB-10001, CALGB-8461, CALGB-9665, CALGB-9862
http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_1631

1737 Imatinib and Autologous Stem Cell Transplantation for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) – CALGB study 10001

M. Wetzler, W. Stock, C. Linker, R. A. Larson Ann Hematol vol 87 (Suppl 1) S92-S93 2008
Abstract Leukemia <http://www.springerlink.com/content/u34p00527070m826/fulltext.pdf>

1738 Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance)

M. Wetzler, D. Watson, W. Stock, K. Owzar, G. Koval, E. Hoke, J. M. Mccarty, W. Blum, B. L. Powell, G. Marcucci, C. D. Bloomfield, C. Linker, R. A. Larson Blood vol 120 (21) -816 2012
Abstract Leukemia <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/816>

1739 Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia – Cancer and leukemia group B study 10107

Meir Wetzler, Kathleen A. Donohue, Olatoyosi M. Odenike, Eric J. Feldman, David D. Hurd, Richard M. Stone, Peter Westerfelt, Clara D. Bloomfield, Richard A. Larson *Leuk. Lymphoma* vol 49 (7) 1274-1278 2008
Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/18452072>

1740 Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification

Meir Wetzler, Krzysztof Mrózek, Jessica Kohlschmidt, Hervé Dombret, Hartmut Döhner, Sylvain Pilorge, Utz Krug, Andrew J. Carroll, Richard A. Larson, Guido Marcucci, Wolfgang Hiddemann, Thomas Büchner, Clara D. Bloomfield *Haematologica* vol 99 (2) 308-313 2014
Manuscript *Leuk Corr Sci* C8221, C8525, C9720, CALGB-10201, CALGB-8923
<http://www.ncbi.nlm.nih.gov/pubmed/24097631>

1741 Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511

Meir Wetzler, Ben L. Sanford, Joanne Kurtzberg, Divino DeOliveira, Stanley R. Frankel, Bayard L. Powell, Jonathan E. Kolitz, Clara D. Bloomfield, Richard A. Larson *Blood* vol 109 (10) 4164-4167 2007
Manuscript *Leuk Corr Sci* CALGB-8461, CALGB-9511
<http://www.ncbi.nlm.nih.gov/pubmed/17264295>

1742 Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)

Meir Wetzler, Dorothy Watson, Wendy Stock, Gregory Koval, Flora A. Mulkey, Eva E. Hoke, John M. McCarty, William G. Blum, Bayard L. Powell, Guido Marcucci, Clara D. Bloomfield, Charles A. Linker, Richard A. Larson *Haematologica* vol 99 (1) 111-115 2014
Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/24077846>

1743 Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory peripheral neuropathy

Heather E. Wheeler, Eric R. Gamazon, Claudia Wing, Uchenna O. Njiaju, Chidiamara Njoku, R. Michael Baldwin, Kouros Owzar, Chen Jiang, Dorothy Watson, Ivo Shterev, Michiaki Kubo, Hitoshi Zembutsu, Eric Winer, Clifford Hudis, Lawrence N. Shulman, Yusuke Nakamura, Mark J. Ratain, Deanna L. Kroetz, Nancy J. Cox, M. Eileen Dolan *Clin. Cancer Res.* vol 19 (2) 491-499 2013
Manuscript *PPP* <http://www.ncbi.nlm.nih.gov/pubmed/23204130>

1744 Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older ≥ 60 Years (Y) De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study

S. P. Whitman, K. Maharry, M. D. Radmacher, K. Mrozek, D. Margeson, K. B. Holland, H. Becker, Y. Z. Wu, S. Schwind, M. R. Baer, B. L. Powell, R. M. Stone, A. J. Carroll, R. A. Larson, M. A. Caligiuri, G. Marcucci, C. D. Bloomfield *Blood* vol 114 (22) 631-632 2009
Abstract *Leuk Corr Sci* CALGB-10201, CALGB-20202, CALGB-8461, CALGB-9720
<http://www.bloodjournal.org/content/114/22/1579>

1745 Improved clinical outcome of cytogenetically normal acute myeloid leukemia patients with the MLL partial tandem duplication: A Cancer and Leukemia Group B (CALGB) study

S. P. Whitman, A. S. Ruppert, G. Marcucci, K. A. Mrozek, P. Paschka, C. Langer, C. D. Baldus, J. Wen, T. Vukosavljevic, B. L. Powell, A. J. Carroll, M. A. Caligiuri, J. E. Kolitz, R. A. Larson, C. D.

Bloomfield Cancer Res. vol 67 abstr 2439 2007

Abstract Leuk Corr Sci CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665, CALGB-9769

http://cancerres.aacrjournals.org/content/67/9_Supplement/2439.abstract?sid=00413711-0287-4de7-a621

1746 FLT3 D835/I836 mutations predict worse disease-free survival (DFS) in younger adults with cytogenetically normal acute myeloid leukemia (CN AML) without FLT3 internal tandem duplications (ITD): A Cancer and Leukemia Group B (CALGB) study

S. P. Whitman, A. S. Ruppert, M. D. Radmacher, K. A. Mrozek, P. Paschka, J. E. Kolitz, R. A. Larson, M. A. Caligiuri, G. Marcucci, C. D. Bloomfield J. Clin. Oncol. vol 25 (18s) 10532 2007
Abstract Leuk Corr Sci CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665

http://meeting.ascopubs.org/gca?gca=ascomtg%3B25%2F18_suppl%2F10532&allch=&submit=Go

1747 Adverse Prognostic Impact of GAS6 Expression in De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance)

S. Whitman, J. Kohlschmidt, K. Maharry, D. Nicolet, S. Schwind, H. Becker, K. H. Metzeler, K. Mrozek, J. H. Mendler, Ann-Kathrin Einfeld, S. Volinia, B. L. Powell, T. H. Carter, J. E. Kolitz, R. M. Stone, I.-K. Park, M. A. Caligiuri, G. Marcucci, C. D. Bloomfield Blood vol 120 (21) -1293 2012
Abstract Leuk Corr Sci CALGB-8461, CALGB-9665, CALGB-20202

<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/1293>

1748 The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia

SP Whitman, MA Caligiuri, K Maharry, MD Radmacher, J Kohlschmidt, H Becker, K Mrózek, Y-Z Wu, S Schwind, KH Metzeler, JH Mendler, J Wen, MR Baer, BL Powell, TH Carter, JE Kolitz, M Wetzler, AJ Carroll, RA Larson, G Marcucci, CD Bloomfield Leukemia vol 26 (7) 1713-1717 2012
Manuscript Leuk Corr Sci CALGB-10201, CALGB-8525, CALGB-8923, CALGB-9420, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/22382894>

1749 DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication

Susan P. Whitman, Björn Hackanson, Sandya Liyanarachchi, Shujun Liu, Laura J. Rush, Kati Maharry, Dean Margeson, Ramana Davuluri, Jing Wen, Tatiana Witte, Li Yu, Chunhui Liu, Clara D. Bloomfield, Guido Marcucci, Christoph Plass, Michael A. Caligiuri Blood vol 112 (5) 2013-2016 2008

Manuscript Leuk Corr Sci CALGB-20502, CALGB-9665, CALGB-9769

<http://www.ncbi.nlm.nih.gov/pubmed/18566324>

1750 GAS6 expression identifies high-risk adult AML patients: potential implications for therapy

Susan P. Whitman, Jessica Kohlschmidt, Kati Maharry, Stefano Volinia, Krzysztof Mrózek, Deedra Nicolet, Sebastian Schwind, Heiko Becker, Klaus H. Metzeler, Jason H. Mendler, Ann-Kathrin Einfeld, Andrew J. Carroll, Bayard L. Powell, Thomas H. Carter, Maria R. Baer, Jonathan E. Kolitz, Il-Kyoo Park, Richard M. Stone, Michael A. Caligiuri, Guido Marcucci, Clara D. Bloomfield Leukemia vol 28 (6) 1252-1258 2014

Manuscript Leuk Corr Sci CALGB-8525, CALGB-8923, CALGB-9420, CALGB-9621,

CALGB-9720, CALGB-10201, CALGB-19808 <http://www.ncbi.nlm.nih.gov/pubmed/24326683>

1751 FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Susan P. Whitman, Kati Maharry, Michael D. Radmacher, Heiko Becker, Krzysztof Mrózek, Dean Margeson, Kelsi B. Holland, Yue-Zhong Wu, Sebastian Schwind, Klaus H. Metzeler, Jing Wen, Maria

R. Baer, Bayard L. Powell, Thomas H. Carter, Jonathan E. Kolitz, Meir Wetzler, Joseph O. Moore, Richard M. Stone, Andrew J. Carroll, Richard A. Larson, Michael A. Caligiuri, Guido Marcucci, Clara D. Bloomfield *Blood* vol 116 (18) 3622-3626 2010
Manuscript *Leuk Corr Sci* C8461, C8525, CALGB-10201, CALGB-8923, CALGB-9420, CALGB-9720 <http://www.ncbi.nlm.nih.gov/pubmed/20656931>

1752 Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study

Susan P. Whitman, Amy S. Ruppert, Guido Marcucci, Krzysztof Mrózek, Peter Paschka, Christian Langer, Claudia D. Baldus, Jing Wen, Tamara Vukosavljevic, Bayard L. Powell, Andrew J. Carroll, Jonathan E. Kolitz, Richard A. Larson, Michael A. Caligiuri, Clara D. Bloomfield *Blood* vol 109 (12) 5164-5167 2007
Manuscript *Leuk Corr Sci* CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665, CALGB-9769 <http://www.ncbi.nlm.nih.gov/pubmed/17341662>

1753 FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications

Susan P. Whitman, Amy S. Ruppert, Michael D. Radmacher, Krzysztof Mrózek, Peter Paschka, Christian Langer, Claudia D. Baldus, Jing Wen, Frederick Racke, Bayard L. Powell, Jonathan E. Kolitz, Richard A. Larson, Michael A. Caligiuri, Guido Marcucci, Clara D. Bloomfield *Blood* vol 111 (3) 1552-1559 2008
Manuscript *Leuk Corr Sci* CALGB-19808, CALGB-20502, CALGB-8461, CALGB-9621, CALGB-9665 <http://www.ncbi.nlm.nih.gov/pubmed/17940205>

1754 A phase II study of dasatinib and dexamethasone as primary therapy followed by hematopoietic cell transplantation for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: CALGB Study 10701 (Alliance)

Matthew J. Wieduwilt, Jun Yin, Meir Wetzler, Geoff Uy, Bayard L. Powell, Jonathan Kolitz, Michaela Liedtke, Wendy Stock, Jan H. Beumer, Ryan J. Mattison, Alese Halvorson, Steven Devine, Scott Smith, Richard M. Stone, Richard A. Larson *Blood* vol 128 (22) abstr 2782 2016
Abstract *Leukemia* <http://www.bloodjournal.org/content/128/22/2782>

1755 A phase II study of dasatinib and dexamethasone as primary therapy followed by transplantation for adults with newly diagnosed PH/BCR-ABL1-positive acute lymphoblastic leukemia: Final results of Alliance/CALGB study 10701

Matthew J. Wieduwilt, Jun Yin, Meir Wetzler, Geoff Uy, Bayard L. Powell, Jonathan Kolitz, Michaela Liedtke, Wendy Stock, Jan H. Beumer, Ryan J. Mattison, Elizabeth Storricks, Steven Devine, Scott Smith, Richard M. Stone, Richard A. Larson *Blood* vol 132 (suppl 1) abstr 309 2018
Abstract *Leukemia* http://www.bloodjournal.org/content/132/Suppl_1/309

1756 Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC)

Ryan E. Wilcox, Qian Shi, Frank A. Sinicrope, Daniel J. Sargent, Nathan R. Foster, Jeffrey P. Meyers, Richard M. Goldberg, Suresh Nair, Anthony F. Shields, Emily Chan, Sharlene Gill, Morton S. Kahlenberg, Steven R. Alberts *J. Clin. Oncol.* vol 33 (suppl) abstr 3590 2015
Abstract *GI* http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3590

1757 Adherence to the National Quality Forum (NQF) Breast Cancer Measures Within Cancer Clinical Trials: A Review From ACOSOG Z0010

Lee G. Wilke, Karla V. Ballman, Linda M. McCall, Armando E. Giuliano, Pat W. Whitworth, Peter W. Blumencranz, Douglas S. Reintgen, William E. Burak, A. Marilyn Leitch, Kelly K. Hunt *Ann Surg Oncol* vol 17 (8) 1989-1994 2010

1758 A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype

W. H. Wilson, S. H. Jung, P. Porcu, D. Hurd, J. Johnson, S. E. Martin, M. Czuczman, R. Lai, J. Said, A. Chadburn, D. Jones, K. Dunleavy, G. Canellos, A. D. Zelenetz, B. D. Cheson, E. D. Hsi
Haematologica vol 97 (5) 758-765 2012

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/22133772>

1759 Multi-center study of dose-adjusted epoch-r in untreated diffuse large b-cell lymphoma: CALGB 50103

W. H. Wilson, A. D. Zelenetz, D. Niedzwiecki, D. D. Hurd, S. E. Martin, M. S. Czuczman, J. L. Johnson, G. P. Canellos, B. D. Cheson *Ann. Oncol.* vol 19 (suppl 4) 146-147 abstr206 2008

Abstract Lymphoma http://annonc.oxfordjournals.org/content/19/suppl_4/iv141.full.pdf+html

1760 Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: Alliance/CALGB 50303

Wyndham H. Wilson, Sin-Ho Jung, Brandelyn Pitcher, Eric Hsi, Jonathan Friedberg, Bruce D. Cheson, Nancy Bartlett, Scott E. Smith, Nina Wagner Johnston, Brad S. Kahl, Louis Staudt, Kristie Blum, Jeremy Abramson, Oliver W. Press, Richard I. Fisher, Kristy Richards, Heiko Schoder, Julie Chang, Andrew Zelenetz, John P. Leonard *Blood* vol 128 (22) abstr 469 2016

Abstract Lymphoma <http://www.bloodjournal.org/content/128/22/469>

1761 Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342.

Eric P Winer, Donald A Berry, Susan Woolf, David Duggan, Alice Kornblith, Lyndsay N Harris, Richard A Michaelson, Jeffrey A Kirshner, Gini F Fleming, Michael C Perry, Mark L Graham, Stewart A Sharp, Roger Keresztes, I Craig Henderson, Clifford Hudis, Hyman Muss, Larry Norton *J. Clin. Oncol.* vol 22 (11) 2061-8 2004

Manuscript Breast <http://www.ncbi.nlm.nih.gov/pubmed/15169793>

1762 High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)

T E Witzig, B LaPlant, T M Habermann, E McPhail, D J Inwards, I N Micallef, J P Colgan, G S Nowakowski, S M Ansell, P B Johnston *Blood Cancer J* vol 7 (6) e576- 2017

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/28649983>

1763 Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group

Thomas E. Witzig, Susan M. Geyer, Paul J. Kurtin, Joseph P. Colgan, David J. Inwards, Ivana N. M. Micallef, Betsy R. LaPlant, John C. Michalak, Muhammad Salim, Robert J. Dalton, Dennis F. Moore, Craig B. Reeder *Leuk. Lymphoma* vol 49 (6) 1074-1080 2008

Manuscript Lymphoma <http://www.ncbi.nlm.nih.gov/pubmed/18569634>

1764 Patient-specific integrative pathway analysis using PARADIGM identifies key activities in I-SPY 1 breast cancer patients (CALGB 150007/150012; ACRIN 6657)

D. Wolf, C. Yau, S. Benz, C. Vaske, J. Stuart, R. Roy, A. Olshen, A. Boudreau, D. Haussler, J. W. Gray, P. Spellman, S. E. Davis, N. Hylton, L. Van't Veer, L. J. Esserman *Cancer Res.* vol 71 (24 suppl) 179s (abstr p171-106-109) 2011

Abstract Correl Sci NOS ACRIN-6657, CALGB-150007

http://cancerres.aacrjournals.org/content/71/24_Supplement/P1-06-09

1765 Gene expression changes associated with response to neoadjuvant chemotherapy are observed

early in treatment: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

D. Wolf, C. Yau, M. Magbanua, A. Boudreau, S. Davis, C. Haqq, J. Park, L. Esserman, L. Van't Veer
Cancer Res. vol 72 (24 suppl) Abstract nr P2-05-01 2012
Abstract Correl Sci NOS CALGB-150007, CALGB-150012
http://cancerres.aacrjournals.org/cgi/content/short/72/24_MeetingAbstracts/P2-05-01?rss=1

1766 The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA

S. L. Wolf, D. L. Barton, R. Qin, E. J. Wos, J. A. Sloan, H. Liu, N. K. Aaronson, D. V. Satele, B. I. Mattar, N. B. Green, C. L. Loprinzi Support Care Cancer vol 20 (3) 625-632 2012
Manuscript Health Outcome <http://www.ncbi.nlm.nih.gov/pubmed/21479990>

1767 Relationship of sensory symptoms and motor function in patients with chemotherapy-induced peripheral neuropathy (CIPN) utilizing the EORTC QLQ CIPN20: NCCTG study N06CA

S. L. Wolf, R. Qin, D. L. Barton, J. A. Sloan, H. Liu, N. K. Aaronson, D. V. Satele, N. B. Green, B. I. Mattar, C. L. Loprinzi J. Clin. Oncol. vol 27 (15s) abstr 9587 2009
Abstract Health Outcome
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID

1768 Evaluation of a urea/lactic acid-based topical keratolytic agent (ULABTKA) for prevention of capecitabine-induced hand and foot syndrome (HFS): NCCTG trial N05C5

S. L. Wolf, R. Qin, S. P. Menon, K. M. Rowland Jr, J. W. Kugler, P. J. Flynn, D. Christian, D. Satele, J. L. Berenberg, C. L. Loprinzi J. Clin. Oncol. vol 28 (15s) abstr 9017 2010
Abstract Symptom Inter
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID

1769 Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Central Cancer Treatment Group Study N05C5

Sherry L. Wolf, Rui Qin, Smitha P. Menon, Kendrith M. Rowland, Sachdev Thomas, Robert Delaune, Diana Christian, Eduardo R. Pajon, Daniel V. Satele, Jeffrey L. Berenberg, Charles L. Loprinzi J Clin Oncol vol 28 (35) 5182-5187 2010
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/21060036>

1770 Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer

Brian M. Wolpin, Cosmeri Rizzato, Peter Kraft, Charles Kooperberg, Gloria M. Petersen, Zhaoming Wang, Alan A. Arslan, Laura Beane-Freeman, Paige M. Bracci, Julie Buring, Federico Canzian, Eric J. Duell, Steven Gallinger, Graham G. Giles, Gary E. Goodman, Phyllis J. Goodman, Eric J. Jacobs, Aruna Kamineni, Alison P. Klein, Laurence N. Kolonel, Matthew H. Kulke, Donghui Li, Núria Malats, Sara H. Olson, Harvey A. Risch, Howard D. Sesso, Kala Visvanathan, Emily White, Wei Zheng, Christian C. Abnet, Demetrius Albanes, Gabriella Andreotti, Melissa A. Austin, Richard Barfield, Daniela Basso, Sonja I. Berndt, Marie-Christine Boutron-Ruault, Michelle Brotzman, Markus W. Büchler, H. Bas Bueno-de-Mesquita, Peter Bugert, Laurie Burdette, Daniele Campa, Neil E. Caporaso, Gabriele Capurso, Charles Chung, Michelle Cotterchio, Eithne Costello, Joanne Elena, Niccola Funel, J. Michael Gaziano, Nathalia A. Giese, Edward L. Giovannucci, Michael Goggins, Megan J. Gorman, Myron Gross, Christopher A. Haiman, Manal Hassan, Kathy J. Helzlsouer, Brian E. Henderson, Elizabeth A. Holly, Nan Hu, David J. Hunter, Federico Innocenti, Mazda Jenab, Rudolf Kaaks, Timothy J. Key, Kay-Tee Khaw, Eric A. Klein, Manolis Kogevinas, Vittorio Krogh, Juozas Kupcinskis, Robert C. Kurtz, Andrea LaCroix, Maria T. Landi, Stefano Landi, Loic Le Marchand, Andrea Mambrini, Satu Mannisto, Roger L. Milne, Yusuke Nakamura, Ann L. Oberg, Kouros Owzar, Alpa V. Patel, Petra H. M. Peeters, Ulrike Peters, Raffaele Pezzilli, Ada Piepoli, Miquel Porta, Francisco X. Real, Elio Riboli, Nathaniel Rothman, Aldo Scarpa, Xiao-Ou Shu, Debra T. Silverman,

Pavel Soucek, Malin Sund, Renata Talar-Wojnarowska, Philip R. Taylor, George E. Theodoropoulos, Mark Thornquist, Anne Tjønneland, Geoffrey S. Tobias, Dimitrios Trichopoulos, Pavel Vodicka, Jean Wactawski-Wende, Nicolas Wentzensen, Chen Wu, Herbert Yu, Kai Yu, Anne Zeleniuch-Jacquotte, Robert Hoover, Patricia Hartge, Charles Fuchs, Stephen J. Chanock, Rachael S. Stolzenberg-Solomon, Laufey T. Amundadottir Nat. Genet. vol 46 (9) 994-1000 2014
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/25086665>

1771 Comparison of chemotherapy toxicity over time according to age and performance status in patients with advanced non-small cell lung cancer: a toxicity over time analysis of CALGB 9730 (Alliance A151729)

Melisa L. Wong, Junheng Gao, Gita Thanarajasingam, Jeff A. Sloan, Amylou C. Dueck, Paul J. Novotny, Aminah Jatoi, Arti Hurria, William A. Wood, Josephine L. Feliciano, Louise C. Walter, Christine Miaskowski, Thomas E. Stinchcombe, Xiaofei Wang J Geriatric Oncol vol 9 (6S1) S76-S77 2018
Abstract Older Adult
<https://reader.elsevier.com/reader/sd/pii/S1879406818304405?token=F8007FAE58BF8DB848CB25BEF>

1772 Cost Implications of New Treatments for Advanced Colorectal Cancer

Yu-Ning Wong, Neal J. Meropol, William Speier, Daniel Sargent, Richard M. Goldberg, J. Robert Beck Cancer vol 115 (10) 2081-2091 2009
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/19309745>

1773 A randomized phase II trial of vitamin D vs placebo in premenopausal women: CALGB 70806

M. E. Wood, F. Kinglsey, A. B. Ambaye, L. Yee, S. J. Jung, J. R. Marshall, E. Paskett Cancer Res. vol 71 (24 suppl) 613s (abstr OT612-604-601) 2011
Abstract Prevention http://cancerres.aacrjournals.org/content/71/24_Supplement/OT2-04-01

1774 Change in mammographic density with metformin use: A companion study to NCIC study MA.32.

Marie E. Wood, Rui Qin, Huong T. Le-Petross, E Shelley Hwang, Jennifer A. Ligibel, Ingrid A. Mayer, James Roger Marshall, Pamela Jean Goodwin J. Clin. Oncol. vol 31 (15 suppl) abstr TPS1608 2013
Abstract Breast http://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.tps1608

1775 Influence of vitamin D (Vit D) on mammographic density (MD) and insulin like growth factor 1 (IGF1): results of CALGB (Alliance) 70806

Marie Wood, Drew K. Seisler, Meng-Kang Hsieh, Despina Kontos, Abiy Ambaye, Huong T. Le-Petross, Sin-Ho Jung, Heshan Liu, Patricia Zekan, Lucien Cardinal, Jayne Charlamb, Lili X. Wang, Gary W. Unzeitig, Judy Garber, James Marshall J. Clin. Oncol. vol 36 (15_suppl) 1549 2018
Abstract Prevention

1776 Objective Measures of Performance Status in Cancer: A pilot Alliance study

WA Wood, X Tan, NS Grover, A Stover, A Kannappan, Burkes R Carr, P, TC Shea, A Artz, SM Devine, J Ligibel, AV Bennett, EM Basch J Clin Oncol vol 36 (30_suppl) abstr 284 2018
Abstract Disparities http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.30_suppl.284

1777 Pathways: patient-centred decision counselling for women at risk of cancer-related infertility: a protocol for a comparative effectiveness cluster randomised trial

Terri Lynn Woodard, Aubri S Hoffman, Laura C Crocker, Deborah A Holman, Derek B Hoffman, Jusheng Ma, Roland L Bassett, Viola B Leal, Robert J Volk BMJ Open vol 8 (2) e019994. 2018
Manuscript ACS CCDRC <http://www.ncbi.nlm.nih.gov/pubmed/29467138>

1778 Outcome of Adolescents and Young Adults with Acute Myeloid Leukemia Treated on COG

Trials Compared to CALGB and SWOG Trials

William G. Woods, Anna R.K. Franklin, Todd A. Alonzo, Robert B. Gerbing, Kathleen A. Donohue, Megan Othus, John Horan, Frederick R. Appelbaum, Elihu H. Estey, Clara D. Bloomfield, Richard A. Larson *Cancer* vol 119 (23) 2013
Manuscript *Leukemia* CALGB-8525, CALGB-9022, CALGB-9222, CALGB-9621, CALGB-19808, CALGB-8461 <http://www.ncbi.nlm.nih.gov/pubmed/24104597>

1779 Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies

J. A. Woyach, A. S. Ruppert, B. Peterson, K. R. Rai, T. S. Lin, F. R. Appelbaum, M. S. Tallman, A. R. Belch, R. A. Larson, J. C. Byrd *Blood* vol 118 (21) 134-134 2011
Abstract *Leukemia* C9011, CALGB-10101, CALGB-9712
<https://ash.confex.com/ash/2011/webprogram/Paper43135.html>

1780 Treatment with fludarabine and rituximab produces extended remissions and survival in chronic lymphocytic leukemia (CLL) without increased risk of second malignancy: Long-term follow up of CALGB study 9712

J. Woyach, N. A. Heerema, A. Stark, B. L. Peterson, J. G. Gribben, V. A. Morrison, K. R. Rai, R. A. Larson, J. C. Byrd *Blood* vol 114 (22) abstr 539 2009
Abstract *Leukemia*
<http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;114/22/539?maxtoshow=&hits=10&R>

1781 Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712

Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Bercedis L. Peterson, John G. Gribben, Vicki A. Morrison, Kanti R. Rai, Richard A. Larson, John C. Byrd *J Clin Oncol* vol 29 (10) 1349-1355 2011
Manuscript *Leukemia* <http://www.ncbi.nlm.nih.gov/pubmed/21321292>

1782 Ibrutinib alone or in combination with rituximab produces superior progression free survival compared with bendamustine plus rituximab in untreated older patients with chronic lymphocytic leukemia: Results of Alliance A041202

Jennifer A. Woyach, Amy S. Ruppert, Nyla Heerema, Weiqiang Zhao, Allison M Booth, Wei Ding, Nancy Bartlett, Danielle M Brander, Paul M Barr, Kerry A Rogers, Sameer Parikh, Steven Coutre, Arti Hurria, Gerard Lozanski, Sreenivasa Nattam, Richard A. Larson, Harry Erba, Mark Litzow, Carolyn Owen, James Atkins, Jeremy Abramson, Richard M. Stone, Sumithra Mandrekar, John C. Byrd *Blood* vol 132 (Suppl 1) 6 2018
Abstract *Leukemia* http://www.bloodjournal.org/content/132/Suppl_1/6.abstract?sso-checked=true

1783 Impact of Age on Outcomes After Initial Therapy With Chemotherapy and Different Chemoimmunotherapy Regimens in Patients With Chronic Lymphocytic Leukemia: Results of Sequential Cancer and Leukemia Group B Studies

Jennifer A. Woyach, Amy S. Ruppert, Kanti Rai, Thomas S. Lin, Susan Geyer, Jonathan Kolitz, Frederick R. Appelbaum, Martin S. Tallman, Andrew R. Belch, Vicki A. Morrison, Richard A. Larson, John C. Byrd *J. Clin. Oncol.* vol 31 (4) 440-447 2013
Manuscript *Leukemia* C9011, CALGB-9712, CALGB-19901, CALGB-10101
<http://www.ncbi.nlm.nih.gov/pubmed/23233702>

1784 Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Jennifer A Woyach, Amy S Ruppert, Nyla A Heerema, Weiqiang Zhao, Allison M Booth, Wei Ding, Nancy L Bartlett, Danielle M Brander, Paul M Barr, Kerry A Rogers, Sameer A Parikh, Steven Coutre,

Arti Hurria, Jennifer R Brown, Gerard Lozanski, James S Blachly, Hatice G Ozer, Brittny Major-Elechi, Briant Fruth, Sreenivasa Nattam, Richard A Larson, Harry Erba, Mark Litzow, Carolyn Owen, Charles Kuzma, Jeremy S Abramson, Richard F Little, Scott E Smith, Richard M Stone, Sumithra J Mandrekar, John C Byrd N. Engl. J. Med. vol 379 (26) 2517-28 2018
Manuscript Leukemia <http://www.ncbi.nlm.nih.gov/pubmed/30501481>

1785 Deletions in HSP110 T17 and Patient Prognosis in Stage III Microsatellite Instable (MSI) Colon Cancers: Findings from CALGB 89803 and NCCTG N0147.

Christina Wu, Qian Shi, Jerneja Tomsic, Jeffrey Meyers, Wendy L. Frankel, Cynthia Timmers, Leonard B. Saltz, Steven R. Alberts, Daniel J. Sargent, Heather Hampel, Albert de la Chapelle, Richard M. Goldberg J. Clin. Oncol. vol 34 (suppl) abstr 315148 2016
Abstract GI CALGB-89803, NCCTG-N0147 <http://meetinglibrary.asco.org/content/164224-176>

1786 Relationship between overall survival and progression-free survival for recent NCCTG glioblastoma multiforme trials

W. Wu, E. Galanis, J. C. Buckner, K. A. Jaeckle, D. J. Sargent J. Clin. Oncol. vol 30 (15 suppl) abstr 2004 2012
Abstract Neuro-Onc http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/2004

1787 Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma

Wenting Wu, Kathleen R. Lamborn, Jan C. Buckner, Paul J. Novotny, Susan M. Chang, Judith R. O'Fallon, Kurt A. Jaeckle, Michael D. Prados Neuro Oncol vol 12 (2) 164-172 2010
Manuscript Neuro-Onc <http://www.ncbi.nlm.nih.gov/pubmed/20150383>

1788 Discovery of a new phosphoHER2+/FISH- molecular subtype of human breast cancer by functional pathway mapping

J. Wulfkuhle, M. Pierobon, J. Laird, V. Espina, L. Liotta, L. J. Esserman, E. Petricoin J. Clin. Oncol. vol 25 (15s) abstr 11009 2009
Abstract Correl Sci NOS <http://meetinglibrary.asco.org/content/32961-65>

1789 Protein pathway activation mapping of I-SPY 1 biopsy specimens identifies new network focused drug targets for patients with HR+/HER2- tumors

J. Wulfkuhle, C. Yau, R. Gallagher, D. Wolf, V. Calvert, V. Espina, J. Illi, Q. Wu, M. Boe, Y. Yan, L. Liotta, L Van't Veer, L. Esserman, E. Petricoin Cancer Res. vol 72 (24 suppl) Abstract nr P3-04-02 2012
Abstract Correl Sci NOS CALGB-150007, CALGB-150012
http://cancerres.aacrjournals.org/content/72/24_Supplement/P3-04-02

1790 Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping

Julia D. Wulfkuhle, Daniela Berg, Claudia Wolff, Rupert Langer, Kai Tran, Julie Illi, Virginia Espina, Mariaelena Pierobon, Jianghong Deng, Angela DeMichele, Axel Walch, Holger Bronger, Ingrid Becker, Christine Waldhör, Heinz Höfler, Laura Esserman, Lance A. Liotta, Karl-Friedrich Becker, Emanuel F. Petricoin Clin. Cancer Res. vol 18 (23) 6426-6435 2012
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/23045247>

1791 Morphological Appearance of Radiofrequency Ablated Stage IA NSCLC in Medically Inoperable Patients as Related to Recurrence: Results from the ACOSOG Z4033 (Alliance Trial)

Lillian Xiong, Erica Alexander, Shauna Hillman, Angelina Tan, Grayson Baird, Hiran Fernando, Damian Dupuy 2015
Abstract Respiratory <http://archive.rsna.org/2015/15008022.html>

1792 Tumor and germline markers for gemcitabine sensitivity in pancreatic cancer

S. Yee, E. Collisson, S. Gysin, K. Owzar, C. Jiang, E. Jorgenson, J. Paquette, T. Tokuyasu, P. Matsson, F. Innocenti, M. J. Ratain, M. McMahon, A. Ko, M. A. Tempero, K. M. Giacomini 2009
Abstract PPP

1793 Event-free survival as a surrogate endpoint for overall survival in previously untreated acute myeloid leukemia: An individual patient-level analysis of multiple randomized trials (Alliance A151614)

Jun Yin, Betsy LaPlant, Elizabeth Storricks, Geoffrey L. Uy, Guido Marcucci, Hugo F. Fernandez, Zhuoxin Sun, Frederick R. Appelbaum, Megan Othus, Williams G. Blum, Stephen H. Petersdorf, Richard A. Larson, Richard M. Stone, Sumithra J. Mandrekar Blood vol 132 (Suppl 1) 1386 2018
Abstract Leukemia A151614, CALGB-10201, E1900, CALGB-10603, S0106
http://www.bloodjournal.org/content/132/Suppl_1/1386.abstract

1794 Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)

Jun Yin, Betsy LaPlant, Geoffrey L. Uy, Guido Marcucci, William Blum, Richard A. Larson, Richard M. Stone, Sumithra J. Mandrekar Blood Adv vol 3 (11) 1714-21 2019
Manuscript Leukemia A151614, CALGB-10201, CALGB-10503, CALGB-10603, CALGB-10801, CALGB-11001 <http://www.ncbi.nlm.nih.gov/pubmed/31171508>

1795 Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia

Jun Yin, Betsy R. Laplant, Geoffrey L. Uy, Guido Marcucci, William Blum, Richard A. Larson, Richard M. Stone, Sumithra Mandrekar JAMA Oncol vol 128 214 2016
Abstract Leukemia CALGB-10201, A151614, CALGB-10503, CALGB-10603, CALGB-10801, CALGB-11001 <http://www.bloodjournal.org/content/128/22/214>

1796 Radiofrequency Ablation of Medically Inoperable Stage IA Non–Small Cell Lung Cancer: Are Early Posttreatment PET Findings Predictive of Treatment Outcome?

Don C. Yoo, Damian E. Dupuy, Shauna L. Hillman, Hiran C. Fernando, William S. Rilling, Jo-Anne O. Shepard, Barry A. Siegel AJR Am J Roentgenol vol 197 (2) 334-340 2011
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/21785078>

1797 Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (Alliance)

H. H. Yoon, N. R. Foster, J. P. Meyers, P. D. Steen, D. W. Visscher, R. Pillai, D. M. Prow, C. M. Reynolds, B. T. Marchello, R. B. Mowat, B. I. Mattar, C. Erlichman, M. P. Goetz Ann. Oncol vol 27 (2) 339-344 2016
Manuscript Experimental <http://www.ncbi.nlm.nih.gov/pubmed/26578722>

1798 Prognostic impact of specific KRAS mutations in codon 12 and 13 in 2,165 BRAF-wildtype colon cancers: Results from NCCTG N0147 (Alliance)

H. H. Yoon, D. Tougeron, M. R. Mahoney, Q. Shi, D. J. Sargent, S. N. Thibodeau, F. A. Sinicrope, S. R. Alberts European Journal of Cancer vol 49 abstract 2160 2013
Abstract GI
<http://eccamsterdam2013.ecco-org.eu/Scientific-Programme/Searchable-Programme.aspx#anchorScpr>

1799 Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients

Harry H. Yoon, Qian Shi, Steven R. Alberts, Richard M. Goldberg, Stephen N. Thibodeau, Daniel J. Sargent, Frank A. Sinicrope J. Natl. Cancer Inst vol 107 (10) 2015
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/26160882>

1800 Racial differences in KRAS/BRAF mutation rates and survival in colon cancer (NCCTG N0147 [Alliance]).

Harry H. Yoon, Qian Shi, Steven R. Alberts, Richard M. Goldberg, Stephen N. Thibodeau, Daniel J. Sargent, Frank A. Sinicrope J. Clin. Oncol. vol 32 (15_suppl) 3536 2014
Abstract GI http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3536

1801 Inter-tumoral heterogeneity of CD3+ and CD8+ T-cell densities in the microenvironment of DNA mismatch repair-deficient colon cancers: implications for prognosis

Harry H. Yoon, Qian Shi, Erica N. Heying, Andrea Muranyi, Joerg Bredno, Faith Ough, Azita Djalilvand, June Clements, Rebecca Bowermaster, Wen-Wei Liu, Michael Barnes, Steven R. Alberts, Kandavel Shanmugam, Frank A. Sinicrope Clin. Cancer Res. vol 25 (1) 125-33 2019
Manuscript Correl Sci NOS <http://www.ncbi.nlm.nih.gov/pubmed/30301825>

1802 CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (Alliance)

Harry H. Yoon, Qian Shi, Erica N. Heying, Andrea Muranyi, Faith Ough, Azita Djalilvand, June Clements, Rebecca Bowermaster, Wen-Wei Liu, Michael Barnes, Steven R. Alberts, Kandavel Shanmugam, Frank A. Sinicrope J Clin Oncol vol 36 (Suppl) abstr 3598 2018
Abstract Correl Sci NOS <https://meetinglibrary.asco.org/record/158879/abstract>

1803 KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance)

Harry H. Yoon, David Tougeron, Qian Shi, Steven R. Alberts, Michelle R. Mahoney, Garth D. Nelson, Suresh G. Nair, Stephen N. Thibodeau, Richard M. Goldberg, Daniel J. Sargent, Frank A. Sinicrope Clin. Cancer Res. vol 20 (11) 3033-3043 2014
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/24687927>

1804 Outcomes in white (W) patients (pts) and those of African (A) descent receiving adjuvant therapy for colon cancer (CC)

G. Yothers, A. W. Blackstock, N. Wolmark, R. M. Goldberg, M. J. O'Connell, J. Benedetti, J. Dignam, D. J. Sargent J. Clin. Oncol. vol 25 (18s) abstr 4017 2007
Abstract GI C89803, NCCTG-N0441
http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=3

1805 Outcomes Among Black Patients With Stage II and III Colon Cancer Receiving Chemotherapy: An Analysis of ACCENT Adjuvant Trials

Greg Yothers, Daniel J. Sargent, Norman Wolmark, Richard M. Goldberg, Michael J. O'Connell, Jacqueline K. Benedetti, Leonard B. Saltz, James J. Dignam, A. William Blackstock J Natl Cancer Inst vol 103 (20) 1498-1506 2011
Manuscript GI <http://www.ncbi.nlm.nih.gov/pubmed/21997132>

1806 Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer

Chen Yuan, Lindsay Renfro, Pratibha B. Ambadwar, Fang-Shu Ou, Howard L. McLeod, Federico Innocenti, Jeffrey A. Meyerhardt, Brian M. Wolpin, Richard M. Goldberg, Axel Grothey, Charles S. Fuchs, Kimmie Ng Cancer Causes Control vol 30 (7) 757-65 2019
Manuscript PPP <http://www.ncbi.nlm.nih.gov/pubmed/31104167>

1807 Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy

Aziz Zaanani, Qian Shi, Julien Taieb, Steven R. Alberts, Jeffrey P. Meyers, Thomas C. Smyrk, Catherine Julie, Ayman Zawadi, Josep Taberner, Enrico Mini, Richard M. Goldberg, Gunnar Folprecht, Jean Luc Van Laethem, Karine Le Malicot, Daniel J. Sargent, Pierre Laurent-Puig, Frank A.

1808 Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients treated with adjuvant FOLFOX + cetuximab in the PETACC8 and N0147 adjuvant trials.

Aziz Zaanan, Qian Shi, Julien Taieb, Steven R. Alberts, Thomas C. Smyrk, Catherine Julié, Ayman Zawadi, Josep Tabernero, Enrico Mini, Richard M. Goldberg, Gunnar Folprecht, Jean L. Van Laethem, Karine Le Malicot, Daniel J. Sargent, Pierre Laurent-Puig, Frank A. Sinicrope J. Clin. Oncol. vol 33 (suppl) abstr 3506 2015
Abstract GI <http://meetinglibrary.asco.org/content/146390-156>

1809 PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated RENal Cell CancEr (Alliance A031704)

Tian Zhang, Karla Ballman, Atish Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen, Tyler Zemla, Hamid Emamekhoo, Shilpa Gupta, Michael J. Morris, Daniel J. George, Toni K. Choueiri J Clin Oncol vol 37 (suppl) abstr TPS4596 2019
Abstract GU https://abstracts.asco.org/239/AbstView_239_257269.html

1810 A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin and Concurrent Thoracic Radiation Therapy for Non-Small Cell Lung Cancer: NCCTG-N0321

Yujie Zhao, Nathan R. Foster, Jeffrey P. Meyers, Sachdev P. Thomas, Donald W. Northfelt, Kendrith M. Rowland, Bassam I. Mattar, David B. Johnson, Julian R. Molina, Sumithra J. Mandrekar, Steven E. Schild, James D. Bearden, Marie-Christine Aubry, Alex A. Adjei J Thorac Oncol vol 10 (1) 172-180 2015
Manuscript Respiratory <http://www.ncbi.nlm.nih.gov/pubmed/25247339>

1811 Venlafaxine to prevent oxaliplatin-induced neuropathy?: A pilot randomized placebo-controlled trial.

Collin Thomas Zimmerman, Pamela J. Atherton, Deirdre R. Pachman, Drew K. Seisler, Nina D. Wagner-Johnston, Shaker R. Dakhil, Jacqueline M. Lafky, Rui Qin, Axel Grothey, Charles L. Loprinzi J. Clin. Oncol. vol 33 (suppl 15) e20734 2015
Abstract Symptom Inter <http://meetinglibrary.asco.org/content/143704-156>

1812 Venlafaxine to Prevent Oxaliplatin-Induced Neuropathy? A Pilot Randomized Placebo Controlled Trial

Collin Zimmerman, Pam Atherton, Deirdre Pachman, Drew Seisler, Nina Wagner-Johnston, Shaker Dakhil, Jacqueline M Lafky, Rui Qin, Axel Grothey, Charles L Loprinzi Support Care Cancer vol 23 (suppl 1) S152 (abstract 112-106-P) 2015
Abstract Symptom Inter http://mascc2015.kenes.com/Documents/10.1007_s00520-015-2712-y.pdf

1813 MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy

Collin Zimmerman, Pamela J. Atherton, Deirdre Pachman, Drew Seisler, Nina Wagner-Johnston, Shaker Dakhil, Jacqueline M. Lafky, Rui Qin, Axel Grothey, Charles L. Loprinzi Support Care Cancer vol 24 (3) 1071-1078 2016
Manuscript Symptom Inter <http://www.ncbi.nlm.nih.gov/pubmed/26248652>

1814 Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set

Aimery de Gramont, Joleen Hubbard, Qian Shi, Michael J. O'Connell, Marc Buyse, Jacqueline Benedetti, Brian Bot, Chris O'Callaghan, Greg Yothers, Richard M. Goldberg, Charles D. Blanke, Al Benson, Qiqi Deng, Steven R. Alberts, Thierry Andre, Norman Wolmark, Axel Grothey, Daniel

